[
    {
        "answer":"Mother-to-child transmission (MTCT) is the main cause of HIV-1 infection in children worldwide. ",
        "answer_pt":"A transmiss\u00e3o de m\u00e3e para filho (MTCT) \u00e9 a principal causa de infec\u00e7\u00e3o pelo HIV-1 em crian\u00e7as em todo o mundo.",
        "id":"262",
        "question":"What is the main cause of HIV-1 infection in children?",
        "question_pt":"Qual \u00e9 a principal causa da infec\u00e7\u00e3o pelo HIV-1 em crian\u00e7as?"
    },
    {
        "answer":"DC-SIGNR plays a crucial role in MTCT of HIV-1 and that impaired placental DC-SIGNR expression increases risk of transmission.",
        "answer_pt":"O DC-SIGNR desempenha um papel crucial na MTCT do HIV-1 e essa express\u00e3o diminu\u00edda da DC-SIGNR da placenta aumenta o risco de transmiss\u00e3o.",
        "id":"276",
        "question":"What plays the crucial role in the Mother to Child Transmission of HIV-1 and what increases the risk",
        "question_pt":"O que desempenha o papel crucial na transmiss\u00e3o de m\u00e3e para filho do HIV-1 e o que aumenta o risco"
    },
    {
        "answer":"more than 400,000 children were infected worldwide, mostly through MTCT and 90% of them lived in sub-Saharan Africa. ",
        "answer_pt":"mais de 400.000 crian\u00e7as foram infectadas em todo o mundo, principalmente atrav\u00e9s da MTCT e 90% delas viviam na \u00c1frica Subsaariana.",
        "id":"278",
        "question":"How many children were infected by HIV-1 in 2008-2009, worldwide?",
        "question_pt":"Quantas crian\u00e7as foram infectadas pelo HIV-1 em 2008-2009, em todo o mundo?"
    },
    {
        "answer":"High copy numbers of CCL3L1, a potent HIV-1 suppressive ligand for CCR5, are associated with higher chemokine production and lower risk of MTCT of HIV-1 among South African infants",
        "answer_pt":"Um n\u00famero elevado de c\u00f3pias de CCL3L1, um potente ligante supressor de HIV-1 para CCR5, est\u00e1 associado a maior produ\u00e7\u00e3o de quimiocinas e menor risco de MTCT de HIV-1 em crian\u00e7as sul-africanas",
        "id":"316",
        "question":"What is the role of C-C Motif Chemokine Ligand 3 Like 1 (CCL3L1) in mother to child transmission of HIV-1?",
        "question_pt":"Qual \u00e9 o papel do ligante 3 da quimioterapia C-C Motif 3 Like 1 (CCL3L1) na transmiss\u00e3o de m\u00e3e para filho do HIV-1?"
    },
    {
        "answer":"Dendritic cell-specific ICAM-grabbing non-integrin-related (DC-SIGNR, also known as CD209L or liver/lymph node-specific ICAM-grabbing non-integrin (L-SIGN)) can interact with a plethora of pathogens including HIV-1 and is expressed in placental capillary endothelial cells",
        "answer_pt":"A n\u00e3o-integrina espec\u00edfica para captura de ICAM para c\u00e9lulas dendr\u00edticas n\u00e3o relacionada \u00e0 integrina (DC-SIGNR, tamb\u00e9m conhecida como CD209L ou n\u00e3o-integrina espec\u00edfica para captura de ICAM para f\u00edgado / linfonodo (L-SIGN)) pode interagir com uma infinidade de pat\u00f3genos, incluindo HIV- 1 e \u00e9 expresso em c\u00e9lulas endoteliais capilares da placenta",
        "id":"305",
        "question":"What is DC-GENR and where is  it expressed?",
        "question_pt":"O que \u00e9 o DC-GENR e onde \u00e9 expresso?"
    },
    {
        "answer":"the presence of DC-SIGNR at the placental endothelial cell surface may protect infants from HIV-1 infection by capturing virus and promoting its degradation/presentation. ",
        "answer_pt":"a presen\u00e7a de DC-SIGNR na superf\u00edcie celular endotelial da placenta pode proteger os beb\u00eas da infec\u00e7\u00e3o pelo HIV-1 capturando v\u00edrus e promovendo sua degrada\u00e7\u00e3o / apresenta\u00e7\u00e3o.",
        "id":"306",
        "question":"How does the presence of DC-SIGNR affect the MTCT of HIV-1?",
        "question_pt":"Como a presen\u00e7a do DC-SIGNR afeta a MTCT do HIV-1?"
    },
    {
        "answer":"in placenta containing low levels of DC-SIGNR, HIV-1 would preferentially binds CCR5 on endothelial cells resulting in a loss of placental barrier integrity and enhanced passage of maternal HIV-1-infected cells in foetal circulation leading to MTCT of HIV-1",
        "answer_pt":"Na placenta contendo baixos n\u00edveis de DC-SIGNR, o HIV-1 liga preferencialmente o CCR5 nas c\u00e9lulas endoteliais, resultando em uma perda da integridade da barreira placent\u00e1ria e na passagem aprimorada das c\u00e9lulas maternas infectadas pelo HIV-1 na circula\u00e7\u00e3o fetal, levando \u00e0 MTCT do HIV-1.",
        "id":"307",
        "question":"Why do low levels of DC-SIGNR enhance Mother to Child Transmission of HIV-1?",
        "question_pt":"Por que baixos n\u00edveis de DC-SIGNR melhoram a transmiss\u00e3o de m\u00e3e para filho do HIV-1?"
    },
    {
        "answer":"Without specific interventions, the rate of HIV-1 mother-tochild transmission (MTCT) is approximately 15-45%",
        "answer_pt":"Sem interven\u00e7\u00f5es espec\u00edficas, a taxa de transmiss\u00e3o m\u00e3e-filho (MTCT) do HIV-1 \u00e9 de aproximadamente 15-45%",
        "id":"277",
        "question":"What is the percentage of Mother to Child Transmission of HIV-1, when there is no intervention?",
        "question_pt":"Qual \u00e9 a porcentagem de transmiss\u00e3o de m\u00e3e para filho do HIV-1, quando n\u00e3o h\u00e1 interven\u00e7\u00e3o?"
    },
    {
        "answer":"Genetic variants in CCR5 have been shown to influence vertical transmission of HIV-1. CCR5 promoter variants resulting in higher expression of the receptor were associated with increased risk of MTCT of HIV-1 among sub-Saharan Africans",
        "answer_pt":"Demonstrou-se que variantes gen\u00e9ticas no CCR5 influenciam a transmiss\u00e3o vertical do HIV-1. As variantes do promotor CCR5, resultando em maior express\u00e3o do receptor, foram associadas ao aumento do risco de MTCT do HIV-1 entre os africanos subsaarianos",
        "id":"312",
        "question":"Does C-C chemokine receptor type 5 (CCR5) affect the transmission of HIV-1?",
        "question_pt":"O receptor de quimiocina C-C tipo 5 (CCR5) afeta a transmiss\u00e3o do HIV-1?"
    },
    {
        "answer":"Mannose-binding lectin (MBL) is an innate immune receptor synthesised in the liver and secreted in the bloodstream in response to inflammation signal. MBL promotes pathogen elimination by opsonization and phagocytosis,",
        "answer_pt":"A lectina de liga\u00e7\u00e3o \u00e0 manose (MBL) \u00e9 um receptor imune inato, sintetizado no f\u00edgado e secretado na corrente sangu\u00ednea em resposta ao sinal de inflama\u00e7\u00e3o. O MBL promove a elimina\u00e7\u00e3o de pat\u00f3genos por opsoniza\u00e7\u00e3o e fagocitose,",
        "id":"318",
        "question":"How does Mannanose Binding Lectin (MBL) affect elimination of HIV-1 pathogen?",
        "question_pt":"Como a Mannanose Binding Lectin (MBL) afeta a elimina\u00e7\u00e3o do pat\u00f3geno HIV-1?"
    },
    {
        "answer":"The 32-pb deletion polymorphism in CCR5 has be shown to protect from vertical transmission of HIV-1",
        "answer_pt":"Demonstrou-se que o polimorfismo de dele\u00e7\u00e3o de 32-pb no CCR5 protege da transmiss\u00e3o vertical do HIV-1",
        "id":"321",
        "question":"How can CCR5's effect in HIV-1 transmission be reduced?",
        "question_pt":"Como o efeito do CCR5 na transmiss\u00e3o do HIV-1 pode ser reduzido?"
    },
    {
        "answer":"interferon-induced transmembrane",
        "answer_pt":"transmembrana induzida por interferon",
        "id":"568",
        "question":"What is IFITM?",
        "question_pt":"O que \u00e9 o IFITM?"
    },
    {
        "answer":"three",
        "answer_pt":"tr\u00eas",
        "id":"569",
        "question":"How many cysteine residues are contained in the first transmembrane domain of IFITM3?",
        "question_pt":"Quantos res\u00edduos de ciste\u00edna est\u00e3o contidos no primeiro dom\u00ednio transmembranar do IFITM3?"
    },
    {
        "answer":"2-bromopalmitic acid (2BP)",
        "answer_pt":"\u00c1cido 2-bromopalm\u00edtico (2BP)",
        "id":"570",
        "question":"What inhibits S-palmitoylation?",
        "question_pt":"O que inibe a S-palmitoila\u00e7\u00e3o?"
    },
    {
        "answer":"IFITM5 with FKBP11",
        "answer_pt":"IFITM5 com FKBP11",
        "id":"571",
        "question":"What interaction is inhibited by the presence of 2-bromopalmitic acid (2BP)?",
        "question_pt":"Que intera\u00e7\u00e3o \u00e9 inibida pela presen\u00e7a de \u00e1cido 2-bromopalm\u00edtico (2BP)?"
    },
    {
        "answer":"bone formation factor.",
        "answer_pt":"fator de forma\u00e7\u00e3o \u00f3ssea.",
        "id":"572",
        "question":"What is a function associated with IFITM5?",
        "question_pt":"O que \u00e9 uma fun\u00e7\u00e3o associada ao IFITM5?"
    },
    {
        "answer":"S-palmitoylation on the protein",
        "answer_pt":"S-palmitoila\u00e7\u00e3o na prote\u00edna",
        "id":"573",
        "question":"What regulates the antiviral activity of IFITM3?",
        "question_pt":"O que regula a atividade antiviral do IFITM3?"
    },
    {
        "answer":"bonerestricted IFITM-like (BRIL) protein",
        "answer_pt":"prote\u00edna tipo IFITM restrita por ossos (BRIL)",
        "id":"574",
        "question":"What is another name for IFITM5?",
        "question_pt":"Qual \u00e9 o outro nome para IFITM5?"
    },
    {
        "answer":"the region upstream of the ifitm5 gene lacks the interferon regulatory elements",
        "answer_pt":"a regi\u00e3o a montante do gene ifitm5 n\u00e3o possui os elementos reguladores do interferon",
        "id":"575",
        "question":"Why is the expression of IFITM5 not promoted by interferons?",
        "question_pt":"Por que a express\u00e3o do IFITM5 n\u00e3o \u00e9 promovida por interferons?"
    },
    {
        "answer":"~ 65% similarity",
        "answer_pt":"~ 65% de similaridade",
        "id":"576",
        "question":"What is the amino acid similarity between IFITM5 and the other IFITM proteins?",
        "question_pt":"Qual \u00e9 a semelhan\u00e7a de amino\u00e1cidos entre o IFITM5 e as outras prote\u00ednas IFITM?"
    },
    {
        "answer":"~ 85% similarity",
        "answer_pt":"~ 85% de similaridade",
        "id":"577",
        "question":"What is the amino acid similarity between IFITM 1, IFITM 2, and IFITM 3?",
        "question_pt":"Qual \u00e9 a semelhan\u00e7a de amino\u00e1cidos entre IFITM 1, IFITM 2 e IFITM 3?"
    },
    {
        "answer":"aspartate",
        "answer_pt":"aspartato",
        "id":"580",
        "question":"What amino acid might be involved in calcium binding in the C-terminal region of a protein?",
        "question_pt":"Qual amino\u00e1cido pode estar envolvido na liga\u00e7\u00e3o do c\u00e1lcio na regi\u00e3o C-terminal de uma prote\u00edna?"
    },
    {
        "answer":"31 kb",
        "answer_pt":"31 kb",
        "id":"917",
        "question":"What is the size of bovine coronavirus?",
        "question_pt":"Qual \u00e9 o tamanho do coronav\u00edrus bovino?"
    },
    {
        "answer":"single-stranded, linear, and nonsegmented RNA",
        "answer_pt":"RNA de fita simples, linear e n\u00e3o segmentado",
        "id":"918",
        "question":"What is the molecular structure of bovine coronavirus?",
        "question_pt":"Qual \u00e9 a estrutura molecular do coronav\u00edrus bovino?"
    },
    {
        "answer":"30,847 nucleotides",
        "answer_pt":"30.847 nucleot\u00eddeos",
        "id":"919",
        "question":"How many nucleotides does bovine coronavirus contain?",
        "question_pt":"Quantos nucleot\u00eddeos cont\u00e9m o coronav\u00edrus bovino?"
    },
    {
        "answer":"20kb",
        "answer_pt":"20kb",
        "id":"920",
        "question":"What is the size of the orf1ab gene in bovine coronavirus?",
        "question_pt":"Qual \u00e9 o tamanho do gene orf1ab no coronav\u00edrus bovino?"
    },
    {
        "answer":"5= side",
        "answer_pt":"5 = lado",
        "id":"921",
        "question":"Is the orf1ab gene at the 3' or 5' end of the bovine coronavirus genome?",
        "question_pt":"O gene orf1ab est\u00e1 na extremidade 3 'ou 5' do genoma do coronav\u00edrus bovino?"
    },
    {
        "answer":"HCoV",
        "answer_pt":"HCoV",
        "id":"1658",
        "question":"What is a significant cause of Influenze like illness among healthy adolescents and adults presenting for medical evaluation?",
        "question_pt":"Qual \u00e9 uma causa significativa de doen\u00e7a semelhante \u00e0 gripe entre adolescentes e adultos saud\u00e1veis \u200b\u200bque se apresentam para avalia\u00e7\u00e3o m\u00e9dica?"
    },
    {
        "answer":"HCoV-OC43",
        "answer_pt":"HCoV-OC43",
        "id":"1659",
        "question":"What is the most common species of Human Coronavirus among adults?\n",
        "question_pt":"Qual \u00e9 a esp\u00e9cie mais comum de Coronav\u00edrus Humano entre adultos?"
    },
    {
        "answer":"HCoV\u2010HKU1",
        "answer_pt":"HCoV \u2010 HKU1",
        "id":"1660",
        "question":"Which Human Coronavirus showed species specific clinical characteristics of its infection?",
        "question_pt":"Qual coronav\u00edrus humano mostrou caracter\u00edsticas cl\u00ednicas espec\u00edficas da esp\u00e9cie de sua infec\u00e7\u00e3o?"
    },
    {
        "answer":"Highly virulent species of HCoV",
        "answer_pt":"Esp\u00e9cies altamente virulentas de HCoV",
        "id":"1717",
        "question":"What causes the outbreak of SARS and MERS.",
        "question_pt":"O que causa o surto de SARS e MERS."
    },
    {
        "answer":"ranged from 14% to 45%",
        "answer_pt":"variou de 14% a 45%",
        "id":"1718",
        "question":"What is the case fatality rate of SARS and MERS?",
        "question_pt":"Qual \u00e9 a taxa de mortalidade de casos de SARS e MERS?"
    },
    {
        "answer":" HCoV-OC43 and HCoV-229E",
        "answer_pt":"HCoV-OC43 e HCoV-229E",
        "id":"1719",
        "question":"What were the common HCOV strains in the 5 year USA study?",
        "question_pt":"Quais foram as cepas comuns de HCOV no estudo de 5 anos nos EUA?"
    },
    {
        "answer":"HCoV-HKU1, HCoV-OC43, HCoV-NL63, and HCoV-229E",
        "answer_pt":"HCoV-HKU1, HCoV-OC43, HCoV-NL63 e HCoV-229E",
        "id":"1720",
        "question":"Which species are more prevalent but less severe?",
        "question_pt":"Quais esp\u00e9cies s\u00e3o mais prevalentes, mas menos graves?"
    },
    {
        "answer":"both intracellular and cell-surface factors",
        "answer_pt":"fatores intracelulares e da superf\u00edcie celular",
        "id":"2996",
        "question":"What is required for a Hepatitis B infection in cells?",
        "question_pt":"O que \u00e9 necess\u00e1rio para uma infec\u00e7\u00e3o por hepatite B nas c\u00e9lulas?"
    },
    {
        "answer":"heparan sulfates in the membrane proteins",
        "answer_pt":"sulfatos de heparano nas prote\u00ednas da membrana",
        "id":"2997",
        "question":"What regulates the broad, but less specific, virus-cell interaction in a hepatitis B infection?",
        "question_pt":"O que regula a ampla, mas menos espec\u00edfica, intera\u00e7\u00e3o c\u00e9lula-v\u00edrus em uma infec\u00e7\u00e3o por hepatite B?"
    },
    {
        "answer":"Nterminus of HBV preS1 (amino acids 1-47) ",
        "answer_pt":"Fim do HBV pr\u00e9S1 (amino\u00e1cidos 1-47)",
        "id":"2998",
        "question":"Which protein domain of the Hepatitis B envelope is necessary for infection?",
        "question_pt":"Qual dom\u00ednio proteico do envelope da hepatite B \u00e9 necess\u00e1rio para a infec\u00e7\u00e3o?"
    },
    {
        "answer":"lateral surface (canalicular) of hepatocytes",
        "answer_pt":"superf\u00edcie lateral (canalicular) dos hepat\u00f3citos",
        "id":"2999",
        "question":"Where is NTCP located in the body?",
        "question_pt":"Onde o NTCP est\u00e1 localizado no corpo?"
    },
    {
        "answer":"bile acid transport ",
        "answer_pt":"transporte de \u00e1cido biliar",
        "id":"3000",
        "question":"What does the NTCP protein mediate?",
        "question_pt":"O que a prote\u00edna NTCP medeia?"
    },
    {
        "answer":"not sufficient",
        "answer_pt":"n\u00e3o suficiente",
        "id":"3001",
        "question":"Is NTCP sufficient to allow HBV infection?",
        "question_pt":"O NTCP \u00e9 suficiente para permitir a infec\u00e7\u00e3o por HBV?"
    },
    {
        "answer":"the majority of HepaRG cells were found to express NPCT but not to be infected",
        "answer_pt":"Verificou-se que a maioria das c\u00e9lulas HepaRG expressa NPCT, mas n\u00e3o est\u00e1 infectada",
        "id":"3002",
        "question":"Why is NTCP thought to not be sufficient for HBV infection?",
        "question_pt":"Por que o NTCP \u00e9 considerado insuficiente para a infec\u00e7\u00e3o pelo HBV?"
    },
    {
        "answer":"arboviruses",
        "answer_pt":"arbov\u00edrus",
        "id":"3003",
        "question":"What kinds of viruses are Japanese encephalitis virus(JEV), tick-borne encephalitis virus(TBEV), eastern equine encephalitis virus (EEEV), sindbis virus(SV), and dengue virus(DV)?",
        "question_pt":"Que tipos de v\u00edrus s\u00e3o o v\u00edrus da encefalite japonesa (JEV), v\u00edrus da encefalite transmitida por carrapatos (TBEV), v\u00edrus da encefalite equina oriental (EEEV), v\u00edrus sindbis (SV) e v\u00edrus da dengue (DV)?"
    },
    {
        "answer":"ELISA and IFA",
        "answer_pt":"ELISA e IFA",
        "id":"3004",
        "question":"What are the current clinically-available methods to detect encephalitis viral antigens?",
        "question_pt":"Quais s\u00e3o os m\u00e9todos clinicamente dispon\u00edveis atualmente para detectar ant\u00edgenos virais de encefalite?"
    },
    {
        "answer":"two-dimensional gel electrophoresis , protein chip, mass spectrometry, and suspension array technology",
        "answer_pt":"eletroforese em gel bidimensional, chip de prote\u00edna, espectrometria de massa e tecnologia de matriz de suspens\u00e3o",
        "id":"3005",
        "question":"What methods exist for detecting multiple antigens simultaneously in a one-sample, laboratory test?",
        "question_pt":"Quais m\u00e9todos existem para detectar v\u00e1rios ant\u00edgenos simultaneamente em um teste de laborat\u00f3rio de uma amostra?"
    },
    {
        "answer":"9",
        "answer_pt":"9",
        "id":"3006",
        "question":"How many antigens could be detected by Liew's multiplex ELISA test?",
        "question_pt":"Quantos ant\u00edgenos foram detectados pelo teste ELISA multiplex de Liew?"
    },
    {
        "answer":"monoclonal",
        "answer_pt":"monoclonal",
        "id":"3007",
        "question":"What kind of antibodies were used in the ELISA-array assay?",
        "question_pt":"Que tipo de anticorpos foram utilizados no ensaio ELISA-array?"
    },
    {
        "answer":"using cultured viruses and inoculated chicken eggs with patient sera",
        "answer_pt":"usando v\u00edrus cultivados e ovos de galinha inoculados com soros de pacientes",
        "id":"3008",
        "question":"How was the ELISA assay validated?",
        "question_pt":"Como foi validado o ensaio ELISA?"
    },
    {
        "answer":"4D5, 2B5, 1F1, 2B8, 4F9, and 4E11",
        "answer_pt":"4D5, 2B5, 1F1, 2B8, 4F9 e 4E11",
        "id":"3009",
        "question":"What capture antibodies were used in the study?",
        "question_pt":"Quais anticorpos de captura foram usados \u200b\u200bno estudo?"
    },
    {
        "answer":"from 0.2 to 0.0125 mg/ml",
        "answer_pt":"de 0,2 a 0,0125 mg / ml",
        "id":"3010",
        "question":"What was the spotting concentration range for the capture antibodies?",
        "question_pt":"Qual foi o intervalo de concentra\u00e7\u00e3o de detec\u00e7\u00e3o para os anticorpos de captura?"
    },
    {
        "answer":"combination of minimized cross reaction and higher signal intensity",
        "answer_pt":"combina\u00e7\u00e3o de rea\u00e7\u00e3o cruzada minimizada e maior intensidade de sinal",
        "id":"3011",
        "question":"How was the proper spotting concentration determined?",
        "question_pt":"Como foi determinada a concentra\u00e7\u00e3o adequada de detec\u00e7\u00e3o?"
    },
    {
        "answer":"by applying JEV, YF, and DV cultures",
        "answer_pt":"aplicando culturas JEV, YF e DV",
        "id":"3012",
        "question":"How was cross reaction detection determined?",
        "question_pt":"Como foi determinada a detec\u00e7\u00e3o de rea\u00e7\u00e3o cruzada?"
    },
    {
        "answer":"using cultured viruses and inoculated chicken eggs with patient sera",
        "answer_pt":"usando v\u00edrus cultivados e ovos de galinha inoculados com soros de pacientes",
        "id":"3013",
        "question":"How was the ELISA-array assay validated?",
        "question_pt":"Como foi validado o ensaio ELISA-array?"
    },
    {
        "answer":"108 per 100,000",
        "answer_pt":"108 por 100.000",
        "id":"3014",
        "question":"In 2010, how many cases of tuberculosis were estimated in China?",
        "question_pt":"Em 2010, quantos casos de tuberculose foram estimados na China?"
    },
    {
        "answer":"94 million",
        "answer_pt":"94 milh\u00f5es",
        "id":"3015",
        "question":"What is the population of Shandong province?",
        "question_pt":"Qual \u00e9 a popula\u00e7\u00e3o da prov\u00edncia de Shandong?"
    },
    {
        "answer":"estimate the TB prevalence in Shandong",
        "answer_pt":"estimar a preval\u00eancia de TB em Shandong",
        "id":"3016",
        "question":"What was the purpose of this study?",
        "question_pt":"Qual foi o objetivo deste estudo?"
    },
    {
        "answer":"15 years old or above",
        "answer_pt":"15 anos ou mais",
        "id":"3017",
        "question":"What was the age range for the people surveyed?",
        "question_pt":"Qual era a faixa et\u00e1ria das pessoas pesquisadas?"
    },
    {
        "answer":"in accordance with WHO recommendations",
        "answer_pt":"de acordo com as recomenda\u00e7\u00f5es da OMS",
        "id":"3018",
        "question":"How was the survey designed?",
        "question_pt":"Como foi projetada a pesquisa?"
    },
    {
        "answer":"52500",
        "answer_pt":"52500",
        "id":"3019",
        "question":"Was was the sample size?",
        "question_pt":"Foi o tamanho da amostra?"
    },
    {
        "answer":"A stratified multi stage random sampling",
        "answer_pt":"Uma amostragem aleat\u00f3ria estratificada em v\u00e1rios est\u00e1gios",
        "id":"3020",
        "question":"How were the clusters selected?",
        "question_pt":"Como os clusters foram selecionados?"
    },
    {
        "answer":"1250 to 1750",
        "answer_pt":"1250 a 1750",
        "id":"3021",
        "question":"How many people were in a community cluster?",
        "question_pt":"Quantas pessoas estavam em um cluster da comunidade?"
    },
    {
        "answer":"Military barracks and prisons",
        "answer_pt":"Quartel e pris\u00f5es militares",
        "id":"3022",
        "question":"Who was excluded from the study?",
        "question_pt":"Quem foi exclu\u00eddo do estudo?"
    },
    {
        "answer":"March to June 2010",
        "answer_pt":"Mar\u00e7o a junho de 2010",
        "id":"3023",
        "question":"When was the study conducted?",
        "question_pt":"Quando foi realizado o estudo?"
    },
    {
        "answer":"clinicians, public health doctors, radiologists, laboratory technicians and nurses",
        "answer_pt":"m\u00e9dicos, m\u00e9dicos de sa\u00fade p\u00fablica, radiologistas, t\u00e9cnicos de laborat\u00f3rio e enfermeiros",
        "id":"3024",
        "question":"Who conducted the study?",
        "question_pt":"Quem conduziu o estudo?"
    },
    {
        "answer":"L\u00f6wenstein-Jensen medium",
        "answer_pt":"Meio L\u00f6wenstein-Jensen",
        "id":"3025",
        "question":"What medium was used to collect the sputum samples?",
        "question_pt":"Qual meio foi usado para coletar as amostras de escarro?"
    },
    {
        "answer":"95% to 97%",
        "answer_pt":"95% a 97%",
        "id":"3026",
        "question":"What was the response rate for the study?",
        "question_pt":"Qual foi a taxa de resposta do estudo?"
    },
    {
        "answer":"46 years",
        "answer_pt":"46 anos",
        "id":"3027",
        "question":"What was the average age of a study participant?",
        "question_pt":"Qual era a idade m\u00e9dia de um participante do estudo?"
    },
    {
        "answer":"22.1",
        "answer_pt":"22,1",
        "id":"3028",
        "question":"What was the prevalence rate in Shandong in 2010 for sputum positive cases of tuberculosis?",
        "question_pt":"Qual foi a taxa de preval\u00eancia em Shandong em 2010 para casos de tuberculose com escarro?"
    },
    {
        "answer":"a large proportion of TB patients did not present consistent cough",
        "answer_pt":"uma grande propor\u00e7\u00e3o de pacientes com TB n\u00e3o apresentou tosse consistente",
        "id":"3029",
        "question":"What was the most striking finding of the study regarding tuberculosis patients?",
        "question_pt":"Qual foi o achado mais marcante do estudo em pacientes com tuberculose?"
    },
    {
        "answer":"45%",
        "answer_pt":"45%",
        "id":"3030",
        "question":"How many cases of sputum positive tuberculosis patients had no persistent cough?",
        "question_pt":"Quantos casos de pacientes com tuberculose com escarro n\u00e3o tiveram tosse persistente?"
    },
    {
        "answer":"over half",
        "answer_pt":"mais da metade",
        "id":"3031",
        "question":"How many tuberculosis patients in Shandong were over 65 years old?",
        "question_pt":"Quantos pacientes com tuberculose em Shandong tinham mais de 65 anos?"
    },
    {
        "answer":"cysteine proteases",
        "answer_pt":"proteases de ciste\u00edna",
        "id":"3041",
        "question":"What enzymes have been reported to be linked with severity of infection and various pathological conditions caused by microorganisms?",
        "question_pt":"Quais enzimas foram relatadas como estando relacionadas \u00e0 gravidade da infec\u00e7\u00e3o e a v\u00e1rias condi\u00e7\u00f5es patol\u00f3gicas causadas por microorganismos?"
    },
    {
        "answer":"32uC, 37uC, 42uC",
        "answer_pt":"32uC, 37uC, 42uC",
        "id":"3042",
        "question":"At what temperatures was the assay completed?",
        "question_pt":"A que temperatura o ensaio foi conclu\u00eddo?"
    },
    {
        "answer":"Lipinski's ''Rule of five''",
        "answer_pt":"Regra dos cinco de Lipinski",
        "id":"3043",
        "question":"What criteria sets the guideline for drug-like properties?",
        "question_pt":"Quais crit\u00e9rios definem as diretrizes para propriedades semelhantes a medicamentos?"
    },
    {
        "answer":"1-substituted pyridylimidazo[1,5-a]pyridine derivatives",
        "answer_pt":"Derivados de piridilimidazo [1,5-a] piridina 1-substitu\u00eddos",
        "id":"3044",
        "question":"What could be novel candidates as potent inhibitors of papain like cysteine proteases in resistant microorganisms?",
        "question_pt":"O que poderiam ser novos candidatos como inibidores potentes da papa\u00edna, como as proteases da ciste\u00edna em microorganismos resistentes?"
    },
    {
        "answer":"Intranasal",
        "answer_pt":"Intranasal",
        "id":"1612",
        "question":"What method is useful in administering small molecules for systemic delivery to the body?",
        "question_pt":"Que m\u00e9todo \u00e9 \u00fatil na administra\u00e7\u00e3o de pequenas mol\u00e9culas para entrega sist\u00eamica ao corpo?"
    },
    {
        "answer":"the surface area can result in rapid absorption of the medication into the blood",
        "answer_pt":"a \u00e1rea da superf\u00edcie pode resultar em r\u00e1pida absor\u00e7\u00e3o do medicamento no sangue",
        "id":"1615",
        "question":"Why is the nasal mucosa useful in the delivery of small molecules into the body?",
        "question_pt":"Por que a mucosa nasal \u00e9 \u00fatil na libera\u00e7\u00e3o de pequenas mol\u00e9culas no corpo?"
    },
    {
        "answer":"Metered dose inhalers (MDIs) and dry powder inhalers (DPIs)",
        "answer_pt":"Inaladores de dose medida (MDIs) e inaladores de p\u00f3 seco (DPIs)",
        "id":"1616",
        "question":"What are the most common methods of inhaled delivery of medications?",
        "question_pt":"Quais s\u00e3o os m\u00e9todos mais comuns de administra\u00e7\u00e3o inalat\u00f3ria de medicamentos?"
    },
    {
        "answer":"insulin [39] and low-molecular-weight heparin [40]",
        "answer_pt":"insulina [39] e heparina de baixo peso molecular [40]",
        "id":"1617",
        "question":"What medications have shown good promise to in vivo delivery via dry powder inhalers?",
        "question_pt":"Quais medicamentos mostraram boa promessa para entrega in vivo atrav\u00e9s de inaladores de p\u00f3 seco?"
    },
    {
        "answer":"intratracheal or intranasal delivery",
        "answer_pt":"parto intratraqueal ou intranasal",
        "id":"1618",
        "question":"How are siRNAs typically delivered for systemic effect?",
        "question_pt":"Como os siRNAs s\u00e3o normalmente fornecidos para efeito sist\u00eamico?"
    },
    {
        "answer":"respiratory bronchioles, alveolar ducts, and alveolar sacs",
        "answer_pt":"bronqu\u00edolos respirat\u00f3rios, ductos alveolares e sacos alveolares",
        "id":"1619",
        "question":"What structures form the human airway?",
        "question_pt":"Quais estruturas formam as vias a\u00e9reas humanas?"
    },
    {
        "answer":"1-5 \u03bcm",
        "answer_pt":"1-5 \u03bcm",
        "id":"1620",
        "question":"What size of particle has been shown to be most effective in the delivery to the lower airway?",
        "question_pt":"Qual o tamanho da part\u00edcula demonstrou ser mais eficaz na administra\u00e7\u00e3o das vias a\u00e9reas inferiores?"
    },
    {
        "answer":"delivered to their site of action, be stable, enter the target cells, and be present in the cytoplasm at sufficient concentration",
        "answer_pt":"entregue no local de a\u00e7\u00e3o, seja est\u00e1vel, entre nas c\u00e9lulas-alvo e esteja presente no citoplasma em concentra\u00e7\u00e3o suficiente",
        "id":"1621",
        "question":"What are the essential conditions in siRNA delivery to effectively produce gene silencing in the lungs?",
        "question_pt":"Quais s\u00e3o as condi\u00e7\u00f5es essenciais na entrega do siRNA para produzir efetivamente o silenciamento de genes nos pulm\u00f5es?"
    },
    {
        "answer":"27,534 nucleotides",
        "answer_pt":"27.534 nucleot\u00eddeos",
        "id":"1622",
        "question":"How long is the SAIBK gene?",
        "question_pt":"Quanto tempo dura o gene SAIBK?"
    },
    {
        "answer":"10",
        "answer_pt":"10",
        "id":"1623",
        "question":"How many open reading frames are in the SAIBK gene?",
        "question_pt":"Quantos quadros de leitura abertos est\u00e3o no gene SAIBK?"
    },
    {
        "answer":"Chinese IBV strain SC021202",
        "answer_pt":"Estirpe IBV chinesa SC021202",
        "id":"1624",
        "question":"What virus has the closest genetic identity with the SAIBK gene?",
        "question_pt":"Qual v\u00edrus tem a identidade gen\u00e9tica mais pr\u00f3xima do gene SAIBK?"
    },
    {
        "answer":"an estimated 7.3 billion",
        "answer_pt":"estimados 7,3 bilh\u00f5es",
        "id":"257",
        "question":"How many surgical masks or respirators have past studies projected will be required for a pandemic in the United States?",
        "question_pt":"Quantas m\u00e1scaras cir\u00fargicas ou respiradores os estudos anteriores projetados ser\u00e3o necess\u00e1rios para uma pandemia nos Estados Unidos?"
    },
    {
        "answer":"Middle East respiratory syndrome coronavirus",
        "answer_pt":"Coronav\u00edrus da s\u00edndrome respirat\u00f3ria no Oriente M\u00e9dio",
        "id":"248",
        "question":"What is the acronym MERS-CoV?",
        "question_pt":"Qual \u00e9 o acr\u00f4nimo MERS-CoV?"
    },
    {
        "answer":"Transmissibility and severity",
        "answer_pt":"Transmissibilidade e severidade",
        "id":"249",
        "question":"What are the critical factors that determine the effect of an epidemic?",
        "question_pt":"Quais s\u00e3o os fatores cr\u00edticos que determinam o efeito de uma epidemia?"
    },
    {
        "answer":"January 30, 2020",
        "answer_pt":"30 de janeiro de 2020",
        "id":"250",
        "question":"When did the World Health Organization (WHO) officially declare the 2019-nCoV epidemic as a Public Health Emergency of International Concern?",
        "question_pt":"Quando a Organiza\u00e7\u00e3o Mundial da Sa\u00fade (OMS) declarou oficialmente a epidemia de 2019-nCoV como uma emerg\u00eancia de sa\u00fade p\u00fablica de interesse internacional?"
    },
    {
        "answer":"H7N9",
        "answer_pt":"H7N9",
        "id":"251",
        "question":"What influenza virus was identified in China in 2013?",
        "question_pt":"Qual v\u00edrus influenza foi identificado na China em 2013?"
    },
    {
        "answer":"After a new influenza virus (H7N9) was identified in China in 2013, a series of modeling articles described the effect of, and level of preparedness for, a severe, single-wave pandemic in the United States.",
        "answer_pt":"Depois que um novo v\u00edrus influenza (H7N9) foi identificado na China em 2013, uma s\u00e9rie de artigos de modelagem descreveu o efeito e o n\u00edvel de prepara\u00e7\u00e3o para uma pandemia grave de onda \u00fanica nos Estados Unidos.",
        "id":"252",
        "question":"What past research has been done on severe, single-wave pandemics?",
        "question_pt":"Que pesquisas anteriores foram feitas sobre pandemias graves de onda \u00fanica?"
    },
    {
        "answer":"the proportion of individuals who become ill with or die from a disease in a population initially uninfected",
        "answer_pt":"a propor\u00e7\u00e3o de indiv\u00edduos que adoecem ou morrem de uma doen\u00e7a em uma popula\u00e7\u00e3o inicialmente n\u00e3o infectada",
        "id":"253",
        "question":"What is a clinical attack rate?",
        "question_pt":"O que \u00e9 uma taxa de ataque cl\u00ednico?"
    },
    {
        "answer":"20%",
        "answer_pt":"20%",
        "id":"254",
        "question":"What was the clinical attack rate in the 2009 H1N1 pandemic?",
        "question_pt":"Qual foi a taxa de ataque cl\u00ednico na pandemia de H1N1 de 2009?"
    },
    {
        "answer":"2.2",
        "answer_pt":"2.2",
        "id":"255",
        "question":"What is the estimated R0 of COVID-19?",
        "question_pt":"Qual \u00e9 o R0 estimado do COVID-19?"
    },
    {
        "answer":"35\u202f000 to 60\u202f000",
        "answer_pt":"35000 a 60000",
        "id":"1657",
        "question":"How many ventilators have past studies projected will be required for a pandemic in the United States?\n",
        "question_pt":"Quantos ventiladores os estudos anteriores projetados ser\u00e3o necess\u00e1rios para uma pandemia nos Estados Unidos?"
    },
    {
        "answer":"the isolation of respiratory viruses",
        "answer_pt":"o isolamento de v\u00edrus respirat\u00f3rios",
        "id":"5193",
        "question":"How is exhaled breath condensate used in viral research?",
        "question_pt":"Como o condensado da respira\u00e7\u00e3o exalada \u00e9 usado na pesquisa viral?"
    },
    {
        "answer":"102",
        "answer_pt":"102",
        "id":"5194",
        "question":"How many patients were i this study?",
        "question_pt":"Quantos pacientes foram este estudo?"
    },
    {
        "answer":"EBC collection using the RTube\u2122 is not reliable for diagnosis of respiratory infections",
        "answer_pt":"A coleta de hem\u00e1cias usando o RTube \u2122 n\u00e3o \u00e9 confi\u00e1vel para o diagn\u00f3stico de infec\u00e7\u00f5es respirat\u00f3rias",
        "id":"5195",
        "question":"What was the conclusion of this study?",
        "question_pt":"Qual foi a conclus\u00e3o deste estudo?"
    },
    {
        "answer":"10 minutes",
        "answer_pt":"10 minutos",
        "id":"5196",
        "question":"How long did the patient breath into the RTube?",
        "question_pt":"Por quanto tempo o paciente respirou no RTube?"
    },
    {
        "answer":"denaturation step",
        "answer_pt":"etapa de desnatura\u00e7\u00e3o",
        "id":"5197",
        "question":"What followed the reverse transcription step in the analysis?",
        "question_pt":"O que seguiu a etapa de transcri\u00e7\u00e3o reversa na an\u00e1lise?"
    },
    {
        "answer":"amplification step",
        "answer_pt":"etapa de amplifica\u00e7\u00e3o",
        "id":"5198",
        "question":"What was the last step in the analysis?",
        "question_pt":"Qual foi o \u00faltimo passo na an\u00e1lise?"
    },
    {
        "answer":"52%",
        "answer_pt":"52%",
        "id":"5199",
        "question":"What percentage of the patients were between 20 and 30 years old in this study?",
        "question_pt":"Qual a porcentagem de pacientes entre 20 e 30 anos neste estudo?"
    },
    {
        "answer":"easy to perform and can be conducted in a home environment",
        "answer_pt":"f\u00e1cil de executar e pode ser conduzido em um ambiente dom\u00e9stico",
        "id":"5200",
        "question":"Why is EBC an attractive method for screening?",
        "question_pt":"Por que a EBC \u00e9 um m\u00e9todo atraente para a triagem?"
    },
    {
        "answer":"Pneumonia remains the leading cause of death in children outside the neonatal period,",
        "answer_pt":"A pneumonia continua sendo a principal causa de morte em crian\u00e7as fora do per\u00edodo neonatal,",
        "id":"502",
        "question":"What is the leading cause of death among children after the age of 1 month?",
        "question_pt":"Qual \u00e9 a principal causa de morte entre crian\u00e7as ap\u00f3s 1 m\u00eas de idade?"
    },
    {
        "answer":"New conjugate vaccines against Haemophilus influenzae type b and Streptococcus pneumoniae have contributed to decreases in radiologic, clinical and complicated pneumonia cases",
        "answer_pt":"Novas vacinas conjugadas contra Haemophilus influenzae tipo be Streptococcus pneumoniae contribu\u00edram para a diminui\u00e7\u00e3o de casos radiol\u00f3gicos, cl\u00ednicos e complicados de pneumonia",
        "id":"504",
        "question":"How has the number  of  childhood pneumonia been reduced?",
        "question_pt":"Como foi reduzido o n\u00famero de pneumonia infantil?"
    },
    {
        "answer":" approximately 900,000 of the estimated 6.3 million child deaths in 2013 ",
        "answer_pt":"aproximadamente 900.000 das 6,3 milh\u00f5es de mortes infantis estimadas em 2013",
        "id":"507",
        "question":"What percentage of childhood deaths are due to  pneumonia?",
        "question_pt":"Qual a porcentagem de mortes na inf\u00e2ncia devido a pneumonia?"
    },
    {
        "answer":"global childhood population from 605 million in 2000 to 664 million in 2015 ",
        "answer_pt":"popula\u00e7\u00e3o mundial infantil de 605 milh\u00f5es em 2000 para 664 milh\u00f5es em 2015",
        "id":"510",
        "question":"How has the childhood population grown in the last two  decades?",
        "question_pt":"Como a popula\u00e7\u00e3o infantil cresceu nas \u00faltimas duas d\u00e9cadas?"
    },
    {
        "answer":"Recent data suggest that there has been a 25% decrease in the incidence of pneumonia, from 0.29 episodes per child year in low-and middle-income countries in 2000, to 0.22 episodes per child year in 2010 [3] . This is substantiated by a 58% decrease in pneumonia-associated disability-adjusted life years between 1990 and 2013, from 186 million to 78 million ",
        "answer_pt":"Dados recentes sugerem que houve uma diminui\u00e7\u00e3o de 25% na incid\u00eancia de pneumonia, de 0,29 epis\u00f3dios por ano-crian\u00e7a em pa\u00edses de baixa e m\u00e9dia renda em 2000, para 0,22 epis\u00f3dios por ano-crian\u00e7a em 2010 [3]. Isso \u00e9 comprovado por uma diminui\u00e7\u00e3o de 58% nos anos de vida ajustados \u00e0 incapacidade associados \u00e0 pneumonia entre 1990 e 2013, de 186 para 78 milh\u00f5es",
        "id":"511",
        "question":"What is the reduction in the number of childhood pneumonia cases?",
        "question_pt":"Qual \u00e9 a redu\u00e7\u00e3o no n\u00famero de casos de pneumonia infantil?"
    },
    {
        "answer":"Pneumonia deaths decreased from 1.8 million in 2000 to 900,000 in 2013",
        "answer_pt":"As mortes por pneumonia diminu\u00edram de 1,8 milh\u00f5es em 2000 para 900.000 em 2013",
        "id":"512",
        "question":"How much  is the reduction in the childhood pneumonia deaths?",
        "question_pt":"Quanto \u00e9 a redu\u00e7\u00e3o nas mortes por pneumonia infantil?"
    },
    {
        "answer":"The incidence in high-income countries is estimated at 0.015 episodes per child year, compared to 0.22 episodes per child year in low-and middle-income countries [3] . On average, 1 in 66 children in high-income countries is affected by pneumonia per year, compared to 1 in 5 children in low-and middle-income countries.",
        "answer_pt":"A incid\u00eancia em pa\u00edses de alta renda \u00e9 estimada em 0,015 epis\u00f3dios por ano-crian\u00e7a, em compara\u00e7\u00e3o com 0,22 epis\u00f3dios por ano-crian\u00e7a em pa\u00edses de baixa e m\u00e9dia renda [3]. Em m\u00e9dia, 1 em 66 crian\u00e7as em pa\u00edses de alta renda \u00e9 afetada por pneumonia por ano, em compara\u00e7\u00e3o com 1 em cada 5 crian\u00e7as em pa\u00edses de baixa e m\u00e9dia renda.",
        "id":"513",
        "question":"Childhood pneumonia rate for  high income countries vs low and middle income countries.",
        "question_pt":"Taxa de pneumonia infantil em pa\u00edses de alta renda versus pa\u00edses de baixa e m\u00e9dia renda."
    },
    {
        "answer":"up to 81% of severe pneumonia deaths occur outside a hospital ",
        "answer_pt":"at\u00e9 81% das mortes graves por pneumonia ocorrem fora de um hospital",
        "id":"514",
        "question":"What  percentage of childhood pneumonia deaths occur outside hospital in low and middle  income countries?",
        "question_pt":"Que porcentagem de mortes por pneumonia infantil ocorre fora do hospital em pa\u00edses de baixa e m\u00e9dia renda?"
    },
    {
        "answer":"the case fatality rate is estimated to be almost 10-fold higher in low-and middle-income countries as compared to high-income countries",
        "answer_pt":"estima-se que a taxa de letalidade seja quase 10 vezes maior nos pa\u00edses de baixa e m\u00e9dia renda em compara\u00e7\u00e3o aos pa\u00edses de alta renda",
        "id":"515",
        "question":"Case Fatality Rates for Childhood Pneumonia in high income vs low and middle income countries.",
        "question_pt":"Taxas de mortalidade por casos de pneumonia infantil em pa\u00edses de alta renda versus baixa e m\u00e9dia renda."
    },
    {
        "answer":"Early life pneumonia can impair longterm lung health by decreasing lung function [6] . Severe or recurrent pneumonia can have a worse effect on lung function; increasing evidence suggests that chronic obstructive pulmonary disease might be related to early childhood pneumonia",
        "answer_pt":"A pneumonia no in\u00edcio da vida pode prejudicar a sa\u00fade pulmonar a longo prazo, diminuindo a fun\u00e7\u00e3o pulmonar [6]. Pneumonia grave ou recorrente pode ter um efeito pior na fun\u00e7\u00e3o pulmonar; evid\u00eancias crescentes sugerem que a doen\u00e7a pulmonar obstrutiva cr\u00f4nica pode estar relacionada \u00e0 pneumonia na primeira inf\u00e2ncia",
        "id":"516",
        "question":"How can childhood pneumonia affect the subsequent health of a person?",
        "question_pt":"Como a pneumonia infantil afeta a sa\u00fade subsequente de uma pessoa?"
    },
    {
        "answer":"The risk of developing at least one of the major sequelae was estimated as 6% after an ambulatory pneumonia event and 14% after an episode of hospitalized pneumonia.",
        "answer_pt":"O risco de desenvolver pelo menos uma das principais sequelas foi estimado em 6% ap\u00f3s um evento de pneumonia ambulatorial e 14% ap\u00f3s um epis\u00f3dio de pneumonia hospitalizada.",
        "id":"517",
        "question":"What is the increase in the risk of respiratory disease after having childhood pneumonia.",
        "question_pt":"Qual \u00e9 o aumento do risco de doen\u00e7a respirat\u00f3ria ap\u00f3s pneumonia infantil?"
    },
    {
        "answer":"Chest radiologic changes have been considered the gold standard for defining a pneumonia event",
        "answer_pt":"As altera\u00e7\u00f5es radiol\u00f3gicas do t\u00f3rax t\u00eam sido consideradas o padr\u00e3o-ouro na defini\u00e7\u00e3o de um evento de pneumonia",
        "id":"518",
        "question":"Which is the best method to identify pneumonia in a person?",
        "question_pt":"Qual \u00e9 o melhor m\u00e9todo para identificar pneumonia em uma pessoa?"
    },
    {
        "answer":"Widespread use of pneumococcal conjugate vaccination and Haemophilus influenzae type B conjugate vaccination has decreased the incidence of radiologic pneumonia.",
        "answer_pt":"O uso generalizado da vacina\u00e7\u00e3o conjugada pneumoc\u00f3cica e da vacina contra o Haemophilus influenzae tipo B diminuiu a incid\u00eancia de pneumonia radiol\u00f3gica.",
        "id":"520",
        "question":"What is responsible for the reduction of radiologic pneumonia?",
        "question_pt":"O que \u00e9 respons\u00e1vel pela redu\u00e7\u00e3o da pneumonia radiol\u00f3gica?"
    },
    {
        "answer":"Haemophilus influenzae type B conjugate vaccination in high-burden communities, the vaccination was associated with an 18% decrease in radiologic pneumonia [13] . Introduction of pneumococcal conjugate vaccination was associated with a 26% decrease in radiologic pneumonia in California between 1995 and 1998 [14] . In vaccine efficacy trials in low-and middle-income countries, pneumococcal conjugate vaccination reduced radiologic pneumonia by 37% in the Gambia [15] , 25% in South Africa [16] and 26% in the Philippines ",
        "answer_pt":"Vacina\u00e7\u00e3o do Haemophilus influenzae tipo B em comunidades de alto \u00f4nus, a vacina\u00e7\u00e3o foi associada a uma diminui\u00e7\u00e3o de 18% na pneumonia radiol\u00f3gica [13]. A introdu\u00e7\u00e3o da vacina\u00e7\u00e3o pneumoc\u00f3cica conjugada foi associada a uma diminui\u00e7\u00e3o de 26% na pneumonia radiol\u00f3gica na Calif\u00f3rnia entre 1995 e 1998 [14]. Nos ensaios de efic\u00e1cia da vacina em pa\u00edses de baixa e m\u00e9dia renda, a vacina\u00e7\u00e3o pneumoc\u00f3cica conjugada reduziu a pneumonia radiol\u00f3gica em 37% na G\u00e2mbia [15], 25% na \u00c1frica do Sul [16] e 26% nas Filipinas",
        "id":"521",
        "question":"What is the percentage reduction in pneumonia cases due to  vaccination?",
        "question_pt":"Qual \u00e9 a redu\u00e7\u00e3o percentual nos casos de pneumonia devido \u00e0 vacina\u00e7\u00e3o?"
    },
    {
        "answer":" A revised case definition of \"presumed bacterial pneumonia\" has been introduced, and this definition includes pneumonia cases with WHO-defined alveolar consolidation, as well as those with other abnormal chest radiograph infiltrates and a serum C-reactive protein of at least 40 mg/L ",
        "answer_pt":"Foi introduzida uma defini\u00e7\u00e3o revisada de caso de \"pneumonia bacteriana presumida\" e essa defini\u00e7\u00e3o inclui casos de pneumonia com consolida\u00e7\u00e3o alveolar definida pela OMS, bem como aqueles com outros infiltrados anormais de radiografia de t\u00f3rax e uma prote\u00edna C reativa s\u00e9rica de pelo menos 40 mg / eu",
        "id":"522",
        "question":"What is the revised WHO definition of Bacterial Pneumonia?",
        "question_pt":"Qual \u00e9 a defini\u00e7\u00e3o revisada da OMS de Pneumonia bacteriana?"
    },
    {
        "answer":" Using the revised definition, the 10-valent pneumococcal conjugate vaccine (pneumococcal conjugate vaccination-10), had a vaccine efficacy of 22% in preventing presumed bacterial pneumonia in young children in South America [22] , and pneumococcal conjugate vaccination-13 had a vaccine efficacy of 39% in preventing presumed bacterial pneumonia in children older than 16 weeks who were not infected with human immunodeficiency virus (HIV) in South Africa [21]",
        "answer_pt":"Usando a defini\u00e7\u00e3o revisada, a vacina pneumoc\u00f3cica 10-valente conjugada (vacina\u00e7\u00e3o pneumoc\u00f3cica conjugada-10) teve uma efic\u00e1cia de 22% na preven\u00e7\u00e3o de pneumonia bacteriana presumida em crian\u00e7as pequenas na Am\u00e9rica do Sul [22], e a vacina pneumoc\u00f3cica conjugada-13 teve uma efic\u00e1cia da vacina de 39% na preven\u00e7\u00e3o de pneumonia bacteriana presumida em crian\u00e7as com mais de 16 semanas que n\u00e3o foram infectadas pelo v\u00edrus da imunodefici\u00eancia humana (HIV) na \u00c1frica do Sul [21]",
        "id":"524",
        "question":"What is the reduction in bacterial pneumonia under the revised WHO  definition of bacterial pneumonia?",
        "question_pt":"Qual \u00e9 a redu\u00e7\u00e3o na pneumonia bacteriana sob a defini\u00e7\u00e3o revisada da OMS de pneumonia bacteriana?"
    },
    {
        "answer":" An increased incidence of empyema in children was noted in some high-income countries following pneumococcal conjugate vaccination-7 introduction, and this was attributed to pneumococcal serotypes not included in pneumococcal conjugate vaccination-7, especially 3 and 19A",
        "answer_pt":"Observou-se um aumento da incid\u00eancia de empiema em crian\u00e7as em alguns pa\u00edses de alta renda ap\u00f3s a introdu\u00e7\u00e3o da vacina pneumoc\u00f3cica conjugada-7, e isso foi atribu\u00eddo aos sorotipos pneumoc\u00f3cicos n\u00e3o inclu\u00eddos na vacina\u00e7\u00e3o pneumoc\u00f3cica conjugada-7, especialmente 3 e 19A",
        "id":"530",
        "question":"What caused the increase in the  incidence of empyema in children in the recent past?",
        "question_pt":"O que causou o aumento da incid\u00eancia de empiema em crian\u00e7as no passado recente?"
    },
    {
        "answer":"These trends have been reversed since the introduction of pneumococcal conjugate vaccination-13. Data from the United States suggest that empyema decreased by 50% in children younger than 5 years ",
        "answer_pt":"Essas tend\u00eancias foram revertidas desde a introdu\u00e7\u00e3o da vacina pneumoc\u00f3cica conjugada-13. Dados dos Estados Unidos sugerem que o empiema diminuiu 50% em crian\u00e7as menores de 5 anos",
        "id":"532",
        "question":"How have the incidence Empyema been reduced?",
        "question_pt":"Como a incid\u00eancia de empiema foi reduzida?"
    },
    {
        "answer":"chest radiography should not be routinely performed in children with ambulatory pneumonia [31] [32] [33] . Indications for chest radiography include hospitalization, severe hypoxemia or respiratory distress, failed initial antibiotic therapy, or suspicion for other diseases (tuberculosis, inhaled foreign body) or complications. ",
        "answer_pt":"a radiografia de t\u00f3rax n\u00e3o deve ser realizada rotineiramente em crian\u00e7as com pneumonia ambulatorial [31] [32] [33]. As indica\u00e7\u00f5es para radiografia de t\u00f3rax incluem hospitaliza\u00e7\u00e3o, hipoxemia grave ou dificuldade respirat\u00f3ria, antibioticoterapia inicial com falha ou suspeita de outras doen\u00e7as (tuberculose, corpo estranho inalado) ou complica\u00e7\u00f5es.",
        "id":"533",
        "question":"What pneumonia related or chest conditions indicate the need for child radiography?",
        "question_pt":"Que pneumonia ou condi\u00e7\u00f5es tor\u00e1cicas indicam a necessidade de radiografia infantil?"
    },
    {
        "answer":"prior to availability of new conjugate vaccines confirmed S. pneumoniae and H. influenzae type B as the most important bacterial causes of pneumonia, with Staphylococcus aureus and Klebsiella pneumoniae associated with some severe cases. Respiratory syncytial virus was the leading viral cause, identified in 15-40% of pneumonia cases, followed by influenza A and B, parainfluenza, human metapneumovirus and adenovirus",
        "answer_pt":"antes da disponibilidade de novas vacinas conjugadas confirmaram S. pneumoniae e H. influenzae tipo B como as causas bacterianas mais importantes da pneumonia, com Staphylococcus aureus e Klebsiella pneumoniae associados a alguns casos graves. O v\u00edrus sincicial respirat\u00f3rio foi a principal causa viral, identificada em 15-40% dos casos de pneumonia, seguida pela influenza A e B, parainfluenza, metapneumov\u00edrus humano e adenov\u00edrus",
        "id":"534",
        "question":"What chest diseases and pneumonia were identified as leading causes prior to  the availability of vaccines?",
        "question_pt":"Quais doen\u00e7as no peito e pneumonia foram identificadas como principais causas antes da disponibilidade de vacinas?"
    },
    {
        "answer":"Because pertussis immunity after acellular pertussis vaccination is less long-lasting than immunity after wild-type infection or whole-cell vaccination, many women of child-bearing age have waning pertussis antibody levels. ",
        "answer_pt":"Como a imunidade \u00e0 coqueluche ap\u00f3s a vacina\u00e7\u00e3o acelular contra coqueluche \u00e9 menos duradoura do que a imunidade ap\u00f3s infec\u00e7\u00e3o do tipo selvagem ou vacina\u00e7\u00e3o em c\u00e9lulas inteiras, muitas mulheres em idade f\u00e9rtil apresentam n\u00edveis decrescentes de anticorpos contra a coqueluche.",
        "id":"535",
        "question":"Why has pertussis immunity in infants has decreased in infants?",
        "question_pt":"Por que a imunidade \u00e0 coqueluche em beb\u00eas diminuiu em beb\u00eas?"
    },
    {
        "answer":"A recent systematic review of tuberculosis as a comorbidity of childhood pneumonia reported culture-confirmed disease in about 8% of cases [50] . Because intrathoracic tuberculosis disease is only culture-confirmed in a minority of cases, the true burden could be even higher; tuberculosis could therefore be an important contributor to childhood pneumonia incidence and mortality in high-prevalence areas",
        "answer_pt":"Uma revis\u00e3o sistem\u00e1tica recente da tuberculose como uma comorbidade de pneumonia infantil relatou doen\u00e7a confirmada por cultura em cerca de 8% dos casos [50]. Como a doen\u00e7a intrator\u00e1cica da tuberculose \u00e9 apenas confirmada pela cultura em uma minoria de casos, a verdadeira carga pode ser ainda maior; a tuberculose poderia, portanto, ser um importante contribuinte para a incid\u00eancia e mortalidade de pneumonia infantil em \u00e1reas de alta preval\u00eancia",
        "id":"536",
        "question":"What is the effect of childhood tuberculosis in childhood pneumonia?",
        "question_pt":"Qual \u00e9 o efeito da tuberculose infantil na pneumonia infantil?"
    },
    {
        "answer":" incomplete or inadequate vaccination must be considered as a major preventable risk factor for childhood pneumonia. Other risk factors include low birth weight, which is associated with 3.2 times increased odds of severe pneumonia in low-and middle-income countries, and 1.8 times increased odds in high-income countries [51] . Similarly, lack of exclusive breastfeeding for the first 4 months of life increases odds of severe pneumonia by 2.7 times in low-and middle-income countries and 1.3 times in highincome countries. ",
        "answer_pt":"vacina\u00e7\u00e3o incompleta ou inadequada deve ser considerada como um importante fator de risco evit\u00e1vel para pneumonia infantil. Outros fatores de risco incluem baixo peso ao nascer, que est\u00e1 associado a chances 3,2 vezes maiores de pneumonia grave em pa\u00edses de baixa e m\u00e9dia renda, e chances 1,8 vezes maiores em pa\u00edses de alta renda [51]. Da mesma forma, a falta de aleitamento materno exclusivo nos primeiros 4 meses de vida aumenta as chances de pneumonia grave em 2,7 vezes nos pa\u00edses de baixa e m\u00e9dia renda e 1,3 vezes nos pa\u00edses de renda alta.",
        "id":"537",
        "question":"What are the risk factors in childhood pneumonia?",
        "question_pt":"Quais s\u00e3o os fatores de risco na pneumonia infantil?"
    },
    {
        "answer":" Indoor air pollution from use of solid or biomass fuels increases odds of pneumonia by 1.6 times; lack of measles vaccination by the end of the first year of age increases odds of pneumonia by 1.8 times ",
        "answer_pt":"A polui\u00e7\u00e3o do ar no interior do uso de combust\u00edveis s\u00f3lidos ou de biomassa aumenta as chances de pneumonia em 1,6 vezes; falta de vacina\u00e7\u00e3o contra o sarampo at\u00e9 o final do primeiro ano de idade aumenta as chances de pneumonia em 1,8 vezes",
        "id":"538",
        "question":"How does air pollution affect the incidence of childhood pneumonia?",
        "question_pt":"Como a polui\u00e7\u00e3o do ar afeta a incid\u00eancia de pneumonia infantil?"
    },
    {
        "answer":"The single strongest risk factor for pneumonia is HIV infection, which is especially prevalent in children in sub-Saharan Africa. HIV-infected children have 6 times increased odds of developing severe pneumonia or of death compared to HIV-uninfected children",
        "answer_pt":"O \u00fanico fator de risco mais forte para pneumonia \u00e9 a infec\u00e7\u00e3o pelo HIV, que \u00e9 especialmente prevalente em crian\u00e7as na \u00c1frica Subsaariana. Crian\u00e7as infectadas pelo HIV t\u00eam 6 vezes mais chances de desenvolver pneumonia grave ou morte em compara\u00e7\u00e3o com crian\u00e7as n\u00e3o infectadas pelo HIV",
        "id":"539",
        "question":"What is the strongest risk factor for childhood pneumonia?",
        "question_pt":"Qual \u00e9 o fator de risco mais forte para pneumonia infantil?"
    },
    {
        "answer":" By the end of 2015, Haemophilus influenzae type B conjugate vaccination had been introduced in 73 countries, with global coverage estimated at 68%. However, inequities are still apparent among regions: in the Americas coverage is estimated at 90%, while in the Western Pacific it is only 25%. By 2015, pneumococcal conjugate vaccination had been introduced into 54 countries, with global coverage of 35% for three doses of pneumococcal conjugate vaccination for infant populations",
        "answer_pt":"At\u00e9 o final de 2015, a vacina\u00e7\u00e3o conjugada contra o Haemophilus influenzae tipo B havia sido introduzida em 73 pa\u00edses, com cobertura global estimada em 68%. No entanto, as desigualdades ainda s\u00e3o aparentes entre as regi\u00f5es: nas Am\u00e9ricas a cobertura \u00e9 estimada em 90%, enquanto no Pac\u00edfico Ocidental \u00e9 de apenas 25%. At\u00e9 2015, a vacina\u00e7\u00e3o contra pneumococos conjugados havia sido introduzida em 54 pa\u00edses, com cobertura global de 35% para tr\u00eas doses de vacina\u00e7\u00e3o contra pneumococos conjugados para popula\u00e7\u00f5es infantis",
        "id":"540",
        "question":"What is the global coverage of influenza and pneumonia vaccines?",
        "question_pt":"Qual \u00e9 a cobertura global das vacinas contra influenza e pneumonia?"
    },
    {
        "answer":"Influenza vaccination during pregnancy is safe, provides reasonable maternal protection against influenza, and also protects infants for a limited period from confirmed influenza infection (vaccine efficacy 63% in Bangladesh [63] and 50.4% in South Africa [64] ). However as antibody levels drop sharply after birth, infant protection does not persist much beyond 8 weeks",
        "answer_pt":"A vacina\u00e7\u00e3o contra influenza durante a gravidez \u00e9 segura, fornece prote\u00e7\u00e3o materna razo\u00e1vel contra influenza e tamb\u00e9m protege os beb\u00eas por um per\u00edodo limitado de infec\u00e7\u00e3o confirmada por influenza (efic\u00e1cia da vacina em 63% em Bangladesh [63] e 50,4% na \u00c1frica do Sul [64]). No entanto, como os n\u00edveis de anticorpos caem acentuadamente ap\u00f3s o nascimento, a prote\u00e7\u00e3o infantil n\u00e3o persiste muito al\u00e9m de 8 semanas",
        "id":"541",
        "question":"Is influenza vaccination during pregnancy safe? How long does it protect the child?",
        "question_pt":"A vacina\u00e7\u00e3o contra influenza durante a gravidez \u00e9 segura? Quanto tempo protege a crian\u00e7a?"
    },
    {
        "answer":"a rare complication of pneumonia",
        "answer_pt":"uma complica\u00e7\u00e3o rara de pneumonia",
        "id":"923",
        "question":"What is emphyema?",
        "question_pt":"O que \u00e9 enfisema?"
    },
    {
        "answer":"as a dense or fluffy opacity that occupies a portion or whole of a lobe, or the entire lung.",
        "answer_pt":"como uma opacidade densa ou fofa que ocupa uma parte ou todo o lobo ou todo o pulm\u00e3o.",
        "id":"4573",
        "question":"How is the term end point consolidation described  with regard to pneumonia diagnosis?",
        "question_pt":"Como \u00e9 descrito o termo consolida\u00e7\u00e3o de terminal em rela\u00e7\u00e3o ao diagn\u00f3stico de pneumonia?"
    },
    {
        "answer":"rapid spread and high pathogenicity",
        "answer_pt":"propaga\u00e7\u00e3o r\u00e1pida e alta patogenicidade",
        "id":"5217",
        "question":"What factors make H5N1 a worldwide threat to public health?",
        "question_pt":"Quais fatores fazem do H5N1 uma amea\u00e7a mundial \u00e0 sa\u00fade p\u00fablica?"
    },
    {
        "answer":"fever, encephalitis, pneumonia, and severe acute respiratory syndrome (SARS)",
        "answer_pt":"febre, encefalite, pneumonia e s\u00edndrome respirat\u00f3ria aguda grave (SARS)",
        "id":"5218",
        "question":"What are the symptoms of H5N1 infection in humans?",
        "question_pt":"Quais s\u00e3o os sintomas da infec\u00e7\u00e3o pelo H5N1 em humanos?"
    },
    {
        "answer":"zanamivir (Relenza) and oseltamivir (Tamiflu)",
        "answer_pt":"zanamivir (Relenza) e oseltamivir (Tamiflu)",
        "id":"5219",
        "question":"Name some medications used to treat influenza.",
        "question_pt":"Cite alguns medicamentos usados \u200b\u200bpara tratar a gripe."
    },
    {
        "answer":"drug-resistance and frequent antigenic mutation",
        "answer_pt":"resist\u00eancia a drogas e muta\u00e7\u00e3o antig\u00eanica frequente",
        "id":"5220",
        "question":"Why have antiretrovirals medications had limited benefit in treating influenza?",
        "question_pt":"Por que os medicamentos anti-retrovirais tiveram benef\u00edcios limitados no tratamento da gripe?"
    },
    {
        "answer":"effect of EAP against H5N1 influenza infection",
        "answer_pt":"efeito do EAP contra a infec\u00e7\u00e3o pelo v\u00edrus influenza H5N1",
        "id":"5221",
        "question":"What is the focus of the current study?",
        "question_pt":"Qual \u00e9 o foco do presente estudo?"
    },
    {
        "answer":"the anti-H5N1 effects of EAP offer an alternative strategy for developing antiinfluenza agents",
        "answer_pt":"os efeitos anti-H5N1 do EAP oferecem uma estrat\u00e9gia alternativa para o desenvolvimento de agentes anti-influenza",
        "id":"5222",
        "question":"What is the result of the current study?",
        "question_pt":"Qual \u00e9 o resultado do presente estudo?"
    },
    {
        "answer":"enhance the secretion of cytokines and chemokines, such as TNF-, IL-6, IL-8, and IL-12",
        "answer_pt":"aumentar a secre\u00e7\u00e3o de citocinas e quimiocinas, como TNF-, IL-6, IL-8 e IL-12",
        "id":"5223",
        "question":"How do the polysaccharides in plants effect the immune response?",
        "question_pt":"Como os polissacar\u00eddeos nas plantas afetam a resposta imune?"
    },
    {
        "answer":"EAP leaf extract is a prophylactic and immune enhancement agent against H5N1 influenza virus infection",
        "answer_pt":"O extrato foliar de EAP \u00e9 um agente profil\u00e1tico e imunol\u00f3gico contra a infec\u00e7\u00e3o pelo v\u00edrus influenza H5N1",
        "id":"5224",
        "question":"What does this study demonstrate?",
        "question_pt":"O que este estudo demonstra?"
    },
    {
        "answer":"did not provide a survival advantage",
        "answer_pt":"n\u00e3o forneceu uma vantagem de sobreviv\u00eancia",
        "id":"5225",
        "question":"In this study, how did treatment of EAP after infection affect survival?",
        "question_pt":"Neste estudo, como o tratamento da EAP ap\u00f3s a infec\u00e7\u00e3o afetou a sobreviv\u00eancia?"
    },
    {
        "answer":"The most frequently reported viruses include respiratory syncytial virus (RSV), influenza viruses A and B (IAV, IBV), parainfluenza viruses (PIVs), human rhinovirus (HRV) and adenovirus (ADV), ",
        "answer_pt":"Os v\u00edrus relatados com mais frequ\u00eancia incluem v\u00edrus sincicial respirat\u00f3rio (RSV), v\u00edrus influenza A e B (IAV, IBV), v\u00edrus parainfluenza (PIVs), rinov\u00edrus humano (HRV) e adenov\u00edrus (ADV),",
        "id":"550",
        "question":"What viruses have been responsible for most common childhood acute respiratory track infections (ARTI)?",
        "question_pt":"Quais v\u00edrus foram respons\u00e1veis \u200b\u200bpelas infec\u00e7\u00f5es agudas do trato respirat\u00f3rio infantil (ARTI) mais comuns?"
    },
    {
        "answer":"Currently, there are no approved vaccines or medications available for most of the respiratory viruses",
        "answer_pt":"Atualmente, n\u00e3o existem vacinas ou medicamentos aprovados dispon\u00edveis para a maioria dos v\u00edrus respirat\u00f3rios",
        "id":"553",
        "question":"Are there any vaccines against to protect against respiratory viral infections?",
        "question_pt":"Existem vacinas contra para proteger contra infec\u00e7\u00f5es virais respirat\u00f3rias?"
    },
    {
        "answer":"Gammaproteobacteria",
        "answer_pt":"Gammaproteobacteria",
        "id":"544",
        "question":"Which type of bacteria are implicated in carrying genes of drug resistance?",
        "question_pt":"Que tipo de bact\u00e9ria est\u00e1 implicada no transporte de genes de resist\u00eancia a drogas?"
    },
    {
        "answer":"via a common sanitary pipe",
        "answer_pt":"atrav\u00e9s de um tubo sanit\u00e1rio comum",
        "id":"545",
        "question":"What may be a likely cause of sink-to-sink spreading of pathogens in the hospital setting?",
        "question_pt":"O que pode ser uma causa prov\u00e1vel da dissemina\u00e7\u00e3o de pat\u00f3genos de pia para pia no ambiente hospitalar?"
    },
    {
        "answer":"influenza and parainfluenza viruses, RSV, adenovirus, rhinovirus, human metapneumovirus, enterovirus, bocavirus and coronavirus",
        "answer_pt":"v\u00edrus influenza e parainfluenza, RSV, adenov\u00edrus, rinov\u00edrus, metapneumov\u00edrus humano, enterov\u00edrus, bocav\u00edrus e coronav\u00edrus",
        "id":"327",
        "question":"What types of acute respiratory infections can be screened and diagnosed with multiplex PCR?",
        "question_pt":"Que tipos de infec\u00e7\u00f5es respirat\u00f3rias agudas podem ser rastreados e diagnosticados com PCR multiplex?"
    },
    {
        "answer":"Antibodies against foreign antigens are a critical component of the overall immune response and can facilitate pathogen clearance during a primary infection and also protect against subsequent infections.",
        "answer_pt":"Os anticorpos contra ant\u00edgenos estranhos s\u00e3o um componente cr\u00edtico da resposta imune geral e podem facilitar a libera\u00e7\u00e3o de pat\u00f3genos durante uma infec\u00e7\u00e3o prim\u00e1ria e tamb\u00e9m proteger contra infec\u00e7\u00f5es subsequentes.",
        "id":"465",
        "question":"What is the role of antibodies during infection?",
        "question_pt":"Qual \u00e9 o papel dos anticorpos durante a infec\u00e7\u00e3o?"
    },
    {
        "answer":"Dysregulation of the antibody response can lead to an autoimmune disease, malignancy, or enhanced infection. ",
        "answer_pt":"A desregula\u00e7\u00e3o da resposta do anticorpo pode levar a uma doen\u00e7a auto-imune, malignidade ou infec\u00e7\u00e3o aumentada.",
        "id":"467",
        "question":"How can antibodies also create health problems?",
        "question_pt":"Como os anticorpos tamb\u00e9m podem criar problemas de sa\u00fade?"
    },
    {
        "answer":" in the 1970s with the development of hybridoma technology to produce monoclonal antibodies ",
        "answer_pt":"na d\u00e9cada de 1970, com o desenvolvimento da tecnologia de hibridoma para produzir anticorpos monoclonais",
        "id":"474",
        "question":"Which technology  invention produced antibodies that are clones of a unique parent cell?",
        "question_pt":"Qual inven\u00e7\u00e3o de tecnologia produziu anticorpos que s\u00e3o clones de uma c\u00e9lula-m\u00e3e \u00fanica?"
    },
    {
        "answer":"somatic rearrangement during B cell differentiation was responsible for antibody diversification ",
        "answer_pt":"rearranjo som\u00e1tico durante a diferencia\u00e7\u00e3o de c\u00e9lulas B foi respons\u00e1vel pela diversifica\u00e7\u00e3o de anticorpos",
        "id":"476",
        "question":"What mechanism is responsible for the creation of diversified repertoire for antibodies?",
        "question_pt":"Qual mecanismo \u00e9 respons\u00e1vel pela cria\u00e7\u00e3o de repert\u00f3rio diversificado para anticorpos?"
    },
    {
        "answer":"(1) vaccine candidates that elicit protective antibodies; (2) antibodies that prevent disease when given prophylactically; and (3) antibodies that can be given as therapy after the onset of disease.",
        "answer_pt":"(1) candidatos a vacina que provocam anticorpos protetores; (2) anticorpos que previnem a doen\u00e7a quando administrados profilaticamente; e (3) anticorpos que podem ser administrados como terapia ap\u00f3s o in\u00edcio da doen\u00e7a.",
        "id":"478",
        "question":"What  developments have been made possible by the study of B-cell repertoire?",
        "question_pt":"Quais desenvolvimentos foram poss\u00edveis pelo estudo do repert\u00f3rio de c\u00e9lulas B?"
    },
    {
        "answer":"discovery of broadly neutralizing antibodies (bnAbs) that protect against infection across diverse viral isolates has intensified efforts to understand the developmental pathway of the rare B cells that produce these antibodies",
        "answer_pt":"A descoberta de anticorpos amplamente neutralizantes (bnAbs) que protegem contra infec\u00e7\u00f5es em diversos isolados virais intensificou os esfor\u00e7os para entender o caminho do desenvolvimento das c\u00e9lulas B raras que produzem esses anticorpos.",
        "id":"485",
        "question":"What motivates the study of the rare B-cells that produce Broadly Neutralizing Antibodies (bnAb)?",
        "question_pt":"O que motiva o estudo das c\u00e9lulas B raras que produzem anticorpos amplamente neutralizantes (bnAb)?"
    },
    {
        "answer":"For RSV, stabilized versions of the fusion (F) protein in the pre-fusion conformation have led to insights in the B cell's response to infection and has generated potentially safer and more efficacious vaccine candidates",
        "answer_pt":"Para o RSV, vers\u00f5es estabilizadas da prote\u00edna de fus\u00e3o (F) na conforma\u00e7\u00e3o pr\u00e9-fus\u00e3o levaram a insights sobre a resposta da c\u00e9lula B \u00e0 infec\u00e7\u00e3o e geraram candidatos potencialmente mais seguros e eficazes \u00e0 vacina",
        "id":"489",
        "question":"How has the study of B-cells helped the treatment for Respiratory syncytial virus (RSV)?",
        "question_pt":"Como o estudo das c\u00e9lulas B ajudou o tratamento do v\u00edrus sincicial respirat\u00f3rio (VSR)?"
    },
    {
        "answer":"Influenza also performs fusion through the stem region of the hemagglutinin protein, and the identification of B cells that target this relatively conserved site has spurred research on the development of a universal influenza vaccine (",
        "answer_pt":"A gripe tamb\u00e9m realiza a fus\u00e3o atrav\u00e9s da regi\u00e3o-tronco da prote\u00edna hemaglutinina, e a identifica\u00e7\u00e3o de c\u00e9lulas B que visam esse local relativamente conservado estimulou a pesquisa sobre o desenvolvimento de uma vacina universal contra a gripe (",
        "id":"490",
        "question":"How are the studies on B-cells helping the development of a universal influenza vaccine?",
        "question_pt":"Como os estudos sobre c\u00e9lulas B ajudam no desenvolvimento de uma vacina universal contra influenza?"
    },
    {
        "answer":" Rare memory B cells producing antibodies specific for the EBV fusion machinery have been isolated; these can neutralize both B cell and epithelial cell infection (20). A new paradigm in malaria vaccine development is also emerging with the discovery of IgM+ and IgD+ memory B cells targeting the Merozoite Surface Protein 1, that rapidly respond to malaria re-infection",
        "answer_pt":"Foram isoladas c\u00e9lulas B de mem\u00f3ria rara que produzem anticorpos espec\u00edficos para o mecanismo de fus\u00e3o EBV; estes podem neutralizar a infec\u00e7\u00e3o das c\u00e9lulas B e das c\u00e9lulas epiteliais (20). Um novo paradigma no desenvolvimento de vacinas contra a mal\u00e1ria tamb\u00e9m est\u00e1 emergindo com a descoberta de c\u00e9lulas B da mem\u00f3ria IgM + e IgD +, direcionadas \u00e0 prote\u00edna de superf\u00edcie 1 do Merozoite, que responde rapidamente \u00e0 re-infec\u00e7\u00e3o da mal\u00e1ria",
        "id":"494",
        "question":"What role B-cell  play in malaria infection and prevention?",
        "question_pt":"Qual o papel das c\u00e9lulas B na infec\u00e7\u00e3o e preven\u00e7\u00e3o da mal\u00e1ria?"
    },
    {
        "answer":"The study of autoantigen-specific B cells and a detailed analysis of B cell subsets with pathogenic potential in humans could lead to a better understanding of how to prevent and treat autoimmune diseases.",
        "answer_pt":"O estudo de c\u00e9lulas B espec\u00edficas para auto-ant\u00edgeno e uma an\u00e1lise detalhada de subconjuntos de c\u00e9lulas B com potencial patog\u00eanico em humanos podem levar a uma melhor compreens\u00e3o de como prevenir e tratar doen\u00e7as auto-imunes.",
        "id":"497",
        "question":"How can the study of B-cells help in the prevention and treatment of autoimmune diseases?",
        "question_pt":"Como o estudo das c\u00e9lulas B pode ajudar na preven\u00e7\u00e3o e tratamento de doen\u00e7as autoimunes?"
    },
    {
        "answer":"(MERS-CoV) was first isolated in 2012, in a 60-year-old man who died in Jeddah, KSA due to severe acute pneumonia and multiple organ failure",
        "answer_pt":"(MERS-CoV) foi isolado pela primeira vez em 2012, em um homem de 60 anos que morreu em Jeddah, KSA, devido a pneumonia aguda grave e fal\u00eancia de m\u00faltiplos \u00f3rg\u00e3os",
        "id":"557",
        "question":"When was the  Middle East Respiratory Syndrome Coronavirus isolated first?",
        "question_pt":"Quando o Coronav\u00edrus da S\u00edndrome Respirat\u00f3ria do Oriente M\u00e9dio foi isolado pela primeira vez?"
    },
    {
        "answer":"Recent fatality rate (CFR) of 21%",
        "answer_pt":"Taxa de fatalidade recente (CFR) de 21%",
        "id":"558",
        "question":"What is the Case fatality rate for MERS Coronavirus?",
        "question_pt":"Qual \u00e9 a taxa de mortalidade de casos para o coronav\u00edrus MERS?"
    },
    {
        "answer":" MERS-CoV infects males more than females",
        "answer_pt":"MERS-CoV infecta mais homens do que mulheres",
        "id":"559",
        "question":"How does gender influence MERS-COV infection?",
        "question_pt":"Como o g\u00eanero influencia a infec\u00e7\u00e3o por MERS-COV?"
    },
    {
        "answer":"Dromedary camels are the major animal source of MERS-CoV transmission to humans.",
        "answer_pt":"Camelos dromed\u00e1rios s\u00e3o a principal fonte animal de transmiss\u00e3o de MERS-CoV para humanos.",
        "id":"560",
        "question":"Which is the source animal for the MERS-COV?",
        "question_pt":"Qual \u00e9 o animal de origem do MERS-COV?"
    },
    {
        "answer":"median time until death is 11-13 days (range 5-27 days) among severely ill patients",
        "answer_pt":"O tempo m\u00e9dio at\u00e9 a morte \u00e9 de 11 a 13 dias (intervalo de 5 a 27 dias) entre pacientes gravemente doentes",
        "id":"562",
        "question":"What is the median time until death in MERS-COV?",
        "question_pt":"Qual \u00e9 o tempo m\u00e9dio at\u00e9 a morte no MERS-COV?"
    },
    {
        "answer":" incubation period of 16 days with a mean of 5-6 days [",
        "answer_pt":"per\u00edodo de incuba\u00e7\u00e3o de 16 dias, com m\u00e9dia de 5-6 dias [",
        "id":"563",
        "question":"What is the incubation period for MERS-COV?",
        "question_pt":"Qual \u00e9 o per\u00edodo de incuba\u00e7\u00e3o do MERS-COV?"
    },
    {
        "answer":"ere is no specific treatment for MERS-CoV. Like most viral infections, the treatment options are supportive and symptomatic",
        "answer_pt":"N\u00e3o existe tratamento espec\u00edfico para MERS-CoV. Como a maioria das infec\u00e7\u00f5es virais, as op\u00e7\u00f5es de tratamento s\u00e3o favor\u00e1veis \u200b\u200be sintom\u00e1ticas",
        "id":"564",
        "question":"What is the treatment for MERS-COV?",
        "question_pt":"Qual \u00e9 o tratamento para MERS-COV?"
    },
    {
        "answer":"majority of confirmed cases of MERS-CoV were reported among people aged 40 and above",
        "answer_pt":"A maioria dos casos confirmados de MERS-CoV foi relatada entre pessoas com 40 anos ou mais",
        "id":"565",
        "question":"What age group had the most MERS-COV infections?",
        "question_pt":"Qual faixa et\u00e1ria teve mais infec\u00e7\u00f5es por MERS-COV?"
    },
    {
        "answer":"they inhibit cellular DNA/RNA polymerases",
        "answer_pt":"eles inibem polimerases celulares de DNA / RNA",
        "id":"5232",
        "question":"Why are nucleosides analogs used for chemotheraphy?",
        "question_pt":"Por que os an\u00e1logos de nucleos\u00eddeos s\u00e3o usados \u200b\u200bpara quimioterapia?"
    },
    {
        "answer":"gemcitabine",
        "answer_pt":"gemcitabina",
        "id":"5233",
        "question":"What nucleoside analog is the focus of the current study?",
        "question_pt":"Qual an\u00e1logo de nucleos\u00eddeo \u00e9 o foco do presente estudo?"
    },
    {
        "answer":"Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV), Zika virus (ZIKV), HCV, poliovirus (PV), influenza A virus (IAV), HIV, and enteroviruses (EV)",
        "answer_pt":"Coronav\u00edrus com s\u00edndrome respirat\u00f3ria no Oriente M\u00e9dio (MERS-CoV), coronav\u00edrus com s\u00edndrome respirat\u00f3ria aguda grave (SARS-CoV), v\u00edrus Zika (ZIKV), HCV, poliov\u00edrus (PV), v\u00edrus influenza A (IAV), HIV e enterov\u00edrus (EV)",
        "id":"5234",
        "question":"Gemcitabine has been shown to have antiviral activity against which viruses?",
        "question_pt":"Foi demonstrado que a gencitabina possui atividade antiviral contra quais v\u00edrus?"
    },
    {
        "answer":"by targeting the salvage pathway of pyrimidine biosynthesis",
        "answer_pt":"visando a via de resgate da bioss\u00edntese de pirimidina",
        "id":"5235",
        "question":"How does gemcitabine disrupt viral activity?",
        "question_pt":"Como a gemcitabina interrompe a atividade viral?"
    },
    {
        "answer":"its well defined immunological and genetic information, costeffectiveness, and abundant inbred strains and research reagents",
        "answer_pt":"suas informa\u00e7\u00f5es imunol\u00f3gicas e gen\u00e9ticas bem definidas, rela\u00e7\u00e3o custo-benef\u00edcio e cepas consangu\u00edneas abundantes e reagentes de pesquisa",
        "id":"1631",
        "question":"Why are cotton rats considered a strong animal model for biomedical research?",
        "question_pt":"Por que ratos de algod\u00e3o s\u00e3o considerados um forte modelo animal para pesquisa biom\u00e9dica?"
    },
    {
        "answer":"a sandwiched extracellular structure composed of a \u03b2-sheet, \u03b1-helix loop, and a \u03b2-sheet",
        "answer_pt":"uma estrutura extracelular imprensada composta de uma folha \u03b2, loop de h\u00e9lice \u03b1 e uma folha \u03b2",
        "id":"1632",
        "question":"What is the structure of the CD40 Ligand?",
        "question_pt":"Qual \u00e9 a estrutura do ligante CD40?"
    },
    {
        "answer":"it promotes cytokine production, the induction of cell surface co-stimulatory molecules, and facilitates the cross-presentation of antigen by these cells",
        "answer_pt":"promove a produ\u00e7\u00e3o de citocinas, a indu\u00e7\u00e3o de mol\u00e9culas co-estimuladoras da superf\u00edcie celular e facilita a apresenta\u00e7\u00e3o cruzada de ant\u00edgeno por essas c\u00e9lulas",
        "id":"1633",
        "question":"What is the effect of CD40L on Dendritic Cells?",
        "question_pt":"Qual \u00e9 o efeito do CD40L nas c\u00e9lulas dendr\u00edticas?"
    },
    {
        "answer":"it promotes germinal center formation, immunoglobulin (Ig) isotype switching, somatic hypermutation to enhance antigen affinity, and lastly, the formation of long-lived plasma cells and memory B cells",
        "answer_pt":"promove a forma\u00e7\u00e3o do centro germinativo, a mudan\u00e7a do isotipo da imunoglobulina (Ig), a hipermuta\u00e7\u00e3o som\u00e1tica para aumentar a afinidade do ant\u00edgeno e, por \u00faltimo, a forma\u00e7\u00e3o de c\u00e9lulas plasm\u00e1ticas de longa dura\u00e7\u00e3o e c\u00e9lulas B de mem\u00f3ria",
        "id":"1634",
        "question":"What is the effect of CD40L on B Cells?",
        "question_pt":"Qual \u00e9 o efeito do CD40L nas c\u00e9lulas B?"
    },
    {
        "answer":"the average codon usage frequencies in the host genome",
        "answer_pt":"as frequ\u00eancias m\u00e9dias de uso de c\u00f3dons no genoma do host",
        "id":"567",
        "question":"What factor may influence viral replication and gene expression?",
        "question_pt":"Que fator pode influenciar a replica\u00e7\u00e3o viral e a express\u00e3o g\u00eanica?"
    },
    {
        "answer":"mutational pressure and translational selection",
        "answer_pt":"press\u00e3o mutacional e sele\u00e7\u00e3o translacional",
        "id":"566",
        "question":"What accounts for the variation of codon usage among open reading frameworks?",
        "question_pt":"O que explica a varia\u00e7\u00e3o do uso de c\u00f3dons entre estruturas de leitura aberta?"
    },
    {
        "answer":"common cold, pharyngitis, otitis, sinusitis, laryngotracheitis, epiglottitis",
        "answer_pt":"resfriado comum, faringite, otite, sinusite, laringotraque\u00edte, epiglotite",
        "id":"328",
        "question":"What conditions are considered upper respiratory tracts infections?",
        "question_pt":"Quais condi\u00e7\u00f5es s\u00e3o consideradas infec\u00e7\u00f5es do trato respirat\u00f3rio superior?"
    },
    {
        "answer":"bronchitis, pneumonia and bronchiolitis",
        "answer_pt":"bronquite, pneumonia e bronquiolite",
        "id":"329",
        "question":"What conditions are considered lower respiratory tract infections?",
        "question_pt":"Quais condi\u00e7\u00f5es s\u00e3o consideradas infec\u00e7\u00f5es do trato respirat\u00f3rio inferior?"
    },
    {
        "answer":"NK cells (CD3-/CD16+/CD56+)",
        "answer_pt":"C\u00e9lulas NK (CD3- / CD16 + / CD56 +)",
        "id":"330",
        "question":"What immune cells are primarily involved in eliminating virus-infected cells?",
        "question_pt":"Quais c\u00e9lulas imunes est\u00e3o envolvidas principalmente na elimina\u00e7\u00e3o de c\u00e9lulas infectadas por v\u00edrus?"
    },
    {
        "answer":"Excessive reactive oxygen species (ROS)",
        "answer_pt":"Esp\u00e9cies reativas de oxig\u00eanio em excesso (ROS)",
        "id":"331",
        "question":"What molecules have been shown to hinder T cell responses to viral infections?",
        "question_pt":"Que mol\u00e9culas demonstraram dificultar as respostas das c\u00e9lulas T a infec\u00e7\u00f5es virais?"
    },
    {
        "answer":"reactive oxygen species (ROS)",
        "answer_pt":"esp\u00e9cies reativas de oxig\u00eanio (ERO)",
        "id":"332",
        "question":"The accumulation of what molecule hinders phagocytic activity in T cells?",
        "question_pt":"O ac\u00famulo de qual mol\u00e9cula dificulta a atividade fagoc\u00edtica nas c\u00e9lulas T?"
    },
    {
        "answer":"June 30, 2017",
        "answer_pt":"30 de junho de 2017",
        "id":"1592",
        "question":"When did the last Director General of the WHO resign?",
        "question_pt":"Quando o \u00faltimo Diretor-Geral da OMS renunciou?"
    },
    {
        "answer":"to promote, set standards in, and evaluate progress toward better health for people in all countries",
        "answer_pt":"promover, estabelecer padr\u00f5es e avaliar o progresso em dire\u00e7\u00e3o a uma sa\u00fade melhor para as pessoas em todos os pa\u00edses",
        "id":"1593",
        "question":"Why might an organization like the WHO be necessary?",
        "question_pt":"Por que uma organiza\u00e7\u00e3o como a OMS \u00e9 necess\u00e1ria?"
    },
    {
        "answer":"a lowincome or middle-income country",
        "answer_pt":"um pa\u00eds de baixa ou m\u00e9dia renda",
        "id":"1595",
        "question":"Where should the next Director General for the WHO come from?",
        "question_pt":"De onde deve vir o pr\u00f3ximo Diretor-Geral da OMS?"
    },
    {
        "answer":"open-minded and creative",
        "answer_pt":"mente aberta e criativa",
        "id":"1596",
        "question":"What traits should the new Director General of the WHO have?",
        "question_pt":"Quais s\u00e3o as caracter\u00edsticas do novo diretor-geral da OMS?"
    },
    {
        "answer":"enveloped, positive-stranded RNA virus",
        "answer_pt":"v\u00edrus de RNA encapsulado positivo",
        "id":"1625",
        "question":"What is the Hepatitis C virus?",
        "question_pt":"O que \u00e9 o v\u00edrus da hepatite C?"
    },
    {
        "answer":"170 million people worldwide",
        "answer_pt":"170 milh\u00f5es de pessoas em todo o mundo",
        "id":"1626",
        "question":"How many people have persistent hepatitis C virus?",
        "question_pt":"Quantas pessoas t\u00eam o v\u00edrus da hepatite C persistente?"
    },
    {
        "answer":"cirrhosis and hepatocellular carcinoma",
        "answer_pt":"cirrose e carcinoma hepatocelular",
        "id":"1627",
        "question":"What is the long-term risk of chronic hepatitis C infection?",
        "question_pt":"Qual o risco a longo prazo de infec\u00e7\u00e3o cr\u00f4nica pela hepatite C?"
    },
    {
        "answer":"pegylated alpha-interferon and ribavirin",
        "answer_pt":"interfer\u00e3o alfa peguilado e ribavirina",
        "id":"1628",
        "question":"What antiviral treatments are used for hepatitis C infection?",
        "question_pt":"Quais tratamentos antivirais s\u00e3o usados \u200b\u200bpara a infec\u00e7\u00e3o pela hepatite C?"
    },
    {
        "answer":"Calf septicemia",
        "answer_pt":"Septicemia de bezerro",
        "id":"2129",
        "question":"What is the main cause of death in the neonatal period of calves?",
        "question_pt":"Qual \u00e9 a principal causa de morte no per\u00edodo neonatal de bezerros?"
    },
    {
        "answer":"human urine",
        "answer_pt":"urina humana",
        "id":"2131",
        "question":"Where was hepcidin first discovered?",
        "question_pt":"Onde a hepcidina foi descoberta pela primeira vez?"
    },
    {
        "answer":"low molecular weight, antimicrobial peptide hormone",
        "answer_pt":"baixo peso molecular, horm\u00f4nio pept\u00eddico antimicrobiano",
        "id":"2130",
        "question":"What is hepcidin?",
        "question_pt":"O que \u00e9 hepcidina?"
    },
    {
        "answer":"liver",
        "answer_pt":"f\u00edgado",
        "id":"2132",
        "question":"What organ produces hepcidin?",
        "question_pt":"Qual \u00f3rg\u00e3o produz hepcidina?"
    },
    {
        "answer":"inflammatory reactions and high Fe concentrations",
        "answer_pt":"rea\u00e7\u00f5es inflamat\u00f3rias e altas concentra\u00e7\u00f5es de Fe",
        "id":"2133",
        "question":"What stimulates the release of hepcidin?",
        "question_pt":"O que estimula a libera\u00e7\u00e3o de hepcidina?"
    },
    {
        "answer":"Fe",
        "answer_pt":"Fe",
        "id":"2134",
        "question":"What element does hepcidin play a roles in regulating during metabolism?",
        "question_pt":"Que elemento a hepcidina desempenha um papel na regula\u00e7\u00e3o durante o metabolismo?"
    },
    {
        "answer":"potentially toxic",
        "answer_pt":"potencialmente t\u00f3xico",
        "id":"2135",
        "question":"Is hepcidin toxic?",
        "question_pt":"A hepcidina \u00e9 t\u00f3xica?"
    },
    {
        "answer":"bacteria utilize Fe for survival, growth and proliferation",
        "answer_pt":"bact\u00e9rias utilizam Fe para sobreviv\u00eancia, crescimento e prolifera\u00e7\u00e3o",
        "id":"2136",
        "question":"Why is iron critical to bacteria?",
        "question_pt":"Por que o ferro \u00e9 cr\u00edtico para as bact\u00e9rias?"
    },
    {
        "answer":"control of excessive Fe absorption",
        "answer_pt":"controle da absor\u00e7\u00e3o excessiva de Fe",
        "id":"2137",
        "question":"How does hepcidin work in the duodenum?",
        "question_pt":"Como a hepcidina funciona no duodeno?"
    },
    {
        "answer":"regulation of Fe release",
        "answer_pt":"regula\u00e7\u00e3o da libera\u00e7\u00e3o de Fe",
        "id":"2138",
        "question":"How does hepcidin affect macrophages?",
        "question_pt":"Como a hepcidina afeta os macr\u00f3fagos?"
    },
    {
        "answer":"production of ROS",
        "answer_pt":"produ\u00e7\u00e3o de ROS",
        "id":"2139",
        "question":"What leads to oxidative stress in the body?",
        "question_pt":"O que leva ao estresse oxidativo no corpo?"
    },
    {
        "answer":"superoxide dismutase",
        "answer_pt":"superoxido dismuta\u00e7\u00e3o",
        "id":"2140",
        "question":"What parameter is used to measure antioxidant levels?",
        "question_pt":"Qual par\u00e2metro \u00e9 usado para medir os n\u00edveis de antioxidantes?"
    },
    {
        "answer":"a rare form of acute disseminated encephalomyelitis",
        "answer_pt":"uma forma rara de encefalomielite disseminada aguda",
        "id":"3032",
        "question":"What is Acute hemorrhagic encephalomyelitis?",
        "question_pt":"O que \u00e9 encefalomielite hemorr\u00e1gica aguda?"
    },
    {
        "answer":"fulminant encephalopathy with hemorrhagic necrosis",
        "answer_pt":"encefalopatia fulminante com necrose hemorr\u00e1gica",
        "id":"3033",
        "question":"What are the salient findings in Acute hemorrhagic encephalomyelitis?",
        "question_pt":"Quais s\u00e3o os achados marcantes na encefalomielite hemorr\u00e1gica aguda?"
    },
    {
        "answer":"nuclear pore protein",
        "answer_pt":"prote\u00edna de poro nuclear",
        "id":"3034",
        "question":"What is RANBP2?",
        "question_pt":"O que \u00e9 o RANBP2?"
    },
    {
        "answer":"intracellular protein trafficking or energy maintenance and homeostasis of neuronal cells",
        "answer_pt":"tr\u00e1fico intracelular de prote\u00ednas ou manuten\u00e7\u00e3o de energia e homeostase de c\u00e9lulas neuronais",
        "id":"3035",
        "question":"What is the suggested role of RANBP2 in the cell?",
        "question_pt":"Qual \u00e9 o papel sugerido do RANBP2 na c\u00e9lula?"
    },
    {
        "answer":"multiple, symmetric brain lesions located in the thalami bilaterally, putamina, deep periventricular white matter, cerebellum, and brainstem",
        "answer_pt":"les\u00f5es cerebrais m\u00faltiplas e sim\u00e9tricas localizadas no t\u00e1lamo bilateralmente, putamina, subst\u00e2ncia branca periventricular profunda, cerebelo e tronco cerebral",
        "id":"3036",
        "question":"What is the hallmark finding of acute necrotizing encephalopathy?",
        "question_pt":"Qual \u00e9 o achado marcante da encefalopatia necrosante aguda?"
    },
    {
        "answer":"viral infection in previously healthy children",
        "answer_pt":"infec\u00e7\u00e3o viral em crian\u00e7as previamente saud\u00e1veis",
        "id":"3037",
        "question":"What could trigger acute necrotizing encephalopathy?",
        "question_pt":"O que poderia desencadear encefalopatia necrosante aguda?"
    },
    {
        "answer":"1 month later",
        "answer_pt":"1 m\u00eas depois",
        "id":"3038",
        "question":"When did she present with rapidly progressive right-hand weakness?",
        "question_pt":"Quando ela se apresentou com fraqueza rapidamente progressiva na m\u00e3o direita?"
    },
    {
        "answer":"quinazolin-4-one",
        "answer_pt":"quinazolin-4-ona",
        "id":"3039",
        "question":"Compounds from what framework have shown promising anticancer and antiviral properties?",
        "question_pt":"Compostos de qual estrutura mostrou propriedades anticancer\u00edgenas e antivirais promissoras?"
    },
    {
        "answer":"tobacco mosaic virus",
        "answer_pt":"v\u00edrus do mosaico do tabaco",
        "id":"3040",
        "question":"The replication of what virus is strongly inhibited by 2-(4-hydroxybenzyl)quinazolin-4(3H)-one (1)?",
        "question_pt":"A replica\u00e7\u00e3o de qual v\u00edrus \u00e9 fortemente inibido pela 2- (4-hidroxibenzil) quinazolin-4 (3H) -ona (1)?"
    },
    {
        "answer":"11,399",
        "answer_pt":"11.399",
        "id":"3267",
        "question":"How many samples were obtained?",
        "question_pt":"Quantas amostras foram obtidas?"
    },
    {
        "answer":"49.2%",
        "answer_pt":"49,2%",
        "id":"3268",
        "question":"What percentage of patients were positive for at least one respiratory pathogen?",
        "question_pt":"Qual a porcentagem de pacientes positivos para pelo menos um pat\u00f3geno respirat\u00f3rio?"
    },
    {
        "answer":"2.2%",
        "answer_pt":"2,2%",
        "id":"3269",
        "question":"What percentage of patients tested positive for HBoV1?",
        "question_pt":"Qual a porcentagem de pacientes com resultado positivo para HBoV1?"
    },
    {
        "answer":"2005",
        "answer_pt":"2005",
        "id":"3270",
        "question":"When was HBoV1 first identified?",
        "question_pt":"Quando o HBoV1 foi identificado pela primeira vez?"
    },
    {
        "answer":"cough, rhinitis, fever",
        "answer_pt":"tosse, rinite, febre",
        "id":"3271",
        "question":"What are the symptoms of HBoV1 infection?",
        "question_pt":"Quais s\u00e3o os sintomas da infec\u00e7\u00e3o por HBoV1?"
    },
    {
        "answer":"\u226414 years old",
        "answer_pt":"\u2264 14 anos",
        "id":"3272",
        "question":"What are the ages of the patients in this study?",
        "question_pt":"Quais s\u00e3o as idades dos pacientes neste estudo?"
    },
    {
        "answer":"1.82:1",
        "answer_pt":"1,82: 1",
        "id":"3273",
        "question":"What was the male to female ratio for this study?",
        "question_pt":"Qual foi a propor\u00e7\u00e3o de homens para mulheres neste estudo?"
    },
    {
        "answer":"Human metapneumovirus (HMPV)",
        "answer_pt":"Metapneumov\u00edrus humano (HMPV)",
        "id":"4059",
        "question":"What causes acute respiratory illness in young children?",
        "question_pt":"O que causa doen\u00e7as respirat\u00f3rias agudas em crian\u00e7as pequenas?"
    },
    {
        "answer":"single-stranded RNA virus",
        "answer_pt":"v\u00edrus RNA de fita simples",
        "id":"4060",
        "question":"What is the molecular structure of the Human metapneumovirus (HMPV)?",
        "question_pt":"Qual \u00e9 a estrutura molecular do metapneumov\u00edrus humano (HMPV)?"
    },
    {
        "answer":"Human metapneumovirus (HMPV)",
        "answer_pt":"Metapneumov\u00edrus humano (HMPV)",
        "id":"4061",
        "question":"What virus is closely related to the human respiratory syncytial virus (RSV)?",
        "question_pt":"Qual v\u00edrus est\u00e1 intimamente relacionado ao v\u00edrus sincicial respirat\u00f3rio humano (RSV)?"
    },
    {
        "answer":"mild upper respiratory infection to bronchiolitis and pneumonia",
        "answer_pt":"infec\u00e7\u00e3o respirat\u00f3ria superior leve a bronquiolite e pneumonia",
        "id":"4062",
        "question":"What diseases are caused by HMPV?",
        "question_pt":"Quais doen\u00e7as s\u00e3o causadas pelo HMPV?"
    },
    {
        "answer":"13 kb",
        "answer_pt":"13 kb",
        "id":"4063",
        "question":"How large is the HMPV genome?",
        "question_pt":"Qual \u00e9 o tamanho do genoma do HMPV?"
    },
    {
        "answer":"eight",
        "answer_pt":"oito",
        "id":"4064",
        "question":"How many open reading frames are in the HMPV genome?",
        "question_pt":"Quantos quadros de leitura abertos existem no genoma do HMPV?"
    },
    {
        "answer":"A and B",
        "answer_pt":"A e B",
        "id":"4065",
        "question":"What are the two major genotypes of HMPV?",
        "question_pt":"Quais s\u00e3o os dois principais gen\u00f3tipos do HMPV?"
    },
    {
        "answer":"HMPV A2",
        "answer_pt":"HMPV A2",
        "id":"4066",
        "question":"What is the most common subgroup of HMPV?",
        "question_pt":"Qual \u00e9 o subgrupo mais comum de HMPV?"
    },
    {
        "answer":"children under 6 months of age",
        "answer_pt":"crian\u00e7as menores de 6 meses de idade",
        "id":"4067",
        "question":"Who accounted for 44% of HMPV positive cases in Kenya between 2007 and 2011?",
        "question_pt":"Quem foi respons\u00e1vel por 44% dos casos positivos de HMPV no Qu\u00eania entre 2007 e 2011?"
    },
    {
        "answer":"a whole genome sequencing (WGS) approach for HMPV",
        "answer_pt":"uma abordagem de sequenciamento do genoma inteiro (WGS) para HMPV",
        "id":"4068",
        "question":"What does this study describe?",
        "question_pt":"O que este estudo descreve?"
    },
    {
        "answer":"The length of the F-M2 intergenic region",
        "answer_pt":"O comprimento da regi\u00e3o interg\u00eanica F-M2",
        "id":"4069",
        "question":"What was the difference in the group A and B genomes?",
        "question_pt":"Qual foi a diferen\u00e7a nos genomas dos grupos A e B?"
    },
    {
        "answer":" to comprehensively investigate the viral epidemiology of adult RTIs",
        "answer_pt":"investigar de forma abrangente a epidemiologia viral de ITRs de adultos",
        "id":"4077",
        "question":"What was the purpose of this study?",
        "question_pt":"Qual foi o objetivo deste estudo?"
    },
    {
        "answer":"27",
        "answer_pt":"27",
        "id":"4078",
        "question":"How many control samples were used in this study?",
        "question_pt":"Quantas amostras de controle foram usadas neste estudo?"
    },
    {
        "answer":"4.1% of cases",
        "answer_pt":"4,1% dos casos",
        "id":"4079",
        "question":"What was the prevalence of coinfection?",
        "question_pt":"Qual foi a preval\u00eancia de co-infec\u00e7\u00e3o?"
    },
    {
        "answer":"parainfluenza infection, old age, and immunosuppression",
        "answer_pt":"infec\u00e7\u00e3o por parainfluenza, velhice e imunossupress\u00e3o",
        "id":"4080",
        "question":"What risks factors were associated with lower RTIs?",
        "question_pt":"Quais fatores de risco foram associados a ITRs mais baixos?"
    },
    {
        "answer":"multilocus polymerase chain reaction coupled with electrospray ionization mass spectrometry",
        "answer_pt":"rea\u00e7\u00e3o em cadeia da polimerase multilocus acoplada \u00e0 espectrometria de massa de ioniza\u00e7\u00e3o por electropulveriza\u00e7\u00e3o",
        "id":"4081",
        "question":"What tests can simultaneously identify and subtype multiple respiratory viruses?",
        "question_pt":"Quais testes podem identificar e subtipos simultaneamente de v\u00e1rios v\u00edrus respirat\u00f3rios?"
    },
    {
        "answer":"corticosteroid treatment, solid organ or hematopoietic stem cell recipient, or chemotherapy for an underlying malignancy during the past 6 months",
        "answer_pt":"tratamento com corticoster\u00f3ide, \u00f3rg\u00e3o s\u00f3lido ou receptor de c\u00e9lulas-tronco hematopoi\u00e9ticas ou quimioterapia para uma malignidade subjacente nos \u00faltimos 6 meses",
        "id":"4082",
        "question":"What was the definition for an immunocompromised state in this study?",
        "question_pt":"Qual foi a defini\u00e7\u00e3o para um estado imunocomprometido neste estudo?"
    },
    {
        "answer":"9-month",
        "answer_pt":"9 meses",
        "id":"4083",
        "question":"What was the length of the study?",
        "question_pt":"Qual foi a dura\u00e7\u00e3o do estudo?"
    },
    {
        "answer":"263",
        "answer_pt":"263",
        "id":"4084",
        "question":"How many patients had acute RTIs?",
        "question_pt":"Quantos pacientes tiveram ITR agudos?"
    },
    {
        "answer":"rhinovirus",
        "answer_pt":"rinov\u00edrus",
        "id":"4085",
        "question":"What was the most frequent coinfection?",
        "question_pt":"Qual foi a coinfec\u00e7\u00e3o mais frequente?"
    },
    {
        "answer":"forbid the display of sheep in the latter third of their pregnancy and require regular testing of animals for C. burnetii in petting zoos",
        "answer_pt":"pro\u00edbem a exibi\u00e7\u00e3o de ovelhas no \u00faltimo ter\u00e7o da gravidez e exigem testes regulares de animais para C. burnetii em zool\u00f3gicos",
        "id":"5201",
        "question":"What health regulations were changes due to the outbreak of C. burnetti?",
        "question_pt":"Quais regulamentos sanit\u00e1rios foram alterados devido ao surto de C. burnetii?"
    },
    {
        "answer":"1%",
        "answer_pt":"1%",
        "id":"5202",
        "question":"What was the median seropresence of C. burnetti in sheep flocks not linked to human outbreaks?",
        "question_pt":"Qual foi a presen\u00e7a sero mediana de C. burnetii em rebanhos ovinos n\u00e3o relacionados a surtos humanos?"
    },
    {
        "answer":"close proximity to the ewe and duration of exposure",
        "answer_pt":"proximidade da ovelha e dura\u00e7\u00e3o da exposi\u00e7\u00e3o",
        "id":"5203",
        "question":"What important risk factors to infection were found during the second case-controlled study?",
        "question_pt":"Quais fatores de risco importantes para a infec\u00e7\u00e3o foram encontrados durante o segundo estudo controlado por caso?"
    },
    {
        "answer":"16 to 24 days",
        "answer_pt":"16 a 24 dias",
        "id":"5204",
        "question":"What was the interquartile range of the incubation period?",
        "question_pt":"Qual foi o intervalo interquartil do per\u00edodo de incuba\u00e7\u00e3o?"
    },
    {
        "answer":"36",
        "answer_pt":"36.",
        "id":"5205",
        "question":"How many controls were used in the second case study?",
        "question_pt":"Quantos controles foram usados \u200b\u200bno segundo estudo de caso?"
    },
    {
        "answer":"farmers' market",
        "answer_pt":"mercado dos fazendeiros",
        "id":"5206",
        "question":"What public event was linked with the outbreak?",
        "question_pt":"Que evento p\u00fablico foi relacionado ao surto?"
    },
    {
        "answer":"Coxiella burnetii (C. burnetii)",
        "answer_pt":"Coxiella burnetii (C. burnetii)",
        "id":"5207",
        "question":"What causes Q fever?",
        "question_pt":"O que causa a febre Q?"
    },
    {
        "answer":"small, gram-negative obligate intracellular bacterium",
        "answer_pt":"bact\u00e9ria intracelular obrigat\u00f3ria gram-negativa",
        "id":"5208",
        "question":"What is Coxiella burnetii?",
        "question_pt":"O que \u00e9 Coxiella burnetii?"
    },
    {
        "answer":"sheep, goat and cattle",
        "answer_pt":"ovinos, caprinos e bovinos",
        "id":"5209",
        "question":"What is the primary reservoir for Coxiella burnetii?",
        "question_pt":"Qual \u00e9 o principal reservat\u00f3rio de Coxiella burnetii?"
    },
    {
        "answer":"inhalation of contaminated aerosols from parturient fluids, placenta or wool",
        "answer_pt":"inala\u00e7\u00e3o de aeross\u00f3is contaminados de fluidos parturientes, placenta ou l\u00e3",
        "id":"5210",
        "question":"How are humans typically infected with Coxiella burnetii?",
        "question_pt":"Como os seres humanos normalmente s\u00e3o infectados com Coxiella burnetii?"
    },
    {
        "answer":"long non-coding RNAs",
        "answer_pt":"RNAs n\u00e3o codificadores longos",
        "id":"3687",
        "question":"What are critical to regulate cellular biological processes?",
        "question_pt":"O que \u00e9 cr\u00edtico para regular os processos biol\u00f3gicos celulares?"
    },
    {
        "answer":"calculate the relatedness of objects with the same or different types",
        "answer_pt":"calcular a rela\u00e7\u00e3o de objetos com os mesmos ou diferentes tipos",
        "id":"3688",
        "question":"How is the HeteSim measured used?",
        "question_pt":"Como o HeteSim \u00e9 medido?"
    },
    {
        "answer":"weighted protein interactions",
        "answer_pt":"intera\u00e7\u00f5es proteicas ponderadas",
        "id":"3689",
        "question":"What kind of data is included in the STRING database?",
        "question_pt":"Que tipo de dados est\u00e1 inclu\u00eddo no banco de dados STRING?"
    },
    {
        "answer":"regulates cell cycle and survival",
        "answer_pt":"regula o ciclo celular e a sobreviv\u00eancia",
        "id":"3690",
        "question":"What is the function of MALAT1?",
        "question_pt":"Qual \u00e9 a fun\u00e7\u00e3o do MALAT1?"
    },
    {
        "answer":"faecal oocyst count reduction test (FOCRT)",
        "answer_pt":"teste de redu\u00e7\u00e3o da contagem de oocistos fecais (FOCRT)",
        "id":"593",
        "question":"What test can detect reduced anticoccidial efficacy in the field?",
        "question_pt":"Que teste pode detectar efic\u00e1cia anticoccidiana reduzida em campo?"
    },
    {
        "answer":"anticoccidial",
        "answer_pt":"anticoccidiano",
        "id":"595",
        "question":"What is toltrazuril used to treat?",
        "question_pt":"O que \u00e9 toltrazuril usado para tratar?"
    },
    {
        "answer":"a rare, sudden onset of unilateral chorioretinopathy",
        "answer_pt":"um in\u00edcio raro e repentino de coriorretinopatia unilateral",
        "id":"581",
        "question":"What is multiple evanescent white dot syndrome?",
        "question_pt":"O que \u00e9 a s\u00edndrome do ponto branco evanescente m\u00faltiplo?"
    },
    {
        "answer":"flu-like illness",
        "answer_pt":"doen\u00e7a semelhante \u00e0 gripe",
        "id":"582",
        "question":"What precedes about half of the reported cases of MEWDS?",
        "question_pt":"O que precede cerca de metade dos casos relatados de MEWDS?"
    },
    {
        "answer":"herpes simplex virus (HSV) I-II, varicella zoster virus (VZV), West Nile virus, coxsackievirus, echovirus (subgroup of enterovirus), and corona virus",
        "answer_pt":"v\u00edrus herpes simplex (HSV) I-II, v\u00edrus varicela zoster (VZV), v\u00edrus do Nilo Ocidental, v\u00edrus coxsackievirus, echov\u00edrus (subgrupo de enterov\u00edrus) e v\u00edrus corona",
        "id":"583",
        "question":"What types of viruses can be diagnosed through serological testing?",
        "question_pt":"Que tipos de v\u00edrus podem ser diagnosticados atrav\u00e9s de testes sorol\u00f3gicos?"
    },
    {
        "answer":"multimodal imaging",
        "answer_pt":"imagem multimodal",
        "id":"584",
        "question":"What type of clinical test can differentiate multiple evanescent white dot syndrome (MEWDS) from optic neuritis?",
        "question_pt":"Que tipo de teste cl\u00ednico pode diferenciar a s\u00edndrome do ponto branco evanescente m\u00faltiplo (MEWDS) da neurite \u00f3ptica?"
    },
    {
        "answer":"Parainfluenza virus 4, respiratory syncytial virus B and enterovirus",
        "answer_pt":"V\u00edrus da parainfluenza 4, v\u00edrus sincicial respirat\u00f3rio B e enterov\u00edrus",
        "id":"1597",
        "question":"What were the most common viruses sampled from nasal swabs in Ilorin, Nigeria",
        "question_pt":"Quais foram os v\u00edrus mais comuns coletados em amostras de swabs nasais em Ilorin, Nig\u00e9ria"
    },
    {
        "answer":"Coronavirus OC43",
        "answer_pt":"Coronavirus OC43",
        "id":"1598",
        "question":"What was the most common virus detected in community members in this sample?",
        "question_pt":"Qual foi o v\u00edrus mais comum detectado nos membros da comunidade nesta amostra?"
    },
    {
        "answer":"2-5 times higher than in developed countries",
        "answer_pt":"2-5 vezes maior do que nos pa\u00edses desenvolvidos",
        "id":"1599",
        "question":"How bad is the burden of disease in developing countries?",
        "question_pt":"Qu\u00e3o grande \u00e9 o \u00f4nus da doen\u00e7a nos pa\u00edses em desenvolvimento?"
    },
    {
        "answer":"Africa",
        "answer_pt":"\u00c1frica",
        "id":"1600",
        "question":"Where do the majority of all infectious disease outbreaks happen?",
        "question_pt":"Onde ocorre a maioria de todos os surtos de doen\u00e7as infecciosas?"
    },
    {
        "answer":"age, sex, overcrowding, nutritional status, socio-economic status, and where study of ARIs is currently limited",
        "answer_pt":"idade, sexo, superlota\u00e7\u00e3o, estado nutricional, status socioecon\u00f4mico e onde atualmente o estudo de IRA \u00e9 limitado",
        "id":"1601",
        "question":"What are some risk factors for countries to experience a high prevalence of Acute Respiratory Infections?",
        "question_pt":"Quais s\u00e3o alguns fatores de risco para os pa\u00edses experimentarem uma alta preval\u00eancia de infec\u00e7\u00f5es respirat\u00f3rias agudas?"
    },
    {
        "answer":"sore throat, fever, couch, running nose, vomiting, body ache, leg pain, nausea, chills, shortness of breath ",
        "answer_pt":"dor de garganta, febre, sof\u00e1, coriza, v\u00f4mito, dor no corpo, dor nas pernas, n\u00e1usea, calafrios, falta de ar",
        "id":"1602",
        "question":"What symptoms are associated with acute respiratory infections?",
        "question_pt":"Quais sintomas est\u00e3o associados a infec\u00e7\u00f5es respirat\u00f3rias agudas?"
    },
    {
        "answer":"Coronavirus OC43",
        "answer_pt":"Coronavirus OC43",
        "id":"1603",
        "question":"What was the most common virus detected in community samples in Ilorin, Nigeria?",
        "question_pt":"Qual foi o v\u00edrus mais comum detectado em amostras da comunidade em Ilorin, Nig\u00e9ria?"
    },
    {
        "answer":"13.3% (95% CI 6.9-23.6%)",
        "answer_pt":"13,3% (IC95% 6,9-23,6%)",
        "id":"1604",
        "question":"What was the prevalence of Coronavirus OC43 in community samples in Ilorin, Nigeria?",
        "question_pt":"Qual foi a preval\u00eancia do Coronavirus OC43 em amostras da comunidade em Ilorin, Nig\u00e9ria?"
    },
    {
        "answer":"12.5%",
        "answer_pt":"12,5%",
        "id":"1605",
        "question":"What was the prevalence of Coronavirus OC 229 E/NL63 in clinical subjects in Ilorin, Nigeria?",
        "question_pt":"Qual foi a preval\u00eancia do Coronavirus OC 229 E / NL63 em indiv\u00edduos cl\u00ednicos em Ilorin, Nig\u00e9ria?"
    },
    {
        "answer":"increased severity of illness in the clinical sample",
        "answer_pt":"aumento da gravidade da doen\u00e7a na amostra cl\u00ednica",
        "id":"1606",
        "question":"What was the difference between community and clinic cases of acute respiratory infections?",
        "question_pt":"Qual a diferen\u00e7a entre casos comunit\u00e1rios e cl\u00ednicos de infec\u00e7\u00f5es respirat\u00f3rias agudas?"
    },
    {
        "answer":"active community surveillance",
        "answer_pt":"vigil\u00e2ncia comunit\u00e1ria ativa",
        "id":"1607",
        "question":"How can countries enhance public health surveillance?",
        "question_pt":"Como os pa\u00edses podem melhorar a vigil\u00e2ncia da sa\u00fade p\u00fablica?"
    },
    {
        "answer":"world-wide occurrence, ease of transmission and considerable morbidity and mortality effecting people of all ages",
        "answer_pt":"ocorr\u00eancia mundial, facilidade de transmiss\u00e3o e consider\u00e1vel morbimortalidade afetando pessoas de todas as idades",
        "id":"1608",
        "question":"Why do respiratory tract infections pose major public health problems?",
        "question_pt":"Por que as infec\u00e7\u00f5es do trato respirat\u00f3rio apresentam grandes problemas de sa\u00fade p\u00fablica?"
    },
    {
        "answer":"two to three times more frequently",
        "answer_pt":"duas a tr\u00eas vezes mais frequentemente",
        "id":"1609",
        "question":"How much of a greater risk are children than adults to viral infections?",
        "question_pt":"Quanto maior o risco de crian\u00e7as do que adultos sofrerem infec\u00e7\u00f5es virais?"
    },
    {
        "answer":"acute RTI",
        "answer_pt":"ITR aguda",
        "id":"1610",
        "question":"What is the most common infection in childhood?",
        "question_pt":"Qual \u00e9 a infec\u00e7\u00e3o mais comum na inf\u00e2ncia?"
    },
    {
        "answer":"common colds, pharyngitis, croup, bronchiolitis, viral pneumonia and otitis media",
        "answer_pt":"resfriados comuns, faringite, garupa, bronquiolite, pneumonia viral e otite m\u00e9dia",
        "id":"1611",
        "question":"What can respiratory viruses cause?",
        "question_pt":"O que podem causar v\u00edrus respirat\u00f3rios?"
    },
    {
        "answer":"during winter and early spring months",
        "answer_pt":"durante os meses de inverno e in\u00edcio da primavera",
        "id":"1613",
        "question":"When do respiratory infections usually happen?",
        "question_pt":"Quando as infec\u00e7\u00f5es respirat\u00f3rias geralmente acontecem?"
    },
    {
        "answer":"respiratory syncytial virus (RSV), influenza A and B (INF-A, INF-B) viruses, parainfluenza viruses (PIVs), and human adenoviruses (HAdVs)",
        "answer_pt":"v\u00edrus sincicial respirat\u00f3rio (RSV), v\u00edrus influenza A e B (INF-A, INF-B), v\u00edrus parainfluenza (PIVs) e adenov\u00edrus humanos (HAdVs)",
        "id":"1614",
        "question":"What are the most common viruses?",
        "question_pt":"Quais s\u00e3o os v\u00edrus mais comuns?"
    },
    {
        "answer":"RSV",
        "answer_pt":"RSV",
        "id":"1629",
        "question":"What is the most common viral infection for infants up to 3 months old?",
        "question_pt":"Qual \u00e9 a infec\u00e7\u00e3o viral mais comum em beb\u00eas de at\u00e9 3 meses de idade?"
    },
    {
        "answer":"13%",
        "answer_pt":"13%",
        "id":"1630",
        "question":"What is the incidence of RSV in children older than 3 years of age?",
        "question_pt":"Qual \u00e9 a incid\u00eancia de VSR em crian\u00e7as com mais de 3 anos de idade?"
    },
    {
        "answer":"544 base pairs",
        "answer_pt":"544 pares de bases",
        "id":"2125",
        "question":"What is the distance between the p4.7 and p12.7 genes in the Irish versus Japanese equine coronavirus variants?",
        "question_pt":"Qual \u00e9 a dist\u00e2ncia entre os genes p4.7 e p12.7 nas variantes de coronav\u00edrus equino irland\u00eas versus japon\u00eas?"
    },
    {
        "answer":"148-nucleotide insertion",
        "answer_pt":"Inser\u00e7\u00e3o de 148 nucleot\u00eddeos",
        "id":"2126",
        "question":"What is the difference between the Tokachi09 and Irish coronavirus genomic sequences?",
        "question_pt":"Qual \u00e9 a diferen\u00e7a entre as seq\u00fc\u00eancias gen\u00f4micas do coronav\u00edrus Tokachi09 e irland\u00eas?"
    },
    {
        "answer":"high level of homology between viruses",
        "answer_pt":"alto n\u00edvel de homologia entre v\u00edrus",
        "id":"2127",
        "question":"What suggests that Irish equine coronaviruses may have a low genetic diversity?",
        "question_pt":"O que sugere que os coronav\u00edrus equinos irlandeses podem ter uma baixa diversidade gen\u00e9tica?"
    },
    {
        "answer":"adult riding, racing and show horses",
        "answer_pt":"Cavalos, corridas e cavalos para adultos",
        "id":"2128",
        "question":"Where have most outbreaks of equine coronavirus occurred in the United States?",
        "question_pt":"Onde ocorreram a maioria dos surtos de coronav\u00edrus equino nos Estados Unidos?"
    },
    {
        "answer":"acellular",
        "answer_pt":"acelular",
        "id":"2167",
        "question":"What kind of pertussis vaccine is used in middle and high income countries?",
        "question_pt":"Que tipo de vacina contra coqueluche \u00e9 usada em pa\u00edses de renda m\u00e9dia e alta?"
    },
    {
        "answer":"Southeast Asia",
        "answer_pt":"Sudeste da \u00c1sia",
        "id":"2168",
        "question":"Where is the highest rate of childhood pertussis globally?",
        "question_pt":"Onde est\u00e1 a maior taxa de coqueluche infantil em todo o mundo?"
    },
    {
        "answer":"whole cell pertussis vaccines",
        "answer_pt":"vacinas contra a coqueluche de c\u00e9lulas inteiras",
        "id":"2169",
        "question":"What type of pertussis vaccine has been recently recommended by the WHO?",
        "question_pt":"Que tipo de vacina contra coqueluche foi recentemente recomendado pela OMS?"
    },
    {
        "answer":"apnea, cyanosis, cough with vomit, or whoop/whooping cough",
        "answer_pt":"apneia, cianose, tosse com v\u00f4mito ou tosse convulsa",
        "id":"2170",
        "question":"What are the clinical symptoms of pertussis?",
        "question_pt":"Quais s\u00e3o os sintomas cl\u00ednicos da coqueluche?"
    },
    {
        "answer":"mid-nasal nylon flocked",
        "answer_pt":"nylon m\u00e9dio nasal reunido",
        "id":"2171",
        "question":"What type of swabs are used to sample patients with pertussis?",
        "question_pt":"Que tipo de zaragatoa \u00e9 usada para amostrar pacientes com coqueluche?"
    },
    {
        "answer":"every 2 to 4 years",
        "answer_pt":"a cada 2 a 4 anos",
        "id":"2173",
        "question":"How frequently do pertussis outbreaks peak?",
        "question_pt":"Com que frequ\u00eancia os surtos de coqueluche atingem o pico?"
    },
    {
        "answer":"a minimum of 2 weeks of cough, whoop, or posttussive vomiting",
        "answer_pt":"um m\u00ednimo de 2 semanas de tosse, grito ou v\u00f4mito p\u00f3s-tosse",
        "id":"2174",
        "question":"What is the WHO criteria for a pertussis infection?",
        "question_pt":"Quais s\u00e3o os crit\u00e9rios da OMS para uma infec\u00e7\u00e3o por coqueluche?"
    },
    {
        "answer":"weekly proportion of laboratory tests that are positive for influenza",
        "answer_pt":"propor\u00e7\u00e3o semanal de exames laboratoriais positivos para influenza",
        "id":"2175",
        "question":"What is used by the Canadian Public Health System to identify periods of influenza activity?",
        "question_pt":"O que \u00e9 usado pelo Sistema de Sa\u00fade P\u00fablica do Canad\u00e1 para identificar per\u00edodos de atividade da influenza?"
    },
    {
        "answer":"diagnosis will often not alter patient management, a paucity of real-time, accurate, inexpensive testing methods [4] and because influenza is not recognized as the etiology of the clinical presentation",
        "answer_pt":"o diagn\u00f3stico geralmente n\u00e3o altera a gest\u00e3o do paciente, uma escassez de m\u00e9todos de teste em tempo real, precisos e baratos [4] e porque a influenza n\u00e3o \u00e9 reconhecida como a etiologia da apresenta\u00e7\u00e3o cl\u00ednica",
        "id":"2176",
        "question":"Why is laboratory confirmation of influenza infection not commonly performed?",
        "question_pt":"Por que a confirma\u00e7\u00e3o laboratorial da infec\u00e7\u00e3o por influenza n\u00e3o \u00e9 realizada normalmente?"
    },
    {
        "answer":"nfluenza, respiratory syncytial virus (RSV), para-influenza virus (PIV), and adenovirus",
        "answer_pt":"influenza, v\u00edrus sincicial respirat\u00f3rio (RSV), v\u00edrus da parainfluenza (HPIV) e adenov\u00edrus",
        "id":"2177",
        "question":"What types of viral infections are monitored through Canada's Respiratory Virus Detection Surveillance System (RVDSS)?",
        "question_pt":"Que tipos de infec\u00e7\u00f5es virais s\u00e3o monitoradas pelo Sistema de Vigil\u00e2ncia de V\u00edrus Respirat\u00f3rio do Canad\u00e1 (RVDSS)?"
    },
    {
        "answer":"the potential anti-virus activity of inositol-requiring enzyme 1 (IRE1), a well characterized effector of the cellular homeostatic response to an overloading of the endoplasmic reticulum (ER) protein-folding capacity. IRE1, an ER-membrane-resident ribonuclease (RNase), upon activation catalyses regulated cleavage of select protein-coding and non-coding host RNAs, using an RNase domain which is homologous to that of the known anti-viral effector RNaseL. ",
        "answer_pt":"a potencial atividade antiv\u00edrus da enzima 1 requerente de inositol (IRE1), um efetor bem caracterizado da resposta homeost\u00e1tica celular a uma sobrecarga da capacidade de dobrar prote\u00ednas do ret\u00edculo endoplasm\u00e1tico (ER). O IRE1, uma ribonuclease residente na membrana ER (RNase), ap\u00f3s a ativa\u00e7\u00e3o catalisa a clivagem regulada de RNAs hospedeiros codificadores e n\u00e3o codificadores de prote\u00ednas selecionados, usando um dom\u00ednio RNase que \u00e9 hom\u00f3logo ao do efetor antiviral conhecido RNaseL.",
        "id":"2466",
        "question":"What is discussed in this publication?",
        "question_pt":"O que \u00e9 discutido nesta publica\u00e7\u00e3o?"
    },
    {
        "answer":"The review first discusses the anti-viral mechanism of the OAS/RNaseL system and evasion tactics employed by different viruses. This is followed by a review of the RIDD pathway and its potential effect on the stability of viral RNAs. ",
        "answer_pt":"A revis\u00e3o discute primeiro o mecanismo antiviral do sistema OEA / RNaseL e as t\u00e1ticas de evas\u00e3o empregadas por diferentes v\u00edrus. Isto \u00e9 seguido por uma revis\u00e3o da via RIDD e seu potencial efeito na estabilidade dos RNAs virais.",
        "id":"2467",
        "question":"What is discussed in this publication?",
        "question_pt":"O que \u00e9 discutido nesta publica\u00e7\u00e3o?"
    },
    {
        "answer":"comparison of the enzymatic activity of the two RNases followed by deliberations on the physiological consequences of their activation.",
        "answer_pt":"compara\u00e7\u00e3o da atividade enzim\u00e1tica das duas RNases seguida de delibera\u00e7\u00f5es sobre as conseq\u00fc\u00eancias fisiol\u00f3gicas de sua ativa\u00e7\u00e3o.",
        "id":"2468",
        "question":"What is reported in this publication?",
        "question_pt":"O que \u00e9 relatado nesta publica\u00e7\u00e3o?"
    },
    {
        "answer":"In the context of a virus infection, the pathway leading from both these proteins have the potential to lead to cell death. Notwithstanding the fact that this might be an efficient way of virus clearance, it also portends pathological outcomes for the infected organism. Future research would probably lead to design of drugs targeting these proteins based on the structural homology of their effector domains, regulating the pathological denouement of their activation without compromising their anti-viral or potential anti-viral functions.",
        "answer_pt":"No contexto de uma infec\u00e7\u00e3o por v\u00edrus, o caminho que leva a essas duas prote\u00ednas tem o potencial de levar \u00e0 morte celular. Apesar de ser uma maneira eficiente de elimina\u00e7\u00e3o do v\u00edrus, tamb\u00e9m indica resultados patol\u00f3gicos para o organismo infectado. Pesquisas futuras provavelmente levariam ao design de medicamentos direcionados a essas prote\u00ednas com base na homologia estrutural de seus dom\u00ednios efetores, regulando o desfecho patol\u00f3gico de sua ativa\u00e7\u00e3o sem comprometer suas fun\u00e7\u00f5es antivirais ou antivirais potenciais.",
        "id":"2469",
        "question":"What is the conclusion regarding IRE1 and RNaseL proteins?",
        "question_pt":"Qual \u00e9 a conclus\u00e3o sobre as prote\u00ednas IRE1 e RNaseL?"
    },
    {
        "answer":"nonenveloped, single-stranded, positive-sense RNA",
        "answer_pt":"RNA n\u00e3o-envelope, fita simples, sentido positivo",
        "id":"2988",
        "question":"What is the structure of an Echovirus?",
        "question_pt":"Qual \u00e9 a estrutura de um ecov\u00edrus?"
    },
    {
        "answer":"respiratory illness, hand-foot-and-mouth disease, and aseptic meningitis,",
        "answer_pt":"doen\u00e7a respirat\u00f3ria, doen\u00e7a m\u00e3o-p\u00e9-boca-boca e meningite ass\u00e9ptica,",
        "id":"2989",
        "question":"What diseases are associated with echoviruses?",
        "question_pt":"Quais doen\u00e7as est\u00e3o associadas aos echov\u00edrus?"
    },
    {
        "answer":"California Department of Public Health (CDPH)",
        "answer_pt":"Departamento de Sa\u00fade P\u00fablica da Calif\u00f3rnia (CDPH)",
        "id":"2990",
        "question":"In California, to where are meningitis cases reported according to the California Code of Regulations?",
        "question_pt":"Na Calif\u00f3rnia, onde s\u00e3o relatados os casos de meningite de acordo com o C\u00f3digo de Regulamentos da Calif\u00f3rnia?"
    },
    {
        "answer":"within 1 day of identification",
        "answer_pt":"dentro de 1 dia ap\u00f3s a identifica\u00e7\u00e3o",
        "id":"2991",
        "question":"According to the California Code of Regulations, when should a meningitis case be reported?",
        "question_pt":"De acordo com o C\u00f3digo de Regulamentos da Calif\u00f3rnia, quando um caso de meningite deve ser relatado?"
    },
    {
        "answer":"CDPH",
        "answer_pt":"CDPH",
        "id":"2992",
        "question":"Where is the Viral and Rickettsial Disease Laboratory located?",
        "question_pt":"Onde est\u00e1 localizado o Laborat\u00f3rio de Doen\u00e7as Virais e Rickettsiais?"
    },
    {
        "answer":"E-30",
        "answer_pt":"E-30",
        "id":"2993",
        "question":"What type of reference genome was used in the study?",
        "question_pt":"Que tipo de genoma de refer\u00eancia foi usado no estudo?"
    },
    {
        "answer":"260-fold",
        "answer_pt":"260 vezes",
        "id":"2994",
        "question":"What was the read coverage for the E-30 genome in this study?",
        "question_pt":"Qual foi a cobertura de leitura para o genoma do E-30 neste estudo?"
    },
    {
        "answer":"one structural (P1-capsid) and two nonstructural (P2 and P3) regions",
        "answer_pt":"uma regi\u00e3o estrutural (caps\u00eddeo P1) e duas regi\u00f5es n\u00e3o estruturais (P2 e P3)",
        "id":"2995",
        "question":"What are the structural regions of the enterovirus polyprotein in this study?",
        "question_pt":"Quais s\u00e3o as regi\u00f5es estruturais da poliprote\u00edna de enterov\u00edrus neste estudo?"
    },
    {
        "answer":"homeostasis, differentiation, embryonic development, and organ physiology",
        "answer_pt":"homeostase, diferencia\u00e7\u00e3o, desenvolvimento embrion\u00e1rio e fisiologia de \u00f3rg\u00e3os",
        "id":"1635",
        "question":"What can nuclear receptors regulate?",
        "question_pt":"O que os receptores nucleares podem regular?"
    },
    {
        "answer":"Nuclear receptors (NRs)",
        "answer_pt":"Receptores nucleares (NRs)",
        "id":"3258",
        "question":"What are associated with cancer, diabetes, inflammatory disease, and osteoporosis?",
        "question_pt":"O que est\u00e1 associado ao c\u00e2ncer, diabetes, doen\u00e7a inflamat\u00f3ria e osteoporose?"
    },
    {
        "answer":"class of ligand-inducible transcription factors",
        "answer_pt":"classe de fatores de transcri\u00e7\u00e3o induz\u00edveis por ligantes",
        "id":"3259",
        "question":"What are nuclear receptors (NRs)?",
        "question_pt":"O que s\u00e3o receptores nucleares (NRs)?"
    },
    {
        "answer":"homeostasis, differentiation, embryonic development, and organ physiology",
        "answer_pt":"homeostase, diferencia\u00e7\u00e3o, desenvolvimento embrion\u00e1rio e fisiologia de \u00f3rg\u00e3os",
        "id":"3260",
        "question":"What biological factors for nuclear receptors regulate?",
        "question_pt":"Quais fatores biol\u00f3gicos para receptores nucleares regulam?"
    },
    {
        "answer":"seven",
        "answer_pt":"Sete",
        "id":"3261",
        "question":"How many families are in the NR superfamily?",
        "question_pt":"Quantas fam\u00edlias est\u00e3o na superfam\u00edlia de NR?"
    },
    {
        "answer":"a reliable 3D (three dimensional) structure of the target protein",
        "answer_pt":"uma estrutura 3D (tridimensional) confi\u00e1vel da prote\u00edna alvo",
        "id":"3262",
        "question":"What is a prerequisite to make a molecular docking study feasible?",
        "question_pt":"Qual \u00e9 um pr\u00e9-requisito para viabilizar um estudo de acoplamento molecular?"
    },
    {
        "answer":"X-ray crystallography",
        "answer_pt":"Cristalografia de raio-x",
        "id":"3263",
        "question":"What tool can be used to determine the 3D structure of proteins?",
        "question_pt":"Que ferramenta pode ser usada para determinar a estrutura 3D das prote\u00ednas?"
    },
    {
        "answer":"time-consuming and expensive",
        "answer_pt":"demorado e caro",
        "id":"3264",
        "question":"What are the shortcomings of X-ray crystallography?",
        "question_pt":"Quais s\u00e3o as defici\u00eancias da cristalografia de raios-X?"
    },
    {
        "answer":"membrane proteins",
        "answer_pt":"prote\u00ednas de membrana",
        "id":"3265",
        "question":"What types of proteins are difficult to crystallize?",
        "question_pt":"Que tipos de prote\u00ednas s\u00e3o dif\u00edceis de cristalizar?"
    },
    {
        "answer":"KEGG (Kyoto Encyclopedia of Genes and Genomes)",
        "answer_pt":"KEGG (Enciclop\u00e9dia de Kyoto de genes e genomas)",
        "id":"3266",
        "question":"Where were the data collected for this study?",
        "question_pt":"Onde os dados foram coletados para este estudo?"
    },
    {
        "answer":"veterinarians",
        "answer_pt":"Veterin\u00e1rios",
        "id":"3680",
        "question":"Who performed the sampling procedures?",
        "question_pt":"Quem realizou os procedimentos de amostragem?"
    },
    {
        "answer":"from November 2004 to November 2014",
        "answer_pt":"de novembro de 2004 a novembro de 2014",
        "id":"3681",
        "question":"When were the fecal samples collected?",
        "question_pt":"Quando as amostras fecais foram coletadas?"
    },
    {
        "answer":"BatCoV HKU10",
        "answer_pt":"BatCoV HKU10",
        "id":"3682",
        "question":"What reference genome was used in the study?",
        "question_pt":"Que genoma de refer\u00eancia foi usado no estudo?"
    },
    {
        "answer":"20.4 kb",
        "answer_pt":"20,4 kb",
        "id":"3684",
        "question":"What is the length of the replicase gene ORF1ab?",
        "question_pt":"Qual \u00e9 o comprimento do gene da replicase ORF1ab?"
    },
    {
        "answer":"BtCoV/Rh/YN2012",
        "answer_pt":"BtCoV / Rh / YN2012",
        "id":"3683",
        "question":"What type of coronavirus was detected in R. affinis and R. sinicus species?",
        "question_pt":"Que tipo de coronav\u00edrus foi detectado nas esp\u00e9cies R. affinis e R. sinicus?"
    },
    {
        "answer":"Bats",
        "answer_pt":"Morcegos",
        "id":"3675",
        "question":"What is a natural reservoir of coronavirus?",
        "question_pt":"O que \u00e9 um reservat\u00f3rio natural de coronav\u00edrus?"
    },
    {
        "answer":"26-32 kb",
        "answer_pt":"26-32 kb",
        "id":"3676",
        "question":"What is the genome size of the coronavirus?",
        "question_pt":"Qual \u00e9 o tamanho do genoma do coronav\u00edrus?"
    },
    {
        "answer":"enveloped, non-segmented, positive-strand RNA viruses",
        "answer_pt":"v\u00edrus de RNA de fita positiva n\u00e3o segmentados e envelopados",
        "id":"3677",
        "question":"What is the structure of the coronavirus?",
        "question_pt":"Qual \u00e9 a estrutura do coronav\u00edrus?"
    },
    {
        "answer":"birds",
        "answer_pt":"p\u00e1ssaros",
        "id":"3678",
        "question":"What animals do gamma and delta coronavirus mainly infect?",
        "question_pt":"Quais animais os coronav\u00edrus gama e delta infectam principalmente?"
    },
    {
        "answer":"Six",
        "answer_pt":"Seis",
        "id":"3679",
        "question":"How many types of coronaviruses are known to cause human disease?",
        "question_pt":"Quantos tipos de coronav\u00edrus causam doen\u00e7as humanas?"
    },
    {
        "answer":"NF-\u03baB",
        "answer_pt":"NF-\u03baB",
        "id":"3685",
        "question":"What plays a role in regulating the immune response to a viral infection?",
        "question_pt":"O que desempenha um papel na regula\u00e7\u00e3o da resposta imune a uma infec\u00e7\u00e3o viral?"
    },
    {
        "answer":"Rhinolophus bats seem to harbor a wide diversity of CoVs",
        "answer_pt":"Os morcegos Rhinolophus parecem abrigar uma grande diversidade de CoVs",
        "id":"3686",
        "question":"What is the conclusion of the coronavirus long-term surveillance studies?",
        "question_pt":"Qual \u00e9 a conclus\u00e3o dos estudos de vigil\u00e2ncia a longo prazo do coronav\u00edrus?"
    },
    {
        "answer":"FIP virus (FIPV)",
        "answer_pt":"V\u00edrus FIP (FIPV)",
        "id":"4051",
        "question":"What is the cause of Feline Infectious Peritonitis (FIP)?",
        "question_pt":"Qual \u00e9 a causa da peritonite infecciosa felina (PIF)?"
    },
    {
        "answer":"enveloped virus with a nonsegmented, positive sense, single-stranded RNA genome",
        "answer_pt":"v\u00edrus envolvido com um genoma de RNA de cadeia simples, n\u00e3o-segmentado, com sentido positivo",
        "id":"4052",
        "question":"What is the molecular structure of Feline Infectious Peritonitis Virus?",
        "question_pt":"Qual \u00e9 a estrutura molecular do v\u00edrus da peritonite infecciosa felina?"
    },
    {
        "answer":"shedding in their faeces",
        "answer_pt":"derramando em suas fezes",
        "id":"4053",
        "question":"How is FECV detected in cats?",
        "question_pt":"Como o FECV \u00e9 detectado em gatos?"
    },
    {
        "answer":"an attenuated, temperature-sensitive strain of type II FIPV",
        "answer_pt":"uma cepa atenuada e sens\u00edvel \u00e0 temperatura do FIPV tipo II",
        "id":"4055",
        "question":"What type of vaccine is used to protect against FIPV infection?",
        "question_pt":"Que tipo de vacina \u00e9 usada para proteger contra a infec\u00e7\u00e3o pelo FIPV?"
    },
    {
        "answer":"the vaccine contains type 2 strain, whereas type 1 viruses are more prevalent in the field",
        "answer_pt":"a vacina cont\u00e9m cepa do tipo 2, enquanto os v\u00edrus do tipo 1 s\u00e3o mais prevalentes no campo",
        "id":"4056",
        "question":"Why is their controversy surrounding the FIPV vaccine?",
        "question_pt":"Por que a controv\u00e9rsia em torno da vacina FIPV?"
    },
    {
        "answer":"30 minutes",
        "answer_pt":"30 minutos",
        "id":"4057",
        "question":"For how long was the denatured polyacrylamide gel polymerized?",
        "question_pt":"Por quanto tempo o gel de poliacrilamida desnaturado foi polimerizado?"
    },
    {
        "answer":"nano Isothermal Titration Calorimeter (ITC)",
        "answer_pt":"Calor\u00edmetro de titula\u00e7\u00e3o isot\u00e9rmica nano (ITC)",
        "id":"4058",
        "question":"How was the binding strength measured?",
        "question_pt":"Como foi medida a for\u00e7a de uni\u00e3o?"
    },
    {
        "answer":" the anti-influenza A (H2N2) virus activity of patchouli alcohol",
        "answer_pt":"atividade do v\u00edrus anti-influenza A (H2N2) do \u00e1lcool patchouli",
        "id":"4070",
        "question":"What was the focus of this study?",
        "question_pt":"Qual foi o foco deste estudo?"
    },
    {
        "answer":"NA glycoproteins of influenza A and B virus",
        "answer_pt":"Glicoprote\u00ednas NA do v\u00edrus influenza A e B",
        "id":"4071",
        "question":"What do neuroaminidase inhibitors target?",
        "question_pt":"O que os inibidores da neuroaminidase t\u00eam como alvo?"
    },
    {
        "answer":"cleave the \u03b1-ketosidic linkage between terminal sialic acid and an adjacent sugar residue",
        "answer_pt":"cliva a liga\u00e7\u00e3o \u03b1-cetos\u00eddica entre o \u00e1cido si\u00e1lico terminal e um res\u00edduo de a\u00e7\u00facar adjacente",
        "id":"4072",
        "question":"What is the function of neuroaminidase in the influenza virus?",
        "question_pt":"Qual \u00e9 a fun\u00e7\u00e3o da neuroaminidase no v\u00edrus influenza?"
    },
    {
        "answer":"NA inhibitor",
        "answer_pt":"Inibidor de NA",
        "id":"4073",
        "question":"What is Tamiflu?",
        "question_pt":"O que \u00e9 o Tamiflu?"
    },
    {
        "answer":"CC 50",
        "answer_pt":"CC 50",
        "id":"4074",
        "question":"What was the test for the level of cytotoxicity used in this study?",
        "question_pt":"Qual foi o teste para o n\u00edvel de citotoxicidade utilizado neste estudo?"
    },
    {
        "answer":"MTT method",
        "answer_pt":"M\u00e9todo MTT",
        "id":"4075",
        "question":"What method was used to measure the inhibition of viral replication?",
        "question_pt":"Que m\u00e9todo foi usado para medir a inibi\u00e7\u00e3o da replica\u00e7\u00e3o viral?"
    },
    {
        "answer":" patchouli alcohol possesses anti-influenza A (H2N2) virus activity",
        "answer_pt":"\u00e1lcool de patchouli possui atividade do v\u00edrus anti-influenza A (H2N2)",
        "id":"4076",
        "question":"What was the conclusion of this study?",
        "question_pt":"Qual foi a conclus\u00e3o deste estudo?"
    },
    {
        "answer":"time, equipment, and technical expertise requirements",
        "answer_pt":"requisitos de tempo, equipamento e conhecimentos t\u00e9cnicos",
        "id":"4434",
        "question":"Why have nucleic acid amplification tests been restricted to laboratory settings?",
        "question_pt":"Por que os testes de amplifica\u00e7\u00e3o de \u00e1cidos nucleicos foram restritos \u00e0s configura\u00e7\u00f5es de laborat\u00f3rio?"
    },
    {
        "answer":"HIV-1 RT-LAMP assay",
        "answer_pt":"Ensaio de HIV-1 RT-LAMP",
        "id":"4435",
        "question":"What screening method was evaluated in this study?",
        "question_pt":"Qual m\u00e9todo de triagem foi avaliado neste estudo?"
    },
    {
        "answer":"whole blood specimens",
        "answer_pt":"amostras de sangue total",
        "id":"4436",
        "question":"What was used to measure the performance of the NINA heaters?",
        "question_pt":"O que foi usado para medir o desempenho dos aquecedores NINA?"
    },
    {
        "answer":"20%",
        "answer_pt":"20%",
        "id":"4437",
        "question":"What percentage of HIV-infected people go undetected in the United States?",
        "question_pt":"Qual a porcentagem de pessoas infectadas pelo HIV n\u00e3o \u00e9 detectada nos Estados Unidos?"
    },
    {
        "answer":"35 to 50%",
        "answer_pt":"35 a 50%",
        "id":"4438",
        "question":"What percentage of patients do not return for followup after HIV testing?",
        "question_pt":"Qual a porcentagem de pacientes que n\u00e3o retornam para acompanhamento ap\u00f3s o teste de HIV?"
    },
    {
        "answer":"Chi-square test and Fisher's exact test",
        "answer_pt":"Teste qui-quadrado e teste exato de Fisher",
        "id":"5211",
        "question":"What statistical tests were used to compare categorical variables?",
        "question_pt":"Quais testes estat\u00edsticos foram utilizados para comparar vari\u00e1veis \u200b\u200bcateg\u00f3ricas?"
    },
    {
        "answer":"unable to evaluate the levels of immunomodulators in the serum samples of a control group",
        "answer_pt":"incapaz de avaliar os n\u00edveis de imunomoduladores nas amostras de soro de um grupo controle",
        "id":"5212",
        "question":"What was a severe limitation of this study?",
        "question_pt":"Qual foi uma limita\u00e7\u00e3o grave deste estudo?"
    },
    {
        "answer":"a larger, longitudinal study on the etiology and severity of pneumonia",
        "answer_pt":"um estudo longitudinal maior sobre a etiologia e gravidade da pneumonia",
        "id":"5213",
        "question":"What followup is needed to confirm the results of the current study?",
        "question_pt":"Que acompanhamento \u00e9 necess\u00e1rio para confirmar os resultados do estudo atual?"
    },
    {
        "answer":"mixed respiratory infections and IP-10 may play major, interconnected roles in the pathogenesis of pneumonia",
        "answer_pt":"infec\u00e7\u00f5es respirat\u00f3rias mistas e IP-10 podem desempenhar pap\u00e9is importantes e interconectados na patog\u00eanese da pneumonia",
        "id":"5214",
        "question":"What is the conclusion of this study?",
        "question_pt":"Qual \u00e9 a conclus\u00e3o deste estudo?"
    },
    {
        "answer":"highest serum IP-10 levels",
        "answer_pt":"n\u00edveis s\u00e9ricos de IP-10 mais altos",
        "id":"5215",
        "question":"What suggests that IP-10 plays a significant role on the pathogenesis of pneumonia?",
        "question_pt":"O que sugere que o IP-10 desempenha um papel significativo na patog\u00eanese da pneumonia?"
    },
    {
        "answer":"airway epithelial cells 19 , resident alveolar macrophages (AMs) and blood monocytes-derived macrophages",
        "answer_pt":"c\u00e9lulas epiteliais das vias a\u00e9reas 19, macr\u00f3fagos alveolares residentes (MAs) e macr\u00f3fagos derivados de mon\u00f3citos sangu\u00edneos",
        "id":"5216",
        "question":"What cell types help prevent pneumococcal and influenza infection in the lungs?",
        "question_pt":"Quais tipos de c\u00e9lulas ajudam a prevenir a infec\u00e7\u00e3o pneumoc\u00f3cica e influenza nos pulm\u00f5es?"
    },
    {
        "answer":"Methicillin-resistant Staphylococcus aureus (MRSA)",
        "answer_pt":"Staphylococcus aureus resistente \u00e0 meticilina (MRSA)",
        "id":"5226",
        "question":"What is the most common, clinically-relevant multiresistant pathogen in both healthcare and community acquired infections?",
        "question_pt":"Qual \u00e9 o pat\u00f3geno multirresistente clinicamente relevante mais comum em infec\u00e7\u00f5es adquiridas na \u00e1rea da sa\u00fade e na comunidade?"
    },
    {
        "answer":"vancomycin",
        "answer_pt":"vancomicina",
        "id":"5227",
        "question":"What is the treatment of choice for MRSA infections?",
        "question_pt":"Qual \u00e9 o tratamento de escolha para infec\u00e7\u00f5es por MRSA?"
    },
    {
        "answer":"isocitrate lyase",
        "answer_pt":"isocitrato de liase",
        "id":"5228",
        "question":"What enzyme is essential for the metabolism of fatty acids?",
        "question_pt":"Qual enzima \u00e9 essencial para o metabolismo dos \u00e1cidos graxos?"
    },
    {
        "answer":"to assess the overall in vitro bactericidal activity of nine newly synthesized diamides",
        "answer_pt":"avaliar a atividade bactericida in vitro geral de nove diamidas sintetizadas recentemente",
        "id":"5229",
        "question":"What was the purpose of this research?",
        "question_pt":"Qual foi o objetivo desta pesquisa?"
    },
    {
        "answer":"the marmoset an appropriate animal model for biodefense-related pathogens",
        "answer_pt":"o sagui um modelo animal apropriado para pat\u00f3genos relacionados \u00e0 biodefesa",
        "id":"5230",
        "question":"What is the conclusion of the study?",
        "question_pt":"Qual \u00e9 a conclus\u00e3o do estudo?"
    },
    {
        "answer":"the small size of marmosets, their immune response to infection that is comparable to humans, and the ability to house more statistically relevant numbers within high containment",
        "answer_pt":"o pequeno tamanho dos saguis, sua resposta imune \u00e0 infec\u00e7\u00e3o que \u00e9 compar\u00e1vel aos seres humanos e a capacidade de abrigar n\u00fameros mais estatisticamente relevantes dentro de alta conten\u00e7\u00e3o",
        "id":"5231",
        "question":"Why makes the marmoset an appropriate animal model for pathogen research?",
        "question_pt":"Por que torna o sagui um modelo animal apropriado para a pesquisa de pat\u00f3genos?"
    },
    {
        "answer":"the presence of resistance-associated substitutions",
        "answer_pt":"presen\u00e7a de substitui\u00e7\u00f5es associadas \u00e0 resist\u00eancia",
        "id":"3895",
        "question":"How can the efficacy of DAAs be diminished?",
        "question_pt":"Como a efic\u00e1cia dos DAAs pode ser diminu\u00edda?"
    },
    {
        "answer":"up to 98%",
        "answer_pt":"at\u00e9 98%",
        "id":"3896",
        "question":"Was is the response rate of the Hepatitis C virus to direct-acting antiviral treatments?",
        "question_pt":"Foi a taxa de resposta do v\u00edrus da hepatite C aos tratamentos antivirais de a\u00e7\u00e3o direta?"
    },
    {
        "answer":"inhibit polymerase activity by allosteric mechanisms",
        "answer_pt":"inibe a atividade da polimerase por mecanismos alost\u00e9ricos",
        "id":"3897",
        "question":"How do nonnucleoside NS5B polymerase inhibitors work?",
        "question_pt":"Como funcionam os inibidores da polimerase NS5B n\u00e3o-nucleos\u00eddeo?"
    },
    {
        "answer":"31",
        "answer_pt":"31",
        "id":"3898",
        "question":"How many patients were studied?",
        "question_pt":"Quantos pacientes foram estudados?"
    },
    {
        "answer":"was obtained",
        "answer_pt":"foi obtido",
        "id":"3899",
        "question":"Was written consent obtained?",
        "question_pt":"Foi obtido o consentimento por escrito?"
    },
    {
        "answer":"5 \u03bcl",
        "answer_pt":"5 \u03bcl",
        "id":"3900",
        "question":"How much of the RNA template was in the reverse transcription reaction mixture?",
        "question_pt":"Quanto do molde de RNA estava na mistura da rea\u00e7\u00e3o de transcri\u00e7\u00e3o reversa?"
    },
    {
        "answer":"2 strains out of 25 (8%)",
        "answer_pt":"2 cepas de 25 (8%)",
        "id":"3901",
        "question":"How many RASs to NS5A inhibitors were identified?",
        "question_pt":"Quantos RASs para inibidores de NS5A foram identificados?"
    },
    {
        "answer":"confers a higher level of resistance than the one achieved by the RAS alone",
        "answer_pt":"confere um n\u00edvel de resist\u00eancia mais alto do que o alcan\u00e7ado apenas pelo RAS",
        "id":"3902",
        "question":"Why is the substitution E62D important in drug resistance?",
        "question_pt":"Por que a substitui\u00e7\u00e3o E62D \u00e9 importante na resist\u00eancia aos medicamentos?"
    },
    {
        "answer":"baseline and emergent resistance variants",
        "answer_pt":"variantes de linha de base e resist\u00eancia emergente",
        "id":"3903",
        "question":"What are the key factors preventing the elimination of HCV infection in some patients?",
        "question_pt":"Quais s\u00e3o os principais fatores que impedem a elimina\u00e7\u00e3o da infec\u00e7\u00e3o pelo HCV em alguns pacientes?"
    },
    {
        "answer":"Infectious cDNA clones",
        "answer_pt":"Clones de cDNA infecciosos",
        "id":"5242",
        "question":"What is needed to direct genetic mutations in RNA viruses?",
        "question_pt":"O que \u00e9 necess\u00e1rio para direcionar muta\u00e7\u00f5es gen\u00e9ticas nos v\u00edrus RNA?"
    },
    {
        "answer":"single stranded positive sense RNA genomes",
        "answer_pt":"genomas de RNA de sentido positivo de cadeia simples",
        "id":"5243",
        "question":"What is the structure of the pestivirus?",
        "question_pt":"Qual \u00e9 a estrutura do pestiv\u00edrus?"
    },
    {
        "answer":"5\u2032 and 3\u2032 untranslated regions (UTRs)",
        "answer_pt":"Regi\u00f5es n\u00e3o traduzidas (UTRs) 5 \u2032 e 3 \u2032",
        "id":"5244",
        "question":"What sequences are critical for the autonomous replication of the pestivirus genome?",
        "question_pt":"Quais seq\u00fc\u00eancias s\u00e3o cr\u00edticas para a replica\u00e7\u00e3o aut\u00f4noma do genoma do pestiv\u00edrus?"
    },
    {
        "answer":"nucleocapsid protein C, envelope glycoproteins E rns , E1 and E2",
        "answer_pt":"prote\u00edna C do nucleoc\u00e1pside, glicoprote\u00ednas E rns do envelope, E1 e E2",
        "id":"5245",
        "question":"What are the 4 structural proteins of the pestivirus polyprotein?",
        "question_pt":"Quais s\u00e3o as 4 prote\u00ednas estruturais da poliprote\u00edna dos pestiv\u00edrus?"
    },
    {
        "answer":"aa",
        "answer_pt":"aa",
        "id":"5246",
        "question":"The BAC differed from the parental cDNA sequence by what amino acid substitutions?",
        "question_pt":"O BAC diferiu da sequ\u00eancia de cDNA dos pais por quais substitui\u00e7\u00f5es de amino\u00e1cidos?"
    },
    {
        "answer":"to examine whether a relationship exists between operation volumes and SSIs",
        "answer_pt":"para examinar se existe um relacionamento entre volumes de opera\u00e7\u00e3o e SSIs",
        "id":"5247",
        "question":"What is the purpose of this research study?",
        "question_pt":"Qual \u00e9 o objetivo desta pesquisa?"
    },
    {
        "answer":"The total length of stay and expenditure for patients with SSIs after CABG surgery is significantly longer and higher than those without SSIs",
        "answer_pt":"O tempo total de perman\u00eancia e gastos para pacientes com ISC ap\u00f3s cirurgia de revasculariza\u00e7\u00e3o do mioc\u00e1rdio \u00e9 significativamente maior e mais alto do que aqueles sem ISC",
        "id":"5248",
        "question":"Why are SSIs important to the overall burden on the healthcare system?",
        "question_pt":"Por que as ISC s\u00e3o importantes para o \u00f4nus geral do sistema de sa\u00fade?"
    },
    {
        "answer":"hospitals would no longer receive higher payments for the additional costs associated with treating patients for certain healthcare-acquired infections",
        "answer_pt":"os hospitais n\u00e3o receberiam mais pagamentos mais altos pelos custos adicionais associados ao tratamento de pacientes para certas infec\u00e7\u00f5es adquiridas na \u00e1rea da sa\u00fade",
        "id":"5249",
        "question":"What is the \"Never Event\" policy?",
        "question_pt":"O que \u00e9 a pol\u00edtica \"Nunca evento\"?"
    },
    {
        "answer":"19",
        "answer_pt":"19",
        "id":"5250",
        "question":"Patients from how many medical centers were studied?",
        "question_pt":"Pacientes de quantos centros m\u00e9dicos foram estudados?"
    },
    {
        "answer":"CABG patients under the age of 18 years or over 85 years",
        "answer_pt":"Pacientes com CRM com idade inferior a 18 anos ou superior a 85 anos",
        "id":"5251",
        "question":"Which patients were excluded from the study?",
        "question_pt":"Quais pacientes foram exclu\u00eddos do estudo?"
    },
    {
        "answer":"cannot reliably represent effects originating from stochasticity, from effects in small populations, or from heterogeneities",
        "answer_pt":"n\u00e3o pode representar de forma confi\u00e1vel efeitos provenientes de estoc\u00e1stica, de efeitos em pequenas popula\u00e7\u00f5es ou de heterogeneidades",
        "id":"5255",
        "question":"What are the limitations of a deterministic model?",
        "question_pt":"Quais s\u00e3o as limita\u00e7\u00f5es de um modelo determin\u00edstico?"
    },
    {
        "answer":"fecal-oral contact",
        "answer_pt":"contato fecal-oral",
        "id":"5266",
        "question":"How does PEDV spread?",
        "question_pt":"Como o PEDV se espalha?"
    },
    {
        "answer":"destroys the lining of piglets' intestines",
        "answer_pt":"destr\u00f3i o revestimento do intestino dos leit\u00f5es",
        "id":"5267",
        "question":"How does PEDV cause illness?",
        "question_pt":"Como o PEDV causa doen\u00e7as?"
    },
    {
        "answer":"26 to 32 kb",
        "answer_pt":"26 a 32 kb",
        "id":"5268",
        "question":"What is the size of the PEDV genome?",
        "question_pt":"Qual \u00e9 o tamanho do genoma do PEDV?"
    },
    {
        "answer":"Lassa and Lujo viruses",
        "answer_pt":"V\u00edrus Lassa e Lujo",
        "id":"5271",
        "question":"Which viruses are part of the Old World complex of Arenaviridae?",
        "question_pt":"Quais v\u00edrus fazem parte do complexo Arenaviridae do Velho Mundo?"
    },
    {
        "answer":"through the use of serological assays",
        "answer_pt":"atrav\u00e9s do uso de ensaios sorol\u00f3gicos",
        "id":"5272",
        "question":"How can Old World and New World Arenaviruses be differentiated?",
        "question_pt":"Como os Arenav\u00edrus do Velho Mundo e do Novo Mundo podem ser diferenciados?"
    },
    {
        "answer":"1-3 weeks",
        "answer_pt":"1-3 semanas",
        "id":"5273",
        "question":"What is the incubation period for arenavirus?",
        "question_pt":"Qual \u00e9 o per\u00edodo de incuba\u00e7\u00e3o do arenav\u00edrus?"
    },
    {
        "answer":"bisegmented, negative-sense, single stranded RNA genome",
        "answer_pt":"genoma de RNA de cadeia simples, bisegmentado, com sentido negativo",
        "id":"5274",
        "question":"What is the structure of the Arenavirus?",
        "question_pt":"Qual \u00e9 a estrutura do Arenavirus?"
    },
    {
        "answer":"a glycoprotein, a nucleoprotein (NP), a matrix protein (Z), and a polymerase (L)",
        "answer_pt":"uma glicoprote\u00edna, uma nucleoprote\u00edna (NP), uma prote\u00edna da matriz (Z) e uma polimerase (L)",
        "id":"5275",
        "question":"What proteins does the Arenavirus produce?",
        "question_pt":"Quais prote\u00ednas o Arenav\u00edrus produz?"
    },
    {
        "answer":"PCR assays",
        "answer_pt":"Ensaios de PCR",
        "id":"5276",
        "question":"What diagnostic test has been show to have excellent sensitivity in detecting viral infections?",
        "question_pt":"Que teste de diagn\u00f3stico demonstrou ter excelente sensibilidade na detec\u00e7\u00e3o de infec\u00e7\u00f5es virais?"
    },
    {
        "answer":"neuraminidase inhibitors",
        "answer_pt":"inibidores da neuraminidase",
        "id":"5236",
        "question":"What is the effect of oseltamivir and zanamivir?",
        "question_pt":"Qual \u00e9 o efeito do oseltamivir e zanamivir?"
    },
    {
        "answer":"a triterpene saponine",
        "answer_pt":"uma saponina triterpeno",
        "id":"5237",
        "question":"What is Glycyrrhizin?",
        "question_pt":"O que \u00e9 glicirrizizina?"
    },
    {
        "answer":"interfere with replication and/or cytopathogenic effect (CPE) induction of many viruses",
        "answer_pt":"interferir na replica\u00e7\u00e3o e / ou indu\u00e7\u00e3o do efeito citopatog\u00eanico (CPE) de muitos v\u00edrus",
        "id":"5238",
        "question":"What is the effect of Glycyrrhizin in viral infections?",
        "question_pt":"Qual \u00e9 o efeito da glicirrizina nas infec\u00e7\u00f5es virais?"
    },
    {
        "answer":"cytokine storm'",
        "answer_pt":"tempestade de citocinas '",
        "id":"5239",
        "question":"What is another word for hypercytokinaemia?",
        "question_pt":"Qual \u00e9 a outra palavra para hipercitinemia?"
    },
    {
        "answer":"caspase-dependent apoptosis in airway cells",
        "answer_pt":"apoptose dependente de caspase em c\u00e9lulas das vias a\u00e9reas",
        "id":"5240",
        "question":"What has been correlated with the pathogenicity of the H5N1 infection?",
        "question_pt":"O que tem sido correlacionado com a patogenicidade da infec\u00e7\u00e3o pelo H5N1?"
    },
    {
        "answer":"glycyrrhizin might also serve as lead structure for the development of novel anti-influenza drugs",
        "answer_pt":"a glicirrizina tamb\u00e9m pode servir como estrutura principal para o desenvolvimento de novos medicamentos anti-influenza",
        "id":"5241",
        "question":"What is the conclusion of the study?",
        "question_pt":"Qual \u00e9 a conclus\u00e3o do estudo?"
    },
    {
        "answer":"2 days",
        "answer_pt":"2 dias",
        "id":"3240",
        "question":"What is the mean duration of time from single lobe consolidation to bilateral multilobar lung infiltrates in human adenovirus type 55 (HAdV-55)?",
        "question_pt":"Qual \u00e9 a dura\u00e7\u00e3o m\u00e9dia do tempo entre a consolida\u00e7\u00e3o do lobo \u00fanico e os infiltrados pulmonares multilobar bilaterais no adenov\u00edrus humano tipo 55 (HAdV-55)?"
    },
    {
        "answer":"4.8 days",
        "answer_pt":"4,8 dias",
        "id":"3241",
        "question":"What is the mean duration of time from first positive chest x-ray to bilateral multilobar lung infiltrates in human adenovirus type 55 (HAdV-55)?",
        "question_pt":"Qual \u00e9 a dura\u00e7\u00e3o m\u00e9dia do primeiro tempo entre a primeira radiografia de t\u00f3rax positiva e os infiltrados pulmonares multilobar bilaterais no adenov\u00edrus humano tipo 55 (HAdV-55)?"
    },
    {
        "answer":"Persistent high fever, dyspnea and rapid progression to respiratory failure within 2 weeks, together with bilateral consolidations and infiltrates",
        "answer_pt":"Febre alta persistente, dispn\u00e9ia e r\u00e1pida progress\u00e3o para insufici\u00eancia respirat\u00f3ria em 2 semanas, juntamente com consolida\u00e7\u00f5es e infiltra\u00e7\u00f5es bilaterais",
        "id":"3242",
        "question":"What are the most frequent clinical manifestations of human adenovirus type 55 (HAdV-55) induced ARDS?",
        "question_pt":"Quais s\u00e3o as manifesta\u00e7\u00f5es cl\u00ednicas mais frequentes da SDRA induzida por adenov\u00edrus humano tipo 55 (HAdV-55)?"
    },
    {
        "answer":"This pathogen was fully characterized by whole-genome sequencing",
        "answer_pt":"Esse pat\u00f3geno foi totalmente caracterizado pelo seq\u00fcenciamento de todo o genoma",
        "id":"3243",
        "question":"What do we know about the genomics of human adenovirus type 55 (HAdV-55)?",
        "question_pt":"O que sabemos sobre a gen\u00f4mica do adenov\u00edrus humano tipo 55 (HAdV-55)?"
    },
    {
        "answer":"Flulike symptoms, such as fever, cough and little sputum, were commonly observed at the onset of illness",
        "answer_pt":"Sintomas semelhantes \u00e0 gripe, como febre, tosse e escarro, foram comumente observados no in\u00edcio da doen\u00e7a",
        "id":"3244",
        "question":"What are the clinical symptoms of human adenovirus type 55 (HAdV-55)?",
        "question_pt":"Quais s\u00e3o os sintomas cl\u00ednicos do adenov\u00edrus humano tipo 55 (HAdV-55)?"
    },
    {
        "answer":"5 days",
        "answer_pt":"5 dias",
        "id":"3245",
        "question":"What is the mean time from onset of symptoms to dyspnea in human adenovirus type 55 (HAdV-55)?",
        "question_pt":"Qual \u00e9 o tempo m\u00e9dio desde o in\u00edcio dos sintomas at\u00e9 a dispn\u00e9ia no adenov\u00edrus humano tipo 55 (HAdV-55)?"
    },
    {
        "answer":"9.6 days",
        "answer_pt":"9,6 dias",
        "id":"3246",
        "question":"What is the mean time of onset of symptoms to ICU admission in human adenovirus type 55 (HAdV-55)?",
        "question_pt":"Qual \u00e9 o tempo m\u00e9dio de aparecimento dos sintomas at\u00e9 a admiss\u00e3o na UTI no adenov\u00edrus humano tipo 55 (HAdV-55)?"
    },
    {
        "answer":"43 breaths per minute",
        "answer_pt":"43 respira\u00e7\u00f5es por minuto",
        "id":"3247",
        "question":"What is the mean rate of respiration upon admission to the ICU when admitted for human adenovirus type 55 (HAdV-55)?",
        "question_pt":"Qual \u00e9 a taxa m\u00e9dia de respira\u00e7\u00e3o na admiss\u00e3o na UTI quando admitida para adenov\u00edrus humano tipo 55 (HAdV-55)?"
    },
    {
        "answer":" low or in the normal range",
        "answer_pt":"baixo ou na faixa normal",
        "id":"3248",
        "question":"What is the white blood cell count in severe cases of human adenovirus type 55 (HAdV-55)?",
        "question_pt":"Qual \u00e9 a contagem de gl\u00f3bulos brancos em casos graves de adenov\u00edrus humano tipo 55 (HAdV-55)?"
    },
    {
        "answer":"CXRs revealed multiple bilateral lobar or segment consolidation in the lungs of all five patients, and radiographic lesions progressed rapidly after ICU admission",
        "answer_pt":"As radiografias revelaram consolida\u00e7\u00e3o lobar ou segmento bilateral m\u00faltipla nos pulm\u00f5es dos cinco pacientes, e as les\u00f5es radiogr\u00e1ficas progrediram rapidamente ap\u00f3s a admiss\u00e3o na UTI",
        "id":"3249",
        "question":"What does a chest x-ray look like for a patient with a severe case of human adenovirus type 55 (HAdV-55)?",
        "question_pt":"Como \u00e9 a radiografia de t\u00f3rax em um paciente com um caso grave de adenov\u00edrus humano tipo 55 (HAdV-55)?"
    },
    {
        "answer":"Consolidations within a single lobe or several lobes with a clear border and air bronchogram were the most common findings on HRCT scans. Nodules, patches, pleural effusion, abscess and a cavity were also seen visualized by HRCT",
        "answer_pt":"Consolida\u00e7\u00f5es em um \u00fanico lobo ou em v\u00e1rios l\u00f3bulos com borda clara e broncograma a\u00e9reo foram os achados mais comuns em exames de TCAR. N\u00f3dulos, adesivos, derrame pleural, abscesso e cavidade tamb\u00e9m foram visualizados pela TCAR",
        "id":"3250",
        "question":"What are the high resolution pulmonary CT scan findings for patients with severe cases of human adenovirus type 55 (HAdV-55)?",
        "question_pt":"Quais s\u00e3o os achados da tomografia pulmonar de alta resolu\u00e7\u00e3o para pacientes com casos graves de adenov\u00edrus humano tipo 55 (HAdV-55)?"
    },
    {
        "answer":"All patients had HAdV-55 viremia. In four of the five patients, it was first detected in endotracheal aspirate (ETA) samples",
        "answer_pt":"Todos os pacientes apresentaram viremia por HAdV-55. Em quatro dos cinco pacientes, foi detectado pela primeira vez em amostras de aspirado endotraqueal (ETA)",
        "id":"3251",
        "question":"Where could a clinician acquire a positive viral sample in severe cases of human adenovirus type 55 (HAdV-55)?",
        "question_pt":"Onde um cl\u00ednico poderia adquirir uma amostra viral positiva em casos graves de adenov\u00edrus humano tipo 55 (HAdV-55)?"
    },
    {
        "answer":"1 to 10 days",
        "answer_pt":"1 a 10 dias",
        "id":"3252",
        "question":"How long did it take for patients with positive human adenovirus type 55 (HAdV-55) endotracheal aspirates to develop a measurable viremia?",
        "question_pt":"Quanto tempo levou para pacientes com aspirados endotraqueais de adenov\u00edrus humano positivo tipo 55 (HAdV-55) desenvolver uma viremia mensur\u00e1vel?"
    },
    {
        "answer":" HAdV-55 may cause severe ARDS in immunocompetent young men with blood type B",
        "answer_pt":"O HAdV-55 pode causar SDRA grave em homens jovens imunocompetentes com sangue tipo B",
        "id":"3253",
        "question":"Does blood type play a role in the severity of human adenovirus type 55 (HAdV-55) infection?",
        "question_pt":"O tipo sangu\u00edneo desempenha um papel na gravidade da infec\u00e7\u00e3o por adenov\u00edrus humano tipo 55 (HAdV-55)?"
    },
    {
        "answer":"Persistent high fever, dyspnea and rapid progression to respiratory failure within 2 weeks, together with bilateral consolidations and infiltrates at the same time, are the most frequent clinical manifestations",
        "answer_pt":"Febre alta persistente, dispn\u00e9ia e r\u00e1pida progress\u00e3o para insufici\u00eancia respirat\u00f3ria em 2 semanas, juntamente com consolida\u00e7\u00f5es bilaterais e infiltrados ao mesmo tempo, s\u00e3o as manifesta\u00e7\u00f5es cl\u00ednicas mais frequentes",
        "id":"3254",
        "question":"What are the most common clinical manifestations of severe human adenovirus type 55 (HAdV-55) induced ARDS?",
        "question_pt":"Quais s\u00e3o as manifesta\u00e7\u00f5es cl\u00ednicas mais comuns de SDRA induzida por adenov\u00edrus humano grave tipo 55 (HAdV-55)?"
    },
    {
        "answer":"HAdV-55-induced severe ARDS has a very high mortality rate (80%) despite appropriate respiratory support.",
        "answer_pt":"A SDRA grave induzida pelo HAdV-55 tem uma taxa de mortalidade muito alta (80%), apesar do suporte respirat\u00f3rio apropriado.",
        "id":"3255",
        "question":"What is the mortality rate of severe ARDS from human adenovirus type 55 (HAdV-55)?",
        "question_pt":"Qual \u00e9 a taxa de mortalidade por SDRA grave do adenov\u00edrus humano tipo 55 (HAdV-55)?"
    },
    {
        "answer":"a lower T-cell count may be a risk factor for HAdV-55 infection in young adults",
        "answer_pt":"uma contagem mais baixa de c\u00e9lulas T pode ser um fator de risco para a infec\u00e7\u00e3o por HAdV-55 em adultos jovens",
        "id":"3256",
        "question":"What role does T-cell count play in severe human adenovirus type 55 (HAdV-55) infection?",
        "question_pt":"Qual o papel da contagem de c\u00e9lulas T na infec\u00e7\u00e3o grave por adenov\u00edrus humano tipo 55 (HAdV-55)?"
    },
    {
        "answer":"we found that severe HAdV-55 infection could cause a rapid progression of respiratory failure, with a very high failure rate for NPPV and IMV",
        "answer_pt":"descobrimos que a infec\u00e7\u00e3o grave por HAdV-55 poderia causar uma r\u00e1pida progress\u00e3o da insufici\u00eancia respirat\u00f3ria, com uma taxa de falha muito alta para NPPV e IMV",
        "id":"3257",
        "question":"How successful are the use of invasive mechanical ventilation (IMV) and non-invasive positive pressure ventilation (NPPV) in the treatment of severe ARDS from human adenovirus type 55 infection?",
        "question_pt":"Qual \u00e9 o \u00eaxito do uso de ventila\u00e7\u00e3o mec\u00e2nica invasiva (VMI) e ventila\u00e7\u00e3o n\u00e3o invasiva por press\u00e3o positiva (VPN) no tratamento de SDRA grave da infec\u00e7\u00e3o por adenov\u00edrus humano tipo 55?"
    },
    {
        "answer":"Two hundred",
        "answer_pt":"Duzentos",
        "id":"5252",
        "question":"How many patients were analyzed in the study?",
        "question_pt":"Quantos pacientes foram analisados \u200b\u200bno estudo?"
    },
    {
        "answer":"600,000",
        "answer_pt":"600.000",
        "id":"5253",
        "question":"How many patients with community-acquired pneumonia are hospitalized each year?",
        "question_pt":"Quantos pacientes com pneumonia adquirida na comunidade s\u00e3o hospitalizados a cada ano?"
    },
    {
        "answer":"the presence of new parenchymal infiltrates",
        "answer_pt":"presen\u00e7a de novos infiltrados parenquimatosos",
        "id":"5254",
        "question":"What chest X-ray findings are typically indicative of community-acquired pneumonia?",
        "question_pt":"Que achados na radiografia de t\u00f3rax s\u00e3o tipicamente indicativos de pneumonia adquirida na comunidade?"
    },
    {
        "answer":"11 June 2009",
        "answer_pt":"11 de junho de 2009",
        "id":"5256",
        "question":"When did WHO declare a pandemic of pH1N1/2009v influenza?",
        "question_pt":"Quando a OMS declarou uma pandemia de influenza pH1N1 / 2009v?"
    },
    {
        "answer":"1/40",
        "answer_pt":"1/40",
        "id":"5257",
        "question":"What is the classical cutoff value for antibody titers?",
        "question_pt":"Qual \u00e9 o valor de corte cl\u00e1ssico para os t\u00edtulos de anticorpos?"
    },
    {
        "answer":"conferring 50% protection against a viral challenge",
        "answer_pt":"conferindo 50% de prote\u00e7\u00e3o contra um desafio viral",
        "id":"5258",
        "question":"What is meant by a protective HIA titer?",
        "question_pt":"O que se entende por um t\u00edtulo protetor de HIA?"
    },
    {
        "answer":"a substantial proportion of Reunion Island's population had pre-existing immunity to 2009 pandemic influenza virus",
        "answer_pt":"uma propor\u00e7\u00e3o substancial da popula\u00e7\u00e3o da ilha da Reuni\u00e3o tinha imunidade pr\u00e9-existente ao v\u00edrus da influenza pand\u00eamica de 2009",
        "id":"5259",
        "question":"What are the results of the study?",
        "question_pt":"Quais s\u00e3o os resultados do estudo?"
    },
    {
        "answer":"the remote exposure of these individuals to H1N1 viruses circulating before 1957",
        "answer_pt":"a exposi\u00e7\u00e3o remota desses indiv\u00edduos aos v\u00edrus H1N1 que circulavam antes de 1957",
        "id":"5260",
        "question":"What was the interpretation for the crossreactive antibodies?",
        "question_pt":"Qual foi a interpreta\u00e7\u00e3o para os anticorpos reativos cruzados?"
    },
    {
        "answer":"9 weeks",
        "answer_pt":"9 semanas",
        "id":"5261",
        "question":"How long did the pH1N1/2009 viral outbreak last?",
        "question_pt":"Quanto tempo durou o surto viral de pH1N1 / 2009?"
    },
    {
        "answer":"to investigate the different pathogens involved in ILI and describe the associated symptoms",
        "answer_pt":"investigar os diferentes pat\u00f3genos envolvidos no ILI e descrever os sintomas associados",
        "id":"5262",
        "question":"What were the aims of this study?",
        "question_pt":"Quais foram os objetivos deste estudo?"
    },
    {
        "answer":"R\u00e9seau Sentinelles",
        "answer_pt":"R\u00e9seau Sentinelles",
        "id":"5263",
        "question":"What network of physicians provides real-time clinical data on the spread of influenza in France?",
        "question_pt":"Que rede de m\u00e9dicos fornece dados cl\u00ednicos em tempo real sobre a dissemina\u00e7\u00e3o da gripe na Fran\u00e7a?"
    },
    {
        "answer":"a sudden fever above 39uC with myalgia and respiratory signs",
        "answer_pt":"febre s\u00fabita acima de 39uC com mialgia e sinais respirat\u00f3rios",
        "id":"5264",
        "question":"What are the criteria used to define an influenza-like illness in France?",
        "question_pt":"Quais s\u00e3o os crit\u00e9rios usados \u200b\u200bpara definir uma doen\u00e7a semelhante \u00e0 gripe na Fran\u00e7a?"
    },
    {
        "answer":"rhinovirus",
        "answer_pt":"rinov\u00edrus",
        "id":"5265",
        "question":"What virus was the most common among the H1N1v negative patients?",
        "question_pt":"Qual v\u00edrus foi o mais comum entre os pacientes com H1N1v negativo?"
    },
    {
        "answer":"to elucidate the proximate causes of breeding failure behind the recent decline in productivity in the Spanish Pyrenees",
        "answer_pt":"elucidar as causas imediatas de falha na cria\u00e7\u00e3o por tr\u00e1s do recente decl\u00ednio da produtividade nos Piren\u00e9us espanh\u00f3is",
        "id":"5269",
        "question":"What was the aim of this study?",
        "question_pt":"Qual foi o objetivo deste estudo?"
    },
    {
        "answer":"the Pyrenees",
        "answer_pt":"os Pirineus",
        "id":"5270",
        "question":"Where is the bearded vulture (Gypaetus barbatus) commonly found?",
        "question_pt":"Onde \u00e9 comum encontrar o abutre-barbudo (Gypaetus barbatus)?"
    },
    {
        "answer":"the antiproliferative effect of a copper (II) complex on HT-29 colon cancer cells",
        "answer_pt":"o efeito antiproliferativo de um complexo de cobre (II) nas c\u00e9lulas cancer\u00edgenas do c\u00f3lon HT-29",
        "id":"5277",
        "question":"What was the focus of this study?",
        "question_pt":"Qual foi o foco deste estudo?"
    },
    {
        "answer":"colorectal cancer",
        "answer_pt":"c\u00e2ncer colorretal",
        "id":"5278",
        "question":"What is the third most prevalent cancer in females in the United States?",
        "question_pt":"Qual \u00e9 o terceiro c\u00e2ncer mais prevalente em mulheres nos Estados Unidos?"
    },
    {
        "answer":"83.2%",
        "answer_pt":"83,2%",
        "id":"5279",
        "question":"What is the 1-year survival rate for colorectal cancer patients?",
        "question_pt":"Qual \u00e9 a taxa de sobrevida em 1 ano para pacientes com c\u00e2ncer colorretal?"
    },
    {
        "answer":"64.3%",
        "answer_pt":"64,3%",
        "id":"5280",
        "question":"What is the 5-year survival rate for colorectal cancer patients?",
        "question_pt":"Qual \u00e9 a taxa de sobrevida em 5 anos para pacientes com c\u00e2ncer colorretal?"
    },
    {
        "answer":"detection of nuclear condensation",
        "answer_pt":"detec\u00e7\u00e3o de condensa\u00e7\u00e3o nuclear",
        "id":"5281",
        "question":"How were nuclear morphological changes in HT-29 cells measured?",
        "question_pt":"Como foram medidas as altera\u00e7\u00f5es morfol\u00f3gicas nucleares nas c\u00e9lulas HT-29?"
    },
    {
        "answer":"apoptotic chromatin changes",
        "answer_pt":"altera\u00e7\u00f5es apopt\u00f3ticas da cromatina",
        "id":"5282",
        "question":"What is directly related to nuclear condensation?",
        "question_pt":"O que est\u00e1 diretamente relacionado \u00e0 condensa\u00e7\u00e3o nuclear?"
    },
    {
        "answer":"membrane permeability, cell shrinkage, disruption of the mitochondrial membrane, and chromatin condensation",
        "answer_pt":"permeabilidade da membrana, encolhimento celular, ruptura da membrana mitocondrial e condensa\u00e7\u00e3o da cromatina",
        "id":"5283",
        "question":"What morphological cell changes are most associated with apoptosis?",
        "question_pt":"Quais altera\u00e7\u00f5es morfol\u00f3gicas das c\u00e9lulas est\u00e3o mais associadas \u00e0 apoptose?"
    },
    {
        "answer":"HT-29 cells",
        "answer_pt":"C\u00e9lulas HT-29",
        "id":"5284",
        "question":"What types of cells are suitable for colon cancer studies?",
        "question_pt":"Que tipos de c\u00e9lulas s\u00e3o adequados para estudos de c\u00e2ncer de c\u00f3lon?"
    },
    {
        "answer":"to explore the feasibility of DNA vaccination of poultry",
        "answer_pt":"explorar a viabilidade da vacina\u00e7\u00e3o de DNA de aves de capoeira",
        "id":"5285",
        "question":"What was the goal of this study?",
        "question_pt":"Qual foi o objetivo deste estudo?"
    },
    {
        "answer":"it is possible to develop a multivalent DNA vaccine for poultry that can protect against multiple HPAI H5N1 strains and that could keep pace with the continued evolution of avian influenza viruses",
        "answer_pt":"\u00e9 poss\u00edvel desenvolver uma vacina de DNA multivalente para aves de capoeira que possa proteger contra v\u00e1rias cepas de HPAI H5N1 e que possa acompanhar a evolu\u00e7\u00e3o cont\u00ednua dos v\u00edrus da influenza avi\u00e1ria",
        "id":"5286",
        "question":"What is the conclusion of this study?",
        "question_pt":"Qual \u00e9 a conclus\u00e3o deste estudo?"
    },
    {
        "answer":"Two E. coli W mutants were engineered that could effectively produce the bio-active flavonol glycosides hyperoside and quercitrin",
        "answer_pt":"Dois mutantes de E. coli W foram projetados para produzir efetivamente os glicos\u00eddeos de flavonol bioativos, hiperos\u00eddeo e quercitrina",
        "id":"5298",
        "question":"What was the conclusion of this study?",
        "question_pt":"Qual foi a conclus\u00e3o deste estudo?"
    },
    {
        "answer":"the economically viable production of various glycosides",
        "answer_pt":"a produ\u00e7\u00e3o economicamente vi\u00e1vel de v\u00e1rios glicos\u00eddeos",
        "id":"5299",
        "question":"What are the implications of the novel fermentation-based glycosylation strategy described in this study?",
        "question_pt":"Quais s\u00e3o as implica\u00e7\u00f5es da nova estrat\u00e9gia de glicosila\u00e7\u00e3o baseada em fermenta\u00e7\u00e3o descrita neste estudo?"
    },
    {
        "answer":"solubility, stability and bio-activity",
        "answer_pt":"solubilidade, estabilidade e bioatividade",
        "id":"5300",
        "question":"What characteristics does glycosylation have on flavonoids?",
        "question_pt":"Quais s\u00e3o as caracter\u00edsticas da glicosila\u00e7\u00e3o nos flavon\u00f3ides?"
    },
    {
        "answer":"a pro-coagulant protein",
        "answer_pt":"uma prote\u00edna pr\u00f3-coagulante",
        "id":"5292",
        "question":"What is fibrinogen-like protein 2 (FgI2)?",
        "question_pt":"O que \u00e9 a prote\u00edna 2 semelhante ao fibrinog\u00eanio (FgI2)?"
    },
    {
        "answer":"Fgl2 depletion",
        "answer_pt":"Deple\u00e7\u00e3o de Fgl2",
        "id":"5293",
        "question":"What represses murine hepatitis virus strain 3 (MHV-3) infection?",
        "question_pt":"O que reprime a infec\u00e7\u00e3o pelo v\u00edrus da hepatite murina cepa 3 (MHV-3)?"
    },
    {
        "answer":"to determine the role of CC10 in FH and the regulation of Fgl2 by CC10",
        "answer_pt":"determinar o papel da CC10 na SF e a regula\u00e7\u00e3o da Fgl2 pela CC10",
        "id":"5294",
        "question":"What was the goal of this study?",
        "question_pt":"Qual foi o objetivo deste estudo?"
    },
    {
        "answer":"a serious life-threatening disease characterized by massive hepatocyte necrosis",
        "answer_pt":"uma doen\u00e7a grave com risco de vida caracterizada por necrose maci\u00e7a de hepat\u00f3citos",
        "id":"5295",
        "question":"What is fulminant hepatitis?",
        "question_pt":"O que \u00e9 hepatite fulminante?"
    },
    {
        "answer":"transforming prothrombin directly into thrombin,",
        "answer_pt":"transformar protrombina diretamente em trombina,",
        "id":"5296",
        "question":"How does Prothrombinase Fgl2 affect the coagulation process?",
        "question_pt":"Como a protrombinase Fgl2 afeta o processo de coagula\u00e7\u00e3o?"
    },
    {
        "answer":"72 h",
        "answer_pt":"72 h",
        "id":"5297",
        "question":"How long after MHV-3 infection were liver samples taken?",
        "question_pt":"Quanto tempo ap\u00f3s a infec\u00e7\u00e3o pelo MHV-3 foram coletadas amostras de f\u00edgado?"
    },
    {
        "answer":" findings suggest that urbanization spatially combines risk factors to produce particular types of peri-urban landscapes with significantly higher HPAI H5N1 emergence risk.",
        "answer_pt":"os resultados sugerem que a urbaniza\u00e7\u00e3o combina espacialmente fatores de risco para produzir tipos particulares de paisagens peri-urbanas com um risco de emerg\u00eancia HPAI H5N1 significativamente maior.",
        "id":"585",
        "question":"What is the relationship between urbanization and risk of emergence of flu-like diseases?",
        "question_pt":"Qual a rela\u00e7\u00e3o entre urbaniza\u00e7\u00e3o e risco de surgimento de doen\u00e7as semelhantes \u00e0 gripe?"
    },
    {
        "answer":" higher levels of chicken densities, duck and geese flock size diversities, and fraction of land under rice or aquaculture than rural and urban areas. We also found that land-use diversity, a surrogate measure for potential mixing of host populations and other factors that likely influence viral transmission",
        "answer_pt":"n\u00edveis mais altos de densidade de galinhas, diversidades de tamanho de rebanhos de patos e gansos e fra\u00e7\u00e3o de terra sob arroz ou aquicultura do que nas \u00e1reas rurais e urbanas. Tamb\u00e9m descobrimos que a diversidade do uso da terra, uma medida substituta para potencial mistura de popula\u00e7\u00f5es hospedeiras e outros fatores que provavelmente influenciam a transmiss\u00e3o viral",
        "id":"586",
        "question":"What factors and characteristics of semi-urban landscapes promote viral transmission?",
        "question_pt":"Quais fatores e caracter\u00edsticas das paisagens semi-urbanas promovem a transmiss\u00e3o viral?"
    },
    {
        "answer":" landscapes where intensive and extensive forms of poultry production overlap were found at greater risk",
        "answer_pt":"paisagens onde formas intensivas e extensas de produ\u00e7\u00e3o de aves se sobrep\u00f5em foram encontradas com maior risco",
        "id":"587",
        "question":"What is the relationship between HIN1 viral transmission and poultry production.",
        "question_pt":"Qual \u00e9 a rela\u00e7\u00e3o entre a transmiss\u00e3o viral HIN1 e a produ\u00e7\u00e3o de aves?"
    },
    {
        "answer":"The convergence model can be so adapted by incorporating the dynamics of urban, agricultural, and natural ecosystem transformations proposed with this framework. These associated multifaceted interactions including feedbacks that affect ecological communities, hosts and pathogen populations, are the proximate drivers of disease emergence.",
        "answer_pt":"O modelo de converg\u00eancia pode ser adaptado incorporando a din\u00e2mica das transforma\u00e7\u00f5es urbanas, agr\u00edcolas e naturais dos ecossistemas propostas com essa estrutura. Essas intera\u00e7\u00f5es multifacetadas associadas, incluindo feedbacks que afetam comunidades ecol\u00f3gicas, hospedeiros e popula\u00e7\u00f5es de pat\u00f3genos, s\u00e3o os principais impulsionadores do surgimento da doen\u00e7a.",
        "id":"588",
        "question":"What is the principle behind infection Convergence Model ?",
        "question_pt":"Qual \u00e9 o princ\u00edpio por tr\u00e1s do Modelo de Converg\u00eancia da infec\u00e7\u00e3o?"
    },
    {
        "answer":"BRT utilizes regression trees and boosting algorithms to fit several models and combines them for improving prediction by performing iterative loop throughout the model ",
        "answer_pt":"O BRT utiliza \u00e1rvores de regress\u00e3o e algoritmos de otimiza\u00e7\u00e3o para ajustar-se a v\u00e1rios modelos e os combina para melhorar a previs\u00e3o executando loop iterativo em todo o modelo",
        "id":"590",
        "question":"What is the Boosted Regression Tree method?",
        "question_pt":"O que \u00e9 o m\u00e9todo da \u00c1rvore de Regress\u00e3o Refor\u00e7ada?"
    },
    {
        "answer":"The advantage of BRT is that it applies stochastic processes that include probabilistic components to improve predictive performance.",
        "answer_pt":"A vantagem do BRT \u00e9 que ele aplica processos estoc\u00e1sticos que incluem componentes probabil\u00edsticos para melhorar o desempenho preditivo.",
        "id":"591",
        "question":"What is the advantage of Boosted Regression Tree method?",
        "question_pt":"Qual \u00e9 a vantagem do m\u00e9todo Boosted Regression Tree?"
    },
    {
        "answer":" high land-use diversity landscapes, a variable not previously considered in spatial studies of HPAI H5N1, are at significantly greater risk for HPAI H5N1 outbreaks",
        "answer_pt":"As paisagens com alta diversidade de uso da terra, uma vari\u00e1vel n\u00e3o considerada anteriormente em estudos espaciais do HPAI H5N1, correm um risco significativamente maior de surtos de HPAI H5N1",
        "id":"592",
        "question":"What is the relationship between land use and emergence of HPAI H5N1?",
        "question_pt":"Qual \u00e9 a rela\u00e7\u00e3o entre uso da terra e emerg\u00eancia do HPAI H5N1?"
    },
    {
        "answer":"Emergence risk should be highest in the most rapidly transforming urban areas, peri-urban zones where mixes of urban-rural, modern-traditional land uses and poultry husbandry coincide most intensely.",
        "answer_pt":"O risco de emerg\u00eancia deve ser mais alto nas \u00e1reas urbanas que se transformam mais rapidamente, nas zonas peri-urbanas, onde as misturas de usos da terra urbano-rural, moderno-tradicional e cria\u00e7\u00e3o de aves coincidem mais intensamente.",
        "id":"589",
        "question":"Where is the highest risk of  HPAI H5N1 like disease emergence?",
        "question_pt":"Onde est\u00e1 o maior risco de HPAI H5N1 como surgimento de doen\u00e7a?"
    },
    {
        "answer":"Landscape fragmentation produces ecotones, defined as abrupt edges or transitions zones between different ecological systems, thought to facilitate disease emergence by increasing the intensity and frequency of contact between host species [31] Furthermore, fragmentation of natural habitat tends to interrupt and degrade natural processes, including interspecies interactions that regulate densities of otherwise opportunistic species that may serve as competent hosts",
        "answer_pt":"A fragmenta\u00e7\u00e3o da paisagem produz ec\u00f3tonos, definidos como arestas abruptas ou zonas de transi\u00e7\u00e3o entre diferentes sistemas ecol\u00f3gicos, pensados \u200b\u200bpara facilitar o surgimento da doen\u00e7a, aumentando a intensidade e a frequ\u00eancia do contato entre as esp\u00e9cies hospedeiras [31]. Al\u00e9m disso, a fragmenta\u00e7\u00e3o do habitat natural tende a interromper e degradar os processos naturais, incluindo intera\u00e7\u00f5es interesp\u00e9cies que regulam densidades de esp\u00e9cies oportunistas que possam servir como hospedeiros competentes",
        "id":"594",
        "question":"How does land use fragmentation increase the risk of flu-like diseases?",
        "question_pt":"Como a fragmenta\u00e7\u00e3o do uso da terra aumenta o risco de doen\u00e7as semelhantes \u00e0 gripe?"
    },
    {
        "answer":" extent of rice cultivation is a risk factor, mainly due its association with free ranging ducks acting as scavengers",
        "answer_pt":"A extens\u00e3o do cultivo de arroz \u00e9 um fator de risco, principalmente devido \u00e0 sua associa\u00e7\u00e3o com patos livres que atuam como catadores",
        "id":"596",
        "question":"What is the relationship between the outbreak of HPAI H5N1 like diseases and rice cultivation?",
        "question_pt":"Qual \u00e9 a rela\u00e7\u00e3o entre o surto de HPAI H5N1, como doen\u00e7as e o cultivo de arroz?"
    },
    {
        "answer":"extent of aquaculture is a known risk factor [10] , possibly because water bodies offer routes for transmission and persistence of the virus",
        "answer_pt":"A extens\u00e3o da aquicultura \u00e9 um fator de risco conhecido [10], possivelmente porque os corpos d'\u00e1gua oferecem rotas para transmiss\u00e3o e persist\u00eancia do v\u00edrus.",
        "id":"597",
        "question":"What is the relationship between aquaculture and spread of H5N1 like diseases?",
        "question_pt":"Qual \u00e9 a rela\u00e7\u00e3o entre a aquicultura e a propaga\u00e7\u00e3o do H5N1 como doen\u00e7as?"
    },
    {
        "answer":"Proximity to water bodies increases the risk of outbreaks [47, [50] [51] [52] , possibly by increasing the chance of contact between wild water birds and domestic poultry.",
        "answer_pt":"A proximidade de corpos d'\u00e1gua aumenta o risco de surtos [47, [50] [51] [52], possivelmente aumentando a chance de contato entre aves aqu\u00e1ticas selvagens e aves dom\u00e9sticas.",
        "id":"598",
        "question":"What is the relationship between proximity ofwater bodies to agricultural lands and spread of H5N1 like diseases?",
        "question_pt":"Qual \u00e9 a rela\u00e7\u00e3o entre a proximidade dos corpos d'\u00e1gua com as terras agr\u00edcolas e a propaga\u00e7\u00e3o do H5N1 como doen\u00e7as?"
    },
    {
        "answer":"diversity of chicken flock-size had a strong association with HPAI H5N1 ",
        "answer_pt":"diversidade de tamanho de rebanho de frango teve forte associa\u00e7\u00e3o com HPAI H5N1",
        "id":"599",
        "question":"What is the effect of diversity of chicken flock on H5N1 disease?",
        "question_pt":"Qual \u00e9 o efeito da diversidade do rebanho de frango na doen\u00e7a H5N1?"
    },
    {
        "answer":"Compound Topographical Index (CTI, also known as Topographical Wetness Index) is a measure of the tendency for water to pool. Studies in Thailand and elsewhere [54] have shown that the extent of surface water is a strong risk factor, possibly due to the role of water in long-range transmission and persistence of the virus. I",
        "answer_pt":"O \u00cdndice Topogr\u00e1fico Composto (CTI, tamb\u00e9m conhecido como \u00cdndice de Umidade Topogr\u00e1fica) \u00e9 uma medida da tend\u00eancia da \u00e1gua a se acumular. Estudos na Tail\u00e2ndia e em outros pa\u00edses [54] mostraram que a extens\u00e3o da \u00e1gua superficial \u00e9 um forte fator de risco, possivelmente devido ao papel da \u00e1gua na transmiss\u00e3o a longo prazo e na persist\u00eancia do v\u00edrus. Eu",
        "id":"600",
        "question":"What is Compound Topological Index and how is it related to the risk of disease transmission?",
        "question_pt":"O que \u00e9 o \u00cdndice Topol\u00f3gico Composto e como est\u00e1 relacionado ao risco de transmiss\u00e3o da doen\u00e7a?"
    },
    {
        "answer":"compare the antiviral activity of CQ versus HCQ, the dose-response curves",
        "answer_pt":"comparar a atividade antiviral de CQ versus HCQ, as curvas dose-resposta",
        "id":"655",
        "question":"In vitro comparison of antiviral activity of Chloroquine(CQ) and Hydroxychloroquine(HCQ) against COVID-19?",
        "question_pt":"Compara\u00e7\u00e3o in vitro da atividade antiviral de cloroquina (CQ) e hidroxicloroquina (HCQ) contra COVID-19?"
    },
    {
        "answer":" two potential drugs, CQ appears to be the drug of choice for large-scale use due to its availability, proven safety record, and a relatively low cost.",
        "answer_pt":"Como dois medicamentos em potencial, o CQ parece ser o medicamento de escolha para uso em larga escala devido \u00e0 sua disponibilidade, registro de seguran\u00e7a comprovado e custo relativamente baixo.",
        "id":"651",
        "question":"What will be the drug of choice for treating COVID-19 between Chloroquine and Remdesivir?",
        "question_pt":"Qual ser\u00e1 o medicamento de escolha no tratamento do COVID-19 entre a cloroquina e o remdesivir?"
    },
    {
        "answer":"CQ and HCQ are weak bases that are known to elevate the pH of acidic intracellular organelles",
        "answer_pt":"CQ e HCQ s\u00e3o bases fracas que s\u00e3o conhecidas por elevar o pH das organelas intracelulares \u00e1cidas",
        "id":"658",
        "question":"Mechanism of action of Chloroquine(CQ) and Hydroxychloroquine(HCQ) against COVID-19?",
        "question_pt":"Mecanismo de a\u00e7\u00e3o da cloroquina (CQ) e hidroxicloroquina (HCQ) contra o COVID-19?"
    },
    {
        "answer":"Since acidification is crucial for endosome maturation and function, we surmise that endosome maturation might be blocked at intermediate stages of endocytosis,",
        "answer_pt":"Como a acidifica\u00e7\u00e3o \u00e9 crucial para a matura\u00e7\u00e3o e fun\u00e7\u00e3o do endossoma, supomos que a matura\u00e7\u00e3o do endossoma possa ser bloqueada em est\u00e1gios intermedi\u00e1rios da endocitose,",
        "id":"661",
        "question":"What is the effect of Chloroquine(CQ) and Hydroxychloroquine(HCQ) on endosomal maturation and endocytosis in COVID-19 treatment?",
        "question_pt":"Qual \u00e9 o efeito da cloroquina (CQ) e hidroxicloroquina (HCQ) na matura\u00e7\u00e3o endoss\u00f4mica e endocitose no tratamento com COVID-19?"
    },
    {
        "answer":" HCQ is a safe and successful anti-inflammatory agent",
        "answer_pt":"HCQ \u00e9 um agente anti-inflamat\u00f3rio seguro e bem-sucedido",
        "id":"662",
        "question":"Evidence of Hydroxychloroquine(HCQ) being anti inflammatory in SARS-CoV-2 critically ill patients with elevated plasma cytokines?",
        "question_pt":"Evid\u00eancia de hidroxicloroquina (HCQ) ser anti-inflamat\u00f3ria em pacientes cr\u00edticos com SARS-CoV-2 com citocinas plasm\u00e1ticas elevadas?"
    },
    {
        "answer":"50.4%",
        "answer_pt":"50,4%",
        "id":"3459",
        "question":"What proportion of healthcare workers reported symptoms  of depression?",
        "question_pt":"Qual a propor\u00e7\u00e3o de profissionais de sa\u00fade que relataram sintomas de depress\u00e3o?"
    },
    {
        "answer":"[44.6%",
        "answer_pt":"[44,6%",
        "id":"3460",
        "question":"What proportion of healthcare workers reported symptoms of anxiety?",
        "question_pt":"Qual a propor\u00e7\u00e3o de profissionais de sa\u00fade que relataram sintomas de ansiedade?"
    },
    {
        "answer":"34.0%",
        "answer_pt":"34,0%",
        "id":"3461",
        "question":"What proportion of healthcare workers reported symptoms of insomnia?",
        "question_pt":"Qual a propor\u00e7\u00e3o de profissionais de sa\u00fade que relataram sintomas de ins\u00f4nia?"
    },
    {
        "answer":"[71.5%",
        "answer_pt":"[71,5%",
        "id":"3462",
        "question":"What proportion reported distress?",
        "question_pt":"Que propor\u00e7\u00e3o relatou sofrimento?"
    },
    {
        "answer":"among men vs women: 2.0 [0-6.0] vs 4.0 [1.0-7.0]; P < .001",
        "answer_pt":"entre homens e mulheres: 2,0 [0-6,0] vs 4,0 [1,0-7,0]; P <0,001",
        "id":"3463",
        "question":"What were the Generalized Anxiety Disorder scale scores?",
        "question_pt":"Quais foram os escores da escala do Transtorno de Ansiedade Generalizada?"
    },
    {
        "answer":"among frontline vs second-line workers: 6.0 [2.0-11.0] vs 4.0 [1.0-8.0]; P < .001",
        "answer_pt":"entre funcion\u00e1rios da linha de frente e trabalhadores de segunda linha: 6,0 [2,0-11,0] vs 4,0 [1,0-8,0]; P <0,001",
        "id":"3464",
        "question":"What were the  Insomnia Severity Index scores ?",
        "question_pt":"Quais foram as pontua\u00e7\u00f5es no \u00cdndice de Gravidade da Ins\u00f4nia?"
    },
    {
        "answer":" 21.0 [8.5-34.5] vs 18.0 [6.0-28.0] in Hubei outside Wuhan and 15.0 [4.0-26.0] outside Hubei; P < .001).",
        "answer_pt":"21,0 [8,5-34,5] vs 18,0 [6,0-28,0] em Hubei fora de Wuhan e 15,0 [4,0-26,0] fora de Hubei; P <0,001).",
        "id":"3465",
        "question":"What were the  Impact of Event Scale\u2013Revised scores?",
        "question_pt":"Quais foram as pontua\u00e7\u00f5es do Impact of Event Scale \u2013 Revised?"
    },
    {
        "answer":"participants from outside Hubei province were associated with lower risk of experiencing symptoms of distress compared with those in Wuhan (odds ratio [OR], 0.62; 95% CI, 0.43-0.88; P = .008)",
        "answer_pt":"participantes de fora da prov\u00edncia de Hubei foram associados a menor risco de apresentar sintomas de ang\u00fastia em compara\u00e7\u00e3o com os de Wuhan (odds ratio [OR], 0,62; IC 95%, 0,43-0,88; P = 0,008)",
        "id":"3466",
        "question":"What were the results of analysis?",
        "question_pt":"Quais foram os resultados da an\u00e1lise?"
    },
    {
        "answer":"Frontline health care workers engaged in direct diagnosis, treatment, and care of patients with COVID-19 were associated with a higher risk of symptoms of depression (OR, 1.52; 95% CI, 1.11-2.09; P = .01), anxiety (OR, 1.57; 95% CI, 1.22-2.02; P < .001), insomnia (OR, 2.97; 95% CI, 1.92-4.60; P < .001), and distress (OR, 1.60; 95% CI, 1.25-2.04; P < .001).",
        "answer_pt":"Os profissionais de sa\u00fade de primeira linha envolvidos no diagn\u00f3stico, tratamento e atendimento diretos de pacientes com COVID-19 foram associados a um maior risco de sintomas de depress\u00e3o (OR, 1,52; IC95%: 1,11-2,09; P = 0,01), ansiedade ( OR, 1,57; IC95%, 1,22-2,02; P <0,001), ins\u00f4nia (OR, 2,97; IC95%, 1,92-4,60; P <0,001) e ang\u00fastia (OR, 1,60; IC95%, 1,25 -2,04; P <0,001).",
        "id":"3467",
        "question":"What were the results of analysis?",
        "question_pt":"Quais foram os resultados da an\u00e1lise?"
    },
    {
        "answer":"In this survey of heath care workers in hospitals equipped with fever clinics or wards for patients with COVID-19 in Wuhan and other regions in China, participants reported experiencing psychological burden, especially nurses, women, those in Wuhan, and frontline health care workers directly engaged in the diagnosis, treatment, and care for patients with COVID-19.",
        "answer_pt":"Nesta pesquisa com profissionais de sa\u00fade em hospitais equipados com cl\u00ednicas ou enfermarias para pacientes com COVID-19 em Wuhan e outras regi\u00f5es da China, os participantes relataram ter sofrido carga psicol\u00f3gica, especialmente enfermeiras, mulheres, pessoas em Wuhan e profissionais de sa\u00fade de primeira linha. envolvidos no diagn\u00f3stico, tratamento e atendimento de pacientes com COVID-19.",
        "id":"3468",
        "question":"What are the conclusions of this study?",
        "question_pt":"Quais s\u00e3o as conclus\u00f5es deste estudo?"
    },
    {
        "answer":"a family of AAA-ATPase proteins",
        "answer_pt":"uma fam\u00edlia de prote\u00ednas AAA-ATPase",
        "id":"924",
        "question":"What are microtubule severing enzymes?",
        "question_pt":"O que s\u00e3o enzimas cortadoras de microt\u00fabulos?"
    },
    {
        "answer":"SPG4",
        "answer_pt":"SPG4",
        "id":"926",
        "question":"What genetic mutation is associated with hereditary spastic paraplegia?",
        "question_pt":"Que muta\u00e7\u00e3o gen\u00e9tica est\u00e1 associada \u00e0 paraplegia esp\u00e1stica heredit\u00e1ria?"
    },
    {
        "answer":"KATNB1",
        "answer_pt":"KATNB1",
        "id":"927",
        "question":"What genetic mutation is associated with cerebral malformations?",
        "question_pt":"Que muta\u00e7\u00e3o gen\u00e9tica est\u00e1 associada a malforma\u00e7\u00f5es cerebrais?"
    },
    {
        "answer":"KATNAL2",
        "answer_pt":"KATNAL2",
        "id":"928",
        "question":"What genetic mutation is associated with autism?",
        "question_pt":"Que muta\u00e7\u00e3o gen\u00e9tica est\u00e1 associada ao autismo?"
    },
    {
        "answer":"microtubule severing enzyme",
        "answer_pt":"enzima de separa\u00e7\u00e3o de microt\u00fabulos",
        "id":"929",
        "question":"What is KATNAL1?",
        "question_pt":"O que \u00e9 o KATNAL1?"
    },
    {
        "answer":"central nervous system",
        "answer_pt":"sistema nervoso central",
        "id":"930",
        "question":"What organ is most associated with the KATNAL1 gene?",
        "question_pt":"Qual \u00f3rg\u00e3o est\u00e1 mais associado ao gene KATNAL1?"
    },
    {
        "answer":"working memory and spatial memory",
        "answer_pt":"mem\u00f3ria de trabalho e mem\u00f3ria espacial",
        "id":"931",
        "question":"What CNS functions can be measured by studying the movement of mice in a T-maze?",
        "question_pt":"Que fun\u00e7\u00f5es do SNC podem ser medidas estudando o movimento de camundongos em um labirinto em T?"
    },
    {
        "answer":"circadian rhythms, sleep and behaviour",
        "answer_pt":"ritmos circadianos, sono e comportamento",
        "id":"932",
        "question":"What CNS functions are changed by mutations in the KATNAL1 gene?",
        "question_pt":"Quais fun\u00e7\u00f5es do SNC s\u00e3o alteradas por muta\u00e7\u00f5es no gene KATNAL1?"
    },
    {
        "answer":"arthropod",
        "answer_pt":"artr\u00f3pode",
        "id":"1220",
        "question":"How is Japanese encephalitis transmitted?",
        "question_pt":"Como a encefalite japonesa \u00e9 transmitida?"
    },
    {
        "answer":"calcium",
        "answer_pt":"c\u00e1lcio",
        "id":"1222",
        "question":"What element is essential to promoting JEV infection?",
        "question_pt":"Que elemento \u00e9 essencial para promover a infec\u00e7\u00e3o por JEV?"
    },
    {
        "answer":"transmembrane domain 3",
        "answer_pt":"dom\u00ednio transmembranar 3",
        "id":"1223",
        "question":"Where is Q130 located in the NS4B protein?",
        "question_pt":"Onde est\u00e1 localizado o Q130 na prote\u00edna NS4B?"
    },
    {
        "answer":"voltage-gated Ca(2+) channel (VGCC) inhibitor",
        "answer_pt":"inibidor de canal Ca (2+) dependente de voltagem (VGCC)",
        "id":"1224",
        "question":"What is the mechanism of action for manidipine?",
        "question_pt":"Qual \u00e9 o mecanismo de a\u00e7\u00e3o da manidipina?"
    },
    {
        "answer":"70",
        "answer_pt":"70",
        "id":"1225",
        "question":"How many different pathogens are members of the Flaviviridae family of virus?",
        "question_pt":"Quantos pat\u00f3genos diferentes s\u00e3o membros da fam\u00edlia de v\u00edrus Flaviviridae?"
    },
    {
        "answer":"11-kb",
        "answer_pt":"11 kb",
        "id":"1226",
        "question":"What is the size of a flavivirus?",
        "question_pt":"Qual \u00e9 o tamanho de um flaviv\u00edrus?"
    },
    {
        "answer":"single",
        "answer_pt":"solteiro",
        "id":"1227",
        "question":"How many open reading frames are in the flavivirus genome?",
        "question_pt":"Quantos quadros de leitura abertos est\u00e3o no genoma do flaviv\u00edrus?"
    },
    {
        "answer":"capsid (C), membrane (premembrane [prM] and membrane [M] ), and envelope (E)",
        "answer_pt":"caps\u00eddeo (C), membrana (pr\u00e9-membrana [prM] e membrana [M]) e envelope (E)",
        "id":"1228",
        "question":"What are the structural protein elements of a flavivirus?",
        "question_pt":"Quais s\u00e3o os elementos estruturais proteicos de um flaviv\u00edrus?"
    },
    {
        "answer":"viral replication, virion assembly, and virus escape from immune surveillance.",
        "answer_pt":"replica\u00e7\u00e3o viral, montagem de v\u00edrus e escape de v\u00edrus da vigil\u00e2ncia imunol\u00f3gica.",
        "id":"1229",
        "question":"What is the function of the nonstructural protein elements of the flavivirus?",
        "question_pt":"Qual \u00e9 a fun\u00e7\u00e3o dos elementos proteicos n\u00e3o estruturais do flaviv\u00edrus?"
    },
    {
        "answer":"Recombinant viral particles",
        "answer_pt":"Part\u00edculas virais recombinantes",
        "id":"1230",
        "question":"What are RVPs?",
        "question_pt":"O que s\u00e3o RVPs?"
    },
    {
        "answer":"high-throughput screening",
        "answer_pt":"rastreio de alto rendimento",
        "id":"1231",
        "question":"What is HTS?",
        "question_pt":"O que \u00e9 o HTS?"
    },
    {
        "answer":"the 50% cytotoxic concentration",
        "answer_pt":"a concentra\u00e7\u00e3o citot\u00f3xica de 50%",
        "id":"1232",
        "question":"What is the selective index in high throughput screening?",
        "question_pt":"Qual \u00e9 o \u00edndice seletivo na triagem de alto rendimento?"
    },
    {
        "answer":"a natural virus-like envelope on the outside and a replicon on the inside",
        "answer_pt":"um envelope natural semelhante a um v\u00edrus por fora e um replic\u00e3o por dentro",
        "id":"1233",
        "question":"What is the structure of a recombiant  viral particle?",
        "question_pt":"Qual \u00e9 a estrutura de uma part\u00edcula viral recombinante?"
    },
    {
        "answer":"selective index of >10",
        "answer_pt":"\u00edndice seletivo> 10",
        "id":"1234",
        "question":"What measure is used in high-throughput screening to identify potential antiviral compounds?",
        "question_pt":"Que medida \u00e9 usada na triagem de alto rendimento para identificar poss\u00edveis compostos antivirais?"
    },
    {
        "answer":"nine species",
        "answer_pt":"nove esp\u00e9cies",
        "id":"430",
        "question":"How many known species of Rotavirus exist?",
        "question_pt":"Quantas esp\u00e9cies conhecidas de rotav\u00edrus existem?"
    },
    {
        "answer":"double-stranded ribonucleic acid",
        "answer_pt":"\u00e1cido ribonucleico de fita dupla",
        "id":"431",
        "question":"Is Rotavirus single or double-stranded?",
        "question_pt":"O Rotavirus \u00e9 \u00fanico ou de fita dupla?"
    },
    {
        "answer":"VP1-VP4, VP6 and VP7",
        "answer_pt":"VP1-VP4, VP6 e VP7",
        "id":"432",
        "question":"What structural proteins are coded by Rotavirus?",
        "question_pt":"Quais prote\u00ednas estruturais s\u00e3o codificadas pelo Rotav\u00edrus?"
    },
    {
        "answer":"NSP1-NSP5/NSP6",
        "answer_pt":"NSP1-NSP5 / NSP6",
        "id":"433",
        "question":"What non-structural proteins are coded by Rotavirus?",
        "question_pt":"Quais prote\u00ednas n\u00e3o estruturais s\u00e3o codificadas pelo Rotav\u00edrus?"
    },
    {
        "answer":"qualitative real-time polymerase chain reaction",
        "answer_pt":"rea\u00e7\u00e3o em cadeia da polimerase qualitativa em tempo real",
        "id":"434",
        "question":"What is qRT-PCR?",
        "question_pt":"O que \u00e9 qRT-PCR?"
    },
    {
        "answer":"the generation of antigen-specific \"memory\" B and T lymphocytes",
        "answer_pt":"a gera\u00e7\u00e3o de linf\u00f3citos B e T \"mem\u00f3ria\" espec\u00edfica de ant\u00edgeno",
        "id":"4255",
        "question":"What is required to establish a secondary immune response to a viral infection?",
        "question_pt":"O que \u00e9 necess\u00e1rio para estabelecer uma resposta imune secund\u00e1ria a uma infec\u00e7\u00e3o viral?"
    },
    {
        "answer":"expression of AID",
        "answer_pt":"express\u00e3o de AID",
        "id":"4256",
        "question":"What do immunoglobulin isotype recombination and somatic hyper mutation depend on?",
        "question_pt":"De que dependem a recombina\u00e7\u00e3o do isotipo de imunoglobulina e a hiper muta\u00e7\u00e3o som\u00e1tica?"
    },
    {
        "answer":"ELISpot technique",
        "answer_pt":"T\u00e9cnica ELISpot",
        "id":"4257",
        "question":"What was used to quantify the amount of IgM secreting cells?",
        "question_pt":"O que foi usado para quantificar a quantidade de c\u00e9lulas secretoras de IgM?"
    },
    {
        "answer":"Wuhan, China",
        "answer_pt":"Wuhan, China",
        "id":"4393",
        "question":"Where was the coronavirus discovered?",
        "question_pt":"Onde o coronav\u00edrus foi descoberto?"
    },
    {
        "answer":"34,598",
        "answer_pt":"34.598",
        "id":"4394",
        "question":"What is the number of confirmed cases reached on 8 February 2020?",
        "question_pt":"Qual \u00e9 o n\u00famero de casos confirmados atingidos em 8 de fevereiro de 2020?"
    },
    {
        "answer":"new forecasting model to estimate and forecast the number of confirmed cases of COVID-19 in the upcoming ten days based on the previously confirmed cases recorded in China",
        "answer_pt":"novo modelo de previs\u00e3o para estimar e prever o n\u00famero de casos confirmados de COVID-19 nos pr\u00f3ximos dez dias, com base nos casos confirmados anteriormente registrados na China",
        "id":"4395",
        "question":"What is presented in this study?",
        "question_pt":"O que \u00e9 apresentado neste estudo?"
    },
    {
        "answer":"an improved adaptive neuro-fuzzy inference system (ANFIS) using an enhanced flower pollination algorithm (FPA) by using the salp swarm algorithm (SSA)",
        "answer_pt":"um sistema de infer\u00eancia neuro-fuzzy adapt\u00e1vel aprimorado (ANFIS) usando um algoritmo aprimorado de poliniza\u00e7\u00e3o de flores (FPA) usando o algoritmo salp swarm (SSA)",
        "id":"4396",
        "question":"What is the proposed model?",
        "question_pt":"Qual \u00e9 o modelo proposto?"
    },
    {
        "answer":"to improve FPA to avoid its drawbacks (i.e., getting trapped at the local optima)",
        "answer_pt":"para melhorar o FPA para evitar suas desvantagens (ou seja, ficar preso nas \u00f3timas localidades)",
        "id":"4397",
        "question":"When is SSA generally employed?",
        "question_pt":"Quando o SSA geralmente \u00e9 empregado?"
    },
    {
        "answer":"to improve the performance of ANFIS by determining the parameters of ANFIS using FPASSA.",
        "answer_pt":"melhorar o desempenho do ANFIS, determinando os par\u00e2metros do ANFIS usando FPASSA.",
        "id":"4398",
        "question":"What is the main idea behind the proposed model?",
        "question_pt":"Qual \u00e9 a principal id\u00e9ia por tr\u00e1s do modelo proposto?"
    },
    {
        "answer":" FPASSA-ANFIS",
        "answer_pt":"FPASSA-ANFIS",
        "id":"4399",
        "question":"What is the proposed model called?",
        "question_pt":"Como \u00e9 chamado o modelo proposto?"
    },
    {
        "answer":"using the World Health Organization (WHO) official data of the outbreak of the COVID-19 to forecast the confirmed cases of the upcoming ten days.",
        "answer_pt":"usando os dados oficiais da Organiza\u00e7\u00e3o Mundial da Sa\u00fade (OMS) sobre o surto do COVID-19 para prever os casos confirmados dos pr\u00f3ximos dez dias.",
        "id":"4400",
        "question":"How is FPASSA-ANFIS model evaluated?",
        "question_pt":"Como \u00e9 avaliado o modelo FPASSA-ANFIS?"
    },
    {
        "answer":"it showed better performance in terms of Mean Absolute Percentage Error (MAPE), Root Mean Squared Relative Error (RMSRE), Root Mean Squared Relative Error (RMSRE), coefficient of determination ( R 2 ), and computing time. ",
        "answer_pt":"apresentou melhor desempenho em termos de erro m\u00e9dio percentual absoluto (MAPE), erro relativo quadr\u00e1tico m\u00e9dio da raiz (RMSRE), erro relativo quadr\u00e1tico m\u00e9dio da raiz (RMSRE), coeficiente de determina\u00e7\u00e3o (R \u200b\u200b2) e tempo de computa\u00e7\u00e3o.",
        "id":"4401",
        "question":"What did the comparison of  the FPASSA-ANFIS model with several existing models, show?",
        "question_pt":"O que mostrou a compara\u00e7\u00e3o do modelo FPASSA-ANFIS com v\u00e1rios modelos existentes?"
    },
    {
        "answer":" using two different datasets of weekly influenza confirmed cases in two countries, namely the USA and China",
        "answer_pt":"usando dois conjuntos de dados diferentes de casos confirmados semanais de gripe em dois pa\u00edses, EUA e China",
        "id":"4402",
        "question":"How was the proposed model tested?",
        "question_pt":"Como foi testado o modelo proposto?"
    },
    {
        "answer":"showed good performances",
        "answer_pt":"mostrou bons desempenhos",
        "id":"4403",
        "question":"What were the outcomes of the test?",
        "question_pt":"Quais foram os resultados do teste?"
    },
    {
        "answer":" pathogens for human beings, which infect respiratory, hepatic, gastrointestinal, and neurologic diseases.",
        "answer_pt":"pat\u00f3genos para seres humanos, que infectam doen\u00e7as respirat\u00f3rias, hep\u00e1ticas, gastrointestinais e neurol\u00f3gicas.",
        "id":"4404",
        "question":"What are the large family of viruses, called coronaviruses?",
        "question_pt":"Qual \u00e9 a grande fam\u00edlia de v\u00edrus, chamados coronav\u00edrus?"
    },
    {
        "answer":" among humans, birds, livestock, mice, bats, and other wild animals ",
        "answer_pt":"entre seres humanos, aves, gado, ratos, morcegos e outros animais selvagens",
        "id":"4405",
        "question":"Among whom are the coronaviruses distributed?",
        "question_pt":"Entre quem s\u00e3o distribu\u00eddos os coronav\u00edrus?"
    },
    {
        "answer":" in time series prediction and forecasting problems",
        "answer_pt":"na previs\u00e3o de s\u00e9ries temporais e problemas de previs\u00e3o",
        "id":"4406",
        "question":"In what the Adaptive Neuro-Fuzzy Inference System (ANFIS) [22] is widely applied?",
        "question_pt":"Em que o Sistema de Infer\u00eancia Adaptativa Neuro-Difusa (ANFIS) [22] \u00e9 amplamente aplicado?"
    },
    {
        "answer":"flexibility in determining nonlinearity in the time series data, as well as combining the properties of both artificial neural networks (ANN) and fuzzy logic systems.",
        "answer_pt":"flexibilidade na determina\u00e7\u00e3o da n\u00e3o linearidade nos dados de s\u00e9ries temporais, al\u00e9m de combinar as propriedades das redes neurais artificiais (RNA) e dos sistemas l\u00f3gicos difusos.",
        "id":"4407",
        "question":"What does ANFIS offer?",
        "question_pt":"O que a ANFIS oferece?"
    },
    {
        "answer":"in various forecasting applications, for example, in [23] , a stock price forecasting model was proposed using ANFIS and empirical mode decomposition",
        "answer_pt":"em v\u00e1rias aplica\u00e7\u00f5es de previs\u00e3o, por exemplo, em [23], um modelo de previs\u00e3o de pre\u00e7o das a\u00e7\u00f5es foi proposto usando ANFIS e decomposi\u00e7\u00e3o do modo emp\u00edrico",
        "id":"4408",
        "question":"In which applications has it been applied?",
        "question_pt":"Em quais aplicativos ele foi aplicado?"
    },
    {
        "answer":"swarm intelligence",
        "answer_pt":"intelig\u00eancia enxame",
        "id":"4421",
        "question":"What is SI?",
        "question_pt":"O que \u00e9 SI?"
    },
    {
        "answer":"particle swarm optimization",
        "answer_pt":"otimiza\u00e7\u00e3o de enxame de particulas",
        "id":"4422",
        "question":"What is PSO?",
        "question_pt":"O que \u00e9 PSO?"
    },
    {
        "answer":"sine-cosine algorithm",
        "answer_pt":"algoritmo seno-cosseno",
        "id":"4423",
        "question":"What is SCA?",
        "question_pt":"O que \u00e9 SCA?"
    },
    {
        "answer":"multi-verse optimizer",
        "answer_pt":"otimizador multi-verso",
        "id":"4424",
        "question":"What is MVO?",
        "question_pt":"O que \u00e9 o MVO?"
    },
    {
        "answer":"to forecast oil consumption in three countries, namely, Canada, Germany, and Japan.",
        "answer_pt":"prever o consumo de petr\u00f3leo em tr\u00eas pa\u00edses, Canad\u00e1, Alemanha e Jap\u00e3o.",
        "id":"4425",
        "question":"For what SCA algorithm was applied to improve the ANFIS model ?",
        "question_pt":"Para que algoritmo SCA foi aplicado para melhorar o modelo ANFIS?"
    },
    {
        "answer":"may stock at local optima",
        "answer_pt":"pode estocar na optima local",
        "id":"4426",
        "question":"What may be a problem with individual SI algorithm?",
        "question_pt":"O que pode ser um problema com o algoritmo SI individual?"
    },
    {
        "answer":" ordered weighted averaging",
        "answer_pt":"m\u00e9dia ponderada ordenada",
        "id":"4427",
        "question":"What is OWA?",
        "question_pt":"O que \u00e9 o OWA?"
    },
    {
        "answer":"an improved ANFIS model based on a modified flower pollination algorithm (FPA) using the salp swarm algorithm (SSA).",
        "answer_pt":"um modelo ANFIS aprimorado, baseado em um algoritmo de poliniza\u00e7\u00e3o por flores modificado (FPA), usando o algoritmo de enxame de salp (SSA).",
        "id":"4428",
        "question":"What is proposed in the current study?",
        "question_pt":"O que \u00e9 proposto no presente estudo?"
    },
    {
        "answer":"inspired by the flow pollination process of the flowering plants.",
        "answer_pt":"inspirado no processo de poliniza\u00e7\u00e3o por fluxo das plantas com flores.",
        "id":"4429",
        "question":"What  is the FPA optimization algorithm inspired by?",
        "question_pt":"Em que \u00e9 inspirado o algoritmo de otimiza\u00e7\u00e3o da FPA?"
    },
    {
        "answer":"inspired by the behavior of salp chains",
        "answer_pt":"inspirado pelo comportamento das cadeias de sal",
        "id":"4430",
        "question":"What is the SSA optimization algorithm inspired by?",
        "question_pt":"Em que \u00e9 inspirado o algoritmo de otimiza\u00e7\u00e3o SSA?"
    },
    {
        "answer":" is a hybrid of FPA and SSA, in which the SSA is applied as a local search method for FPA",
        "answer_pt":"\u00e9 um h\u00edbrido de FPA e SSA, no qual o SSA \u00e9 aplicado como um m\u00e9todo de pesquisa local para FPA",
        "id":"4431",
        "question":"What is the proposed FPASSA method?",
        "question_pt":"Qual \u00e9 o m\u00e9todo FPASSA proposto?"
    },
    {
        "answer":" by receiving the historical COVID-19 dataset.",
        "answer_pt":"recebendo o conjunto de dados hist\u00f3rico COVID-19.",
        "id":"4432",
        "question":"How does the proposed FPASSA start?",
        "question_pt":"Como come\u00e7a o FPASSA proposto?"
    },
    {
        "answer":"an efficient forecasting model to forecast the confirmed cases of the COVID-19 in China for the upcoming ten days based on previously confirmed cases.",
        "answer_pt":"um modelo de previs\u00e3o eficiente para prever os casos confirmados do COVID-19 na China para os pr\u00f3ximos dez dias, com base em casos confirmados anteriormente.",
        "id":"4433",
        "question":"What do the authors propose?",
        "question_pt":"O que os autores prop\u00f5em?"
    },
    {
        "answer":"the major proton pump that acidifies intracellular compartments of eukaryotic cells",
        "answer_pt":"a principal bomba de pr\u00f3tons que acidifica os compartimentos intracelulares das c\u00e9lulas eucari\u00f3ticas",
        "id":"5301",
        "question":"What is vacuolar-type H(+)-ATPase (v-ATPase)?",
        "question_pt":"O que \u00e9 vacuolar do tipo H (+) - ATPase (v-ATPase)?"
    },
    {
        "answer":"v-ATPase inhibitor",
        "answer_pt":"inibidor da v-ATPase",
        "id":"5302",
        "question":"What is archazolid?",
        "question_pt":"O que \u00e9 archazolid?"
    },
    {
        "answer":"two",
        "answer_pt":"dois",
        "id":"5303",
        "question":"How many complexes are within v-ATPase?",
        "question_pt":"Quantos complexos existem no v-ATPase?"
    },
    {
        "answer":"they pump protons into the extracellular space",
        "answer_pt":"eles bombeiam pr\u00f3tons para o espa\u00e7o extracelular",
        "id":"5304",
        "question":"What is the role of v-ATPase in the plasma membrane of osteoclasts and renal epithelial cells?",
        "question_pt":"Qual o papel da v-ATPase na membrana plasm\u00e1tica dos osteoclastos e c\u00e9lulas epiteliais renais?"
    },
    {
        "answer":"the proliferation, migration and differentiation of endothelial cells",
        "answer_pt":"prolifera\u00e7\u00e3o, migra\u00e7\u00e3o e diferencia\u00e7\u00e3o de c\u00e9lulas endoteliais",
        "id":"5305",
        "question":"What does angiogenesis depend on?",
        "question_pt":"Do que depende a angiog\u00eanese?"
    },
    {
        "answer":"CellTracker Green CMFDA Dye",
        "answer_pt":"Corante CellTracker CMFDA verde",
        "id":"5306",
        "question":"How were untreated MDA-MB-231 cells labeled?",
        "question_pt":"Como foram marcadas as c\u00e9lulas MDA-MB-231 n\u00e3o tratadas?"
    },
    {
        "answer":"describe GE and RTI outbreaks with infection and all-cause lethality rates according to the individual characteristics of nursing home residents",
        "answer_pt":"descrever surtos de GE e ITR com taxas de infec\u00e7\u00e3o e letalidade por todas as causas, de acordo com as caracter\u00edsticas individuais dos residentes de asilos",
        "id":"5307",
        "question":"What was the goal of the study?",
        "question_pt":"Qual foi o objetivo do estudo?"
    },
    {
        "answer":"30.0%",
        "answer_pt":"30,0%",
        "id":"5308",
        "question":"What was the reported infection rate for influenza?",
        "question_pt":"Qual foi a taxa de infec\u00e7\u00e3o relatada para influenza?"
    },
    {
        "answer":"1.5 to 1.6 times",
        "answer_pt":"1,5 a 1,6 vezes",
        "id":"5309",
        "question":"How many times more likely was an infection found in patients over 85 years old?",
        "question_pt":"Quantas vezes mais prov\u00e1vel foi encontrada uma infec\u00e7\u00e3o em pacientes com mais de 85 anos?"
    },
    {
        "answer":" (1) early identification of outbreak, (2) rapid expansion of patients, (3) high risk of nosocomial transmission, (4) unpredictability of size impacted, and (5) lack of backup resource.",
        "answer_pt":"(1) identifica\u00e7\u00e3o precoce do surto, (2) expans\u00e3o r\u00e1pida dos pacientes, (3) alto risco de transmiss\u00e3o hospitalar, (4) imprevisibilidade do tamanho impactado e (5) falta de recursos de backup.",
        "id":"634",
        "question":"What can be the main challenges in managing a hospital outbreak of COVID-19?",
        "question_pt":"Quais podem ser os principais desafios na gest\u00e3o de um surto hospitalar de COVID-19?"
    },
    {
        "answer":"Early identification of 2019-nCoV infection presents a major challenge",
        "answer_pt":"A identifica\u00e7\u00e3o precoce da infec\u00e7\u00e3o por 2019-nCoV apresenta um grande desafio",
        "id":"642",
        "question":"Why early identification of COVID-19 patients can be difficult?",
        "question_pt":"Por que a identifica\u00e7\u00e3o precoce de pacientes com COVID-19 pode ser dif\u00edcil?"
    },
    {
        "answer":"2019-nCoV patients should be admitted",
        "answer_pt":"Pacientes 2019-nCoV devem ser admitidos",
        "id":"644",
        "question":"What are the steps that a hospital should take after COVID-19 outbreak?",
        "question_pt":"Quais s\u00e3o as medidas que um hospital deve tomar ap\u00f3s o surto de COVID-19?"
    },
    {
        "answer":" substantial exposure risk for ICU staff because of the following reasons",
        "answer_pt":"risco de exposi\u00e7\u00e3o substancial para a equipe da UTI devido aos seguintes motivos",
        "id":"645",
        "question":"Why exposure risk of COVID-19 is very high for ICU staff and what precautions should be taken?",
        "question_pt":"Por que o risco de exposi\u00e7\u00e3o ao COVID-19 \u00e9 muito alto para a equipe da UTI e que precau\u00e7\u00f5es devem ser tomadas?"
    },
    {
        "answer":"susceptible persons is S, infected (persons who are sick and spread the infection) -I, removed (persons who do not spread the infection anymore, this number is the sum of isolated, recovered and dead people) -R; the infection and immunization rates ",
        "answer_pt":"pessoas suscet\u00edveis \u00e9 S, infectadas (pessoas doentes e espalham a infec\u00e7\u00e3o) -I, removidas (pessoas que n\u00e3o espalham mais a infec\u00e7\u00e3o, esse n\u00famero \u00e9 a soma de pessoas isoladas, recuperadas e mortas) -R; as taxas de infec\u00e7\u00e3o e imuniza\u00e7\u00e3o",
        "id":"669",
        "question":"Use of SIR/SEIR model in Statistics-Based Predictions of Coronavirus Epidemic Spreading?",
        "question_pt":"Uso do modelo SIR / SEIR em previs\u00f5es baseadas em estat\u00edstica da dissemina\u00e7\u00e3o epid\u00eamica de coronav\u00edrus?"
    },
    {
        "answer":"Pseudorabies (PRV) and Rabies viruses (RABV)",
        "answer_pt":"Pseudo-raiva (PRV) e v\u00edrus da raiva (RABV)",
        "id":"1935",
        "question":"What virus are used by the most successful neuronal circuit tracing methods?",
        "question_pt":"Que v\u00edrus \u00e9 usado pelos m\u00e9todos de rastreamento de circuitos neuronais mais bem-sucedidos?"
    },
    {
        "answer":"anterograde",
        "answer_pt":"anter\u00f3grado",
        "id":"1936",
        "question":"In what direction does the Vesicular stomatitis virus spread through the nervous system?",
        "question_pt":"Em que dire\u00e7\u00e3o o v\u00edrus da estomatite vesicular se espalha pelo sistema nervoso?"
    },
    {
        "answer":"method of delivery of the G gene",
        "answer_pt":"m\u00e9todo de entrega do gene G",
        "id":"1937",
        "question":"What determines the whether the spread of Vesicular stomatitis virus is monosynaptic or polysynaptic?",
        "question_pt":"O que determina se a propaga\u00e7\u00e3o do v\u00edrus da estomatite vesicular \u00e9 monossin\u00e1ptica ou polissin\u00e1ptica?"
    },
    {
        "answer":"rVSV vectors",
        "answer_pt":"vetores rVSV",
        "id":"1938",
        "question":"What types of viruses can be used to study the connectivity of neuronal circuitry?",
        "question_pt":"Que tipos de v\u00edrus podem ser usados \u200b\u200bpara estudar a conectividade dos circuitos neuronais?"
    },
    {
        "answer":"a clinically proven and marketed compound for the treatment of viral upper respiratory tract infections",
        "answer_pt":"um composto clinicamente comprovado e comercializado para o tratamento de infec\u00e7\u00f5es virais do trato respirat\u00f3rio superior",
        "id":"2141",
        "question":"What is Carrageenan?",
        "question_pt":"O que \u00e9 Carragenina?"
    },
    {
        "answer":"carrageenan and Zanamivir act synergistically against several influenza A virus strains (H1N1(09)pdm, H3N2, H5N1, H7N7)",
        "answer_pt":"carragenina e zanamivir agem sinergicamente contra v\u00e1rias cepas do v\u00edrus influenza A (H1N1 (09) pdm, H3N2, H5N1, H7N7)",
        "id":"2142",
        "question":"What is a potential therapeutic benefit of carageenan?",
        "question_pt":"Qual \u00e9 o potencial benef\u00edcio terap\u00eautico da carragenina?"
    },
    {
        "answer":"72 hours post infection",
        "answer_pt":"72 horas ap\u00f3s a infec\u00e7\u00e3o",
        "id":"2143",
        "question":"What is the optimal window for initiating treatment with carageenan and Zanamivir?",
        "question_pt":"Qual \u00e9 a janela ideal para iniciar o tratamento com carragenina e zanamivir?"
    },
    {
        "answer":"more than 35%",
        "answer_pt":"mais de 35%",
        "id":"2144",
        "question":"What was the mortality rate of influenza a virus subtype h7n9 (avian or bird flu)?",
        "question_pt":"Qual foi a taxa de mortalidade do v\u00edrus influenza a subtipo h7n9 (gripe avi\u00e1ria ou avi\u00e1ria)?"
    },
    {
        "answer":"more than 400 human cases",
        "answer_pt":"mais de 400 casos humanos",
        "id":"2145",
        "question":"How many human cases were there of influenza a virus subtype h7n9?",
        "question_pt":"Quantos casos humanos houve do v\u00edrus influenza subtipo h7n9?"
    },
    {
        "answer":"Most patients with A(H7N9) infections had contact with poultry or visited live animal markets",
        "answer_pt":"A maioria dos pacientes com infec\u00e7\u00e3o A (H7N9) teve contato com aves dom\u00e9sticas ou visitou mercados de animais vivos",
        "id":"2146",
        "question":"How did most patients contract influenza a virus subtype h7n9?",
        "question_pt":"Como a maioria dos pacientes contraiu o v\u00edrus influenza subtipo h7n9?"
    },
    {
        "answer":"some sporadic cases seemed to be a result of human to human transmissions",
        "answer_pt":"alguns casos espor\u00e1dicos pareciam ser resultado de transmiss\u00f5es de humano para humano",
        "id":"2147",
        "question":"Can influenza a virus subtype h7n9 be transmit human to human?",
        "question_pt":"O v\u00edrus da gripe subtipo h7n9 pode ser transmitido de humano para humano?"
    },
    {
        "answer":" influenza is an acute respiratory disease",
        "answer_pt":"a gripe \u00e9 uma doen\u00e7a respirat\u00f3ria aguda",
        "id":"2148",
        "question":"What kind of disease is caused by influenza?",
        "question_pt":"Que tipo de doen\u00e7a \u00e9 causada pela gripe?"
    },
    {
        "answer":" Worldwide, annual epidemics result in about three to five million cases of severe illness",
        "answer_pt":"Em todo o mundo, epidemias anuais resultam em cerca de tr\u00eas a cinco milh\u00f5es de casos de doen\u00e7as graves",
        "id":"2149",
        "question":"How many severe cases are there for annual influenza epidemics?",
        "question_pt":"Quantos casos graves existem para epidemias anuais de influenza?"
    },
    {
        "answer":"250,000 to 500,000",
        "answer_pt":"250.000 a 500.000",
        "id":"2150",
        "question":"How many deaths occur annually as a result of annual influenza epidemics?",
        "question_pt":"Quantas mortes ocorrem anualmente como resultado de epidemias anuais de influenza?"
    },
    {
        "answer":"influenza virus infections are often accompanied by other viral pathogens",
        "answer_pt":"infec\u00e7\u00f5es pelo v\u00edrus influenza s\u00e3o frequentemente acompanhadas por outros pat\u00f3genos virais",
        "id":"2151",
        "question":"Is coinfection common in influenza infection?",
        "question_pt":"A co-infec\u00e7\u00e3o \u00e9 comum na infec\u00e7\u00e3o por influenza?"
    },
    {
        "answer":"Analysis by qRT-PCR revealed that 54.5-83.3% of influenza A or B positive patients were found to have at least one concomitant respiratory viral infection [9] [10] [11] [12] . The detection frequency with immunofluorescence was found to be even higher (90-100%) [13, 14] . ",
        "answer_pt":"A an\u00e1lise por qRT-PCR revelou que 54,5-83,3% dos pacientes positivos para influenza A ou B apresentaram pelo menos uma infec\u00e7\u00e3o viral respirat\u00f3ria concomitante [9] [10] [11] [12]. A frequ\u00eancia de detec\u00e7\u00e3o com imunofluoresc\u00eancia foi ainda maior (90-100%) [13, 14].",
        "id":"2153",
        "question":"What percentage of people infected with influenza have a viral coinfection?",
        "question_pt":"Qual a porcentagem de pessoas infectadas com influenza tem co-infec\u00e7\u00e3o viral?"
    },
    {
        "answer":"human rhinovirus (hRV), respiratory syncytial virus, adenovirus, human coronavirus, human metapneumovirus and parainfluenza virus",
        "answer_pt":"rinov\u00edrus humano (hRV), v\u00edrus sincicial respirat\u00f3rio, adenov\u00edrus, coronav\u00edrus humano, metapneumov\u00edrus humano e v\u00edrus parainfluenza",
        "id":"2154",
        "question":"What are common concamitant infections during the course of influenza infection?",
        "question_pt":"O que s\u00e3o infec\u00e7\u00f5es concamitantes comuns durante o curso da infec\u00e7\u00e3o por influenza?"
    },
    {
        "answer":"The antiviral mechanism of carrageenan is based on the interference with viral attachment; as a consequence, viral entry is inhibited ",
        "answer_pt":"O mecanismo antiviral da carragenina \u00e9 baseado na interfer\u00eancia na liga\u00e7\u00e3o viral; como conseq\u00fc\u00eancia, a entrada viral \u00e9 inibida",
        "id":"2155",
        "question":"What is the anti-viral mechanism of action for carrageenan?",
        "question_pt":"Qual \u00e9 o mecanismo de a\u00e7\u00e3o antiviral da carragenina?"
    },
    {
        "answer":"a protective physical barrier in the nasal cavity",
        "answer_pt":"uma barreira f\u00edsica protetora na cavidade nasal",
        "id":"2156",
        "question":"What is the hypothetical mechanical benefit for carageenan in preventing and treating upper respiratory infections?",
        "question_pt":"Qual \u00e9 o benef\u00edcio mec\u00e2nico hipot\u00e9tico da carragenina na preven\u00e7\u00e3o e tratamento de infec\u00e7\u00f5es respirat\u00f3rias superiores?"
    },
    {
        "answer":"a high molecular weight sulfated polymer derived from red seaweed (Rhodophyceae) that has been extensively used in food, cosmetic and pharmaceutical industry and is generally recognized as safe by the FDA ",
        "answer_pt":"um pol\u00edmero sulfatado de alto peso molecular derivado de alga vermelha (Rhodophyceae) que tem sido amplamente utilizado na ind\u00fastria aliment\u00edcia, cosm\u00e9tica e farmac\u00eautica e \u00e9 geralmente reconhecido como seguro pelo FDA",
        "id":"2157",
        "question":"What is carageenan?",
        "question_pt":"O que \u00e9 carragenina?"
    },
    {
        "answer":"1.9 day faster recovery from common cold symptoms than placebo treated patients in the intention-to-treat population",
        "answer_pt":"Recupera\u00e7\u00e3o 1,9 dias mais r\u00e1pida de sintomas de resfriado comum do que pacientes tratados com placebo na popula\u00e7\u00e3o com inten\u00e7\u00e3o de tratar",
        "id":"2158",
        "question":"What is the recovery benefit of carageenan in patients with any respiratory virus?",
        "question_pt":"Qual \u00e9 o benef\u00edcio de recupera\u00e7\u00e3o da carragenina em pacientes com algum v\u00edrus respirat\u00f3rio?"
    },
    {
        "answer":"anti-influenza activity was shown by subgroup analysis of 49 influenza infected patients who benefited from a 3.3 days faster recovery from symptoms",
        "answer_pt":"A atividade anti-influenza foi demonstrada pela an\u00e1lise de subgrupos de 49 pacientes infectados por influenza que se beneficiaram de uma recupera\u00e7\u00e3o mais r\u00e1pida de 3,3 dias dos sintomas",
        "id":"2159",
        "question":"What is the anti-influenza benefit of carageenan?",
        "question_pt":"Qual \u00e9 o benef\u00edcio anti-influenza da carragenina?"
    },
    {
        "answer":"a significant reduction of the influenza viral load in nasal fluids and a significant increase in the number of virus free patients within the treatment period of 7 days",
        "answer_pt":"uma redu\u00e7\u00e3o significativa da carga viral da influenza nos l\u00edquidos nasais e um aumento significativo no n\u00famero de pacientes livres de v\u00edrus no per\u00edodo de tratamento de 7 dias",
        "id":"2160",
        "question":"What is the association between influenza viral load and carageenan?",
        "question_pt":"Qual \u00e9 a associa\u00e7\u00e3o entre carga viral da influenza e carragenina?"
    },
    {
        "answer":"In contrast to Oseltamivir, which needs to be activated by metabolic conversion, Zanamivir is directly applied as active drug and can also be administered intranasally",
        "answer_pt":"Ao contr\u00e1rio do oseltamivir, que precisa ser ativado pela convers\u00e3o metab\u00f3lica, o zanamivir \u00e9 aplicado diretamente como medicamento ativo e tamb\u00e9m pode ser administrado por via intranasal.",
        "id":"2163",
        "question":"Is Oseltamivir effective when taken intranasally?",
        "question_pt":"O oseltamivir \u00e9 eficaz quando tomado por via intranasal?"
    },
    {
        "answer":"challenge trials showed that treatment starting before and up to 36 hours post virus inoculation was associated with prevention of laboratory confirmed influenza and febrile illness as well as a reduction in viral titers, duration of shedding and symptoms",
        "answer_pt":"Os ensaios de desafio mostraram que o tratamento iniciado antes e at\u00e9 36 horas ap\u00f3s a inocula\u00e7\u00e3o do v\u00edrus estava associado \u00e0 preven\u00e7\u00e3o de influenza e doen\u00e7a febril confirmadas em laborat\u00f3rio, al\u00e9m de uma redu\u00e7\u00e3o nos t\u00edtulos virais, dura\u00e7\u00e3o do derramamento e sintomas",
        "id":"2164",
        "question":"What is the effect of intranasal Zanamivir on laboratory confirmed infleunza infection?",
        "question_pt":"Qual \u00e9 o efeito do Zanamivir intranasal na infec\u00e7\u00e3o por influenza confirmada em laborat\u00f3rio?"
    },
    {
        "answer":"the combination of two effective, established mono-therapies resulted in a significantly enhanced survival in lethally H7N7 infected mice",
        "answer_pt":"a combina\u00e7\u00e3o de duas monoterapias eficazes e estabelecidas resultou em uma sobreviv\u00eancia significativamente aprimorada em camundongos infectados com H7N7",
        "id":"2165",
        "question":"Do carageenan and Zanamivir delivered intranasally have a benefit when taken for influenza subtype H7N7 infection?",
        "question_pt":"O carageenano e o zanamivir administrados por via intranasal t\u00eam um benef\u00edcio quando tomados para a infec\u00e7\u00e3o pelo subtipo H7N7 da gripe?"
    },
    {
        "answer":"carrageenan and Zanamivir starting 72 hpi significantly protects lethally influenza H1N1(09)pdm infected mice",
        "answer_pt":"carragena e zanamivir a partir de 72 hpi protegem significativamente camundongos infectados letalmente por influenza H1N1 (09) pdm",
        "id":"2166",
        "question":"Do carageenan and Zanamivir delivered intranasally have a benefit when taken for influenza subtype H1N1 infection?",
        "question_pt":"O carageenano e o zanamivir administrados por via intranasal t\u00eam um benef\u00edcio quando tomados para a infec\u00e7\u00e3o pelo subtipo H1N1 da gripe?"
    },
    {
        "answer":"While H1N1(09)pdm was highly sensitive to inhibition by both substances alone, H7N7 required much higher concentrations of carrageenan and Zanamivir, respectively, to achieve similar inhibition efficiencies",
        "answer_pt":"Enquanto o H1N1 (09) pdm foi altamente sens\u00edvel \u00e0 inibi\u00e7\u00e3o por ambas as subst\u00e2ncias isoladamente, o H7N7 exigiu concentra\u00e7\u00f5es muito mais altas de carragenina e zanamivir, respectivamente, para obter efici\u00eancias de inibi\u00e7\u00e3o semelhantes",
        "id":"2179",
        "question":"Is there a dose-dependent response to carageenan and Zanamavir intranasal therapy?",
        "question_pt":"Existe uma resposta dependente da dose \u00e0 terapia intranasal de carragenina e zanamivir?"
    },
    {
        "answer":"the H1N1(09)pdm model the combination of carrageenan with 1 mg/kg BW/day Zanamivir showed statistically significant enhanced survival in comparison to placebo treatment even after a treatment start 72 hpi",
        "answer_pt":"o modelo H1N1 (09) pdm, a combina\u00e7\u00e3o de carragenina com 1 mg / kg de peso corporal / dia de zanamivir mostrou sobrevida aumentada estatisticamente significativa em compara\u00e7\u00e3o com o tratamento com placebo, mesmo ap\u00f3s o in\u00edcio do tratamento 72 hpi",
        "id":"2180",
        "question":"Do carageenan and Zanamavir together have a greater benefit than either in monotherapy?",
        "question_pt":"A carragenina e o zanamivir juntos t\u00eam um benef\u00edcio maior do que em monoterapia?"
    },
    {
        "answer":"A second scope of this combination is the protection against newly emerging pandemic viruses during the time until identification of the virus followed by manufacturing and distribution of vaccines",
        "answer_pt":"Um segundo escopo dessa combina\u00e7\u00e3o \u00e9 a prote\u00e7\u00e3o contra v\u00edrus pand\u00eamicos emergentes recentemente, at\u00e9 a identifica\u00e7\u00e3o do v\u00edrus, seguida pela fabrica\u00e7\u00e3o e distribui\u00e7\u00e3o de vacinas.",
        "id":"2182",
        "question":"Did the use of carageenan play a role in pandemic's caused by novel viruses?",
        "question_pt":"O uso de carragenina teve algum papel em pandemias causadas por novos v\u00edrus?"
    },
    {
        "answer":"as a sudden onset of fever more than 38 degrees Celsius and cough, associated or not with other symptoms such as breathing difficulty, headache, etc. ",
        "answer_pt":"como um in\u00edcio repentino de febre acima de 38 graus Celsius e tosse, associado ou n\u00e3o a outros sintomas, como dificuldade respirat\u00f3ria, dor de cabe\u00e7a etc.",
        "id":"4101",
        "question":"How was ILI defined?",
        "question_pt":"Como foi definido o ILI?"
    },
    {
        "answer":"on the multiplex ligation-dependent probe amplification (MLPA) technology.",
        "answer_pt":"na tecnologia de amplifica\u00e7\u00e3o da sonda dependente de liga\u00e7\u00e3o multiplex (MLPA).",
        "id":"4104",
        "question":"What is this assay based on?",
        "question_pt":"Em que esse teste se baseia?"
    },
    {
        "answer":" with Excel 1 using the anonymized surveillance database of the Cire OI. The sampling frame contained identification number of swab assigned by Cire OI, laboratory identification number, sex, age, date of onset of symptoms, date of swab collection and result of influenza RT-PCR.",
        "answer_pt":"no Excel 1 usando o banco de dados de vigil\u00e2ncia an\u00f4nima do Cire OI. A estrutura de amostragem continha o n\u00famero de identifica\u00e7\u00e3o do swab designado pelo Cire OI, n\u00famero de identifica\u00e7\u00e3o do laborat\u00f3rio, sexo, idade, data de in\u00edcio dos sintomas, data da coleta do swab e resultado da influenza RT-PCR.",
        "id":"4102",
        "question":"How was random sampling performed?",
        "question_pt":"Como foi realizada a amostragem aleat\u00f3ria?"
    },
    {
        "answer":" Respifinder 1 Smart 22 kits a multiplex RT-PCR (PathoFinder, Maastricht, The Netherlands) which can detect 22 respiratory pathogens. ",
        "answer_pt":"O Respifinder 1 Smart 22 fornece um RT-PCR multiplex (PathoFinder, Maastricht, Pa\u00edses Baixos) que pode detectar 22 pat\u00f3genos respirat\u00f3rios.",
        "id":"4103",
        "question":"What used to detect pathogens?",
        "question_pt":"O que costumava detectar pat\u00f3genos?"
    },
    {
        "answer":"nasal swabs collected by sentinel GPs from ILI patients in 2011 and 2012.",
        "answer_pt":"swabs nasais coletados por GP sentinela de pacientes com ILI em 2011 e 2012.",
        "id":"4033",
        "question":"What does the retrospective study use?",
        "question_pt":"O que o estudo retrospectivo usa?"
    },
    {
        "answer":"250 ",
        "answer_pt":"250",
        "id":"4034",
        "question":"How many swabs were randomly selected and analyzed?",
        "question_pt":"Quantos swabs foram selecionados e analisados \u200b\u200baleatoriamente?"
    },
    {
        "answer":" by multiplex reverse transcriptase polymerase chain reaction (RT-PCR) including research of 18 viruses and 4 bacteria.",
        "answer_pt":"por rea\u00e7\u00e3o em cadeia da polimerase por transcriptase reversa multiplexa (RT-PCR) incluindo pesquisa de 18 v\u00edrus e 4 bact\u00e9rias.",
        "id":"4035",
        "question":"How were the swabs analyzed?",
        "question_pt":"Como os swabs foram analisados?"
    },
    {
        "answer":"respiratory viruses in 169/222 (76.1%) samples, mostly rhinovirus (23.4%), influenza A virus (21.2%), influenza B virus (12.6%), coronavirus (4.9%) and Human metapneumovirus (3.6%). ",
        "answer_pt":"v\u00edrus respirat\u00f3rios em 169/222 (76,1%) amostras, principalmente rinov\u00edrus (23,4%), v\u00edrus influenza A (21,2%), v\u00edrus influenza B (12,6%), coronav\u00edrus (4,9%) e metapneumov\u00edrus humano (3,6%).",
        "id":"4037",
        "question":"What viruses were detected?",
        "question_pt":"Quais v\u00edrus foram detectados?"
    },
    {
        "answer":"Nine swabs (5.3% of positive swabs) revealed co-infections with two viruses identified, among which six concerned co-infections with influenza viruses.",
        "answer_pt":"Nove swabs (5,3% dos swabs positivos) revelaram coinfec\u00e7\u00f5es com dois v\u00edrus identificados, dentre os quais seis eram coinfec\u00e7\u00f5es por v\u00edrus influenza.",
        "id":"4038",
        "question":"What co-infections were found?",
        "question_pt":"Quais co-infec\u00e7\u00f5es foram encontradas?"
    },
    {
        "answer":"seasonal differences, with circulation of Human Metapneumoviruses, RSV A and B and coronavirus only during summer; whereas parainfluenza viruses were identified only during winter.",
        "answer_pt":"diferen\u00e7as sazonais, com circula\u00e7\u00e3o de metapneumov\u00edrus humanos, RSV A e B e coronav\u00edrus apenas durante o ver\u00e3o; enquanto que os v\u00edrus parainfluenza foram identificados apenas durante o inverno.",
        "id":"4039",
        "question":"What seasonal differences were found?",
        "question_pt":"Que diferen\u00e7as sazonais foram encontradas?"
    },
    {
        "answer":" a substantial circulation of multiple respiratory pathogens in R\u00e9union Island throughout the year. I",
        "answer_pt":"uma circula\u00e7\u00e3o substancial de v\u00e1rios pat\u00f3genos respirat\u00f3rios na Ilha da Reuni\u00e3o ao longo do ano. Eu",
        "id":"4040",
        "question":"What does the study highlight?",
        "question_pt":"O que o estudo destaca?"
    },
    {
        "answer":"that ILI are not only attributable to influenza and underlines the need for biological surveillance. As the use of multiplex RT-PCR showed its efficacy, it is now used routinely in the surveillance of ILI.",
        "answer_pt":"que o ILI n\u00e3o \u00e9 apenas atribu\u00eddo \u00e0 gripe e sublinha a necessidade de vigil\u00e2ncia biol\u00f3gica. Como o uso do RT-PCR multiplex mostrou sua efic\u00e1cia, agora \u00e9 usado rotineiramente na vigil\u00e2ncia de ILI.",
        "id":"4041",
        "question":"What does the study show?",
        "question_pt":"O que mostra o estudo?"
    },
    {
        "answer":"Influenza viruses, Respiratory Syncytial viruses (RSV) and Parainfluenza viruses",
        "answer_pt":"V\u00edrus influenza, v\u00edrus sincicial respirat\u00f3rio (RSV) e v\u00edrus parainfluenza",
        "id":"4042",
        "question":"Which are identified  as major viruses mostly responsible for ILI and pneumonia in several studies?",
        "question_pt":"Quais s\u00e3o os principais v\u00edrus identificados como respons\u00e1veis \u200b\u200bpor ILI e pneumonia em v\u00e1rios estudos?"
    },
    {
        "answer":"less than 50%",
        "answer_pt":"menos de 50%",
        "id":"4087",
        "question":"What percentage of these infections are identified?",
        "question_pt":"Qual a porcentagem dessas infec\u00e7\u00f5es identificadas?"
    },
    {
        "answer":" a French overseas territory",
        "answer_pt":"um territ\u00f3rio ultramarino franc\u00eas",
        "id":"4088",
        "question":"What is Reunion Island?",
        "question_pt":"O que \u00e9 a Ilha da Reuni\u00e3o?"
    },
    {
        "answer":" 850,000",
        "answer_pt":"850.000",
        "id":"4089",
        "question":"What is the number of inhabitants of Reunion Island?",
        "question_pt":"Qual \u00e9 o n\u00famero de habitantes da Ilha da Reuni\u00e3o?"
    },
    {
        "answer":"n the southern hemisphere between Madagascar and Mauritius in the Indian Ocean (Latitude: 21\u00b005.2920 S Longitude: 55\u00b036.4380 E.)",
        "answer_pt":"no hemisf\u00e9rio sul entre Madagascar e Maur\u00edcio no Oceano \u00cdndico (Latitude: 21 \u00b0 05.2920 S Longitude: 55 \u00b0 36.4380 E.)",
        "id":"4090",
        "question":"Where is Reunion Island located?",
        "question_pt":"Onde est\u00e1 localizada a Ilha da Reuni\u00e3o?"
    },
    {
        "answer":" to mainland France and epidemiological surveillance has been developed by the regional office of the French Institute for Public Health Surveillance (Cire OI), based on the surveillance system of mainland France",
        "answer_pt":"para a Fran\u00e7a continental e a vigil\u00e2ncia epidemiol\u00f3gica foi desenvolvida pelo escrit\u00f3rio regional do Instituto Franc\u00eas de Vigil\u00e2ncia em Sa\u00fade P\u00fablica (Cire OI), com base no sistema de vigil\u00e2ncia da Fran\u00e7a continental",
        "id":"4091",
        "question":"What is the island's health care system similar  to?",
        "question_pt":"Como \u00e9 o sistema de sa\u00fade da ilha?"
    },
    {
        "answer":" during austral winter, corresponding to summer in Europe",
        "answer_pt":"durante o inverno austral, correspondente ao ver\u00e3o na Europa",
        "id":"4092",
        "question":"When does influenza activity increase?",
        "question_pt":"Quando a atividade da gripe aumenta?"
    },
    {
        "answer":"April ",
        "answer_pt":"abril",
        "id":"4093",
        "question":"When does the  influenza vaccination campaign in Reunion Island start?",
        "question_pt":"Quando come\u00e7a a campanha de vacina\u00e7\u00e3o contra a gripe na Ilha da Reuni\u00e3o?"
    },
    {
        "answer":"a sentinel practitioner's network",
        "answer_pt":"rede de um praticante sentinela",
        "id":"4094",
        "question":"What is the  clinical and biological influenza surveillance has been based on?",
        "question_pt":"Em que baseou-se a vigil\u00e2ncia cl\u00ednica e biol\u00f3gica da influenza?"
    },
    {
        "answer":"58 general practitioners (GPs) spread over the island and represented around 7% of all R\u00e9union Island GPs.",
        "answer_pt":"58 m\u00e9dicos de cl\u00ednica geral (GP) espalharam-se pela ilha e representaram cerca de 7% de todos os GP da ilha da Reuni\u00e3o.",
        "id":"4095",
        "question":"What is this network composed of?",
        "question_pt":"De que \u00e9 composta essa rede?"
    },
    {
        "answer":" Nasal swabs are randomly collected all along the year and are tested by RT-PCR for influenza viruses",
        "answer_pt":"As zaragatoas nasais s\u00e3o coletadas aleatoriamente durante todo o ano e s\u00e3o testadas por RT-PCR para v\u00edrus influenza",
        "id":"4096",
        "question":"How are the influenza tests carried out?",
        "question_pt":"Como s\u00e3o realizados os testes de influenza?"
    },
    {
        "answer":" for influenza A virus, A(H1N1)pdm09 or B virus",
        "answer_pt":"para v\u00edrus influenza A, v\u00edrus A (H1N1) pdm09 ou B",
        "id":"4097",
        "question":"What do 40-50% of the samples test positive for?",
        "question_pt":"Para que 40-50% das amostras s\u00e3o positivas?"
    },
    {
        "answer":"are of unknown etiology",
        "answer_pt":"s\u00e3o de etiologia desconhecida",
        "id":"4098",
        "question":"What are the ILI samples wich test negative for influence?",
        "question_pt":"Quais s\u00e3o as amostras de ILI com teste negativo para influ\u00eancia?"
    },
    {
        "answer":", multiplex reverse transcriptase polymerase chain reaction (RT-PCR) ",
        "answer_pt":", rea\u00e7\u00e3o em cadeia da polimerase da transcriptase reversa multiplexa (RT-PCR)",
        "id":"4099",
        "question":"What tool has been developed to identify several viruses simultaneously?",
        "question_pt":"Qual ferramenta foi desenvolvida para identificar v\u00e1rios v\u00edrus simultaneamente?"
    },
    {
        "answer":"to characterize respiratory pathogens responsible for ILI consultations in sentinel GPs in 2011 and 2012. Secondary objectives were to highlight seasonal trends on respiratory pathogens circulation and to describe occurrence of co-infections, especially during the flu season.",
        "answer_pt":"caracterizar pat\u00f3genos respirat\u00f3rios respons\u00e1veis \u200b\u200bpelas consultas de ILI nos GPs sentinela em 2011 e 2012. Os objetivos secund\u00e1rios foram destacar tend\u00eancias sazonais na circula\u00e7\u00e3o de pat\u00f3genos respirat\u00f3rios e descrever a ocorr\u00eancia de co-infec\u00e7\u00f5es, especialmente durante a temporada de gripe.",
        "id":"4100",
        "question":"What are the objectives of the study?",
        "question_pt":"Quais s\u00e3o os objetivos do estudo?"
    },
    {
        "answer":"on the epgradient Mastercycler 1 (Eppendorf) and the hybridization, ligation and detection steps on the LightCycler 1 480 system (Roche Applied Science).",
        "answer_pt":"no epgradiente Mastercycler 1 (Eppendorf) e nas etapas de hibrida\u00e7\u00e3o, liga\u00e7\u00e3o e detec\u00e7\u00e3o no sistema LightCycler 1 480 (Roche Applied Science).",
        "id":"4105",
        "question":"On which system the reverse transcription and preamplification steps were performed?",
        "question_pt":"Em qual sistema foram executadas as etapas de transcri\u00e7\u00e3o reversa e pr\u00e9-amplifica\u00e7\u00e3o?"
    },
    {
        "answer":"winter season during weeks 23 to 39 between June and September and summer season during the rest of the year.",
        "answer_pt":"temporada de inverno nas semanas 23 a 39 entre junho e setembro e temporada de ver\u00e3o durante o resto do ano.",
        "id":"4106",
        "question":"Which two seasons were identified for trends in virus circulation??",
        "question_pt":"Quais foram as duas esta\u00e7\u00f5es do ano identificadas para tend\u00eancias na circula\u00e7\u00e3o de v\u00edrus?"
    },
    {
        "answer":" rhinovirus (23.4%), influenza A not H1N1 (21.2%) and influenza B (12.6%) ",
        "answer_pt":"rinov\u00edrus (23,4%), influenza A n\u00e3o H1N1 (21,2%) e influenza B (12,6%)",
        "id":"4107",
        "question":"Which were the most frequently identified respiratory pathogens?",
        "question_pt":"Quais foram os pat\u00f3genos respirat\u00f3rios mais frequentemente identificados?"
    },
    {
        "answer":"Human Metapneumovirus, RSV A and B, and influenza A(H1N1)pdm09",
        "answer_pt":"Metapneumov\u00edrus humano, RSV A e B e influenza A (H1N1) pdm09",
        "id":"4108",
        "question":"What were detected  only in summer?",
        "question_pt":"O que foi detectado apenas no ver\u00e3o?"
    },
    {
        "answer":"Parainfluenza 1,2 and 4 viruses",
        "answer_pt":"V\u00edrus parainfluenza 1,2 e 4",
        "id":"4109",
        "question":"What viruses were identified only in winter?",
        "question_pt":"Quais v\u00edrus foram identificados apenas no inverno?"
    },
    {
        "answer":"76.1",
        "answer_pt":"76,1",
        "id":"4111",
        "question":"Respiratory viral pathogens were present in what percentage of samples?",
        "question_pt":"Pat\u00f3genos virais respirat\u00f3rios estavam presentes em qual porcentagem de amostras?"
    },
    {
        "answer":"several co-infections, showing that concomitant the multiple etiology of ILI",
        "answer_pt":"co-infec\u00e7\u00f5es, mostrando que concomitante a etiologia m\u00faltipla do ILI",
        "id":"4112",
        "question":"What did the study highlight?",
        "question_pt":"O que o estudo destacou?"
    },
    {
        "answer":" 53 swabs, representing 24% of the sample",
        "answer_pt":"53 zaragatoas, representando 24% da amostra",
        "id":"4113",
        "question":"How many swabs remained without etiology?",
        "question_pt":"Quantas zaragatoas permaneceram sem etiologia?"
    },
    {
        "answer":" a poor quality of swabs, preventing from identifying a pathogen, noninfectious causes or other pathogens not included in the multiplex PCR.",
        "answer_pt":"baixa qualidade dos swabs, impedindo a identifica\u00e7\u00e3o de um pat\u00f3geno, causas n\u00e3o infecciosas ou outros pat\u00f3genos n\u00e3o inclu\u00eddos no PCR multiplex.",
        "id":"4114",
        "question":"What hypotheses can explain this result?",
        "question_pt":"Que hip\u00f3teses podem explicar esse resultado?"
    },
    {
        "answer":"RNAse P, a marker of human cells,",
        "answer_pt":"RNAse P, um marcador de c\u00e9lulas humanas,",
        "id":"4115",
        "question":"What could not be tested  for?",
        "question_pt":"O que n\u00e3o p\u00f4de ser testado?"
    },
    {
        "answer":" circulation of multiple pathogens in R\u00e9union Island throughout the year.",
        "answer_pt":"circula\u00e7\u00e3o de v\u00e1rios pat\u00f3genos na Ilha da Reuni\u00e3o ao longo do ano.",
        "id":"4116",
        "question":"What does this study highlight?",
        "question_pt":"O que esse estudo destaca?"
    },
    {
        "answer":"that ILI is not specific to influenza and so it is essential to have biological results in order to establish the differential diagnosis and thus explain the etiology of symptoms.",
        "answer_pt":"que o ILI n\u00e3o \u00e9 espec\u00edfico da influenza e, portanto, \u00e9 essencial ter resultados biol\u00f3gicos para estabelecer o diagn\u00f3stico diferencial e, assim, explicar a etiologia dos sintomas.",
        "id":"4117",
        "question":"What does the  study show?",
        "question_pt":"O que mostra o estudo?"
    },
    {
        "answer":"to repeat this study every 3 or 5 years adding clinical data to monitor the evolution of respiratory pathogens in R\u00e9union Island over time.",
        "answer_pt":"repetir este estudo a cada 3 ou 5 anos, adicionando dados cl\u00ednicos para monitorar a evolu\u00e7\u00e3o de pat\u00f3genos respirat\u00f3rios na Ilha da Reuni\u00e3o ao longo do tempo.",
        "id":"4118",
        "question":"What would be interesting to do?",
        "question_pt":"O que seria interessante fazer?"
    },
    {
        "answer":"bat beta-coronaviruses, with the highest being >96% identity ",
        "answer_pt":"beta-coronav\u00edrus de morcego, sendo o mais alto> 96% de identidade",
        "id":"3593",
        "question":"What  is it most similar to?",
        "question_pt":"O que \u00e9 mais parecido?"
    },
    {
        "answer":"greater than 40,000",
        "answer_pt":"maior que 40.000",
        "id":"3589",
        "question":"How many people were affected as of Feb. 10, 2020?",
        "question_pt":"Quantas pessoas foram afetadas em 10 de fevereiro de 2020?"
    },
    {
        "answer":" as coronavirus disease discovered in 2019 (COVID-19)",
        "answer_pt":"como doen\u00e7a do coronav\u00edrus descoberta em 2019 (COVID-19)",
        "id":"3590",
        "question":"How is the SARS-CoV-2 referred to?",
        "question_pt":"Como \u00e9 referido o SARS-CoV-2?"
    },
    {
        "answer":"\u223c80% identity with SARS-CoV",
        "answer_pt":"\u223c80% de identidade com SARS-CoV",
        "id":"3592",
        "question":"How much  similarity the SARS-COV-2 genome sequence has with SARS-COV?",
        "question_pt":"Quanta semelhan\u00e7a a sequ\u00eancia do genoma SARS-COV-2 tem com SARS-COV?"
    },
    {
        "answer":" 99.8% homology, with a total of 202 single-nucleotide (nt) variations (SNVs) identified across the genome ",
        "answer_pt":"99,8% de homologia, com um total de 202 varia\u00e7\u00f5es de nucleot\u00eddeo \u00fanico (nt) (SNVs) identificadas no genoma",
        "id":"3594",
        "question":"what similarity human SARS-COV and palm civet SARSlike COV share?",
        "question_pt":"que semelhan\u00e7a entre SARS-COV humano e palm civet como SARV semelhante ao COV?"
    },
    {
        "answer":"greater than 1,100 nt ",
        "answer_pt":"superior a 1.100 nt",
        "id":"3595",
        "question":"How much is the difference between the human SARS-CoV-2 and the bat RaTG13-CoV?",
        "question_pt":"Qual \u00e9 a diferen\u00e7a entre o SARS-CoV-2 humano e o morcego RaTG13-CoV?"
    },
    {
        "answer":"are distributed throughout the genome in a naturally occurring pattern following the evolutionary characteristics typical of CoVs",
        "answer_pt":"s\u00e3o distribu\u00eddos por todo o genoma em um padr\u00e3o que ocorre naturalmente, seguindo as caracter\u00edsticas evolutivas t\u00edpicas dos CoVs",
        "id":"3596",
        "question":"Why is it highly unlikely that RaTG13 CoV is the immediate source of SARS-CoV-2. ",
        "question_pt":"Por que \u00e9 altamente improv\u00e1vel que o RaTG13 CoV seja a fonte imediata do SARS-CoV-2."
    },
    {
        "answer":"The absence of a logical targeted pattern in the new viral sequences and a close relative in a wildlife species (bat",
        "answer_pt":"A aus\u00eancia de um padr\u00e3o l\u00f3gico direcionado nas novas seq\u00fc\u00eancias virais e de um parente pr\u00f3ximo em uma esp\u00e9cie de vida selvagem (morcego",
        "id":"3597",
        "question":"What are the most revealing signs that SARS-CoV-2 evolved by natural evolution. ",
        "question_pt":"Quais s\u00e3o os sinais mais reveladores de que o SARS-CoV-2 evoluiu pela evolu\u00e7\u00e3o natural."
    },
    {
        "answer":"the construction of a chimeric CoV with a bat CoV S gene (SHC014) in the backbone of a SARS CoV that has adapted to infect mice (MA15) and is capable of infecting human cells",
        "answer_pt":"a constru\u00e7\u00e3o de um CoV quim\u00e9rico com um gene CoV S de morcego (SHC014) na espinha dorsal de um SARS CoV adaptado para infectar camundongos (MA15) e capaz de infectar c\u00e9lulas humanas",
        "id":"3598",
        "question":"What did the Nature Medicine paper report?",
        "question_pt":"O que o artigo da Nature Medicine relatou?"
    },
    {
        "answer":" because of significant divergence in the genetic sequence of this construct with the new SARS-CoV-2 (>5,000 nucleotides).",
        "answer_pt":"devido a diverg\u00eancia significativa na sequ\u00eancia gen\u00e9tica desta constru\u00e7\u00e3o com o novo SARS-CoV-2 (> 5.000 nucleot\u00eddeos).",
        "id":"3599",
        "question":"Why does the claim lack any scientific  basis?",
        "question_pt":"Por que a alega\u00e7\u00e3o carece de base cient\u00edfica?"
    },
    {
        "answer":"by serial passage of an infectious wildtype SARS CoV clone in the respiratory tract of BALB/c mice.",
        "answer_pt":"por passagem em s\u00e9rie de um clone infeccioso de SARS CoV infeccioso no trato respirat\u00f3rio de camundongos BALB / c.",
        "id":"3600",
        "question":"How was the mouse-adapted SARS virus (MA15) generated?",
        "question_pt":"Como foi gerado o v\u00edrus SARS adaptado ao mouse (MA15)?"
    },
    {
        "answer":"due to six coding genetic mutations associated with mouse adaptation. ",
        "answer_pt":"devido a seis muta\u00e7\u00f5es gen\u00e9ticas codificantes associadas \u00e0 adapta\u00e7\u00e3o do mouse.",
        "id":"3601",
        "question":"How did  the SARS-CoV gain elevated replication and lung pathogenesis in aged mice ?",
        "question_pt":"Como o SARS-CoV obteve replica\u00e7\u00e3o elevada e patog\u00eanese pulmonar em camundongos idosos?"
    },
    {
        "answer":"due to the mouse adaptation.",
        "answer_pt":"devido \u00e0 adapta\u00e7\u00e3o do mouse.",
        "id":"3602",
        "question":"Why is it likely that MA15 is highly attenuated to  replicate in human cells?",
        "question_pt":"Por que \u00e9 prov\u00e1vel que o MA15 seja altamente atenuado para se replicar nas c\u00e9lulas humanas?"
    },
    {
        "answer":"t was proposed that the S gene from bat-derived CoV, unlike that from human patients-or civetsderived viruses, was unable to use human ACE2 as a receptor for entry into human cells ",
        "answer_pt":"Foi proposto que o gene S do CoV derivado de morcego, diferentemente do de pacientes humanos ou v\u00edrus derivados da civiliza\u00e7\u00e3o, n\u00e3o era capaz de usar a ACE2 humana como um receptor para entrada nas c\u00e9lulas humanas",
        "id":"3604",
        "question":"Why were civets proposed to be an intermediate host of the bat-CoVs, capable of spreading SARS CoV to humans?",
        "question_pt":"Por que os civets foram propostos para serem um host intermedi\u00e1rio dos Co-morcegos, capazes de espalhar o SARS CoV para os seres humanos?"
    },
    {
        "answer":"several novel bat coronaviruses were isolated from Chinese horseshoe bats and the bat SARS-like or SL-CoV-WIV1 was able to use ACE2 from humans, civets and Chinese horseshoe bats for entry ",
        "answer_pt":"v\u00e1rios novos coronav\u00edrus de morcegos foram isolados de morcegos-ferradura chineses eo SARS-like ou SL-CoV-WIV1 foi capaz de usar o ACE2 de humanos, civetas e morcegos-ferradura chineses para entrada",
        "id":"3605",
        "question":"What was the finding  in 2013?",
        "question_pt":"Qual foi a constata\u00e7\u00e3o em 2013?"
    },
    {
        "answer":"Combined with evolutionary evidence that the bat ACE2 gene has been positively selected at the same contact sites as the human ACE2 gene for interacting with SARS CoV [",
        "answer_pt":"Combinado com evid\u00eancias evolutivas de que o gene morcego ACE2 foi selecionado positivamente nos mesmos locais de contato que o gene humano ACE2 para interagir com SARS CoV [",
        "id":"3606",
        "question":" Why is it proposed that some bat SL-CoVs may be able to directly infect human hosts?",
        "question_pt":"Por que \u00e9 proposto que alguns SL-CoVs de morcego possam infectar diretamente hospedeiros humanos?"
    },
    {
        "answer":" the exact S gene from bat coronavirus SL-SHC014 was synthesized and used to generate a chimeric virus in the mouse adapted MA15 SARS-CoV backbone. ",
        "answer_pt":"o gene S exato do coronav\u00edrus de morcego SL-SHC014 foi sintetizado e usado para gerar um v\u00edrus quim\u00e9rico no backbone MA15 SARS-CoV adaptado ao mouse.",
        "id":"3607",
        "question":"What was done to test if  an intermediate host may not be necessary and that some bat SL-CoVs may be able to directly infect human hosts. T",
        "question_pt":"O que foi feito para testar se um host intermedi\u00e1rio pode n\u00e3o ser necess\u00e1rio e que alguns SL-CoVs de morcego podem infectar diretamente hospedeiros humanos. T"
    },
    {
        "answer":"The resultant SL-SHC014-MA15 virus could indeed efficiently use human ACE2 and replicate in primary human airway cells to similar titres as epidemic strains of SARS-CoV. While SL-SHC014-MA15 can replicate efficiently in young and aged mouse lungs, infection was attenuated, and less virus antigen was present in the airway epithelium as compared to SARS MA15, which causes lethal outcomes in aged mice",
        "answer_pt":"O v\u00edrus SL-SHC014-MA15 resultante poderia de fato usar eficientemente a ACE2 humana e replicar-se em c\u00e9lulas prim\u00e1rias das vias a\u00e9reas humanas com t\u00edtulos semelhantes aos das cepas epid\u00eamicas de SARS-CoV. Embora o SL-SHC014-MA15 possa se replicar com efici\u00eancia em pulm\u00f5es de ratos jovens e idosos, a infec\u00e7\u00e3o foi atenuada e menos ant\u00edgeno viral estava presente no epit\u00e9lio das vias a\u00e9reas em compara\u00e7\u00e3o com o SARS MA15, que causa resultados letais em ratos idosos",
        "id":"3608",
        "question":"What were the results of this test?",
        "question_pt":"Quais foram os resultados deste teste?"
    },
    {
        "answer":"as gain of function (GOF) studies under the US government-mandated pause policy ",
        "answer_pt":"estudos de ganho de fun\u00e7\u00e3o (GOF) sob a pol\u00edtica de pausa exigida pelo governo dos EUA",
        "id":"3609",
        "question":"Why were experiments with SL-SHC014-MA15 chimeric virus were later restricted?",
        "question_pt":"Por que as experi\u00eancias com o v\u00edrus quim\u00e9rico SL-SHC014-MA15 foram mais tarde restringidas?"
    },
    {
        "answer":"upon careful phylogenetic analyses by multiple international groups [5, 14] , the SARS-CoV-2 is undoubtedly distinct from SL-SHC014-MA15, with >6,000 nucleotide differences across the whole genome.",
        "answer_pt":"ap\u00f3s cuidadosas an\u00e1lises filogen\u00e9ticas por v\u00e1rios grupos internacionais [5, 14], o SARS-CoV-2 \u00e9 indubitavelmente distinto do SL-SHC014-MA15, com> 6.000 diferen\u00e7as de nucleot\u00eddeos em todo o genoma.",
        "id":"3610",
        "question":"Why is there  no credible evidence to support the claim that the SARS-CoV-2 is derived from the chimeric SL-SHC014-MA15 virus?",
        "question_pt":"Por que n\u00e3o h\u00e1 evid\u00eancias confi\u00e1veis \u200b\u200bpara sustentar a alega\u00e7\u00e3o de que o SARS-CoV-2 \u00e9 derivado do v\u00edrus quim\u00e9rico SL-SHC014-MA15?"
    },
    {
        "answer":"that SARS-CoV-2 has HIV sequence in it and was thus likely generated in the laboratory. I",
        "answer_pt":"que o SARS-CoV-2 possui sequ\u00eancia de HIV e, portanto, provavelmente foi gerado em laborat\u00f3rio. Eu",
        "id":"3611",
        "question":"What did the rumour that the virus was made by humans in the lab, claim?",
        "question_pt":"Qual foi o boato de que o v\u00edrus foi produzido por humanos no laborat\u00f3rio?"
    },
    {
        "answer":" they used careful bioinformatics analyses to demonstrate that the original claim of multiple HIV insertions into the SARS-CoV-2 is not HIV-1 specific but random ",
        "answer_pt":"eles usaram an\u00e1lises bioinform\u00e1ticas cuidadosas para demonstrar que a reivindica\u00e7\u00e3o original de m\u00faltiplas inser\u00e7\u00f5es de HIV na SARS-CoV-2 n\u00e3o \u00e9 espec\u00edfica para o HIV-1, mas aleat\u00f3ria",
        "id":"3612",
        "question":"What was reported in  a rebuttal paper led by an HIV-1 virologist Dr. Feng Gao?",
        "question_pt":"O que foi relatado em um artigo de refuta\u00e7\u00e3o liderado por um virologista do HIV-1, Dr. Feng Gao?"
    },
    {
        "answer":" Because of the many concerns raised by the international community, the authors who made the initial claim have already withdrawn this report.",
        "answer_pt":"Devido \u00e0s muitas preocupa\u00e7\u00f5es levantadas pela comunidade internacional, os autores que fizeram a reivindica\u00e7\u00e3o inicial j\u00e1 retiraram este relat\u00f3rio.",
        "id":"3613",
        "question":"What happened to the report with initial claims?",
        "question_pt":"O que aconteceu com o relat\u00f3rio com reivindica\u00e7\u00f5es iniciais?"
    },
    {
        "answer":"Evolution is stepwise and accrues mutations gradually over time, whereas synthetic constructs would typically use a known backbone and introduce logical or targeted changes instead of the randomly occurring mutations that are present in naturally isolated viruses such as bat CoV RaTG13.",
        "answer_pt":"A evolu\u00e7\u00e3o \u00e9 gradual e acumula muta\u00e7\u00f5es gradualmente ao longo do tempo, enquanto constru\u00e7\u00f5es sint\u00e9ticas normalmente usam um backbone conhecido e introduzem mudan\u00e7as l\u00f3gicas ou direcionadas, em vez das muta\u00e7\u00f5es que ocorrem aleatoriamente, presentes em v\u00edrus naturalmente isolados, como o CoV RaTG13 de morcego.",
        "id":"3614",
        "question":"What is the difference between evolution and synthetic constructs?",
        "question_pt":"Qual \u00e9 a diferen\u00e7a entre evolu\u00e7\u00e3o e constru\u00e7\u00f5es sint\u00e9ticas?"
    },
    {
        "answer":" there is currently no credible evidence to support the claim that SARS-CoV-2 originated from a laboratory-engineered CoV. It is more likely that SARS-CoV-2 is a recombinant CoV generated in nature between a bat CoV and another coronavirus in an intermediate animal host. ",
        "answer_pt":"Atualmente, n\u00e3o h\u00e1 evid\u00eancias cred\u00edveis para sustentar a alega\u00e7\u00e3o de que o SARS-CoV-2 se originou de um CoV desenvolvido em laborat\u00f3rio. \u00c9 mais prov\u00e1vel que o SARS-CoV-2 seja um CoV recombinante gerado na natureza entre um CoV de morcego e outro coronav\u00edrus em um hospedeiro animal intermedi\u00e1rio.",
        "id":"3615",
        "question":"What is the conclusion of this report?",
        "question_pt":"Qual \u00e9 a conclus\u00e3o deste relat\u00f3rio?"
    },
    {
        "answer":"More studies are needed to explore this possibility and resolve the natural origin of SARS-CoV-2. We should emphasize that, although SARS-CoV-2 shows no evidence of laboratory origin, viruses with such great public health threats must be handled properly in the laboratory and also properly regulated by the scientific community and governments.",
        "answer_pt":"Mais estudos s\u00e3o necess\u00e1rios para explorar essa possibilidade e resolver a origem natural da SARS-CoV-2. Devemos enfatizar que, embora o SARS-CoV-2 n\u00e3o mostre evid\u00eancias de origem laboratorial, os v\u00edrus com grandes amea\u00e7as \u00e0 sa\u00fade p\u00fablica devem ser tratados adequadamente no laborat\u00f3rio e tamb\u00e9m devidamente regulamentados pela comunidade cient\u00edfica e pelos governos.",
        "id":"3616",
        "question":"What is the conclusion of this report?",
        "question_pt":"Qual \u00e9 a conclus\u00e3o deste relat\u00f3rio?"
    },
    {
        "answer":"to that of the severe acute respiratory syndrome (SARS) caused by SARS-CoV. ",
        "answer_pt":"ao da s\u00edndrome respirat\u00f3ria aguda grave (SARS) causada pelo SARS-CoV.",
        "id":"4574",
        "question":"what is the clinical manifestation similar to?",
        "question_pt":"qual \u00e9 a manifesta\u00e7\u00e3o cl\u00ednica semelhante?"
    },
    {
        "answer":"to evaluate the effectiveness of zinc supplementation on diarrhea and average daily weight gain (ADG) in pre-weaned dairy calves",
        "answer_pt":"avaliar a efic\u00e1cia da suplementa\u00e7\u00e3o de zinco na diarr\u00e9ia e no ganho m\u00e9dio di\u00e1rio de peso (ADG) em bezerros pr\u00e9-desmamados",
        "id":"5173",
        "question":"What was the purpose of the research?",
        "question_pt":"Qual foi o objetivo da pesquisa?"
    },
    {
        "answer":"Zinc supplementation",
        "answer_pt":"Suplementa\u00e7\u00e3o de zinco",
        "id":"5174",
        "question":"What preventative measure has been taken to decrease the incidence of diarrhea in children?",
        "question_pt":"Que medidas preventivas foram tomadas para diminuir a incid\u00eancia de diarr\u00e9ia em crian\u00e7as?"
    },
    {
        "answer":"an outbreak in 1993\u201394 in the southwestern United States",
        "answer_pt":"um surto em 1993-94 no sudoeste dos Estados Unidos",
        "id":"4442",
        "question":"What  led to a great increase in their study among virologists worldwide?",
        "question_pt":"O que levou a um grande aumento no estudo entre virologistas em todo o mundo?"
    },
    {
        "answer":"Well over 40",
        "answer_pt":"Bem acima de 40",
        "id":"4443",
        "question":"How many hantaviral genotypes have been described",
        "question_pt":"Quantos gen\u00f3tipos hantavirais foram descritos"
    },
    {
        "answer":"nearly half of them",
        "answer_pt":"quase metade deles",
        "id":"4444",
        "question":"How many of them are pathogenic for humans?",
        "question_pt":"Quantos deles s\u00e3o patog\u00eanicos para os seres humanos?"
    },
    {
        "answer":"persistent infections",
        "answer_pt":"infec\u00e7\u00f5es persistentes",
        "id":"4445",
        "question":"What do Hantaviruses cause in their reservoir hosts?",
        "question_pt":"O que os Hantav\u00edrus causam em seus hospedeiros reservat\u00f3rios?"
    },
    {
        "answer":" a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS)",
        "answer_pt":"comprometimento cardiopulmonar, s\u00edndrome cardiopulmonar por hantav\u00edrus (HCPS)",
        "id":"4446",
        "question":"What does hantavirus human disease  manifest as?",
        "question_pt":"Como se manifesta a doen\u00e7a humana por hantav\u00edrus?"
    },
    {
        "answer":"between 30% and 40%",
        "answer_pt":"entre 30% e 40%",
        "id":"4448",
        "question":"What is the  case-fatality ratios, for the most common viral serotypes? ",
        "question_pt":"Quais s\u00e3o as taxas de letalidade, para os sorotipos virais mais comuns?"
    },
    {
        "answer":" Habitat disturbance and larger-scale ecological disturbances, perhaps including climate change,",
        "answer_pt":"Perturba\u00e7\u00e3o do habitat e perturba\u00e7\u00f5es ecol\u00f3gicas em larga escala, talvez incluindo altera\u00e7\u00f5es clim\u00e1ticas,",
        "id":"4449",
        "question":" What are among the factors that may have increased the human caseload of HCPS between 1993 and the present?",
        "question_pt":"Quais s\u00e3o os fatores que podem ter aumentado o n\u00famero de casos humanos de HCPS entre 1993 e o presente?"
    },
    {
        "answer":" the features that influence the structure of host population dynamics that may lead to viral outbreaks",
        "answer_pt":"as caracter\u00edsticas que influenciam a estrutura da din\u00e2mica da popula\u00e7\u00e3o hospedeira que podem levar a surtos virais",
        "id":"4450",
        "question":"What do authors consider  in this study?",
        "question_pt":"O que os autores consideram neste estudo?"
    },
    {
        "answer":"the macromolecular determinants of hantaviruses that have been regarded as having potential contribution to pathogenicity.",
        "answer_pt":"os determinantes macromoleculares dos hantav\u00edrus que foram considerados como tendo potencial contribui\u00e7\u00e3o para a patogenicidade.",
        "id":"4451",
        "question":"What do authors consider  in this study?",
        "question_pt":"O que os autores consideram neste estudo?"
    },
    {
        "answer":" emerging zoonotic diseases",
        "answer_pt":"doen\u00e7as zoon\u00f3ticas emergentes",
        "id":"4452",
        "question":"Which diseases are a major concern among scientists studying infectious diseases?",
        "question_pt":"Quais doen\u00e7as s\u00e3o uma grande preocupa\u00e7\u00e3o entre os cientistas que estudam doen\u00e7as infecciosas?"
    },
    {
        "answer":"Changes in biotic and abiotic conditions",
        "answer_pt":"Mudan\u00e7as nas condi\u00e7\u00f5es bi\u00f3ticas e abi\u00f3ticas",
        "id":"4453",
        "question":"What may alter population disease dynamics and lead to the emergence of zoonotic infections? ",
        "question_pt":"O que pode alterar a din\u00e2mica das doen\u00e7as da popula\u00e7\u00e3o e levar ao surgimento de infec\u00e7\u00f5es zoon\u00f3ticas?"
    },
    {
        "answer":" influenza A, Ebola virus, hepatitis C virus, severe adult respiratory distress (SARS), coronavirus, and human immunodeficiency virus",
        "answer_pt":"influenza A, v\u00edrus Ebola, v\u00edrus da hepatite C, dificuldade respirat\u00f3ria grave do adulto (SARS), coronav\u00edrus e v\u00edrus da imunodefici\u00eancia humana",
        "id":"4454",
        "question":"Which are among the conspicuous examples which challenge prevention and control measures of public health systems?",
        "question_pt":"Quais s\u00e3o alguns dos exemplos consp\u00edcuos que desafiam as medidas de preven\u00e7\u00e3o e controle dos sistemas p\u00fablicos de sa\u00fade?"
    },
    {
        "answer":"hantaviruses, and the expansion of the geographic range of West Nile virus.",
        "answer_pt":"hantav\u00edrus e a expans\u00e3o da \u00e1rea geogr\u00e1fica do v\u00edrus do Nilo Ocidental.",
        "id":"4456",
        "question":"More recently,  what did outbreaks of several viral-related diseases that  have emerged or re-emerged, involve?",
        "question_pt":"Mais recentemente, o que envolveram os surtos de v\u00e1rias doen\u00e7as relacionadas a v\u00edrus que surgiram ou ressurgiram?"
    },
    {
        "answer":"arenaviruses and dengue viruses",
        "answer_pt":"arenav\u00edrus e v\u00edrus da dengue",
        "id":"4455",
        "question":"What did, In the last century,  outbreaks of viral-related diseases that have emerged or re-emerged, involve?",
        "question_pt":"O que, no \u00faltimo s\u00e9culo, surtos de doen\u00e7as relacionadas a v\u00edrus que surgiram ou ressurgiram, envolveram?"
    },
    {
        "answer":"small mammals",
        "answer_pt":"pequenos mam\u00edferos",
        "id":"4457",
        "question":"Among zoonotic diseases, what are hosts of several pathogenic RNA viruses?",
        "question_pt":"Entre as doen\u00e7as zoon\u00f3ticas, quais s\u00e3o os hospedeiros de v\u00e1rios v\u00edrus de RNA patog\u00eanico?"
    },
    {
        "answer":" Arenaviridae and Bunyaviridae: Hantavirus ",
        "answer_pt":"Arenaviridae e Bunyaviridae: Hantavirus",
        "id":"4458",
        "question":"Which pathogenic RNA viruses are hosted by small mammals?",
        "question_pt":"Quais v\u00edrus de RNA patog\u00eanico s\u00e3o hospedados por pequenos mam\u00edferos?"
    },
    {
        "answer":" disease, hantavirus cardiopulmonary syndrome, HCPS (or hantavirus pulmonary syndrome), was linked to ",
        "answer_pt":"cardiopulmonar do hantav\u00edrus, HCPS (ou s\u00edndrome pulmonar do hantav\u00edrus), foi associada a",
        "id":"4459",
        "question":"When did Hantavirus infections became a concern in the Americas?",
        "question_pt":"Quando as infec\u00e7\u00f5es por Hantav\u00edrus se tornaram uma preocupa\u00e7\u00e3o nas Am\u00e9ricas?"
    },
    {
        "answer":"infection by the newly-discovered Sin Nombre virus (SNV)",
        "answer_pt":"infec\u00e7\u00e3o pelo rec\u00e9m-descoberto v\u00edrus Sin Nombre (SNV)",
        "id":"4460",
        "question":" What was the  hantavirus cardiopulmonary syndrome, HCPS (or hantavirus pulmonary syndrome), linked to?",
        "question_pt":"A que estava ligada a s\u00edndrome cardiopulmonar do hantav\u00edrus, a HCPS (ou s\u00edndrome pulmonar do hantav\u00edrus)?"
    },
    {
        "answer":" the rodent Peromyscus maniculatus (deer mouse)",
        "answer_pt":"o roedor Peromyscus maniculatus (camundongo)",
        "id":"4461",
        "question":"What was identified as the reservoir of SNV?",
        "question_pt":"O que foi identificado como o reservat\u00f3rio do SNV?"
    },
    {
        "answer":"descriptions closely resembling hemorrhagic fever with renal syndrome (HFRS), the syndrome caused by Old World hantaviruses",
        "answer_pt":"descri\u00e7\u00f5es que se assemelham \u00e0 febre hemorr\u00e1gica com s\u00edndrome renal (HFRS), a s\u00edndrome causada pelos hantav\u00edrus do Velho Mundo",
        "id":"4462",
        "question":" What did a review of ancient Chinese writings in 960 AD, reveal?",
        "question_pt":"O que revelou uma revis\u00e3o dos escritos chineses antigos em 960 DC?"
    },
    {
        "answer":"with an outbreak that occurred among United Nations troops during the Korean conflict between 1951 and 1954",
        "answer_pt":"com um surto que ocorreu entre as tropas das Na\u00e7\u00f5es Unidas durante o conflito coreano entre 1951 e 1954",
        "id":"4463",
        "question":"How was HFRS  first brought to the attention of western medicine ?",
        "question_pt":"Como o HFRS foi trazido \u00e0 aten\u00e7\u00e3o da medicina ocidental?"
    },
    {
        "answer":" etiologic agent, Hantaan virus",
        "answer_pt":"agente etiol\u00f3gico, v\u00edrus Hantaan",
        "id":"4464",
        "question":"What is HTNV?",
        "question_pt":"O que \u00e9 HTNV?"
    },
    {
        "answer":" from the striped field mouse Apodemus agrarius,",
        "answer_pt":"do mouse listrado Apodemus agrarius,",
        "id":"4465",
        "question":"Where was HTNV isolated from?",
        "question_pt":"De onde foi isolado o HTNV?"
    },
    {
        "answer":"Hantavirus of the family Bunyaviridae",
        "answer_pt":"Hantav\u00edrus da fam\u00edlia Bunyaviridae",
        "id":"4466",
        "question":"Which new genus was the virus later found to represent?",
        "question_pt":"Qual novo g\u00eanero foi encontrado posteriormente para o v\u00edrus representar?"
    },
    {
        "answer":"The categorization of hantaviruses as belonging to the family Bunyaviridae is due in part to",
        "answer_pt":"A categoriza\u00e7\u00e3o dos hantav\u00edrus como pertencentes \u00e0 fam\u00edlia Bunyaviridae deve-se em parte a",
        "id":"4467",
        "question":"Which was  the first hantavirus to be isolated?",
        "question_pt":"Qual foi o primeiro hantav\u00edrus a ser isolado?"
    },
    {
        "answer":" the consistent presence of three RNA genomes that are circularized in vivo as a result of the presence of terminal complementary nucleotides that help fold the genome into a -hairpin\u2016 morphology,",
        "answer_pt":"a presen\u00e7a consistente de tr\u00eas genomas de RNA que s\u00e3o circularizados in vivo como resultado da presen\u00e7a de nucleot\u00eddeos complementares terminais que ajudam a dobrar o genoma em uma morfologia de \"gancho de gancho\",",
        "id":"4468",
        "question":"What is the categorization of hantaviruses as belonging to the family Bunyaviridae due in part to?",
        "question_pt":"Qual \u00e9 a classifica\u00e7\u00e3o dos hantav\u00edrus como pertencente \u00e0 fam\u00edlia Bunyaviridae devido em parte a?"
    },
    {
        "answer":"Uukuniemi phlebovirus ",
        "answer_pt":"Flebov\u00edrus de Uukuniemi",
        "id":"4469",
        "question":"What was the hairpin morphology first described for?",
        "question_pt":"Para que foi descrita a morfologia hairpin?"
    },
    {
        "answer":"a membrane -bound protease into Gn and Gc, a cleavage that occurs",
        "answer_pt":"uma protease ligada \u00e0 membrana em Gn e Gc, uma clivagem que ocorre",
        "id":"4470",
        "question":"How is the the precursor form GPC processed, during virus maturation?",
        "question_pt":"Como \u00e9 processado o formul\u00e1rio precursor do GPC durante a matura\u00e7\u00e3o do v\u00edrus?"
    },
    {
        "answer":"after the conserved peptide signal WAASA at the C-terminal of Gn ",
        "answer_pt":"ap\u00f3s o sinal pept\u00eddico conservado WAASA no terminal C de Gn",
        "id":"4471",
        "question":"When does the cleavage appear to be signaled?",
        "question_pt":"Quando o decote parece ser sinalizado?"
    },
    {
        "answer":"to allow them stability so that the two can be assembled correctly in the Golg",
        "answer_pt":"para permitir estabilidade para que os dois possam ser montados corretamente no Golf",
        "id":"4472",
        "question":"Why must the two proteins Gn and Gc be co-expressed?",
        "question_pt":"Por que as duas prote\u00ednas Gn e Gc devem ser co-expressas?"
    },
    {
        "answer":" the \uf0623 integrin chain and decay accelerating factor, or DAF",
        "answer_pt":"a cadeia integrina \uf0623 e o fator acelerador de decaimento, ou DAF",
        "id":"4473",
        "question":"Which two distinct cellular receptors the glycoproteins are the known or presumed ligands for?",
        "question_pt":"Para quais dois receptores celulares distintos as glicoprote\u00ednas s\u00e3o os ligantes conhecidos ou presumidos?"
    },
    {
        "answer":" blunt any pathological response in the host [",
        "answer_pt":"embotar qualquer resposta patol\u00f3gica no hospedeiro [",
        "id":"4474",
        "question":"What is the underlying premise for many of these studies?",
        "question_pt":"Qual \u00e9 a premissa b\u00e1sica de muitos desses estudos?"
    },
    {
        "answer":"would tend to induce an earlier innate response that would render it more likely that the virus would be quickly cleared or rendered less competent in its replication",
        "answer_pt":"tenderia a induzir uma resposta inata anterior que tornaria mais prov\u00e1vel que o v\u00edrus fosse rapidamente eliminado ou tornado menos competente em sua replica\u00e7\u00e3o",
        "id":"4482",
        "question":"What is the premise for apathogenic forms to  blunt any pathological response in the host?",
        "question_pt":"Qual \u00e9 a premissa das formas apatog\u00eanicas para embotar qualquer resposta patol\u00f3gica no hospedeiro?"
    },
    {
        "answer":"hantaviruses have been identified as adversely affecting",
        "answer_pt":"hantav\u00edrus foram identificados como afetando adversamente",
        "id":"4483",
        "question":"Which proteins and mRNAs prominently induced by hantaviruses include?",
        "question_pt":"Quais prote\u00ednas e mRNAs induzidos proeminentemente por hantav\u00edrus incluem?"
    },
    {
        "answer":"endothelial migration over substrata ",
        "answer_pt":"migra\u00e7\u00e3o endotelial sobre substratos",
        "id":"4492",
        "question":" What have hantaviruses been identified as adversely affect?",
        "question_pt":"O que os hantav\u00edrus foram identificados como afetando adversamente?"
    },
    {
        "answer":" VEG-F-induced endothelial permeability",
        "answer_pt":"Permeabilidade endotelial induzida por VEG-F",
        "id":"4493",
        "question":" What have hantaviruses been identified in potentiating?",
        "question_pt":"O que os hantav\u00edrus foram identificados na potencializa\u00e7\u00e3o?"
    },
    {
        "answer":"a structural component of the viral nucleocapsid",
        "answer_pt":"um componente estrutural do nucleoc\u00e1pside viral",
        "id":"4494",
        "question":"What is N-protein?",
        "question_pt":"O que \u00e9 a prote\u00edna N?"
    },
    {
        "answer":"engages the hairpin termini of the genomic segments with high affinity",
        "answer_pt":"envolve os terminais hairpin dos segmentos gen\u00f4micos com alta afinidade",
        "id":"4495",
        "question":"What does the N-protein, as an RNA-binding protein, do?",
        "question_pt":"O que a prote\u00edna N, como uma prote\u00edna de liga\u00e7\u00e3o ao RNA, faz?"
    },
    {
        "answer":" it limits the access of the RNA to host nucleases ",
        "answer_pt":"limita o acesso do RNA a hospedar nucleases",
        "id":"4496",
        "question":"As an RNA-binding protein that engages the hairpin termini of the genomic segments, what does the N-protein of hantavirus do?",
        "question_pt":"Como uma prote\u00edna de liga\u00e7\u00e3o a RNA que envolve os terminais em gancho dos segmentos gen\u00f4micos, o que a prote\u00edna N do hantav\u00edrus faz?"
    },
    {
        "answer":" helps to render viral replication a closed process within the cytoplasm",
        "answer_pt":"ajuda a tornar a replica\u00e7\u00e3o viral um processo fechado no citoplasma",
        "id":"4497",
        "question":"As an RNA-binding protein that engages the hairpin termini of the genomic segments, what does the N-protein of hantavirus do?",
        "question_pt":"Como uma prote\u00edna de liga\u00e7\u00e3o a RNA que envolve os terminais em gancho dos segmentos gen\u00f4micos, o que a prote\u00edna N do hantav\u00edrus faz?"
    },
    {
        "answer":"a peripheral membrane protein",
        "answer_pt":"uma prote\u00edna de membrana perif\u00e9rica",
        "id":"4498",
        "question":"What does the N-protein act as?",
        "question_pt":"Como atua a prote\u00edna N?"
    },
    {
        "answer":" to the interference with an array of the intracellular processes of the normal cell",
        "answer_pt":"\u00e0 interfer\u00eancia com uma matriz dos processos intracelulares da c\u00e9lula normal",
        "id":"4499",
        "question":" What can  some of the other activities of N have, be linked to?",
        "question_pt":"Com o que algumas das outras atividades de N podem estar ligadas?"
    },
    {
        "answer":" to fundamental requirements of replication",
        "answer_pt":"aos requisitos fundamentais de replica\u00e7\u00e3o",
        "id":"4500",
        "question":" What can  some of the other activities of N have, be linked to?",
        "question_pt":"Com o que algumas das outras atividades de N podem estar ligadas?"
    },
    {
        "answer":"with actin microfilaments, and the SUMO-1 protein",
        "answer_pt":"com microfilamentos de actina e a prote\u00edna SUMO-1",
        "id":"4501",
        "question":"What is  N  also reported to interact with?",
        "question_pt":"Com o que N tamb\u00e9m \u00e9 relatado para interagir?"
    },
    {
        "answer":" through their interaction with N and DCP1",
        "answer_pt":"atrav\u00e9s da intera\u00e7\u00e3o com N e DCP1",
        "id":"4502",
        "question":"How do the viral RNAs become concentrated in P bodies during hantavirus infection?",
        "question_pt":"Como os RNAs virais se concentram nos corpos P durante a infec\u00e7\u00e3o por hantav\u00edrus?"
    },
    {
        "answer":" that N tracks along microtubules",
        "answer_pt":"que N acompanha os microt\u00fabulos",
        "id":"4503",
        "question":"What have confocal microscopy and biochemical-inhibitor studies shown?",
        "question_pt":"O que demonstraram estudos de microscopia confocal e inibidores bioqu\u00edmicos?"
    },
    {
        "answer":"not with actin filaments ",
        "answer_pt":"n\u00e3o com filamentos de actina",
        "id":"4504",
        "question":"What have confocal microscopy and biochemical-inhibitor studies shown on what N tracks?",
        "question_pt":"O que os estudos de microscopia confocal e inibidores bioqu\u00edmicos mostraram em quais faixas N?"
    },
    {
        "answer":"the Golgi",
        "answer_pt":"o Golgi",
        "id":"4505",
        "question":"What is the ultimate destination for N, for its assembly into viral particles?",
        "question_pt":"Qual \u00e9 o destino final de N, para sua montagem em part\u00edculas virais?"
    },
    {
        "answer":" via the endoplasmic reticulum-Golgi intermediate complex (ERGIC), also known as vesicular-tubular cluster ",
        "answer_pt":"via complexo intermedi\u00e1rio do ret\u00edculo endoplasm\u00e1tico-Golgi (ERGIC), tamb\u00e9m conhecido como aglomerado vesicular-tubular",
        "id":"4506",
        "question":"How does it traffic?",
        "question_pt":"Como trafega?"
    },
    {
        "answer":" dynamitin",
        "answer_pt":"dinamite",
        "id":"4507",
        "question":"What is a dominant negative inhibitor?",
        "question_pt":"O que \u00e9 um inibidor negativo dominante?"
    },
    {
        "answer":"dynein-mediated transport",
        "answer_pt":"transporte mediado por dine\u00edna",
        "id":"4508",
        "question":"What is dynamitin associated with?",
        "question_pt":"Com o que est\u00e1 associada a dinamite?"
    },
    {
        "answer":" reduced N's accumulation in the Golgi",
        "answer_pt":"reduzido ac\u00famulo de N no Golgi",
        "id":"4509",
        "question":"What is dynamitin associated with?",
        "question_pt":"Com o que est\u00e1 associada a dinamite?"
    },
    {
        "answer":" that microtubular transport is indeed utilized for the New World hantavirus SNV",
        "answer_pt":"que o transporte microtubular \u00e9 realmente utilizado para o SNV do hantav\u00edrus do Novo Mundo",
        "id":"4510",
        "question":"What does recent data indicate?",
        "question_pt":"O que os dados recentes indicam?"
    },
    {
        "answer":"plasma viral RNA with",
        "answer_pt":"RNA viral plasm\u00e1tico com",
        "id":"4511",
        "question":"Why have Hantavirus diseases of man been suspected of having an immunopathogenic basis?",
        "question_pt":"Por que suspeita-se que as doen\u00e7as humanas do Hantav\u00edrus tenham uma base imunopatog\u00eanica?"
    },
    {
        "answer":" a transient (~ 1-5 days) capillary leak involving the kidney and retroperitoneal space in HFRS and the lungs in HCPS",
        "answer_pt":"um vazamento capilar transit\u00f3rio (~ 1-5 dias) envolvendo o rim e o espa\u00e7o retroperitoneal no HFRS e os pulm\u00f5es no HCPS",
        "id":"4542",
        "question":"What is a critical feature of both?",
        "question_pt":"Qual \u00e9 uma caracter\u00edstica cr\u00edtica de ambos?"
    },
    {
        "answer":"is exudative in character, with chemical composition high in protein and resembling plasma.",
        "answer_pt":"tem car\u00e1ter exsudativo, com composi\u00e7\u00e3o qu\u00edmica rica em prote\u00ednas e semelhante a plasma.",
        "id":"4543",
        "question":"What is the character of he resulting leakage?",
        "question_pt":"Qual \u00e9 o car\u00e1ter do vazamento resultante?"
    },
    {
        "answer":" \u03b23 integrin",
        "answer_pt":"integrina \u03b23",
        "id":"4544",
        "question":"Which is an especially attractive candidate as an important in vivo receptor for hantaviruses?",
        "question_pt":"Qual \u00e9 um candidato especialmente atraente como um importante receptor in vivo para hantav\u00edrus?"
    },
    {
        "answer":"through uptake by regional lymph nodes, perhaps with or within an escorting lung histiocyte",
        "answer_pt":"atrav\u00e9s da capta\u00e7\u00e3o de linfonodos regionais, talvez com ou dentro de um histi\u00f3cito pulmonar",
        "id":"4545",
        "question":"What  is the likely way that hantaviruses arrive at their target tissues?",
        "question_pt":"Qual \u00e9 a maneira prov\u00e1vel que os hantav\u00edrus chegam aos tecidos alvo?"
    },
    {
        "answer":"local endothelium",
        "answer_pt":"endot\u00e9lio local",
        "id":"4546",
        "question":"What does the virus seed?",
        "question_pt":"O que o v\u00edrus semeia?"
    },
    {
        "answer":" the first few infected cells give rise, ultimately, to a primary viremia",
        "answer_pt":"as primeiras c\u00e9lulas infectadas d\u00e3o origem, finalmente, a uma viremia prim\u00e1ria",
        "id":"4547",
        "question":"What happens with the viral seeding at the  local endothelium?",
        "question_pt":"O que acontece com a propaga\u00e7\u00e3o viral no endot\u00e9lio local?"
    },
    {
        "answer":"appears to take a long time ",
        "answer_pt":"parece demorar muito",
        "id":"4548",
        "question":"How long does the process of giving rise to primary viremia for hantavirus infections?",
        "question_pt":"Quanto tempo leva o processo de dar origem \u00e0 viremia prim\u00e1ria para infec\u00e7\u00f5es por hantav\u00edrus?"
    },
    {
        "answer":" the agents of the more severe forms of HFRS and HCPS have begun to achieve sufficient mass",
        "answer_pt":"os agentes das formas mais graves de HFRS e HCPS come\u00e7aram a atingir massa suficiente",
        "id":"4549",
        "question":"What happens by the time that secondary viremia emerges?",
        "question_pt":"O que acontece quando a viremia secund\u00e1ria surge?"
    },
    {
        "answer":" through PAMP-PRR interactions and other means",
        "answer_pt":"atrav\u00e9s de intera\u00e7\u00f5es PAMP-PRR e outros meios",
        "id":"4550",
        "question":"How is the  the expression of proinflammatory cytokines induced?",
        "question_pt":"Como \u00e9 induzida a express\u00e3o de citocinas pr\u00f3-inflamat\u00f3rias?"
    },
    {
        "answer":"the pulmonary bed and lymphoid organs",
        "answer_pt":"leito pulmonar e \u00f3rg\u00e3os linf\u00f3ides",
        "id":"4551",
        "question":" For HCPS, what does that expression favor?",
        "question_pt":"Para o HCPS, o que essa express\u00e3o favorece?"
    },
    {
        "answer":"the retroperitoneum and, in general, the kidney",
        "answer_pt":"retroperit\u00f4nio e, em geral, o rim",
        "id":"4552",
        "question":" For HCPS, what does that expression spare?",
        "question_pt":"Para o HCPS, o que essa express\u00e3o poupa?"
    },
    {
        "answer":" For HCPS, that expression favors the pulmonary bed and lymphoid organs, yet, for unknown reasons, spares the retroperitoneum and, in general, the kidney. In HFRS the situation is reversed,",
        "answer_pt":"Para o HCPS, essa express\u00e3o favorece o leito pulmonar e os \u00f3rg\u00e3os linf\u00f3ides, mas, por raz\u00f5es desconhecidas, poupa o retroperit\u00f4nio e, em geral, o rim. No HFRS, a situa\u00e7\u00e3o \u00e9 revertida,",
        "id":"4553",
        "question":"What happens for HFRS?",
        "question_pt":"O que acontece com o HFRS?"
    },
    {
        "answer":"Local elaboration of inflammatory and chemotactic mediators ",
        "answer_pt":"Elabora\u00e7\u00e3o local de mediadores inflamat\u00f3rios e quimiot\u00e1ticos",
        "id":"4554",
        "question":"What is considered to be  a requirement for the development of systemic disease symptoms?",
        "question_pt":"O que \u00e9 considerado um requisito para o desenvolvimento de sintomas de doen\u00e7as sist\u00eamicas?"
    },
    {
        "answer":"shock and death",
        "answer_pt":"choque e morte",
        "id":"4555",
        "question":"What do those abnormalities sometimes culminate in?",
        "question_pt":"Em que essas anormalidades \u00e0s vezes culminam?"
    },
    {
        "answer":" not hypoxemia, due to the prominent pulmonary edema",
        "answer_pt":"hipoxemia, devido ao proeminente edema pulmonar",
        "id":"4556",
        "question":"What leads to death in most fatal cases of HCPS?",
        "question_pt":"O que leva \u00e0 morte na maioria dos casos fatais de HCPS?"
    },
    {
        "answer":"intoxication of the heart by as-yet-undefined mediators that leads to the low cardiac output state and the associated shock syndrome ",
        "answer_pt":"intoxica\u00e7\u00e3o do cora\u00e7\u00e3o por mediadores ainda n\u00e3o definidos que levam ao estado de baixo d\u00e9bito card\u00edaco e \u00e0 s\u00edndrome de choque associada",
        "id":"4557",
        "question":"What leads to death in most fatal cases of HCPS?",
        "question_pt":"O que leva \u00e0 morte na maioria dos casos fatais de HCPS?"
    },
    {
        "answer":" Innate immune mechanisms.",
        "answer_pt":"Mecanismos imunes inatos.",
        "id":"4558",
        "question":"What potential mechanism,  could be presumed to underlie the pathogenesis of HCPS?",
        "question_pt":"Qual mecanismo em potencial poderia presumir a patog\u00eanese do HCPS?"
    },
    {
        "answer":"Direct viral effects",
        "answer_pt":"Efeitos virais diretos",
        "id":"4559",
        "question":"What potential mechanism,  could be presumed to underlie the pathogenesis of HCPS?",
        "question_pt":"Qual mecanismo em potencial poderia presumir a patog\u00eanese do HCPS?"
    },
    {
        "answer":"Pathogenic effects caused by the activities of specific viral macromolecules.",
        "answer_pt":"Efeitos patog\u00eanicos causados \u200b\u200bpelas atividades de macromol\u00e9culas virais espec\u00edficas.",
        "id":"4560",
        "question":"What potential mechanism,  could be presumed to underlie the pathogenesis of HCPS?",
        "question_pt":"Qual mecanismo em potencial poderia presumir a patog\u00eanese do HCPS?"
    },
    {
        "answer":"direct viral toxicity, acting through the inhibition of endothelial cell barrier function",
        "answer_pt":"toxicidade viral direta, atuando atrav\u00e9s da inibi\u00e7\u00e3o da fun\u00e7\u00e3o da barreira celular endotelial",
        "id":"4561",
        "question":"What  explanation have some investigators favored   for much of the capillary leak?",
        "question_pt":"Que explica\u00e7\u00e3o alguns pesquisadores favoreceram para grande parte do vazamento capilar?"
    },
    {
        "answer":"their native carrier rodents, the bank vole Myodes glareolus and the deer mouse P. maniculatus",
        "answer_pt":"roedores nativos, a ratazana do banco Myodes glareolus e o camundongo P. maniculatus",
        "id":"4562",
        "question":" What animal models exist for both the asymptomatic carriage of PUUV and SNV?",
        "question_pt":"Quais modelos animais existem para o transporte assintom\u00e1tico de PUUV e SNV?"
    },
    {
        "answer":"ANDV or the related Maporal virus from Venezuela, for which an HCPS-mimetic disease is observed",
        "answer_pt":"ANDV ou o v\u00edrus Maporal relacionado da Venezuela, para o qual \u00e9 observada uma doen\u00e7a mim\u00e9tica para o HCPS",
        "id":"4563",
        "question":"For what can the Syrian hamster model used?",
        "question_pt":"Para que o modelo de hamster s\u00edrio pode ser usado?"
    },
    {
        "answer":"by capillary leak that results in pulmonary edema and the production of a pleural effusion with exudative characteristics",
        "answer_pt":"por vazamento capilar que resulta em edema pulmonar e na produ\u00e7\u00e3o de derrame pleural com caracter\u00edsticas exsudativas",
        "id":"4564",
        "question":"What does the hamster model for HCPS caused by?",
        "question_pt":"O que o modelo de hamster para HCPS causado por?"
    },
    {
        "answer":"11 and 14-d",
        "answer_pt":"11 e 14-d",
        "id":"4565",
        "question":" Typically how long do the hamsters die post-inoculation?",
        "question_pt":"Por quanto tempo os hamsters morrem ap\u00f3s a inocula\u00e7\u00e3o?"
    },
    {
        "answer":"abundant fibrin deposition, thickened alveolar septa, and viral antigen expressed abundantly in the microvascular endothelium.",
        "answer_pt":"deposi\u00e7\u00e3o abundante de fibrina, septos alveolares espessados \u200b\u200be ant\u00edgeno viral expressos abundantemente no endot\u00e9lio microvascular.",
        "id":"4566",
        "question":"What does the microscopic examination of the lung reveal, as with human HCPS?",
        "question_pt":"O que o exame microsc\u00f3pico do pulm\u00e3o revela, como acontece com o HCPS humano?"
    },
    {
        "answer":"diminished pulse pressures, tachycardia, and hypotension",
        "answer_pt":"press\u00f5es de pulso diminu\u00eddas, taquicardia e hipotens\u00e3o",
        "id":"4567",
        "question":"What do ANDV-infected hamsters fitted with physiologic monitoring devices exhibit?",
        "question_pt":"O que exibem hamsters infectados com ANDV equipados com dispositivos de monitoramento fisiol\u00f3gico?"
    },
    {
        "answer":"the shock that is believed to be the proximate cause of demise in patients who succumb to HCPS ",
        "answer_pt":"o choque que se acredita ser a causa imediata da morte em pacientes que sucumbem ao HCPS",
        "id":"4568",
        "question":"What do diminished pulse pressures, tachycardia, and hypotension in ANDV infected hamsters appear to closely mimic?",
        "question_pt":"O que as press\u00f5es de pulso diminu\u00eddas, taquicardia e hipotens\u00e3o nos hamsters infectados com ANDV parecem imitar de perto?"
    },
    {
        "answer":"exceptionally high titers of live ANDV in their tissues, with much of the viral replication occurring in hepatocytes",
        "answer_pt":"t\u00edtulos excepcionalmente altos de ANDV vivo em seus tecidos, com grande parte da replica\u00e7\u00e3o viral ocorrendo em hepat\u00f3citos",
        "id":"4570",
        "question":"Compared to  humans, what do ANDV infected hamsters exhibit?",
        "question_pt":"Comparado aos seres humanos, o que os hamsters infectados com ANDV exibem?"
    },
    {
        "answer":"with disease severity for HCPS and HFRS,",
        "answer_pt":"com gravidade da doen\u00e7a para HCPS e HFRS,",
        "id":"4572",
        "question":"With what have three studies correlated  plasma viral RNA?",
        "question_pt":"Com o que tr\u00eas estudos correlacionaram o RNA viral plasm\u00e1tico?"
    },
    {
        "answer":"Ty21a for typhoid fever in humans, several Salmonella serovars against salmonellosis in chickens and other animals",
        "answer_pt":"Ty21a para febre tif\u00f3ide em humanos, v\u00e1rios sorovares de Salmonella contra salmonelose em galinhas e outros animais",
        "id":"809",
        "question":"What are examples of delivery vectors for commercial anti-Salmonella vaccines?",
        "question_pt":"Quais s\u00e3o os exemplos de vetores de entrega para vacinas anti-Salmonella comerciais?"
    },
    {
        "answer":"commonly employed vectors, for example Salmonella and adenovirus, often have pre-existing immune responses in the host and this has the potential to modify the subsequent immune response to a vectored antigen. ",
        "answer_pt":"vetores comumente empregados, por exemplo, Salmonella e adenov\u00edrus, geralmente t\u00eam respostas imunes pr\u00e9-existentes no hospedeiro e isso tem o potencial de modificar a resposta imune subsequente a um ant\u00edgeno vetorizado.",
        "id":"798",
        "question":"What can be a factor in using common vectors for the delivery of vaccines?",
        "question_pt":"O que pode ser um fator no uso de vetores comuns para a entrega de vacinas?"
    },
    {
        "answer":"for bacterial vectors there can in fact, in some cases, be an enhancement in immunogenicity, typically humoral, while for viral vectors pre-existing immunity is a hindrance for subsequent induction of cell-mediated responses.",
        "answer_pt":"para vetores bacterianos, de fato, em alguns casos, pode haver um aumento na imunogenicidade, tipicamente humoral, enquanto que para vetores virais a imunidade preexistente \u00e9 um obst\u00e1culo para a indu\u00e7\u00e3o subsequente de respostas mediadas por c\u00e9lulas.",
        "id":"800",
        "question":"Is a pre-existing immune response to commonly used delivery vector an advantage or a disadvantage?",
        "question_pt":"Uma resposta imune preexistente ao vetor de entrega comumente usado \u00e9 uma vantagem ou uma desvantagem?"
    },
    {
        "answer":" attenuated bacteria, including Escherichia coli, Vibrio cholerae, lactic acid bacteria (LAB), specifically Lactococcus lactis, Mycobacterium, Listeria, Shigella and Salmonella, have been tested for the targeted delivery of heterologous antigens of bacterial, viral and parasitic origin into a variety of animal hosts",
        "answer_pt":"bact\u00e9rias atenuadas, incluindo Escherichia coli, Vibrio cholerae, bact\u00e9rias do \u00e1cido l\u00e1tico (LAB), especificamente Lactococcus lactis, Mycobacterium, Listeria, Shigella e Salmonella, foram testadas quanto \u00e0 entrega direcionada de ant\u00edgenos heter\u00f3logos de origem bacteriana, viral e parasit\u00e1ria em uma variedade de hospedeiros de animais",
        "id":"802",
        "question":"What bacterial delivery vectors have been tested in animal hosts?",
        "question_pt":"Quais vetores de entrega bacteriana foram testados em hospedeiros animais?"
    },
    {
        "answer":"Bacteria such as E. coli and lactic acid bacteria ",
        "answer_pt":"Bact\u00e9rias como E. coli e bact\u00e9rias do \u00e1cido l\u00e1ctico",
        "id":"804",
        "question":"Which bacteial delivery vectors have gained favor for vaccines?",
        "question_pt":"Quais vetores de entrega bacteriana foram favorecidos pelas vacinas?"
    },
    {
        "answer":"E. coli is a commensal and lactic acid bacteria are present in most fermented food items and are therefore naturally present in the host. They are also a much safer option than traditional attenuated vaccines in children and immunecompromised people.",
        "answer_pt":"E. coli \u00e9 uma bact\u00e9ria comensal e de \u00e1cido l\u00e1ctico, presente na maioria dos alimentos fermentados e, portanto, naturalmente presente no hospedeiro. Eles tamb\u00e9m s\u00e3o uma op\u00e7\u00e3o muito mais segura do que as vacinas atenuadas tradicionais em crian\u00e7as e pessoas imunocomprometidas.",
        "id":"805",
        "question":"Why are E Coli and lactic acid are safe choices as delivery vectors for vaccines?",
        "question_pt":"Por que E Coli e \u00e1cido l\u00e1tico s\u00e3o escolhas seguras como vetores de entrega de vacinas?"
    },
    {
        "answer":" Listeria species are Gram-positive intracellular food-borne pathogens",
        "answer_pt":"As esp\u00e9cies de Listeria s\u00e3o pat\u00f3genos intracelulares transmitidos por alimentos Gram-positivos",
        "id":"812",
        "question":"What is Listeria?",
        "question_pt":"O que \u00e9 Listeria?"
    },
    {
        "answer":"The advantages of Listeria are that it can invade a variety of cells, including antigen presenting cells (APCs). After invading the host cell, Listeria resides inside the phagosome; however, it can escape the phagosome with the help of listeriolysin O (LLO; Hly) and reside in the cytoplasm of the cells, thereby efficiently presenting antigen to both CD8 and CD4 T cells ",
        "answer_pt":"As vantagens do Listeria s\u00e3o que ele pode invadir uma variedade de c\u00e9lulas, incluindo c\u00e9lulas apresentadoras de ant\u00edgeno (APCs). Ap\u00f3s invadir a c\u00e9lula hospedeira, Listeria reside dentro do fagossomo; no entanto, ele pode escapar do fagossomo com a ajuda da listeriolisina O (LLO; Hly) e residir no citoplasma das c\u00e9lulas, apresentando com efici\u00eancia o ant\u00edgeno nas c\u00e9lulas T CD8 e CD4",
        "id":"813",
        "question":"What is the advantage of Listeria as a  delivery vector for vaccines?",
        "question_pt":"Qual \u00e9 a vantagem do Listeria como vetor de entrega de vacinas?"
    },
    {
        "answer":"recombinant vaccines are based on both DNA viruses (such as fowlpox virus-based vaccines which target avian influenza virus and fowlpox virus, or vaccinia virusbased vectors against the rabies virus in wildlife) and RNA viruses [such as Newcastle disease virus-based vaccines to be used in poultry or yellow fever virus (YFV)-based vaccines to be used in horses against West Nile virus] ",
        "answer_pt":"As vacinas recombinantes baseiam-se em v\u00edrus de DNA (como vacinas baseadas no v\u00edrus da var\u00edola), que t\u00eam como alvo o v\u00edrus da influenza avi\u00e1ria e o v\u00edrus da var\u00edola, ou vetores baseados no v\u00edrus da vacina contra o v\u00edrus da raiva na vida selvagem) e v\u00edrus de RNA [como as vacinas baseadas no v\u00edrus da doen\u00e7a de Newcastle. usado em vacinas \u00e0 base de aves ou v\u00edrus da febre amarela (YFV) para uso em cavalos contra o v\u00edrus do Nilo Ocidental]",
        "id":"817",
        "question":"What are examples of  viral vectors for delivering vaccines?",
        "question_pt":"Quais s\u00e3o os exemplos de vetores virais para a entrega de vacinas?"
    },
    {
        "answer":"YFV (YF-17D strain) was the first to be licensed for use in humans, where the cDNAs encoding the envelope proteins of YFV were replaced with the corresponding genes of an attenuated Japanese encephalitis virus strain, SA14-14-2",
        "answer_pt":"O YFV (cepa YF-17D) foi o primeiro a ser licenciado para uso em seres humanos, onde os cDNAs que codificam as prote\u00ednas do envelope do YFV foram substitu\u00eddos pelos genes correspondentes de uma cepa do v\u00edrus da encefalite japonesa atenuada, SA14-14-2",
        "id":"825",
        "question":"Which viral vaccine delivery vector was first licensed?",
        "question_pt":"Qual vetor de entrega de vacina viral foi licenciado pela primeira vez?"
    },
    {
        "answer":"modified vaccinia virus Ankara (MVA) and New York attenuated vaccinia virus NYVAC strains",
        "answer_pt":"v\u00edrus vaccinia modificado Ankara (MVA) e Nova York atenuaram as cepas NYVAC do v\u00edrus vaccinia",
        "id":"831",
        "question":"What are examples of attenuated poxvirus vaccine delivery vectors?",
        "question_pt":"Quais s\u00e3o os exemplos de vetores atenuados de entrega de vacinas contra o poxv\u00edrus?"
    },
    {
        "answer":"Chickens (Gallus gallus) are a natural animal reservoir for Salmonella, which makes them an important source of Salmonella-associated gastroenteritis in humans. ",
        "answer_pt":"As galinhas (Gallus gallus) s\u00e3o um reservat\u00f3rio natural de animais para Salmonella, o que as torna uma fonte importante de gastroenterite associada a Salmonella em humanos.",
        "id":"872",
        "question":"What is the connection between chicken and Salmonella?",
        "question_pt":"Qual \u00e9 a conex\u00e3o entre frango e Salmonella?"
    },
    {
        "answer":"They are ideal candidate vectors due to their large DNA-packing capacity and their thermal and genetic stability ",
        "answer_pt":"S\u00e3o vetores candidatos ideais devido \u00e0 sua grande capacidade de empacotamento de DNA e \u00e0 sua estabilidade t\u00e9rmica e gen\u00e9tica",
        "id":"833",
        "question":"Why are some poxvirus  ideally suited as vaccine delivery vectors?",
        "question_pt":"Por que alguns poxv\u00edrus s\u00e3o ideais como vetores de entrega de vacinas?"
    },
    {
        "answer":"adenovirus (Ad) vector is another of the most widely evaluated vectors to date to express heterologous antigens, due to ease of production, safety profile, genetic stability, the ease of DNA genome manipulation, and the ability to stimulate both innate and adaptive immune responses and induce both T and B cell responses ",
        "answer_pt":"O vetor adenov\u00edrus (Ad) \u00e9 outro dos vetores mais amplamente avaliados at\u00e9 o momento para expressar ant\u00edgenos heter\u00f3logos, devido \u00e0 facilidade de produ\u00e7\u00e3o, perfil de seguran\u00e7a, estabilidade gen\u00e9tica, facilidade de manipula\u00e7\u00e3o do genoma do DNA e capacidade de estimular respostas imunes inatas e adaptativas e induzir respostas de c\u00e9lulas T e B",
        "id":"836",
        "question":"What is the advantage of adenovirus as vaccine delivery vector?",
        "question_pt":"Qual \u00e9 a vantagem do adenov\u00edrus como vetor de entrega de vacina?"
    },
    {
        "answer":"a vaccine should be inexpensive, so that it can be administered to a large population at minimal cost",
        "answer_pt":"uma vacina deve ser barata, para que possa ser administrada a uma grande popula\u00e7\u00e3o a um custo m\u00ednimo",
        "id":"838",
        "question":"What are important criteria for selecting vaccine delivery vectors?",
        "question_pt":"Quais s\u00e3o os crit\u00e9rios importantes para selecionar vetores de entrega de vacina?"
    },
    {
        "answer":"Safety is a major concern, as even a low level of toxicity is unacceptable ",
        "answer_pt":"A seguran\u00e7a \u00e9 uma grande preocupa\u00e7\u00e3o, pois mesmo um baixo n\u00edvel de toxicidade \u00e9 inaceit\u00e1vel",
        "id":"841",
        "question":"What are important criteria for selecting vaccine delivery vectors?",
        "question_pt":"Quais s\u00e3o os crit\u00e9rios importantes para selecionar vetores de entrega de vacina?"
    },
    {
        "answer":"long-lasting cellular and (where appropriate) humoral immune responses to the vectored antigen must be induced following administration of these vaccines, preferably with a single dose",
        "answer_pt":"respostas imunes celulares e (quando apropriado) humorais duradouras ao ant\u00edgeno vetorizado devem ser induzidas ap\u00f3s a administra\u00e7\u00e3o dessas vacinas, de prefer\u00eancia com uma dose \u00fanica",
        "id":"845",
        "question":"What are important criteria for selecting vaccine delivery vectors?",
        "question_pt":"Quais s\u00e3o os crit\u00e9rios importantes para selecionar vetores de entrega de vacina?"
    },
    {
        "answer":"considering a vector such as Salmonella, if a host has previously been infected there will exist robust B and T memory responses, and as such, when a vaccination is delivered, an anamnestic response to the Salmonella antigens will be induced (while the response to the vectored antigen will be a primary response)",
        "answer_pt":"considerando um vetor como Salmonella, se um hospedeiro tiver sido infectado anteriormente, haver\u00e1 respostas robustas de mem\u00f3ria B e T e, como tal, quando uma vacina for administrada, uma resposta anamn\u00e9stica aos ant\u00edgenos de Salmonella ser\u00e1 induzida (enquanto a resposta ao v\u00edrus ant\u00edgeno vetorizado ser\u00e1 uma resposta prim\u00e1ria)",
        "id":"858",
        "question":"What happens when a recipient of a vaccine has immune response to the delivery vector?",
        "question_pt":"O que acontece quando um destinat\u00e1rio de uma vacina tem resposta imune ao vetor de entrega?"
    },
    {
        "answer":"for virally vectored antigens, the existence of pre-existing immunity to the vector (particularly neutralizing antibody) will restrict delivery of the virus into cells, thereby effectively reducing the dose of the vectored antigen. Again, this might be expected to result in a reduction in the antigenicity of the vectored antigen.",
        "answer_pt":"para ant\u00edgenos viralmente vetorizados, a exist\u00eancia de imunidade preexistente ao vetor (anticorpo neutralizante particularmente) restringir\u00e1 a entrega do v\u00edrus nas c\u00e9lulas, reduzindo efetivamente a dose do ant\u00edgeno vetorizado. Novamente, isso pode resultar em uma redu\u00e7\u00e3o na antigenicidade do ant\u00edgeno vetorizado.",
        "id":"864",
        "question":"What is the effect of host immune response to the delivery vector on the efficacy of vaccination?",
        "question_pt":"Qual \u00e9 o efeito da resposta imune do hospedeiro ao vetor de entrega na efic\u00e1cia da vacina\u00e7\u00e3o?"
    },
    {
        "answer":"theoretically reduce the exposure of the heterologous antigen to the immune system, as the vector is rapidly cleared.",
        "answer_pt":"teoricamente, reduza a exposi\u00e7\u00e3o do ant\u00edgeno heter\u00f3logo ao sistema imunol\u00f3gico, \u00e0 medida que o vetor \u00e9 rapidamente eliminado.",
        "id":"861",
        "question":"What is the effect of host immune response to the delivery vector on the efficacy of vaccination?",
        "question_pt":"Qual \u00e9 o efeito da resposta imune do hospedeiro ao vetor de entrega na efic\u00e1cia da vacina\u00e7\u00e3o?"
    },
    {
        "answer":"mice that had been primed with Salmonella alone, and then boosted with Salmonella expressing tetC, induced much lower anti-tetC responses than mice that had not been primed. This argues strongly that prior immunological immunity to the vector can seriously dampen subsequent antigen-specific humoral responses.",
        "answer_pt":"camundongos que haviam sido iniciados apenas com Salmonella e depois estimulados com Salmonella expressando tetC, induziam respostas anti-tetC muito mais baixas do que os que n\u00e3o haviam sido iniciados. Isto argumenta fortemente que a imunidade imunol\u00f3gica pr\u00e9via ao vetor pode prejudicar seriamente as respostas humorais subsequentes espec\u00edficas do ant\u00edgeno.",
        "id":"870",
        "question":"What is an example  of the effect of immunity to the  delivery vector on the efficacy of vaccination?",
        "question_pt":"Qual \u00e9 um exemplo do efeito da imunidade ao vetor de entrega na efic\u00e1cia da vacina\u00e7\u00e3o?"
    },
    {
        "answer":"pre-existing immunity is a major obstacle of many viralvectored vaccines, such as Ad serotype 5 or herpes simplex virus type 1 (HSV-1), where the rate of seroprevalence to these viruses is very high [40-45 % and 70 % (or more) of the US population, respectively] ",
        "answer_pt":"a imunidade preexistente \u00e9 um grande obst\u00e1culo para muitas vacinas viralizadas, como o sorotipo Ad 5 ou o v\u00edrus do herpes simplex tipo 1 (HSV-1), em que a taxa de soropreval\u00eancia desses v\u00edrus \u00e9 muito alta [40-45% e 70% ( ou mais) da popula\u00e7\u00e3o dos EUA, respectivamente]",
        "id":"874",
        "question":"What is the effect of host immune response to viral delivery vectors in the efficacy of vaccination?",
        "question_pt":"Qual \u00e9 o efeito da resposta imune do hospedeiro aos vetores de entrega viral na efic\u00e1cia da vacina\u00e7\u00e3o?"
    },
    {
        "answer":"Vector-specific antibodies may impede the induction of immune responses to the vaccine-encoded antigens, as they may reduce the dose and time of exposure of the target cells to the vaccinated antigens",
        "answer_pt":"Os anticorpos espec\u00edficos do vetor podem impedir a indu\u00e7\u00e3o de respostas imunes aos ant\u00edgenos codificados pela vacina, pois podem reduzir a dose e o tempo de exposi\u00e7\u00e3o das c\u00e9lulas-alvo aos ant\u00edgenos vacinados.",
        "id":"875",
        "question":"What is the effect of host immune response to  the viral delivery vector on the efficacy of vaccination?",
        "question_pt":"Qual \u00e9 o efeito da resposta imune do hospedeiro ao vetor de entrega viral na efic\u00e1cia da vacina\u00e7\u00e3o?"
    },
    {
        "answer":" In a large-scale clinical trial (STEP) of an Ad serotype 5 (AdHu5)-based HIV-1 vaccine, the vaccines showed a lack of efficacy and tended to increase the risk of HIV-1 infection in vaccine recipients who had pre-existing neutralizing antibodies to AdHu5 (",
        "answer_pt":"Em um ensaio cl\u00ednico em larga escala (STEP) de uma vacina contra o HIV-1 baseada no sorotipo 5 (AdHu5), as vacinas mostraram uma falta de efic\u00e1cia e tenderam a aumentar o risco de infec\u00e7\u00e3o pelo HIV-1 em receptores de vacinas anticorpos neutralizantes existentes ao AdHu5 (",
        "id":"876",
        "question":"What is the effect of host immune response to the delivery vector on  the efficacy of vaccination?",
        "question_pt":"Qual \u00e9 o efeito da resposta imune do hospedeiro ao vetor de entrega na efic\u00e1cia da vacina\u00e7\u00e3o?"
    },
    {
        "answer":" the use of vectors derived from nonhuman sources, using human viruses of rare serotypes (Kahl et al., 2010; Lasaro & Ertl, 2009) , heterologous prime-boost approaches (Liu et al., 2008) , homologous reimmunization (Steffensen et al., 2012) and removing key neutralizing epitopes on the surface of viral capsid proteins (Gabitzsch & Jones, 2011; Roberts et al., 2006) ",
        "answer_pt":"o uso de vetores derivados de fontes n\u00e3o humanas, usando v\u00edrus humanos de sorotipos raros (Kahl et al., 2010; Lasaro & Ertl, 2009), abordagens heter\u00f3logas de refor\u00e7o prim\u00e1rio (Liu et al., 2008), reimuniza\u00e7\u00e3o hom\u00f3loga (Steffensen et al. ., 2012) e remo\u00e7\u00e3o dos principais ep\u00edtopos neutralizantes na superf\u00edcie das prote\u00ednas do caps\u00eddeo viral (Gabitzsch & Jones, 2011; Roberts et al., 2006)",
        "id":"877",
        "question":"What are methods to avoid the effect vector immunity on the efficacy of vaccination?",
        "question_pt":"Quais s\u00e3o os m\u00e9todos para evitar o efeito da imunidade do vetor na efic\u00e1cia da vacina\u00e7\u00e3o?"
    },
    {
        "answer":"The inhibitory effect of pre-existing immunity can also be avoided by masking the Ad vector inside dendritic cells (DCs) (Steffensen et al., 2012) . In addition, mucosal vaccination or administration of higher vaccine doses can overcome pre-existing immunity problems (Alexander et al., 2012; Belyakov et al., 1999; Priddy et al., 2008; Xiang et al., 2003) .\n",
        "answer_pt":"O efeito inibit\u00f3rio da imunidade preexistente tamb\u00e9m pode ser evitado ocultando o vetor Ad dentro de c\u00e9lulas dendr\u00edticas (DCs) (Steffensen et al., 2012). Al\u00e9m disso, a vacina\u00e7\u00e3o da mucosa ou a administra\u00e7\u00e3o de doses mais altas de vacina podem superar problemas de imunidade preexistentes (Alexander et al., 2012; Belyakov et al., 1999; Priddy et al., 2008; Xiang et al., 2003).",
        "id":"878",
        "question":"What are methods to  avoid the effect of vector immune response on the efficacy of vaccination?",
        "question_pt":"Quais s\u00e3o os m\u00e9todos para evitar o efeito da resposta imune do vetor na efic\u00e1cia da vacina\u00e7\u00e3o?"
    },
    {
        "answer":" this is because viruses will induce neutralizing antibody on the first dose, and in subsequent doses this antibody will limit the number of transduced cells, therefore limiting the responses. This is particularly a problem with a common viral vector such as Ad, where a large proportion of the population will have immunological memory against common serotypes",
        "answer_pt":"isso ocorre porque os v\u00edrus induzir\u00e3o o anticorpo neutralizante na primeira dose e, nas doses subsequentes, esse anticorpo limitar\u00e1 o n\u00famero de c\u00e9lulas transduzidas, limitando, portanto, as respostas. Isso \u00e9 particularmente um problema com um vetor viral comum como o Ad, em que uma grande propor\u00e7\u00e3o da popula\u00e7\u00e3o ter\u00e1 mem\u00f3ria imunol\u00f3gica contra sorotipos comuns",
        "id":"879",
        "question":"How does cell-mediated immunity to viral delivery vector, reduce the immune response to vaccine?",
        "question_pt":"Como a imunidade mediada por c\u00e9lulas ao vetor de entrega viral reduz a resposta imune \u00e0 vacina?"
    },
    {
        "answer":" it will be possible to utilize such vectors only by developing vaccines from alternative serotypes. It may be that a vector such as Pre-existing immunity against vaccine vectors attenuated influenza virus, with the ability to easily develop reassortants, will be useful in this context.\n\nIn addition, immunological memory in the form of opsonizing antibody certainly plays an important role in the early uptake of Salmonella by macrophages and DC. This may be beneficial, as the live bacterial vector used for delivery purposes harbours mutations in genes encoding proteins responsible for their survival in the animal host. This not only encumbers their ability to cause disease, making them safe live vectors, but also limits the number of replications. The presence of opsonizing antibodies should mean a higher level of bacterial uptake, leading to higher presentation to the immune system and therefore a better immune response.",
        "answer_pt":"ser\u00e1 poss\u00edvel utilizar tais vetores apenas desenvolvendo vacinas a partir de sorotipos alternativos. Pode ser que um vetor como imunidade pr\u00e9-existente contra vetores de vacina atenuasse o v\u00edrus influenza, com a capacidade de desenvolver facilmente recombinantes, seja \u00fatil nesse contexto.\n\nAl\u00e9m disso, a mem\u00f3ria imunol\u00f3gica na forma de anticorpo opsonizante certamente desempenha um papel importante na absor\u00e7\u00e3o precoce de Salmonella por macr\u00f3fagos e DC. Isso pode ser ben\u00e9fico, pois o vetor bacteriano vivo usado para fins de entrega abriga muta\u00e7\u00f5es em genes que codificam prote\u00ednas respons\u00e1veis \u200b\u200bpor sua sobreviv\u00eancia no hospedeiro animal. Isso n\u00e3o apenas prejudica sua capacidade de causar doen\u00e7as, tornando-os vetores vivos seguros, mas tamb\u00e9m limita o n\u00famero de repeti\u00e7\u00f5es. A presen\u00e7a de anticorpos opsonizantes deve significar um maior n\u00edvel de capta\u00e7\u00e3o bacteriana, levando a uma maior apresenta\u00e7\u00e3o ao sistema imunol\u00f3gico e, portanto, a uma melhor resposta imune.",
        "id":"880",
        "question":"How can vectors for which host has immunity, be used differently to increase the efficacy of vaccination?",
        "question_pt":"Como os vetores para os quais o hospedeiro possui imunidade podem ser usados \u200b\u200bde maneira diferente para aumentar a efic\u00e1cia da vacina\u00e7\u00e3o?"
    },
    {
        "answer":"fecal\u2013oral contact",
        "answer_pt":"contato fecal-oral",
        "id":"601",
        "question":"How does the PED virus transmit between animals?",
        "question_pt":"Como o v\u00edrus PED transmite entre animais?"
    },
    {
        "answer":"recombinant vaccine carrier",
        "answer_pt":"portador de vacina recombinante",
        "id":"602",
        "question":"How can Bacilius subtilis be used as an oral vaccine?",
        "question_pt":"Como o Bacillus subtilis pode ser usado como vacina oral?"
    },
    {
        "answer":"intestine epithelial cells",
        "answer_pt":"c\u00e9lulas epiteliais do intestino",
        "id":"603",
        "question":"What cells are infected by the PED virus?",
        "question_pt":"Quais c\u00e9lulas est\u00e3o infectadas pelo v\u00edrus PED?"
    },
    {
        "answer":"mucosal",
        "answer_pt":"mucosa",
        "id":"604",
        "question":"What kind of immune responses are most effective in preventing PED virus?",
        "question_pt":"Que tipo de resposta imune \u00e9 mais eficaz na preven\u00e7\u00e3o do v\u00edrus PED?"
    },
    {
        "answer":"gastric acids, pepsin, and trypsin",
        "answer_pt":"\u00e1cidos g\u00e1stricos, pepsina e tripsina",
        "id":"605",
        "question":"What intestinal factors may reduce the effectiveness of orally-administered immunizations?",
        "question_pt":"Quais fatores intestinais podem reduzir a efic\u00e1cia das imuniza\u00e7\u00f5es administradas por via oral?"
    },
    {
        "answer":"Gram-positive bacterium",
        "answer_pt":"Bact\u00e9ria Gram-positiva",
        "id":"606",
        "question":"What is Bacillus subtilis?",
        "question_pt":"O que \u00e9 Bacillus subtilis?"
    },
    {
        "answer":"antigen-presenting cells",
        "answer_pt":"c\u00e9lulas apresentadoras de ant\u00edgenos",
        "id":"607",
        "question":"What is the role of dendritic cells in the immune response?",
        "question_pt":"Qual \u00e9 o papel das c\u00e9lulas dendr\u00edticas na resposta imune?"
    },
    {
        "answer":"gut-associated lymphoid tissue (GALT)",
        "answer_pt":"tecido linf\u00f3ide associado ao intestino (GALT)",
        "id":"608",
        "question":"Where do dendritic cells exist in the body?",
        "question_pt":"Onde as c\u00e9lulas dendr\u00edticas existem no corpo?"
    },
    {
        "answer":"Peyer's patches (PPs), isolated lymphoid follicles (ILFs), mesenteric lymph nodes (MLNs), and scatter throughout the subepithelial lamina propria (LP) of the small intestine and colon",
        "answer_pt":"Manchas de Peyer (PPs), fol\u00edculos linf\u00f3ides isolados (ILFs), linfonodos mesent\u00e9ricos (MLNs) e espalham-se pela l\u00e2mina pr\u00f3pria subepitelial (LP) do intestino delgado e do c\u00f3lon",
        "id":"609",
        "question":"What are the components of the gut-associated lymphoid tissue?",
        "question_pt":"Quais s\u00e3o os componentes do tecido linf\u00f3ide associado ao intestino?"
    },
    {
        "answer":"lymphoid cells",
        "answer_pt":"c\u00e9lulas linf\u00f3ides",
        "id":"610",
        "question":"What type of cells form the intestinal mucosal barrier?",
        "question_pt":"Que tipo de c\u00e9lula forma a barreira da mucosa intestinal?"
    },
    {
        "answer":"serum IgG and mucosal SIgA",
        "answer_pt":"IgG s\u00e9rica e SIgA da mucosa",
        "id":"611",
        "question":"What factors determine an effective mucosal immune response?",
        "question_pt":"Quais fatores determinam uma resposta imunol\u00f3gica eficaz da mucosa?"
    },
    {
        "answer":"cytokines",
        "answer_pt":"citocinas",
        "id":"612",
        "question":"What is an effective indicator of a vaccine's ability to generate an immune response?",
        "question_pt":"Qual \u00e9 um indicador eficaz da capacidade de uma vacina gerar uma resposta imune?"
    },
    {
        "answer":"pro-inflammatory cytokines",
        "answer_pt":"Citocinas pr\u00f3-inflamat\u00f3rias",
        "id":"613",
        "question":"What is interleukin-1Beta?",
        "question_pt":"O que \u00e9 interleucina-1Beta?"
    },
    {
        "answer":"Wuhan City, China",
        "answer_pt":"Cidade de Wuhan, China",
        "id":"1197",
        "question":"When was the first case of COVID-19 identified?",
        "question_pt":"Quando foi identificado o primeiro caso de COVID-19?"
    },
    {
        "answer":"Wuhan City, China",
        "answer_pt":"Cidade de Wuhan, China",
        "id":"1199",
        "question":"Where did SARS-CoV-2 originate?",
        "question_pt":"De onde se originou o SARS-CoV-2?"
    },
    {
        "answer":" rapid and transparent sharing of information between countries and agencies",
        "answer_pt":"compartilhamento r\u00e1pido e transparente de informa\u00e7\u00f5es entre pa\u00edses e ag\u00eancias",
        "id":"1201",
        "question":"In what year did the first SARS epidemic occur?",
        "question_pt":"Em que ano ocorreu a primeira epidemia de SARS?"
    },
    {
        "answer":"31 December",
        "answer_pt":"31 de dezembro",
        "id":"1202",
        "question":"When was World Health Organization (WHO) first notified about the SARS-CoV-2 epidemic in Wuhan City, China?",
        "question_pt":"Quando a Organiza\u00e7\u00e3o Mundial da Sa\u00fade (OMS) foi notificada pela primeira vez sobre a epidemia de SARS-CoV-2 na cidade de Wuhan, China?"
    },
    {
        "answer":"26 January 2020",
        "answer_pt":"26 de janeiro de 2020",
        "id":"1203",
        "question":"When did we discover that SARS-CoV-2, which causes COVID-19, was a novel coronavirus?",
        "question_pt":"Quando descobrimos que o SARS-CoV-2, que causa o COVID-19, era um novo coronav\u00edrus?"
    },
    {
        "answer":"4 weeks",
        "answer_pt":"4 semanas",
        "id":"1204",
        "question":"How long did it take to identify the cause of COVID-19?",
        "question_pt":"Quanto tempo levou para identificar a causa do COVID-19?"
    },
    {
        "answer":" reverse transcription polymerase chain reaction",
        "answer_pt":"rea\u00e7\u00e3o em cadeia da polimerase com transcri\u00e7\u00e3o reversa",
        "id":"1205",
        "question":"What type of test was initially developed to screen for SARS-CoV-2?",
        "question_pt":"Que tipo de teste foi desenvolvido inicialmente para rastrear o SARS-CoV-2?"
    },
    {
        "answer":"1000 bed hospital",
        "answer_pt":"1000 bed hospital",
        "id":"1206",
        "question":"How big was the temporary hospital built in Wuhan City for treatment of COVID-19 patients?",
        "question_pt":"Qual o tamanho do hospital tempor\u00e1rio constru\u00eddo em Wuhan City para o tratamento de pacientes com COVID-19?"
    },
    {
        "answer":"10 days",
        "answer_pt":"10 dias",
        "id":"1207",
        "question":"How long did it take China to build the temporary hospital in Wuhan for COVID-19 patients?",
        "question_pt":"Quanto tempo levou a China para construir o hospital tempor\u00e1rio em Wuhan para pacientes com COVID-19?"
    },
    {
        "answer":"transparent sharing of information between countries and agencies",
        "answer_pt":"compartilhamento transparente de informa\u00e7\u00f5es entre pa\u00edses e ag\u00eancias",
        "id":"1208",
        "question":"What is a key factor in managing emerging infectious disease threats?",
        "question_pt":"Qual \u00e9 um fator chave no gerenciamento de amea\u00e7as emergentes a doen\u00e7as infecciosas?"
    },
    {
        "answer":"2012",
        "answer_pt":"2012",
        "id":"1209",
        "question":"In what year did the MERS epidemic occur?",
        "question_pt":"Em que ano ocorreu a epidemia de MERS?"
    },
    {
        "answer":"2 weeks",
        "answer_pt":"2 semanas",
        "id":"1210",
        "question":"How long did it take to publish the full genomic sequence of SARS-CoV-2 after it was identified?",
        "question_pt":"Quanto tempo levou para publicar a sequ\u00eancia gen\u00f4mica completa do SARS-CoV-2 depois que ele foi identificado?"
    },
    {
        "answer":"10%",
        "answer_pt":"10%",
        "id":"1211",
        "question":"What was the fatality rate for SARS-CoV?",
        "question_pt":"Qual foi a taxa de mortalidade para SARS-CoV?"
    },
    {
        "answer":"34%",
        "answer_pt":"34%",
        "id":"1212",
        "question":"What was the fatality rate for MERS?",
        "question_pt":"Qual foi a taxa de mortalidade para MERS?"
    },
    {
        "answer":"the volume and diversity of the information available and the relative lack of verification mechanisms",
        "answer_pt":"o volume e a diversidade das informa\u00e7\u00f5es dispon\u00edveis e a relativa falta de mecanismos de verifica\u00e7\u00e3o",
        "id":"1213",
        "question":"What are some challenges associated with using media and social media to capture information about an emerging epidemic?",
        "question_pt":"Quais s\u00e3o alguns dos desafios associados ao uso da m\u00eddia e da m\u00eddia social para capturar informa\u00e7\u00f5es sobre uma epidemia emergente?"
    },
    {
        "answer":"autoinfection, but also in infection of patients hospitalised for other causes when they provide care",
        "answer_pt":"auto-infec\u00e7\u00e3o, mas tamb\u00e9m na infec\u00e7\u00e3o de pacientes hospitalizados por outras causas quando prestam cuidados",
        "id":"1214",
        "question":"What are the risks of health workers failing to wash hands?",
        "question_pt":"Quais s\u00e3o os riscos de os profissionais de sa\u00fade n\u00e3o lavarem as m\u00e3os?"
    },
    {
        "answer":" the health worker, but also for their families and the communities in which they live",
        "answer_pt":"profissional de sa\u00fade, mas tamb\u00e9m para suas fam\u00edlias e comunidades em que vivem",
        "id":"1215",
        "question":"Who is at risk when health workers fail to wash their hands?",
        "question_pt":"Quem est\u00e1 em risco quando os profissionais de sa\u00fade deixam de lavar as m\u00e3os?"
    },
    {
        "answer":"3",
        "answer_pt":"3",
        "id":"1216",
        "question":"What was the R0 of SARS in absence of control measures?",
        "question_pt":"Qual foi o R0 da SARS na aus\u00eancia de medidas de controle?"
    },
    {
        "answer":"where a case infected significantly more contacts than the average",
        "answer_pt":"onde um caso infectou significativamente mais contatos do que a m\u00e9dia",
        "id":"1217",
        "question":"What is superspreading?",
        "question_pt":"O que \u00e9 superspread?"
    },
    {
        "answer":"5 m people",
        "answer_pt":"5 m pessoas",
        "id":"1218",
        "question":"How many people may have left Wuhan before travel restrictions were imposed?",
        "question_pt":"Quantas pessoas podem ter deixado Wuhan antes da imposi\u00e7\u00e3o de restri\u00e7\u00f5es de viagem?"
    },
    {
        "answer":"Between 3-5 million",
        "answer_pt":"Entre 3-5 milh\u00f5es",
        "id":"1939",
        "question":"How many severe cases of influenza-related illnesses are reported per year?",
        "question_pt":"Quantos casos graves de doen\u00e7as relacionadas \u00e0 influenza s\u00e3o notificados por ano?"
    },
    {
        "answer":"over 250 000",
        "answer_pt":"mais de 250 000",
        "id":"1940",
        "question":"How many influenza-related deaths are reported each year?",
        "question_pt":"Quantas mortes relacionadas \u00e0 influenza s\u00e3o relatadas a cada ano?"
    },
    {
        "answer":"53%",
        "answer_pt":"53%",
        "id":"1941",
        "question":"What is the mortality rate of the H5N1 strain of influenza?",
        "question_pt":"Qual \u00e9 a taxa de mortalidade da cepa H5N1 da influenza?"
    },
    {
        "answer":"primary human alveolar epithelial type II (ATII) cells",
        "answer_pt":"c\u00e9lulas epiteliais alveolares humanas prim\u00e1rias tipo II (ATII)",
        "id":"1942",
        "question":"What cells are the main target of the influenza A virus in the lungs?",
        "question_pt":"Quais c\u00e9lulas s\u00e3o o principal alvo do v\u00edrus influenza A nos pulm\u00f5es?"
    },
    {
        "answer":"four",
        "answer_pt":"quatro",
        "id":"1944",
        "question":"How many extracellular domains are in the CEAMCAM1 protein?",
        "question_pt":"Quantos dom\u00ednios extracelulares existem na prote\u00edna CEAMCAM1?"
    },
    {
        "answer":"epithelial and endothelial cells 11 , as well as B cells, T cells, neutrophils, NK cells, macrophages and dendritic cells (DCs)",
        "answer_pt":"c\u00e9lulas epiteliais e endoteliais 11, bem como c\u00e9lulas B, c\u00e9lulas T, neutr\u00f3filos, c\u00e9lulas NK, macr\u00f3fagos e c\u00e9lulas dendr\u00edticas (DCs)",
        "id":"1945",
        "question":"Where is CEACAM1 expressed in the body?",
        "question_pt":"Onde o CEACAM1 \u00e9 expresso no corpo?"
    },
    {
        "answer":"immunoreceptor tyrosine-based inhibitory motifs (ITIMs)",
        "answer_pt":"motivos inibidores baseados em tirosina (ITIMs) imunorreceptores",
        "id":"1946",
        "question":"What motifs are absent in the short form of CEACAM1 protein?",
        "question_pt":"Que motivos est\u00e3o ausentes na forma abreviada da prote\u00edna CEACAM1?"
    },
    {
        "answer":"CEACAM1-4L and CEACAM1-3L",
        "answer_pt":"CEACAM1-4L e CEACAM1-3L",
        "id":"1947",
        "question":"What are the most common isoforms of CEACAM1?",
        "question_pt":"Quais s\u00e3o as isoformas mais comuns do CEACAM1?"
    },
    {
        "answer":"heterophilically",
        "answer_pt":"heterofilicamente",
        "id":"1948",
        "question":"How do CEACAM1 and CEACAM5 interact?",
        "question_pt":"Como CEACAM1 e CEACAM5 interagem?"
    },
    {
        "answer":"signaling molecules",
        "answer_pt":"mol\u00e9culas de sinaliza\u00e7\u00e3o",
        "id":"1949",
        "question":"What are the SRC-family of kinases? ",
        "question_pt":"O que s\u00e3o a fam\u00edlia SRC de cinases?"
    },
    {
        "answer":"pattern recognition receptors (PRRs)",
        "answer_pt":"receptores de reconhecimento de padr\u00f5es (PRRs)",
        "id":"1950",
        "question":"What triggers the release of pro-inflammatory cytokines/chemokines to assist in viral clearance?",
        "question_pt":"O que desencadeia a libera\u00e7\u00e3o de citocinas / quimiocinas pr\u00f3-inflamat\u00f3rias para auxiliar na depura\u00e7\u00e3o viral?"
    },
    {
        "answer":"Phosphorylation of CEACAM1 ITIM motifs and activation of caspase-3",
        "answer_pt":"Fosforila\u00e7\u00e3o dos motivos CEACAM1 ITIM e ativa\u00e7\u00e3o da caspase-3",
        "id":"1951",
        "question":"What mediates the anti-apoptosis of neutrophils?",
        "question_pt":"O que medeia a anti-apoptose dos neutr\u00f3filos?"
    },
    {
        "answer":"by recognizing and killing infected cells",
        "answer_pt":"reconhecendo e matando c\u00e9lulas infectadas",
        "id":"1952",
        "question":"How do natural killer cells fight influenza viruses?",
        "question_pt":"Como as c\u00e9lulas assassinas naturais combatem os v\u00edrus influenza?"
    },
    {
        "answer":"modification of influenza hemagglutinin (HA) glycosylation",
        "answer_pt":"modifica\u00e7\u00e3o da glicosila\u00e7\u00e3o da hemaglutinina da gripe (HA)",
        "id":"1953",
        "question":"How do influenza viruses escape binding by the natural killer cell activating receptors?",
        "question_pt":"Como os v\u00edrus influenza escapam da liga\u00e7\u00e3o pelos receptores naturais de ativa\u00e7\u00e3o das c\u00e9lulas assassinas?"
    },
    {
        "answer":"HIV fusion inhibitor",
        "answer_pt":"Inibidor da fus\u00e3o do HIV",
        "id":"2250",
        "question":"What is Enfuvirtide?",
        "question_pt":"O que \u00e9 o Enfuvirtide?"
    },
    {
        "answer":"residues corresponding to the NHR pocket region",
        "answer_pt":"res\u00edduos correspondentes \u00e0 regi\u00e3o do bolso do NHR",
        "id":"2251",
        "question":"What is labeled in red?",
        "question_pt":"O que est\u00e1 marcado em vermelho?"
    },
    {
        "answer":"residues for the PBD",
        "answer_pt":"res\u00edduos para o PBD",
        "id":"2252",
        "question":"What is marked in blue?",
        "question_pt":"O que est\u00e1 marcado em azul?"
    },
    {
        "answer":"MT-hook residues adjacent to the N terminus of PBD",
        "answer_pt":"Res\u00edduos de gancho MT adjacentes ao terminal N do PBD",
        "id":"2253",
        "question":"What is marked in green?",
        "question_pt":"O que est\u00e1 marcado em verde?"
    },
    {
        "answer":"mutant residues in PBD of AP2 and AP3",
        "answer_pt":"res\u00edduos mutantes no PBD de AP2 e AP3",
        "id":"2254",
        "question":"What is labeled in pink?",
        "question_pt":"O que est\u00e1 marcado em rosa?"
    },
    {
        "answer":"twice",
        "answer_pt":"duas vezes",
        "id":"2255",
        "question":"How many times was the experiment repeated?",
        "question_pt":"Quantas vezes o experimento foi repetido?"
    },
    {
        "answer":"AP3, exhibited improved antiviral activity, drug resistance profile and pharmacological properties over T20",
        "answer_pt":"AP3 exibiu atividade antiviral aprimorada, perfil de resist\u00eancia a medicamentos e propriedades farmacol\u00f3gicas sobre T20",
        "id":"2256",
        "question":"What was the main finding in the study?",
        "question_pt":"Qual foi a principal descoberta no estudo?"
    },
    {
        "answer":"AP3 has potential for development as a new anti-HIV drug",
        "answer_pt":"AP3 tem potencial para desenvolvimento como um novo medicamento anti-HIV",
        "id":"2257",
        "question":"What do the results suggest?",
        "question_pt":"O que os resultados sugerem?"
    },
    {
        "answer":"adding two amino acids of Met and Thr to the N-terminus of a CHR-peptide ",
        "answer_pt":"adi\u00e7\u00e3o de dois amino\u00e1cidos de Met e Thr ao terminal N de um pept\u00eddeo CHR",
        "id":"2258",
        "question":"What enhanced anti-HIV1 activity?",
        "question_pt":"O que aumentou a atividade anti-HIV1?"
    },
    {
        "answer":"Fig. 1b",
        "answer_pt":"Fig. 1b",
        "id":"2259",
        "question":"What figure shows that AP3 exhibited higher inhibitory activities on infection by HIV-1 IIIB and HIV-1 Bal strains?",
        "question_pt":"Que figura mostra que AP3 exibiu atividades inibit\u00f3rias mais altas na infec\u00e7\u00e3o por cepas de HIV-1 IIIB e HIV-1 Bal?"
    },
    {
        "answer":"about 2 h",
        "answer_pt":"cerca de 2 h",
        "id":"2260",
        "question":"What is the serum half-life of T20?",
        "question_pt":"Qual \u00e9 a meia-vida s\u00e9rica do T20?"
    },
    {
        "answer":"non-compartment model",
        "answer_pt":"modelo sem compartimento",
        "id":"2261",
        "question":"What kind of model best describes the pharmacokinetic profiles of AP3 and AP2?",
        "question_pt":"Que tipo de modelo melhor descreve os perfis farmacocin\u00e9ticos de AP3 e AP2?"
    },
    {
        "answer":"6.02 h",
        "answer_pt":"6.02 h",
        "id":"2262",
        "question":"What is the in vivo elimination half-life of AP3?",
        "question_pt":"Qual \u00e9 a meia-vida de elimina\u00e7\u00e3o in vivo do AP3?"
    },
    {
        "answer":"Because T20 lacks the pocket-binding domain (PBD)",
        "answer_pt":"Como o T20 n\u00e3o possui o dom\u00ednio de encaderna\u00e7\u00e3o de bolso (PBD)",
        "id":"2263",
        "question":"Why did the T20/N36 complex not show a typical alpha helical conformation?",
        "question_pt":"Por que o complexo T20 / N36 n\u00e3o mostrou uma conforma\u00e7\u00e3o alfa helicoidal t\u00edpica?"
    },
    {
        "answer":"GIV motif (residues 36-45: GIVQQQNNLL) in the gp41 NHR domain 10",
        "answer_pt":"Motivo GIV (res\u00edduos 36-45: GIVQQQNNLL) no dom\u00ednio gp41 NHR 10",
        "id":"2264",
        "question":"What mutations have been typically associated with T20-resistant HIV-1 variants?",
        "question_pt":"Que muta\u00e7\u00f5es t\u00eam sido tipicamente associadas a variantes de HIV-1 resistentes a T20?"
    },
    {
        "answer":"firstly, early recognition of the deteriorating patient; secondly, HCW safety; thirdly, bystander safety; fourthly, contingency plans for medical emergencies during transport; fifthly, post-transport decontamination",
        "answer_pt":"primeiro, reconhecimento precoce do paciente em deteriora\u00e7\u00e3o; segundo, a seguran\u00e7a dos profissionais de sa\u00fade; terceiro, seguran\u00e7a dos espectadores; quarto, planos de conting\u00eancia para emerg\u00eancias m\u00e9dicas durante o transporte; quinto, descontamina\u00e7\u00e3o p\u00f3s-transporte",
        "id":"641",
        "question":"What are main steps for mitigating the COVID -19 transmission during transport of suspected and confirmed patients?",
        "question_pt":"Quais s\u00e3o as principais etapas para mitigar a transmiss\u00e3o do COVID -19 durante o transporte de pacientes suspeitos e confirmados?"
    },
    {
        "answer":"two to three million",
        "answer_pt":"dois a tr\u00eas milh\u00f5es",
        "id":"900",
        "question":"How many deaths each year are caused by gastroenteritis?",
        "question_pt":"Quantas mortes por ano s\u00e3o causadas por gastroenterite?"
    },
    {
        "answer":"60%",
        "answer_pt":"60%",
        "id":"901",
        "question":"What percentage of sporadic diarrhea are caused by norovirus?",
        "question_pt":"Qual a porcentagem de diarr\u00e9ia espor\u00e1dica causada pelo norov\u00edrus?"
    },
    {
        "answer":"Rotavirus",
        "answer_pt":"Rotav\u00edrus",
        "id":"902",
        "question":"What is the most common cause of viral gastroenteritis in children?",
        "question_pt":"Qual \u00e9 a causa mais comum de gastroenterite viral em crian\u00e7as?"
    },
    {
        "answer":"type 40 and 41",
        "answer_pt":"tipo 40 e 41",
        "id":"903",
        "question":"Which types of adenovirus are associated with diarrhea?",
        "question_pt":"Quais tipos de adenov\u00edrus est\u00e3o associados \u00e0 diarr\u00e9ia?"
    },
    {
        "answer":"1907",
        "answer_pt":"1907",
        "id":"904",
        "question":"When was the first tissue culture system developed?",
        "question_pt":"Quando foi desenvolvido o primeiro sistema de cultura de tecidos?"
    },
    {
        "answer":"1. Universal primer-PCR [41] ; 2. Random priming-based PCR [42] ; 3. Virus Discovery cDNA, Amplified Fragment Length Polymorphism (VIDISCA) [43] ; and 4. Sequence-Independent Single Primer Amplification (SISPA)",
        "answer_pt":"1. Primer-PCR universal [41]; 2. PCR baseado em inicia\u00e7\u00e3o aleat\u00f3ria [42]; 3. cDNA da descoberta de v\u00edrus, polimorfismo de comprimento de fragmento amplificado (VIDISCA) [43]; e 4. Amplifica\u00e7\u00e3o de iniciador \u00fanico independente de sequ\u00eancia (SISPA)",
        "id":"905",
        "question":"What are the most common DNA-based techniques for detecting viruses?",
        "question_pt":"Quais s\u00e3o as t\u00e9cnicas mais comuns baseadas em DNA para detectar v\u00edrus?"
    },
    {
        "answer":"detect novel variants",
        "answer_pt":"detectar novas variantes",
        "id":"906",
        "question":"What is Universal primer-PCR used for in viral studies?",
        "question_pt":"Para que \u00e9 utilizado o Universal primer-PCR em estudos virais?"
    },
    {
        "answer":"The microbe occurs in every case of the disease in question and under circumstances which can account for the pathological changes and clinical course of the disease",
        "answer_pt":"O micr\u00f3bio ocorre em todos os casos da doen\u00e7a em quest\u00e3o e em circunst\u00e2ncias que podem explicar as altera\u00e7\u00f5es patol\u00f3gicas e o curso cl\u00ednico da doen\u00e7a.",
        "id":"907",
        "question":"What is Koch's first postulate?",
        "question_pt":"Qual \u00e9 o primeiro postulado de Koch?"
    },
    {
        "answer":"the microbe occurs in no other disease as a fortuitous and nonpathogenic parasite",
        "answer_pt":"o micr\u00f3bio n\u00e3o ocorre em nenhuma outra doen\u00e7a como um parasita fortuito e n\u00e3o patog\u00eanico",
        "id":"908",
        "question":"What is Koch's second postulate?",
        "question_pt":"Qual \u00e9 o segundo postulado de Koch?"
    },
    {
        "answer":"after being fully isolated from the body and repeatedly grown in pure culture, the microbe can induce the disease anew",
        "answer_pt":"depois de totalmente isolado do corpo e cultivado repetidamente em cultura pura, o micr\u00f3bio pode induzir a doen\u00e7a novamente",
        "id":"909",
        "question":"What is Koch's third postulate?",
        "question_pt":"Qual \u00e9 o terceiro postulado de Koch?"
    },
    {
        "answer":"microbe is the cause of the disease",
        "answer_pt":"micr\u00f3bio \u00e9 a causa da doen\u00e7a",
        "id":"911",
        "question":"If all 3 of Koch's postulates are met, what does this indicate?",
        "question_pt":"Se todos os tr\u00eas postulados de Koch forem cumpridos, o que isso indica?"
    },
    {
        "answer":"not applicable",
        "answer_pt":"n\u00e3o aplic\u00e1vel",
        "id":"912",
        "question":"Is Koch's postulate applicable to enteric viruses?",
        "question_pt":"O postulado de Koch \u00e9 aplic\u00e1vel a v\u00edrus ent\u00e9ricos?"
    },
    {
        "answer":"point mutations on immunodominant regions of surface proteins",
        "answer_pt":"muta\u00e7\u00f5es pontuais em regi\u00f5es imunodominantes de prote\u00ednas de superf\u00edcie",
        "id":"5163",
        "question":"What changes do viruses make to be unrecognizable to previously neutralizing antibodies?",
        "question_pt":"Que mudan\u00e7as os v\u00edrus fazem para serem irreconhec\u00edveis em rela\u00e7\u00e3o aos anticorpos neutralizantes anteriormente?"
    },
    {
        "answer":"positive-sense single stranded RNA enveloped virus",
        "answer_pt":"v\u00edrus com RNA de fita simples de sentido positivo",
        "id":"5164",
        "question":"What is hepatitis C?",
        "question_pt":"O que \u00e9 hepatite C?"
    },
    {
        "answer":"3,000 aminoacids",
        "answer_pt":"3.000 amino\u00e1cidos",
        "id":"5165",
        "question":"How large is the HCV genome?",
        "question_pt":"Qual \u00e9 o tamanho do genoma do HCV?"
    },
    {
        "answer":"p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B",
        "answer_pt":"p7, NS2, NS3, NS4A, NS4B, NS5A e NS5B",
        "id":"5166",
        "question":"What are the non-structural proteins encoded by the HCV genome?",
        "question_pt":"Quais s\u00e3o as prote\u00ednas n\u00e3o estruturais codificadas pelo genoma do HCV?"
    },
    {
        "answer":"high mutation rate",
        "answer_pt":"alta taxa de muta\u00e7\u00e3o",
        "id":"5167",
        "question":"Why has it been difficult to develop a therapy for the Hepatitis C virus?",
        "question_pt":"Por que tem sido dif\u00edcil desenvolver uma terapia para o v\u00edrus da hepatite C?"
    },
    {
        "answer":"glycoproteins E1 and E2",
        "answer_pt":"glicoprote\u00ednas E1 e E2",
        "id":"5168",
        "question":"An antibody response to which proteins correlates with reduced HCV levels?",
        "question_pt":"Resposta de um anticorpo ao qual prote\u00ednas se correlacionam com n\u00edveis reduzidos de HCV?"
    },
    {
        "answer":"antigenic differences of their nucleoprotein and matrix protein",
        "answer_pt":"diferen\u00e7as antig\u00eanicas de sua nucleoprote\u00edna e prote\u00edna da matriz",
        "id":"5169",
        "question":"How are type A, B, and C viruses determined?",
        "question_pt":"Como s\u00e3o determinados os v\u00edrus do tipo A, B e C?"
    },
    {
        "answer":"influenza A",
        "answer_pt":"gripe A",
        "id":"5170",
        "question":"Which type of influenza causes epidemics and pandemics?",
        "question_pt":"Que tipo de gripe causa epidemias e pandemias?"
    },
    {
        "answer":"By Mid Pleistocene (,500,000 years ago)",
        "answer_pt":"Por Mid Pleistocene (, 500.000 years ago)",
        "id":"5171",
        "question":"When did lions first occupy Europe?",
        "question_pt":"Quando os le\u00f5es ocuparam a Europa pela primeira vez?"
    },
    {
        "answer":"to assess the evolutionary history of lion",
        "answer_pt":"para avaliar a hist\u00f3ria evolutiva do le\u00e3o",
        "id":"5172",
        "question":"What was the purpose of this study?",
        "question_pt":"Qual foi o objetivo deste estudo?"
    },
    {
        "answer":"protein\u2013protein interactions.",
        "answer_pt":"intera\u00e7\u00f5es prote\u00edna-prote\u00edna.",
        "id":"1721",
        "question":"What has been the application of phage display technology?",
        "question_pt":"Qual tem sido a aplica\u00e7\u00e3o da tecnologia de exibi\u00e7\u00e3o de fagos?"
    },
    {
        "answer":" inherent biological, biochemical, and biophysical properties of filamentous bacteriophage, as well as the ease of its genetic manipulation",
        "answer_pt":"propriedades biol\u00f3gicas, bioqu\u00edmicas e biof\u00edsicas inerentes ao bacteri\u00f3fago filamentoso, bem como a facilidade de sua manipula\u00e7\u00e3o gen\u00e9tica",
        "id":"1722",
        "question":"What makes phage display technology useful for other applications?",
        "question_pt":"O que torna a tecnologia de exibi\u00e7\u00e3o de fagos \u00fatil para outras aplica\u00e7\u00f5es?"
    },
    {
        "answer":"high immunogenicity, relative antigenic simplicity and ability to activate a range of immune responses",
        "answer_pt":"alta imunogenicidade, relativa simplicidade antig\u00eanica e capacidade de ativar uma variedade de respostas imunes",
        "id":"1723",
        "question":"What are the advantages of phage as a vaccine carrier?",
        "question_pt":"Quais s\u00e3o as vantagens do fago como portador da vacina?"
    },
    {
        "answer":"prophylactic and therapeutic agent",
        "answer_pt":"agente profil\u00e1tico e terap\u00eautico",
        "id":"1724",
        "question":"What is the potential of phage for infectious and chronic diseases?",
        "question_pt":"Qual \u00e9 o potencial do fago para doen\u00e7as infecciosas e cr\u00f4nicas?"
    },
    {
        "answer":" enables a variety of bioconjugation and surface chemistry applications, particularly in nanomaterials",
        "answer_pt":"permite uma variedade de aplica\u00e7\u00f5es de bioconjuga\u00e7\u00e3o e qu\u00edmica de superf\u00edcie, particularmente em nanomateriais",
        "id":"1725",
        "question":"What is the regularity of the virion major coat protein lattice useful for?\n",
        "question_pt":"Para que serve a regularidade da rede de prote\u00ednas do revestimento principal do viri\u00e3o principal?"
    },
    {
        "answer":"the phage\u2019s large population sizes and fast generation times",
        "answer_pt":"os grandes tamanhos populacionais do fago e os r\u00e1pidos tempos de gera\u00e7\u00e3o",
        "id":"1726",
        "question":"Why is the phage ab excellent model system for directed protein evolution?",
        "question_pt":"Por que o fago ab \u00e9 um excelente sistema de modelos para a evolu\u00e7\u00e3o direcionada de prote\u00ednas?"
    },
    {
        "answer":"non-enveloped, rod-shaped viruses of Escherichia coli whose long helical capsids encapsulate a single-stranded circular DNA genome.",
        "answer_pt":"v\u00edrus n\u00e3o envelopados e em forma de bastonete de Escherichia coli cujos longos caps\u00eddeos helicoidais encapsulam um genoma de DNA circular de fita simples.",
        "id":"1727",
        "question":"What are filamentous bacteriophages genera Inovirua and Plectrovirus?",
        "question_pt":"Quais s\u00e3o os g\u00eaneros de bacteri\u00f3fagos filamentosos Inovirua e Plectrovirus?"
    },
    {
        "answer":"principle of modifying the filamentous phage genome to display polypeptides as fusions to coat proteins on the virion surface ",
        "answer_pt":"princ\u00edpio de modificar o genoma do fago filamentoso para exibir polipept\u00eddeos como fus\u00f5es para revestir prote\u00ednas na superf\u00edcie do viri\u00e3o",
        "id":"1728",
        "question":"What invention has made bacteriophage useful for research?",
        "question_pt":"Que inven\u00e7\u00e3o tornou o bacteri\u00f3fago \u00fatil para pesquisas?"
    },
    {
        "answer":"the ability to seamlessly connect genetic information with protein function for a large number of protein variants simultaneously, and has been widely and productively exploited in studies of proteinprotein interactions",
        "answer_pt":"a capacidade de conectar informa\u00e7\u00f5es gen\u00e9ticas \u00e0 fun\u00e7\u00e3o das prote\u00ednas de maneira uniforme para um grande n\u00famero de variantes de prote\u00ednas simultaneamente e tem sido amplamente e produtivamente explorada em estudos de intera\u00e7\u00f5es entre prote\u00ednas e prote\u00ednas",
        "id":"1730",
        "question":"What has the bacteriphage technology and the library of folded protein variants enabled?",
        "question_pt":"O que a tecnologia de bacteri\u00f3fagos e a biblioteca de variantes de prote\u00ednas dobradas ativaram?"
    },
    {
        "answer":"(i) filamentous phage as a vaccine carrier; (ii) engineered filamentous phage as a therapeutic biologic agent in infectious and chronic diseases; (iii) filamentous phage as a scaffold for bioconjugation and surface chemistry; and (iv) filamentous phage as an engine for evolving variants of displayed proteins with novel functions. ",
        "answer_pt":"(i) fago filamentoso como transportador de vacina; (ii) fagos filamentosos manipulados como agente biol\u00f3gico terap\u00eautico em doen\u00e7as infecciosas e cr\u00f4nicas; (iii) fago filamentoso como andaime para bioconjuga\u00e7\u00e3o e qu\u00edmica de superf\u00edcie; e (iv) fago filamentoso como um motor para a evolu\u00e7\u00e3o de variantes de prote\u00ednas exibidas com novas fun\u00e7\u00f5es.",
        "id":"1731",
        "question":"What are the potential novel applications of the filamentous phage?",
        "question_pt":"Quais s\u00e3o as novas aplica\u00e7\u00f5es potenciais do fago filamentoso?"
    },
    {
        "answer":" unique biological, immunological, and physicochemical properties of the phage, its ability to display a variety of biomolecules in modular fashion, and its relative simplicity and ease of manipulation",
        "answer_pt":"propriedades biol\u00f3gicas, imunol\u00f3gicas e f\u00edsico-qu\u00edmicas exclusivas do fago, sua capacidade de exibir uma variedade de biomol\u00e9culas de maneira modular e sua relativa simplicidade e facilidade de manipula\u00e7\u00e3o",
        "id":"1732",
        "question":"What themes are common in  the applications of filamentous phage?",
        "question_pt":"Que temas s\u00e3o comuns nas aplica\u00e7\u00f5es de fagos filamentosos?"
    },
    {
        "answer":"its ability to display polypeptides on the virion's surface as fusions to phage coat proteins ",
        "answer_pt":"sua capacidade de exibir polipept\u00eddeos na superf\u00edcie do viri\u00e3o como fus\u00f5es para prote\u00ednas de revestimento de fago",
        "id":"1733",
        "question":"What do applications of filamentous phage depend on?",
        "question_pt":"Do que dependem as aplica\u00e7\u00f5es de fago filamentoso?"
    },
    {
        "answer":" maximum tolerated size of the fused polypeptide, its copy number on the phage, and potentially, the structure of the displayed polypeptide",
        "answer_pt":"tamanho m\u00e1ximo tolerado do polipept\u00eddeo fundido, seu n\u00famero de c\u00f3pias no fago e, potencialmente, a estrutura do polipept\u00eddeo exibido",
        "id":"1734",
        "question":"What characteristics are determined by the display  mode?",
        "question_pt":"Quais caracter\u00edsticas s\u00e3o determinadas pelo modo de exibi\u00e7\u00e3o?"
    },
    {
        "answer":" by fusing DNA encoding a polypeptide of interest directly to the gene encoding a coat protein within the phage genome (type 8 display on pVIII, type 3 display on pIII, etc.)",
        "answer_pt":"fundindo o DNA que codifica um polipept\u00eddeo de interesse diretamente ao gene que codifica uma prote\u00edna de revestimento no genoma do fago (exibi\u00e7\u00e3o do tipo 8 no pVIII, exibi\u00e7\u00e3o do tipo 3 no pIII, etc.)",
        "id":"1735",
        "question":"How may the display be achieved?",
        "question_pt":"Como a exibi\u00e7\u00e3o pode ser alcan\u00e7ada?"
    },
    {
        "answer":" a recombinant filamentous phage displaying a single polypeptide sequence on its surface (or more rarely, bispecific display achieved via fusion of polypeptides to two different capsid proteins)",
        "answer_pt":"um fago filamentoso recombinante que exibe uma \u00fanica sequ\u00eancia de polipept\u00eddeo em sua superf\u00edcie (ou mais raramente, exibi\u00e7\u00e3o biespec\u00edfica obtida por fus\u00e3o de polipept\u00eddeos a duas prote\u00ednas diferentes do caps\u00eddeo)",
        "id":"1736",
        "question":"What does  the term \"phage display\" refer to?",
        "question_pt":"A que se refere o termo \"exibi\u00e7\u00e3o de fagos\"?"
    },
    {
        "answer":"a diverse pool of recombinant filamentous phage displaying an array of polypeptide variants (e.g., antibody fragments; peptides)",
        "answer_pt":"um conjunto diversificado de fagos filamentosos recombinantes exibindo uma matriz de variantes de polipept\u00eddeos (por exemplo, fragmentos de anticorpo; pept\u00eddeos)",
        "id":"1737",
        "question":"What does the term \"phage displayed library\" refer to?",
        "question_pt":"A que se refere o termo \"biblioteca exibida em fagos\"?"
    },
    {
        "answer":"is highly immunogenic in the absence of adjuvants (Meynell and Lawn, 1968 ) and that only the major coat protein, pVIII, and the minor coat protein, pIII, are targeted by antibodies",
        "answer_pt":"\u00e9 altamente imunog\u00eanico na aus\u00eancia de adjuvantes (Meynell e Lawn, 1968) e que apenas a principal prote\u00edna de revestimento, pVIII, e a menor prote\u00edna de revestimento, pIII, s\u00e3o alvo de anticorpos",
        "id":"1738",
        "question":"What characteristic of filamentous phage has been demonstrated?",
        "question_pt":"Que caracter\u00edstica do fago filamentoso foi demonstrada?"
    },
    {
        "answer":"as carrier to elicit antibodies against poorly immunogenic haptens or polypeptide",
        "answer_pt":"como portador para desencadear anticorpos contra haptenos ou polipept\u00eddeos mal imunog\u00eanicos",
        "id":"1739",
        "question":"What application is a natural extension of the  ability to display recombinant exogenous sequences on its surface?",
        "question_pt":"Que aplica\u00e7\u00e3o \u00e9 uma extens\u00e3o natural da capacidade de exibir seq\u00fc\u00eancias ex\u00f3genas recombinantes em sua superf\u00edcie?"
    },
    {
        "answer":"The phage particle's low cost of production, high stability and potential for high valency display of foreign antigen",
        "answer_pt":"Baixo custo de produ\u00e7\u00e3o, alta estabilidade e potencial para exibi\u00e7\u00e3o de alta val\u00eancia de ant\u00edgenos estranhos",
        "id":"1740",
        "question":"What makes it an attractive vaccine carrier?",
        "question_pt":"O que o torna um portador de vacina atraente?"
    },
    {
        "answer":" the maximum tolerated size of the fused polypeptide, its copy number on the phage, and potentially, the structure of the displayed polypeptide. ",
        "answer_pt":"o tamanho m\u00e1ximo tolerado do polipept\u00eddeo fundido, seu n\u00famero de c\u00f3pias no fago e potencialmente a estrutura do polipept\u00eddeo exibido.",
        "id":"1741",
        "question":"What does the display mode determine?",
        "question_pt":"O que o modo de exibi\u00e7\u00e3o determina?"
    },
    {
        "answer":"(i) in many cases, peptides incompletely or inadequately mimic epitopes on folded proteins (Irving et al., 2010 ; see below); (ii) antibodies against a single epitope may be of limited utility, especially for highly variable pathogens (Van Regenmortel, 2012); and (iii) for pathogens for which protective immune responses are generated efficiently during natural infection, peptide vaccines offer few advantages over recombinant subunit and live vector vaccines, which have become easier to produce over time.",
        "answer_pt":"(i) em muitos casos, pept\u00eddeos imitam incompleta ou inadequadamente ep\u00edtopos em prote\u00ednas dobradas (Irving et al., 2010; veja abaixo); (ii) os anticorpos contra um \u00fanico ep\u00edtopo podem ser de utilidade limitada, especialmente para pat\u00f3genos altamente vari\u00e1veis \u200b\u200b(Van Regenmortel, 2012); e (iii) para pat\u00f3genos para os quais as respostas imunes protetoras s\u00e3o geradas eficientemente durante a infec\u00e7\u00e3o natural, as vacinas pept\u00eddicas oferecem poucas vantagens sobre as subunidades recombinantes e as vacinas de vetores vivos, que se tornaram mais f\u00e1ceis de produzir ao longo do tempo.",
        "id":"1742",
        "question":"Why are antibody epitope based peptide vaccines are no longer an active research area?",
        "question_pt":"Por que as vacinas pept\u00eddicas baseadas em ep\u00edtopos de anticorpos n\u00e3o s\u00e3o mais uma \u00e1rea de pesquisa ativa?"
    },
    {
        "answer":"Phage displaying peptide ligands of an anti-IgE antibody elicited antibodies that bound purified IgE molecules",
        "answer_pt":"Fago exibindo ligantes pept\u00eddicos de um anticorpo anti-IgE suscitou anticorpos que ligavam mol\u00e9culas de IgE purificadas",
        "id":"1743",
        "question":"What phage may be useful in allergy immunotherapy?",
        "question_pt":"Que fago pode ser \u00fatil na imunoterapia contra alergias?"
    },
    {
        "answer":" immunization with phage displaying follicle-stimulating hormone peptides on pVIII elicited antibodies that impaired the fertility of mice and ewes ",
        "answer_pt":"imuniza\u00e7\u00e3o com fago exibindo pept\u00eddeos de horm\u00f4nio fol\u00edculo-estimulante em anticorpos desencadeados por pVIII que prejudicam a fertilidade de camundongos e ovelhas",
        "id":"1744",
        "question":"Which are some phage based contraceptive vaccines for animals?",
        "question_pt":"Quais s\u00e3o algumas vacinas contraceptivas baseadas em fagos para animais?"
    },
    {
        "answer":"Phage displaying or chemically Rubinchik and Chow (2000) conjugated to sperm antigen peptides or peptide mimics (Samoylova et al., 2012a,b) and gonadotropin-releasing hormone (Samoylov et al., 2012) are also in development.",
        "answer_pt":"Os fagos que apresentam ou quimicamente Rubinchik e Chow (2000) conjugados com pept\u00eddeos de ant\u00edgenos esperm\u00e1ticos ou imita\u00e7\u00f5es de pept\u00eddeos (Samoylova et al., 2012a, b) e horm\u00f4nio liberador de gonadotropina (Samoylov et al., 2012) tamb\u00e9m est\u00e3o em desenvolvimento.",
        "id":"1745",
        "question":"Which are some phage based contraceptive vaccines for animals?",
        "question_pt":"Quais s\u00e3o algumas vacinas contraceptivas baseadas em fagos para animais?"
    },
    {
        "answer":" it seems that peptide antigens elicit a set of topologically restricted antibodies that are largely unable to recognize discontinuous or complex epitopes on larger biomolecules. While the peptide may mimic the chemistry of a given epitope on a folded protein (allowing it to crossreact with a targeted antibody), being a smaller molecule, it cannot mimic the topology of that antibody's full epitope.",
        "answer_pt":"parece que os ant\u00edgenos pept\u00eddicos provocam um conjunto de anticorpos topologicamente restritos que s\u00e3o amplamente incapazes de reconhecer ep\u00edtopos descont\u00ednuos ou complexos em biomol\u00e9culas maiores. Embora o pept\u00eddeo possa imitar a qu\u00edmica de um dado ep\u00edtopo em uma prote\u00edna dobrada (permitindo a rea\u00e7\u00e3o cruzada com um anticorpo alvo), sendo uma mol\u00e9cula menor, n\u00e3o pode imitar a topologia do ep\u00edtopo completo desse anticorpo.",
        "id":"1747",
        "question":"What is one reason for the lack of success of immunization phage displayed peptides with native protein?",
        "question_pt":"Qual \u00e9 uma das raz\u00f5es da falta de sucesso dos fagos de imuniza\u00e7\u00e3o que apresentaram pept\u00eddeos com prote\u00edna nativa?"
    },
    {
        "answer":"as a carrier for peptides with relatively simple secondary structures, which may be stablilized via anchoring to the coat proteins (Henry et al., 2011) . This may be especially true of peptides with poor inherent immunogenicity, which may be increased by high-valency display and phage-associated adjuvanticity",
        "answer_pt":"como portador de pept\u00eddeos com estruturas secund\u00e1rias relativamente simples, que podem ser estabilizadas via ancoragem \u00e0s prote\u00ednas do revestimento (Henry et al., 2011). Isso pode ser especialmente verdadeiro para pept\u00eddeos com baixa imunogenicidade inerente, que podem ser aumentados pela exibi\u00e7\u00e3o de alta val\u00eancia e adjuvanticidade associada a fagos",
        "id":"1748",
        "question":"Despite shortcomings, what has the filamentous phage has been useful for?",
        "question_pt":"Apesar das defici\u00eancias, para que serve o fago filamentoso?"
    },
    {
        "answer":" is immunogenic without adjuvant in all species tested to date, including mice (Willis et al., 1993) , rats (Dente et al., 1994) , rabbits (de la Cruz et al., 1988) , guinea pigs (Frenkel et al., 2000; Kim et al., 2004) , fish (Coull et al., 1996; Xia et al., 2005) , non-human primates (Chen et al., 2001) , and humans (Roehnisch et al., 2014) ",
        "answer_pt":"\u00e9 imunog\u00eanico sem adjuvante em todas as esp\u00e9cies testadas at\u00e9 o momento, incluindo camundongos (Willis et al., 1993), ratos (Dente et al., 1994), coelhos (de la Cruz et al., 1988), porquinhos-da-\u00edndia (Frenkel et al. ., 2000; Kim et al., 2004), peixes (Coull et al., 1996; Xia et al., 2005), primatas n\u00e3o humanos (Chen et al., 2001) e humanos (Roehnisch et al., 2014)",
        "id":"1749",
        "question":"What is the result of all species tests of phage particles?",
        "question_pt":"Qual \u00e9 o resultado de todos os testes de esp\u00e9cies de part\u00edculas de fago?"
    },
    {
        "answer":"serum antibody titers against the phage typically reach 1:10 5 -1:10 6 after 2-3 immunizations, and are maintained for at least 1 year postimmunization (Frenkel et al., 2000) . ",
        "answer_pt":"os t\u00edtulos de anticorpos s\u00e9ricos contra o fago atingem tipicamente 1:10 5 -1: 10 6 ap\u00f3s 2-3 imuniza\u00e7\u00f5es e s\u00e3o mantidos por pelo menos 1 ano ap\u00f3s a imuniza\u00e7\u00e3o (Frenkel et al., 2000).",
        "id":"1750",
        "question":"What are the results of filamentous phage immunizations in mice?",
        "question_pt":"Quais s\u00e3o os resultados das imuniza\u00e7\u00f5es de fagos filamentosos em ratos?"
    },
    {
        "answer":"composed of a mixture of IgM and IgG2b isotypes in C57BL/6 mice, while secondary antibody responses are composed primarily of IgG1 and IgG2b isotypes, with a lesser contribution of IgG2c and IgG3 isotypes (Hashiguchi et al., 2010) .",
        "answer_pt":"composto por uma mistura de isotipos IgM e IgG2b em camundongos C57BL / 6, enquanto as respostas secund\u00e1rias a anticorpos s\u00e3o compostas principalmente por isotipos IgG1 e IgG2b, com uma menor contribui\u00e7\u00e3o dos isotipos IgG2c e IgG3 (Hashiguchi et al., 2010).",
        "id":"1751",
        "question":"What is the primary antibody response against the phage?",
        "question_pt":"Qual \u00e9 a resposta prim\u00e1ria do anticorpo contra o fago?"
    },
    {
        "answer":"Host cell wall-derived LPS enhances the virion's immunogenicity, and its removal by polymyxin B chromatography reduces antibody titers against phage coat proteins (Grabowska et al., 2000) . The phage's singlestranded DNA genome contains CpG motifs and may also have an adjuvant effect. ",
        "answer_pt":"O LPS derivado da parede da c\u00e9lula hospedeira aumenta a imunogenicidade do v\u00edrus, e sua remo\u00e7\u00e3o por cromatografia com polimixina B reduz os t\u00edtulos de anticorpos contra as prote\u00ednas do revestimento de fago (Grabowska et al., 2000). O genoma de DNA de cadeia simples do fago cont\u00e9m motivos de CpG e tamb\u00e9m pode ter um efeito adjuvante.",
        "id":"1752",
        "question":"Why is phage self-adjuvanting?",
        "question_pt":"Por que o fago \u00e9 auto-adjuvante?"
    },
    {
        "answer":"MyD88 signaling and is modulated by stimulation of several Toll-like receptors (Hashiguchi et al., 2010) , indicating that innate immunity plays an important ",
        "answer_pt":"Sinaliza\u00e7\u00e3o MyD88 e \u00e9 modulado pela estimula\u00e7\u00e3o de v\u00e1rios receptores do tipo Toll (Hashiguchi et al., 2010), indicando que a imunidade inata desempenha um papel importante",
        "id":"1753",
        "question":"On what does the antibody  response to phage depend on?",
        "question_pt":"De que depende a resposta do anticorpo ao fago?"
    },
    {
        "answer":" it is cleared from the blood within hours through the reticuloendothelial system (Molenaar et al., 2002) , particularly of the liver and spleen, where it is retained for days (Zou et al., 2004) , potentially activating marginal-zone B-cell responses. ",
        "answer_pt":"\u00e9 eliminado do sangue em poucas horas atrav\u00e9s do sistema reticuloendotelial (Molenaar et al., 2002), particularmente do f\u00edgado e ba\u00e7o, onde \u00e9 retido por dias (Zou et al., 2004), potencialmente ativando a zona marginal B- respostas celulares.",
        "id":"1754",
        "question":"What do biodistribution studies of the phage after intravenous injection show?",
        "question_pt":"O que mostram os estudos de biodistribui\u00e7\u00e3o do fago ap\u00f3s a inje\u00e7\u00e3o intravenosa?"
    },
    {
        "answer":" the filamentous phage is not only a highly immunogenic carrier, but by virtue of activating a range of innate and adaptive immune responses, serves as an excellent model virus-like particle antigen.",
        "answer_pt":"o fago filamentoso n\u00e3o \u00e9 apenas um ve\u00edculo altamente imunog\u00eanico, mas em virtude da ativa\u00e7\u00e3o de uma s\u00e9rie de respostas imunes inatas e adaptativas, serve como um excelente modelo de ant\u00edgeno de part\u00edculas semelhante a v\u00edrus.",
        "id":"1755",
        "question":"What are the merits of the filamentous phage carriers?",
        "question_pt":"Quais s\u00e3o os m\u00e9ritos dos portadores de fagos filamentosos?"
    },
    {
        "answer":" as elements of combination therapeutics against certain drug-resistant infections.",
        "answer_pt":"como elementos de terap\u00eautica combinada contra certas infec\u00e7\u00f5es resistentes a medicamentos.",
        "id":"1756",
        "question":"What is a future potential of filamentous phage?",
        "question_pt":"Qual \u00e9 o potencial futuro do fago filamentoso?"
    },
    {
        "answer":"M13 or fd phage displaying either a targeting peptide or antibody fragment and tethered to chloramphenicol by a labile crosslinker ",
        "answer_pt":"Fago M13 ou fd exibindo um pept\u00eddeo alvo ou fragmento de anticorpo e amarrado ao cloranfenicol por um reticulante l\u00e1bil",
        "id":"1757",
        "question":"What were more potent inhibitors of Staphylococcus aureus growth than high-concentration free chloramphenicol?",
        "question_pt":"Quais foram os inibidores mais potentes do crescimento de Staphylococcus aureus do que o cloranfenicol livre de alta concentra\u00e7\u00e3o?"
    },
    {
        "answer":"M13 phage loaded with doxorubicin and displaying a targeting peptide on pIII",
        "answer_pt":"Fago M13 carregado com doxorrubicina e exibindo um pept\u00eddeo alvo em pIII",
        "id":"1758",
        "question":"What killed prostate cancer cells in vitro?",
        "question_pt":"O que matou c\u00e9lulas de c\u00e2ncer de pr\u00f3stata in vitro?"
    },
    {
        "answer":"Using the B16-OVA tumor model, Eriksson et al. (2007) showed that phage displaying peptides and/or Fabs specific for tumor antigens delayed tumor growth and improved survival, owing in large part to activation of tumor-associated macrophages and recruitment of neutrophils to the tumor site (Eriksson et al., 2009) ",
        "answer_pt":"Usando o modelo de tumor B16-OVA, Eriksson et al. (2007) mostraram que fagos exibindo pept\u00eddeos e / ou Fabs espec\u00edficos para ant\u00edgenos tumorais retardavam o crescimento tumoral e melhoravam a sobreviv\u00eancia, devido em grande parte \u00e0 ativa\u00e7\u00e3o de macr\u00f3fagos associados a tumores e ao recrutamento de neutr\u00f3filos para o local do tumor (Eriksson et al., 2009)",
        "id":"1759",
        "question":"What was the effect of phage displaying  peptides on tumor?",
        "question_pt":"Qual foi o efeito do fago exibindo pept\u00eddeos no tumor?"
    },
    {
        "answer":" ability of the phage to penetrate into brain tissue (Ksendzovsky et al., 2012) ",
        "answer_pt":"capacidade do fago de penetrar no tecido cerebral (Ksendzovsky et al., 2012)",
        "id":"1760",
        "question":"Why is the phage displaying  an scFv against \u03b2-amyloid fibrils  is a good diagnostic for Alzheimers and Parkinson's disease?",
        "question_pt":"Por que o fago que apresenta um scFv contra fibrilas \u03b2-amil\u00f3ides \u00e9 um bom diagn\u00f3stico para Alzheimers e doen\u00e7a de Parkinson?"
    },
    {
        "answer":"is enclosed by a rod-like protein capsid, \u223c1000 nm long and 5 nm wide, made up almost entirely of overlapping pVIII monomers, each of which lies \u223c27 angstroms from its nearest neighbor and exposes two amine groups as well as at least three carboxyl groups (Henry et al., 2011)",
        "answer_pt":"\u00e9 envolvida por um caps\u00eddeo prot\u00e9ico em forma de bastonete, com 1000 nm de comprimento e 5 nm de largura, composto quase inteiramente de mon\u00f4meros pVIII sobrepostos, cada um dos quais situado a 27 angstroms de seu vizinho mais pr\u00f3ximo e exp\u00f5e dois grupos de aminas e pelo menos tr\u00eas grupos carboxila (Henry et al., 2011)",
        "id":"1761",
        "question":"What is the structure of a filamentous phage particle?",
        "question_pt":"Qual \u00e9 a estrutura de uma part\u00edcula de fago filamentoso?"
    },
    {
        "answer":"The regularity of the phage pVIII lattice and its diversity of chemically addressable groups",
        "answer_pt":"A regularidade da rede de fagos pVIII e sua diversidade de grupos quimicamente endere\u00e7\u00e1veis",
        "id":"1762",
        "question":"What makes filamentous phage ideal scaffold for bioconjugation?",
        "question_pt":"O que torna o fago filamentoso um andaime ideal para bioconjuga\u00e7\u00e3o?"
    },
    {
        "answer":"Lee et al. (2002) engineered M13 phage to display a ZnS-binding peptide on pIII and showed that, in the presence of ZnS nanoparticles, they selfassemble into highly ordered film biomaterials that can be aligned using magnetic fields.",
        "answer_pt":"Lee et al. (2002) projetaram o fago M13 para exibir um pept\u00eddeo de liga\u00e7\u00e3o ao ZnS no pIII e mostraram que, na presen\u00e7a de nanopart\u00edculas de ZnS, eles se auto-montam em biomateriais de filmes altamente ordenados que podem ser alinhados usando campos magn\u00e9ticos.",
        "id":"1763",
        "question":"What trials have been done to demonstrate the potential of phage in applications for nanomaterials?",
        "question_pt":"Quais ensaios foram realizados para demonstrar o potencial do fago em aplica\u00e7\u00f5es para nanomateriais?"
    },
    {
        "answer":"Taking advantage of the ability to display substrate-specific peptides at known locations on the phage filament Hess et al., 2012) , this pioneering FIGURE 3 | Chemically addressable groups of the filamentous bacteriophage major coat protein lattice. ",
        "answer_pt":"Aproveitando a capacidade de exibir pept\u00eddeos espec\u00edficos do substrato em locais conhecidos no filamento do fago Hess et al., 2012), este pioneiro FIGURA 3 | Grupos quimicamente endere\u00e7\u00e1veis \u200b\u200bda estrutura principal da prote\u00edna do revestimento do bacteri\u00f3fago filamentoso.",
        "id":"1764",
        "question":"What trials have been done to demonstrate the potential of phage in applications for nanomaterials?",
        "question_pt":"Quais ensaios foram realizados para demonstrar o potencial do fago em aplica\u00e7\u00f5es para nanomateriais?"
    },
    {
        "answer":"made up of \u223c2,500-4,000 overlapping copies of the 50-residue major coat protein, pVIII, arranged in a shingle-type lattice. Each monomer has an array of chemically addressable groups available for bioorthogonal conjugation, including two primary amine groups (shown in red), three carboxyl groups (show in blue) and two hydroxyl groups (show in green). The 12 N-terminal residues generally exposed to the immune system for antibody binding ",
        "answer_pt":"composto de 2.500 a 4.000 c\u00f3pias sobrepostas da prote\u00edna de revestimento principal de 50 res\u00edduos, pVIII, dispostas em uma treli\u00e7a do tipo cascalho. Cada mon\u00f4mero possui uma matriz de grupos quimicamente endere\u00e7\u00e1veis \u200b\u200bdispon\u00edveis para conjuga\u00e7\u00e3o bio-ortogonal, incluindo dois grupos amina prim\u00e1rios (mostrados em vermelho), tr\u00eas grupos carboxil (mostrados em azul) e dois grupos hidroxil (mostrados em verde). Os 12 res\u00edduos do terminal N geralmente expostos ao sistema imunol\u00f3gico para liga\u00e7\u00e3o de anticorpos",
        "id":"1765",
        "question":"What is the filamentous phage varion is made of?",
        "question_pt":"De que \u00e9 feita a varia\u00e7\u00e3o do fago filamentoso?"
    },
    {
        "answer":"construction of two-and threedimensional nanomaterials with more advanced architectures, including semiconducting nanowires (Mao et al., 2003 (Mao et al., , 2004 , nanoparticles , and nanocomposites (Oh et al., 2012; Chen et al., 2014)",
        "answer_pt":"constru\u00e7\u00e3o de nanomateriais bidimensionais e tridimensionais com arquiteturas mais avan\u00e7adas, incluindo nanofios semicondutores (Mao et al., 2003 (Mao et al., 2004, nanopart\u00edculas e nanocomp\u00f3sitos) (Oh et al., 2012; Chen et al., 2014)",
        "id":"1766",
        "question":"What demonstrate the potential of phage in applications for nanomaterials?",
        "question_pt":"O que demonstra o potencial do fago nas aplica\u00e7\u00f5es de nanomateriais?"
    },
    {
        "answer":"The capacities of nanopore sequencing for viral diagnostics",
        "answer_pt":"As capacidades do seq\u00fcenciamento de nanoporos para diagn\u00f3stico viral",
        "id":"5287",
        "question":"What was investigated in this study?",
        "question_pt":"O que foi investigado neste estudo?"
    },
    {
        "answer":"19.2 to 103.5X",
        "answer_pt":"19,2 a 103,5X",
        "id":"5288",
        "question":"What was the range of genomic sequencing depths?",
        "question_pt":"Qual foi o alcance das profundidades de sequenciamento gen\u00f4mico?"
    },
    {
        "answer":"lower than 7",
        "answer_pt":"inferior a 7",
        "id":"5289",
        "question":"Which q-score reads were eliminated from the analysis?",
        "question_pt":"Quais leituras do q-score foram eliminadas da an\u00e1lise?"
    },
    {
        "answer":"816 nt",
        "answer_pt":"816 nt",
        "id":"5290",
        "question":"What was the mean length of the sequenced read?",
        "question_pt":"Qual foi o comprimento m\u00e9dio da leitura sequenciada?"
    },
    {
        "answer":"17V079",
        "answer_pt":"17V079",
        "id":"5291",
        "question":"Which strain was similar to other Belgian porcine kobuvirus isolates?",
        "question_pt":"Que cepa foi semelhante a outros isolados de kobuv\u00edrus su\u00ednos belgas?"
    },
    {
        "answer":"Gram positive, anaerobic bacterium",
        "answer_pt":"Bact\u00e9ria anaer\u00f3bica Gram-positiva",
        "id":"913",
        "question":"What is Clodstridium difficile?",
        "question_pt":"O que \u00e9 o Clostridium difficile?"
    },
    {
        "answer":"adaptive strategy that enables bacteria to survive harsh environmental conditions for prolonged periods of time",
        "answer_pt":"estrat\u00e9gia adaptativa que permite que as bact\u00e9rias sobrevivam a condi\u00e7\u00f5es ambientais adversas por per\u00edodos prolongados",
        "id":"914",
        "question":"What is sporulation?",
        "question_pt":"O que \u00e9 esporula\u00e7\u00e3o?"
    },
    {
        "answer":"Spo0A",
        "answer_pt":"Spo0A",
        "id":"915",
        "question":"What is the key regulator to sporulation?",
        "question_pt":"Qual \u00e9 o principal regulador da esporula\u00e7\u00e3o?"
    },
    {
        "answer":"toxins A and B",
        "answer_pt":"toxinas A e B",
        "id":"916",
        "question":"What are the main virulence factors in C. difficle?",
        "question_pt":"Quais s\u00e3o os principais fatores de virul\u00eancia em C. difficile?"
    },
    {
        "answer":"Western blot",
        "answer_pt":"Western blot",
        "id":"941",
        "question":"What laboratory test can be used to monitor protein expression?",
        "question_pt":"Que teste de laborat\u00f3rio pode ser usado para monitorar a express\u00e3o de prote\u00ednas?"
    },
    {
        "answer":"by mosquitoes",
        "answer_pt":"por mosquitos",
        "id":"933",
        "question":"How is Venezuelan equine encephalitis virus transmitted?",
        "question_pt":"Como \u00e9 transmitido o v\u00edrus da encefalite equina da Venezuela?"
    },
    {
        "answer":"fever, malaise, and vomiting",
        "answer_pt":"febre, mal-estar e v\u00f4mito",
        "id":"934",
        "question":"What are the symptoms of Venezuelan equine encephalitis virus?",
        "question_pt":"Quais s\u00e3o os sintomas do v\u00edrus da encefalite equina da Venezuela?"
    },
    {
        "answer":"35%",
        "answer_pt":"35%",
        "id":"935",
        "question":"What is the mortality rate of Venezuelan equine encephalitis virus in children?",
        "question_pt":"Qual \u00e9 a taxa de mortalidade do v\u00edrus da encefalite equina venezuelana em crian\u00e7as?"
    },
    {
        "answer":"10%",
        "answer_pt":"10%",
        "id":"936",
        "question":"What is the mortality rate of Venezuelan equine encephalitis virus in adults?",
        "question_pt":"Qual \u00e9 a taxa de mortalidade do v\u00edrus da encefalite equina venezuelana em adultos?"
    },
    {
        "answer":"TC83",
        "answer_pt":"TC83",
        "id":"937",
        "question":"What vaccine can be used to prevent Venezuelan equine encephalitis virus?",
        "question_pt":"Que vacina pode ser usada para prevenir o v\u00edrus da encefalite equina venezuelana?"
    },
    {
        "answer":"changes in gene expression",
        "answer_pt":"altera\u00e7\u00f5es na express\u00e3o g\u00eanica",
        "id":"938",
        "question":"What can RNA sequencing be used to monitor?",
        "question_pt":"O que o seq\u00fcenciamento de RNA pode ser usado para monitorar?"
    },
    {
        "answer":"protein misfolding",
        "answer_pt":"desdobramento de prote\u00ednas",
        "id":"939",
        "question":"What activates the UPR pathway in the cell?",
        "question_pt":"O que ativa o caminho UPR na c\u00e9lula?"
    },
    {
        "answer":"inositolrequiring enzyme 1 (IRE1), protein kinase RNA-like ER kinase (PERK), and activating transcription factor 6 (ATF6)",
        "answer_pt":"enzima inositolrequiring 1 (IRE1), ER quinase semelhante ao RNA da prote\u00edna quinase (PERK) e fator de transcri\u00e7\u00e3o ativador 6 (ATF6)",
        "id":"940",
        "question":"What indicators does the UPR pathway use to regulate protein folding and secretion in the cell?",
        "question_pt":"Quais indicadores a via UPR usa para regular a dobra e secre\u00e7\u00e3o de prote\u00ednas na c\u00e9lula?"
    },
    {
        "answer":"nucleus",
        "answer_pt":"n\u00facleo",
        "id":"942",
        "question":"Where does EGR1 accumulate in the cell?",
        "question_pt":"Onde o EGR1 se acumula na c\u00e9lula?"
    },
    {
        "answer":"a transcription factor",
        "answer_pt":"um fator de transcri\u00e7\u00e3o",
        "id":"943",
        "question":"What is EGR1?",
        "question_pt":"O que \u00e9 o EGR1?"
    },
    {
        "answer":" the ability of a given host to tolerate an infection, and to return to a state of health",
        "answer_pt":"a capacidade de um determinado hospedeiro tolerar uma infec\u00e7\u00e3o e retornar a um estado de sa\u00fade",
        "id":"1249",
        "question":"What is disease resilience?",
        "question_pt":"O que \u00e9 resili\u00eancia \u00e0 doen\u00e7a?"
    },
    {
        "answer":"coronavirus",
        "answer_pt":"coronav\u00edrus",
        "id":"1250",
        "question":"What family of virus does SARS reside in?",
        "question_pt":"Em que fam\u00edlia de v\u00edrus reside o SARS?"
    },
    {
        "answer":"coronavirus",
        "answer_pt":"coronav\u00edrus",
        "id":"1251",
        "question":"What family of virus does MERS reside in?",
        "question_pt":"Em que fam\u00edlia de v\u00edrus reside o MERS?"
    },
    {
        "answer":"2003",
        "answer_pt":"2003",
        "id":"1252",
        "question":"When was SARS-CoV first identified?",
        "question_pt":"Quando o SARS-CoV foi identificado pela primeira vez?"
    },
    {
        "answer":"8000",
        "answer_pt":"8000",
        "id":"1253",
        "question":"How many people did SARS-CoV infect?",
        "question_pt":"Quantas pessoas infectaram o SARS-CoV?"
    },
    {
        "answer":"35-50%",
        "answer_pt":"35-50%",
        "id":"1256",
        "question":"What percentage of people infected with MERS-CoV died?",
        "question_pt":"Qual a porcentagem de pessoas infectadas com MERS-CoV morreu?"
    },
    {
        "answer":"10%",
        "answer_pt":"10%",
        "id":"1255",
        "question":"What percentage of people infected with SARS-CoV died?",
        "question_pt":"Qual a porcentagem de pessoas infectadas com SARS-CoV morreu?"
    },
    {
        "answer":"animal reservoirs",
        "answer_pt":"reservat\u00f3rios de animais",
        "id":"1258",
        "question":"What was the reservoir for SARS-CoV and MERS-CoV?",
        "question_pt":"Qual foi o reservat\u00f3rio para SARS-CoV e MERS-CoV?"
    },
    {
        "answer":"severe lung pathology",
        "answer_pt":"patologia pulmonar grave",
        "id":"1260",
        "question":"What was the primary threatening clinical finding in patients infected with SARS-CoV and MERS-CoV?",
        "question_pt":"Qual foi o principal achado cl\u00ednico amea\u00e7ador em pacientes infectados com SARS-CoV e MERS-CoV?"
    },
    {
        "answer":"Many infected patients have acute lung injury (ALI)",
        "answer_pt":"Muitos pacientes infectados t\u00eam les\u00e3o pulmonar aguda (LPA)",
        "id":"1262",
        "question":"What is the relationship between SARS-CoV and acute lung injury (ALI)?",
        "question_pt":"Qual \u00e9 a rela\u00e7\u00e3o entre SARS-CoV e les\u00e3o pulmonar aguda (LPA)?"
    },
    {
        "answer":" In some patients there is a progression to the more severe form of ALI, acute respiratory distress syndrome (ARDS)",
        "answer_pt":"Em alguns pacientes, h\u00e1 uma progress\u00e3o para a forma mais grave de LPA, s\u00edndrome do desconforto respirat\u00f3rio agudo (SDRA)",
        "id":"1263",
        "question":"What is the relationship between SARS-CoV and acute respiratory distress syndrome (ARDS)?",
        "question_pt":"Qual \u00e9 a rela\u00e7\u00e3o entre SARS-CoV e s\u00edndrome do desconforto respirat\u00f3rio agudo (SDRA)?"
    },
    {
        "answer":" a successful host must not only be able to clear the pathogen, but tolerate damage caused by the pathogen itself and also by the host's immune response",
        "answer_pt":"um hospedeiro bem-sucedido deve n\u00e3o apenas ser capaz de eliminar o pat\u00f3geno, mas tamb\u00e9m tolerar os danos causados \u200b\u200bpelo pr\u00f3prio pat\u00f3geno e tamb\u00e9m pela resposta imune do hospedeiro",
        "id":"1265",
        "question":"What is required for a person to survive a serious SARS-CoV infection?",
        "question_pt":"O que \u00e9 necess\u00e1rio para uma pessoa sobreviver a uma infec\u00e7\u00e3o grave por SARS-CoV?"
    },
    {
        "answer":"SARS-CoV uses the ACE2 receptor to gain entry to cells, while MERS-CoV uses the ectopeptidase DPP4",
        "answer_pt":"O SARS-CoV usa o receptor ACE2 para entrar nas c\u00e9lulas, enquanto o MERS-CoV usa a ectopeptidase DPP4",
        "id":"1266",
        "question":"How does cell-entry differ between SARS-CoV and MERS-CoV?",
        "question_pt":"Como a entrada de c\u00e9lulas difere entre SARS-CoV e MERS-CoV?"
    },
    {
        "answer":"Unlike SARS-CoV infection, which causes primarily a severe respiratory syndrome, MERS-CoV infection can also lead to kidney failure",
        "answer_pt":"Ao contr\u00e1rio da infec\u00e7\u00e3o por SARS-CoV, que causa principalmente uma s\u00edndrome respirat\u00f3ria grave, a infec\u00e7\u00e3o por MERS-CoV tamb\u00e9m pode levar \u00e0 insufici\u00eancia renal",
        "id":"1267",
        "question":"What is a major difference in clinical progression between SARS-CoV and MERS-CoV?",
        "question_pt":"Qual \u00e9 a principal diferen\u00e7a na progress\u00e3o cl\u00ednica entre SARS-CoV e MERS-CoV?"
    },
    {
        "answer":" SARS-CoV also spreads more rapidly between hosts, while MERS-CoV has been more easily contained, but it is unclear if this is due to the affected patient populations and regions",
        "answer_pt":"O SARS-CoV tamb\u00e9m se espalha mais rapidamente entre os hospedeiros, enquanto o MERS-CoV foi mais facilmente contido, mas n\u00e3o est\u00e1 claro se isso se deve \u00e0s popula\u00e7\u00f5es e regi\u00f5es afetadas de pacientes",
        "id":"1268",
        "question":"How does transmission differ between SARS-CoV and MERS-CoV?",
        "question_pt":"Como a transmiss\u00e3o difere entre SARS-CoV e MERS-CoV?"
    },
    {
        "answer":"SARS-CoV and MERS-CoV are contained in double membrane vesicles",
        "answer_pt":"SARS-CoV e MERS-CoV est\u00e3o contidos em ves\u00edculas de membrana dupla",
        "id":"1269",
        "question":"How do SARS-CoV and MERS-CoV evade the immune system sensing it's genome?",
        "question_pt":"Como o SARS-CoV e o MERS-CoV evitam o sistema imunol\u00f3gico, detectando seu genoma?"
    },
    {
        "answer":"In patients with high initial viral titers there is a poor prognosis",
        "answer_pt":"Em pacientes com altos t\u00edtulos virais iniciais, h\u00e1 um progn\u00f3stico ruim",
        "id":"1270",
        "question":"What role does initial viral titer play in the prognosis of SARS-CoV and MERS-CoV?",
        "question_pt":"Qual o papel do t\u00edtulo viral inicial no progn\u00f3stico de SARS-CoV e MERS-CoV?"
    },
    {
        "answer":"In a mouse model of SARS-CoV infection, the type I IFN response is delayed",
        "answer_pt":"Em um modelo de mouse com infec\u00e7\u00e3o por SARS-CoV, a resposta do IFN tipo I \u00e9 atrasada",
        "id":"1272",
        "question":"What is the timeline of the type I interferon (IFN) response in SARS-CoV infection?",
        "question_pt":"Qual \u00e9 o cronograma da resposta do interferon tipo I (IFN) na infec\u00e7\u00e3o por SARS-CoV?"
    },
    {
        "answer":"several viral proteins suppress the type I IFN response, and other aspects of innate antiviral immunity",
        "answer_pt":"v\u00e1rias prote\u00ednas virais suprimem a resposta do IFN tipo I e outros aspectos da imunidade antiviral inata",
        "id":"1271",
        "question":"How do SARS-CoV viral proteins interact with the immune response?",
        "question_pt":"Como as prote\u00ednas virais de SARS-CoV interagem com a resposta imune?"
    },
    {
        "answer":"Retrospective analysis revealed that, when given at the correct time and to the appropriate patients, corticosteroid use could decrease mortality and also length of hospital stays",
        "answer_pt":"A an\u00e1lise retrospectiva revelou que, quando administrado no momento correto e aos pacientes apropriados, o uso de corticosteroides poderia diminuir a mortalidade e tamb\u00e9m o tempo de interna\u00e7\u00e3o",
        "id":"1273",
        "question":"What was the role of corticosteroid use in hospitalized patients with SARS-CoV?",
        "question_pt":"Qual o papel do uso de corticoster\u00f3ide em pacientes hospitalizados com SARS-CoV?"
    },
    {
        "answer":" there is some evidence that simultaneous treatment with IFNs could increase the potential benefits",
        "answer_pt":"existem evid\u00eancias de que o tratamento simult\u00e2neo com IFNs pode aumentar os benef\u00edcios potenciais",
        "id":"1274",
        "question":"What is the role of interferon's (IFNs) in the treatment of SARS-CoV?",
        "question_pt":"Qual o papel do interferon (IFNs) no tratamento da SARS-CoV?"
    },
    {
        "answer":"decreasing immunopathology by immunomodulation is problematic because it can lead to increased pathogen burden, and thus increase virus-induced pathology",
        "answer_pt":"diminuir a imunopatologia por imunomodula\u00e7\u00e3o \u00e9 problem\u00e1tico porque pode levar ao aumento da carga patog\u00eanica e, assim, aumentar a patologia induzida por v\u00edrus",
        "id":"1275",
        "question":"What are some negative effects of decreasing immunopathology by immunomodulation?",
        "question_pt":"Quais s\u00e3o alguns efeitos negativos da diminui\u00e7\u00e3o da imunopatologia por imunomodula\u00e7\u00e3o?"
    },
    {
        "answer":"A recent paper demonstrates that topoisomerase I can protect against inflammation-induced death from a variety of viral infections including IAV",
        "answer_pt":"Um artigo recente demonstra que a topoisomerase I pode proteger contra a morte induzida por inflama\u00e7\u00e3o de uma variedade de infec\u00e7\u00f5es virais, incluindo o IAV",
        "id":"1276",
        "question":"What is the role of topoisomerase I in improving host resilience in viral lung infections?",
        "question_pt":"Qual o papel da topoisomerase I na melhoria da resili\u00eancia do hospedeiro em infec\u00e7\u00f5es pulmonares virais?"
    },
    {
        "answer":"Blockade of C5a complement signaling has also been suggested as a possible option in decreasing inflammation during IAV infection",
        "answer_pt":"O bloqueio da sinaliza\u00e7\u00e3o do complemento C5a tamb\u00e9m tem sido sugerido como uma op\u00e7\u00e3o poss\u00edvel na diminui\u00e7\u00e3o da inflama\u00e7\u00e3o durante a infec\u00e7\u00e3o pelo IAV",
        "id":"1277",
        "question":"What is the role of complement 5a (C5a) in increasing host resilience to viral lung infection?",
        "question_pt":"Qual o papel do complemento 5a (C5a) no aumento da resili\u00eancia do hospedeiro \u00e0 infec\u00e7\u00e3o pulmonar viral?"
    },
    {
        "answer":"They act to stabilize the activation of aspects of the innate immune response and prevent excessive inflammation",
        "answer_pt":"Eles agem para estabilizar a ativa\u00e7\u00e3o de aspectos da resposta imune inata e prevenir a inflama\u00e7\u00e3o excessiva",
        "id":"1278",
        "question":"What is the role of statins in increasing host resilience to viral lung infections?",
        "question_pt":"Qual o papel das estatinas no aumento da resili\u00eancia do hospedeiro a infec\u00e7\u00f5es pulmonares virais?"
    },
    {
        "answer":"if they were obese, immunocompromised, diabetic or had cardiac disease",
        "answer_pt":"se eram obesos, imunocomprometidos, diab\u00e9ticos ou tinham doen\u00e7a card\u00edaca",
        "id":"1279",
        "question":"Which medical comorbidities most profoundly influenced MERS-CoV outcomes?",
        "question_pt":"Quais comorbidades m\u00e9dicas influenciaram mais profundamente os resultados do MERS-CoV?"
    },
    {
        "answer":"a higher neutrophil count and low T-cell counts",
        "answer_pt":"maior contagem de neutr\u00f3filos e baixa contagem de c\u00e9lulas T",
        "id":"1280",
        "question":"Which immune factors were associated with increased SARS-CoV morbidity and mortality?",
        "question_pt":"Quais fatores imunes foram associados ao aumento da morbimortalidade por SARS-CoV?"
    },
    {
        "answer":"One factor that increased disease for patients infected with SARS-CoV and MERS-CoV was infection with other viruses or bacteria",
        "answer_pt":"Um fator que aumentou a doen\u00e7a em pacientes infectados com SARS-CoV e MERS-CoV foi a infec\u00e7\u00e3o por outros v\u00edrus ou bact\u00e9rias",
        "id":"1281",
        "question":"What is the prognostic role of coinfection in SARS-CoV and MERS-CoV infections?",
        "question_pt":"Qual \u00e9 o papel progn\u00f3stico da co-infec\u00e7\u00e3o nas infec\u00e7\u00f5es por SARS-CoV e MERS-CoV?"
    },
    {
        "answer":"A recent study looking at malaria infections in animal models and human patients demonstrated that resilient hosts can be predicted",
        "answer_pt":"Um estudo recente que analisou infec\u00e7\u00f5es por mal\u00e1ria em modelos animais e pacientes humanos demonstrou que \u00e9 poss\u00edvel prever hospedeiros resilientes",
        "id":"1282",
        "question":"Can host resilience be predicted?",
        "question_pt":"A resili\u00eancia do host pode ser prevista?"
    },
    {
        "answer":"Clinical studies have started to correlate specific biomarkers with disease outcomes in ARDS patients",
        "answer_pt":"Estudos cl\u00ednicos come\u00e7aram a correlacionar biomarcadores espec\u00edficos com resultados de doen\u00e7as em pacientes com SDRA",
        "id":"1283",
        "question":"Can biomarkers be used to predict outcomes in acute respiratory distress (ARDS) patients?",
        "question_pt":"Os biomarcadores podem ser usados \u200b\u200bpara prever resultados em pacientes com insufici\u00eancia respirat\u00f3ria aguda (SDRA)?"
    },
    {
        "answer":"A systematic search was carried out in three major electronic databases (PubMed, Embase and Cochrane Library) to identify published studies in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Supplementary strategies through Google Search and personal communications were used. ",
        "answer_pt":"Uma pesquisa sistem\u00e1tica foi realizada em tr\u00eas grandes bancos de dados eletr\u00f4nicos (PubMed, Embase e Cochrane Library) para identificar estudos publicados de acordo com as diretrizes de itens de relat\u00f3rio preferenciais para revis\u00f5es sistem\u00e1ticas e meta-an\u00e1lises (PRISMA). Estrat\u00e9gias complementares atrav\u00e9s da Pesquisa Google e comunica\u00e7\u00f5es pessoais foram usadas.",
        "id":"3617",
        "question":"What work has been carried out this study?",
        "question_pt":"Que trabalho foi realizado neste estudo?"
    },
    {
        "answer":" 25,000",
        "answer_pt":"25.000",
        "id":"3618",
        "question":"How many confirmed cases were identified in February 2020?",
        "question_pt":"Quantos casos confirmados foram identificados em fevereiro de 2020?"
    },
    {
        "answer":" 2%",
        "answer_pt":"2%",
        "id":"3619",
        "question":"What was the case fatality rate?",
        "question_pt":"Qual foi a taxa de mortalidade de casos?"
    },
    {
        "answer":"males with a median age of 55 years and linked to the Huanan Seafood Wholesale Market ",
        "answer_pt":"homens com idade mediana de 55 anos e vinculados ao Mercado Atacadista de Frutos do Mar de Huanan",
        "id":"3620",
        "question":"Who are the majority of cases?",
        "question_pt":"Quem \u00e9 a maioria dos casos?"
    },
    {
        "answer":"fever, cough, and myalgia or fatigue.",
        "answer_pt":"febre, tosse e mialgia ou fadiga.",
        "id":"3621",
        "question":"What are the symptoms at the onset?",
        "question_pt":"Quais s\u00e3o os sintomas no in\u00edcio?"
    },
    {
        "answer":"betacoronavirus",
        "answer_pt":"betacoronav\u00edrus",
        "id":"3622",
        "question":"What  type of virus is 2019-nCOV?",
        "question_pt":"Que tipo de v\u00edrus \u00e9 2019-nCOV?"
    },
    {
        "answer":" forms a clade within the subgenus sarbecovirus of the Orthocoronavirinae subfamily ",
        "answer_pt":"forma um clado dentro do subg\u00eanero sarbecov\u00edrus da subfam\u00edlia Orthocoronavirinae",
        "id":"3623",
        "question":"What clade does it belong to?",
        "question_pt":"A que clado pertence?"
    },
    {
        "answer":"The severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV)",
        "answer_pt":"O coronav\u00edrus da s\u00edndrome respirat\u00f3ria aguda grave (SARS-CoV) e o coronav\u00edrus da s\u00edndrome respirat\u00f3ria do Oriente M\u00e9dio (MERS-CoV)",
        "id":"3624",
        "question":"What other betacoronaviruses are zoonotic in origin?",
        "question_pt":"Quais outros betacoronav\u00edrus t\u00eam origem zoon\u00f3tica?"
    },
    {
        "answer":"Based on current evidence, pathogenicity for 2019-nCoV is about 3%, which is significantly lower than SARS-CoV (10%) and MERS-CoV (40%)",
        "answer_pt":"Com base nas evid\u00eancias atuais, a patogenicidade para 2019-nCoV \u00e9 de cerca de 3%, o que \u00e9 significativamente menor que o SARS-CoV (10%) e o MERS-CoV (40%)",
        "id":"3625",
        "question":"How does the pathogenicity of 2019-nCOV compare with other viruses?",
        "question_pt":"Como a patogenicidade do 2019-nCOV se compara a outros v\u00edrus?"
    },
    {
        "answer":"2019-nCoV has potentially higher transmissibility (R0: 1.4-5.5) than both SARS-CoV (R0: [2] [3] [4] [5] and MERS-CoV (R0: <1)",
        "answer_pt":"2019-nCoV tem potencialmente maior transmissibilidade (R0: 1.4-5.5) do que SARS-CoV (R0: [2] [3] [4] [5] e MERS-CoV (R0: <1)",
        "id":"3626",
        "question":"How does the transmissibility of 2019-nCOV compare with other viruses?",
        "question_pt":"Como a transmissibilidade do 2019-nCOV se compara com outros v\u00edrus?"
    },
    {
        "answer":"PubMed, Embase and Cochrane Library",
        "answer_pt":"Biblioteca PubMed, Embase e Cochrane",
        "id":"3627",
        "question":"Which electronic databases were used for this study?",
        "question_pt":"Quais bancos de dados eletr\u00f4nicos foram utilizados para este estudo?"
    },
    {
        "answer":" to identify published studies examining the diagnosis, therapeutic drugs and vaccines for Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS) and the 2019 novel coronavirus (2019-nCoV), in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.",
        "answer_pt":"identificar estudos publicados que examinam o diagn\u00f3stico, medicamentos e vacinas terap\u00eauticas para S\u00edndrome Respirat\u00f3ria Aguda Grave (SARS), S\u00edndrome Respirat\u00f3ria do Oriente M\u00e9dio (MERS) e o novo coronav\u00edrus de 2019 (2019-nCoV) de 2019, de acordo com os itens de relat\u00f3rio preferenciais para revis\u00f5es sistem\u00e1ticas e Diretrizes de meta-an\u00e1lises (PRISMA).",
        "id":"3628",
        "question":"What was the purpose of the search?",
        "question_pt":"Qual foi o objetivo da pesquisa?"
    },
    {
        "answer":"randomized controlled trials (RCTs) and validation trials (for diagnostics test) published in English, that measured (a) the sensitivity and/or specificity of a rapid diagnostic test or a point-of-care testing kit, (b) the impact of drug therapy or (c) vaccine efficacy against either of these diseases with no date restriction applied. For the 2019-nCoV, we searched for all in vitro, animal, or human studies published in English between 1 December 2019 and 6 February 2020, on the same outcomes of interest. ",
        "answer_pt":"ensaios cl\u00ednicos randomizados (ECR) e ensaios de valida\u00e7\u00e3o (para teste de diagn\u00f3stico) publicados em ingl\u00eas, que mediram (a) a sensibilidade e / ou especificidade de um teste r\u00e1pido de diagn\u00f3stico ou de um kit de teste no local de atendimento, (b) o impacto de terapia medicamentosa ou (c) efic\u00e1cia da vacina contra qualquer uma dessas doen\u00e7as sem restri\u00e7\u00e3o de data aplicada. Para o 2019-nCoV, pesquisamos todos os estudos in vitro, animais ou humanos publicados em ingl\u00eas entre 1 de dezembro de 2019 e 6 de fevereiro de 2020, com os mesmos resultados de interesse.",
        "id":"3629",
        "question":"What topics were searched for?",
        "question_pt":"Quais t\u00f3picos foram pesquisados?"
    },
    {
        "answer":" Studies that examined the mechanisms of diagnostic tests, drug therapy or vaccine efficacy against SARS, MERS and 2019-nCoV",
        "answer_pt":"Estudos que examinaram os mecanismos de testes de diagn\u00f3stico, terapia medicamentosa ou efic\u00e1cia da vacina contra SARS, MERS e 2019-nCoV",
        "id":"3630",
        "question":"What studies  were excluded?",
        "question_pt":"Quais estudos foram exclu\u00eddos?"
    },
    {
        "answer":"A Google search for 2019-nCoV diagnostics (as of 6 February 2020; Table S2 ) yielded five webpage links from government and international bodies with official information and guidelines (WHO, Europe CDC, US CDC, US FDA), three webpage links on diagnostic protocols and scientific commentaries, and five webpage links on market news and press releases. Six protocols for diagnostics using reverse transcriptase polymerase chain reaction (RT-PCR) from six countries were published on WHO's website [9] . Google search for 2019-nCoV vaccines yielded 19 relevant articles.",
        "answer_pt":"Uma pesquisa no Google por diagn\u00f3sticos 2019-nCoV (em 6 de fevereiro de 2020; Tabela S2) produziu cinco links de p\u00e1ginas de \u00f3rg\u00e3os governamentais e internacionais com informa\u00e7\u00f5es e diretrizes oficiais (OMS, CDC da Europa, CDC dos EUA, FDA dos EUA), tr\u00eas links de p\u00e1ginas da Web sobre diagn\u00f3stico protocolos e coment\u00e1rios cient\u00edficos e cinco links de p\u00e1ginas da Web sobre not\u00edcias e comunicados de imprensa do mercado. Seis protocolos para diagn\u00f3stico usando a rea\u00e7\u00e3o em cadeia da polimerase com transcriptase reversa (RT-PCR) de seis pa\u00edses foram publicados no site da OMS [9]. A pesquisa no Google de vacinas 2019-nCoV produziu 19 artigos relevantes.",
        "id":"3631",
        "question":"What did the searches yield?",
        "question_pt":"O que as pesquisas renderam?"
    },
    {
        "answer":"real time RT-PCR",
        "answer_pt":"RT-PCR em tempo real",
        "id":"3632",
        "question":" What is the the primary means for diagnosing the new virus strain?",
        "question_pt":"Qual \u00e9 o principal meio de diagnosticar a nova cepa de v\u00edrus?"
    },
    {
        "answer":"It was found that the respiratory specimens were positive for the virus while serum was negative in the early period. It has also suggested that in the early days of illness, patients have high levels of virus despite the mild symptoms.",
        "answer_pt":"Verificou-se que as amostras respirat\u00f3rias eram positivas para o v\u00edrus, enquanto o soro era negativo no per\u00edodo inicial. Tamb\u00e9m sugeriu que, nos primeiros dias da doen\u00e7a, os pacientes apresentam altos n\u00edveis de v\u00edrus, apesar dos sintomas leves.",
        "id":"3633",
        "question":"What are roles of  the period and type of specimens?",
        "question_pt":"Quais s\u00e3o as fun\u00e7\u00f5es do per\u00edodo e tipo de amostras?"
    },
    {
        "answer":"reverse transcription loop-mediated isothermal amplification (RT-LAMP), RT-insulated isothermal PCR (RT-iiPCR) and a one-step rRT-PCR assay based on specific TaqMan probes.",
        "answer_pt":"amplifica\u00e7\u00e3o isot\u00e9rmica mediada por al\u00e7a de transcri\u00e7\u00e3o reversa (RT-LAMP), PCR isot\u00e9rmica isolada por RT (RT-iiPCR) e um teste de rRT-PCR de uma etapa com base em sondas TaqMan espec\u00edficas.",
        "id":"3634",
        "question":"What  are some of the other diagnostic methods?",
        "question_pt":"Quais s\u00e3o alguns dos outros m\u00e9todos de diagn\u00f3stico?"
    },
    {
        "answer":" RT-LAMP has similar sensitivity as real time RT-PCR. It is also highly specific and is used to detect MERS-CoV. It is comparable to the usual diagnostic tests and is rapid, simple and convenient.",
        "answer_pt":"O RT-LAMP tem sensibilidade semelhante ao RT-PCR em tempo real. Tamb\u00e9m \u00e9 altamente espec\u00edfico e \u00e9 usado para detectar MERS-CoV. \u00c9 compar\u00e1vel aos testes de diagn\u00f3stico usuais e \u00e9 r\u00e1pido, simples e conveniente.",
        "id":"3635",
        "question":"How does RT-LAMP compare with other methods?",
        "question_pt":"Como o RT-LAMP se compara com outros m\u00e9todos?"
    },
    {
        "answer":" have also shown similar sensitivity and high specificity for MER-CoV.",
        "answer_pt":"tamb\u00e9m mostraram sensibilidade semelhante e alta especificidade para MER-CoV.",
        "id":"3636",
        "question":"How do RT-iiPCR and a one-step rRT-PCR compare with other methods?",
        "question_pt":"Como o RT-iiPCR e um rRT-PCR de uma etapa se comparam com outros m\u00e9todos?"
    },
    {
        "answer":"high levels of PCR inhibition may hinder PCR sensitivity ",
        "answer_pt":"altos n\u00edveis de inibi\u00e7\u00e3o da PCR podem prejudicar a sensibilidade da PCR",
        "id":"3637",
        "question":" Why is RT-PCR not the best method sometimes?",
        "question_pt":"Por que o RT-PCR \u00e0s vezes n\u00e3o \u00e9 o melhor m\u00e9todo?"
    },
    {
        "answer":" that the molecular test has better sensitivity and specificity. ",
        "answer_pt":"que o teste molecular tem melhor sensibilidade e especificidade.",
        "id":"3638",
        "question":"What did the comparison between the molecular test  and serological test show?",
        "question_pt":"O que a compara\u00e7\u00e3o entre o teste molecular e o teste sorol\u00f3gico mostrou?"
    },
    {
        "answer":"Studies looked at using nested PCR to include a pre-amplification step or incorporating N gene as an additional sensitive molecular marker to improve on the sensitivity ",
        "answer_pt":"Os estudos analisaram o uso de PCR aninhado para incluir uma etapa de pr\u00e9-amplifica\u00e7\u00e3o ou a incorpora\u00e7\u00e3o do gene N como marcador molecular sens\u00edvel adicional para melhorar a sensibilidade",
        "id":"3639",
        "question":"What enhancements to the molecular tests were looked at?",
        "question_pt":"Quais aprimoramentos foram feitos nos testes moleculares?"
    },
    {
        "answer":"10 genome equivalents per reaction",
        "answer_pt":"10 equivalentes de genoma por rea\u00e7\u00e3o",
        "id":"3640",
        "question":"What is the threshold sensitivity of  Real time PCR?",
        "question_pt":"Qual \u00e9 a sensibilidade do limiar da PCR em tempo real?"
    },
    {
        "answer":"has a good reproducibility with the inter-assay coefficients of variation of 1.73 to 2.72%.",
        "answer_pt":"apresenta boa reprodutibilidade com os coeficientes de varia\u00e7\u00e3o entre ensaios de 1,73 a 2,72%.",
        "id":"3641",
        "question":"How is the reproducibility of real time PCR?",
        "question_pt":"Como \u00e9 a reprodutibilidade da PCR em tempo real?"
    },
    {
        "answer":"messenger RNA, DNA-based, nanoparticle, synthetic and modified virus-like particle)",
        "answer_pt":"RNA mensageiro, \u00e0 base de DNA, nanopart\u00edculas, part\u00edcula sint\u00e9tica e modificada de v\u00edrus)",
        "id":"3642",
        "question":"What are potential vaccines based on?",
        "question_pt":"Em que se baseiam as vacinas em potencial?"
    },
    {
        "answer":" kit developed by the BGI have passed emergency approval procedure of the National Medical Products Administration, and are currently used in clinical and surveillance centers of China",
        "answer_pt":"kit desenvolvido pela BGI passou no procedimento de aprova\u00e7\u00e3o de emerg\u00eancia da Administra\u00e7\u00e3o Nacional de Produtos M\u00e9dicos e atualmente \u00e9 usado em centros cl\u00ednicos e de vigil\u00e2ncia da China",
        "id":"3643",
        "question":"Which  kit is currently used in China?",
        "question_pt":"Qual kit \u00e9 atualmente usado na China?"
    },
    {
        "answer":"Most studies on SARS and MERS vaccines were excluded as they were performed in cell or animal models ",
        "answer_pt":"A maioria dos estudos sobre vacinas contra SARS e MERS foi exclu\u00edda por serem realizados em modelos de c\u00e9lulas ou animais",
        "id":"3644",
        "question":"Why were only four studies included?",
        "question_pt":"Por que apenas quatro estudos foram inclu\u00eddos?"
    },
    {
        "answer":" Phase I clinical trials on SARS or MERS vaccines",
        "answer_pt":"Ensaios cl\u00ednicos de fase I em vacinas SARS ou MERS",
        "id":"3645",
        "question":"Which  four studies were included?",
        "question_pt":"Quais quatro estudos foram inclu\u00eddos?"
    },
    {
        "answer":" All vaccine candidates for SARS and MERS were reported to be safe, ",
        "answer_pt":"Todos os candidatos a vacina para SARS e MERS foram relatados como seguros,",
        "id":"3646",
        "question":"What is te safety of the vaccines?\n",
        "question_pt":"Qual \u00e9 a seguran\u00e7a das vacinas?"
    },
    {
        "answer":"well-tolerated and able to trigger the relevant and appropriate immune responses in the participants",
        "answer_pt":"bem tolerado e capaz de desencadear respostas imunol\u00f3gicas relevantes e apropriadas nos participantes",
        "id":"3647",
        "question":"What was the performance of the vaccine candidates?",
        "question_pt":"Qual foi o desempenho dos candidatos a vacina?"
    },
    {
        "answer":"nine",
        "answer_pt":"nove",
        "id":"3648",
        "question":"How many clinical trials are registered?",
        "question_pt":"Quantos ensaios cl\u00ednicos est\u00e3o registrados?"
    },
    {
        "answer":" five studies on hydroxychloroquine, lopinavir plus ritonavir and arbidol, mesenchymal stem cells, traditional Chinese medicine and glucocorticoid therapy usage have commenced recruitment. The remaining four studies encompass investigation of antivirals, interferon atomization, darunavir and cobicistat, arbidol, and remdesivir usage for 2019-nCoV patients",
        "answer_pt":"cinco estudos sobre hidroxicloroquina, lopinavir mais ritonavir e arbidol, c\u00e9lulas-tronco mesenquimais, medicina tradicional chinesa e uso de terapia com glicocortic\u00f3ides iniciaram o recrutamento. Os quatro estudos restantes abrangem a investiga\u00e7\u00e3o de antivirais, atomiza\u00e7\u00e3o por interferon, uso de darunavir e cobicistat, arbidol e remdesivir para pacientes com 2019-nCoV",
        "id":"3649",
        "question":"What is the status of the nine trials?",
        "question_pt":"Qual \u00e9 o status dos nove ensaios?"
    },
    {
        "answer":" Seroconversion measured by S1-ELISA occurred in 86% and 94% participants after 2 and 3 doses, respectively, and was maintained in 79% participants up to study end at week 60.",
        "answer_pt":"A soroconvers\u00e3o medida pelo S1-ELISA ocorreu em 86% e 94% dos participantes ap\u00f3s 2 e 3 doses, respectivamente, e foi mantida em 79% dos participantes at\u00e9 o final do estudo na semana 60.",
        "id":"3650",
        "question":"What are the results on seroconversion?",
        "question_pt":"Quais s\u00e3o os resultados da soroconvers\u00e3o?"
    },
    {
        "answer":"Neutralising antibodies were detected in 50% participants at one or more time points during the study, but only 3% maintained neutralisation activity to end of study.",
        "answer_pt":"Anticorpos neutralizantes foram detectados em 50% dos participantes em um ou mais momentos durante o estudo, mas apenas 3% mantiveram a atividade de neutraliza\u00e7\u00e3o at\u00e9 o final do estudo.",
        "id":"3651",
        "question":"What were the results on antibodies?",
        "question_pt":"Quais foram os resultados dos anticorpos?"
    },
    {
        "answer":" detected in 71% and 76% participants after 2 and 3 doses, respectively.",
        "answer_pt":"detectado em 71% e 76% dos participantes ap\u00f3s 2 e 3 doses, respectivamente.",
        "id":"3652",
        "question":"What were  the T-cell responses?",
        "question_pt":"Quais foram as respostas das c\u00e9lulas T?"
    },
    {
        "answer":"no differences in immune responses between dose groups after 6 weeks and vaccine-induced humoral and cellular responses were respectively detected in 77% and 64% participants at week 60",
        "answer_pt":"n\u00e3o foram detectadas diferen\u00e7as nas respostas imunes entre os grupos de doses ap\u00f3s 6 semanas e respostas humorais e celulares induzidas pela vacina em 77% e 64% dos participantes na semana 60",
        "id":"3653",
        "question":"What were the differences in immune responses?",
        "question_pt":"Quais foram as diferen\u00e7as nas respostas imunes?"
    },
    {
        "answer":"Molecules developed by the university scientists inhibit two coronavirus enzymes and prevent its replication. The discovered drug targets are said to be more than 95% similar to enzyme targets found on the SARS virus. ",
        "answer_pt":"As mol\u00e9culas desenvolvidas pelos cientistas da universidade inibem duas enzimas do coronav\u00edrus e impedem sua replica\u00e7\u00e3o. Os alvos de drogas descobertos s\u00e3o considerados mais de 95% semelhantes aos alvos de enzimas encontrados no v\u00edrus da SARS.",
        "id":"3654",
        "question":"What is the observed benefit of the molecules?",
        "question_pt":"Qual \u00e9 o benef\u00edcio observado das mol\u00e9culas?"
    },
    {
        "answer":"It investigates the usage of Lopinavir/Ritonavir and Interferon Beta 1B.",
        "answer_pt":"Ele investiga o uso de Lopinavir / Ritonavir e Interferon Beta 1B.",
        "id":"3655",
        "question":"What is the ongoing randomized trial investigating?",
        "question_pt":"O que o estudo randomizado em andamento est\u00e1 investigando?"
    },
    {
        "answer":" usage of ribavirin with lopinavir/ritonavir/ribavirin, interferon, and convalescent plasma usage.",
        "answer_pt":"uso de ribavirina com lopinavir / ritonavir / ribavirina, interferon e uso de plasma convalescente.",
        "id":"3656",
        "question":"What are the many prospective and restrospective studies  conducted on?",
        "question_pt":"Quais s\u00e3o os muitos estudos prospectivos e retrospectivos realizados?"
    },
    {
        "answer":"The trial conducted in the United States in 2017 demonstrated SAB-301 to be safe and well-tolerated at single doses. ",
        "answer_pt":"O estudo realizado nos Estados Unidos em 2017 demonstrou que o SAB-301 \u00e9 seguro e bem tolerado em doses \u00fanicas.",
        "id":"3657",
        "question":"What was the result of the phase 1 trial of IgG immunoglobin?",
        "question_pt":"Qual foi o resultado do estudo de fase 1 da imunoglobulina IgG?"
    },
    {
        "answer":"enables prompt and accurate public health surveillance, prevention and control measures. Local transmission and clusters can be prevented or delayed by isolation of laboratory-confirmed cases and their close contacts quarantined and monitored at home",
        "answer_pt":"permite medidas imediatas e precisas de vigil\u00e2ncia, preven\u00e7\u00e3o e controle da sa\u00fade p\u00fablica. A transmiss\u00e3o e os clusters locais podem ser evitados ou atrasados \u200b\u200bpelo isolamento de casos confirmados em laborat\u00f3rio e seus contatos pr\u00f3ximos em quarentena e monitorados em casa",
        "id":"3658",
        "question":"What role rapid diagnostics plays?",
        "question_pt":"Qual o papel do diagn\u00f3stico r\u00e1pido?"
    },
    {
        "answer":"specific public health interventions such as closure of high-risk facilities and areas associated with the confirmed cases for prompt infection control and environmental decontamination ",
        "answer_pt":"interven\u00e7\u00f5es espec\u00edficas de sa\u00fade p\u00fablica, como fechamento de instala\u00e7\u00f5es de alto risco e \u00e1reas associadas aos casos confirmados para controle imediato de infec\u00e7\u00f5es e descontamina\u00e7\u00e3o ambiental",
        "id":"3659",
        "question":"What other measures rapid diagnostics facilitates?",
        "question_pt":"Que outras medidas o diagn\u00f3stico r\u00e1pido facilita?"
    },
    {
        "answer":" (a) detecting the genetic material of the virus, (b) detecting the antibodies that neutralize the viral particles of interest, (c) detecting the viral epitopes of interest with antibodies (serological testing), or (d) culture and isolation of viable virus particles.",
        "answer_pt":"(a) detectar o material gen\u00e9tico do v\u00edrus, (b) detectar os anticorpos que neutralizam as part\u00edculas virais de interesse, (c) detectar os ep\u00edtopos virais de interesse com anticorpos (testes sorol\u00f3gicos) ou (d) cultura e isolamento de subst\u00e2ncias vi\u00e1veis part\u00edculas de v\u00edrus.",
        "id":"3660",
        "question":"What  are ways to perform laboratory diagnostics?",
        "question_pt":"Quais s\u00e3o as maneiras de realizar diagn\u00f3sticos de laborat\u00f3rio?"
    },
    {
        "answer":"lack of knowledge of the presence of viable virus, the potential cross-reactivity with non-specific genetic regions and the short timeframe for accurate detection during the acute infection phase.",
        "answer_pt":"falta de conhecimento da presen\u00e7a de v\u00edrus vi\u00e1veis, potencial reatividade cruzada com regi\u00f5es gen\u00e9ticas inespec\u00edficas e prazo curto para detec\u00e7\u00e3o precisa durante a fase aguda da infec\u00e7\u00e3o.",
        "id":"3661",
        "question":"What are key limtations of genetic detection?",
        "question_pt":"Quais s\u00e3o as principais limita\u00e7\u00f5es da detec\u00e7\u00e3o gen\u00e9tica?"
    },
    {
        "answer":"the need to collect paired serum samples (in the acute and convalescent phases) from cases under investigation for confirmation to eliminate potential cross-reactivity from non-specific antibodies from past exposure and/or infection by other coronaviruses.",
        "answer_pt":"a necessidade de coletar amostras de soro emparelhadas (nas fases aguda e convalescente) de casos sob investiga\u00e7\u00e3o para confirma\u00e7\u00e3o para eliminar a reatividade cruzada potencial de anticorpos n\u00e3o espec\u00edficos de exposi\u00e7\u00e3o passada e / ou infec\u00e7\u00e3o por outros coronav\u00edrus.",
        "id":"3662",
        "question":"What is a key limitation of serological  testing?",
        "question_pt":"Qual \u00e9 a principal limita\u00e7\u00e3o dos testes sorol\u00f3gicos?"
    },
    {
        "answer":" the long duration and the highly specialized skills required of the technicians to process the samples. ",
        "answer_pt":"a longa dura\u00e7\u00e3o e as habilidades altamente especializadas exigidas dos t\u00e9cnicos para processar as amostras.",
        "id":"3663",
        "question":"What is the limitation in virus testing?",
        "question_pt":"Qual \u00e9 a limita\u00e7\u00e3o no teste de v\u00edrus?"
    },
    {
        "answer":"Significantly shorted time from the disease onset to the symptom improvement in treatment (5.10 \u00b1 2.83 days) compared to control group (7.62 \u00b1 2.27 days) (p < 0.05) No significant difference in blood routine improvement, pulmonary chest shadow in chest film improvement and corticosteroid usgae between the 2 groups. ",
        "answer_pt":"Tempo significativamente reduzido desde o in\u00edcio da doen\u00e7a at\u00e9 a melhora dos sintomas no tratamento (5,10 \u00b1 2,83 dias) em compara\u00e7\u00e3o com o grupo controle (7,62 \u00b1 2,27 dias) (p <0,05). usgas corticoster\u00f3ides entre os 2 grupos.",
        "id":"3664",
        "question":"What was the result of the treatment?",
        "question_pt":"Qual foi o resultado do tratamento?"
    },
    {
        "answer":"in the respect of improving clinical symptoms, elevating quality of life, promoting immune function recovery, promoting absorption of pulmonary inflammation, reducing the dosage of cortisteroid and shortening the therapeutic course",
        "answer_pt":"no que diz respeito a melhorar os sintomas cl\u00ednicos, elevar a qualidade de vida, promover a recupera\u00e7\u00e3o da fun\u00e7\u00e3o imune, promover a absor\u00e7\u00e3o da inflama\u00e7\u00e3o pulmonar, reduzir a dose de cortister\u00f3ide e encurtar o curso terap\u00eautico",
        "id":"3665",
        "question":"What  superiority did the treatment with integrative chinese and western medicine treatment have compared with using control treatment alone?",
        "question_pt":"Que superioridade o tratamento com medicina integrativa e medicina ocidental e ocidental comparou com o uso de tratamento controle sozinho?"
    },
    {
        "answer":"have higher and more prolonged levels of viral RNA because of the tropism of the virus. ",
        "answer_pt":"t\u00eam n\u00edveis mais altos e mais prolongados de RNA viral por causa do tropismo do v\u00edrus.",
        "id":"3666",
        "question":" What was a characteristic of  SARS-CoV and MERS-CoV, specimens collected from the lower respiratory tract such as sputum and tracheal aspirates?",
        "question_pt":"Qual era a caracter\u00edstica de SARS-CoV e MERS-CoV, amostras coletadas do trato respirat\u00f3rio inferior, como expectora\u00e7\u00e3o e aspirados traqueais?"
    },
    {
        "answer":"viral loads are also higher for severe cases and have longer viral shedding compared to mild cases",
        "answer_pt":"as cargas virais tamb\u00e9m s\u00e3o mais altas em casos graves e t\u00eam maior derramamento viral em compara\u00e7\u00e3o com casos leves",
        "id":"3667",
        "question":"How do severe cases compare with mild cases?",
        "question_pt":"Como os casos graves se comparam aos casos leves?"
    },
    {
        "answer":"hey have potentially lower viral loads and may have higher risk of false-negatives among the mild MERS and SARS cases [102, 103] , and likely among the 2019-nCoV cases.\n",
        "answer_pt":"Eles t\u00eam cargas virais potencialmente mais baixas e podem ter maior risco de falso-negativos entre os casos leves de MERS e SARS [102, 103] e provavelmente entre os casos de 2019-nCoV.",
        "id":"3668",
        "question":"What is the disadvantage of upper respiratory tract specimens?",
        "question_pt":"Qual \u00e9 a desvantagem das amostras do trato respirat\u00f3rio superior?"
    },
    {
        "answer":"(a) reverse transcription-polymerase chain reaction (RT-PCR), (b) real-time RT-PCR (rRT-PCR), (c) reverse transcription loop-mediated isothermal amplification (RT-LAMP) and (d) real-time RT-LAMP [104] . ",
        "answer_pt":"(a) rea\u00e7\u00e3o em cadeia da polimerase com transcri\u00e7\u00e3o reversa (RT-PCR), (b) RT-PCR em tempo real (rRT-PCR), (c) amplifica\u00e7\u00e3o isot\u00e9rmica mediada por loop de transcri\u00e7\u00e3o reversa (RT-LAMP) e (d) real RT-LAMP de tempo [104].",
        "id":"3669",
        "question":"What  are the existing practices in detecting  genetic material of viruses?",
        "question_pt":"Quais s\u00e3o as pr\u00e1ticas existentes na detec\u00e7\u00e3o de material gen\u00e9tico de v\u00edrus?"
    },
    {
        "answer":"it has the highest sensitivity at the earliest time point in the acute phase of infection ",
        "answer_pt":"tem a maior sensibilidade no momento mais precoce da fase aguda da infec\u00e7\u00e3o",
        "id":"3670",
        "question":"Why are Nucleic amplification tests (NAAT) usually preferred as in the case of MERS-CoV diagnosis?",
        "question_pt":"Por que os testes de amplifica\u00e7\u00e3o nuclear (NAAT) geralmente s\u00e3o preferidos, como no caso do diagn\u00f3stico MERS-CoV?"
    },
    {
        "answer":" in Germany",
        "answer_pt":"Na Alemanha",
        "id":"3671",
        "question":"Where  was the first validated diagnostic test designed?",
        "question_pt":"Onde foi projetado o primeiro teste de diagn\u00f3stico validado?"
    },
    {
        "answer":"based on the match against 2019-nCoV upon inspection of the sequence alignment. ",
        "answer_pt":"com base na partida contra 2019-nCoV ap\u00f3s a inspe\u00e7\u00e3o do alinhamento da sequ\u00eancia.",
        "id":"3672",
        "question":"How were the assays selected ?",
        "question_pt":"Como foram selecionados os ensaios?"
    },
    {
        "answer":"Two assays were used for the RNA dependent RNA polymerase (RdRP) gene and E gene where E gene assay acts as the first-line screening tool and RdRp gene assay as the confirmatory testing. ",
        "answer_pt":"Foram utilizados dois ensaios para o gene da RNA polimerase dependente de RNA (RdRP) e o gene E, onde o ensaio do gene E atua como a ferramenta de triagem de primeira linha e o ensaio do gene RdRp como teste confirmat\u00f3rio.",
        "id":"3673",
        "question":"How  were the assays used?",
        "question_pt":"Como foram utilizados os ensaios?"
    },
    {
        "answer":"All assays were highly sensitive and specific in that they did not cross-react with other coronavirus and also human clinical samples that contained respiratory viruses ",
        "answer_pt":"Todos os ensaios foram altamente sens\u00edveis e espec\u00edficos, pois n\u00e3o reagiram com outros coronav\u00edrus e tamb\u00e9m com amostras cl\u00ednicas humanas que continham v\u00edrus respirat\u00f3rios",
        "id":"3674",
        "question":"What were the results?",
        "question_pt":"Quais foram os resultados?"
    },
    {
        "answer":" to be safe and well-tolerated at single doses.",
        "answer_pt":"ser seguro e bem tolerado em doses \u00fanicas.",
        "id":"3691",
        "question":"What did the trial on SAB-301 demonstrate?",
        "question_pt":"O que o julgamento no SAB-301 demonstrou?"
    },
    {
        "answer":"mild skin infections to fatal necrotizing pneumonia",
        "answer_pt":"infec\u00e7\u00f5es de pele leves a pneumonia necrosante fatal",
        "id":"5175",
        "question":"What conditions are caused by Staphylococcus aureus?",
        "question_pt":"Quais s\u00e3o as condi\u00e7\u00f5es causadas pelo Staphylococcus aureus?"
    },
    {
        "answer":"8-30%",
        "answer_pt":"8-30%",
        "id":"5176",
        "question":"What percentage of healthy adults are asymptotically colonized by pneumococcus bacteria?",
        "question_pt":"Que porcentagem de adultos saud\u00e1veis \u200b\u200b\u00e9 colonizada assintoticamente por bact\u00e9rias pneumococos?"
    },
    {
        "answer":"alveolar macrophages",
        "answer_pt":"macr\u00f3fagos alveolares",
        "id":"5177",
        "question":"What types of cells follow epithelial cells in the immune response to infections in the lung?",
        "question_pt":"Que tipos de c\u00e9lulas seguem c\u00e9lulas epiteliais na resposta imune a infec\u00e7\u00f5es nos pulm\u00f5es?"
    },
    {
        "answer":"The subsequent infection with Gram-positive bacteria",
        "answer_pt":"A infec\u00e7\u00e3o subsequente por bact\u00e9rias Gram-positivas",
        "id":"5178",
        "question":"What enhances the expression of type I interferon?",
        "question_pt":"O que melhora a express\u00e3o do interferon tipo I?"
    },
    {
        "answer":"Reduced TNF\u03b1 production by NK cells",
        "answer_pt":"Produ\u00e7\u00e3o reduzida de TNF\u03b1 pelas c\u00e9lulas NK",
        "id":"5179",
        "question":"What reduces the antimicrobial activities of alveolar macrophages?",
        "question_pt":"O que reduz as atividades antimicrobianas dos macr\u00f3fagos alveolares?"
    },
    {
        "answer":"a pneumococcal pore-forming toxin",
        "answer_pt":"uma toxina pneumoc\u00f3cica formadora de poros",
        "id":"5180",
        "question":"What is Pneumolysin?",
        "question_pt":"O que \u00e9 pneumolisina?"
    },
    {
        "answer":"epithelial barrier damage, exaggerated innate immune response, and cytokine storm",
        "answer_pt":"dano epitelial da barreira, resposta imune inata exagerada e tempestade de citocinas",
        "id":"5181",
        "question":"What factors make bacterial and viral co-infections so lethal?",
        "question_pt":"Quais fatores tornam as co-infec\u00e7\u00f5es bacterianas e virais t\u00e3o letais?"
    },
    {
        "answer":"engineered, non-lytic, filamentous bacteriophages",
        "answer_pt":"bacteri\u00f3fagos filamentosos n\u00e3o-l\u00edticos e de engenharia",
        "id":"325",
        "question":"What are inovirus-associated vectors?",
        "question_pt":"O que s\u00e3o vetores associados a inov\u00edrus?"
    },
    {
        "answer":"the identification of peptide ligands by receptors, the mapping of substrate sites for enzymes, and the creation of antibody peptide libraries",
        "answer_pt":"a identifica\u00e7\u00e3o de ligantes pept\u00eddicos por receptores, o mapeamento de locais de substratos para enzimas e a cria\u00e7\u00e3o de bibliotecas pept\u00eddicas de anticorpos",
        "id":"326",
        "question":"How can random peptide libraries be used in applications?",
        "question_pt":"Como as bibliotecas pept\u00eddicas aleat\u00f3rias podem ser usadas em aplicativos?"
    },
    {
        "answer":"pgsA-sM2/L. casei",
        "answer_pt":"pgsA-sM2 / L. casei",
        "id":"5182",
        "question":"Which Lactobacililus casei strain does not have the cholera toxin subunit A1 (CTA1) on the surface?",
        "question_pt":"Qual linhagem de Lactobacililus casei n\u00e3o possui a subunidade A1 da toxina do c\u00f3lera (CTA1) na superf\u00edcie?"
    },
    {
        "answer":"Vaccination",
        "answer_pt":"Vacina\u00e7\u00e3o",
        "id":"5183",
        "question":"What is the most effective treatment against influenza?",
        "question_pt":"Qual \u00e9 o tratamento mais eficaz contra a gripe?"
    },
    {
        "answer":"75%",
        "answer_pt":"75%",
        "id":"5184",
        "question":"What is the percentage decrease in influenza antibodies after 8 months after inoculation with the inactivated vaccine?",
        "question_pt":"Qual \u00e9 a redu\u00e7\u00e3o percentual nos anticorpos contra influenza ap\u00f3s 8 meses ap\u00f3s a inocula\u00e7\u00e3o com a vacina inativada?"
    },
    {
        "answer":"highly conserved among influenza A virus strains",
        "answer_pt":"altamente conservado entre as cepas do v\u00edrus influenza A",
        "id":"5185",
        "question":"Why is matrix protein 2 (M2) an attractive target for a universal influenza vaccine?",
        "question_pt":"Por que a prote\u00edna 2 da matriz (M2) \u00e9 um alvo atraente para uma vacina universal contra influenza?"
    },
    {
        "answer":"low immunogenicity",
        "answer_pt":"baixa imunogenicidade",
        "id":"5186",
        "question":"Why have M2-based vaccines been ineffective?",
        "question_pt":"Por que as vacinas baseadas em M2 foram ineficazes?"
    },
    {
        "answer":"considered safe and exhibits an adjuvant-like effect on mucosal and systemic immunity",
        "answer_pt":"considerado seguro e apresenta um efeito adjuvante na imunidade mucosa e sist\u00eamica",
        "id":"5187",
        "question":"Why are lactic acid bacteria considered an attractive delivery system for a live influenza vaccine?",
        "question_pt":"Por que as bact\u00e9rias do \u00e1cido l\u00e1tico s\u00e3o consideradas um sistema de entrega atraente para uma vacina viva contra influenza?"
    },
    {
        "answer":"59-GGGGTACCTCATTATTAACA-39, and 59-ACGTCGACT-CATTATTCAAGTTCAATAATG AC-39",
        "answer_pt":"59-GGGGTACCTCATTATTAACA-39 e 59-ACGTCGACT-CATTATTCAAGTTCAATAATG AC-39",
        "id":"5188",
        "question":"What primer pairs were used for PCR?",
        "question_pt":"Quais pares de iniciadores foram usados \u200b\u200bpara PCR?"
    },
    {
        "answer":"the incorporation of an adjuvant",
        "answer_pt":"a incorpora\u00e7\u00e3o de um adjuvante",
        "id":"5189",
        "question":"What is considered essential to boost the interaction of the influenza vaccine with the mucosal immune system?",
        "question_pt":"O que \u00e9 considerado essencial para aumentar a intera\u00e7\u00e3o da vacina contra influenza com o sistema imunol\u00f3gico da mucosa?"
    },
    {
        "answer":"liposomes, nanoparticles, and immunostimulating complexes (ISCOMs)",
        "answer_pt":"lipossomas, nanopart\u00edculas e complexos imunoestimulantes (ISCOMs)",
        "id":"5190",
        "question":"Name some adjuvants that have been used with an influenza vaccine.",
        "question_pt":"Cite alguns adjuvantes que foram usados \u200b\u200bcom uma vacina contra influenza."
    },
    {
        "answer":"severe pneumonitis",
        "answer_pt":"pneumonite grave",
        "id":"5191",
        "question":"What was found in the lungs of the control mice in this study?",
        "question_pt":"O que foi encontrado nos pulm\u00f5es dos ratos controle neste estudo?"
    },
    {
        "answer":"recombinant L. casei expressing CTA1-sM2 induced long-lasting immunity and conferred protection against lethal infections by influenza",
        "answer_pt":"L. casei recombinante que expressa CTA1-sM2 induziu imunidade duradoura e conferiu prote\u00e7\u00e3o contra infec\u00e7\u00f5es letais por influenza",
        "id":"5192",
        "question":"What did this study show?",
        "question_pt":"O que este estudo mostrou?"
    },
    {
        "answer":"Nod-like receptor family, pyrin domain-containing 3",
        "answer_pt":"Fam\u00edlia de receptores do tipo nod, contendo 3 dom\u00ednios de pirina",
        "id":"279",
        "question":"What regulates the secretion of proinflammatory cytokines?",
        "question_pt":"O que regula a secre\u00e7\u00e3o de citocinas pr\u00f3-inflamat\u00f3rias?"
    },
    {
        "answer":"in lipopolysaccharide-primed macrophages",
        "answer_pt":"em macr\u00f3fagos iniciados por lipopolissacar\u00eddeos",
        "id":"280",
        "question":"Where does the NLRP3 inflammasome activate after a SARS-CoV infection?",
        "question_pt":"Onde o inflamassoma NLRP3 \u00e9 ativado ap\u00f3s uma infec\u00e7\u00e3o por SARS-CoV?"
    },
    {
        "answer":"ion channel activity of the 3a protein",
        "answer_pt":"atividade do canal i\u00f4nico da prote\u00edna 3a",
        "id":"281",
        "question":"What ion channel is essential for 3a-mediated IL-1Beta secretion?",
        "question_pt":"Qual canal i\u00f4nico \u00e9 essencial para a secre\u00e7\u00e3o de IL-1Beta mediada por 3a?"
    },
    {
        "answer":"transmembrane pore-forming viral proteins",
        "answer_pt":"prote\u00ednas virais formadoras de poros transmembranares",
        "id":"282",
        "question":"What are viroporins?",
        "question_pt":"O que s\u00e3o viroporinas?"
    },
    {
        "answer":"Betacoronavirus",
        "answer_pt":"Betacoronav\u00edrus",
        "id":"283",
        "question":"What is the genus of the SARS coronavirus?",
        "question_pt":"Qual \u00e9 o g\u00eanero do coronav\u00edrus SARS?"
    },
    {
        "answer":"Coronaviridae",
        "answer_pt":"Coronaviridae",
        "id":"284",
        "question":"What is the family of the SARS coronavirus?",
        "question_pt":"Qual \u00e9 a fam\u00edlia do coronav\u00edrus SARS?"
    },
    {
        "answer":"enveloped",
        "answer_pt":"envelope",
        "id":"285",
        "question":"Is the SARS coronavirus enveloped?",
        "question_pt":"O coronav\u00edrus SARS est\u00e1 envolto?"
    },
    {
        "answer":"single-stranded",
        "answer_pt":"fita simples",
        "id":"287",
        "question":"Is the SARS coronavirus single-stranded or double-stranded?",
        "question_pt":"O coronav\u00edrus SARS \u00e9 de fita simples ou dupla?"
    },
    {
        "answer":"At least 8,098",
        "answer_pt":"Pelo menos 8.098",
        "id":"288",
        "question":"How many laboratory-confirmed cases of SARS coronavirus infections were reported between November 2002 and July 2003?",
        "question_pt":"Quantos casos confirmados em laborat\u00f3rio de infec\u00e7\u00f5es por coronav\u00edrus por SARS foram relatados entre novembro de 2002 e julho de 2003?"
    },
    {
        "answer":"9.6%",
        "answer_pt":"9,6%",
        "id":"289",
        "question":"What was the fatality rate of the SARS coronavirus outbreak between November 2002 and July 2003?",
        "question_pt":"Qual foi a taxa de mortalidade do surto de coronav\u00edrus da SARS entre novembro de 2002 e julho de 2003?"
    },
    {
        "answer":"tumor necrosis factor (TNF)-\u03b1, interleukin (IL)-1\u03b2, and IL-6",
        "answer_pt":"fator de necrose tumoral (TNF) -\u03b1, interleucina (IL) -1\u03b2 e IL-6",
        "id":"290",
        "question":"What are examples of proinflammatory cytokines?",
        "question_pt":"Quais s\u00e3o os exemplos de citocinas pr\u00f3-inflamat\u00f3rias?"
    },
    {
        "answer":"by sensing the cellular damage or distress induced by viroporins",
        "answer_pt":"detectando o dano ou sofrimento celular induzido pelas viroporinas",
        "id":"292",
        "question":"How does NLRP3 detect RNA viral infection?",
        "question_pt":"Como o NLRP3 detecta a infec\u00e7\u00e3o viral por RNA?"
    },
    {
        "answer":"76 amino acids",
        "answer_pt":"76 amino\u00e1cidos",
        "id":"293",
        "question":"How many amino acids are in the SARS-CoV E protein?",
        "question_pt":"Quantos amino\u00e1cidos existem na prote\u00edna SARS-CoV E?"
    },
    {
        "answer":"Ca 2+ -permeable",
        "answer_pt":"Perme\u00e1vel ao Ca 2+",
        "id":"294",
        "question":"What type of ion channels are formed by the SARS-CoV E protein?",
        "question_pt":"Que tipo de canais i\u00f4nicos s\u00e3o formados pela prote\u00edna SARS-CoV E?"
    },
    {
        "answer":"NLRP3 inflammasome",
        "answer_pt":"Inflamassoma NLRP3",
        "id":"296",
        "question":"What does the SARS-CoV protein activate?",
        "question_pt":"O que a prote\u00edna SARS-CoV ativa?"
    },
    {
        "answer":"tumor necrosis factor-\u03b1",
        "answer_pt":"fator de necrose tumoral-\u03b1",
        "id":"887",
        "question":"What is critical to the development of a protective granuloma in tuberculosis infections?",
        "question_pt":"O que \u00e9 cr\u00edtico para o desenvolvimento de um granuloma protetor nas infec\u00e7\u00f5es por tuberculose?"
    },
    {
        "answer":"cytokines",
        "answer_pt":"citocinas",
        "id":"888",
        "question":"What is tumor necrosis factor-alpha?",
        "question_pt":"O que \u00e9 fator de necrose tumoral alfa?"
    },
    {
        "answer":"MAPK phosphatase-1",
        "answer_pt":"MAPK fosfatase-1",
        "id":"889",
        "question":"What regulates the activity of MAPK activity?",
        "question_pt":"O que regula a atividade da atividade MAPK?"
    },
    {
        "answer":"Mycobacterium tuberculosis",
        "answer_pt":"Mycobacterium tuberculosis",
        "id":"890",
        "question":"What causes tuberculosis?",
        "question_pt":"O que causa a tuberculose?"
    },
    {
        "answer":"one third of the world's population",
        "answer_pt":"um ter\u00e7o da popula\u00e7\u00e3o mundial",
        "id":"891",
        "question":"What percentage of the world has been infected by tuberculosis?",
        "question_pt":"Que porcentagem do mundo foi infectada pela tuberculose?"
    },
    {
        "answer":"9.2 million",
        "answer_pt":"9,2 milh\u00f5es",
        "id":"892",
        "question":"How many new tuberculosis cases are there each year worldwide?",
        "question_pt":"Quantos novos casos de tuberculose ocorrem anualmente em todo o mundo?"
    },
    {
        "answer":"extracellular signal-regulated kinase 1 and 2 (ERK1/2), p38 MAPK, and c-Jun N-terminal kinase (JNK)",
        "answer_pt":"quinase 1 e 2 regulada por sinal extracelular (ERK1 / 2), p38 MAPK e c-Jun N-terminal kinase (JNK)",
        "id":"893",
        "question":"What are some mitogen activated protein kinases?",
        "question_pt":"Quais s\u00e3o algumas das prote\u00ednas quinases ativadas por mitog\u00eanio?"
    },
    {
        "answer":"phosphorylation",
        "answer_pt":"fosforila\u00e7\u00e3o",
        "id":"894",
        "question":"How is MAPK activated?",
        "question_pt":"Como o MAPK \u00e9 ativado?"
    },
    {
        "answer":"tyrosine phosphatases, serine/threonine phosphatases, and dual-specificity phosphatases (DUSPs)",
        "answer_pt":"tirosina fosfatases, serina / treonina fosfatases e fosfatases de dupla especificidade (DUSPs)",
        "id":"895",
        "question":"What enzymes are involved with phosphorylation?",
        "question_pt":"Quais enzimas est\u00e3o envolvidas na fosforila\u00e7\u00e3o?"
    },
    {
        "answer":"at least 10",
        "answer_pt":"pelo menos 10",
        "id":"896",
        "question":"How many MAPK phosphatases exist?",
        "question_pt":"Quantas fosfatases MAPK existem?"
    },
    {
        "answer":"a cell wall component of Gram-negative bacteria",
        "answer_pt":"um componente da parede celular de bact\u00e9rias Gram-negativas",
        "id":"897",
        "question":"What is lipopolysaccharide?",
        "question_pt":"O que \u00e9 lipopolissacar\u00eddeo?"
    },
    {
        "answer":"Gram positive bacteria",
        "answer_pt":"Bact\u00e9rias Gram-positivas",
        "id":"898",
        "question":"What is Staph aureus?",
        "question_pt":"O que \u00e9 Staph aureus?"
    },
    {
        "answer":"MAPK",
        "answer_pt":"MAPK",
        "id":"899",
        "question":"What protein is in the critical path of immunity and cytokine expression?",
        "question_pt":"Qual prote\u00edna est\u00e1 no caminho cr\u00edtico da imunidade e express\u00e3o de citocinas?"
    },
    {
        "answer":"Constant evolution of circulating influenza virus strains and the emergence of new strains",
        "answer_pt":"Evolu\u00e7\u00e3o constante das cepas circulantes do v\u00edrus influenza e surgimento de novas cepas",
        "id":"1241",
        "question":"What diminishes the effectiveness of annual influenza vaccinations?",
        "question_pt":"O que diminui a efic\u00e1cia das vacinas anuais contra influenza?"
    },
    {
        "answer":"efficacious vaccines conferring cross-clade protection to avoid the need for biannual reformulation of seasonal influenza vaccines.",
        "answer_pt":"vacinas eficazes que conferem prote\u00e7\u00e3o cruzada para evitar a necessidade de reformula\u00e7\u00e3o semestral de vacinas sazonais contra influenza.",
        "id":"1242",
        "question":"what new  type of influenza vaccines are needed?",
        "question_pt":"que novo tipo de vacina contra influenza \u00e9 necess\u00e1ria?"
    },
    {
        "answer":"Recombinant virus-vectored vaccines",
        "answer_pt":"Vacinas recombinantes vetorizadas por v\u00edrus",
        "id":"1243",
        "question":"What alternatives to classical vectored vaccines are needed?",
        "question_pt":"Que alternativas \u00e0s vacinas vetorizadas cl\u00e1ssicas s\u00e3o necess\u00e1rias?"
    },
    {
        "answer":"a vectored vaccine often enables delivery of the vaccine to sites of inductive immunity such as the respiratory tract ",
        "answer_pt":"uma vacina vetorizada geralmente permite a entrega da vacina a locais de imunidade indutiva, como o trato respirat\u00f3rio",
        "id":"1244",
        "question":"What is the advantage of virus vectored vaccine?",
        "question_pt":"Qual \u00e9 a vantagem da vacina vetorizada por v\u00edrus?"
    },
    {
        "answer":" virus vectors enable native expression of influenza antigens, even from virulent influenza viruses, while expressed in the context of the vector that can improve immunogenicity. ",
        "answer_pt":"os vetores de v\u00edrus permitem a express\u00e3o nativa de ant\u00edgenos da influenza, mesmo a partir de v\u00edrus virulentos da gripe, enquanto expressos no contexto do vetor que pode melhorar a imunogenicidade.",
        "id":"1245",
        "question":"What is the advantage of virus vectored vaccines?",
        "question_pt":"Qual \u00e9 a vantagem das vacinas vetorizadas por v\u00edrus?"
    },
    {
        "answer":" low efficacy in the populations at greatest risk of complications from influenza virus infection, i.e., the young and elderly",
        "answer_pt":"baixa efic\u00e1cia nas popula\u00e7\u00f5es com maior risco de complica\u00e7\u00f5es da infec\u00e7\u00e3o pelo v\u00edrus influenza, ou seja, jovens e idosos",
        "id":"1246",
        "question":"What is one of the issues with present vaccines?",
        "question_pt":"Qual \u00e9 um dos problemas das vacinas atuais?"
    },
    {
        "answer":"trivalent inactivated influenza vaccine (TIV), quadrivalent influenza vaccine (QIV), and live attenuated influenza vaccine (LAIV; in trivalent and quadrivalent forms)",
        "answer_pt":"vacina trivalente inativada contra influenza (TIV), vacina quadrivalente contra influenza (QIV) e vacina viva contra influenza atenuada (LAIV; em formas trivalentes e quadrivalentes)",
        "id":"1247",
        "question":"What general types of vaccines are available?",
        "question_pt":"Quais tipos gerais de vacinas est\u00e3o dispon\u00edveis?"
    },
    {
        "answer":"whole virus inactivated, split virus inactivated, and subunit vaccines.",
        "answer_pt":"vacinas inativadas por v\u00edrus inteiro, inativadas por v\u00edrus dividido e subunidades.",
        "id":"1248",
        "question":"What inactivated vaccines are available?",
        "question_pt":"Quais vacinas inativadas est\u00e3o dispon\u00edveis?"
    },
    {
        "answer":"the virus is disrupted by a detergent",
        "answer_pt":"o v\u00edrus \u00e9 interrompido por um detergente",
        "id":"1254",
        "question":"How is the split virus inactivated?",
        "question_pt":"Como o v\u00edrus dividido \u00e9 inativado?"
    },
    {
        "answer":"intramuscularly ",
        "answer_pt":"por via intramuscular",
        "id":"1257",
        "question":"How is the TIV administered?",
        "question_pt":"Como o TIV \u00e9 administrado?"
    },
    {
        "answer":" three or four inactivated viruses, i.e., two type A strains (H1 and H3) and one or two type B strains. ",
        "answer_pt":"tr\u00eas ou quatro v\u00edrus inativados, isto \u00e9, duas cepas do tipo A (H1 e H3) e uma ou duas cepas do tipo B.",
        "id":"1259",
        "question":"What does the TIV contain?",
        "question_pt":"O que cont\u00e9m o TIV?"
    },
    {
        "answer":"humoral responses to the hemagglutinin (HA) protein,",
        "answer_pt":"respostas humorais \u00e0 prote\u00edna hemaglutinina (HA),",
        "id":"1261",
        "question":"How is the TIV efficacy measured?",
        "question_pt":"Como \u00e9 medida a efic\u00e1cia do TIV?"
    },
    {
        "answer":"hemagglutinin (HA) protein,",
        "answer_pt":"prote\u00edna hemaglutinina (HA),",
        "id":"1264",
        "question":"Which is the major surface and attachment glycoprotein on influenza virus?",
        "question_pt":"Qual \u00e9 a principal glicoprote\u00edna de superf\u00edcie e liga\u00e7\u00e3o ao v\u00edrus influenza?"
    },
    {
        "answer":" by the hemagglutination-inhibition (HI) assay,",
        "answer_pt":"pelo ensaio de inibi\u00e7\u00e3o da hemaglutina\u00e7\u00e3o (HI),",
        "id":"1472",
        "question":"How is the serum antibody response measured?",
        "question_pt":"Como \u00e9 medida a resposta de anticorpos s\u00e9ricos?"
    },
    {
        "answer":"strain-specific HI titer ",
        "answer_pt":"t\u00edtulo HI para estirpes espec\u00edficas",
        "id":"1473",
        "question":"What is a gold standard for correlation with immunity to influenza?",
        "question_pt":"O que \u00e9 um padr\u00e3o-ouro para correla\u00e7\u00e3o com imunidade \u00e0 influenza?"
    },
    {
        "answer":" a four-fold increase in titer post-vaccination, or a HI titer of \u22651:40 is considered protective ",
        "answer_pt":"um aumento de quatro vezes no t\u00edtulo ap\u00f3s a vacina\u00e7\u00e3o ou um t\u00edtulo HI de \u22651: 40 \u00e9 considerado protetor",
        "id":"1474",
        "question":"What is the indication for protection to influenza?",
        "question_pt":"Qual \u00e9 a indica\u00e7\u00e3o para prote\u00e7\u00e3o da gripe?"
    },
    {
        "answer":"serum antibodies",
        "answer_pt":"anticorpos s\u00e9ricos",
        "id":"1475",
        "question":"What gives protection against clinical disease?",
        "question_pt":"O que oferece prote\u00e7\u00e3o contra doen\u00e7as cl\u00ednicas?"
    },
    {
        "answer":"mucosal IgA antibodies also may contribute to resistance against infection",
        "answer_pt":"anticorpos IgA da mucosa tamb\u00e9m podem contribuir para a resist\u00eancia contra a infec\u00e7\u00e3o",
        "id":"1476",
        "question":"What can give protection against clinical disease?",
        "question_pt":"O que pode dar prote\u00e7\u00e3o contra doen\u00e7as cl\u00ednicas?"
    },
    {
        "answer":"nasal spray",
        "answer_pt":"spray nasal",
        "id":"1477",
        "question":"How is the LAIV administered?",
        "question_pt":"Como o LAIV \u00e9 administrado?"
    },
    {
        "answer":"the same three or four influenza virus strains as inactivated vaccines but on an attenuated vaccine backbone ",
        "answer_pt":"as mesmas tr\u00eas ou quatro cepas do v\u00edrus influenza que as vacinas inativadas, mas em uma espinha dorsal da vacina atenuada",
        "id":"1478",
        "question":"What does the LAIV contain?",
        "question_pt":"O que cont\u00e9m a LAIV?"
    },
    {
        "answer":"they do not replicate effectively at core body temperature",
        "answer_pt":"eles n\u00e3o se replicam efetivamente \u00e0 temperatura corporal central",
        "id":"1480",
        "question":"Do LAIV replicate at body temperature?",
        "question_pt":"O LAIV se replica \u00e0 temperatura corporal?"
    },
    {
        "answer":"LAIV are temperature-sensitive and cold-adapted ",
        "answer_pt":"A LAIV \u00e9 sens\u00edvel \u00e0 temperatura e adaptada ao frio",
        "id":"1481",
        "question":"What is a characteristic of LAIV?",
        "question_pt":"O que \u00e9 uma caracter\u00edstica da LAIV?"
    },
    {
        "answer":"replicate in the mucosa of the nasopharynx",
        "answer_pt":"replicar na mucosa da nasofaringe",
        "id":"1482",
        "question":"Where do the LAIV replicate?",
        "question_pt":"Onde a LAIV se replica?"
    },
    {
        "answer":"LAIV immunization induces serum antibody responses, mucosal antibody responses (IgA), and T cell responses.",
        "answer_pt":"A imuniza\u00e7\u00e3o com LAIV induz respostas s\u00e9ricas de anticorpos, respostas de anticorpos da mucosa (IgA) e c\u00e9lulas T.",
        "id":"1483",
        "question":"What does LAIV immunization do?",
        "question_pt":"O que a imuniza\u00e7\u00e3o com LAIV faz?"
    },
    {
        "answer":"specific antibody responses to the HA, and to a lesser extent NA proteins for protection.",
        "answer_pt":"respostas de anticorpos espec\u00edficos ao HA e, em menor grau, \u00e0s prote\u00ednas NA para prote\u00e7\u00e3o.",
        "id":"1484",
        "question":"What do the inactivated vaccines rely on?",
        "question_pt":"Em que se baseiam as vacinas inativadas?"
    },
    {
        "answer":"The immunodominant portions of the HA and NA molecules undergo a constant process of antigenic drift, a natural accumulation of mutations",
        "answer_pt":"As por\u00e7\u00f5es imunodominantes das mol\u00e9culas de HA e NA passam por um processo constante de deriva antig\u00eanica, um ac\u00famulo natural de muta\u00e7\u00f5es",
        "id":"1485",
        "question":"What enables virus invasion from immunity?",
        "question_pt":"O que permite a invas\u00e3o de v\u00edrus da imunidade?"
    },
    {
        "answer":"in February",
        "answer_pt":"em fevereiro",
        "id":"1486",
        "question":"When does the vaccine strain selection occur in the northern hemisphere?",
        "question_pt":"Quando a sele\u00e7\u00e3o da cepa vacinal ocorre no hemisf\u00e9rio norte?"
    },
    {
        "answer":"it is generally considered to be as effective as inactivated vaccines and may be more efficacious in children ",
        "answer_pt":"geralmente \u00e9 considerado t\u00e3o eficaz quanto as vacinas inativadas e pode ser mais eficaz em crian\u00e7as",
        "id":"1487",
        "question":"What is the efficacy of LAIV?",
        "question_pt":"Qual \u00e9 a efic\u00e1cia da LAIV?"
    },
    {
        "answer":"antigenic match",
        "answer_pt":"correspond\u00eancia antig\u00eanica",
        "id":"1488",
        "question":"What does LAIV rely on?",
        "question_pt":"Em que o LAIV depende?"
    },
    {
        "answer":" the HA and NA antigens are replaced on the same schedule as the TIV",
        "answer_pt":"os ant\u00edgenos HA e NA s\u00e3o substitu\u00eddos no mesmo hor\u00e1rio que o TIV",
        "id":"1489",
        "question":"What is the LAIV replacement schedule?",
        "question_pt":"Qual \u00e9 o cronograma de substitui\u00e7\u00e3o do LAIV?"
    },
    {
        "answer":"due to the diversity of the immune response consistent with inducing virus-neutralizing serum and mucosal antibodies, as well as broadly reactive T cell responses",
        "answer_pt":"devido \u00e0 diversidade da resposta imune consistente com a indu\u00e7\u00e3o de anticorpos s\u00e9ricos e mucosos neutralizantes de v\u00edrus, bem como respostas de c\u00e9lulas T amplamente reativas",
        "id":"1490",
        "question":"Why LAIV may provide broader broader  protection than TIV?",
        "question_pt":"Por que o LAIV pode fornecer prote\u00e7\u00e3o mais ampla que o TIV?"
    },
    {
        "answer":"improved understanding of immunity to conserved influenza virus antigens",
        "answer_pt":"melhor compreens\u00e3o da imunidade a ant\u00edgenos conservados do v\u00edrus influenza",
        "id":"1491",
        "question":"What has raised the possibility of universal influenza vaccine?",
        "question_pt":"O que levantou a possibilidade da vacina universal contra influenza?"
    },
    {
        "answer":"allow ready manipulation and modification of the vector genome",
        "answer_pt":"permite pronta manipula\u00e7\u00e3o e modifica\u00e7\u00e3o do genoma do vetor",
        "id":"1492",
        "question":"What is the advantage of recombinant DNA systems?",
        "question_pt":"Qual \u00e9 a vantagem dos sistemas de DNA recombinante?"
    },
    {
        "answer":"enables modification of the vectors to attenuate the virus or enhance immunogenicity",
        "answer_pt":"permite a modifica\u00e7\u00e3o dos vetores para atenuar o v\u00edrus ou aumentar a imunogenicidade",
        "id":"1493",
        "question":"What is the advantage of recombinant DNA system?",
        "question_pt":"Qual \u00e9 a vantagem do sistema de DNA recombinante?"
    },
    {
        "answer":"adding and manipulating the influenza virus antigens",
        "answer_pt":"adi\u00e7\u00e3o e manipula\u00e7\u00e3o dos ant\u00edgenos do v\u00edrus influenza",
        "id":"1494",
        "question":"What is the advantage of recombinant DNA systems?",
        "question_pt":"Qual \u00e9 a vantagem dos sistemas de DNA recombinante?"
    },
    {
        "answer":"is either replication-defective or causes a self-limiting infection",
        "answer_pt":"tem defeito de replica\u00e7\u00e3o ou causa uma infec\u00e7\u00e3o autolimitada",
        "id":"1495",
        "question":"What is the issue with each of these vaccines?",
        "question_pt":"Qual \u00e9 o problema de cada uma dessas vacinas?"
    },
    {
        "answer":" like LAIV, safety in immunocompromised individuals",
        "answer_pt":"como LAIV, seguran\u00e7a em indiv\u00edduos imunocomprometidos",
        "id":"1496",
        "question":"What is a concern with these vaccines?",
        "question_pt":"O que \u00e9 uma preocupa\u00e7\u00e3o com essas vacinas?"
    },
    {
        "answer":"53 ",
        "answer_pt":"53",
        "id":"1497",
        "question":"How many serotypes of adenovirus are there?",
        "question_pt":"Quantos sorotipos de adenov\u00edrus existem?"
    },
    {
        "answer":" A live adenovirus vaccine containing serotypes 4 and 7 has been in use by the military for decades",
        "answer_pt":"Uma vacina viva contra adenov\u00edrus contendo os sorotipos 4 e 7 tem sido usada pelos militares h\u00e1 d\u00e9cadas",
        "id":"1498",
        "question":"Why adenovirus may be the safest vaccine vector?",
        "question_pt":"Por que o adenov\u00edrus pode ser o vetor de vacina mais seguro?"
    },
    {
        "answer":"Adenovirus 5 (Ad5) ",
        "answer_pt":"Adenov\u00edrus 5 (Ad5)",
        "id":"1501",
        "question":"Which is the most studied serotype?",
        "question_pt":"Qual \u00e9 o sorotipo mais estudado?"
    },
    {
        "answer":"having been tested for gene delivery and anti-cancer agents, as well as for infectious disease vaccines",
        "answer_pt":"tendo sido testado para entrega de genes e agentes antic\u00e2ncer, bem como para vacinas de doen\u00e7as infecciosas",
        "id":"1503",
        "question":"Why is Ad5 is the most studied serotype? ",
        "question_pt":"Por que Ad5 \u00e9 o sorotipo mais estudado?"
    },
    {
        "answer":"their genome is very stable and there are a variety of recombinant systems available which can accommodate up to 10 kb of recombinant genetic material ",
        "answer_pt":"seu genoma \u00e9 muito est\u00e1vel e h\u00e1 uma variedade de sistemas recombinantes dispon\u00edveis que podem acomodar at\u00e9 10 kb de material gen\u00e9tico recombinante",
        "id":"1505",
        "question":"Why are adenovirus vectors most attractive?",
        "question_pt":"Por que os vetores de adenov\u00edrus s\u00e3o mais atraentes?"
    },
    {
        "answer":"is a non-enveloped virus which is relatively stable and can be formulated for long-term storage at 4 \u00b0C, or even storage up to six months at room temperature ",
        "answer_pt":"\u00e9 um v\u00edrus n\u00e3o envelopado que \u00e9 relativamente est\u00e1vel e pode ser formulado para armazenamento a longo prazo a 4 \u00b0 C, ou mesmo armazenamento por at\u00e9 seis meses em temperatura ambiente",
        "id":"1506",
        "question":"What is the advantage of  the adenovirus ?",
        "question_pt":"Qual \u00e9 a vantagem do adenov\u00edrus?"
    },
    {
        "answer":"Adenovirus vaccines can be grown to high titers, exceeding 10 1\u00b0 plaque forming units (PFU) per mL when cultured on 293 or PER.C6 cells ",
        "answer_pt":"As vacinas contra adenov\u00edrus podem ser cultivadas em altos t\u00edtulos, excedendo 10 unidades de forma\u00e7\u00e3o de placa (PFU) por mL quando cultivadas em c\u00e9lulas 293 ou PER.C6",
        "id":"1507",
        "question":"What is the advantage of adenovirus vector?",
        "question_pt":"Qual \u00e9 a vantagem do vetor adenov\u00edrus?"
    },
    {
        "answer":"the virus can be purified by simple methods ",
        "answer_pt":"o v\u00edrus pode ser purificado por m\u00e9todos simples",
        "id":"1508",
        "question":"What is the advantage of adenovirus?",
        "question_pt":"Qual \u00e9 a vantagem do adenov\u00edrus?"
    },
    {
        "answer":" Adenovirus vaccines can also be delivered via multiple routes, including intramuscular injection, subcutaneous injection, intradermal injection, oral delivery using a protective capsule, and by intranasal delivery.",
        "answer_pt":"As vacinas contra adenov\u00edrus tamb\u00e9m podem ser administradas por v\u00e1rias vias, incluindo inje\u00e7\u00e3o intramuscular, inje\u00e7\u00e3o subcut\u00e2nea, inje\u00e7\u00e3o intrad\u00e9rmica, administra\u00e7\u00e3o oral usando uma c\u00e1psula protetora e administra\u00e7\u00e3o intranasal.",
        "id":"1509",
        "question":"What is the advantage of adenovirus vaccines?",
        "question_pt":"Qual \u00e9 a vantagem das vacinas contra adenov\u00edrus?"
    },
    {
        "answer":"induce robust mucosal immune responses and may bypass preexisting vector immunity ",
        "answer_pt":"induzem respostas imunes \u00e0 mucosa robustas e podem ignorar a imunidade de vetor preexistente",
        "id":"1512",
        "question":"What is the advantage of oral capsule and intranasal deliveries?",
        "question_pt":"Qual \u00e9 a vantagem de c\u00e1psulas orais e partos intranasais?"
    },
    {
        "answer":"immunogenicity of recombinant adenovirus 5 (rAd5) expressing the HA of a swine influenza virus, A/Swine/Iowa/1999 (H3N2)",
        "answer_pt":"imunogenicidade do adenov\u00edrus recombinante 5 (rAd5) que expressa a HA de um v\u00edrus da gripe su\u00edna, A / Swine / Iowa / 1999 (H3N2)",
        "id":"1516",
        "question":"What  did the first report on adenovirus as a vector demonstrate?",
        "question_pt":"O que o primeiro relat\u00f3rio sobre adenov\u00edrus como vetor demonstrou?"
    },
    {
        "answer":"A rAd5-HA expressing the HA from A/Puerto Rico/8/1934 (H1N1; PR8) was delivered to humans epicutaneously or intranasally ",
        "answer_pt":"Um rAd5-HA que expressa o HA de A / Puerto Rico / 8/1934 (H1N1; PR8) foi entregue a humanos por via epicut\u00e2nea ou intranasal",
        "id":"1524",
        "question":"Which rAd5 delivery has been tested?",
        "question_pt":"Qual entrega do rAd5 foi testada?"
    },
    {
        "answer":"The vaccine was well tolerated and induced seroconversion with the intranasal administration had a higher conversion rate and higher geometric meant HI titers ",
        "answer_pt":"A vacina foi bem tolerada e a soroconvers\u00e3o induzida com a administra\u00e7\u00e3o intranasal teve uma taxa de convers\u00e3o mais alta e t\u00edtulos HI com maior significado geom\u00e9trico",
        "id":"1526",
        "question":"What was the result of the rAd5-HA testing?",
        "question_pt":"Qual foi o resultado do teste rAd5-HA?"
    },
    {
        "answer":"clinical trials with rAd vectors have overall been successful, demonstrating safety and some level of efficacy,",
        "answer_pt":"os ensaios cl\u00ednicos com vetores de rAd foram bem-sucedidos, demonstrando seguran\u00e7a e algum n\u00edvel de efic\u00e1cia,",
        "id":"1530",
        "question":"What is  the result of rAd5 trials?",
        "question_pt":"Qual \u00e9 o resultado dos testes rAd5?"
    },
    {
        "answer":" a gene therapy examination where high-dose intravenous delivery of an Ad vector resulted in the death of an 18-year-old male",
        "answer_pt":"um exame de terapia gen\u00e9tica em que a administra\u00e7\u00e3o intravenosa de altas doses de um vetor Ad resultou na morte de um homem de 18 anos",
        "id":"1531",
        "question":"What is an example of failure of rAd5?",
        "question_pt":"O que \u00e9 um exemplo de falha do rAd5?"
    },
    {
        "answer":"the study was stopped after interim analysis suggested the vaccine did not achieve efficacy and individuals with high preexisting Ad5 antibody titers might have an increased risk of acquiring HIV-1 ",
        "answer_pt":"o estudo foi interrompido ap\u00f3s a an\u00e1lise intermedi\u00e1ria sugerir que a vacina n\u00e3o alcan\u00e7ou efic\u00e1cia e indiv\u00edduos com altos t\u00edtulos de anticorpos Ad5 pr\u00e9-existentes podem ter um risco aumentado de adquirir o HIV-1",
        "id":"1535",
        "question":"What was the failure of rAd5 vaccine for inducing HIV-1 specific T cell response?",
        "question_pt":"Qual foi o fracasso da vacina rAd5 na indu\u00e7\u00e3o de resposta de c\u00e9lulas T espec\u00edficas para o HIV-1?"
    },
    {
        "answer":"potent cellular and humoral immune responses that are initiated through toll-like receptor-dependent and independent pathways which induce robust pro-inflammatory cytokine responses",
        "answer_pt":"respostas imunes celulares e humorais potentes que s\u00e3o iniciadas por vias independentes e dependentes de receptores de ped\u00e1gio que induzem respostas robustas a citocinas pr\u00f3-inflamat\u00f3rias",
        "id":"1540",
        "question":"What does immunization with adenovirus induce?",
        "question_pt":"O que induz a imuniza\u00e7\u00e3o com adenov\u00edrus?"
    },
    {
        "answer":" to improve immunogenicity and broaden breadth of both humoral and cellular immunity",
        "answer_pt":"melhorar a imunogenicidade e ampliar a imunidade humoral e celular",
        "id":"1543",
        "question":"What is the advantage of inclusion of non-HA antigens to HA based vaccines?",
        "question_pt":"Qual \u00e9 a vantagem da inclus\u00e3o de ant\u00edgenos n\u00e3o HA em vacinas baseadas em HA?"
    },
    {
        "answer":"as both CD8 + T cell and neutralizing antibody responses are generated by the vector and vaccine antigens, immunological memory to these components can reduce efficacy and limit repeated use ",
        "answer_pt":"Como as c\u00e9lulas T CD8 + e as respostas de anticorpos neutralizantes s\u00e3o geradas pelos ant\u00edgenos vetoriais e vacinais, a mem\u00f3ria imunol\u00f3gica desses componentes pode reduzir a efic\u00e1cia e limitar o uso repetido",
        "id":"1544",
        "question":"What is the disadvantage of inclusion of non-HA  antigens to HA based vaccines?",
        "question_pt":"Qual \u00e9 a desvantagem da inclus\u00e3o de ant\u00edgenos n\u00e3o HA em vacinas baseadas em HA?"
    },
    {
        "answer":" using Autographa californica nuclear polyhedrosis virus (AcNPV) expressing the HA of PR8 under control of the CAG promoter (AcCAG-HA) ",
        "answer_pt":"usando o v\u00edrus da poliedrosis nucleares Autographa californica (AcNPV) que expressa o HA do PR8 sob controle do promotor CAG (AcCAG-HA)",
        "id":"1579",
        "question":"What  was the first reported baculovirus vector based vaccine for influenza?",
        "question_pt":"Qual foi a primeira vacina relatada com base em vetor de baculov\u00edrus para influenza?"
    },
    {
        "answer":"preexisting immunity,",
        "answer_pt":"imunidade preexistente,",
        "id":"1549",
        "question":"What is a drawback of Ad5 vector?",
        "question_pt":"O que \u00e9 uma desvantagem do vetor Ad5?"
    },
    {
        "answer":"adenovirus serotypes have been explored as vectors, particularly non-human and uncommon human serotypes",
        "answer_pt":"sorotipos de adenov\u00edrus foram explorados como vetores, particularmente sorotipos humanos n\u00e3o humanos e incomuns",
        "id":"1550",
        "question":"What alternatives to Ad5 vector have been explored?",
        "question_pt":"Quais alternativas ao vetor Ad5 foram exploradas?"
    },
    {
        "answer":"Swine, NHP and bovine adenoviruses expressing H5 HA antigens ",
        "answer_pt":"Adenov\u00edrus su\u00edno, NHP e bovino que expressam ant\u00edgenos H5 HA",
        "id":"1551",
        "question":"What animal adenoviruses have been shown to induce immunity comparable to rdA5-HA?",
        "question_pt":"Quais adenov\u00edrus animais demonstraram induzir imunidade compar\u00e1vel ao rdA5-HA?"
    },
    {
        "answer":" Low prevalence serotypes such as adenovirus types 3, 7, 11, and 35",
        "answer_pt":"Sorotipos de baixa preval\u00eancia, como adenov\u00edrus tipos 3, 7, 11 e 35",
        "id":"1553",
        "question":"what can evade anti-Ad5 response and also provide effective antigen delivery and immunogenicity?",
        "question_pt":"o que pode evitar a resposta anti-Ad5 e tamb\u00e9m fornecer a entrega e a imunogenicidade eficazes de ant\u00edgenos?"
    },
    {
        "answer":"Prime-boost strategies, using DNA or protein immunization in conjunction with an adenovirus vaccine booster immunization",
        "answer_pt":"Estrat\u00e9gias de refor\u00e7o prim\u00e1rio, usando imuniza\u00e7\u00e3o de DNA ou prote\u00edna em conjunto com uma imuniza\u00e7\u00e3o de refor\u00e7o de vacina contra adenov\u00edrus",
        "id":"1557",
        "question":"What additional strategies have been explored to avoid preexisting immunity?",
        "question_pt":"Que estrat\u00e9gias adicionais foram exploradas para evitar imunidade preexistente?"
    },
    {
        "answer":"Like rAd vectors, rAAV have broad tropism infecting a variety of hosts, tissues, and proliferating and non-proliferating cell types ",
        "answer_pt":"Como os vetores rAd, os rAAV t\u00eam amplo tropismo, infectando uma variedade de hospedeiros, tecidos e tipos de c\u00e9lulas em prolifera\u00e7\u00e3o e n\u00e3o prolifera\u00e7\u00e3o",
        "id":"1559",
        "question":"What is the advantage of AAV vector?",
        "question_pt":"Qual \u00e9 a vantagem do vetor AAV?"
    },
    {
        "answer":" The wild type viruses are non-pathogenic and replication incompetent in humans and the recombinant AAV vector systems are even further attenuated ",
        "answer_pt":"Os v\u00edrus do tipo selvagem n\u00e3o s\u00e3o patog\u00eanicos e a replica\u00e7\u00e3o \u00e9 incompetente em humanos e os sistemas vetoriais de AAV recombinantes s\u00e3o ainda mais atenuados",
        "id":"1560",
        "question":"What is the advantage of the AAV vector?",
        "question_pt":"Qual \u00e9 a vantagem do vetor AAV?"
    },
    {
        "answer":"As members of the parvovirus family, AAVs are small non-enveloped viruses that are stable and amenable to long-term storage without a cold chain.",
        "answer_pt":"Como membros da fam\u00edlia dos parvov\u00edrus, os AAVs s\u00e3o pequenos v\u00edrus n\u00e3o envelopados, est\u00e1veis \u200b\u200be pass\u00edveis de armazenamento a longo prazo sem uma cadeia de frio.",
        "id":"1561",
        "question":"What is the advantage of AAV vector?",
        "question_pt":"Qual \u00e9 a vantagem do vetor AAV?"
    },
    {
        "answer":"While there is limited preexisting immunity, availability of non-human strains as vaccine candidates eliminates these concerns.",
        "answer_pt":"Embora a imunidade preexistente seja limitada, a disponibilidade de cepas n\u00e3o humanas como candidatas a vacina elimina essas preocupa\u00e7\u00f5es.",
        "id":"1562",
        "question":"What is the advantage of AAV vector?",
        "question_pt":"Qual \u00e9 a vantagem do vetor AAV?"
    },
    {
        "answer":"There are limited studies ",
        "answer_pt":"Existem estudos limitados",
        "id":"1563",
        "question":"Has AAV been studied as  vectors for influenza?",
        "question_pt":"O AAV foi estudado como vetores da gripe?"
    },
    {
        "answer":"positive-sense, single-stranded RNA viruses of the Togaviridae family",
        "answer_pt":"v\u00edrus de RNA de cadeia simples de sentido positivo da fam\u00edlia Togaviridae",
        "id":"1564",
        "question":"What are alphaviruses?",
        "question_pt":"O que s\u00e3o alfav\u00edrus?"
    },
    {
        "answer":"Semliki Forest virus (SFV), Sindbis (SIN) virus, Venezuelan equine encephalitis (VEE) virus, as well as chimeric viruses incorporating portions of SIN and VEE viruses",
        "answer_pt":"V\u00edrus da Floresta Semliki (SFV), v\u00edrus Sindbis (SIN), v\u00edrus da encefalite equina venezuelana (VEE), bem como v\u00edrus quim\u00e9ricos que incorporam partes dos v\u00edrus SIN e VEE",
        "id":"1565",
        "question":"What are some alphavirus vectors that have been developed?",
        "question_pt":"Quais s\u00e3o alguns vetores de alfav\u00edrus que foram desenvolvidos?"
    },
    {
        "answer":" The replication defective vaccines or replicons do not encode viral structural proteins, having these portions of the genome replaces with transgenic material.",
        "answer_pt":"As vacinas ou replicons defeituosos para replica\u00e7\u00e3o n\u00e3o codificam prote\u00ednas estruturais virais, tendo essas por\u00e7\u00f5es do genoma substitu\u00eddas por material transg\u00eanico.",
        "id":"1566",
        "question":"How do the alphavirus vectors work?",
        "question_pt":"Como os vetores de alfav\u00edrus funcionam?"
    },
    {
        "answer":"The structural proteins are provided in cell culture production systems.",
        "answer_pt":"As prote\u00ednas estruturais s\u00e3o fornecidas em sistemas de produ\u00e7\u00e3o de cultura de c\u00e9lulas.",
        "id":"1567",
        "question":"How do the alphavirus vectors work?",
        "question_pt":"Como os vetores de alfav\u00edrus funcionam?"
    },
    {
        "answer":"the self-replicating nature of the RNA. Despite the partial viral genome, the RNAs are self-replicating and can express transgenes at very high levels",
        "answer_pt":"a natureza auto-replicante do RNA. Apesar do genoma viral parcial, os RNAs s\u00e3o auto-replicantes e podem expressar transgenes em n\u00edveis muito altos",
        "id":"1568",
        "question":"What is an important feature of the replicon  system?",
        "question_pt":"Qual \u00e9 uma caracter\u00edstica importante do sistema replicon?"
    },
    {
        "answer":"demonstrated to induce potent HA-specific immune response and protected from challenge in a murine model, despite repeated immunization with the vector expressing a control antigen, suggesting preexisting immunity may not be an issue for the replicon vaccine",
        "answer_pt":"demonstrou induzir uma resposta imune potente espec\u00edfica de HA e protegido de desafio em um modelo murino, apesar da repetida imuniza\u00e7\u00e3o com o vetor que expressa um ant\u00edgeno de controle, sugerindo que a imunidade preexistente pode n\u00e3o ser um problema para a vacina de replic\u00e3o",
        "id":"1569",
        "question":"How did the VEE based replicon system incorporating HA from PR8perform?",
        "question_pt":"Como o sistema de replicons baseado em VEE incorporou HA do PR8perform?"
    },
    {
        "answer":"the VEE targets antigen-presenting cells in the lymphatic tissues, priming rapid and robust immune responses",
        "answer_pt":"o VEE tem como alvo c\u00e9lulas apresentadoras de ant\u00edgenos nos tecidos linf\u00e1ticos, iniciando respostas imunol\u00f3gicas r\u00e1pidas e robustas",
        "id":"1570",
        "question":"Why is the VEE replicon system particularly appealing?",
        "question_pt":"Por que o sistema de replic\u00f5es VEE \u00e9 particularmente atraente?"
    },
    {
        "answer":"VEE replicon systems can induce robust mucosal immune responses through intranasal or subcutaneous immunization [72] [73] [74] , and subcutaneous immunization with virus-like replicon particles (VRP) expressing HA-induced antigen-specific systemic IgG and fecal IgA antibodies ",
        "answer_pt":"Os sistemas de replic\u00f5es VEE podem induzir respostas imunes da mucosa robustas por meio de imuniza\u00e7\u00e3o intranasal ou subcut\u00e2nea [72] [73] [74] e imuniza\u00e7\u00e3o subcut\u00e2nea com part\u00edculas de replicon do tipo v\u00edrus (VRP) que expressam anticorpos IgG sist\u00eamicos e IgA fecais espec\u00edficos para ant\u00edgenos induzidos por HA",
        "id":"1571",
        "question":"What is the advantage of the VEE replicon system?",
        "question_pt":"Qual \u00e9 a vantagem do sistema de replic\u00f5es VEE?"
    },
    {
        "answer":"as candidate vaccines for cytomegalovirus (CMV)",
        "answer_pt":"como vacinas candidatas ao citomegalov\u00edrus (CMV)",
        "id":"1572",
        "question":"What were the VRPs derived from VEE developed for?",
        "question_pt":"Para que os VRPs derivados do VEE foram desenvolvidos?"
    },
    {
        "answer":"vaccine was immunogenic, inducing CMV-neutralizing antibody responses and potent T cell responses. Moreover, the vaccine was well tolerated and considered safe ",
        "answer_pt":"A vacina era imunog\u00eanica, induzindo respostas de anticorpos neutralizantes ao CMV e potentes respostas de c\u00e9lulas T. Al\u00e9m disso, a vacina foi bem tolerada e considerada segura",
        "id":"1573",
        "question":"What did the clinical  trial with CMV VRP show?",
        "question_pt":"O que mostrou o ensaio cl\u00ednico com CMV VRP?"
    },
    {
        "answer":"vaccine was safe and despite high vector-specific immunity after initial immunization, continued to boost transgene-specific immune responses upon boost ",
        "answer_pt":"a vacina era segura e, apesar da alta imunidade espec\u00edfica ao vetor ap\u00f3s a imuniza\u00e7\u00e3o inicial, continuou a aumentar as respostas imunes espec\u00edficas ao transgene",
        "id":"1574",
        "question":"What did the clinical trial with VRP show?",
        "question_pt":"O que mostrou o ensaio cl\u00ednico com VRP?"
    },
    {
        "answer":"baculovirus-derived recombinant HA vaccine was approved for human use and was first available for use in the United States for the 2013-2014 influenza season",
        "answer_pt":"A vacina recombinante de HA derivada de baculov\u00edrus foi aprovada para uso humano e foi disponibilizada pela primeira vez nos Estados Unidos na temporada de influenza 2013-2014",
        "id":"1575",
        "question":"Which  baculovirus vaccine has been approved for \n human use?",
        "question_pt":"Qual vacina de baculov\u00edrus foi aprovada para\n uso humano?"
    },
    {
        "answer":"readily manipulated",
        "answer_pt":"prontamente manipulado",
        "id":"1576",
        "question":"What  is the advantage of baculoviruses?",
        "question_pt":"Qual \u00e9 a vantagem dos baculov\u00edrus?"
    },
    {
        "answer":"The vectors can accommodate large gene insertions, show limited cytopathic effect in mammalian cells, and have been shown to infect and express genes of interest in a spectrum of mammalian cells",
        "answer_pt":"Os vetores podem acomodar grandes inser\u00e7\u00f5es g\u00eanicas, mostram efeito citop\u00e1tico limitado em c\u00e9lulas de mam\u00edferos e demonstraram infectar e expressar genes de interesse em um espectro de c\u00e9lulas de mam\u00edferos",
        "id":"1577",
        "question":"What is the advantage of baculovirus vectors?",
        "question_pt":"Qual \u00e9 a vantagem dos vetores de baculov\u00edrus?"
    },
    {
        "answer":"While the insect promoters are not effective for mammalian gene expression, appropriate promoters can be cloned into the baculovirus vaccine vectors.",
        "answer_pt":"Embora os promotores de insetos n\u00e3o sejam eficazes para a express\u00e3o g\u00eanica de mam\u00edferos, promotores apropriados podem ser clonados nos vetores de vacina de baculov\u00edrus.",
        "id":"1578",
        "question":"How can baculovirus vectors be improved?",
        "question_pt":"Como os vetores de baculov\u00edrus podem ser melhorados?"
    },
    {
        "answer":"only intranasal immunization",
        "answer_pt":"\u00fanica imuniza\u00e7\u00e3o intranasal",
        "id":"1580",
        "question":"what baculovirus vector based immunization provided protection from lethal challenge?",
        "question_pt":"que imuniza\u00e7\u00e3o baseada em vetor de baculov\u00edrus forneceu prote\u00e7\u00e3o contra desafio letal?"
    },
    {
        "answer":" non-specific protection from subsequent influenza virus infection",
        "answer_pt":"prote\u00e7\u00e3o inespec\u00edfica contra infec\u00e7\u00e3o subsequente pelo v\u00edrus influenza",
        "id":"1581",
        "question":"What was the benefit of the robust innate immune response to baculovirus vector?",
        "question_pt":"Qual foi o benef\u00edcio da robusta resposta imune inata ao vetor de baculov\u00edrus?"
    },
    {
        "answer":"a single-stranded, negative-sense RNA virus that causes disease in poultry. ",
        "answer_pt":"um v\u00edrus de RNA de fita \u00fanica, sentido negativo, que causa doen\u00e7as em aves de capoeira.",
        "id":"1582",
        "question":"What is the Newcastle disease virus?",
        "question_pt":"O que \u00e9 o v\u00edrus da doen\u00e7a de Newcastle?"
    },
    {
        "answer":"As an avian virus, there is little or no preexisting immunity to NDV in humans and NDV propagates to high titers in both chicken eggs and cell culture. ",
        "answer_pt":"Como um v\u00edrus avi\u00e1rio, existe pouca ou nenhuma imunidade preexistente ao NDV em humanos e o NDV se propaga a altos t\u00edtulos nos ovos de galinha e na cultura de c\u00e9lulas.",
        "id":"1583",
        "question":"What are the appealing qualities of the NDV vector?",
        "question_pt":"Quais s\u00e3o as qualidades atraentes do vetor NDV?"
    },
    {
        "answer":"As a paramyxovirus, there is no DNA phase in the virus lifecycle reducing concerns of integration events, and the levels of gene expression are driven by the proximity to the leader sequence at the 3' end of the viral genome. This gradient of gene expression enables attenuation through rearrangement of the genome, or by insertion of transgenes within the genome.",
        "answer_pt":"Como um paramixov\u00edrus, n\u00e3o h\u00e1 fase de DNA no ciclo de vida do v\u00edrus, reduzindo as preocupa\u00e7\u00f5es com os eventos de integra\u00e7\u00e3o, e os n\u00edveis de express\u00e3o g\u00eanica s\u00e3o conduzidos pela proximidade da sequ\u00eancia l\u00edder na extremidade 3 'do genoma viral. Esse gradiente de express\u00e3o g\u00eanica permite a atenua\u00e7\u00e3o atrav\u00e9s do rearranjo do genoma ou pela inser\u00e7\u00e3o de transgenes no genoma.",
        "id":"1584",
        "question":"What is the appealing quality of the NDV vector?",
        "question_pt":"Qual \u00e9 a qualidade atraente do vetor NDV?"
    },
    {
        "answer":"pathogenicity of NDV is largely determined by features of the fusion protein enabling ready attenuation of the vaccine vector",
        "answer_pt":"A patogenicidade do NDV \u00e9 amplamente determinada pelas caracter\u00edsticas da prote\u00edna de fus\u00e3o, permitindo atenua\u00e7\u00e3o imediata do vetor da vacina",
        "id":"1585",
        "question":"What is the appealing quality of the NDV vector?",
        "question_pt":"Qual \u00e9 a qualidade atraente do vetor NDV?"
    },
    {
        "answer":"it induced a robust serum antibody response and protected against homologous influenza virus challenge in a murine model of infection ",
        "answer_pt":"induziu uma resposta robusta de anticorpos s\u00e9ricos e protegeu contra o desafio do v\u00edrus influenza hom\u00f3logo em um modelo murino de infec\u00e7\u00e3o",
        "id":"1586",
        "question":"What did the first report on the NDV vector test conclude?",
        "question_pt":"O que o primeiro relat\u00f3rio sobre o teste do vetor NDV concluiu?"
    },
    {
        "answer":"providing protection against both the influenza virus and NDV infection.",
        "answer_pt":"fornecendo prote\u00e7\u00e3o contra o v\u00edrus influenza e a infec\u00e7\u00e3o pelo NDV.",
        "id":"1587",
        "question":"What is the added protection of NDV vector?",
        "question_pt":"Qual \u00e9 a prote\u00e7\u00e3o adicional do vetor NDV?"
    },
    {
        "answer":"the NDV vector is well-tolerated, even at high doses delivered intravenously ",
        "answer_pt":"o vetor NDV \u00e9 bem tolerado, mesmo em altas doses administradas por via intravenosa",
        "id":"1588",
        "question":"What have the limited NDV human trails shown?",
        "question_pt":"O que mostram as trilhas humanas limitadas de NDV?"
    },
    {
        "answer":" PIV5 has a stable RNA genome and no DNA phase in virus replication cycle reducing concerns of host genome integration or modification. PIV5 can be grown to very high titers in mammalian vaccine cell culture substrates and is not cytopathic allowing for extended culture and harvest of vaccine virus [98, 99] . Like NDV, PIV5 has a 3'-to 5' gradient of gene expression and insertion of transgenes at different locations in the genome can variably attenuate the virus and alter transgene expression [100] . PIV5 has broad tropism, infecting many cell types, tissues, and species without causing clinical disease, although PIV5 has been associated with -kennel cough\u2016 in dogs",
        "answer_pt":"O PIV5 possui um genoma de RNA est\u00e1vel e nenhuma fase de DNA no ciclo de replica\u00e7\u00e3o de v\u00edrus, reduzindo as preocupa\u00e7\u00f5es de integra\u00e7\u00e3o ou modifica\u00e7\u00e3o do genoma do hospedeiro. O PIV5 pode ser cultivado com t\u00edtulos muito altos em substratos de cultura de c\u00e9lulas de vacina em mam\u00edferos e n\u00e3o \u00e9 citop\u00e1tico, permitindo uma cultura prolongada e a colheita do v\u00edrus da vacina [98, 99]. Como o NDV, o PIV5 possui um gradiente de 3 a 5 a express\u00e3o de genes e a inser\u00e7\u00e3o de transgenes em diferentes locais do genoma pode atenuar de forma vari\u00e1vel o v\u00edrus e alterar a express\u00e3o de transgene [100]. O PIV5 possui amplo tropismo, infectando muitos tipos de c\u00e9lulas, tecidos e esp\u00e9cies sem causar doen\u00e7a cl\u00ednica, embora o PIV5 tenha sido associado \u00e0 tosse de canal em c\u00e3es",
        "id":"1589",
        "question":"What  are the attractive features of the PIV5 vector?",
        "question_pt":"Quais s\u00e3o os recursos atraentes do vetor PIV5?"
    },
    {
        "answer":"Mice intranasally vaccinated with a single dose of PIV5-H5 vaccine had robust serum and mucosal antibody responses, and were protected from lethal challenge. Notably, although cellular immune responses appeared to contribute to protection, serum antibody was sufficient for protection from challenge",
        "answer_pt":"Os ratos vacinados intranasalmente com uma dose \u00fanica da vacina PIV5-H5 apresentaram respostas robustas de anticorpos s\u00e9ricos e da mucosa e foram protegidos do desafio letal. Notavelmente, embora as respostas imunes celulares pare\u00e7am contribuir para a prote\u00e7\u00e3o, o anticorpo s\u00e9rico foi suficiente para a prote\u00e7\u00e3o contra o desafio",
        "id":"1590",
        "question":"What  was the result of the test of efficacy of PIV5 in murine challenge?",
        "question_pt":"Qual foi o resultado do teste de efic\u00e1cia do PIV5 no desafio murino?"
    },
    {
        "answer":"has resulted in a large population of poxvirus-na\u00ef ve individuals that provides the opportunity for the use of poxviruses as vectors without preexisting immunity concerns ",
        "answer_pt":"resultou em uma grande popula\u00e7\u00e3o de indiv\u00edduos n\u00e3o portadores de poxv\u00edrus que oferece a oportunidade para o uso de poxv\u00edrus como vetores sem preocupa\u00e7\u00f5es pr\u00e9-existentes com a imunidade",
        "id":"1636",
        "question":"What opportunity has the termination of smallpox vaccination provided?",
        "question_pt":"Que oportunidade ofereceu o t\u00e9rmino da vacina\u00e7\u00e3o contra a var\u00edola?"
    },
    {
        "answer":"The modified vaccinia virus Ankara (MVA) strain was attenuated by passage 530 times in chick embryo fibroblasts cultures. The second, New York vaccinia virus (NYVAC) was a plaque-purified clone of the Copenhagen vaccine strain rationally attenuated by deletion of 18 open reading frames",
        "answer_pt":"A estirpe modificada do v\u00edrus vaccinia Ankara (MVA) foi atenuada pela passagem 530 vezes em culturas de fibroblastos de embri\u00f5es de galinha. O segundo, o v\u00edrus vaccinia de Nova York (NYVAC), foi um clone purificado em placas da cepa da vacina de Copenhague, atenuado racionalmente pela exclus\u00e3o de 18 quadros de leitura abertos",
        "id":"1637",
        "question":"What vaccinia vectors were created to address safety concerns?",
        "question_pt":"Quais vetores de vaccinia foram criados para tratar de quest\u00f5es de seguran\u00e7a?"
    },
    {
        "answer":"MVA has undergone extensive safety testing and shown to be attenuated in severely immunocompromised animals and safe for use in children, adults, elderly, and immunocompromised persons. With extensive pre-clinical data, recombinant MVA vaccines expressing influenza antigens have been tested in clinical trials and been shown to be safe and immunogenic in humans ",
        "answer_pt":"O MVA passou por extensos testes de seguran\u00e7a e demonstrou ser atenuado em animais severamente imunocomprometidos e seguro para uso em crian\u00e7as, adultos, idosos e pessoas imunocomprometidas. Com extensos dados pr\u00e9-cl\u00ednicos, as vacinas recombinantes de MVA que expressam ant\u00edgenos da influenza foram testadas em ensaios cl\u00ednicos e demonstraram ser seguras e imunog\u00eanicas em seres humanos",
        "id":"1638",
        "question":"How safe is MVA?",
        "question_pt":"Qu\u00e3o seguro \u00e9 o MVA?"
    },
    {
        "answer":"results combined with data from other (non-influenza) clinical and pre-clinical studies support MVA as a leading viral-vectored candidate vaccine.",
        "answer_pt":"os resultados combinados com dados de outros estudos cl\u00ednicos e pr\u00e9-cl\u00ednicos (n\u00e3o influenza) ap\u00f3iam o MVA como a principal vacina candidata com vetor viral.",
        "id":"1639",
        "question":"What is the status of MVA influenza vaccine?",
        "question_pt":"Qual \u00e9 o status da vacina contra a gripe MVA?"
    },
    {
        "answer":"The NYVAC vector is a highly attenuated vaccinia virus strain. NYVAC is replication-restricted",
        "answer_pt":"O vetor NYVAC \u00e9 uma cepa do v\u00edrus vaccinia altamente atenuada. NYVAC \u00e9 restrito \u00e0 replica\u00e7\u00e3o",
        "id":"1640",
        "question":"What  is NYVAC?",
        "question_pt":"O que \u00e9 NYVAC?"
    },
    {
        "answer":"in chick embryo fibroblasts and Vero cells enabling vaccine-scale production. In non-permissive cells, critical late structural proteins are not produced stopping replication at the immature virion stage ",
        "answer_pt":"em fibroblastos de embri\u00f5es de galinha e c\u00e9lulas Vero, permitindo a produ\u00e7\u00e3o em escala de vacina. Nas c\u00e9lulas n\u00e3o permissivas, prote\u00ednas estruturais tardias cr\u00edticas n\u00e3o s\u00e3o produzidas, interrompendo a replica\u00e7\u00e3o no est\u00e1gio de virion imaturo",
        "id":"1642",
        "question":"How is NYVAC grown?",
        "question_pt":"Como \u00e9 cultivada a NYVAC?"
    },
    {
        "answer":" NYVAC is very attenuated and considered safe for use in humans of all ages",
        "answer_pt":"NYVAC \u00e9 muito atenuado e considerado seguro para uso em humanos de todas as idades",
        "id":"1643",
        "question":"How safe is NYVAC?",
        "question_pt":"Qu\u00e3o segura \u00e9 a NYVAC?"
    },
    {
        "answer":"current influenza vaccination strategies rely upon regular immunization with vaccines matched to circulating strains",
        "answer_pt":"As estrat\u00e9gias atuais de vacina\u00e7\u00e3o contra influenza dependem de imuniza\u00e7\u00e3o regular com vacinas compat\u00edveis com cepas circulantes",
        "id":"1644",
        "question":"What would limit the use of poxvirus vectored vaccines?",
        "question_pt":"O que limitaria o uso de vacinas vetorizadas com poxv\u00edrus?"
    },
    {
        "answer":"immunization with this vector induces weaker vaccine-specific immune responses compared to other poxvirus vaccines, a feature that may address the concerns surrounding preexisting immunity ",
        "answer_pt":"A imuniza\u00e7\u00e3o com esse vetor induz respostas imunol\u00f3gicas mais espec\u00edficas da vacina em compara\u00e7\u00e3o com outras vacinas contra o poxv\u00edrus, um recurso que pode abordar as preocupa\u00e7\u00f5es em torno da imunidade preexistente",
        "id":"1645",
        "question":"what is the advantage of the NYVAC as an influenza virus?",
        "question_pt":"qual \u00e9 a vantagem da NYVAC como v\u00edrus influenza?"
    },
    {
        "answer":" licensed poxvirus for veterinary use that include fowlpox-and canarypox-vectored vaccines for avian and equine influenza viruses, respectively ",
        "answer_pt":"poxv\u00edrus licenciado para uso veterin\u00e1rio que inclui vacinas com vetor de var\u00edola e varicela para v\u00edrus da gripe avi\u00e1ria e equina, respectivamente",
        "id":"1646",
        "question":"Where is poxvirus vaccine being used?",
        "question_pt":"Onde est\u00e1 sendo usada a vacina contra o poxv\u00edrus?"
    },
    {
        "answer":" immunization with NP expressed by AAV, rAd5, alphavirus vectors, MVA, or other vector systems induces potent CD8 + T cell responses ",
        "answer_pt":"A imuniza\u00e7\u00e3o com NP expressa por AAV, rAd5, vetores de alfav\u00edrus, MVA ou outros sistemas de vetores induz respostas potentes das c\u00e9lulas T CD8 +",
        "id":"1647",
        "question":"What have the studies on NP shown for the protection against influenza challege?",
        "question_pt":"O que os estudos sobre PN mostraram para a prote\u00e7\u00e3o contra o desafio da influenza?"
    },
    {
        "answer":"protect against infection and disease, while inducing population-based immunity to reduce or eliminate virus transmission within the population",
        "answer_pt":"proteger contra infec\u00e7\u00f5es e doen\u00e7as, ao mesmo tempo que induz imunidade baseada na popula\u00e7\u00e3o para reduzir ou eliminar a transmiss\u00e3o de v\u00edrus na popula\u00e7\u00e3o",
        "id":"1648",
        "question":"What is the goal of vaccine?",
        "question_pt":"Qual \u00e9 o objetivo da vacina?"
    },
    {
        "answer":" recent ability to probe the virus-host interface through RNA interference approaches that facilitate the identification of host genes affecting virus replication, immunity, and disease.",
        "answer_pt":"capacidade recente de sondar a interface v\u00edrus-hospedeiro atrav\u00e9s de abordagens de interfer\u00eancia de RNA que facilitam a identifica\u00e7\u00e3o de genes hospedeiros que afetam a replica\u00e7\u00e3o, imunidade e doen\u00e7a do v\u00edrus.",
        "id":"1649",
        "question":"What has enabled the development of one size fits all vaccine?",
        "question_pt":"O que permitiu o desenvolvimento de um tamanho \u00fanico para todas as vacinas?"
    },
    {
        "answer":"strategies for at-risk populations, particularly those at either end of the age spectrum",
        "answer_pt":"estrat\u00e9gias para popula\u00e7\u00f5es de risco, particularmente aquelas de ambos os lados do espectro et\u00e1rio",
        "id":"1650",
        "question":"Why is a revision of current vaccines is needed?",
        "question_pt":"Por que \u00e9 necess\u00e1ria uma revis\u00e3o das vacinas atuais?"
    },
    {
        "answer":"a vectored influenza virus vaccine that expresses the HA, NA and M and/or NP proteins for the two currently circulating influenza A subtypes and both influenza B strains so that vaccine take and vaccine antigen levels are not an issue in inducing protective immunity",
        "answer_pt":"uma vacina do v\u00edrus da gripe vetorizada que expressa as prote\u00ednas HA, NA e M e / ou NP para os dois subtipos de gripe A atualmente circulantes e ambas as cepas de gripe B, para que a tomada da vacina e os n\u00edveis de ant\u00edgeno da vacina n\u00e3o sejam um problema na indu\u00e7\u00e3o de imunidade protetora",
        "id":"1651",
        "question":"What is an example of an improved vaccine regime?",
        "question_pt":"Qual \u00e9 um exemplo de um regime de vacina aprimorado?"
    },
    {
        "answer":"Recombinant live-attenuated or replication-deficient influenza viruses",
        "answer_pt":"V\u00edrus da gripe recombinantes, atenuados ao vivo ou com defici\u00eancia de replica\u00e7\u00e3o",
        "id":"1652",
        "question":"What can provide an improved vaccine regime?",
        "question_pt":"O que pode proporcionar um melhor regime de vacinas?"
    },
    {
        "answer":"full-length influenza virus proteins, as well as generate conformationally restricted epitopes, features critical in generating appropriate humoral protection.",
        "answer_pt":"prote\u00ednas completas do v\u00edrus influenza, bem como geram ep\u00edtopos restritos de conformidade, s\u00e3o essenciais para gerar prote\u00e7\u00e3o humoral apropriada.",
        "id":"1653",
        "question":"What features can be created for creating vectored vaccines?",
        "question_pt":"Quais recursos podem ser criados para a cria\u00e7\u00e3o de vacinas vetorizadas?"
    },
    {
        "answer":"induce immunity at sites of inductive immunity to natural infection, in this case the respiratory tract",
        "answer_pt":"induzir imunidade em locais de imunidade indutiva a infec\u00e7\u00f5es naturais, neste caso o trato respirat\u00f3rio",
        "id":"1654",
        "question":"How can sustained immunity be generated?",
        "question_pt":"Como \u00e9 poss\u00edvel gerar imunidade sustentada?"
    },
    {
        "answer":"generate antigen for weeks after immunization, in contrast to subunit vaccination. This increased presence and level of vaccine antigen contributes to and helps sustain a durable memory immune response, even augmenting the selection of higher affinity antibody secreting cells",
        "answer_pt":"gerar ant\u00edgeno por semanas ap\u00f3s a imuniza\u00e7\u00e3o, em contraste com a vacina\u00e7\u00e3o por subunidade. Esse aumento da presen\u00e7a e do n\u00edvel de ant\u00edgeno da vacina contribui e ajuda a manter uma resposta imune dur\u00e1vel da mem\u00f3ria, aumentando ainda mais a sele\u00e7\u00e3o de c\u00e9lulas secretoras de anticorpos com maior afinidade",
        "id":"1655",
        "question":"What is the advantage of vectored vaccines?",
        "question_pt":"Qual \u00e9 a vantagem das vacinas vetorizadas?"
    },
    {
        "answer":"intrinsic augmentation of immunity induced by the vector.",
        "answer_pt":"aumento intr\u00ednseco da imunidade induzida pelo vetor.",
        "id":"1656",
        "question":"What  is the enhanced memory immune response linked to?",
        "question_pt":"A que est\u00e1 ligada a resposta imunol\u00f3gica avan\u00e7ada da mem\u00f3ria?"
    },
    {
        "answer":"HIV-1 replication",
        "answer_pt":"Replica\u00e7\u00e3o do HIV-1",
        "id":"5128",
        "question":"What cellular process is the Tat protein essential to?",
        "question_pt":"A que processo celular \u00e9 essencial a prote\u00edna Tat?"
    },
    {
        "answer":"nucleoplasm and the nucleolus",
        "answer_pt":"nucleoplasma e o nucl\u00e9olo",
        "id":"5129",
        "question":"Where does the Tat protein move to in cells?",
        "question_pt":"Para onde a prote\u00edna Tat se move nas c\u00e9lulas?"
    },
    {
        "answer":"a highly dynamic and structured membrane-less sub-nuclear compartment",
        "answer_pt":"um compartimento sub-nuclear altamente din\u00e2mico e estruturado sem membrana",
        "id":"5130",
        "question":"What is a nucleolus?",
        "question_pt":"O que \u00e9 um nucl\u00e9olo?"
    },
    {
        "answer":"nucleolus",
        "answer_pt":"nucl\u00e9olo",
        "id":"5131",
        "question":"Where are rRNA and ribosomes created?",
        "question_pt":"Onde s\u00e3o criados o rRNA e os ribossomos?"
    },
    {
        "answer":"49",
        "answer_pt":"49.",
        "id":"5132",
        "question":"How many proteins were shown to change the amount of Jurkat T-cell nucleolus significantly?",
        "question_pt":"Quantas prote\u00ednas mostraram alterar significativamente a quantidade de nucl\u00e9olo de c\u00e9lulas T Jurkat?"
    },
    {
        "answer":"RNA-polymerase-I-directed rDNA transcription, rRNA processing mediated by small nucleolar ribonucleoproteins (soRNPs) and ribosome assembly",
        "answer_pt":"Transcri\u00e7\u00e3o de rDNA dirigida a RNA-polimerase-I, processamento de rRNA mediado por pequenas ribonucleoprote\u00ednas nucleolares (soRNPs) e montagem de ribossomos",
        "id":"5133",
        "question":"What cellular processes occur in the nucleolus?",
        "question_pt":"Quais processos celulares ocorrem no nucl\u00e9olo?"
    },
    {
        "answer":"HIV-1, hCMV, HSV and KSHV",
        "answer_pt":"HIV-1, hCMV, HSV e KSHV",
        "id":"5134",
        "question":"Which viruses target the nucleolus as part of their replication strategy?",
        "question_pt":"Quais v\u00edrus t\u00eam como alvo o nucl\u00e9olo como parte de sua estrat\u00e9gia de replica\u00e7\u00e3o?"
    },
    {
        "answer":"B23",
        "answer_pt":"B23",
        "id":"5135",
        "question":"What nucleolar antigen is essential of localization of Tat and Rev proteins?",
        "question_pt":"Qual ant\u00edgeno nucleolar \u00e9 essencial para a localiza\u00e7\u00e3o das prote\u00ednas Tat e Rev?"
    },
    {
        "answer":"systematically analysed the nucleolar proteome perturbations occurring in Jurkat T-cells",
        "answer_pt":"analisou sistematicamente as perturba\u00e7\u00f5es do proteoma nucleolar que ocorrem nas c\u00e9lulas T Jurkat",
        "id":"5136",
        "question":"What was studied in this report?",
        "question_pt":"O que foi estudado neste relat\u00f3rio?"
    },
    {
        "answer":"the quantitative changes in the nucleolar proteome of Jurkat T cells constitutively expressing HIV-1 Tat (86aa) versus their Tat-negative counterpart,",
        "answer_pt":"as altera\u00e7\u00f5es quantitativas no proteoma nucleolar das c\u00e9lulas T Jurkat que expressam constitutivamente Tat de HIV-1 (86aa) versus seu hom\u00f3logo negativo de Tat,",
        "id":"5137",
        "question":"What was studied in this report?",
        "question_pt":"O que foi estudado neste relat\u00f3rio?"
    },
    {
        "answer":"light (R0K0)",
        "answer_pt":"leve (R0K0)",
        "id":"5138",
        "question":"Which isotope labeled arginine?",
        "question_pt":"Qual is\u00f3topo marcado como arginina?"
    },
    {
        "answer":"heavy (R6K6)",
        "answer_pt":"pesado (R6K6)",
        "id":"5139",
        "question":"Which isotope labeled lysine?",
        "question_pt":"Qual is\u00f3topo marcou lisina?"
    },
    {
        "answer":"85 million",
        "answer_pt":"85 milh\u00f5es",
        "id":"5140",
        "question":"How many cells were harvested from each culture?",
        "question_pt":"Quantas c\u00e9lulas foram colhidas de cada cultura?"
    },
    {
        "answer":"113 kDa",
        "answer_pt":"113 kDa",
        "id":"5141",
        "question":"How long is the nuclear protein PARP-1?",
        "question_pt":"Quanto tempo dura a prote\u00edna nuclear PARP-1?"
    },
    {
        "answer":"50 kDa",
        "answer_pt":"50 kDa",
        "id":"5142",
        "question":"How long is the protein Alpha-tubulin?",
        "question_pt":"Quanto tempo dura a prote\u00edna alfa-tubulina?"
    },
    {
        "answer":"cytoplasmic",
        "answer_pt":"citoplasm\u00e1tico",
        "id":"5143",
        "question":"Where was alpha-tubulin found most abundantly in the cell?",
        "question_pt":"Onde a alfa-tubulina foi encontrada com mais abund\u00e2ncia na c\u00e9lula?"
    },
    {
        "answer":"nuclear",
        "answer_pt":"nuclear",
        "id":"5144",
        "question":"Where was alpha-tubulin found least abundantly in the cell?",
        "question_pt":"Onde a alfa-tubulina foi encontrada com menos abund\u00e2ncia na c\u00e9lula?"
    },
    {
        "answer":"The fully annotated list of the quantified nucleolar proteins",
        "answer_pt":"A lista totalmente anotada das prote\u00ednas nucleolares quantificadas",
        "id":"5145",
        "question":"What is shown in Table S1?",
        "question_pt":"O que \u00e9 mostrado na Tabela S1?"
    },
    {
        "answer":"Jurkat T-cells",
        "answer_pt":"C\u00e9lulas T Jurkat",
        "id":"5146",
        "question":"What types of cells are used to study Tat-mediated pathogenesis?",
        "question_pt":"Que tipos de c\u00e9lulas s\u00e3o usadas para estudar a patog\u00eanese mediada por Tat?"
    },
    {
        "answer":"49",
        "answer_pt":"49.",
        "id":"5147",
        "question":"How many proteins displayed a significant fold change?",
        "question_pt":"Quantas prote\u00ednas apresentaram uma mudan\u00e7a significativa nas dobras?"
    },
    {
        "answer":"the first proteomic analysis of dynamic composition of the nucleolus in response to HIV-1 Tat expression",
        "answer_pt":"a primeira an\u00e1lise prote\u00f4mica da composi\u00e7\u00e3o din\u00e2mica do nucl\u00e9olo em resposta \u00e0 express\u00e3o de Tat do HIV-1",
        "id":"5148",
        "question":"What is the significance of this study?",
        "question_pt":"Qual \u00e9 o significado deste estudo?"
    },
    {
        "answer":"mucosal exposure to aerosols or by direct contact of abraded skin with infectious material",
        "answer_pt":"exposi\u00e7\u00e3o da mucosa a aeross\u00f3is ou pelo contato direto da pele lesionada com material infeccioso",
        "id":"5149",
        "question":"How are Mammarenaviruses spread from rodents to humans?",
        "question_pt":"Como os mammarenav\u00edrus se espalham dos roedores para os seres humanos?"
    },
    {
        "answer":"Old World (OW) and New World (NW)",
        "answer_pt":"Velho Mundo (OW) e Novo Mundo (NW)",
        "id":"5150",
        "question":"What are the main groups for Mammarenaviruses?",
        "question_pt":"Quais s\u00e3o os principais grupos de mammarenav\u00edrus?"
    },
    {
        "answer":"OW Lassa virus (LASV)",
        "answer_pt":"V\u00edrus OW Lassa (LASV)",
        "id":"5151",
        "question":"What is the cause of Lassa fever?",
        "question_pt":"Qual \u00e9 a causa da febre de Lassa?"
    },
    {
        "answer":"live attenuated",
        "answer_pt":"viver atenuado",
        "id":"5152",
        "question":"What type of vaccine is JUNV, Candid#1?",
        "question_pt":"Que tipo de vacina \u00e9 JUNV, Candid # 1?"
    },
    {
        "answer":"lung epithelial cells are one of the initial cell targets of humans following inhalation of mammarenavirions",
        "answer_pt":"c\u00e9lulas epiteliais pulmonares s\u00e3o um dos alvos celulares iniciais de humanos ap\u00f3s a inala\u00e7\u00e3o de mammarenavirions",
        "id":"5153",
        "question":"Why was the human A549 cell line chosen for this study?",
        "question_pt":"Por que a linha celular humana A549 foi escolhida para este estudo?"
    },
    {
        "answer":"48 h",
        "answer_pt":"48 h",
        "id":"5154",
        "question":"For how long were the cells infected before analysis?",
        "question_pt":"Por quanto tempo as c\u00e9lulas foram infectadas antes da an\u00e1lise?"
    },
    {
        "answer":"ouabain",
        "answer_pt":"ouabain",
        "id":"5155",
        "question":"What drug is used to treat congestive heart failure?",
        "question_pt":"Qual medicamento \u00e9 usado para tratar a insufici\u00eancia card\u00edaca congestiva?"
    },
    {
        "answer":"ATP1A1",
        "answer_pt":"ATP1A1",
        "id":"5156",
        "question":"What does ouabain inhibit?",
        "question_pt":"O que a ouabain inibe?"
    },
    {
        "answer":"Combination therapy",
        "answer_pt":"Terapia combinada",
        "id":"5157",
        "question":"What method can significantly alleviate the emergence of drug-resistant variants in RNA viral infections?",
        "question_pt":"Que m\u00e9todo pode aliviar significativamente o surgimento de variantes resistentes a medicamentos nas infec\u00e7\u00f5es virais por RNA?"
    },
    {
        "answer":"ATP1A1 and PHB",
        "answer_pt":"ATP1A1 e PHB",
        "id":"5158",
        "question":"What factors did this study attribute to the efficient multiplication of mammarenaviruses?",
        "question_pt":"Que fatores este estudo atribuiu \u00e0 multiplica\u00e7\u00e3o eficiente de mammarenav\u00edrus?"
    },
    {
        "answer":"using genetics and pharmacological inhibition of the genes",
        "answer_pt":"usando gen\u00e9tica e inibi\u00e7\u00e3o farmacol\u00f3gica dos genes",
        "id":"5159",
        "question":"How do the authors suggest that ATP1A1 and PHB contribute to the efficient multiplication of mammarenaviruses?",
        "question_pt":"Como os autores sugerem que o ATP1A1 e o PHB contribuem para a multiplica\u00e7\u00e3o eficiente dos mammarenav\u00edrus?"
    },
    {
        "answer":"Viruses ",
        "answer_pt":"V\u00edrus",
        "id":"1175",
        "question":"Which are the most abundant biological entities on Earth?",
        "question_pt":"Quais s\u00e3o as entidades biol\u00f3gicas mais abundantes na Terra?"
    },
    {
        "answer":"Retroviruses ",
        "answer_pt":"Retrov\u00edrus",
        "id":"1176",
        "question":"What contributed to a large part of mammalian genomic sequence?",
        "question_pt":"O que contribuiu para grande parte da sequ\u00eancia gen\u00f4mica de mam\u00edferos?"
    },
    {
        "answer":"ribozymes or viroids",
        "answer_pt":"ribozimas ou vir\u00f3ides",
        "id":"1177",
        "question":"What were the earliest replicating entities that fulfill several criteria for life?",
        "question_pt":"Quais foram as primeiras entidades replicantes que atendem a v\u00e1rios crit\u00e9rios para a vida?"
    },
    {
        "answer":"mitochondria, chloroplasts, Rickettsia ",
        "answer_pt":"mitoc\u00f4ndrias, cloroplastos, Rickettsia",
        "id":"1178",
        "question":"What are some examples of autonomous bacteria that lost their independence and became intracellular  parasites or endosymbionts?",
        "question_pt":"Quais s\u00e3o alguns exemplos de bact\u00e9rias aut\u00f4nomas que perderam sua independ\u00eancia e se tornaram parasitas intracelulares ou endossimbiontes?"
    },
    {
        "answer":"ribozymes, catalytic RNAs closely related to viroids",
        "answer_pt":"ribozimas, RNAs catal\u00edticos intimamente relacionados aos vir\u00f3ides",
        "id":"1179",
        "question":"What entities with no genes satisfy the criteria for life?",
        "question_pt":"Quais entidades sem genes atendem aos crit\u00e9rios da vida?"
    },
    {
        "answer":" catalytically active members, enzymatically active ribozymes. The sequence space for 220-mer RNAs is about 3 \u00d7 10 132 (",
        "answer_pt":"membros cataliticamente ativos, ribozimas enzimaticamente ativas. O espa\u00e7o de sequ\u00eancia para RNAs de 220-mer \u00e9 de cerca de 3 \u00d7 10 132 (",
        "id":"1180",
        "question":"Which group of RNA quasispecies satisfy criteria for life?",
        "question_pt":"Qual grupo de quasispecies de RNA satisfaz os crit\u00e9rios para a vida?"
    },
    {
        "answer":" They can polymerize progeny chemically, allow for mutations to occur and can evolve. One molecule serves as catalyst, the other one as substrate. Replication of ribozymes was demonstrated in the test tube (Lincoln and Joyce, 2009) . Ribozymes can form peptide bonds between amino acids (Zhang and Cech, 1997) . Thus, small peptides were available by ribozyme activity. ",
        "answer_pt":"Eles podem polimerizar a prog\u00eanie quimicamente, permitir a ocorr\u00eancia de muta\u00e7\u00f5es e evoluir. Uma mol\u00e9cula serve como catalisador, a outra como substrato. A replica\u00e7\u00e3o de ribozimas foi demonstrada no tubo de ensaio (Lincoln e Joyce, 2009). As ribozimas podem formar liga\u00e7\u00f5es pept\u00eddicas entre amino\u00e1cidos (Zhang e Cech, 1997). Assim, pequenos pept\u00eddeos estavam dispon\u00edveis pela atividade das ribozimas.",
        "id":"1181",
        "question":"How are the ribozymes able to replicate, join and create peptide bonds?",
        "question_pt":"Como as ribozimas s\u00e3o capazes de se replicar, unir e criar liga\u00e7\u00f5es pept\u00eddicas?"
    },
    {
        "answer":"Replication of RNA molecules can be performed chemically from RNA without polymerase enzymes.",
        "answer_pt":"A replica\u00e7\u00e3o de mol\u00e9culas de RNA pode ser realizada quimicamente a partir do RNA sem enzimas polimerase.",
        "id":"1182",
        "question":"Does RNA replication need polymerase enzymes?",
        "question_pt":"A replica\u00e7\u00e3o do RNA precisa de enzimas polimerase?"
    },
    {
        "answer":"deoxyribozymes can form from ribonucleotides (Wilson and Szostak, 1999) . Thus, DNA can arise from RNA chemically, without the key protein enzyme, the reverse transcriptase.",
        "answer_pt":"desoxirribozimas podem se formar a partir de ribonucleot\u00eddeos (Wilson e Szostak, 1999). Assim, o DNA pode surgir quimicamente do RNA, sem a enzima chave da prote\u00edna, a transcriptase reversa.",
        "id":"1183",
        "question":"How can DNA arise chemically from RNA?",
        "question_pt":"Como o DNA pode surgir quimicamente a partir do RNA?"
    },
    {
        "answer":"circular single-stranded RNAs",
        "answer_pt":"RNAs de fita simples circulares",
        "id":"1184",
        "question":"What do ribozymes consist of?",
        "question_pt":"Em que consistem as ribozimas?"
    },
    {
        "answer":"the genetic triplet code and do not encode proteins",
        "answer_pt":"o c\u00f3digo tripleto gen\u00e9tico e n\u00e3o codifica prote\u00ednas",
        "id":"1185",
        "question":"What do ribozymes lack?",
        "question_pt":"O que faltam ribozimas?"
    },
    {
        "answer":"structural information by hairpin-loops that form hydrogen bonds between incomplete double strands, and loops free to interact with other molecules.",
        "answer_pt":"informa\u00e7\u00f5es estruturais por la\u00e7os em gancho de cabelo que formam liga\u00e7\u00f5es de hidrog\u00eanio entre duplos fios incompletos e loops livres para interagir com outras mol\u00e9culas.",
        "id":"1186",
        "question":"What do ribozymes exhibit?",
        "question_pt":"O que exibem as ribozimas?"
    },
    {
        "answer":"severe joint pain, contorting its victims into unusual postures ",
        "answer_pt":"forte dor nas articula\u00e7\u00f5es, contorcendo suas v\u00edtimas em posturas incomuns",
        "id":"2477",
        "question":"What is CHIKV marked by?",
        "question_pt":"O que \u00e9 CHIKV marcado por?"
    },
    {
        "answer":" fever disease, headache, rash, nausea, vomiting, myalgia, and arthralgia",
        "answer_pt":"febre, dor de cabe\u00e7a, erup\u00e7\u00e3o cut\u00e2nea, n\u00e1usea, v\u00f4mito, mialgia e artralgia",
        "id":"2471",
        "question":"What does Chikungunya cause?",
        "question_pt":"O que Chikungunya causa?"
    },
    {
        "answer":"a mosquito-borne emerging pathogen",
        "answer_pt":"um pat\u00f3geno emergente transmitido por mosquitos",
        "id":"2470",
        "question":"What is Chikungunya virus?",
        "question_pt":"O que \u00e9 o v\u00edrus Chikungunya?"
    },
    {
        "answer":"Currently, there is no vaccine or antiviral treatmen",
        "answer_pt":"Atualmente, n\u00e3o existe vacina ou tratamento antiviral",
        "id":"2472",
        "question":"Is there a treatment?",
        "question_pt":"Existe tratamento?"
    },
    {
        "answer":"With the threat of an emerging global pandemic, the peculiar problems associated with the more immediate and seasonal epidemics warrant the development of an effective vaccine.",
        "answer_pt":"Com a amea\u00e7a de uma pandemia global emergente, os problemas peculiares associados \u00e0s epidemias mais imediatas e sazonais garantem o desenvolvimento de uma vacina eficaz.",
        "id":"2473",
        "question":"What conclusion is drawn in this report?",
        "question_pt":"Que conclus\u00e3o \u00e9 retirada neste relat\u00f3rio?"
    },
    {
        "answer":"a mosquito-borne pathogen listed by National Institute of Allergy and Infectious Diseases (NIAID) as a Category C Priority Pathogen that causes Chikungunya fever (CHIKF)",
        "answer_pt":"um pat\u00f3geno transmitido por mosquito listado pelo Instituto Nacional de Alergia e Doen\u00e7as Infecciosas (NIAID) como um pat\u00f3geno priorit\u00e1rio de categoria C que causa a febre de Chikungunya (CHIKF)",
        "id":"2474",
        "question":"What is Chikungunya virus?",
        "question_pt":"O que \u00e9 o v\u00edrus Chikungunya?"
    },
    {
        "answer":"an arthropod-borne virus (arbovirus",
        "answer_pt":"um v\u00edrus transmitido por artr\u00f3podes (arbov\u00edrus",
        "id":"2475",
        "question":"What is CHIKV?",
        "question_pt":"O que \u00e9 o CHIKV?"
    },
    {
        "answer":"primarily by Aedes aegypti, the infamous yellow fever propagator",
        "answer_pt":"principalmente por Aedes aegypti, o infame propagador da febre amarela",
        "id":"2476",
        "question":"How is CHIKV propagated to  humans?",
        "question_pt":"Como o CHIKV \u00e9 propagado para os seres humanos?"
    },
    {
        "answer":"Kimakonde vernacular language of Tanzania and Mozambique",
        "answer_pt":"L\u00edngua vernacular kimakonde da Tanz\u00e2nia e Mo\u00e7ambique",
        "id":"2478",
        "question":"From what  language the disease gets its name?",
        "question_pt":"De que idioma a doen\u00e7a recebe esse nome?"
    },
    {
        "answer":"'that which contorts or bends up'",
        "answer_pt":"'aquilo que se contorce ou se dobra'",
        "id":"2479",
        "question":"What is the word Chikungunya mean?",
        "question_pt":"Qual \u00e9 a palavra Chikungunya?"
    },
    {
        "answer":"the illness of the bended walker",
        "answer_pt":"a doen\u00e7a do caminhante dobrado",
        "id":"2480",
        "question":"What  does Chikungunya mean in Swahili?",
        "question_pt":"O que significa Chikungunya em sua\u00edli?"
    },
    {
        "answer":" in a sylvatic cycle among forest-dwelling Aedes spp. mosquitoes, wild primates, squirrels, birds, and rodents",
        "answer_pt":"em um ciclo silvestre entre Aedes spp. mosquitos, primatas selvagens, esquilos, p\u00e1ssaros e roedores",
        "id":"2481",
        "question":"How is CHIKV maintained in Africa?",
        "question_pt":"Como o CHIKV \u00e9 mantido na \u00c1frica?"
    },
    {
        "answer":" Ae. aegypti and Ae. albopictus",
        "answer_pt":"Ae. aegypti e Ae. albopictus",
        "id":"2482",
        "question":"What is it vectored by, in Asia?",
        "question_pt":"O que \u00e9 vetorizado na \u00c1sia?"
    },
    {
        "answer":"in an urban cycle whereby the mosquito spreads the disease from an infected human to an uninfected human, following an epidemiological pattern similar to dengue fever",
        "answer_pt":"em um ciclo urbano em que o mosquito transmite a doen\u00e7a de um ser humano infectado para um ser humano n\u00e3o infectado, seguindo um padr\u00e3o epidemiol\u00f3gico semelhante \u00e0 dengue",
        "id":"2483",
        "question":"How does the transmission in Asia occur?",
        "question_pt":"Como ocorre a transmiss\u00e3o na \u00c1sia?"
    },
    {
        "answer":"The 2005-2006 epidemic of CHIKV in La Reunion islands in the Indian Ocean,",
        "answer_pt":"A epidemia de CHIKV em 2005-2006 nas Ilhas Reuni\u00e3o no Oceano \u00cdndico,",
        "id":"2484",
        "question":"What spurred  the discovery of the new vector Ae. albopictus?",
        "question_pt":"O que estimulou a descoberta do novo vetor Ae. albopictus?"
    },
    {
        "answer":"46,000",
        "answer_pt":"46.000",
        "id":"2485",
        "question":"In the epidemic  peak how many cases per week were there on the island?",
        "question_pt":"No pico da epidemia, quantos casos por semana havia na ilha?"
    },
    {
        "answer":"the epidemiology and global expansion of CHIKV",
        "answer_pt":"a epidemiologia e expans\u00e3o global da CHIKV",
        "id":"2486",
        "question":"What does this review detail?",
        "question_pt":"O que essa revis\u00e3o detalha?"
    },
    {
        "answer":" its clinical features and pathogenesis and its symptoms and complications, and finally nominates a possible vaccine approach against CHIKV infection.",
        "answer_pt":"suas caracter\u00edsticas cl\u00ednicas e patog\u00eanese, seus sintomas e complica\u00e7\u00f5es e, finalmente, indica uma poss\u00edvel abordagem vacinal contra a infec\u00e7\u00e3o pelo CHIKV.",
        "id":"2487",
        "question":"What  dose this review describe?",
        "question_pt":"Que dose esta revis\u00e3o descreve?"
    },
    {
        "answer":" three genotypes based on phylogenetic studies.",
        "answer_pt":"tr\u00eas gen\u00f3tipos baseados em estudos filogen\u00e9ticos.",
        "id":"2488",
        "question":"How many genotypes of CHIKV have been isilated?",
        "question_pt":"Quantos gen\u00f3tipos de CHIKV foram isolados?"
    },
    {
        "answer":"the gene sequences of an Envelope protein (E1), are Asian, East/Central/ South African, and West African",
        "answer_pt":"as seq\u00fc\u00eancias gen\u00e9ticas de uma prote\u00edna Envelope (E1) s\u00e3o asi\u00e1ticas, leste / central / sul da \u00c1frica e oeste da \u00c1frica",
        "id":"2489",
        "question":"What are the  genotypes based on?",
        "question_pt":"Em que os gen\u00f3tipos se baseiam?"
    },
    {
        "answer":"between 50 and 310 y ago,",
        "answer_pt":"entre 50 e 310 anos atr\u00e1s,",
        "id":"2490",
        "question":"hen did Asian genotype emerge?",
        "question_pt":"Quando surgiu o gen\u00f3tipo asi\u00e1tico?"
    },
    {
        "answer":" between 100 and 840 y ago",
        "answer_pt":"entre 100 e 840 y atr\u00e1s",
        "id":"2491",
        "question":"When didthe Asian genotype diverge from African genotype?",
        "question_pt":"Quando o gen\u00f3tipo asi\u00e1tico divergiu do gen\u00f3tipo africano?"
    },
    {
        "answer":"has come a long way, with several mutations incorporated, and has continued to wreak epidemics in several regions",
        "answer_pt":"percorreu um longo caminho, com v\u00e1rias muta\u00e7\u00f5es incorporadas, e continuou a causar epidemias em v\u00e1rias regi\u00f5es",
        "id":"2492",
        "question":"What is the status of Asian CHIKV since its emergence?",
        "question_pt":"Qual \u00e9 o status da CHIKV asi\u00e1tica desde o seu surgimento?"
    },
    {
        "answer":" the Indian epidemic in 2005-2006, which was followed by a sudden explosion of cases in 2007. An estimated 1.3 million people across 13 states were reported to be infected in India [12, 16] , and CHIKV was also widespread in Malaysia, Sri Lanka, and Indonesia [17] . In July-August of 2007, CHIKV was reported in Italy, probably brought in by travelers from CHIKV-prone regions of India, Africa, and Indian Ocean islands such as Mauritius, Madagascar, and Seychelles.",
        "answer_pt":"a epidemia indiana em 2005-2006, seguida por uma s\u00fabita explos\u00e3o de casos em 2007. Estima-se que 1,3 milh\u00e3o de pessoas em 13 estados foram infectadas na \u00cdndia [12, 16], e o CHIKV tamb\u00e9m foi disseminado na Mal\u00e1sia, Sri Lanka. Lanka e Indon\u00e9sia [17]. Em julho-agosto de 2007, o CHIKV foi relatado na It\u00e1lia, provavelmente trazido por viajantes de regi\u00f5es propensas ao CHIKV da \u00cdndia, \u00c1frica e ilhas do Oceano \u00cdndico, como Maur\u00edcio, Madagascar e Seychelles.",
        "id":"2493",
        "question":"What are the recent activities of CHIKV?",
        "question_pt":"Quais s\u00e3o as atividades recentes da CHIKV?"
    },
    {
        "answer":"from the Kerala isolate, which was associated with a A226V shift in E1 gene that represents a successful evolutionary adaptation in the mosquito vector similar to the ones observed in Reunion Island [",
        "answer_pt":"do isolado Kerala, que foi associado a uma mudan\u00e7a no gene E1 da A226V, que representa uma adapta\u00e7\u00e3o evolutiva bem-sucedida no vetor do mosquito semelhante aos observados na Ilha da Reuni\u00e3o [",
        "id":"2494",
        "question":"How was the Italian isolation found to have evolved from?",
        "question_pt":"Como foi encontrado o isolamento italiano?"
    },
    {
        "answer":"2-6 d",
        "answer_pt":"2-6 d",
        "id":"2495",
        "question":"How many days is the incubation period?",
        "question_pt":"Quantos dias tem o per\u00edodo de incuba\u00e7\u00e3o?"
    },
    {
        "answer":"4-7 ",
        "answer_pt":"4-7",
        "id":"2496",
        "question":"In how many days do the symptoms arise?",
        "question_pt":"Em quantos dias os sintomas surgem?"
    },
    {
        "answer":"The first stage is acute, while the second stage, experienced by most but not all, is persistent, causing disabling polyarthritis. Characteristics of the acute phase include an abrupt onset of fever, arthralgia, and in some cases, maculopapular rash [6, 23] . The acute phase causes such intense joint and muscular pain that makes movement very difficult and prostrates its victims [",
        "answer_pt":"O primeiro est\u00e1gio \u00e9 agudo, enquanto o segundo est\u00e1gio, vivenciado pela maioria, mas n\u00e3o por todos, \u00e9 persistente, causando poliartrite incapacitante. As caracter\u00edsticas da fase aguda incluem um in\u00edcio abrupto de febre, artralgia e, em alguns casos, erup\u00e7\u00e3o cut\u00e2nea maculopapular [6, 23]. A fase aguda causa dores articulares e musculares t\u00e3o intensas que dificultam os movimentos e prostram suas v\u00edtimas [",
        "id":"2497",
        "question":"What are exhibited in the two phases?",
        "question_pt":"O que \u00e9 exibido nas duas fases?"
    },
    {
        "answer":"Ninety-five percent of infected adults are symptomatic after infection, and of these, most become disabled for weeks to months as a result of decreased dexterity, loss of mobility, and delayed reaction.",
        "answer_pt":"Noventa e cinco por cento dos adultos infectados s\u00e3o sintom\u00e1ticos ap\u00f3s a infec\u00e7\u00e3o e, destes, a maioria fica desativada por semanas a meses como resultado de menor destreza, perda de mobilidade e rea\u00e7\u00e3o tardia.",
        "id":"2498",
        "question":"What are consequences of infection?",
        "question_pt":"Quais s\u00e3o as consequ\u00eancias da infec\u00e7\u00e3o?"
    },
    {
        "answer":"The chronic stage of CHIKF is characterized by",
        "answer_pt":"O est\u00e1gio cr\u00f4nico do CHIKF \u00e9 caracterizado por",
        "id":"2499",
        "question":"What percentage of the patients still have the CHIKV IgM after eighteen months?",
        "question_pt":"Qual a porcentagem de pacientes que ainda t\u00eam o CHIKV IgM ap\u00f3s dezoito meses?"
    },
    {
        "answer":" by polyarthralgia that can last from weeks to years beyond the acute stage",
        "answer_pt":"por poliartralgia que pode durar de semanas a anos al\u00e9m do est\u00e1gio agudo",
        "id":"2500",
        "question":"What is te chronic stage characterized by?",
        "question_pt":"Qual \u00e9 o est\u00e1gio cr\u00f4nico caracterizado?"
    },
    {
        "answer":"fibroblasts",
        "answer_pt":"fibroblastos",
        "id":"2501",
        "question":"What is affected by CHIKV?",
        "question_pt":"O que \u00e9 afetado pelo CHIKV?"
    },
    {
        "answer":" The high number of nociceptive nerve endings found within the joints and muscle connective tissues",
        "answer_pt":"O alto n\u00famero de termina\u00e7\u00f5es nervosas nociceptivas encontradas nas articula\u00e7\u00f5es e nos tecidos conjuntivos musculares",
        "id":"2502",
        "question":"What explains the pain associated with CHIKV?",
        "question_pt":"O que explica a dor associada \u00e0 CHIKV?"
    },
    {
        "answer":"50%",
        "answer_pt":"50%",
        "id":"2503",
        "question":"What percentage of people suffering from the CHIKF are over 65 years old?",
        "question_pt":"Qual a porcentagem de pessoas que sofrem do CHIKF com mais de 65 anos?"
    },
    {
        "answer":"33% ",
        "answer_pt":"33%",
        "id":"2504",
        "question":"What percentage die?",
        "question_pt":"Que porcentagem morre?"
    },
    {
        "answer":"children",
        "answer_pt":"crian\u00e7as",
        "id":"2505",
        "question":"What other group is disproportionately affected?",
        "question_pt":"Que outro grupo \u00e9 afetado desproporcionalmente?"
    },
    {
        "answer":"from most common to least common, include respiratory failure, cardiovascular decompensation, meningoencephalitis, severe acute hepatitis, severe cutaneous effects, other central nervous system problems, and kidney failure",
        "answer_pt":"do mais comum ao menos comum, incluem insufici\u00eancia respirat\u00f3ria, descompensa\u00e7\u00e3o cardiovascular, meningoencefalite, hepatite aguda grave, efeitos cut\u00e2neos graves, outros problemas do sistema nervoso central e insufici\u00eancia renal",
        "id":"2506",
        "question":"What complications are associated with CHIKV?",
        "question_pt":"Quais complica\u00e7\u00f5es est\u00e3o associadas ao CHIKV?"
    },
    {
        "answer":"CHIKV undertakes a complex replication cycle upon host infection (Figure 2 ), which makes its genome susceptible to mutations ",
        "answer_pt":"O CHIKV realiza um ciclo de replica\u00e7\u00e3o complexo ap\u00f3s a infec\u00e7\u00e3o pelo hospedeiro (Figura 2), o que torna seu genoma suscet\u00edvel a muta\u00e7\u00f5es",
        "id":"2507",
        "question":"What happens after  host infection?",
        "question_pt":"O que acontece ap\u00f3s a infec\u00e7\u00e3o do hospedeiro?"
    },
    {
        "answer":"CHIKV with an alanine in the 226 position of the E1 gene (E1-A226)",
        "answer_pt":"CHIKV com uma alanina na posi\u00e7\u00e3o 226 do gene E1 (E1-A226)",
        "id":"2508",
        "question":"What did the Ae.Aegypti which is responsible for epidemics in Kenya, Comoros and Seychelles carry?",
        "question_pt":"O que o Ae.Aegypti, respons\u00e1vel pelas epidemias no Qu\u00eania, Comores e Seychelles?"
    },
    {
        "answer":" in an ecological pressure, favoring replacement of alanine at position 226 with valine (E1-A226V) ",
        "answer_pt":"em press\u00e3o ecol\u00f3gica, favorecendo a substitui\u00e7\u00e3o da alanina na posi\u00e7\u00e3o 226 pela valina (E1-A226V)",
        "id":"2509",
        "question":"what was the result of the decline in population of Ae. Aegyptus  when the virus struck the Reunion Islands, due to massive use dichlorodiphenyltrichloroethane usage?",
        "question_pt":"qual foi o resultado do decl\u00ednio da popula\u00e7\u00e3o de Ae. Aegyptus quando o v\u00edrus atingiu as Ilhas Reuni\u00e3o, devido ao uso maci\u00e7o de diclorodifeniltricloroetano?"
    },
    {
        "answer":"CHIKV's secondary vector species, Ae. albopictus, to supplement Ae. aegypti as its primary vector",
        "answer_pt":"Esp\u00e9cies secund\u00e1rias de vetores de CHIKV, Ae. albopictus, para suplementar Ae. aegypti como seu vetor principal",
        "id":"2510",
        "question":"What did this mutation allow?",
        "question_pt":"O que essa muta\u00e7\u00e3o permitiu?"
    },
    {
        "answer":" Ae. albopictus",
        "answer_pt":"Ae. albopictus",
        "id":"2511",
        "question":"What vectored the large epidemic in La Reunion Islands?",
        "question_pt":"O que vectorou a grande epidemia nas Ilhas Reuni\u00e3o?"
    },
    {
        "answer":"34% ",
        "answer_pt":"34%",
        "id":"2512",
        "question":"What percentage of population was affected?",
        "question_pt":"Qual porcentagem da popula\u00e7\u00e3o foi afetada?"
    },
    {
        "answer":"All of the CHIKV strains isolated from Mayotte carried the E1-A226V mutation, and the mutation was also found in Madagascar in 2007 [",
        "answer_pt":"Todas as cepas de CHIKV isoladas de Mayotte carregavam a muta\u00e7\u00e3o E1-A226V, e a muta\u00e7\u00e3o tamb\u00e9m foi encontrada em Madagascar em 2007 [",
        "id":"2513",
        "question":"Where were  the CHIKV strain found?",
        "question_pt":"Onde foi encontrada a cepa CHIKV?"
    },
    {
        "answer":"mutation was not present at the beginning of the Indian Ocean Islands outbreak (before September 2005). However, more than 90% of later viral strains found there had incorporated the mutation (December-March 2006), indicating a genotype switch during the winter season",
        "answer_pt":"a muta\u00e7\u00e3o n\u00e3o estava presente no in\u00edcio do surto das Ilhas do Oceano \u00cdndico (antes de setembro de 2005). No entanto, mais de 90% das cepas virais posteriores encontradas ali incorporaram a muta\u00e7\u00e3o (dezembro a mar\u00e7o de 2006), indicando uma troca de gen\u00f3tipo durante o inverno",
        "id":"2514",
        "question":"What is the finding on E1-A226V in Indian Ocean?",
        "question_pt":"Qual \u00e9 a conclus\u00e3o sobre o E1-A226V no Oceano \u00cdndico?"
    },
    {
        "answer":"an increase in infectivity of Ae. albopictus when compared to its infectivity of Ae. aegypti ",
        "answer_pt":"um aumento na infecciosidade de Ae. albopictus quando comparado \u00e0 sua infectividade de Ae. aegypti",
        "id":"2515",
        "question":"What has the E1-A226V enabled?",
        "question_pt":"O que o E1-A226V est\u00e1 ativado?"
    },
    {
        "answer":"Ae. albopictus",
        "answer_pt":"Ae. albopictus",
        "id":"2516",
        "question":"What has become the preferred and lethal vector?",
        "question_pt":"O que se tornou o vetor preferido e letal?"
    },
    {
        "answer":" E1-A226V virus was 100 times more infective to Ae. albopictus than it was to Ae. aegypti",
        "answer_pt":"O v\u00edrus E1-A226V foi 100 vezes mais infeccioso para Ae. albopictus do que era para Ae. aegypti",
        "id":"2517",
        "question":"What was the finding on the Green Fluorescent tagged E1-A226V?",
        "question_pt":"Qual foi a conclus\u00e3o sobre o E1-A226V com a marca Green Fluorescent?"
    },
    {
        "answer":"Ae. albopictus",
        "answer_pt":"Ae. albopictus",
        "id":"2518",
        "question":"What became the main vector in the Indian Ocean within 1-2 y after CHIKV was introduced?",
        "question_pt":"O que se tornou o principal vetor no Oceano \u00cdndico dentro de 1-2 anos ap\u00f3s a introdu\u00e7\u00e3o do CHIKV?"
    },
    {
        "answer":"for over 300 ",
        "answer_pt":"por mais de 300",
        "id":"2519",
        "question":"how long Ae. aegypti been established in North America?",
        "question_pt":"quanto tempo. aegypti foi estabelecido na Am\u00e9rica do Norte?"
    },
    {
        "answer":"has been in many areas of the US, since 1985, primarily in Florida [32] and since then has expanded its range in the country.",
        "answer_pt":"est\u00e1 presente em muitas \u00e1reas dos EUA, desde 1985, principalmente na Fl\u00f3rida [32] e, desde ent\u00e3o, amplia sua gama no pa\u00eds.",
        "id":"2520",
        "question":"What is the presence of Ae.albopictus in North America?",
        "question_pt":"Qual \u00e9 a presen\u00e7a de Ae.albopictus na Am\u00e9rica do Norte?"
    },
    {
        "answer":"50%",
        "answer_pt":"50%",
        "id":"2521",
        "question":"What percentage of newborns were infected from their mother?",
        "question_pt":"Qual a porcentagem de rec\u00e9m-nascidos infectados pela m\u00e3e?"
    },
    {
        "answer":"congenital illness and fetal death",
        "answer_pt":"doen\u00e7a cong\u00eanita e morte fetal",
        "id":"2522",
        "question":"What has been some instances of mother to  fetus transmission?",
        "question_pt":"Quais foram alguns casos de transmiss\u00e3o de m\u00e3e para feto?"
    },
    {
        "answer":"During the 2005-2006 La Reunion Island outbreaks, Ramful et al. discovered that mothers could transmit CHIKV to their progeny during the perinatal period (Day 24 to Day +1) [33, 34] , and it is associated with a high degree of morbidity. By mean Day 4 of life, all of the neonates were symptomatic for CHIKV, exhibiting common CHIKF symptoms.",
        "answer_pt":"Durante os surtos de 2005-2006 na Ilha da Reuni\u00e3o, Ramful et al. descobriram que as m\u00e3es poderiam transmitir o CHIKV \u00e0 sua prog\u00eanie durante o per\u00edodo perinatal (dia 24 a dia +1) [33, 34] e est\u00e1 associado a um alto grau de morbidade. Por meio do dia 4 de vida, todos os neonatos eram sintom\u00e1ticos para CHIKV, exibindo sintomas comuns de CHIKF.",
        "id":"2523",
        "question":"What  did the studies reveal regarding transmission from mothers during perinatal period?",
        "question_pt":"O que os estudos revelaram sobre a transmiss\u00e3o das m\u00e3es durante o per\u00edodo perinatal?"
    },
    {
        "answer":"motherto-child transmission most likely happens transplacentally shortly before delivery",
        "answer_pt":"a transmiss\u00e3o m\u00e3e-filho provavelmente ocorre por via transplacent\u00e1ria pouco antes do parto",
        "id":"2524",
        "question":"What is theorized regarding transmission?",
        "question_pt":"O que \u00e9 teorizado em rela\u00e7\u00e3o \u00e0 transmiss\u00e3o?"
    },
    {
        "answer":"neonatal infection associated with intrapartum maternal viremia that progressed to develop encephalitis owing to vertical transmission from infected mothers ",
        "answer_pt":"infec\u00e7\u00e3o neonatal associada \u00e0 viremia materna intraparto que evoluiu com encefalite devido \u00e0 transmiss\u00e3o vertical de m\u00e3es infectadas",
        "id":"2525",
        "question":"What did the study report?",
        "question_pt":"O que o relat\u00f3rio do estudo?"
    },
    {
        "answer":" DNA vaccines could play a major role in combating CHIKV",
        "answer_pt":"As vacinas de DNA podem desempenhar um papel importante no combate ao CHIKV",
        "id":"2526",
        "question":"What is a conclusion of this report?",
        "question_pt":"O que \u00e9 uma conclus\u00e3o deste relat\u00f3rio?"
    },
    {
        "answer":"Vaccines are literally a critical component of CHIKV disease control and therefore research in this area is highly encouraged. ",
        "answer_pt":"As vacinas s\u00e3o literalmente um componente cr\u00edtico do controle da doen\u00e7a pelo CHIKV e, portanto, a pesquisa nessa \u00e1rea \u00e9 altamente incentivada.",
        "id":"2527",
        "question":"What is a conclusion of this report?",
        "question_pt":"O que \u00e9 uma conclus\u00e3o deste relat\u00f3rio?"
    },
    {
        "answer":"as a Category C pathogen alongside the influenza and SARS-CoV viruses ",
        "answer_pt":"como um pat\u00f3geno de categoria C ao lado dos v\u00edrus influenza e SARS-CoV",
        "id":"2528",
        "question":"What is the NIAID designation of CHIKV?",
        "question_pt":"Qual \u00e9 a designa\u00e7\u00e3o NIAID de CHIKV?"
    },
    {
        "answer":" its ability to induce cross-reactive immune responses against the three distinct phylogenetic groups of CHIKV. Also DNA-based vaccines can be produced more rapidly than protein-based vaccines.",
        "answer_pt":"sua capacidade de induzir respostas imunes reativas cruzadas contra os tr\u00eas grupos filogen\u00e9ticos distintos de CHIKV. Tamb\u00e9m vacinas baseadas em DNA podem ser produzidas mais rapidamente do que vacinas baseadas em prote\u00ednas.",
        "id":"2529",
        "question":"What are the strengths and advantages of DNA based vaccine?",
        "question_pt":"Quais s\u00e3o os pontos fortes e as vantagens da vacina baseada em DNA?"
    },
    {
        "answer":"two",
        "answer_pt":"dois",
        "id":"4250",
        "question":"How many facilities were monitored in this study?",
        "question_pt":"Quantas instala\u00e7\u00f5es foram monitoradas neste estudo?"
    },
    {
        "answer":"25.74%",
        "answer_pt":"25,74%",
        "id":"4251",
        "question":"What percentage of facilities believed they were adequately equipped to handle Ebola virus disease?",
        "question_pt":"Qual a porcentagem de instala\u00e7\u00f5es que acreditava estar adequadamente equipada para lidar com a doen\u00e7a pelo v\u00edrus Ebola?"
    },
    {
        "answer":"26",
        "answer_pt":"26",
        "id":"4252",
        "question":"How many facilities believed they were adequately equipped to handle Ebla virus disease?",
        "question_pt":"Quantas instala\u00e7\u00f5es acreditavam estar adequadamente equipadas para lidar com a doen\u00e7a pelo v\u00edrus Ebola?"
    },
    {
        "answer":"less than 50%",
        "answer_pt":"menos de 50%",
        "id":"4253",
        "question":"How many healthcare workers would be willing to continue working during the Ebola virus outbreak?",
        "question_pt":"Quantos profissionais de sa\u00fade estariam dispostos a continuar trabalhando durante o surto de v\u00edrus Ebola?"
    },
    {
        "answer":"if HCWs are assured or guaranteed that they and or their families would be taken care of in case of death or while taking care of an EVD case,",
        "answer_pt":"se os profissionais de sa\u00fade tiverem a garantia ou a garantia de que eles e suas fam\u00edlias ser\u00e3o atendidos em caso de morte ou durante um caso de EVD,",
        "id":"4254",
        "question":"What does the study suggest would make healthcare workers more willing to care for patients during an Ebola virus outbreak?",
        "question_pt":"O que o estudo sugere tornaria os profissionais de sa\u00fade mais dispostos a cuidar de pacientes durante um surto de v\u00edrus Ebola?"
    },
    {
        "answer":"infectious bronchitis virus (IBV)",
        "answer_pt":"v\u00edrus da bronquite infecciosa (IBV)",
        "id":"5160",
        "question":"What causes avian infectious bronchitis?",
        "question_pt":"O que causa bronquite infecciosa avi\u00e1ria?"
    },
    {
        "answer":"serum concentration of mannose-binding lectin (MBL)",
        "answer_pt":"concentra\u00e7\u00e3o s\u00e9rica de lectina de liga\u00e7\u00e3o \u00e0 manose (MBL)",
        "id":"5161",
        "question":"What differentiated the two chicken lines used in this  study?",
        "question_pt":"O que diferenciava as duas linhas de frango usadas neste estudo?"
    },
    {
        "answer":"spleen",
        "answer_pt":"ba\u00e7o",
        "id":"5162",
        "question":"Which organ was used for the RNA sequencing samples?",
        "question_pt":"Qual \u00f3rg\u00e3o foi usado para as amostras de seq\u00fcenciamento de RNA?"
    },
    {
        "answer":"A mechanistic understanding of the impact of bats\u2019 virus hosting capacities, including uniquely constitutive immune pathways, on cellular-scale viral dynamics",
        "answer_pt":"Uma compreens\u00e3o mecanicista do impacto das capacidades de hospedagem de v\u00edrus dos morcegos, incluindo vias imunol\u00f3gicas constitutivas \u00fanicas, na din\u00e2mica viral em escala celular",
        "id":"2719",
        "question":"What is needed to elucidate zoonotic emergence?",
        "question_pt":"O que \u00e9 necess\u00e1rio para elucidar a emerg\u00eancia zoon\u00f3tica?"
    },
    {
        "answer":" heightened immune responses limit pathogen-induced cellular morbidity, which can facilitate the establishment of rapidly-propagating persistent infections within-host. Rapidly-transmitting viruses that have evolved with bat immune systems will likely cause enhanced virulence following emergence into secondary hosts with immune systems that diverge from those unique to bats.",
        "answer_pt":"respostas imunes aumentadas limitam a morbidade celular induzida por pat\u00f3genos, o que pode facilitar o estabelecimento de infec\u00e7\u00f5es persistentes de propaga\u00e7\u00e3o r\u00e1pida no hospedeiro. Os v\u00edrus de transmiss\u00e3o r\u00e1pida que evolu\u00edram com o sistema imunol\u00f3gico dos morcegos provavelmente causar\u00e3o virul\u00eancia aprimorada ap\u00f3s a emerg\u00eancia em hospedeiros secund\u00e1rios com sistemas imunol\u00f3gicos que divergem daqueles exclusivos dos morcegos.",
        "id":"2720",
        "question":"What is the conclusion of  this report?",
        "question_pt":"Qual \u00e9 a conclus\u00e3o deste relat\u00f3rio?"
    },
    {
        "answer":"for their role as reservoir hosts for emerging viral zoonoses, including rabies and related lyssaviruses, Hendra and Nipah henipaviruses, Ebola and Marburg filoviruses, and SARS coronavirus ",
        "answer_pt":"por seu papel de hospedeiros reservat\u00f3rios de zoonoses virais emergentes, incluindo raiva e lisav\u00edrus relacionados, henipav\u00edrus Hendra e Nipah, filov\u00edrus Ebola e Marburg e coronav\u00edrus SARS",
        "id":"2721",
        "question":"Why  have bats received attention in recent years?",
        "question_pt":"Por que os morcegos receberam aten\u00e7\u00e3o nos \u00faltimos anos?"
    },
    {
        "answer":"no obvious disease symptoms upon infection with pathogens that are highly virulent in non-volant mammals (Schountz et al., 2017) but may, instead, support viruses as longterm persistent infections, rather than transient, immunizing pathologies",
        "answer_pt":"n\u00e3o h\u00e1 sintomas \u00f3bvios da doen\u00e7a na infec\u00e7\u00e3o por pat\u00f3genos altamente virulentos em mam\u00edferos n\u00e3o-voadores (Schountz et al., 2017), mas podem, em vez disso, suportar v\u00edrus como infec\u00e7\u00f5es persistentes a longo prazo, em vez de patologias imunol\u00f3gicas transit\u00f3rias",
        "id":"2722",
        "question":"What difference bats demonstrate compared to most non-Chiropteran mammals?",
        "question_pt":"Que diferen\u00e7a os morcegos demonstram em compara\u00e7\u00e3o com a maioria dos mam\u00edferos n\u00e3o quir\u00f3pteros?"
    },
    {
        "answer":"host receptor sequence incompatibilities for some bat-virus combinations (Ng et al., 2015; Takadate et al., 2020) and constitutive expression of the antiviral cytokine",
        "answer_pt":"incompatibilidades da sequ\u00eancia de receptores do hospedeiro para algumas combina\u00e7\u00f5es de v\u00edrus bat (Ng et al., 2015; Takadate et al., 2020) e express\u00e3o constitutiva da citocina antiviral",
        "id":"2723",
        "question":"What suite of species-specific mechanisms do bats have to limit viral load?",
        "question_pt":"Que conjunto de mecanismos espec\u00edficos de esp\u00e9cie os morcegos t\u00eam para limitar a carga viral?"
    },
    {
        "answer":" the presence of viral RNA or DNA in the cytoplasm of mammalian cells will induce secretion of type I interferon proteins (IFN-a and IFN-b), which promote expression and translation of interferon-stimulated genes (ISGs) in neighboring cells ",
        "answer_pt":"a presen\u00e7a de RNA ou DNA viral no citoplasma das c\u00e9lulas de mam\u00edferos induzir\u00e1 a secre\u00e7\u00e3o de prote\u00ednas interferon tipo I (IFN-a e IFN-b), que promovem a express\u00e3o e tradu\u00e7\u00e3o de genes estimulados por interferon (ISGs) nas c\u00e9lulas vizinhas",
        "id":"2724",
        "question":"How are mammalian cells typically rendered antiviral?",
        "question_pt":"Como as c\u00e9lulas dos mam\u00edferos s\u00e3o tipicamente antivirais?"
    },
    {
        "answer":"widespread inflammation and concomitant immunopathology upon viral infection",
        "answer_pt":"inflama\u00e7\u00e3o generalizada e imunopatologia concomitante ap\u00f3s infec\u00e7\u00e3o viral",
        "id":"2725",
        "question":"In non-flying mammals, what what would be elicited by IFN expression upon viral infection?",
        "question_pt":"Em mam\u00edferos n\u00e3o-voadores, o que seria induzido pela express\u00e3o de IFN ap\u00f3s infec\u00e7\u00e3o viral?"
    },
    {
        "answer":"bats support unique adaptations to combat inflammation",
        "answer_pt":"morcegos suportam adapta\u00e7\u00f5es \u00fanicas para combater a inflama\u00e7\u00e3o",
        "id":"2726",
        "question":"What do the bats do instead?",
        "question_pt":"O que os morcegos fazem?"
    },
    {
        "answer":"to mitigate metabolic damage induced during flight",
        "answer_pt":"para mitigar os danos metab\u00f3licos induzidos durante o v\u00f4o",
        "id":"2727",
        "question":"Why may the bats have this unique adaptation?",
        "question_pt":"Por que os morcegos podem ter essa adapta\u00e7\u00e3o \u00fanica?"
    },
    {
        "answer":"to describe the mechanistic underpinnings of long-term patterns of steady-state viral load exhibited by patients in chronic phase infections with HIV, who appeared to produce and clear virus at equivalent rates ",
        "answer_pt":"descrever os fundamentos mecanicistas dos padr\u00f5es de longo prazo da carga viral no estado estacion\u00e1rio exibidos por pacientes em infec\u00e7\u00f5es cr\u00f4nicas por HIV com HIV, que pareciam produzir e limpar v\u00edrus a taxas equivalentes",
        "id":"2728",
        "question":"Why  was the field of virus dynamics developed?",
        "question_pt":"Por que o campo da din\u00e2mica de v\u00edrus foi desenvolvido?"
    },
    {
        "answer":"bats are natural reservoirs for viruses that have some of the highest fatality rates of any viruses that people acquire from wild animals -including rabies, Ebola and the SARS coronavirus.",
        "answer_pt":"os morcegos s\u00e3o reservat\u00f3rios naturais de v\u00edrus que apresentam algumas das mais altas taxas de mortalidade de todos os v\u00edrus que as pessoas adquirem de animais selvagens - incluindo raiva, Ebola e coronav\u00edrus SARS.",
        "id":"2729",
        "question":"How are bats connected to fatal viral diseases?",
        "question_pt":"Como os morcegos est\u00e3o conectados a doen\u00e7as virais fatais?"
    },
    {
        "answer":"some bats have an antiviral immune response called the interferon pathway perpetually switched on",
        "answer_pt":"alguns morcegos t\u00eam uma resposta imune antiviral chamada via do interferon ativamente ligada",
        "id":"2730",
        "question":"What is  an example of anti-viral defense in bats?",
        "question_pt":"O que \u00e9 um exemplo de defesa antiviral em morcegos?"
    },
    {
        "answer":" harmful inflammation",
        "answer_pt":"inflama\u00e7\u00e3o prejudicial",
        "id":"2731",
        "question":"What would be caused by  this hyper-vigilance in most other mammals?",
        "question_pt":"O que seria causado por essa hipervigil\u00e2ncia na maioria dos outros mam\u00edferos?"
    },
    {
        "answer":"Bats, however, have adapted anti-inflammatory traits that protect them from such harm, include the loss of certain genes that normally promote inflammation.",
        "answer_pt":"Os morcegos, no entanto, adaptaram caracter\u00edsticas anti-inflamat\u00f3rias que os protegem de tais danos, incluem a perda de certos genes que normalmente promovem a inflama\u00e7\u00e3o.",
        "id":"2732",
        "question":"How are bats different?",
        "question_pt":"Como os morcegos s\u00e3o diferentes?"
    },
    {
        "answer":"-the black flying fox -in which the interferon pathway is always on, and another -the Egyptian fruit bat -in which this pathway is only activated during an infection.",
        "answer_pt":"- a raposa voadora preta - na qual a via do interferon est\u00e1 sempre ativada e outra - o morcego eg\u00edpcio - em que essa via \u00e9 ativada apenas durante uma infec\u00e7\u00e3o.",
        "id":"2733",
        "question":"What bat species cells were compared?",
        "question_pt":"Quais c\u00e9lulas das esp\u00e9cies de morcegos foram comparadas?"
    },
    {
        "answer":" In both bat species, the strongest antiviral responses were countered by the virus spreading more quickly from cell to cell. This suggests that bat immune defenses may drive the evolution of faster transmitting viruses, and while bats are well protected from the harmful effects of their own prolific viruses, other creatures like humans are not.",
        "answer_pt":"Nas duas esp\u00e9cies de morcegos, as respostas antivirais mais fortes foram combatidas pelo v\u00edrus que se espalhou mais rapidamente de c\u00e9lula para c\u00e9lula. Isso sugere que as defesas imunol\u00f3gicas dos morcegos podem impulsionar a evolu\u00e7\u00e3o de v\u00edrus de transmiss\u00e3o mais r\u00e1pida e, embora os morcegos estejam bem protegidos dos efeitos nocivos de seus pr\u00f3prios v\u00edrus prol\u00edficos, outras criaturas como os humanos n\u00e3o o s\u00e3o.",
        "id":"2734",
        "question":"What was the conclusion of the study ?",
        "question_pt":"Qual foi a conclus\u00e3o do estudo?"
    },
    {
        "answer":"help scientists develop better ways to predict, prevent or limit the spread of viruses from bats to humans. ",
        "answer_pt":"ajude os cientistas a desenvolver maneiras melhores de prever, prevenir ou limitar a propaga\u00e7\u00e3o de v\u00edrus de morcegos para humanos.",
        "id":"2735",
        "question":"What would be the benefit of learning more about bat's defenses and how they  drive virus evolution?",
        "question_pt":"Qual seria o benef\u00edcio de aprender mais sobre as defesas dos morcegos e como elas conduzem a evolu\u00e7\u00e3o dos v\u00edrus?"
    },
    {
        "answer":"demonstrate idiosyncratic induced interferon responses upon viral challenge",
        "answer_pt":"demonstram respostas de interferon induzidas idiossincr\u00e1sicas mediante desafio viral",
        "id":"2736",
        "question":"Which cells are IFN-defective and therefore limited in  antiviral capacity?",
        "question_pt":"Quais c\u00e9lulas s\u00e3o IFN-defeituosas e, portanto, limitadas em capacidade antiviral?"
    },
    {
        "answer":"RoNi/7.1 (Rousettus aegyptiacus) cells",
        "answer_pt":"C\u00e9lulas RoNi / 7.1 (Rousettus aegyptiacus)",
        "id":"2737",
        "question":"What cells demonstrate idiosyncratic interferon response?",
        "question_pt":"Quais c\u00e9lulas demonstram resposta idiossincr\u00e1tica ao interferon?"
    },
    {
        "answer":"PaKiT01 (Pteropus alecto) cell",
        "answer_pt":"C\u00e9lula PaKiT01 (Pteropus alecto)",
        "id":"2738",
        "question":"Which cells express constitutive IFN-a?",
        "question_pt":"Quais c\u00e9lulas expressam IFN-a constitutivo?"
    },
    {
        "answer":"Because plaque assays restrict viral transmission neighbor-to-neighbor in two-dimensional cellular space ",
        "answer_pt":"Como os ensaios em placas restringem a transmiss\u00e3o viral vizinho a vizinho no espa\u00e7o celular bidimensional",
        "id":"2739",
        "question":"How were  the spread of GFP-expressing virus-infected cells across tissue monolayers tracked via inverted fluorescence microscopy?",
        "question_pt":"Como a dissemina\u00e7\u00e3o de c\u00e9lulas infectadas por v\u00edrus que expressam GFP entre monocamadas de tecidos foi rastreada por microscopia de fluoresc\u00eancia invertida?"
    },
    {
        "answer":" For each infection trial, we monitored and re-imaged plates for up to 200 hr of observations or until total monolayer destruction, processed resulting images, and generated a time series of the proportion of infectious-cell occupied plate space across the duration of each trial (see Materials and methods). We used generalized additive models to infer the time course of all cell culture replicates and construct the multi-trial dataset to which we eventually fit our mechanistic transmission model for each cell line-virus-specific combinatio",
        "answer_pt":"Para cada teste de infec\u00e7\u00e3o, monitoramos e redimensionamos as placas por at\u00e9 200 horas de observa\u00e7\u00e3o ou at\u00e9 a destrui\u00e7\u00e3o total de monocamada, processamos as imagens resultantes e geramos uma s\u00e9rie temporal da propor\u00e7\u00e3o de espa\u00e7o ocupado pelas c\u00e9lulas infecciosas ao longo da dura\u00e7\u00e3o de cada teste (consulte Materiais e m\u00e9todos). Usamos modelos aditivos generalizados para inferir o curso do tempo de todas as r\u00e9plicas de cultura de c\u00e9lulas e construir o conjunto de dados de v\u00e1rios ensaios no qual eventualmente ajustamos nosso modelo de transmiss\u00e3o mecanicista para cada combina\u00e7\u00e3o espec\u00edfica de v\u00edrus de linha celular",
        "id":"2740",
        "question":"How were  the spread of GFP-expressing virus-infected cells tracked?",
        "question_pt":"Como foi rastreada a dissemina\u00e7\u00e3o de c\u00e9lulas infectadas por v\u00edrus que expressam GFP?"
    },
    {
        "answer":"an innovative combination of in vitro experimentation and within-host modeling to explore the impact of unique bat immunity on virus dynamics.",
        "answer_pt":"uma combina\u00e7\u00e3o inovadora de experimenta\u00e7\u00e3o in vitro e modelagem dentro do hospedeiro para explorar o impacto da imunidade exclusiva dos morcegos na din\u00e2mica do v\u00edrus.",
        "id":"2741",
        "question":"How was the modeling carried out?",
        "question_pt":"Como foi realizada a modelagem?"
    },
    {
        "answer":"that bat cell lines demonstrated a signature of enhanced interferon-mediated immune response, of either constitutive or induced form, which allowed for establishment of rapid within-host, cell-to-cell virus transmission rates ",
        "answer_pt":"que as linhas celulares de morcego demonstraram uma assinatura de resposta imune mediada por interferon aprimorada, de forma constitutiva ou induzida, o que permitiu o estabelecimento de taxas r\u00e1pidas de transmiss\u00e3o de v\u00edrus c\u00e9lula a c\u00e9lula no hospedeiro",
        "id":"2742",
        "question":"What was the finding in this study?",
        "question_pt":"Qual foi o achado neste estudo?"
    },
    {
        "answer":"by both data-independent bifurcation analysis of our mean field theoretical model, as well as fitting of this model to viral infection time series established in bat cell culture.",
        "answer_pt":"pela an\u00e1lise de bifurca\u00e7\u00e3o independente de dados de nosso modelo te\u00f3rico de campo m\u00e9dio, bem como pelo ajuste desse modelo \u00e0s s\u00e9ries temporais de infec\u00e7\u00e3o viral estabelecidas na cultura de c\u00e9lulas de morcego.",
        "id":"2743",
        "question":"What supports the results?",
        "question_pt":"O que suporta os resultados?"
    },
    {
        "answer":"the antiviral state induced by the interferon pathway protects live cells from mortality in tissue culture, resulting in in vitro epidemics of extended duration that enhance the probability of establishing a long-term persistent infection.",
        "answer_pt":"o estado antiviral induzido pela via do interferon protege as c\u00e9lulas vivas da mortalidade na cultura de tecidos, resultando em epidemias in vitro de dura\u00e7\u00e3o prolongada que aumentam a probabilidade de estabelecer uma infec\u00e7\u00e3o persistente a longo prazo.",
        "id":"2744",
        "question":"What was additionally demonstrated?",
        "question_pt":"O que foi demonstrado adicionalmente?"
    },
    {
        "answer":"that viruses evolved in bat reservoirs possessing enhanced IFN capabilities could achieve more rapid within-host transmission rates without causing pathology to their hosts. Such rapidly-reproducing viruses would likely generate extreme virulence upon spillover to hosts lacking similar immune capacities to bats.",
        "answer_pt":"que os v\u00edrus evolu\u00edram em reservat\u00f3rios de morcegos com recursos aprimorados de IFN poderiam obter taxas de transmiss\u00e3o mais r\u00e1pidas dentro do host sem causar patologia em seus hosts. Tais v\u00edrus de reprodu\u00e7\u00e3o r\u00e1pida provavelmente gerariam extrema virul\u00eancia ao transbordar para hosts sem capacidades imunol\u00f3gicas semelhantes aos dos morcegos.",
        "id":"2745",
        "question":"What do  the studies suggest?",
        "question_pt":"O que os estudos sugerem?"
    },
    {
        "answer":"we first developed a novel, within-host, theoretical model elucidating the effects of unique bat immunity, then undertook bifurcation analysis of the model's equilibrium properties under immune absent, induced, and constitutive assumptions. We considered a cell line to be constitutively immune if possessing any number of antiviral cells at disease-free equilibrium but allowed the extent of constitutive immunity to vary across the parameter range for \", the constitutive rate of antiviral acquisition. ",
        "answer_pt":"primeiro, desenvolvemos um novo modelo te\u00f3rico interno ao hospedeiro, elucidando os efeitos de uma imunidade exclusiva ao morcego, e depois realizamos a an\u00e1lise de bifurca\u00e7\u00e3o das propriedades de equil\u00edbrio do modelo sob suposi\u00e7\u00f5es imunes ausentes, induzidas e constitutivas. Consideramos que uma linha celular \u00e9 constitutivamente imune se possu\u00edrem qualquer n\u00famero de c\u00e9lulas antivirais em equil\u00edbrio livre de doen\u00e7a, mas permitimos que a extens\u00e3o da imunidade constitutiva varie na faixa de par\u00e2metros para \", a taxa constitutiva de aquisi\u00e7\u00e3o antiviral.",
        "id":"2746",
        "question":"What was the methodology for this study?",
        "question_pt":"Qual foi a metodologia para este estudo?"
    },
    {
        "answer":" invasion threshold is elevated at high values of constitutive antiviral acquisition,",
        "answer_pt":"limiar de invas\u00e3o \u00e9 elevado em altos valores de aquisi\u00e7\u00e3o antiviral constitutiva,",
        "id":"2747",
        "question":"What was demonstrated in deriving the equation for R 0?",
        "question_pt":"O que foi demonstrado na deriva\u00e7\u00e3o da equa\u00e7\u00e3o para R 0?"
    },
    {
        "answer":"Constitutive immune processes can thus prohibit pathogen invasion, while induced responses, by definition, can only control infections post-hoc.",
        "answer_pt":"Os processos imunol\u00f3gicos constitutivos podem, assim, proibir a invas\u00e3o de pat\u00f3genos, enquanto as respostas induzidas, por defini\u00e7\u00e3o, s\u00f3 podem controlar infec\u00e7\u00f5es post-hoc.",
        "id":"2748",
        "question":"What is a conclusion of the modeling?",
        "question_pt":"O que \u00e9 uma conclus\u00e3o da modelagem?"
    },
    {
        "answer":"Regardless of mechanism (induced or constitutive), interferon-stimulated antiviral cells appear to play a key role in maintaining longer term or persistent infections by safeguarding susceptible cells from rapid infection and concomitant cell death. ",
        "answer_pt":"Independentemente do mecanismo (induzido ou constitutivo), as c\u00e9lulas antivirais estimuladas por interferon parecem desempenhar um papel fundamental na manuten\u00e7\u00e3o de infec\u00e7\u00f5es persistentes ou de longo prazo, protegendo as c\u00e9lulas suscet\u00edveis de infec\u00e7\u00e3o r\u00e1pida e morte celular concomitante.",
        "id":"2749",
        "question":"What is a conclusion of the study?",
        "question_pt":"O que \u00e9 uma conclus\u00e3o do estudo?"
    },
    {
        "answer":"that the constitutive IFN-a expression characteristic of P. alecto cells may represent more of a constitutive immune priming process than a perpetual, functional, antiviral defense.",
        "answer_pt":"que a caracter\u00edstica constitutiva de express\u00e3o de IFN-a das c\u00e9lulas P. alecto pode representar mais um processo constitutivo de imunidade prim\u00e1ria do que uma defesa antiviral perp\u00e9tua, funcional e funcional.",
        "id":"2750",
        "question":"What do  fits to rVSV-MARV infections on PaKiT01 cells suggest?",
        "question_pt":"O que se encaixa nas infec\u00e7\u00f5es por rVSV-MARV nas c\u00e9lulas PaKiT01?"
    },
    {
        "answer":"enhanced IFN-mediated immune pathways in bat reservoirs may promote elevated within-host virus replication rates prior to cross-species emergence. ",
        "answer_pt":"vias imunol\u00f3gicas melhoradas mediadas por IFN em reservat\u00f3rios de morcegos podem promover taxas elevadas de replica\u00e7\u00e3o de v\u00edrus dentro do hospedeiro antes do surgimento de esp\u00e9cies cruzadas.",
        "id":"2751",
        "question":"What do the findings indicate?",
        "question_pt":"O que os resultados indicam?"
    },
    {
        "answer":"general methods to study cross-scale viral dynamics, which suggest that within-host persistence is supported by robust antiviral responses characteristic of bat immune processes. ",
        "answer_pt":"m\u00e9todos gerais para estudar a din\u00e2mica viral em escala cruzada, que sugerem que a persist\u00eancia dentro do hospedeiro \u00e9 suportada por respostas antivirais robustas, caracter\u00edsticas dos processos imunol\u00f3gicos do morcego.",
        "id":"2752",
        "question":"What is presented in this study?",
        "question_pt":"O que \u00e9 apresentado neste estudo?"
    },
    {
        "answer":" Viruses which evolve rapid replication rates under these robust antiviral defenses may pose the greatest hazard for cross-species pathogen emergence into spillover hosts with immune systems that differ from those unique to bats. ",
        "answer_pt":"Os v\u00edrus que evoluem com taxas de replica\u00e7\u00e3o r\u00e1pida sob essas defesas antivirais robustas podem representar o maior risco para o surgimento de pat\u00f3genos entre esp\u00e9cies em hospedeiros que transbordam com sistemas imunol\u00f3gicos que diferem daqueles exclusivos dos morcegos.",
        "id":"2753",
        "question":"What is a conclusion of  this study?",
        "question_pt":"O que \u00e9 uma conclus\u00e3o deste estudo?"
    },
    {
        "answer":"people 85 years and older",
        "answer_pt":"pessoas com 85 anos ou mais",
        "id":"236",
        "question":"What age group has the highest rate of severe outcomes?",
        "question_pt":"Qual faixa et\u00e1ria tem a maior taxa de resultados graves?"
    },
    {
        "answer":"person-to-person",
        "answer_pt":"pessoa para pessoa",
        "id":"225",
        "question":"How is COVID-19 spread?",
        "question_pt":"Como o COVID-19 se espalha?"
    },
    {
        "answer":"50",
        "answer_pt":"50.",
        "id":"226",
        "question":"How many states in the U.S. have reported cases of COVID-19?",
        "question_pt":"Quantos estados nos EUA relataram casos de COVID-19?"
    },
    {
        "answer":"March 16",
        "answer_pt":"16 de mar\u00e7o",
        "id":"227",
        "question":"When did the White House launch the \"15 Days to Slow the Spread\" program?",
        "question_pt":"Quando a Casa Branca lan\u00e7ou o programa \"15 dias para diminuir a propaga\u00e7\u00e3o\"?"
    },
    {
        "answer":"isolate at home during their illness",
        "answer_pt":"isolar em casa durante a doen\u00e7a",
        "id":"230",
        "question":"What should mildly-ill patients do?",
        "question_pt":"O que os pacientes com doen\u00e7as leves devem fazer?"
    },
    {
        "answer":"betacoronavirus",
        "answer_pt":"betacoronav\u00edrus",
        "id":"231",
        "question":"What type of virus is SARS-CoV-2?",
        "question_pt":"Que tipo de v\u00edrus \u00e9 SARS-CoV-2?"
    },
    {
        "answer":"MERS-CoV and SARS-CoV.",
        "answer_pt":"MERS-CoV e SARS-CoV.",
        "id":"232",
        "question":"What viruses are similar to the COVID-19 coronavirus?",
        "question_pt":"Quais v\u00edrus s\u00e3o semelhantes ao coronav\u00edrus COVID-19?"
    },
    {
        "answer":"investigation phase, followed by recognition, initiation, and acceleration phases",
        "answer_pt":"fase de investiga\u00e7\u00e3o, seguida pelas fases de reconhecimento, inicia\u00e7\u00e3o e acelera\u00e7\u00e3o",
        "id":"233",
        "question":"What are the phases of a pandemic?",
        "question_pt":"Quais s\u00e3o as fases de uma pandemia?"
    },
    {
        "answer":"at the end of the acceleration phase",
        "answer_pt":"no final da fase de acelera\u00e7\u00e3o",
        "id":"234",
        "question":"At which phase does the peak of the pandemic occur?",
        "question_pt":"Em que fase ocorre o pico da pandemia?"
    },
    {
        "answer":"People who have serious chronic medical conditions like:\nHeart disease\nDiabetes\nLung disease",
        "answer_pt":"Pessoas que t\u00eam condi\u00e7\u00f5es m\u00e9dicas cr\u00f4nicas graves, como:\nDoen\u00e7a card\u00edaca\nDiabetes\nDoen\u00e7a pulmonar",
        "id":"237",
        "question":"People with which medical conditions have a higher rate of severe illness?",
        "question_pt":"Pessoas com condi\u00e7\u00f5es m\u00e9dicas com maior taxa de doen\u00e7as graves?"
    },
    {
        "answer":"rRT-PCR test",
        "answer_pt":"teste rRT-PCR",
        "id":"238",
        "question":"What kind of test can diagnose COVID-19?",
        "question_pt":"Que tipo de teste pode diagnosticar o COVID-19?"
    },
    {
        "answer":"bats",
        "answer_pt":"morcegos",
        "id":"235",
        "question":"In what species did the COVID-19 virus likely originate?",
        "question_pt":"Em que esp\u00e9cies o v\u00edrus COVID-19 provavelmente se originou?"
    },
    {
        "answer":"Does the patient have recent travel from an affected area?\nHas the patient been in close contact with someone with COVID-19 or with patients with pneumonia of unknown cause?\nDoes the patient reside in an area where there has been community spread of COVID-19?",
        "answer_pt":"O paciente fez uma viagem recente de uma \u00e1rea afetada?\nO paciente esteve em contato pr\u00f3ximo com algu\u00e9m com COVID-19 ou com pacientes com pneumonia de causa desconhecida?\nO paciente reside em uma \u00e1rea onde houve dissemina\u00e7\u00e3o comunit\u00e1ria do COVID-19?",
        "id":"228",
        "question":"What risk factors should be considered in addition to clinical symptoms?",
        "question_pt":"Quais fatores de risco devem ser considerados al\u00e9m dos sintomas cl\u00ednicos?"
    },
    {
        "answer":"severe acute respiratory syndrome coronavirus 2 ",
        "answer_pt":"s\u00edndrome respirat\u00f3ria aguda grave coronav\u00edrus 2",
        "id":"244",
        "question":"What is the acronym SARS-CoV-2?",
        "question_pt":"Qual \u00e9 o acr\u00f4nimo SARS-CoV-2?"
    },
    {
        "answer":"December 2019",
        "answer_pt":"Dezembro 2019",
        "id":"245",
        "question":"When was SARS-CoV-2 first identified?",
        "question_pt":"Quando o SARS-CoV-2 foi identificado pela primeira vez?"
    },
    {
        "answer":"Wuhan, capital of Hubei Province, China",
        "answer_pt":"Wuhan, capital da prov\u00edncia de Hubei, China",
        "id":"246",
        "question":"Where was SARS-CoV-2 first identified?",
        "question_pt":"Onde o SARS-CoV-2 foi identificado pela primeira vez?"
    },
    {
        "answer":"daily air travel volume",
        "answer_pt":"volume di\u00e1rio de viagens a\u00e9reas",
        "id":"247",
        "question":"What factor positively correlates with imported-and-reported cases counts of SARS-CoV-2 infection?",
        "question_pt":"Que fator se correlaciona positivamente com a contagem de casos importados e relatados de infec\u00e7\u00e3o por SARS-CoV-2?"
    },
    {
        "answer":"\u22486 days",
        "answer_pt":"\u22486 dias",
        "id":"272",
        "question":"What is the doubling time of the COVID-19 pandemic?",
        "question_pt":"Qual \u00e9 o tempo de duplica\u00e7\u00e3o da pandemia de COVID-19?"
    },
    {
        "answer":" in 2012 ",
        "answer_pt":"em 2012",
        "id":"4173",
        "question":"When did the first known cases of Middle East respiratory syndrome (MERS) occur?",
        "question_pt":"Quando os primeiros casos conhecidos de s\u00edndrome respirat\u00f3ria no Oriente M\u00e9dio (MERS) ocorreram?"
    },
    {
        "answer":"in Jordan",
        "answer_pt":"na Jord\u00e2nia",
        "id":"4174",
        "question":"Where did the first known cases of Middle East respiratory syndrome (MERS) occur?",
        "question_pt":"Onde ocorreram os primeiros casos conhecidos de s\u00edndrome respirat\u00f3ria no Oriente M\u00e9dio (MERS)?"
    },
    {
        "answer":"Jeddah, in the Kingdom of Saudi Arabia (KSA)",
        "answer_pt":"Jeddah, no Reino da Ar\u00e1bia Saudita (KSA)",
        "id":"4175",
        "question":"Where was the the case first to be publicly reported was from ?",
        "question_pt":"De onde foi o primeiro caso a ser divulgado publicamente?"
    },
    {
        "answer":"in a bat and in many dromedary camels (DC).",
        "answer_pt":"em um bast\u00e3o e em muitos camelos dromed\u00e1rios (DC).",
        "id":"4176",
        "question":"In what animals MERS-CoV sequences have been found ?",
        "question_pt":"Em quais animais as seq\u00fc\u00eancias de MERS-CoV foram encontradas?"
    },
    {
        "answer":"across the Arabian Peninsula and in parts of Africa",
        "answer_pt":"atrav\u00e9s da Pen\u00ednsula Ar\u00e1bica e em partes da \u00c1frica",
        "id":"4177",
        "question":"Where is MERS-CoV is enzootic in DC?",
        "question_pt":"Onde o MERS-CoV \u00e9 enzo\u00f3tico no CD?"
    },
    {
        "answer":" mild upper respiratory tract illness in its camel reservoir and sporadic, but relatively rare human infections.",
        "answer_pt":"doen\u00e7a leve do trato respirat\u00f3rio superior em seu reservat\u00f3rio de camelo e infec\u00e7\u00f5es humanas espor\u00e1dicas, mas relativamente raras.",
        "id":"4178",
        "question":"What does MERS-COV cause?",
        "question_pt":"O que causa o MERS-COV?"
    },
    {
        "answer":"remains unknown",
        "answer_pt":"permanece desconhecido",
        "id":"4179",
        "question":"Precisely how does the virus transmit to humans?",
        "question_pt":"Precisamente como o v\u00edrus transmite aos seres humanos?"
    },
    {
        "answer":"close and lengthy exposure",
        "answer_pt":"exposi\u00e7\u00e3o pr\u00f3xima e longa",
        "id":"4180",
        "question":"What appears to be a requirement for transmission?",
        "question_pt":"O que parece ser um requisito para a transmiss\u00e3o?"
    },
    {
        "answer":"The KSA ",
        "answer_pt":"The KSA",
        "id":"4181",
        "question":"What is a focal point of MERS?",
        "question_pt":"O que \u00e9 um ponto focal da MERS?"
    },
    {
        "answer":"lower respiratory tract (LRT) disease ",
        "answer_pt":"doen\u00e7a do trato respirat\u00f3rio inferior (LRT)",
        "id":"4182",
        "question":"What is MERS mostly known as?",
        "question_pt":"O que \u00e9 MERS mais conhecido como?"
    },
    {
        "answer":"fever, cough, breathing difficulties and pneumonia that may progress to acute respiratory distress syndrome, multiorgan failure and death in 20 % to 40 % of those infected. ",
        "answer_pt":"febre, tosse, dificuldades respirat\u00f3rias e pneumonia que podem evoluir para s\u00edndrome do desconforto respirat\u00f3rio agudo, fal\u00eancia de v\u00e1rios \u00f3rg\u00e3os e morte em 20% a 40% das pessoas infectadas.",
        "id":"4183",
        "question":"What does the MERS LRT disease involve?",
        "question_pt":"O que a doen\u00e7a de MERS LRT envolve?"
    },
    {
        "answer":" in mild and influenza-like illnesses and in those with no signs or symptoms.",
        "answer_pt":"em doen\u00e7as leves e semelhantes \u00e0 influenza e naquelas sem sinais ou sintomas.",
        "id":"4184",
        "question":"Where else MERS-COV has also been detected?",
        "question_pt":"Onde mais o MERS-COV tamb\u00e9m foi detectado?"
    },
    {
        "answer":"Older males",
        "answer_pt":"Homens mais velhos",
        "id":"4185",
        "question":"Who suffers severe diseases from MERS?",
        "question_pt":"Quem sofre de doen\u00e7as graves por MERS?"
    },
    {
        "answer":"MERS progresses more rapidly to respiratory failure and acute kidney injury (it also has an affinity for growth in kidney cells under laboratory conditions), is more frequently reported in patients with underlying disease and is more often fatal.",
        "answer_pt":"O MERS progride mais rapidamente para insufici\u00eancia respirat\u00f3ria e les\u00e3o renal aguda (tamb\u00e9m possui afinidade pelo crescimento de c\u00e9lulas renais em condi\u00e7\u00f5es de laborat\u00f3rio), \u00e9 mais frequentemente relatado em pacientes com doen\u00e7a subjacente e mais frequentemente fatal.",
        "id":"4186",
        "question":" Compared to severe acute respiratory syndrome (SARS)  and another sometimes- fatal zoonotic coronavirus disease, how does MERS affect the patients?",
        "question_pt":"Comparado \u00e0 s\u00edndrome respirat\u00f3ria aguda grave (SARS) e outra doen\u00e7a zoon\u00f3tica por coronav\u00edrus \u00e0s vezes fatal, como a MERS afeta os pacientes?"
    },
    {
        "answer":"to lapses in infection prevention and control (IPC) in healthcare settings",
        "answer_pt":"lapsos na preven\u00e7\u00e3o e controle de infec\u00e7\u00f5es (IPC) em servi\u00e7os de sa\u00fade",
        "id":"4187",
        "question":"To what have most human cases of MERS  been linked?",
        "question_pt":"Com o que a maioria dos casos humanos de MERS foi associada?"
    },
    {
        "answer":" among healthcare workers (HCWs) and higher exposures in those with occupations that bring them into close contact with camels. ",
        "answer_pt":"entre profissionais de sa\u00fade (profissionais de sa\u00fade) e exposi\u00e7\u00f5es mais altas naqueles com ocupa\u00e7\u00f5es que os colocam em contato pr\u00f3ximo com camelos.",
        "id":"4188",
        "question":"Among whom 20% of the virus detection are reported?",
        "question_pt":"Entre os quais 20% da detec\u00e7\u00e3o de v\u00edrus s\u00e3o relatados?"
    },
    {
        "answer":"widespread evidence of past infection in adult camels and limited past exposure among humans.",
        "answer_pt":"evid\u00eancia generalizada de infec\u00e7\u00e3o passada em camelos adultos e exposi\u00e7\u00e3o passada limitada entre seres humanos.",
        "id":"4189",
        "question":"What have sero-surveys of MERS virus found?",
        "question_pt":"O que encontraram as sero-pesquisas de v\u00edrus MERS?"
    },
    {
        "answer":"An email from Dr Ali Mohamed Zaki, an Egyptian virologist working at the Dr Soliman Fakeeh Hospital in Jeddah in the Kingdom of Saudi Arabia (KSA)",
        "answer_pt":"Um e-mail do Dr. Ali Mohamed Zaki, virologista eg\u00edpcio que trabalha no Hospital Dr. Soliman Fakeeh em Jeddah, no Reino da Ar\u00e1bia Saudita (KSA)",
        "id":"4190",
        "question":"How was the first culture of the new Coronavirus announced?",
        "question_pt":"Como foi anunciada a primeira cultura do novo Coronav\u00edrus?"
    },
    {
        "answer":"on the website of the professional emerging diseases (ProMED) network",
        "answer_pt":"no site da rede profissional de doen\u00e7as emergentes (ProMED)",
        "id":"4191",
        "question":"Where was the Email published?",
        "question_pt":"Onde o email foi publicado?"
    },
    {
        "answer":"20 th September 2012 ",
        "answer_pt":"20 de setembro de 2012",
        "id":"4192",
        "question":"When was the Email  published?",
        "question_pt":"Quando o email foi publicado?"
    },
    {
        "answer":"a 60 year old man from Bisha in the KSA",
        "answer_pt":"um homem de 60 anos de Bisha na KSA",
        "id":"4193",
        "question":"Whose was the first reported case?",
        "question_pt":"De quem foi o primeiro caso relatado?"
    },
    {
        "answer":"1,493",
        "answer_pt":"1.493",
        "id":"4194",
        "question":"How many  viral RNA or virus-specific antibodies been detected?",
        "question_pt":"Quantos RNA virais ou anticorpos espec\u00edficos para v\u00edrus foram detectados?"
    },
    {
        "answer":"over a third of the positive people dying (at least 527, 35 %)",
        "answer_pt":"mais de um ter\u00e7o das pessoas positivas morrendo (pelo menos 527, 35%)",
        "id":"4195",
        "question":"What is the death rate from MERS-COV?",
        "question_pt":"Qual \u00e9 a taxa de mortalidade do MERS-COV?"
    },
    {
        "answer":"a virus that had infected over 90 % of adult dromedary camels (DC; Camelus dromedarius) in the KSA [4] , also DCs across the Arabian Peninsula and parts of Africa that are a source of DC imports for the KSA ",
        "answer_pt":"um v\u00edrus que infectou mais de 90% dos camelos adultos dromed\u00e1rios (CD; Camelus dromedarius) no KSA [4], tamb\u00e9m CD na Pen\u00ednsula Ar\u00e1bica e em partes da \u00c1frica que s\u00e3o uma fonte de importa\u00e7\u00e3o de CD para o KSA",
        "id":"4197",
        "question":"What did the discovery process over two to three years reveal?",
        "question_pt":"O que o processo de descoberta revelou durante dois a tr\u00eas anos?"
    },
    {
        "answer":" relatively close and prolonged exposure ",
        "answer_pt":"exposi\u00e7\u00e3o relativamente pr\u00f3xima e prolongada",
        "id":"4198",
        "question":"What does subsequent transmission of MERS-CoV to other humans require?",
        "question_pt":"O que \u00e9 necess\u00e1ria a transmiss\u00e3o subsequente de MERS-CoV a outros seres humanos?"
    },
    {
        "answer":"The first viral isolate was patented ",
        "answer_pt":"O primeiro isolado viral foi patenteado",
        "id":"4200",
        "question":"What would restrict access to both the virus and to viral diagnostics ?",
        "question_pt":"O que restringiria o acesso ao v\u00edrus e ao diagn\u00f3stico viral?"
    },
    {
        "answer":" sensitive, validated reverse transcriptase real-time polymerase chain reaction (RT-rtPCR)-based diagnostics were quickly described ",
        "answer_pt":"os diagn\u00f3sticos baseados em rea\u00e7\u00e3o em cadeia da polimerase em tempo real da transcriptase reversa validada e sens\u00edvel (RT-rtPCR) foram rapidamente descritos",
        "id":"4201",
        "question":"How was the virus then made freely available? ",
        "question_pt":"Como o v\u00edrus foi disponibilizado gratuitamente?"
    },
    {
        "answer":"as exopeptidase dipeptidyl peptidase 4 (DPP4; also called CD26)",
        "answer_pt":"como exopeptidase dipeptidil peptidase 4 (DPP4; tamb\u00e9m chamado CD26)",
        "id":"4202",
        "question":"What has epidemiology and research identified the MERS-CoV's cell receptor is?",
        "question_pt":"O que a epidemiologia e a pesquisa identificaram \u00e9 o receptor celular do MERS-CoV?"
    },
    {
        "answer":"eliciting a more proinflammatory response than SARS-CoV",
        "answer_pt":"provocando uma resposta mais pr\u00f3-inflamat\u00f3ria do que SARS-CoV",
        "id":"4203",
        "question":"How does MERS-CoV compare with SARS-CoV?",
        "question_pt":"Como o MERS-CoV se compara ao SARS-CoV?"
    },
    {
        "answer":"MERS kills its human host more often than SARS did (20-40 % versus 9 % for SARS ",
        "answer_pt":"O MERS mata seu hospedeiro humano com mais frequ\u00eancia do que o SARS (20-40% versus 9% para o SARS",
        "id":"4204",
        "question":"How does MERS-CoV compare with SARS-CoV?",
        "question_pt":"Como o MERS-CoV se compara ao SARS-CoV?"
    },
    {
        "answer":"From intermittent animal-to-human spill-over events",
        "answer_pt":"De eventos intermitentes de transbordamento de animal para humano",
        "id":"4205",
        "question":"How does MERS-CoV spread among people?",
        "question_pt":"Como o MERS-CoV se espalha entre as pessoas?"
    },
    {
        "answer":"among older adults, especially males, with pre-existing diseases. ",
        "answer_pt":"entre idosos, principalmente homens, com doen\u00e7as pr\u00e9-existentes.",
        "id":"4206",
        "question":"Who gets more severe disease from MERS?",
        "question_pt":"Quem recebe a doen\u00e7a mais grave da MERS?"
    },
    {
        "answer":"with outbreaks in hospitals, with around 20 % of all cases to date involving healthcare workers (HCWs).",
        "answer_pt":"com surtos em hospitais, com cerca de 20% de todos os casos at\u00e9 o momento envolvendo profissionais de sa\u00fade (profissionais de sa\u00fade).",
        "id":"4207",
        "question":"What is the spread of MERS-CoV among humans, associated with?",
        "question_pt":"Qual \u00e9 a dissemina\u00e7\u00e3o do MERS-CoV entre humanos, associada?"
    },
    {
        "answer":" the equivalent of a 'common cold' from MERS-CoV infection,",
        "answer_pt":"o equivalente a um 'resfriado comum' da infec\u00e7\u00e3o por MERS-CoV,",
        "id":"4208",
        "question":"What do the DCs suffer with MERS-CoV infection?",
        "question_pt":"O que os DCs sofrem com a infec\u00e7\u00e3o por MERS-CoV?"
    },
    {
        "answer":" the virus can be a more serious and opportunistic pathogen associated with the death of up to 40 % of reported cases.",
        "answer_pt":"o v\u00edrus pode ser um pat\u00f3geno mais s\u00e9rio e oportunista associado \u00e0 morte de at\u00e9 40% dos casos relatados.",
        "id":"4209",
        "question":"What happens to humans infected by MERS-CoV virus?",
        "question_pt":"O que acontece aos seres humanos infectados pelo v\u00edrus MERS-CoV?"
    },
    {
        "answer":" five to six days, ranging from two to 16 days",
        "answer_pt":"cinco a seis dias, variando de dois a 16 dias",
        "id":"4210",
        "question":"What is the incubation period of MERS?",
        "question_pt":"Qual \u00e9 o per\u00edodo de incuba\u00e7\u00e3o da MERS?"
    },
    {
        "answer":"13 to 14 days",
        "answer_pt":"13 a 14 dias",
        "id":"4211",
        "question":"What is the duration between when illness begins in one person and subsequently spreads to another?",
        "question_pt":"Qual \u00e9 a dura\u00e7\u00e3o entre quando a doen\u00e7a come\u00e7a em uma pessoa e depois se espalha para outra?"
    },
    {
        "answer":"11 to 13 days",
        "answer_pt":"11 a 13 dias",
        "id":"4212",
        "question":"What is the median time to death in case of progressive illness?",
        "question_pt":"Qual \u00e9 o tempo m\u00e9dio at\u00e9 a morte em caso de doen\u00e7a progressiva?"
    },
    {
        "answer":"Fever and gastrointestinal symptoms may form a prodrome, after which symptoms decline, only to be followed by a more severe systemic and respiratory syndrome ",
        "answer_pt":"Febre e sintomas gastrointestinais podem formar um pr\u00f3dromo, ap\u00f3s o qual os sintomas diminuem, apenas para serem seguidos por uma s\u00edndrome sist\u00eamica e respirat\u00f3ria mais grave",
        "id":"4214",
        "question":"What is the progression  of symptoms to disease?",
        "question_pt":"Qual \u00e9 a progress\u00e3o dos sintomas para a doen\u00e7a?"
    },
    {
        "answer":"a confirmed case included any person whose sample was RT-PCR positive for MERS-CoV, or who produced a seroconversion, irrespective of clinical signs and symptoms.",
        "answer_pt":"um caso confirmado incluiu qualquer pessoa cuja amostra fosse positiva para RT-PCR para MERS-CoV ou que produzisse uma soroconvers\u00e3o, independentemente de sinais e sintomas cl\u00ednicos.",
        "id":"4216",
        "question":"What did the later WHO definition of MERS clearly state?",
        "question_pt":"O que a defini\u00e7\u00e3o mais recente de MERS da OMS afirma claramente?"
    },
    {
        "answer":" 79 % ",
        "answer_pt":"79%",
        "id":"4217",
        "question":"What percentage of cases KSA has been a source of?",
        "question_pt":"De que porcentagem de casos o KSA \u00e9 uma fonte?"
    },
    {
        "answer":"its impact among older men with comorbid diseases including diabetes mellitus, cirrhosis and various lung, renal and cardiac conditions ",
        "answer_pt":"seu impacto entre homens mais velhos com doen\u00e7as com\u00f3rbidas, incluindo diabetes mellitus, cirrose e v\u00e1rias condi\u00e7\u00f5es pulmonares, renais e card\u00edacas",
        "id":"4218",
        "question":"What is severe MARS noted for?",
        "question_pt":"O que \u00e9 MARS grave observado?"
    },
    {
        "answer":"fever, cough and upper respiratory tract (URT) signs and symptoms usually occur first, followed within a week by progressive LRT distress and lymphopaenia",
        "answer_pt":"sinais e sintomas de febre, tosse e trato respirat\u00f3rio superior (URTI) geralmente ocorrem primeiro, seguidos dentro de uma semana por ang\u00fastia progressiva da LRT e linfopenia",
        "id":"4222",
        "question":"What symptoms appear among the  confirmed cases of MERS?",
        "question_pt":"Quais sintomas aparecem entre os casos confirmados de MERS?"
    },
    {
        "answer":" pneumonia",
        "answer_pt":"pneumonia",
        "id":"4223",
        "question":"What do patients often present to a hospital with, in cases of MERS?",
        "question_pt":"O que os pacientes costumam apresentar em um hospital, nos casos de MERS?"
    },
    {
        "answer":"acute respiratory distress syndrome and multiorgan system failure",
        "answer_pt":"s\u00edndrome do desconforto respirat\u00f3rio agudo e falha do sistema de v\u00e1rios \u00f3rg\u00e3os",
        "id":"4224",
        "question":"What can  MERS disease progress to?",
        "question_pt":"Para que a doen\u00e7a MERS pode progredir?"
    },
    {
        "answer":" 35 % ",
        "answer_pt":"35%",
        "id":"4225",
        "question":"What percentage of all  reported cases has MERS  reportedly killed ?",
        "question_pt":"Qual a porcentagem de todos os casos relatados que o MERS matou?"
    },
    {
        "answer":"42 %",
        "answer_pt":"42%",
        "id":"4226",
        "question":"What percentage of of all reported cases has MERS  reportedly killed in KSA?",
        "question_pt":"Qual a porcentagem de todos os casos relatados que o MERS matou no KSA?"
    },
    {
        "answer":"ranged from 7 % among younger age groups to 40 % among those aged 60 years and above",
        "answer_pt":"variou de 7% nas faixas et\u00e1rias mais jovens a 40% nas pessoas com 60 anos ou mais",
        "id":"4227",
        "question":"What was mortality in  South Korea from MERS disease?",
        "question_pt":"Qual foi a mortalidade na Cor\u00e9ia do Sul por doen\u00e7a MERS?"
    },
    {
        "answer":" PCR-based techniques ",
        "answer_pt":"T\u00e9cnicas baseadas em PCR",
        "id":"4228",
        "question":"Which are the preferred method for MERS-CoV detection?",
        "question_pt":"Qual \u00e9 o m\u00e9todo preferido para a detec\u00e7\u00e3o de MERS-CoV?"
    },
    {
        "answer":"The first open reading frames ",
        "answer_pt":"Os primeiros quadros de leitura abertos",
        "id":"4229",
        "question":"What  have become a key diagnostic and taxonomic target for CoV species identification?",
        "question_pt":"O que se tornou um importante objetivo taxon\u00f4mico e diagn\u00f3stico para a identifica\u00e7\u00e3o de esp\u00e9cies de CoV?"
    },
    {
        "answer":" less than 80 % identity between the amino acid sequence of MERS ORF 1ab and betacoronavirus relatives, Tylonycteris bat HKU4 and Pipistrellus bat HKU5",
        "answer_pt":"menos de 80% de identidade entre a sequ\u00eancia de amino\u00e1cidos de MERS ORF 1ab e parentes de betacoronav\u00edrus, Tylonycteris morcego HKU4 e Pipistrellus morcego HKU5",
        "id":"4230",
        "question":"Why  it can be concluded that MERS-COV is a novel and distinct virus?",
        "question_pt":"Por que se pode concluir que o MERS-COV \u00e9 um v\u00edrus novo e distinto?"
    },
    {
        "answer":" Detection of viral proteins rather than viral RNA",
        "answer_pt":"Detec\u00e7\u00e3o de prote\u00ednas virais em vez de RNA viral",
        "id":"4231",
        "question":"What  indicates the likely presence of infectious virus?",
        "question_pt":"O que indica a prov\u00e1vel presen\u00e7a de v\u00edrus infeccioso?"
    },
    {
        "answer":"94 %",
        "answer_pt":"94%",
        "id":"4232",
        "question":"What is the sensitivity with which immunochromatographic tool could detect recombinant MERS-CoV nucleocapsid protein?",
        "question_pt":"Qual \u00e9 a sensibilidade com a qual a ferramenta imunocromatogr\u00e1fica pode detectar a prote\u00edna nucleocaps\u00eddica MERS-CoV recombinante?"
    },
    {
        "answer":"100 % ",
        "answer_pt":"100%",
        "id":"4233",
        "question":"What is the specificity with which immunochromatographic tool could detect recombinant MERS-CoV nucleocapsid protein?",
        "question_pt":"Qual \u00e9 a especificidade com a qual a ferramenta imunocromatogr\u00e1fica pode detectar a prote\u00edna nucleocaps\u00eddeo recombinante MERS-CoV?"
    },
    {
        "answer":"monoclonal antibody-based capture ELISA targeting the MERS-CoV nucleocapsid protein",
        "answer_pt":"ELISA de captura \u00e0 base de anticorpo monoclonal, direcionado \u00e0 prote\u00edna nucleocaps\u00eddeo MERS-CoV",
        "id":"4234",
        "question":"What is a different approach for the detection?",
        "question_pt":"Qual \u00e9 uma abordagem diferente para a detec\u00e7\u00e3o?"
    },
    {
        "answer":" to detect a viral footprint, in the form of antibodies",
        "answer_pt":"detectar uma pegada viral, na forma de anticorpos",
        "id":"4235",
        "question":"What is usual in serology testing?",
        "question_pt":"O que \u00e9 comum nos testes sorol\u00f3gicos?"
    },
    {
        "answer":" by creating transfected cells expressing recombinant portions of the MERS-CoV nucleocapsid and spike proteins [",
        "answer_pt":"criando c\u00e9lulas transfectadas que expressam por\u00e7\u00f5es recombinantes das prote\u00ednas nucleocaps\u00eddicas e de espig\u00e3o MERS-CoV [",
        "id":"4238",
        "question":"How have some sero-assays bypassed the risks of working with infectious virus?",
        "question_pt":"Como alguns soropositivos contornaram os riscos de trabalhar com v\u00edrus infeccioso?"
    },
    {
        "answer":"using a recombinant lentivirus expressing MERS-CoV spike protein and luciferase",
        "answer_pt":"usando um lentiv\u00edrus recombinante que expressa a prote\u00edna do pico de MERS-CoV e luciferase",
        "id":"4239",
        "question":"How have some sero-assays bypassed the risks of working with infectious virus?",
        "question_pt":"Como alguns soropositivos contornaram os riscos de trabalhar com v\u00edrus infeccioso?"
    },
    {
        "answer":"by confirmatory IFA and/ or a plaque-reduction neutralization (PRNT) [69, 70, 85] or MNT test.",
        "answer_pt":"por IFA confirmat\u00f3ria e / ou um teste de neutraliza\u00e7\u00e3o de redu\u00e7\u00e3o de placa (PRNT) [69, 70, 85] ou MNT.",
        "id":"4240",
        "question":"What is the  detection of MERS-CoV infection using ELISA or S1 subunit protein microarray [84] is usually followed by?",
        "question_pt":"Qual \u00e9 a detec\u00e7\u00e3o da infec\u00e7\u00e3o por MERS-CoV usando o microarray de prote\u00ednas ELISA ou subunidade S1 [84] \u00e9 geralmente seguida?"
    },
    {
        "answer":"the antibodies detected are able to specifically neutralize the intended virus and are not more broadly reactive to other coronaviruses found in DCs (bovine CoV, BCoV) or humans (HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-HKU1, SARS-CoV).",
        "answer_pt":"os anticorpos detectados s\u00e3o capazes de neutralizar especificamente o v\u00edrus pretendido e n\u00e3o s\u00e3o mais amplamente reativos a outros coronav\u00edrus encontrados em DCs (CoV bovino, BCoV) ou humanos (HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-HKU1, SARS- CoV).",
        "id":"4241",
        "question":"What does the confirmatory process aim to  ensure?",
        "question_pt":"O que o processo confirmat\u00f3rio visa garantir?"
    },
    {
        "answer":"if only mild disease or asymptomatic infection results",
        "answer_pt":"se apenas uma doen\u00e7a leve ou infec\u00e7\u00e3o assintom\u00e1tica resultar",
        "id":"4242",
        "question":"When does  generally MERS infection does not trigger a detectable immune response?",
        "question_pt":"Quando geralmente a infec\u00e7\u00e3o por MERS n\u00e3o desencadeia uma resposta imune detect\u00e1vel?"
    },
    {
        "answer":" when sample collection is delayed by a week or more after onset of symptoms",
        "answer_pt":"quando a coleta de amostras \u00e9 adiada por uma semana ou mais ap\u00f3s o in\u00edcio dos sintomas",
        "id":"4243",
        "question":"When does the WHO recommend samlinf from the LRT?",
        "question_pt":"Quando a OMS recomenda o samlinf do LRT?"
    },
    {
        "answer":"are recommended when URT sampling is to be conducted",
        "answer_pt":"s\u00e3o recomendados quando a amostragem URT deve ser realizada",
        "id":"4244",
        "question":"What do the recommended samples include?",
        "question_pt":"O que incluem as amostras recomendadas?"
    },
    {
        "answer":" an oropharyngeal and throat swab or a nasopharyngeal aspirate/wash",
        "answer_pt":"um swab orofar\u00edngeo e da garganta ou um aspirado / lavagem nasofar\u00edngeo",
        "id":"4245",
        "question":"What are recommended when URT sampling is to  be conducted?",
        "question_pt":"O que \u00e9 recomendado quando a amostragem URT deve ser realizada?"
    },
    {
        "answer":" collected two to three weeks apart",
        "answer_pt":"coletados duas a tr\u00eas semanas de intervalo",
        "id":"4246",
        "question":"What paired sera are preferable?",
        "question_pt":"Quais soros emparelhados s\u00e3o prefer\u00edveis?"
    },
    {
        "answer":"Human urine and stool have been found to contain MERS-CoV RNA",
        "answer_pt":"Verificou-se que a urina e as fezes humanas cont\u00eam RNA MERS-CoV",
        "id":"4247",
        "question":" When is a single sample  suggested to be sufficient?",
        "question_pt":"Quando uma amostra \u00fanica \u00e9 sugerida como suficiente?"
    },
    {
        "answer":"12 to 26 days after symptom onset ",
        "answer_pt":"12 a 26 dias ap\u00f3s o in\u00edcio dos sintomas",
        "id":"4248",
        "question":"How long human urine and stool have been found to contain MERS-CoV RNA?",
        "question_pt":"H\u00e1 quanto tempo a urina e as fezes humanas cont\u00eam RNA de MERS-CoV?"
    },
    {
        "answer":" long periods of viral shedding, sometimes intermittently and not necessarily linked to the presence of disease symptoms.",
        "answer_pt":"longos per\u00edodos de dissemina\u00e7\u00e3o viral, \u00e0s vezes intermitentemente e n\u00e3o necessariamente associados \u00e0 presen\u00e7a de sintomas da doen\u00e7a.",
        "id":"4249",
        "question":"What do individual studies report on viral  shedding?",
        "question_pt":"O que estudos individuais relatam sobre derramamento viral?"
    },
    {
        "answer":"Over three quarters of",
        "answer_pt":"Mais de tr\u00eas quartos dos",
        "id":"4262",
        "question":"What fraction of MERS cases shed viral RNA in their LRT specimens (tracheal aspirates and sputum) ?",
        "question_pt":"Que fra\u00e7\u00e3o dos casos de MERS liberta RNA viral em suas amostras de LRT (aspirado traqueal e escarro)?"
    },
    {
        "answer":"at least 30 days",
        "answer_pt":"pelo menos 30 dias",
        "id":"4263",
        "question":"How long MERS cases shed viral RNA in their LRT specimens (tracheal aspirates and sputum)? ",
        "question_pt":"Por quanto tempo os casos de MERS liberam RNA viral em suas amostras de LRT (aspirado traqueal e escarro)?"
    },
    {
        "answer":"30 %",
        "answer_pt":"30%",
        "id":"4264",
        "question":"What percentage of contacts were still shedding RNA in their URT specimens?",
        "question_pt":"Que porcentagem de contatos ainda estava eliminando RNA em suas amostras de URT?"
    },
    {
        "answer":" the proportion of deaths among those infected with MERS-CoV is much higher than that known for the HCoVs NL63, HKU1, 229E or",
        "answer_pt":"a propor\u00e7\u00e3o de mortes entre os infectados com MERS-CoV \u00e9 muito maior do que a conhecida pelos HCoVs NL63, HKU1, 229E ou",
        "id":"4265",
        "question":"What  samples  returned the highest MERS viral load values?",
        "question_pt":"Quais amostras retornaram os maiores valores de carga viral de MERS?"
    },
    {
        "answer":" nasopharyngeal aspirates",
        "answer_pt":"aspirados nasofar\u00edngeos",
        "id":"4266",
        "question":"What is NPA?",
        "question_pt":"O que \u00e9 NPA?"
    },
    {
        "answer":"URT sample",
        "answer_pt":"Amostra URT",
        "id":"4267",
        "question":"What is  NPA?",
        "question_pt":"O que \u00e9 NPA?"
    },
    {
        "answer":"bronchoalveolar lavage",
        "answer_pt":"lavagem broncoalveolar",
        "id":"4268",
        "question":"What is BAL?",
        "question_pt":"O que \u00e9 BAL?"
    },
    {
        "answer":" is much higher than that known for the HCoVs NL63, HKU1, 229E or OC43",
        "answer_pt":"\u00e9 muito maior do que o conhecido pelos HCoVs NL63, HKU1, 229E ou OC43",
        "id":"4273",
        "question":"What is the the proportion of deaths among those infected with MERS-CoV?",
        "question_pt":"Qual a propor\u00e7\u00e3o de mortes entre os infectados com MERS-CoV?"
    },
    {
        "answer":" above that for SARS-CoV",
        "answer_pt":"acima do SARS-CoV",
        "id":"4274",
        "question":"What is the the proportion of deaths among those infected with MERS-CoV?",
        "question_pt":"Qual a propor\u00e7\u00e3o de mortes entre os infectados com MERS-CoV?"
    },
    {
        "answer":"the low transmission rate",
        "answer_pt":"a baixa taxa de transmiss\u00e3o",
        "id":"4275",
        "question":"What   has prevented worldwide spread of MERS-COV?",
        "question_pt":"O que impediu a dissemina\u00e7\u00e3o mundial do MERS-COV?"
    },
    {
        "answer":"animal MERS-CoV infections",
        "answer_pt":"infec\u00e7\u00f5es por MERS-CoV em animais",
        "id":"4276",
        "question":"What must be reported to the world organization for animal health as an emerging disease ?",
        "question_pt":"O que deve ser relatado \u00e0 organiza\u00e7\u00e3o mundial para a sa\u00fade animal como uma doen\u00e7a emergente?"
    },
    {
        "answer":"virus or viral RNA",
        "answer_pt":"v\u00edrus ou RNA viral",
        "id":"4277",
        "question":"What are juvenile DCs more often positive for?",
        "question_pt":"Para que os CDs juvenis s\u00e3o mais positivos?"
    },
    {
        "answer":"seropositive and RNA or virus negative",
        "answer_pt":"soropositivo e negativo para RNA ou v\u00edrus",
        "id":"4278",
        "question":"What are older DCs are more likely to be positive for?",
        "question_pt":"Para que DCs mais antigos \u00e9 mais prov\u00e1vel que sejam positivos?"
    },
    {
        "answer":"t",
        "answer_pt":"t",
        "id":"4279",
        "question":"When does the camel calving season?",
        "question_pt":"Quando \u00e9 que o parto \u00e9 camelo?"
    },
    {
        "answer":"due to new infections among na\u00efve DC populations",
        "answer_pt":"devido a novas infec\u00e7\u00f5es entre popula\u00e7\u00f5es ing\u00eanuas de DC",
        "id":"4280",
        "question":"Why is there an increased risk to humans of spill-over during calving season?",
        "question_pt":"Por que h\u00e1 um risco aumentado para os seres humanos de transbordar durante a esta\u00e7\u00e3o do parto?"
    },
    {
        "answer":"slaughterhouse workers who kill both younger and older DCs",
        "answer_pt":"trabalhadores de matadouros que matam DCs mais jovens e mais velhos",
        "id":"4281",
        "question":"Which may be an occupational group with significantly higher incidence of seropositivity to MERS-CoV ?",
        "question_pt":"Qual pode ser um grupo ocupacional com incid\u00eancia significativamente maior de soropositividade ao MERS-CoV?"
    },
    {
        "answer":" up to 48 h",
        "answer_pt":"at\u00e9 48 h",
        "id":"4282",
        "question":"How long after Infectious MERS-CoV added to DC, goat or cow milk and stored at 4\u00b0C could be recovered?",
        "question_pt":"Quanto tempo ap\u00f3s o MERS-CoV infeccioso adicionado ao CD, leite de cabra ou vaca e armazenado a 4 \u00b0 C pode ser recuperado?"
    },
    {
        "answer":"up to 48 h",
        "answer_pt":"at\u00e9 48 h",
        "id":"4283",
        "question":"How long after Infectious MERS-CoV added to DC, goat or cow milk and stored at 22\u00b0C could be recovered?",
        "question_pt":"Quanto tempo ap\u00f3s o MERS-CoV infeccioso adicionado ao CD, leite de cabra ou vaca e armazenado a 22 \u00b0 C pode ser recuperado?"
    },
    {
        "answer":"pasteurization",
        "answer_pt":"pasteuriza\u00e7\u00e3o",
        "id":"4284",
        "question":"What ablated MERS-COV infection completely?",
        "question_pt":"O que eliminou completamente a infec\u00e7\u00e3o por MERS-COV?"
    },
    {
        "answer":"for 24 h",
        "answer_pt":"por 24 h",
        "id":"4285",
        "question":"How long MERS-CoV remained viable at high ambient temperature (30\u00b0C) and low RH (30 %) ?",
        "question_pt":"Por quanto tempo o MERS-CoV permaneceu vi\u00e1vel em alta temperatura ambiente (30 \u00b0 C) e baixa UR (30%)?"
    },
    {
        "answer":" for 45 min",
        "answer_pt":"por 45 min",
        "id":"4286",
        "question":"How long can pathogenic bacteria remain viable and airborne in a coughed aerosol?",
        "question_pt":"Por quanto tempo as bact\u00e9rias patog\u00eanicas podem permanecer vi\u00e1veis \u200b\u200be transportadas pelo ar em um aerossol tossido?"
    },
    {
        "answer":"4 m",
        "answer_pt":"4 m",
        "id":"4287",
        "question":"How far can pathogenic bacteria spread in a coughed aerosol?",
        "question_pt":"At\u00e9 que ponto as bact\u00e9rias patog\u00eanicas podem se espalhar em um aerossol tossido?"
    },
    {
        "answer":"Droplet spread between humans",
        "answer_pt":"Gota espalhada entre humanos",
        "id":"4288",
        "question":"What is considered the mechanism of human-to-human transmission of MERS-COV?",
        "question_pt":"O que \u00e9 considerado o mecanismo de transmiss\u00e3o humano-humano de MERS-COV?"
    },
    {
        "answer":"sporadic ",
        "answer_pt":"espor\u00e1dico",
        "id":"4289",
        "question":"What is the transmission of MERS-CoV is defined as?",
        "question_pt":"Como \u00e9 definida a transmiss\u00e3o do MERS-CoV?"
    },
    {
        "answer":"intra-familial,",
        "answer_pt":"intrafamiliar,",
        "id":"4290",
        "question":"What is the transmission of MERS-CoV is defined as?",
        "question_pt":"Como \u00e9 definida a transmiss\u00e3o do MERS-CoV?"
    },
    {
        "answer":"often healthcare associated",
        "answer_pt":"frequentemente associado a cuidados de sa\u00fade",
        "id":"4291",
        "question":"What is the transmission of MERS-CoV is defined as?",
        "question_pt":"Como \u00e9 definida a transmiss\u00e3o do MERS-CoV?"
    },
    {
        "answer":"inefficient ",
        "answer_pt":"ineficiente",
        "id":"4292",
        "question":"What is the transmission of MERS-CoV is defined as?",
        "question_pt":"Como \u00e9 definida a transmiss\u00e3o do MERS-CoV?"
    },
    {
        "answer":"requiring close and prolonged contact",
        "answer_pt":"requerendo contato pr\u00f3ximo e prolongado",
        "id":"4293",
        "question":"What is the transmission of MERS-CoV is defined as?",
        "question_pt":"Como \u00e9 definida a transmiss\u00e3o do MERS-CoV?"
    },
    {
        "answer":"readily transmit to more than one other human",
        "answer_pt":"prontamente transmitir a mais de um outro ser humano",
        "id":"4294",
        "question":"What is the  the rate of general transmission, even in outbreaks?",
        "question_pt":"Qual \u00e9 a taxa de transmiss\u00e3o geral, mesmo em surtos?"
    },
    {
        "answer":"readily transmit to more than one other human ",
        "answer_pt":"prontamente transmitir a mais de um outro ser humano",
        "id":"4296",
        "question":"What do the majority of human cases of MERS-CoV  seem not to do?",
        "question_pt":"O que a maioria dos casos humanos de MERS-CoV parece n\u00e3o fazer?"
    },
    {
        "answer":"the average number of infections caused by one infected individual in a fully susceptible population",
        "answer_pt":"o n\u00famero m\u00e9dio de infec\u00e7\u00f5es causadas por um indiv\u00edduo infectado em uma popula\u00e7\u00e3o totalmente suscet\u00edvel",
        "id":"4298",
        "question":"What is the basic reproduction number (R 0)?",
        "question_pt":"Qual \u00e9 o n\u00famero b\u00e1sico de reprodu\u00e7\u00e3o (R \u200b\u200b0)?"
    },
    {
        "answer":"close to one",
        "answer_pt":"perto de um",
        "id":"4299",
        "question":"What is the basic reproduction number (R 0 )  for MERS-COV?",
        "question_pt":"Qual \u00e9 o n\u00famero b\u00e1sico de reprodu\u00e7\u00e3o (R \u200b\u200b0) para MERS-COV?"
    },
    {
        "answer":"due to ongoing, sporadic spill-over events from DCs amplified by poorly controlled hospital outbreaks.\n",
        "answer_pt":"devido a eventos espor\u00e1dicos cont\u00ednuos de transbordamento de CDs amplificados por surtos hospitalares mal controlados.",
        "id":"4300",
        "question":"Why has MERS had a constant presence in the Arabian Peninsula?",
        "question_pt":"Por que a MERS tem presen\u00e7a constante na Pen\u00ednsula Ar\u00e1bica?"
    },
    {
        "answer":"acute LRT disease",
        "answer_pt":"doen\u00e7a aguda de LRT",
        "id":"4301",
        "question":"What was the first known MERS human-to-human transmission event was one characterized by?",
        "question_pt":"Qual foi o primeiro evento de transmiss\u00e3o humano-humano MERS conhecido foi caracterizado?"
    },
    {
        "answer":"in a healthcare setting in Jordan",
        "answer_pt":"em um ambiente de sa\u00fade na Jord\u00e2nia",
        "id":"4302",
        "question":"Where was the first known MERS human-to-human transmission event?",
        "question_pt":"Onde foi o primeiro evento conhecido de transmiss\u00e3o MERS de humano para humano?"
    },
    {
        "answer":"21 %",
        "answer_pt":"21%",
        "id":"4367",
        "question":"Approximately what percentage of MERS cases were fatal in  KSA?",
        "question_pt":"Aproximadamente qual a porcentagem de casos de MERS foram fatais no KSA?"
    },
    {
        "answer":"21 %",
        "answer_pt":"21%",
        "id":"4368",
        "question":"Approximately what percentage of MERS cases were died outside KSA?",
        "question_pt":"Aproximadamente qual porcentagem de casos de MERS morreu fora do KSA?"
    },
    {
        "answer":"16 %",
        "answer_pt":"16%",
        "id":"4369",
        "question":"What percentage of HCWs comprised of MERS cases in the KSA and South Korea?",
        "question_pt":"Qual a porcentagem de profissionais de sa\u00fade composta por casos de MERS no KSA e na Cor\u00e9ia do Sul?"
    },
    {
        "answer":"using high throughput or \"deep\" sequencing methods for complete genome deduction",
        "answer_pt":"usando m\u00e9todos de alto rendimento ou sequenciamento \"profundo\" para dedu\u00e7\u00e3o completa do genoma",
        "id":"4370",
        "question":"How has most of the analysis of MERS-CoV genetics  been performed?",
        "question_pt":"Como foi realizada a maioria das an\u00e1lises da gen\u00e9tica MERS-CoV?"
    },
    {
        "answer":"only human-derived MERS-CoV genomes",
        "answer_pt":"Apenas genomas de MERS-CoV derivados de humanos",
        "id":"4372",
        "question":"What does Clade A contain?",
        "question_pt":"O que o Clade A cont\u00e9m?"
    },
    {
        "answer":"the majority of human and camel genomes deduced thus far",
        "answer_pt":"a maioria dos genomas humanos e de camelo deduzidos at\u00e9 agora",
        "id":"4373",
        "question":"What does clade B comprise?",
        "question_pt":"O que o clade B compreende?"
    },
    {
        "answer":"has had more MERS cases than any other region of the KSA",
        "answer_pt":"teve mais casos de MERS do que qualquer outra regi\u00e3o do KSA",
        "id":"4371",
        "question":"How many clades have become apparent in genome of  MERS-COV from humans and DCs?",
        "question_pt":"Quantos clades se tornaram aparentes no genoma do MERS-COV de humanos e DCs?"
    },
    {
        "answer":"Riyadh",
        "answer_pt":"Riyadh",
        "id":"4374",
        "question":"Which city has had has had more MERS cases than any other region of the KSA ?",
        "question_pt":"Qual cidade teve mais casos de MERS do que qualquer outra regi\u00e3o do KSA?"
    },
    {
        "answer":" Riyadh",
        "answer_pt":"Riyadh",
        "id":"4375",
        "question":"Which city harbours a wide range of MERS-CoV variants ",
        "question_pt":"Qual cidade abriga uma ampla variedade de variantes de MERS-CoV"
    },
    {
        "answer":"from infected to uninfected humans in close and prolonged contact ",
        "answer_pt":"de humanos infectados para humanos n\u00e3o infectados em contato pr\u00f3ximo e prolongado",
        "id":"4376",
        "question":"How has the vast majority of MERS-CoV transmission occurred?",
        "question_pt":"Como ocorreu a grande maioria da transmiss\u00e3o MERS-CoV?"
    },
    {
        "answer":"by poor infection control in health care settings",
        "answer_pt":"pelo mau controle de infec\u00e7\u00e3o nos servi\u00e7os de sa\u00fade",
        "id":"4377",
        "question":"How were the transmission circumstances created?",
        "question_pt":"Como foram criadas as circunst\u00e2ncias da transmiss\u00e3o?"
    },
    {
        "answer":" nearly 40 %",
        "answer_pt":"quase 40%",
        "id":"4378",
        "question":"What percentage of humans have died  among all humans reported to be infected?",
        "question_pt":"Qual a porcentagem de seres humanos que morreram entre todos os seres humanos relatados como infectados?"
    },
    {
        "answer":"Global alignment of case definitions",
        "answer_pt":"Alinhamento global das defini\u00e7\u00f5es de caso",
        "id":"4379",
        "question":"What would  aid accurate calculation of a case fatality ratio?",
        "question_pt":"O que ajudaria no c\u00e1lculo preciso de uma taxa de mortalidade de casos?"
    },
    {
        "answer":"MERS-CoV has a broader tropism, grows more rapidly in vitro, more rapidly induces cytopathogenic change, triggers distinct transcriptional responses, makes use of a different receptor, induces a more proinflammatory state and has a delayed innate antiviral response compared to SARS-CoV.\n",
        "answer_pt":"O MERS-CoV tem um tropismo mais amplo, cresce mais rapidamente in vitro, induz mais rapidamente altera\u00e7\u00f5es citopatog\u00eanicas, desencadeia respostas transcricionais distintas, utiliza um receptor diferente, induz um estado mais pr\u00f3-inflamat\u00f3rio e tem uma resposta antiviral inata tardia em compara\u00e7\u00e3o com o SARS-CoV.",
        "id":"4380",
        "question":"How does MARS-COV differ from SARS-COV?",
        "question_pt":"Como o MARS-COV difere do SARS-COV?"
    },
    {
        "answer":"There is no evidence that MERS-CoV is a virus of pandemic concern",
        "answer_pt":"N\u00e3o h\u00e1 evid\u00eancias de que o MERS-CoV seja um v\u00edrus de preocupa\u00e7\u00e3o pand\u00eamica",
        "id":"4381",
        "question":"Is there any evidence that MERS-CoV is a virus of pandemic concern?",
        "question_pt":"Existe alguma evid\u00eancia de que o MERS-CoV \u00e9 um v\u00edrus de preocupa\u00e7\u00e3o pand\u00eamica?"
    },
    {
        "answer":"based on the presence of febrile illness, cough and requirement for hospitalization with suspicion of lower respiratory tract (LRT) involvement.",
        "answer_pt":"com base na presen\u00e7a de doen\u00e7a febril, tosse e necessidade de hospitaliza\u00e7\u00e3o com suspeita de envolvimento do trato respirat\u00f3rio inferior (LRT).",
        "id":"4215",
        "question":"How did the first WHO case definition  define probable cases of MERS?",
        "question_pt":"Como a primeira defini\u00e7\u00e3o de caso da OMS definiu os casos prov\u00e1veis \u200b\u200bde MERS?"
    },
    {
        "answer":"Public Health Emergency of International Concern'",
        "answer_pt":"Emerg\u00eancia em Sa\u00fade P\u00fablica de Interesse Internacional '",
        "id":"1238",
        "question":"What is PHEIC?",
        "question_pt":"O que \u00e9 o PHEIC?"
    },
    {
        "answer":"an extraordinary event which is determined to constitute a public health risk to other States through the international spread of disease and to potentially require a coordinated international response",
        "answer_pt":"um evento extraordin\u00e1rio determinado a constituir um risco \u00e0 sa\u00fade p\u00fablica para outros Estados atrav\u00e9s da dissemina\u00e7\u00e3o internacional de doen\u00e7as e a exigir potencialmente uma resposta internacional coordenada",
        "id":"1239",
        "question":"How is PHEIC defined?",
        "question_pt":"Como \u00e9 definido o PHEIC?"
    },
    {
        "answer":"Global Initiative on Sharing All Influenza Data (GISAID)",
        "answer_pt":"Iniciativa Global sobre Compartilhamento de Todos os Dados sobre Influenza (GISAID)",
        "id":"1240",
        "question":"What platform was instrumental in rapid sharing of COVID-19 information?",
        "question_pt":"Qual plataforma foi fundamental para o compartilhamento r\u00e1pido de informa\u00e7\u00f5es do COVID-19?"
    },
    {
        "answer":"The equipment in the contaminated area are wiped with\n2000mg/L chlorine-containing disinfectant. The DR and CT gantry in the contaminated\narea are wiped with 75% ethanol. The equipment in the buffer area is wiped with\n500-1000mg/L chlorine-containing disinfectant or alcohol-containing disposable\ndisinfectant wipes twice a day.",
        "answer_pt":"Os equipamentos na \u00e1rea contaminada s\u00e3o limpos com\n2000mg / L desinfetante contendo cloro. O p\u00f3rtico DR e CT na \u00e1rea contaminada\ns\u00e3o limpas com etanol a 75%. O equipamento na \u00e1rea de amortecimento \u00e9 limpo com\nDesinfetante contendo cloro 500-1000mg / L ou descart\u00e1vel contendo \u00e1lcool\ntoalhetes desinfetantes duas vezes por dia.",
        "id":"239",
        "question":"What's the recommended procedure to disinfect at CT scanner after a COVID-19 exposure?",
        "question_pt":"Qual \u00e9 o procedimento recomendado para desinfetar no scanner ap\u00f3s uma exposi\u00e7\u00e3o ao COVID-19?"
    },
    {
        "answer":"The ground is wiped with 1000mg/L chlorine-containing\ndisinfectant, once /4 hours.",
        "answer_pt":"O solo \u00e9 limpo com 1000 mg / L de cloro contendo\ndesinfetante, uma vez / 4 horas.",
        "id":"240",
        "question":"What's the recommended method to disinfect floors for COVID-19?",
        "question_pt":"Qual \u00e9 o m\u00e9todo recomendado para desinfetar pisos do COVID-19?"
    },
    {
        "answer":"diagnosing and categorizing\nCOVID-19 on the basis of case definitions issued by the WHO",
        "answer_pt":"diagnosticar e categorizar\nCOVID-19 com base nas defini\u00e7\u00f5es de casos emitidas pela OMS",
        "id":"241",
        "question":"What is the role of computed tomography (CT) in COVID-19?",
        "question_pt":"Qual o papel da tomografia computadorizada (TC) no COVID-19?"
    },
    {
        "answer":"N95 mask",
        "answer_pt":"M\u00e1scara n95",
        "id":"242",
        "question":"What kind of masks are recommended to protect healthcare workers from COVID-19 exposure?",
        "question_pt":"Que tipo de m\u00e1scaras s\u00e3o recomendadas para proteger os profissionais de sa\u00fade da exposi\u00e7\u00e3o ao COVID-19?"
    },
    {
        "answer":"1 mm-thick layers",
        "answer_pt":"Camadas de 1 mm de espessura",
        "id":"243",
        "question":"What thickness of layers is recommended for CT image reconstruction in COVID-19 assessment?",
        "question_pt":"Que espessura de camadas \u00e9 recomendada para reconstru\u00e7\u00e3o de imagens de TC na avalia\u00e7\u00e3o COVID-19?"
    },
    {
        "answer":"up-to-date case definitions and information about\nconfirmatory tests to all staff with direct patient contact to allow appropriate barrier precautions\nto be taken.",
        "answer_pt":"defini\u00e7\u00f5es atualizadas de casos e informa\u00e7\u00f5es sobre\ntestes confirmat\u00f3rios a todos os funcion\u00e1rios com contato direto com o paciente para permitir precau\u00e7\u00f5es de barreira apropriadas\npara ser levado.",
        "id":"2458",
        "question":"What must the data gathering include?",
        "question_pt":"O que a coleta de dados deve incluir?"
    },
    {
        "answer":"All typical and atypical imaging features of the disease should be made known to\nall radiologists",
        "answer_pt":"Todos os recursos de imagem t\u00edpicos e at\u00edpicos da doen\u00e7a devem ser conhecidos\ntodos radiologistas",
        "id":"2459",
        "question":"What must be done to assist in recognition of the disease on images and to allow accurate reporting\nof these findings?\n",
        "question_pt":"O que deve ser feito para ajudar no reconhecimento da doen\u00e7a nas imagens e permitir relat\u00f3rios precisos\ndessas descobertas?"
    },
    {
        "answer":"to understand the\nextent and dynamic evolution of lung lesions induced by COVID-19",
        "answer_pt":"para entender o\nextens\u00e3o e evolu\u00e7\u00e3o din\u00e2mica das les\u00f5es pulmonares induzidas pelo COVID-19",
        "id":"2460",
        "question":"What is the major role of chest CT?",
        "question_pt":"Qual o papel principal da TC do t\u00f3rax?"
    },
    {
        "answer":" low-dose chest CT has been\nwidely used in the screening of early lung cancer. It is well known that many early lung cancers\nare ground-glass opacities (GGO), so we believe that low-dose screening is also applicable for\nCOVID-19. In addition, considering the rapid development of COVID-19, many CT\n14\nexaminations may be conducted in the same individual to monitor disease progress. Low-dose\nscanning can reduce the radiation damage to patients.",
        "answer_pt":"tomografia computadorizada de baixa dose\namplamente utilizado na triagem do c\u00e2ncer de pulm\u00e3o precoce. \u00c9 sabido que muitos tipos de c\u00e2ncer de pulm\u00e3o\ns\u00e3o opacidades em vidro fosco (GGO), portanto acreditamos que o rastreamento de doses baixas tamb\u00e9m seja aplic\u00e1vel a\nCOVID-19. Al\u00e9m disso, considerando o r\u00e1pido desenvolvimento do COVID-19, muitos\n14\nexames podem ser realizados no mesmo indiv\u00edduo para monitorar o progresso da doen\u00e7a. Dose baixa\na digitaliza\u00e7\u00e3o pode reduzir os danos causados \u200b\u200bpela radia\u00e7\u00e3o nos pacientes.",
        "id":"2461",
        "question":"What is the reason to adopt low-dose CT?",
        "question_pt":"Qual o motivo da ado\u00e7\u00e3o de tomografia computadorizada de baixa dose?"
    },
    {
        "answer":" (1) coordination between the\nhospital\u2019s management and planning of infection control and radiology departments; (2)\ncollection of the most up-to-date protection-related information to educate and train staff in the\ndepartment; (3) reallocation of staff according to the actual situation; (4) establishment of the\nCT procedures for patients with COVID-19; and (5) establishment of an emergency\nmanagement plan for the radiology department to ensure that the department would run\nnormally.",
        "answer_pt":"1) coordena\u00e7\u00e3o entre os\ngerenciamento e planejamento do hospital dos departamentos de controle de infec\u00e7\u00e3o e radiologia; 2)\ncoleta das informa\u00e7\u00f5es mais atualizadas relacionadas \u00e0 prote\u00e7\u00e3o para educar e treinar a equipe no\ndepartamento; (3) realoca\u00e7\u00e3o de funcion\u00e1rios de acordo com a situa\u00e7\u00e3o real; (4) estabelecimento da\nProcedimentos de TC para pacientes com COVID-19; e (5) estabelecimento de uma emerg\u00eancia\nplano de gerenciamento do departamento de radiologia para garantir que o departamento funcione\nnormalmente.",
        "id":"2448",
        "question":"What did the EMICT responsibilities include?",
        "question_pt":"O que incluem as responsabilidades do EMICT?"
    },
    {
        "answer":"contaminated, semicontaminated,\nbuffer, and clean areas",
        "answer_pt":"contaminado, semi-contaminado,\n\u00e1reas limpas e limpas",
        "id":"2449",
        "question":"How were the radiology department areas divided?",
        "question_pt":"Como as \u00e1reas do departamento de radiologia foram divididas?"
    },
    {
        "answer":"connected to the fever clinic and\nincludes the fever accessway, the CT examination room, and the DR examination room for\n6\nconfirmed and suspected cases. One CT scanner and one DR system closest to the emergency\ndepartment are designated the fever-CT and fever-DR to examine patients with suspected and\nconfirmed COVID-19. There is a separate dedicated access between the contaminated area and\nthe fever screening tents. ",
        "answer_pt":"conectado \u00e0 cl\u00ednica de febre e\ninclui a via de acesso \u00e0 febre, a sala de exames de TC e a sala de exames de DR para\n6\ncasos confirmados e suspeitos. Um tom\u00f3grafo e um sistema de DR mais pr\u00f3ximo da emerg\u00eancia\ndepartamento s\u00e3o designados febre-CT e febre-DR para examinar pacientes com suspeita e\nCOVID-19 confirmado. Existe um acesso dedicado separado entre a \u00e1rea contaminada e\nas barracas de triagem de febre.",
        "id":"2450",
        "question":"How was the contaminated area connected to the CT room and other facilities?",
        "question_pt":"Como a \u00e1rea contaminada foi conectada \u00e0 sala de tomografia computadorizada e outras instala\u00e7\u00f5es?"
    },
    {
        "answer":"he clean area\nincludes the administrative office and the diagnostic room.",
        "answer_pt":"ele limpa a \u00e1rea\ninclui o escrit\u00f3rio administrativo e a sala de diagn\u00f3stico.",
        "id":"2453",
        "question":"What does the clean area include?",
        "question_pt":"O que inclui a \u00e1rea limpa?"
    },
    {
        "answer":" the fever-CT control room,\nfever-DR control room, and other patient examination access areas. ",
        "answer_pt":"sala de controle de febre-CT,\nsala de controle de febre-DR e outras \u00e1reas de acesso ao exame do paciente.",
        "id":"2451",
        "question":"What does the semicontaminated area include?",
        "question_pt":"O que inclui a \u00e1rea semicontaminada?"
    },
    {
        "answer":"access areas for medical personnel and a dressing area for technologists. ",
        "answer_pt":"\u00e1reas de acesso para pessoal m\u00e9dico e uma \u00e1rea de vestir para tecn\u00f3logos.",
        "id":"2452",
        "question":"What does the buffer area include?",
        "question_pt":"O que a \u00e1rea do buffer inclui?"
    },
    {
        "answer":"under the supervision of\nthe infection control nurse.",
        "answer_pt":"Sob a supervis\u00e3o de\na enfermeira de controle de infec\u00e7\u00e3o.",
        "id":"2454",
        "question":"How was the wearing and removing of the equipment performed?",
        "question_pt":"Como foi realizado o uso e a remo\u00e7\u00e3o do equipamento?"
    },
    {
        "answer":" periodically taking time off ",
        "answer_pt":"periodicamente tirando uma folga",
        "id":"2455",
        "question":"What can lower the physical and mental stress levels of staff members?",
        "question_pt":"O que pode diminuir os n\u00edveis de estresse f\u00edsico e mental dos funcion\u00e1rios?"
    },
    {
        "answer":"Pregnant staff ",
        "answer_pt":"Pessoal gr\u00e1vida",
        "id":"2456",
        "question":"Who must be assigned to the clean area?",
        "question_pt":"Quem deve ser designado para a \u00e1rea limpa?"
    },
    {
        "answer":"data gathering, collaboration, needs assessment, and expert advice ",
        "answer_pt":"coleta de dados, colabora\u00e7\u00e3o, avalia\u00e7\u00e3o de necessidades e consultoria especializada",
        "id":"2457",
        "question":"What responses must EMICT consider once a disease has been identified?",
        "question_pt":"Que respostas o EMICT deve considerar ap\u00f3s a identifica\u00e7\u00e3o de uma doen\u00e7a?"
    },
    {
        "answer":"Strategic planning and adequate protections can help protect patients and staff\nagainst a highly infectious disease while maintaining function at a high volume capacity.\nKeywords: Coronavirus, COVID-19, novel coronavirus pneumonia, infection control",
        "answer_pt":"Planejamento estrat\u00e9gico e prote\u00e7\u00f5es adequadas podem ajudar a proteger pacientes e funcion\u00e1rios\ncontra uma doen\u00e7a altamente infecciosa, mantendo a fun\u00e7\u00e3o em uma capacidade de alto volume.\nPalavras-chave: Coronav\u00edrus, COVID-19, nova pneumonia por coronav\u00edrus, controle de infec\u00e7\u00e3o",
        "id":"2462",
        "question":"What is the conclusion of the report?",
        "question_pt":"Qual \u00e9 a conclus\u00e3o do relat\u00f3rio?"
    },
    {
        "answer":"80,793 ",
        "answer_pt":"80.793",
        "id":"2463",
        "question":"What were the number of cases in mainland china as of March 11th?",
        "question_pt":"Qual foi o n\u00famero de casos na China continental em 11 de mar\u00e7o?"
    },
    {
        "answer":"3,169 ",
        "answer_pt":"3.169",
        "id":"2464",
        "question":"How many COVID deaths occurred in Chinese mainland as of March 11th?",
        "question_pt":"Quantas mortes por COVID ocorreram no continente chin\u00eas em 11 de mar\u00e7o?"
    },
    {
        "answer":"677,243 people have been identified as having had close contact with\ninfected patients of whom13,701 ",
        "answer_pt":"677.243 pessoas foram identificadas como tendo tido contato pr\u00f3ximo com\npacientes infectados, dos quais 13.701",
        "id":"2465",
        "question":"How many people have come in contact and how many of these are in observation?",
        "question_pt":"Quantas pessoas entraram em contato e quantas est\u00e3o em observa\u00e7\u00e3o?"
    },
    {
        "answer":"December 2019",
        "answer_pt":"Dezembro 2019",
        "id":"1219",
        "question":"When was the novel Coronavirus first reported?",
        "question_pt":"Quando o romance Coronavirus foi relatado pela primeira vez?"
    },
    {
        "answer":"February 2013",
        "answer_pt":"Fevereiro de 2013",
        "id":"5320",
        "question":"When did China detect the first human case of H7N9 infection?",
        "question_pt":"Quando a China detectou o primeiro caso humano de infec\u00e7\u00e3o pelo H7N9?"
    },
    {
        "answer":"288",
        "answer_pt":"288",
        "id":"5321",
        "question":"How many deaths were associated with MERS-CoV as of July 2014?",
        "question_pt":"Quantas mortes foram associadas ao MERS-CoV em julho de 2014?"
    },
    {
        "answer":"The novel coronavirus (2019-nCoV) infection caused pneumonia. ",
        "answer_pt":"A nova infec\u00e7\u00e3o por coronav\u00edrus (2019-nCoV) causou pneumonia.",
        "id":"1149",
        "question":"What illness is caused by the 2019-nCOV Coronavirus?",
        "question_pt":"Que doen\u00e7a \u00e9 causada pelo coronav\u00edrus 2019-nCOV?"
    },
    {
        "answer":"the 2109-nCoV RNA was readily detected in the blood (6 of 57 patients) and the anal swabs (11 of 28 patients). ",
        "answer_pt":"o RNA 2109-nCoV foi prontamente detectado no sangue (6 de 57 pacientes) e nas zaragatoas anais (11 de 28 pacientes).",
        "id":"1151",
        "question":"In addition to oral swabs, which tests detected the presence of 2019-nCOV virus?",
        "question_pt":"Al\u00e9m dos swabs orais, quais testes detectaram a presen\u00e7a do v\u00edrus 2019-nCOV?"
    },
    {
        "answer":"all of the 6 patients with detectable viral RNA in the blood cohort progressed to severe symptom stage, indicating a strong correlation of serum viral RNA with the disease severity (p-value = 0.0001). Meanwhile, 8 of the 11 patients with annal swab virus-positive was in severe clinical stage.",
        "answer_pt":"todos os 6 pacientes com RNA viral detect\u00e1vel na coorte sangu\u00ednea progrediram para est\u00e1gio grave dos sintomas, indicando uma forte correla\u00e7\u00e3o do RNA viral s\u00e9rico com a gravidade da doen\u00e7a (valor de p = 0,0001). Enquanto isso, 8 dos 11 pacientes com v\u00edrus do swab anal positivo estavam em est\u00e1gio cl\u00ednico grave.",
        "id":"1160",
        "question":"What  is the relationship between the presence of virus in blood and anal swabs and disease severity?",
        "question_pt":"Qual \u00e9 a rela\u00e7\u00e3o entre a presen\u00e7a de v\u00edrus no sangue e os cotonetes anais e a gravidade da doen\u00e7a?"
    },
    {
        "answer":"Patients who were with at least one of the following symptom should be diagnosed to be severe case, 1) distress of respiratory with respiratory rate > = 30/min; 2) Oxygen saturation < = 93% in the rest state, and 3) arterial oxygen tension (PaO\u2082) over inspiratory oxygen fraction (FIO\u2082) of less than 300 mm Hg. In the blood detection cohort (Figure 1 (A)), patients who had at less one serum sample measurement with the PCR method were included. ",
        "answer_pt":"Pacientes com pelo menos um dos seguintes sintomas devem ser diagnosticados como casos graves: 1) dificuldade respirat\u00f3ria com frequ\u00eancia respirat\u00f3ria> = 30 / min; 2) Satura\u00e7\u00e3o de oxig\u00eanio <= 93% no estado de repouso e 3) tens\u00e3o arterial de oxig\u00eanio (PaO\u2082) sobre a fra\u00e7\u00e3o inspirada de oxig\u00eanio (FIO\u2082) inferior a 300 mm Hg. Na coorte de detec\u00e7\u00e3o de sangue (Figura 1 (A)), foram inclu\u00eddos pacientes que tiveram pelo menos uma medida de amostra s\u00e9rica com o m\u00e9todo de PCR.",
        "id":"1168",
        "question":"Which patients were classified as severe in Chinese guidelines?",
        "question_pt":"Quais pacientes foram classificados como graves nas diretrizes chinesas?"
    },
    {
        "answer":" In the 57, 6 cases were detected to be blood positive, all of them (100%) were severe in symptom requiring special care attention, and the blood of the rest 51 cases was without detectable virus in the blood, only 12 of them (23.5%) were severe cases.",
        "answer_pt":"Nos 57, 6 casos foram detectados como positivos para o sangue, todos (100%) apresentavam sintomas graves, exigindo aten\u00e7\u00e3o especial, e o sangue nos demais 51 casos n\u00e3o apresentava v\u00edrus detect\u00e1vel no sangue, apenas 12 deles ( 23,5%) foram casos graves.",
        "id":"1169",
        "question":"What is the relationship between the presence of virus in blood sample and disease severity?",
        "question_pt":"Qual a rela\u00e7\u00e3o entre a presen\u00e7a de v\u00edrus na amostra de sangue e a gravidade da doen\u00e7a?"
    },
    {
        "answer":"presence of viral RNA outside of the respiratory tract might herald the severity of the disease and alarm the requirement of special care",
        "answer_pt":"presen\u00e7a de RNA viral fora do trato respirat\u00f3rio pode anunciar a gravidade da doen\u00e7a e alarmar a necessidade de cuidados especiais",
        "id":"1171",
        "question":"What test could give an indication for special care for 2019-nCOV patients?",
        "question_pt":"Que teste poderia dar uma indica\u00e7\u00e3o para cuidados especiais para pacientes com 2019-nCOV?"
    },
    {
        "answer":"In the anal swab cohort (Figure 1 (B)), 11 of 28 cases were detected to be anal swab positive, 8 of them (72.7%) were with severe symptoms, which was significantly higher than that 4 (23.5%) of the rest 17 cases without detectable virus in anal were severe cases",
        "answer_pt":"Na coorte de swab anal (Figura 1 (B)), 11 dos 28 casos foram detectados como positivos para swab anal, 8 deles (72,7%) apresentavam sintomas graves, significativamente superiores aos 4 (23,5%) dos resto 17 casos sem v\u00edrus detect\u00e1vel no anal foram casos graves",
        "id":"1170",
        "question":"What is the relationship between the presence of virus in anal swabs and disease severity in 2019-nCOV?",
        "question_pt":"Qual \u00e9 a rela\u00e7\u00e3o entre a presen\u00e7a de v\u00edrus em zaragatoas anais e a gravidade da doen\u00e7a em 2019-nCOV?"
    },
    {
        "answer":"digestive tract might be one extrapulmonary site for virus replication",
        "answer_pt":"trato digestivo pode ser um local extrapulmonar para replica\u00e7\u00e3o do v\u00edrus",
        "id":"1172",
        "question":"What could be the implication of 2019-nCOV virus in anal swabs?",
        "question_pt":"Qual poderia ser a implica\u00e7\u00e3o do v\u00edrus 2019-nCOV em zaragatoas anais?"
    },
    {
        "answer":"Intensive structural analysis of the S protein of 2019-nCoV with the SARS-Coronavirus suggested that several critical residues in the viral spike protein might confer favourable interaction with human ACE2 [7] . Of note, ACE2 is also abundantly present in humans in the epithelia of the small intestine besides the respiratory tract and is ubiquitously present in endothelial cells [8] , which might provide possible routes of transmission, and might account for the high transmission capacity of the new virus. ",
        "answer_pt":"A an\u00e1lise estrutural intensiva da prote\u00edna S de 2019-nCoV com o SARS-Coronav\u00edrus sugeriu que v\u00e1rios res\u00edduos cr\u00edticos na prote\u00edna de pico viral podem conferir intera\u00e7\u00e3o favor\u00e1vel com a ACE2 humana [7]. \u00c9 importante notar que a ACE2 tamb\u00e9m est\u00e1 presente abundantemente nos seres humanos nos epit\u00e9lios do intestino delgado, al\u00e9m do trato respirat\u00f3rio, e est\u00e1 presente em todas as c\u00e9lulas endoteliais [8], o que pode fornecer poss\u00edveis rotas de transmiss\u00e3o e pode ser respons\u00e1vel pela alta capacidade de transmiss\u00e3o do v\u00edrus. v\u00edrus recente.",
        "id":"1173",
        "question":"What  could account for the high transmission rate of the 2019-nCOV virus?",
        "question_pt":"O que poderia explicar a alta taxa de transmiss\u00e3o do v\u00edrus 2019-nCOV?"
    },
    {
        "answer":"We propose that rampant coronavirus replication in pulmonary alveolus results in the breakdown of the alveolar vessel and the subsequent virus leakage into the blood flow, through which the virus is disseminated across the whole body. Then the virus succeeds in establishing reinfection in the digestive tract by using the highly expressed ACE2 receptor, which exacerbated the disease vice versa",
        "answer_pt":"Propomos que a replica\u00e7\u00e3o desenfreada de coronav\u00edrus no alv\u00e9olo pulmonar resulta na quebra do vaso alveolar e no subsequente vazamento do v\u00edrus no fluxo sangu\u00edneo, atrav\u00e9s do qual o v\u00edrus \u00e9 disseminado por todo o corpo. Em seguida, o v\u00edrus consegue estabelecer a reinfec\u00e7\u00e3o no trato digestivo usando o receptor ACE2 altamente expresso, que exacerbou a doen\u00e7a vice-versa",
        "id":"1174",
        "question":"What could account for the dissemination of the 2019-nCOV virus across the whole body?",
        "question_pt":"O que poderia explicar a dissemina\u00e7\u00e3o do v\u00edrus 2019-nCOV em todo o corpo?"
    },
    {
        "answer":"8 August 2014",
        "answer_pt":"8 de agosto de 2014",
        "id":"2178",
        "question":"When did the World Health Organization declare the Ebola epidemic in West Africa as a Public Health Emergency of International Concern?",
        "question_pt":"Quando a Organiza\u00e7\u00e3o Mundial da Sa\u00fade declarou a epidemia de Ebola na \u00c1frica Ocidental como uma emerg\u00eancia de sa\u00fade p\u00fablica de interesse internacional?"
    },
    {
        "answer":"Personal Protective Equipment",
        "answer_pt":"Equipamento de prote\u00e7\u00e3o pessoal",
        "id":"2181",
        "question":"What is PPE?",
        "question_pt":"O que \u00e9 EPI?"
    },
    {
        "answer":"neighbouring sub-Saharan countries, North America, and Europe",
        "answer_pt":"pa\u00edses subsaarianos vizinhos, Am\u00e9rica do Norte e Europa",
        "id":"2183",
        "question":"Where did the 2014 Ebola epidemic in West Africa spread to?",
        "question_pt":"Para onde se espalhou a epidemia de Ebola de 2014 na \u00c1frica Ocidental?"
    },
    {
        "answer":"connectedness between health professionals, technological devices, and knowledge",
        "answer_pt":"conex\u00e3o entre profissionais de sa\u00fade, dispositivos tecnol\u00f3gicos e conhecimento",
        "id":"2184",
        "question":"What are the prerequisites for successful emergency preparedness for an epidemic?",
        "question_pt":"Quais s\u00e3o os pr\u00e9-requisitos para uma prepara\u00e7\u00e3o de emerg\u00eancia bem-sucedida para uma epidemia?"
    },
    {
        "answer":"large, non-segmented, positive sense and single stranded RNA animal viruses",
        "answer_pt":"v\u00edrus animais grandes, n\u00e3o segmentados, com sentido positivo e RNA de fita simples",
        "id":"5314",
        "question":"What is the structure of a coronavirus?",
        "question_pt":"Qual \u00e9 a estrutura de um coronav\u00edrus?"
    },
    {
        "answer":"a Bats-Hosts-Reservoir-People transmission network model for simulating the potential transmission from the infection source (probably be bats) to the human infection. ",
        "answer_pt":"um modelo de rede de transmiss\u00e3o Bats-Hosts-Reservoir-People para simular a transmiss\u00e3o potencial da fonte de infec\u00e7\u00e3o (provavelmente morcegos) para a infec\u00e7\u00e3o humana.",
        "id":"2754",
        "question":"What method is developed in this study?",
        "question_pt":"Que m\u00e9todo \u00e9 desenvolvido neste estudo?"
    },
    {
        "answer":"Reservoir-People (RP) transmission network model",
        "answer_pt":"Modelo de rede de transmiss\u00e3o Reservoir-People (RP)",
        "id":"2755",
        "question":"What is the model simplified to?",
        "question_pt":"Para que o modelo \u00e9 simplificado?"
    },
    {
        "answer":"The value of R 0 was estimated of 2.30 from reservoir to person and 3.58 from person to person which means that the expected number of secondary infections that result from introducing a single infected individual into an otherwise susceptible population was 3.5",
        "answer_pt":"O valor de R0 foi estimado em 2,30 de reservat\u00f3rio para pessoa e 3,58 de pessoa para pessoa, o que significa que o n\u00famero esperado de infec\u00e7\u00f5es secund\u00e1rias resultantes da introdu\u00e7\u00e3o de um \u00fanico indiv\u00edduo infectado em uma popula\u00e7\u00e3o suscet\u00edvel foi de 3,5",
        "id":"2756",
        "question":"What is the estimate of R 0?",
        "question_pt":"Qual \u00e9 a estimativa de R 0?"
    },
    {
        "answer":"Our model showed that the transmissibility of SARS-CoV-2 was higher than the Middle East respiratory syndrome in the Middle East countries, similar to severe acute respiratory syndrome, but lower than MERS in the Republic of Korea.",
        "answer_pt":"Nosso modelo mostrou que a transmissibilidade do SARS-CoV-2 era maior que a s\u00edndrome respirat\u00f3ria do Oriente M\u00e9dio nos pa\u00edses do Oriente M\u00e9dio, semelhante \u00e0 s\u00edndrome respirat\u00f3ria aguda grave, mas menor que a MERS na Rep\u00fablica da Cor\u00e9ia.",
        "id":"2757",
        "question":"What is the conclusion of this study?",
        "question_pt":"Qual \u00e9 a conclus\u00e3o deste estudo?"
    },
    {
        "answer":"Huanan Seafood Wholesale Market (reservoir) to people,",
        "answer_pt":"Mercado Atacadista de Frutos do Mar de Huanan (reservat\u00f3rio) para pessoas,",
        "id":"2758",
        "question":"What was the focus of the study?",
        "question_pt":"Qual foi o foco do estudo?"
    },
    {
        "answer":"the virus transmitted among the bats, and then transmitted to unknown hosts (probably some wild animals). The hosts were hunted and sent to the seafood market which was defined as the reservoir of the virus. People exposed to the market got the risks of the infection ",
        "answer_pt":"o v\u00edrus transmitido entre os morcegos e depois transmitido para hospedeiros desconhecidos (provavelmente alguns animais selvagens). Os hospedeiros foram ca\u00e7ados e enviados ao mercado de frutos do mar, definido como o reservat\u00f3rio do v\u00edrus. Pessoas expostas ao mercado t\u00eam os riscos da infec\u00e7\u00e3o",
        "id":"2759",
        "question":"What were the model assumptions?",
        "question_pt":"Quais foram as premissas do modelo?"
    },
    {
        "answer":"susceptible bats (S B ), exposed bats (E B ), infected bats (I B ), and removed bats (R B ).",
        "answer_pt":"morcegos suscet\u00edveis (S B), morcegos expostos (E B), morcegos infectados (I B) e morcegos removidos (R B).",
        "id":"2760",
        "question":"What  compartments were the bats divided into?",
        "question_pt":"Em que compartimentos os morcegos foram divididos?"
    },
    {
        "answer":"The hosts were also divided into four compartments: susceptible hosts (S H ), exposed hosts (E H ), infected hosts (I H ), and removed hosts (R H )",
        "answer_pt":"Os hospedeiros tamb\u00e9m foram divididos em quatro compartimentos: hospedeiros suscet\u00edveis (S H), hospedeiros expostos (E H), hospedeiros infectados (I H) e hospedeiros removidos (R H)",
        "id":"2761",
        "question":"What compartments were the host animals divided into?",
        "question_pt":"Em que compartimentos os animais hospedeiros foram divididos?"
    },
    {
        "answer":"the seafood market",
        "answer_pt":"o mercado de frutos do mar",
        "id":"2762",
        "question":"What was the SARS-COV-2 reservoir?",
        "question_pt":"O que era o reservat\u00f3rio SARS-COV-2?"
    },
    {
        "answer":" into five compartments:\n\nsusceptible people (S P ), exposed people (E P ), symptomatic infected people (I P ), asymptomatic infected people (A P ), and removed people (R P ) including recovered and death people.",
        "answer_pt":"em cinco compartimentos:\n\npessoas suscet\u00edveis (S P), pessoas expostas (E P), pessoas infectadas sintom\u00e1ticas (I P), pessoas infectadas assintom\u00e1ticas (A P) e pessoas removidas (R P), incluindo pessoas recuperadas e mortas.",
        "id":"2763",
        "question":"What were the people divided into?",
        "question_pt":"Em que as pessoas foram divididas?"
    },
    {
        "answer":"5.2 days (95% confidence interval [CI]: 4.1-7.0) ",
        "answer_pt":"5,2 dias (intervalo de confian\u00e7a de 95% [IC]: 4,1-7,0)",
        "id":"2764",
        "question":"What was the mean incubation period?",
        "question_pt":"Qual foi o per\u00edodo m\u00e9dio de incuba\u00e7\u00e3o?"
    },
    {
        "answer":" 5-day",
        "answer_pt":"5 dias",
        "id":"2765",
        "question":"What was the mean delay from symptom onset to detection/hospitalization of a case?",
        "question_pt":"Qual foi o atraso m\u00e9dio entre o in\u00edcio dos sintomas e a detec\u00e7\u00e3o / hospitaliza\u00e7\u00e3o de um caso?"
    },
    {
        "answer":" from 3 to 7 days",
        "answer_pt":"de 3 a 7 dias",
        "id":"2766",
        "question":"How long after onset, the cases detected in Thailand and Japan were hospitalized?",
        "question_pt":"Quanto tempo ap\u00f3s o in\u00edcio, os casos detectados na Tail\u00e2ndia e no Jap\u00e3o foram hospitalizados?"
    },
    {
        "answer":"a mean of 5.8 days (95% CI: 4.3-7.5)",
        "answer_pt":"m\u00e9dia de 5,8 dias (IC95%: 4,3-7,5)",
        "id":"2767",
        "question":"What was the duration from illness onset to first medical visit ?",
        "question_pt":"Qual foi a dura\u00e7\u00e3o desde o in\u00edcio da doen\u00e7a at\u00e9 a primeira consulta m\u00e9dica?"
    },
    {
        "answer":"0.5 times that of symptomatic infection (\u03ba = 0.5), which was the similar value as influenza ",
        "answer_pt":"0,5 vezes o da infec\u00e7\u00e3o sintom\u00e1tica (\u03ba = 0,5), que era o mesmo valor que a gripe",
        "id":"2768",
        "question":"What was the assumption of transmissibility of asymptomatic infection?",
        "question_pt":"Qual foi o pressuposto de transmissibilidade da infec\u00e7\u00e3o assintom\u00e1tica?"
    },
    {
        "answer":" 0.3 million people",
        "answer_pt":"0,3 milh\u00f5es de pessoas",
        "id":"2769",
        "question":"As of January 17, how many people were tested for body temperature?",
        "question_pt":"Em 17 de janeiro, quantas pessoas foram testadas quanto \u00e0 temperatura corporal?"
    },
    {
        "answer":"about 2.87 million",
        "answer_pt":"cerca de 2,87 milh\u00f5es",
        "id":"2770",
        "question":"What is mobile  population in Wuhan?",
        "question_pt":"Qual \u00e9 a popula\u00e7\u00e3o m\u00f3vel em Wuhan?"
    },
    {
        "answer":"2.7-3.4 or 2-4 in Hong Kong",
        "answer_pt":"2.7-3.4 ou 2-4 em Hong Kong",
        "id":"2771",
        "question":"What was  the R0 of SARS?",
        "question_pt":"Qual foi o R0 do SARS?"
    },
    {
        "answer":"R 0 of SARS was about 2.1 in Hong Kong, China, 2.7 in Singapore, and 3.8 in Beijing, China",
        "answer_pt":"R 0 de SARS era de cerca de 2,1 em Hong Kong, China, 2,7 em Cingapura e 3,8 em Pequim, China",
        "id":"2772",
        "question":"What was the value of R0 in other researches?",
        "question_pt":"Qual foi o valor de R0 em outras pesquisas?"
    },
    {
        "answer":"0.8-1.3 ",
        "answer_pt":"0.8-1.3",
        "id":"2773",
        "question":"What is the reported value of R0 for MERS?",
        "question_pt":"Qual \u00e9 o valor reportado de R0 para MERS?"
    },
    {
        "answer":" 2.5-7.2",
        "answer_pt":"2,5-7,2",
        "id":"2774",
        "question":"What was  R0 for  the high transmissibility in  South Korea?",
        "question_pt":"O que foi R0 para a alta transmissibilidade na Cor\u00e9ia do Sul?"
    },
    {
        "answer":" to decrease R 0",
        "answer_pt":"diminuir R 0",
        "id":"2775",
        "question":"What is important for containing the transmission?",
        "question_pt":"O que \u00e9 importante para conter a transmiss\u00e3o?"
    },
    {
        "answer":" the transmissibility of SARS-CoV-2 might be higher than MERS in the Middle East countries, similar to SARS, but lower than MERS in the Republic of Korea.",
        "answer_pt":"a transmissibilidade do SARS-CoV-2 pode ser maior que a MERS nos pa\u00edses do Oriente M\u00e9dio, semelhante \u00e0 SARS, mas menor que a MERS na Rep\u00fablica da Cor\u00e9ia.",
        "id":"2776",
        "question":"What did this model show?",
        "question_pt":"O que esse modelo mostrou?"
    },
    {
        "answer":"provide a mathematical model for calculating the transmissibility of SARS-CoV-2",
        "answer_pt":"fornecer um modelo matem\u00e1tico para o c\u00e1lculo da transmissibilidade do SARS-CoV-2",
        "id":"2777",
        "question":"What was the objective of the study?",
        "question_pt":"Qual foi o objetivo do estudo?"
    },
    {
        "answer":"s are spherical, enveloped, and the largest of positive-strand RNA v",
        "answer_pt":"s s\u00e3o esf\u00e9ricos, envelopados e o maior RNA de cadeia positiva v",
        "id":"2199",
        "question":"What are coronaviruses?",
        "question_pt":"O que s\u00e3o coronav\u00edrus?"
    },
    {
        "answer":"uding birds, farm animals, pets, camels, an",
        "answer_pt":"usando p\u00e1ssaros, animais de fazenda, animais de estima\u00e7\u00e3o, camelos, um",
        "id":"2200",
        "question":"What animals can carry coronavirus?",
        "question_pt":"Quais animais podem transportar coronav\u00edrus?"
    },
    {
        "answer":"199",
        "answer_pt":"199",
        "id":"1187",
        "question":"How many  COVID-19 cases were confirmed on the Diamond Princess cruise ship?",
        "question_pt":"Quantos casos COVID-19 foram confirmados no navio Diamond Princess?"
    },
    {
        "answer":"2 to 4 February 2020,",
        "answer_pt":"2 a 4 de fevereiro de 2020,",
        "id":"1188",
        "question":"What was the time period of peak infection of COVID-19 on  the Diamond Princess cruise ship?",
        "question_pt":"Qual foi o per\u00edodo de pico de infec\u00e7\u00e3o do COVID-19 no navio Diamond Princess?"
    },
    {
        "answer":"102 and 47 cases, respectively.",
        "answer_pt":"102 e 47 casos, respectivamente.",
        "id":"1190",
        "question":"With the intervention of movement restrictions starting on 5th February 2020, what were the confirmed cases for COVID-19, were limited  to?",
        "question_pt":"Com a interven\u00e7\u00e3o das restri\u00e7\u00f5es de movimento a partir de 5 de fevereiro de 2020, quais foram os casos confirmados para o COVID-19, limitados?"
    },
    {
        "answer":"case was diagnosed on 1 February, the ship was requested to remain in the ocean near Yokohama from 3 February onwards.",
        "answer_pt":"Caso o caso tenha sido diagnosticado em 1\u00ba de fevereiro, o navio foi solicitado a permanecer no oceano perto de Yokohama a partir de 3 de fevereiro.",
        "id":"1191",
        "question":"Who was the first COVID-19 identified case patient on the Diamond Princess cruise ship?",
        "question_pt":"Quem foi o primeiro paciente de caso identificado com COVID-19 no navio Diamond Princess?"
    },
    {
        "answer":"he case was diagnosed on 1 February",
        "answer_pt":"o caso foi diagnosticado em 1 de fevereiro",
        "id":"1192",
        "question":"When was  the first  passenger patient on the Diamond Princess cruise ship diagnosed with COVID-19?",
        "question_pt":"Quando o primeiro paciente de passageiro do navio Diamond Princess foi diagnosticado com COVID-19?"
    },
    {
        "answer":"Out of a total of 3711 persons (consisting of 2666 passengers and 1045 crew members), 199 symptomatic cases have been diagnosed on board as of 24 February, and additional asymptomatic infections and symptomatic cases after disembarkation have also been reported",
        "answer_pt":"De um total de 3711 pessoas (consistindo em 2666 passageiros e 1045 tripulantes), 199 casos sintom\u00e1ticos foram diagnosticados a bordo a partir de 24 de fevereiro e tamb\u00e9m foram relatadas infec\u00e7\u00f5es assintom\u00e1ticas e casos sintom\u00e1ticos adicionais ap\u00f3s o desembarque.",
        "id":"1193",
        "question":"How many COVID-19 cases were confirmed on the Diamond Princess cruise ship?",
        "question_pt":"Quantos casos COVID-19 foram confirmados no navio Diamond Princess?"
    },
    {
        "answer":"about 5.0 days",
        "answer_pt":"cerca de 5,0 dias",
        "id":"1194",
        "question":"What is the estimated mean incubation period for COVID-19 infection on the Diamond Princess cruise ship?",
        "question_pt":"Qual \u00e9 o per\u00edodo m\u00e9dio estimado de incuba\u00e7\u00e3o da infec\u00e7\u00e3o por COVID-19 no navio Diamond Princess?"
    },
    {
        "answer":"highly successful in greatly reducing the number of secondary transmissions on board.",
        "answer_pt":"muito bem-sucedido em reduzir bastante o n\u00famero de transmiss\u00f5es secund\u00e1rias a bordo.",
        "id":"1196",
        "question":"What was the effect of movement restriction policy on the Diamond Princess cruise ship started on 5th February 2020.",
        "question_pt":"Qual foi o efeito da pol\u00edtica de restri\u00e7\u00e3o de movimento no navio Diamond Princess come\u00e7ou em 5 de fevereiro de 2020."
    },
    {
        "answer":" the cumulative incidence with and without close contact would have been as large as 1373 (95% CI: 570, 2176) and 766 (95% CI: 587, 946) cases,",
        "answer_pt":"a incid\u00eancia cumulativa com e sem contato pr\u00f3ximo teria sido t\u00e3o grande quanto 1373 (IC 95%: 570, 2176) e 766 (IC 95%: 587, 946) casos,",
        "id":"1189",
        "question":"What would  have the number of confirmed cases on the Diamond Princess cruise ship,  without a movement restriction starting on the 5th February 2020?",
        "question_pt":"Qual seria o n\u00famero de casos confirmados no navio de cruzeiro Diamond Princess, sem uma restri\u00e7\u00e3o de movimento a partir de 5 de fevereiro de 2020?"
    },
    {
        "answer":"31 December 2019,",
        "answer_pt":"31 de dezembro de 2019,",
        "id":"1235",
        "question":"When was the a cluster of pneumonia cases were first reported ?",
        "question_pt":"Quando foi relatado o primeiro grupo de casos de pneumonia?"
    },
    {
        "answer":" 63.1 million per year in 2017 ",
        "answer_pt":"63,1 milh\u00f5es por ano em 2017",
        "id":"1236",
        "question":"What is the number of inbound passengers from China?",
        "question_pt":"Qual \u00e9 o n\u00famero de passageiros que chegam da China?"
    },
    {
        "answer":"2.1%",
        "answer_pt":"2,1%",
        "id":"1237",
        "question":"What percent of inbound passengers from China were from Wuhan?",
        "question_pt":"Qual a porcentagem de passageiros que chegam da China eram de Wuhan?"
    },
    {
        "answer":"prevents cleavage of viral proteins required for replication",
        "answer_pt":"impede a clivagem de prote\u00ednas virais necess\u00e1rias para replica\u00e7\u00e3o",
        "id":"314",
        "question":"What is the mechanism of action for rupintrivir?",
        "question_pt":"Qual \u00e9 o mecanismo de a\u00e7\u00e3o do rupintrivir?"
    },
    {
        "answer":"in studies of natural infection, it did not significantly affect viral loads or symptom severity",
        "answer_pt":"em estudos de infec\u00e7\u00e3o natural, n\u00e3o afetou significativamente as cargas virais ou a gravidade dos sintomas",
        "id":"315",
        "question":"Has rupintrivir been shown to reduce the symptoms of a rhinoviral infection?",
        "question_pt":"Foi demonstrado que o rupintrivir reduz os sintomas de uma infec\u00e7\u00e3o por rinov\u00edrus?"
    },
    {
        "answer":"viral",
        "answer_pt":"viral",
        "id":"308",
        "question":"What is the primary etiology of acute respiratory infection?",
        "question_pt":"Qual \u00e9 a etiologia prim\u00e1ria da infec\u00e7\u00e3o respirat\u00f3ria aguda?"
    },
    {
        "answer":"respiratory syncytial virus",
        "answer_pt":"v\u00edrus sincicial Respirat\u00f3rio",
        "id":"309",
        "question":"What is RSV?",
        "question_pt":"O que \u00e9 RSV?"
    },
    {
        "answer":"human rhinovirus",
        "answer_pt":"rinov\u00edrus humano",
        "id":"310",
        "question":"What virus is most commonly associated with acute respiratory infections?",
        "question_pt":"Qual v\u00edrus \u00e9 mais comumente associado a infec\u00e7\u00f5es respirat\u00f3rias agudas?"
    },
    {
        "answer":"HRVs, coronaviruses (CoV), influenza, respiratory syncytial virus (RSV) and parainfluenza viruses (PIV)",
        "answer_pt":"VFC, coronav\u00edrus (CoV), gripe, v\u00edrus sincicial respirat\u00f3rio (RSV) e v\u00edrus de parainfluenza (PIV)",
        "id":"311",
        "question":"What viruses are most frequently associated with acute respiratory infections?",
        "question_pt":"Quais v\u00edrus est\u00e3o mais frequentemente associados a infec\u00e7\u00f5es respirat\u00f3rias agudas?"
    },
    {
        "answer":"chronic airway inflammation, and a history of respiratory symptoms such as wheeze, shortness of breath, chest tightness and cough",
        "answer_pt":"inflama\u00e7\u00e3o cr\u00f4nica das vias a\u00e9reas e hist\u00f3rico de sintomas respirat\u00f3rios como chiado, falta de ar, aperto no peito e tosse",
        "id":"313",
        "question":"What are the clinical characteristics of asthma?",
        "question_pt":"Quais s\u00e3o as caracter\u00edsticas cl\u00ednicas da asma?"
    },
    {
        "answer":"morbid obesity",
        "answer_pt":"obesidade m\u00f3rbida",
        "id":"317",
        "question":"What risk factor was associated with hospitalization and death during the 2009 H1N1 influence pandemic?",
        "question_pt":"Que fator de risco foi associado \u00e0 hospitaliza\u00e7\u00e3o e morte durante a pandemia de H1N1 de 2009?"
    },
    {
        "answer":"two",
        "answer_pt":"dois",
        "id":"319",
        "question":"How many surface proteins are on the H1N1 influenza virus?",
        "question_pt":"Quantas prote\u00ednas de superf\u00edcie existem no v\u00edrus influenza H1N1?"
    },
    {
        "answer":"haemagglutinin (HA) and the neuraminidase (NA) ",
        "answer_pt":"hemaglutinina (HA) e neuraminidase (NA)",
        "id":"320",
        "question":"What are the 2 surface proteins on the H1N1 influenza virus?",
        "question_pt":"Quais s\u00e3o as 2 prote\u00ednas de superf\u00edcie do v\u00edrus influenza H1N1?"
    },
    {
        "answer":"oseltamivir",
        "answer_pt":"oseltamivir",
        "id":"322",
        "question":"What pharmaceutical targets the NA glycoprotein of the H1N1 influenza virus?",
        "question_pt":"Quais produtos farmac\u00eauticos t\u00eam como alvo a glicoprote\u00edna NA do v\u00edrus influenza H1N1?"
    },
    {
        "answer":"H275Y",
        "answer_pt":"H275Y",
        "id":"323",
        "question":"What genetic mutation decreases a person's susceptibility to the H1N1 influenza virus?",
        "question_pt":"Que muta\u00e7\u00e3o gen\u00e9tica diminui a suscetibilidade de uma pessoa ao v\u00edrus influenza H1N1?"
    },
    {
        "answer":"difficulty with aerosol delivery, cost and potential harm to healthcare workers",
        "answer_pt":"dificuldade na entrega do aerossol, custo e poss\u00edveis danos aos profissionais de sa\u00fade",
        "id":"324",
        "question":"Why is ribavirin treatment limited?",
        "question_pt":"Por que o tratamento com ribavirina \u00e9 limitado?"
    },
    {
        "answer":" lack of awareness or recall bias",
        "answer_pt":"falta de conscientiza\u00e7\u00e3o ou vi\u00e9s de recall",
        "id":"2974",
        "question":"To what the lack of exposure report could be attributed?",
        "question_pt":"A que o relat\u00f3rio de falta de exposi\u00e7\u00e3o pode ser atribu\u00eddo?"
    },
    {
        "answer":" it has direct implications for public health and hospital infection control",
        "answer_pt":"tem implica\u00e7\u00f5es diretas na sa\u00fade p\u00fablica e no controle de infec\u00e7\u00f5es hospitalares",
        "id":"2975",
        "question":"Why is the determination of asymptomatic or pre-symptomatic transmission, an urgent priority?",
        "question_pt":"Por que a determina\u00e7\u00e3o da transmiss\u00e3o assintom\u00e1tica ou pr\u00e9-sintom\u00e1tica \u00e9 uma prioridade urgente?"
    },
    {
        "answer":"10 days after illness onset [7] , consistent with the peak in viral load at around that time",
        "answer_pt":"10 dias ap\u00f3s o in\u00edcio da doen\u00e7a [7], consistente com o pico de carga viral nessa \u00e9poca",
        "id":"2976",
        "question":"When does the infectivity of SARS-COV peak?",
        "question_pt":"Quando a infectividade do SARS-COV atinge o pico?"
    },
    {
        "answer":" from person to person,",
        "answer_pt":"de pessoa para pessoa,",
        "id":"2967",
        "question":"How can the 2019-nCov spread?",
        "question_pt":"Como o 2019-nCov pode se espalhar?"
    },
    {
        "answer":"2.2",
        "answer_pt":"2.2",
        "id":"2968",
        "question":"What is the estimate of the basic reproduction number?",
        "question_pt":"Qual \u00e9 a estimativa do n\u00famero de reprodu\u00e7\u00e3o b\u00e1sico?"
    },
    {
        "answer":" 7.5 days",
        "answer_pt":"7,5 dias",
        "id":"2969",
        "question":"What is assumed for the mean serial interval?",
        "question_pt":"O que \u00e9 assumido para o intervalo serial m\u00e9dio?"
    },
    {
        "answer":"slightly lower basic reproductive number.",
        "answer_pt":"n\u00famero reprodutivo b\u00e1sico ligeiramente mais baixo.",
        "id":"2970",
        "question":"What  would a shorter mean serial interval mean?",
        "question_pt":"O que significaria um intervalo serial m\u00e9dio mais curto?"
    },
    {
        "answer":"Control measures and changes in population behaviou",
        "answer_pt":"Medidas de controle e mudan\u00e7as no comportamento da popula\u00e7\u00e3o",
        "id":"2971",
        "question":"What should have reduced the basic reproduction number in January?",
        "question_pt":"O que deveria ter reduzido o n\u00famero b\u00e1sico de reprodu\u00e7\u00e3o em janeiro?"
    },
    {
        "answer":" around 5\u20136 days, with an upper limit of around 11-14 days [2,5], and delays from illness onset to laboratory confirmation added a further 10 days on average",
        "answer_pt":"em torno de 5 a 6 dias, com um limite superior em torno de 11 a 14 dias [2,5], e os atrasos no in\u00edcio da doen\u00e7a at\u00e9 a confirma\u00e7\u00e3o laboratorial adicionaram mais 10 dias em m\u00e9dia",
        "id":"2972",
        "question":"What  are the delays between infection to illness and illness to laboratory confirmatiion?",
        "question_pt":"Quais s\u00e3o os atrasos entre a infec\u00e7\u00e3o por doen\u00e7a e a confirma\u00e7\u00e3o laboratorial?"
    },
    {
        "answer":"75,000",
        "answer_pt":"75.000",
        "id":"2973",
        "question":"What is the estimate of number of infections in Wuhan on 25 January 2020?",
        "question_pt":"Qual \u00e9 a estimativa do n\u00famero de infec\u00e7\u00f5es em Wuhan em 25 de janeiro de 2020?"
    },
    {
        "answer":"on the day of illness onse",
        "answer_pt":"no dia do in\u00edcio da doen\u00e7a",
        "id":"2977",
        "question":"when is viral shedding the highest?",
        "question_pt":"quando o derramamento viral \u00e9 o mais alto?"
    },
    {
        "answer":"through large respiratory droplets, ",
        "answer_pt":"atrav\u00e9s de grandes got\u00edculas respirat\u00f3rias,",
        "id":"2978",
        "question":"How does the transmission of the respiratory virus happen?",
        "question_pt":"Como ocorre a transmiss\u00e3o do v\u00edrus respirat\u00f3rio?"
    },
    {
        "answer":" through fine particle aerosols",
        "answer_pt":"atrav\u00e9s de aeross\u00f3is de part\u00edculas finas",
        "id":"2979",
        "question":"How do some respiratory viruses spread?",
        "question_pt":"Como alguns v\u00edrus respirat\u00f3rios se espalham?"
    },
    {
        "answer":"indirect transmission via fomites",
        "answer_pt":"transmiss\u00e3o indireta via fomites",
        "id":"2980",
        "question":"What can also play  a role?",
        "question_pt":"O que tamb\u00e9m pode desempenhar um papel?"
    },
    {
        "answer":" faecal-oral transmission ",
        "answer_pt":"transmiss\u00e3o fecal-oral",
        "id":"2981",
        "question":"What can play a role  in the infection of gastrointestinal tract?",
        "question_pt":"O que pode desempenhar um papel na infec\u00e7\u00e3o do trato gastrointestinal?"
    },
    {
        "answer":"through pressure differentials between contaminated effluent pipes, bathroom floor drains and flushing toilets ",
        "answer_pt":"atrav\u00e9s de diferenciais de press\u00e3o entre tubos de efluentes contaminados, ralos de pisos de banheiros e vasos sanit\u00e1rios",
        "id":"2982",
        "question":"What was attributed to the spread of SARS-COV at Amoy Gardens?",
        "question_pt":"O que foi atribu\u00eddo \u00e0 dissemina\u00e7\u00e3o do SARS-COV em Amoy Gardens?"
    },
    {
        "answer":"through a surveillance system for pneumonia of unknown aetiology",
        "answer_pt":"atrav\u00e9s de um sistema de vigil\u00e2ncia de pneumonia de etiologia desconhecida",
        "id":"2983",
        "question":"How were the first human infections identified?",
        "question_pt":"Como foram identificadas as primeiras infec\u00e7\u00f5es humanas?"
    },
    {
        "answer":"that there could be many more mild infections than severe infections",
        "answer_pt":"que pode haver muito mais infec\u00e7\u00f5es leves do que infec\u00e7\u00f5es graves",
        "id":"2984",
        "question":"What do mild clinical presentations of 2019-nCOV indicate?",
        "question_pt":"O que indicam apresenta\u00e7\u00f5es cl\u00ednicas leves de 2019-nCOV?"
    },
    {
        "answer":"because it determines the strength of public health response required.",
        "answer_pt":"porque determina a for\u00e7a da resposta de sa\u00fade p\u00fablica necess\u00e1ria.",
        "id":"2985",
        "question":"Why is important to  determine the spectrum of clinical manifestations of 2019-nCoV infections?",
        "question_pt":"Por que \u00e9 importante determinar o espectro das manifesta\u00e7\u00f5es cl\u00ednicas das infec\u00e7\u00f5es por 2019-nCoV?"
    },
    {
        "answer":" to determine high risk groups.",
        "answer_pt":"para determinar grupos de alto risco.",
        "id":"2986",
        "question":"What, beyond the assessment of severity, is important?",
        "question_pt":"O que, al\u00e9m da avalia\u00e7\u00e3o da gravidade, \u00e9 importante?"
    },
    {
        "answer":"older adults, obese individuals or those with underlying medical conditions,",
        "answer_pt":"idosos, indiv\u00edduos obesos ou com condi\u00e7\u00f5es m\u00e9dicas subjacentes,",
        "id":"2987",
        "question":"For whom would the infections be more severe?",
        "question_pt":"Para quem as infec\u00e7\u00f5es seriam mais graves?"
    },
    {
        "answer":"when not all exacerbation events occurred during the viral infection but may also occur well after viral clearance (Kim et al., 2008; Stolz et al., 2019) in particular the late onset of a bacterial infection",
        "answer_pt":"quando nem todos os eventos de exacerba\u00e7\u00e3o ocorreram durante a infec\u00e7\u00e3o viral, mas tamb\u00e9m podem ocorrer bem ap\u00f3s a depura\u00e7\u00e3o viral (Kim et al., 2008; Stolz et al., 2019), em particular o in\u00edcio tardio de uma infec\u00e7\u00e3o bacteriana",
        "id":"3963",
        "question":"When is this especially true?",
        "question_pt":"Quando isso \u00e9 especialmente verdade?"
    },
    {
        "answer":"that viral infection increases airway inflammation which aggravates disease symptoms.",
        "answer_pt":"essa infec\u00e7\u00e3o viral aumenta a inflama\u00e7\u00e3o das vias a\u00e9reas que agrava os sintomas da doen\u00e7a.",
        "id":"3855",
        "question":"What is the current understanding on viral-induced exacerbations?",
        "question_pt":"Qual \u00e9 o entendimento atual sobre exacerba\u00e7\u00f5es induzidas por v\u00edrus?"
    },
    {
        "answer":"Recent advances in in vitro air-liquid interface 3D cultures, organoid cultures and the use of novel human and animal challenge models",
        "answer_pt":"Avan\u00e7os recentes em culturas 3D de interface ar-l\u00edquido in vitro, culturas organoides e o uso de novos modelos de desafio humano e animal",
        "id":"3856",
        "question":"What have evoked new understandings as to the mechanisms of viral exacerbations?",
        "question_pt":"O que despertou novos entendimentos quanto aos mecanismos de exacerba\u00e7\u00f5es virais?"
    },
    {
        "answer":"Respiratory virus infection",
        "answer_pt":"Infec\u00e7\u00e3o por v\u00edrus respirat\u00f3rio",
        "id":"3854",
        "question":"What is one of  the major sources of exacerbation of chronic airway inflammatory diseases?",
        "question_pt":"Qual \u00e9 uma das principais fontes de exacerba\u00e7\u00e3o de doen\u00e7as inflamat\u00f3rias cr\u00f4nicas das vias a\u00e9reas?"
    },
    {
        "answer":" recent novel findings that elucidate how respiratory viral infections alter the epithelial barrier in the airways, the upper airway microbial environment, epigenetic modifications including miRNA modulation, and other changes in immune responses throughout the upper and lower airways.",
        "answer_pt":"recentes descobertas recentes que elucidam como as infec\u00e7\u00f5es virais respirat\u00f3rias alteram a barreira epitelial nas vias a\u00e9reas, o ambiente microbiano das vias a\u00e9reas superiores, modifica\u00e7\u00f5es epigen\u00e9ticas, incluindo a modula\u00e7\u00e3o do miRNA e outras altera\u00e7\u00f5es nas respostas imunes nas vias a\u00e9reas superiores e inferiores.",
        "id":"3857",
        "question":"What is the focus of this review?",
        "question_pt":"Qual \u00e9 o foco desta revis\u00e3o?"
    },
    {
        "answer":"the prevalence of different respiratory viral infections in causing exacerbations in chronic airway inflammatory diseases.",
        "answer_pt":"a preval\u00eancia de diferentes infec\u00e7\u00f5es virais respirat\u00f3rias em causar exacerba\u00e7\u00f5es em doen\u00e7as inflamat\u00f3rias cr\u00f4nicas das vias a\u00e9reas.",
        "id":"3858",
        "question":"What have the authors reviewed?",
        "question_pt":"O que os autores revisaram?"
    },
    {
        "answer":"how recent models have expanded our appreciation of the mechanisms of viral-induced exacerbations.",
        "answer_pt":"como modelos recentes expandiram nossa aprecia\u00e7\u00e3o dos mecanismos das exacerba\u00e7\u00f5es induzidas por v\u00edrus.",
        "id":"3859",
        "question":"What is summarized?",
        "question_pt":"O que \u00e9 resumido?"
    },
    {
        "answer":"the importance of the virome within the airway microbiome environment and its impact on subsequent bacterial infection.",
        "answer_pt":"a import\u00e2ncia do viroma no ambiente do microbioma das vias a\u00e9reas e seu impacto na infec\u00e7\u00e3o bacteriana subsequente.",
        "id":"3860",
        "question":"What is highlighted by the authors?",
        "question_pt":"O que \u00e9 destacado pelos autores?"
    },
    {
        "answer":"the understanding of viral induced exacerbation in chronic airway inflammatory diseases and indicates pathways that may be targeted for more effective management of chronic inflammatory diseases.",
        "answer_pt":"o entendimento da exacerba\u00e7\u00e3o induzida por v\u00edrus em doen\u00e7as inflamat\u00f3rias cr\u00f4nicas das vias a\u00e9reas e indica caminhos que podem ser direcionados para um tratamento mais eficaz das doen\u00e7as inflamat\u00f3rias cr\u00f4nicas.",
        "id":"3861",
        "question":"What is consolidated in this review?",
        "question_pt":"O que \u00e9 consolidado nesta revis\u00e3o?"
    },
    {
        "answer":" airway inflammation leading to complications such as coughing, wheezing and shortness of breath. ",
        "answer_pt":"inflama\u00e7\u00e3o das vias a\u00e9reas levando a complica\u00e7\u00f5es como tosse, chiado no peito e falta de ar.",
        "id":"3862",
        "question":"What is this disease  characterized by ?",
        "question_pt":"O que \u00e9 essa doen\u00e7a caracterizada?"
    },
    {
        "answer":" in both the upper airway (such as chronic rhinosinusitis, CRS) and lower airway (such as asthma and chronic obstructive pulmonary disease, COPD)",
        "answer_pt":"nas vias a\u00e9reas superiores (como rinossinusite cr\u00f4nica, RSC) e vias a\u00e9reas inferiores (como asma e doen\u00e7a pulmonar obstrutiva cr\u00f4nica, DPOC)",
        "id":"3863",
        "question":"Where can this disease manifest?",
        "question_pt":"Onde esta doen\u00e7a pode se manifestar?"
    },
    {
        "answer":"due to the complexity and heterogeneity of the disease.",
        "answer_pt":"devido \u00e0 complexidade e heterogeneidade da doen\u00e7a.",
        "id":"3864",
        "question":"Why do treatment and management vary in efficacy?",
        "question_pt":"Por que o tratamento e o manejo variam em efic\u00e1cia?"
    },
    {
        "answer":"the effect of episodic exacerbations of the disease, defined as worsening of disease symptoms including wheeze, cough, breathlessness and chest tightness ",
        "answer_pt":"o efeito de exacerba\u00e7\u00f5es epis\u00f3dicas da doen\u00e7a, definidas como agravamento dos sintomas da doen\u00e7a, incluindo chiado, tosse, falta de ar e aperto no peito",
        "id":"3865",
        "question":"What complicates this  further?",
        "question_pt":"O que complica isso ainda mais?"
    },
    {
        "answer":"the effect of enhanced acute airway inflammation impacting upon and worsening the symptoms of the existing disease",
        "answer_pt":"o efeito da inflama\u00e7\u00e3o aguda das vias a\u00e9reas aumentada, impactando e agravando os sintomas da doen\u00e7a existente",
        "id":"3866",
        "question":"What are such exacerbations due to?",
        "question_pt":"A que se devem essas exacerba\u00e7\u00f5es?"
    },
    {
        "answer":"morbidity and sometimes mortality in patients, as well as resulting in major economic burdens worldwide",
        "answer_pt":"morbidade e, \u00e0s vezes, mortalidade em pacientes, al\u00e9m de resultar em grandes encargos econ\u00f4micos em todo o mundo",
        "id":"3867",
        "question":"What do the acute exacerbations cause?",
        "question_pt":"O que as exacerba\u00e7\u00f5es agudas causam?"
    },
    {
        "answer":"the presence of environmental factors such as allergens, pollutants, smoke, cold or dry air and pathogenic microbes in the airway",
        "answer_pt":"presen\u00e7a de fatores ambientais, como al\u00e9rgenos, poluentes, fuma\u00e7a, ar frio ou seco e micr\u00f3bios patog\u00eanicos nas vias a\u00e9reas",
        "id":"3869",
        "question":"What are acute exacerbations  usually due to ?",
        "question_pt":"Quais s\u00e3o as exacerba\u00e7\u00f5es agudas geralmente causadas?"
    },
    {
        "answer":" infiltration of activated immune cells that further release inflammatory mediators that cause acute symptoms such as increased mucus production, cough, wheeze and shortness of breath. ",
        "answer_pt":"infiltra\u00e7\u00e3o de c\u00e9lulas imunes ativadas que liberam mais mediadores inflamat\u00f3rios que causam sintomas agudos, como aumento da produ\u00e7\u00e3o de muco, tosse, chiado no peito e falta de ar.",
        "id":"3870",
        "question":"What does the immune response elicited by these agents lead to?",
        "question_pt":"A que a resposta imune desencadeada por esses agentes leva?"
    },
    {
        "answer":"viral infection is one of the major drivers of asthma exacerbations accounting for up to 80-90% and 45-80% of exacerbations in children and adults respectively",
        "answer_pt":"A infec\u00e7\u00e3o viral \u00e9 um dos principais fatores de exacerba\u00e7\u00e3o da asma, respons\u00e1vel por at\u00e9 80-90% e 45-80% das exacerba\u00e7\u00f5es em crian\u00e7as e adultos, respectivamente",
        "id":"3871",
        "question":"Among these agents which is a major driver?",
        "question_pt":"Entre esses agentes, qual \u00e9 um dos principais fatores?"
    },
    {
        "answer":"30-80% of acute COPD exacerbations",
        "answer_pt":"30-80% das exacerba\u00e7\u00f5es agudas da DPOC",
        "id":"3872",
        "question":"What is the viral involvement in COPD exacerbation? ",
        "question_pt":"Qual \u00e9 o envolvimento viral na exacerba\u00e7\u00e3o da DPOC?"
    },
    {
        "answer":"their ease of transmission and infection",
        "answer_pt":"sua facilidade de transmiss\u00e3o e infec\u00e7\u00e3o",
        "id":"3873",
        "question":"What is the reason for the involvement of respiratory viruses in exacerbation?",
        "question_pt":"Qual o motivo do envolvimento dos v\u00edrus respirat\u00f3rios na exacerba\u00e7\u00e3o?"
    },
    {
        "answer":" important to identify the exact mechanisms underpinning viral exacerbations in susceptible subjects",
        "answer_pt":"importante identificar os mecanismos exatos que sustentam as exacerba\u00e7\u00f5es virais em indiv\u00edduos suscet\u00edveis",
        "id":"3874",
        "question":"What does the involvement of respiratory viruses contribute to?",
        "question_pt":"Para que contribui o envolvimento de v\u00edrus respirat\u00f3rios?"
    },
    {
        "answer":" to properly manage exacerbations via supplementary treatments that may alleviate the exacerbation symptoms or prevent severe exacerbations.",
        "answer_pt":"gerenciar adequadamente as exacerba\u00e7\u00f5es por meio de tratamentos suplementares que possam aliviar os sintomas de exacerba\u00e7\u00e3o ou impedir exacerba\u00e7\u00f5es graves.",
        "id":"3875",
        "question":"Why is it  important to identify the exact mechanisms underpinning viral exacerbations in susceptible subjects?",
        "question_pt":"Por que \u00e9 importante identificar os mecanismos exatos que sustentam as exacerba\u00e7\u00f5es virais em indiv\u00edduos suscet\u00edveis?"
    },
    {
        "answer":"dysregulated inflammation in most chronic airway inflammatory diseases",
        "answer_pt":"inflama\u00e7\u00e3o desregulada na maioria das doen\u00e7as inflamat\u00f3rias cr\u00f4nicas das vias a\u00e9reas",
        "id":"3876",
        "question":"What is the lower airway the site of?",
        "question_pt":"Qual \u00e9 a via a\u00e9rea inferior do local?"
    },
    {
        "answer":"the upper airway",
        "answer_pt":"as vias a\u00e9reas superiores",
        "id":"3877",
        "question":"Where is the the first point of contact with sources of exacerbation",
        "question_pt":"Onde \u00e9 o primeiro ponto de contato com fontes de exacerba\u00e7\u00e3o"
    },
    {
        "answer":" recent findings of viral interaction with the upper airway.",
        "answer_pt":"descobertas recentes de intera\u00e7\u00e3o viral com as vias a\u00e9reas superiores.",
        "id":"3878",
        "question":"What is the focus of this review?",
        "question_pt":"Qual \u00e9 o foco desta revis\u00e3o?"
    },
    {
        "answer":"how viral induced changes to the upper airway may contribute to chronic airway inflammatory disease exacerbations, to provide a unified elucidation of the potential exacerbation mechanisms initiated from predominantly upper airway infections.",
        "answer_pt":"como as altera\u00e7\u00f5es induzidas por v\u00edrus nas vias a\u00e9reas superiores podem contribuir para exacerba\u00e7\u00f5es cr\u00f4nicas de doen\u00e7as inflamat\u00f3rias das vias a\u00e9reas, para fornecer uma elucida\u00e7\u00e3o unificada dos potenciais mecanismos de exacerba\u00e7\u00e3o iniciados por infec\u00e7\u00f5es predominantemente nas vias a\u00e9reas superiores.",
        "id":"3879",
        "question":"What is complied by the authors?",
        "question_pt":"O que \u00e9 cumprido pelos autores?"
    },
    {
        "answer":"Despite being a major cause of exacerbation, reports linking respiratory viruses to acute exacerbations only start to emerge in the late 1950s (Pattemore et al., 1992) ; with bacterial infections previously considered as the likely culprit for acute exacerbation ",
        "answer_pt":"Apesar de ser uma das principais causas de exacerba\u00e7\u00e3o, relatos que ligam v\u00edrus respirat\u00f3rios a exacerba\u00e7\u00f5es agudas s\u00f3 come\u00e7am a surgir no final da d\u00e9cada de 1950 (Pattemore et al., 1992); com infec\u00e7\u00f5es bacterianas anteriormente consideradas como prov\u00e1vel culpado de exacerba\u00e7\u00e3o aguda",
        "id":"3880",
        "question":"Before linking respiratory viruses, what was linked to acute exacerbations?",
        "question_pt":"Antes de vincular v\u00edrus respirat\u00f3rios, o que estava associado a exacerba\u00e7\u00f5es agudas?"
    },
    {
        "answer":" viruses were recovered during acute exacerbations events and reports implicating their role emerged in the late 1980s",
        "answer_pt":"os v\u00edrus foram recuperados durante eventos agudos de exacerba\u00e7\u00f5es e relat\u00f3rios envolvendo seu papel surgiram no final dos anos 80",
        "id":"3881",
        "question":"What did the advent of PCR technology lead to?",
        "question_pt":"A que o advento da tecnologia de PCR levou?"
    },
    {
        "answer":"Rhinovirus (RV) and respiratory syncytial virus (RSV) ",
        "answer_pt":"Rinov\u00edrus (RV) e v\u00edrus sincicial respirat\u00f3rio (RSV)",
        "id":"3882",
        "question":"What are the predominant viruses linked to airway inflammatory diseases?",
        "question_pt":"Quais s\u00e3o os v\u00edrus predominantes ligados a doen\u00e7as inflamat\u00f3rias das vias a\u00e9reas?"
    },
    {
        "answer":"parainfluenza virus (PIV), influenza virus (IFV) and adenovirus (AdV)",
        "answer_pt":"v\u00edrus parainfluenza (PIV), v\u00edrus influenza (IFV) e adenov\u00edrus (AdV)",
        "id":"3883",
        "question":"What other viruses are implicated in acute exacerbations but to a much lesser extent?",
        "question_pt":"Que outros v\u00edrus est\u00e3o implicados em exacerba\u00e7\u00f5es agudas, mas em uma extens\u00e3o muito menor?"
    },
    {
        "answer":" viruses including bocavirus (BoV), human metapneumovirus (HMPV), certain coronavirus (CoV) strains, a specific enterovirus (EV) strain EV-D68, human cytomegalovirus (hCMV) and herpes simplex virus (HSV)",
        "answer_pt":"v\u00edrus, incluindo bocav\u00edrus (BoV), metapneumov\u00edrus humano (HMPV), certas cepas de coronav\u00edrus (CoV), uma cepa espec\u00edfica de enterov\u00edrus (EV) EV-D68, citomegalov\u00edrus humano (hCMV) e v\u00edrus do herpes simplex (HSV)",
        "id":"3884",
        "question":"What other viruses have been recently reported as contributing to acute exacerbations?",
        "question_pt":"Que outros v\u00edrus foram recentemente relatados como contribuindo para exacerba\u00e7\u00f5es agudas?"
    },
    {
        "answer":"they can infect both the upper and/or lower airway, further increasing the inflammatory conditions in the diseased airway",
        "answer_pt":"eles podem infectar as vias a\u00e9reas superiores e / ou inferiores, aumentando ainda mais as condi\u00e7\u00f5es inflamat\u00f3rias nas vias a\u00e9reas doentes",
        "id":"3885",
        "question":"What are the common feature of these viruses share?",
        "question_pt":"Quais s\u00e3o os recursos comuns desses v\u00edrus?"
    },
    {
        "answer":"within airway epithelial cells ",
        "answer_pt":"dentro das c\u00e9lulas epiteliais das vias a\u00e9reas",
        "id":"3886",
        "question":"Where do the respiratory viruses primarily infect and replicate?",
        "question_pt":"Onde os v\u00edrus respirat\u00f3rios infectam e se replicam principalmente?"
    },
    {
        "answer":"the cells release antiviral factors and cytokines that alter local airway inflammation and airway niche ",
        "answer_pt":"as c\u00e9lulas liberam fatores antivirais e citocinas que alteram a inflama\u00e7\u00e3o das vias a\u00e9reas locais e o nicho das vias a\u00e9reas",
        "id":"3887",
        "question":"What happens  during the replication process?",
        "question_pt":"O que acontece durante o processo de replica\u00e7\u00e3o?"
    },
    {
        "answer":"leads to type 1 inflammatory responses consisting of activation of an antiviral state and infiltration of antiviral effector cells. This eventually results in the resolution of the inflammatory response and clearance of the viral infection ",
        "answer_pt":"leva a respostas inflamat\u00f3rias do tipo 1 que consistem na ativa\u00e7\u00e3o de um estado antiviral e infiltra\u00e7\u00e3o de c\u00e9lulas efetoras antivirais. Isso acaba resultando na resolu\u00e7\u00e3o da resposta inflamat\u00f3ria e na elimina\u00e7\u00e3o da infec\u00e7\u00e3o viral",
        "id":"3888",
        "question":"What does the inflammation lead to in healthy airways?",
        "question_pt":"O que leva a inflama\u00e7\u00e3o nas vias a\u00e9reas saud\u00e1veis?"
    },
    {
        "answer":" the responses against the virus may be impaired or aberrant, causing sustained inflammation and erroneous infiltration, resulting in the exacerbation of their symptoms (Mallia and Johnston, 2006; Dougherty and Fahy, 2009; Busse et al., 2010; Britto et al., 2017; Linden et al., 2019) . This is usually further compounded by the increased susceptibility of chronic airway inflammatory disease patients toward viral respiratory infections, thereby increasing the frequency of exacerbation as a whole",
        "answer_pt":"as respostas contra o v\u00edrus podem ser prejudicadas ou aberrantes, causando inflama\u00e7\u00e3o sustentada e infiltra\u00e7\u00e3o incorreta, resultando na exacerba\u00e7\u00e3o de seus sintomas (Mallia e Johnston, 2006; Dougherty e Fahy, 2009; Busse et al., 2010; Britto et al., 2017; Linden et al., 2019). Isso geralmente \u00e9 agravado pelo aumento da suscetibilidade de pacientes com doen\u00e7a inflamat\u00f3ria cr\u00f4nica das vias a\u00e9reas a infec\u00e7\u00f5es respirat\u00f3rias virais, aumentando assim a frequ\u00eancia da exacerba\u00e7\u00e3o como um todo",
        "id":"3891",
        "question":"How may the responses be different in a chronically inflamed airway?",
        "question_pt":"Como as respostas podem ser diferentes em uma via a\u00e9rea com inflama\u00e7\u00e3o cr\u00f4nica?"
    },
    {
        "answer":"compiling and collating the current known mechanisms of viral-induced exacerbation of chronic airway inflammatory diseases; as well as linking the different viral infection pathogenesis to elucidate other potential ways the infection can exacerbate the disease",
        "answer_pt":"compilar e agrupar os atuais mecanismos conhecidos de exacerba\u00e7\u00e3o induzida por v\u00edrus de doen\u00e7as inflamat\u00f3rias cr\u00f4nicas das vias a\u00e9reas; bem como vincular as diferentes patogenias da infec\u00e7\u00e3o viral para elucidar outras formas poss\u00edveis de a infec\u00e7\u00e3o exacerbar a doen\u00e7a",
        "id":"3892",
        "question":"What will the review focus on?",
        "question_pt":"Em que a revis\u00e3o se concentrar\u00e1?"
    },
    {
        "answer":"to provide further understanding of viral induced exacerbation to identify potential pathways and pathogenesis mechanisms that may be targeted as supplementary care for management and prevention of exacerbation.",
        "answer_pt":"fornecer compreens\u00e3o adicional da exacerba\u00e7\u00e3o induzida por v\u00edrus para identificar poss\u00edveis vias e mecanismos de patog\u00eanese que podem ser direcionados como cuidados suplementares para o manejo e preven\u00e7\u00e3o da exacerba\u00e7\u00e3o.",
        "id":"3893",
        "question":"How will this review serve?",
        "question_pt":"Como esta revis\u00e3o ser\u00e1 veiculada?"
    },
    {
        "answer":"due to the current scarcity of antiviral drugs for the management of viral-induced exacerbations.",
        "answer_pt":"devido \u00e0 escassez atual de medicamentos antivirais para o tratamento de exacerba\u00e7\u00f5es induzidas por v\u00edrus.",
        "id":"3894",
        "question":"Why is this approach significant?",
        "question_pt":"Por que essa abordagem \u00e9 significativa?"
    },
    {
        "answer":"viruses evoke an inflammatory response as a means of counteracting the infection.",
        "answer_pt":"os v\u00edrus evocam uma resposta inflamat\u00f3ria como meio de combater a infec\u00e7\u00e3o.",
        "id":"3941",
        "question":"What happens upon infection?",
        "question_pt":"O que acontece ap\u00f3s a infec\u00e7\u00e3o?"
    },
    {
        "answer":"Generally, infected airway epithelial cells release type I (IFN\u03b1/\u03b2) and type III (IFN\u03bb) interferons, cytokines and chemokines such as IL-6, IL-8, IL-12, RANTES, macrophage inflammatory protein 1\u03b1 (MIP-1\u03b1) and monocyte chemotactic protein 1 (MCP-1) (Wark and Gibson, 2006; Matsukura et al., 2013) .",
        "answer_pt":"Geralmente, as c\u00e9lulas epiteliais das vias a\u00e9reas infectadas liberam interfer\u00f5es do tipo I (IFN\u03b1 / \u03b2) e III (IFN\u03bb), citocinas e quimiocinas como IL-6, IL-8, IL-12, RANTES, prote\u00edna inflamat\u00f3ria macr\u00f3fago 1a (MIP-1a) e prote\u00edna quimiot\u00e1tica 1 de mon\u00f3citos (MCP-1) (Wark e Gibson, 2006; Matsukura et al., 2013).",
        "id":"3942",
        "question":"How does the infected airway cell respond?",
        "question_pt":"Como a c\u00e9lula das vias a\u00e9reas infectadas responde?"
    },
    {
        "answer":"enable infiltration of innate immune cells and of professional antigen presenting cells (APCs) that will then in turn release specific mediators to facilitate viral targeting and clearance, including type II interferon (IFN\u03b3), IL-2, IL-4, IL-5, IL-9, and IL-12 (Wark and Gibson, 2006; Singh et al., 2010; Braciale et al., 2012) .",
        "answer_pt":"permitir a infiltra\u00e7\u00e3o de c\u00e9lulas imunes inatas e de c\u00e9lulas apresentadoras de ant\u00edgenos profissionais (APCs) que, por sua vez, liberar\u00e3o mediadores espec\u00edficos para facilitar o direcionamento e a elimina\u00e7\u00e3o viral, incluindo interferon do tipo II (IFN\u03b3), IL-2, IL-4, IL-5, IL-9 e IL-12 (Wark e Gibson, 2006; Singh et al., 2010; Braciale et al., 2012).",
        "id":"3943",
        "question":"What  does the epithelial proteins cause?",
        "question_pt":"O que as prote\u00ednas epiteliais causam?"
    },
    {
        "answer":"These factors heighten local inflammation and the infiltration of granulocytes, T-cells and B-cells (Wark and Gibson, 2006; Braciale et al., 2012) . The increased inflammation, in turn, worsens the symptoms of airway diseases.",
        "answer_pt":"Esses fatores aumentam a inflama\u00e7\u00e3o local e a infiltra\u00e7\u00e3o de granul\u00f3citos, c\u00e9lulas T e c\u00e9lulas B (Wark e Gibson, 2006; Braciale et al., 2012). O aumento da inflama\u00e7\u00e3o, por sua vez, piora os sintomas das doen\u00e7as das vias a\u00e9reas.",
        "id":"3944",
        "question":"What is the effect of these factors?",
        "question_pt":"Qual \u00e9 o efeito desses fatores?"
    },
    {
        "answer":"viral infections such as RV and RSV promote a Type 2-biased immune response (Becker, 2006; Jackson et al., 2014; Jurak et al., 2018) . This amplifies the basal type 2 inflammation resulting in a greater release of IL-4, IL-5, IL-13, RANTES and eotaxin and a further increase in eosinophilia, a key pathological driver of asthma and CRSwNP",
        "answer_pt":"infec\u00e7\u00f5es virais como RV e RSV promovem uma resposta imune enviesada pelo Tipo 2 (Becker, 2006; Jackson et al., 2014; Jurak et al., 2018). Isso amplifica a inflama\u00e7\u00e3o basal do tipo 2, resultando em uma maior libera\u00e7\u00e3o de IL-4, IL-5, IL-13, RANTES e eotaxina e um aumento adicional na eosinofilia, um importante fator patol\u00f3gico da asma e da CRSwNP",
        "id":"3945",
        "question":"What additional effects are caused  in patients with asthma and patients with CRS with nasal polyp ?",
        "question_pt":"Quais efeitos adicionais s\u00e3o causados \u200b\u200bem pacientes com asma e pacientes com RSC com p\u00f3lipo nasal?"
    },
    {
        "answer":"worsens the classical symptoms of disease and may further lead to life-threatening conditions due to breathing difficulties",
        "answer_pt":"piora os sintomas cl\u00e1ssicos da doen\u00e7a e pode levar a condi\u00e7\u00f5es de risco de vida devido a dificuldades respirat\u00f3rias",
        "id":"3946",
        "question":"What is the result of increased eosinophilia?",
        "question_pt":"Qual \u00e9 o resultado do aumento da eosinofilia?"
    },
    {
        "answer":"are more neutrophilic in nature due to the expression of neutrophil chemoattractants such as CXCL9, CXCL10, and CXCL11 (Cukic et al., 2012; Brightling and Greening, 2019) . The pathology of these airway diseases is characterized by airway remodeling due to the presence of remodeling factors such as matrix metalloproteinases (MMPs) released from infiltrating neutrophils (Linden et al., 2019) . Viral infections in such conditions will then cause increase neutrophilic activation; worsening the symptoms and airway remodeling in the airway thereby exacerbating COPD, CRSsNP and even CRSwNP in certain cases ",
        "answer_pt":"s\u00e3o de natureza mais neutrof\u00edlica devido \u00e0 express\u00e3o de quimioatraentes neutr\u00f3filos, como CXCL9, CXCL10 e CXCL11 (Cukic et al., 2012; Brightling e Greening, 2019). A patologia dessas doen\u00e7as das vias a\u00e9reas \u00e9 caracterizada pelo remodelamento das vias a\u00e9reas devido \u00e0 presen\u00e7a de fatores como as metaloproteinases da matriz (MMPs) liberadas pelos neutr\u00f3filos infiltrantes (Linden et al., 2019). Infec\u00e7\u00f5es virais em tais condi\u00e7\u00f5es causar\u00e3o aumento da ativa\u00e7\u00e3o neutrof\u00edlica; agravando os sintomas e a remodela\u00e7\u00e3o das vias a\u00e9reas exacerbando DPOC, CRSsNP e at\u00e9 mesmo CRSwNP em certos casos",
        "id":"3947",
        "question":"What are the effects for patients with COPD and patients with CRS without nasal polyp (CRSsNP) ?",
        "question_pt":"Quais s\u00e3o os efeitos para pacientes com DPOC e pacientes com RSC sem p\u00f3lipo nasal (RSCsNP)?"
    },
    {
        "answer":" IL-25, IL-33 and TSLP ",
        "answer_pt":"IL-25, IL-33 e TSLP",
        "id":"3948",
        "question":" Which are the type 2 inflammatory cytokines expressed by the epithelial cells upon injury to the epithelial barrier?",
        "question_pt":"Quais s\u00e3o as citocinas inflamat\u00f3rias do tipo 2 expressas pelas c\u00e9lulas epiteliais ap\u00f3s les\u00e3o da barreira epitelial?"
    },
    {
        "answer":" ILC2s are a group of lymphoid cells",
        "answer_pt":"ILC2s s\u00e3o um grupo de c\u00e9lulas linf\u00f3ides",
        "id":"3949",
        "question":"Which cells lacking both B and T cell receptors but play a crucial role in secreting type 2 cytokines to perpetuate type 2 inflammation when activated ?",
        "question_pt":"Quais c\u00e9lulas n\u00e3o possuem receptores de c\u00e9lulas B e T, mas desempenham um papel crucial na secre\u00e7\u00e3o de citocinas do tipo 2 para perpetuar a inflama\u00e7\u00e3o do tipo 2 quando ativadas?"
    },
    {
        "answer":"induce the expression of IL-25, IL-33 and TSLP, with heighten expression in an inflamed airway",
        "answer_pt":"induzir a express\u00e3o de IL-25, IL-33 e TSLP, com maior express\u00e3o nas vias a\u00e9reas inflamadas",
        "id":"3950",
        "question":"What is the effect cell death and injury to the epithelial barrier due to infection?",
        "question_pt":"Qual \u00e9 o efeito morte celular e les\u00e3o da barreira epitelial devido \u00e0 infec\u00e7\u00e3o?"
    },
    {
        "answer":"These 3 cytokines then work in concert to activate ILC2s to further secrete type 2 cytokines IL-4, IL-5, and IL-13 which further aggravate the type 2 inflammation in the airway causing acute exacerbation (",
        "answer_pt":"Essas tr\u00eas citocinas trabalham em conjunto para ativar as ILC2s para secretar ainda mais as citocinas do tipo 2 IL-4, IL-5 e IL-13, que agravam ainda mais a inflama\u00e7\u00e3o do tipo 2 nas vias a\u00e9reas, causando exacerba\u00e7\u00e3o aguda (",
        "id":"3951",
        "question":"What happens when the 3 cytokines are expressed?",
        "question_pt":"O que acontece quando as 3 citocinas s\u00e3o expressas?"
    },
    {
        "answer":" increased ILC2 activation, which retain the capability of differentiating to ILC1, may also further augment the neutrophilic response and further aggravate the exacerbation",
        "answer_pt":"O aumento da ativa\u00e7\u00e3o da ILC2, que mant\u00e9m a capacidade de diferenciar a ILC1, tamb\u00e9m pode aumentar ainda mais a resposta neutrof\u00edlica e agravar ainda mais a exacerba\u00e7\u00e3o",
        "id":"3952",
        "question":"What  happens in the case of COPD?",
        "question_pt":"O que acontece no caso da DPOC?"
    },
    {
        "answer":" these factors are not released to any great extent and do not activate an ILC2 response during viral infection in healthy individuals (Yan et al., 2016; Tan et al., 2018a) ; despite augmenting a type 2 exacerbation in chronically inflamed airways (Jurak et al., 2018) . These classical mechanisms of viral induced acute exacerbations are summarized in Figure 1 ",
        "answer_pt":"esses fatores n\u00e3o s\u00e3o liberados em grande medida e n\u00e3o ativam uma resposta da ILC2 durante a infec\u00e7\u00e3o viral em indiv\u00edduos saud\u00e1veis \u200b\u200b(Yan et al., 2016; Tan et al., 2018a); apesar de aumentar a exacerba\u00e7\u00e3o do tipo 2 nas vias a\u00e9reas com inflama\u00e7\u00e3o cr\u00f4nica (Jurak et al., 2018). Esses mecanismos cl\u00e1ssicos de exacerba\u00e7\u00f5es agudas induzidas por v\u00edrus est\u00e3o resumidos na Figura 1",
        "id":"3954",
        "question":"What happens during viral infection of healthy individuals?",
        "question_pt":"O que acontece durante a infec\u00e7\u00e3o viral de indiv\u00edduos saud\u00e1veis?"
    },
    {
        "answer":"antiviral state will be activated to clear the invading pathogen from the airway. Immune response and injury factors released from the infected epithelium normally would induce a rapid type 1 immunity that facilitates viral clearance. ",
        "answer_pt":"o estado antiviral ser\u00e1 ativado para eliminar o pat\u00f3geno invasor das vias a\u00e9reas. A resposta imune e os fatores de les\u00e3o liberados pelo epit\u00e9lio infectado normalmente induziriam uma imunidade r\u00e1pida do tipo 1 que facilita a depura\u00e7\u00e3o viral.",
        "id":"3960",
        "question":"What happens upon viral infection in the airway?",
        "question_pt":"O que acontece com a infec\u00e7\u00e3o viral nas vias a\u00e9reas?"
    },
    {
        "answer":" However, in the inflamed airway, the cytokines and chemokines released instead augmented the inflammation present in the chronically inflamed airway, strengthening the neutrophilic infiltration in COPD airway, and eosinophilic infiltration in the asthmatic airway. The effect is also further compounded by the participation of Th1 and ILC1 cells in the COPD airway; and Th2 and ILC2 cells in the asthmatic airway.",
        "answer_pt":"No entanto, nas vias a\u00e9reas inflamadas, as citocinas e quimiocinas liberadas aumentam a inflama\u00e7\u00e3o presente nas vias a\u00e9reas inflamadas cronicamente, fortalecendo a infiltra\u00e7\u00e3o neutrof\u00edlica nas vias a\u00e9reas da DPOC e a infiltra\u00e7\u00e3o eosinof\u00edlica nas vias a\u00e9reas asm\u00e1ticas. O efeito tamb\u00e9m \u00e9 agravado pela participa\u00e7\u00e3o das c\u00e9lulas Th1 e ILC1 nas vias a\u00e9reas da DPOC; e c\u00e9lulas Th2 e ILC2 nas vias a\u00e9reas asm\u00e1ticas.",
        "id":"3961",
        "question":"What is the effect of the inflammation of the airway?",
        "question_pt":"Qual \u00e9 o efeito da inflama\u00e7\u00e3o das vias a\u00e9reas?"
    },
    {
        "answer":"the synergistic effect of viral infection with other sensitizing agents ",
        "answer_pt":"o efeito sin\u00e9rgico da infec\u00e7\u00e3o viral com outros agentes sensibilizantes",
        "id":"3962",
        "question":"What increases the severity of exacerbations in the airway?",
        "question_pt":"O que aumenta a gravidade das exacerba\u00e7\u00f5es nas vias a\u00e9reas?"
    },
    {
        "answer":"he nasal epithelium remains the primary site of most infections.",
        "answer_pt":"O epit\u00e9lio nasal continua sendo o principal local da maioria das infec\u00e7\u00f5es.",
        "id":"3964",
        "question":"Why viruses do not need to directly infect the lower airway to cause an acute exacerbation?",
        "question_pt":"Por que os v\u00edrus n\u00e3o precisam infectar diretamente as vias a\u00e9reas inferiores para causar uma exacerba\u00e7\u00e3o aguda?"
    },
    {
        "answer":"a more complex interplay between the virus and upper airway epithelium which synergize with the local airway environment in line with the \"united airway\" hypothesis ",
        "answer_pt":"uma intera\u00e7\u00e3o mais complexa entre o v\u00edrus e o epit\u00e9lio das vias a\u00e9reas superiores, sinergizando com o ambiente local das vias a\u00e9reas, de acordo com a hip\u00f3tese da \"via a\u00e9rea unida\"",
        "id":"3965",
        "question":"what is suggested by the fact that  not all viral infections of the airway lead to acute exacerbations?",
        "question_pt":"o que \u00e9 sugerido pelo fato de que nem todas as infec\u00e7\u00f5es virais das vias a\u00e9reas levam a exacerba\u00e7\u00f5es agudas?"
    },
    {
        "answer":"viral infections or their components persist in patients",
        "answer_pt":"infec\u00e7\u00f5es virais ou seus componentes persistem em pacientes",
        "id":"3966",
        "question":"What is the effect of chronic airway inflammatory disease  in patients?",
        "question_pt":"Qual \u00e9 o efeito da doen\u00e7a inflamat\u00f3ria cr\u00f4nica das vias a\u00e9reas em pacientes?"
    },
    {
        "answer":"may further alter the local environment and contribute to current and future exacerbations",
        "answer_pt":"pode alterar ainda mais o ambiente local e contribuir para exacerba\u00e7\u00f5es atuais e futuras",
        "id":"3967",
        "question":"What is the effect of chronic airway inflammatory disease?",
        "question_pt":"Qual \u00e9 o efeito da doen\u00e7a inflamat\u00f3ria cr\u00f4nica das vias a\u00e9reas?"
    },
    {
        "answer":"to determine the contribution of the microbiome and mycobiome to viral infections.",
        "answer_pt":"determinar a contribui\u00e7\u00e3o do microbioma e do micobioma para infec\u00e7\u00f5es virais.",
        "id":"3968",
        "question":"Why should future studies  be performed using metagenomics in addition to PCR analysis ?",
        "question_pt":"Por que estudos futuros devem ser realizados usando metagen\u00f4mica, al\u00e9m da an\u00e1lise por PCR?"
    },
    {
        "answer":" recent data regarding viral interactions with the airway epithelium that could also contribute to, or further aggravate, acute exacerbations of chronic airway inflammatory diseases.",
        "answer_pt":"dados recentes sobre intera\u00e7\u00f5es virais com o epit\u00e9lio das vias a\u00e9reas que tamb\u00e9m poderiam contribuir ou agravar ainda mais as exacerba\u00e7\u00f5es agudas de doen\u00e7as inflamat\u00f3rias cr\u00f4nicas das vias a\u00e9reas.",
        "id":"3969",
        "question":"What is highlighted by the authors in this review?",
        "question_pt":"O que \u00e9 destacado pelos autores nesta revis\u00e3o?"
    },
    {
        "answer":"Patients with chronic airway inflammatory diseases ",
        "answer_pt":"Pacientes com doen\u00e7as inflamat\u00f3rias cr\u00f4nicas das vias a\u00e9reas",
        "id":"3970",
        "question":"Who has impaired or reduced ability of viral clearance ?",
        "question_pt":"Quem tem capacidade prejudicada ou reduzida de depura\u00e7\u00e3o viral?"
    },
    {
        "answer":"a type 2-skewed inflammatory response which deprives the airway of important type 1 responsive CD8 cells that are responsible for the complete clearance of virusinfected cells ",
        "answer_pt":"resposta inflamat\u00f3ria enviesada do tipo 2 que priva as vias a\u00e9reas de importantes c\u00e9lulas CD8 responsivas do tipo 1, respons\u00e1veis \u200b\u200bpela elimina\u00e7\u00e3o completa das c\u00e9lulas infectadas por v\u00edrus",
        "id":"3971",
        "question":"What does their impairment stems from?",
        "question_pt":"Do que decorre sua defici\u00eancia?"
    },
    {
        "answer":"in weak type 1 inflammation-inducing viruses such as RV and RSV",
        "answer_pt":"em v\u00edrus indutores de inflama\u00e7\u00e3o do tipo 1 fracos, como RV e RSV",
        "id":"3972",
        "question":"Where is this  especially evident?",
        "question_pt":"Onde isso \u00e9 especialmente evidente?"
    },
    {
        "answer":"there are also evidence of reduced type I (IFN\u03b2) and III (IFN\u03bb) interferon production due to type 2-skewed inflammation, which contributes to imperfect clearance of the virus resulting in persistence of viral components, or the live virus in the airway epithelium ",
        "answer_pt":"h\u00e1 tamb\u00e9m evid\u00eancias de produ\u00e7\u00e3o reduzida de interferon do tipo I (IFN\u03b2) e III (IFN\u03bb) devido \u00e0 inflama\u00e7\u00e3o enviesada do tipo 2, que contribui para a depura\u00e7\u00e3o imperfeita do v\u00edrus, resultando na persist\u00eancia de componentes virais ou no v\u00edrus vivo no epit\u00e9lio das vias a\u00e9reas",
        "id":"3973",
        "question":"What are other  effects?",
        "question_pt":"Quais s\u00e3o os outros efeitos?"
    },
    {
        "answer":"antiviral genes such as type I interferons, inflammasome activating factors and cytokines remained activated resulting in prolong airway inflammation",
        "answer_pt":"genes antivirais como interferons do tipo I, fatores de ativa\u00e7\u00e3o do inflamassoma e citocinas permaneceram ativados, resultando em prolongamento da inflama\u00e7\u00e3o das vias a\u00e9reas",
        "id":"3974",
        "question":"What is the  effect of viral components remaining in the airway?",
        "question_pt":"Qual \u00e9 o efeito dos componentes virais remanescentes nas vias a\u00e9reas?"
    },
    {
        "answer":"enhance granulocyte infiltration thus prolonging the exacerbation symptoms. Such persistent inflammation may also be found within DNA viruses such as AdV, hCMV and HSV, whose infections generally persist longer (Imperiale and Jiang, 2015) , further contributing to chronic activation of inflammation when they infect the airway",
        "answer_pt":"melhorar a infiltra\u00e7\u00e3o de granul\u00f3citos, prolongando assim os sintomas de exacerba\u00e7\u00e3o. Essa inflama\u00e7\u00e3o persistente tamb\u00e9m pode ser encontrada nos v\u00edrus de DNA, como AdV, hCMV e HSV, cujas infec\u00e7\u00f5es geralmente persistem por mais tempo (Imperiale e Jiang, 2015), contribuindo ainda mais para a ativa\u00e7\u00e3o cr\u00f4nica da inflama\u00e7\u00e3o quando infectam as vias a\u00e9reas.",
        "id":"3975",
        "question":"What do these factors do?",
        "question_pt":"O que esses fatores fazem?"
    },
    {
        "answer":"human papilloma virus (HPV), a DNA virus highly associated with head and neck cancers and respiratory papillomatosis,",
        "answer_pt":"v\u00edrus do papiloma humano (HPV), um v\u00edrus de DNA altamente associado a c\u00e2ncer de cabe\u00e7a e pesco\u00e7o e papilomatose respirat\u00f3ria,",
        "id":"3976",
        "question":"What is also linked with the chronic inflammation that precedes the malignancies?",
        "question_pt":"O que tamb\u00e9m est\u00e1 relacionado \u00e0 inflama\u00e7\u00e3o cr\u00f4nica que precede as malignidades?"
    },
    {
        "answer":" the role of HPV infection in causing chronic inflammation in the airway and their association to exacerbations of chronic airway inflammatory diseases, which is scarcely explored",
        "answer_pt":"o papel da infec\u00e7\u00e3o pelo HPV na inflama\u00e7\u00e3o cr\u00f4nica das vias a\u00e9reas e sua associa\u00e7\u00e3o com exacerba\u00e7\u00f5es de doen\u00e7as inflamat\u00f3rias cr\u00f4nicas das vias a\u00e9reas, pouco explorada",
        "id":"3977",
        "question":"What should be investigated in the future?",
        "question_pt":"O que deve ser investigado no futuro?"
    },
    {
        "answer":"viral persistence which lead to continuous expression of antiviral genes may also lead to the development of steroid resistance, which is seen with RV, RSV, and PIV infection",
        "answer_pt":"persist\u00eancia viral que leva \u00e0 express\u00e3o cont\u00ednua de genes antivirais tamb\u00e9m pode levar ao desenvolvimento de resist\u00eancia a ester\u00f3ides, observada nas infec\u00e7\u00f5es por RV, RSV e PIV",
        "id":"3978",
        "question":"What further can viral persistence lead to?",
        "question_pt":"O que mais a persist\u00eancia viral pode levar?"
    },
    {
        "answer":"may also cause the virus to linger longer in the airway due to the lack of antiviral clearance",
        "answer_pt":"tamb\u00e9m pode levar o v\u00edrus a permanecer mais tempo nas vias a\u00e9reas devido \u00e0 falta de libera\u00e7\u00e3o antiviral",
        "id":"3979",
        "question":"What  effect the use of steroids to  suppress inflammation can have?",
        "question_pt":"Que efeito o uso de ester\u00f3ides para suprimir a inflama\u00e7\u00e3o pode ter?"
    },
    {
        "answer":"The concomitant development of steroid resistance together with recurring or prolong viral infection ",
        "answer_pt":"O desenvolvimento concomitante de resist\u00eancia aos ester\u00f3ides, juntamente com infec\u00e7\u00f5es virais recorrentes ou prolongadas",
        "id":"3980",
        "question":"What should be further focus of research?",
        "question_pt":"Qual deve ser o foco adicional da pesquisa?"
    },
    {
        "answer":"viruses that induce strong type 1 inflammation and cell death such as IFV (Yan et al., 2016; Guibas et al., 2018) and certain CoV (including the recently emerged COVID-19 virus)",
        "answer_pt":"v\u00edrus que induzem forte inflama\u00e7\u00e3o do tipo 1 e morte celular, como o IFV (Yan et al., 2016; Guibas et al., 2018) e certos CoV (incluindo o v\u00edrus COVID-19 recentemente emergido)",
        "id":"3981",
        "question":"Which viruses may not cause prolonged inflammation due to strong induction of antiviral clearance?",
        "question_pt":"Quais v\u00edrus podem n\u00e3o causar inflama\u00e7\u00e3o prolongada devido \u00e0 forte indu\u00e7\u00e3o da depura\u00e7\u00e3o antiviral?"
    },
    {
        "answer":"massive damage and cell death to the epithelial barrier, so much so that areas of the epithelium may be completely absent post infection (Yan et al., 2016; Tan et al., 2019) . Factors such as RANTES and CXCL10, which recruit immune cells to induce apoptosis, are strongly induced from IFV infected epithelium ",
        "answer_pt":"danos maci\u00e7os e morte celular na barreira epitelial, tanto que \u00e1reas do epit\u00e9lio podem estar completamente ausentes ap\u00f3s a infec\u00e7\u00e3o (Yan et al., 2016; Tan et al., 2019). Fatores como RANTES e CXCL10, que recrutam c\u00e9lulas imunes para induzir apoptose, s\u00e3o fortemente induzidos pelo epit\u00e9lio infectado por IFV",
        "id":"3982",
        "question":"What do these infections cause?",
        "question_pt":"O que essas infec\u00e7\u00f5es causam?"
    },
    {
        "answer":" further compounds the cell deaths in IFV infected epithelium . The massive cell death induced may result in worsening of the acute exacerbation due to the release of their cellular content into the airway, further evoking an inflammatory response in the airway ",
        "answer_pt":"compostos adicionais a morte celular no epit\u00e9lio infectado por IFV. A morte celular maci\u00e7a induzida pode resultar em agravamento da exacerba\u00e7\u00e3o aguda devido \u00e0 libera\u00e7\u00e3o de seu conte\u00fado celular nas vias a\u00e9reas, evocando ainda mais uma resposta inflamat\u00f3ria nas vias a\u00e9reas",
        "id":"3983",
        "question":"What do the necroptotic factors such as RIP3 do?",
        "question_pt":"O que os fatores necropt\u00f3ticos, como o RIP3, fazem?"
    },
    {
        "answer":" further contact with other pathogens and allergens in the airway which may then prolong exacerbations or results in new exacerbations.",
        "answer_pt":"contato adicional com outros pat\u00f3genos e al\u00e9rgenos nas vias a\u00e9reas, que podem prolongar as exacerba\u00e7\u00f5es ou resultar em novas exacerba\u00e7\u00f5es.",
        "id":"3984",
        "question":"What  may the destruction of the epithelial barrier  cause?",
        "question_pt":"O que pode causar a destrui\u00e7\u00e3o da barreira epitelial?"
    },
    {
        "answer":"may also promote further epithelial remodeling during its regeneration as viral infection induces the expression of remodeling genes such as MMPs and growth factors . Infections that cause massive destruction of the epithelium, such as IFV, usually result in severe acute exacerbations with non-classical symptoms of chronic airway inflammatory diseases.",
        "answer_pt":"tamb\u00e9m pode promover remodela\u00e7\u00e3o epitelial adicional durante sua regenera\u00e7\u00e3o, pois a infec\u00e7\u00e3o viral induz a express\u00e3o de genes de remodela\u00e7\u00e3o, como MMPs e fatores de crescimento. As infec\u00e7\u00f5es que causam destrui\u00e7\u00e3o maci\u00e7a do epit\u00e9lio, como o IFV, geralmente resultam em exacerba\u00e7\u00f5es agudas graves com sintomas n\u00e3o cl\u00e1ssicos de doen\u00e7as inflamat\u00f3rias cr\u00f4nicas das vias a\u00e9reas.",
        "id":"3985",
        "question":"What may the epithelial destruction cause?",
        "question_pt":"O que pode causar a destrui\u00e7\u00e3o epitelial?"
    },
    {
        "answer":" receive their annual influenza vaccination as the best means to prevent severe IFV induced exacerbation.",
        "answer_pt":"receber a vacina\u00e7\u00e3o anual contra influenza como o melhor meio de prevenir exacerba\u00e7\u00e3o grave induzida por IFV.",
        "id":"3986",
        "question":"What is recommended that patients with chronic airway inflammatory disease?",
        "question_pt":"O que \u00e9 recomendado para pacientes com doen\u00e7a inflamat\u00f3ria cr\u00f4nica das vias a\u00e9reas?"
    },
    {
        "answer":"the induction of vasodilation or tight junction opening factors which may increase the rate of infiltration. ",
        "answer_pt":"a indu\u00e7\u00e3o de vasodilata\u00e7\u00e3o ou fatores de abertura de jun\u00e7\u00e3o apertados que podem aumentar a taxa de infiltra\u00e7\u00e3o.",
        "id":"3987",
        "question":"What is another mechanism that viral infections use to drive acute exacerbations?",
        "question_pt":"Qual \u00e9 outro mecanismo usado pelas infec\u00e7\u00f5es virais para provocar exacerba\u00e7\u00f5es agudas?"
    },
    {
        "answer":"disruption of tight junctions with the resulting increased rate of viral infiltration. This also increases the chances of allergens coming into contact with airway immune cells.",
        "answer_pt":"interrup\u00e7\u00e3o de jun\u00e7\u00f5es estreitas com o aumento resultante da taxa de infiltra\u00e7\u00e3o viral. Isso tamb\u00e9m aumenta as chances de al\u00e9rgenos entrarem em contato com c\u00e9lulas imunes das vias a\u00e9reas.",
        "id":"3988",
        "question":"What does infection of respiratory viruses cause?",
        "question_pt":"O que causa a infec\u00e7\u00e3o por v\u00edrus respirat\u00f3rios?"
    },
    {
        "answer":" IFV infection was found to induce oncostatin M (OSM) which causes tight junction opening (Pothoven et al., 2015; Tian et al., 2018) . Similarly, RV and RSV infections usually cause tight junction opening which may also increase the infiltration rate of eosinophils and thus worsening of the classical symptoms of chronic airway inflammatory diseases ",
        "answer_pt":"Verificou-se que a infec\u00e7\u00e3o por IFV induz a oncostatina M (OSM), que causa a abertura da jun\u00e7\u00e3o apertada (Pothoven et al., 2015; Tian et al., 2018). Da mesma forma, as infec\u00e7\u00f5es por VD e RSV geralmente causam uma abertura estreita da jun\u00e7\u00e3o, o que tamb\u00e9m pode aumentar a taxa de infiltra\u00e7\u00e3o de eosin\u00f3filos e piorar os sintomas cl\u00e1ssicos de doen\u00e7as inflamat\u00f3rias cr\u00f4nicas das vias a\u00e9reas.",
        "id":"3989",
        "question":"What is an example of this?",
        "question_pt":"O que \u00e9 um exemplo disso?"
    },
    {
        "answer":" the expression of vasodilating factors and fluid homeostatic factors such as angiopoietin-like 4 (ANGPTL4) and bactericidal/permeabilityincreasing fold-containing family member A1 (BPIFA1)",
        "answer_pt":"a express\u00e3o de fatores vasodilatadores e fatores homeost\u00e1ticos h\u00eddricos, como angiopoietina 4 (ANGPTL4) e membro da fam\u00edlia bactericida / permeabilidade que aumenta a dobra A1 (BPIFA1)",
        "id":"3990",
        "question":"What are also associated with viral infections and pneumonia development, which may worsen inflammation in the lower airway?",
        "question_pt":"O que tamb\u00e9m est\u00e1 associado a infec\u00e7\u00f5es virais e desenvolvimento de pneumonia, que podem piorar a inflama\u00e7\u00e3o nas vias a\u00e9reas inferiores?"
    },
    {
        "answer":"the relationship between asthma and COPD exacerbations and their association with the airway microbiome.",
        "answer_pt":"a rela\u00e7\u00e3o entre asma e exacerba\u00e7\u00f5es da DPOC e sua associa\u00e7\u00e3o com o microbioma das vias a\u00e9reas.",
        "id":"3991",
        "question":"What is another area of interest?",
        "question_pt":"Qual \u00e9 outra \u00e1rea de interesse?"
    },
    {
        "answer":"specific bacterial species in the microbiome which may thrive in the inflamed airway environment ",
        "answer_pt":"esp\u00e9cies bacterianas espec\u00edficas no microbioma que podem prosperar no ambiente inflamado das vias a\u00e9reas",
        "id":"3992",
        "question":"What is usually linked with the development of chronic airway inflammatory diseases?",
        "question_pt":"O que geralmente est\u00e1 relacionado ao desenvolvimento de doen\u00e7as inflamat\u00f3rias cr\u00f4nicas das vias a\u00e9reas?"
    },
    {
        "answer":" the effect induced by the virus may destabilize the equilibrium of the microbiome present (Molyneaux et al., 2013; Kloepfer et al., 2014; Kloepfer et al., 2017; Jubinville et al., 2018; van Rijn et al., 2019) . In addition, viral infection may disrupt biofilm colonies in the upper airway (e.g., Streptococcus pneumoniae) microbiome to be release into the lower airway and worsening the inflammation",
        "answer_pt":"o efeito induzido pelo v\u00edrus pode desestabilizar o equil\u00edbrio do microbioma presente (Molyneaux et al., 2013; Kloepfer et al., 2014; Kloepfer et al., 2017; Jubinville et al., 2018; van Rijn et al., 2019 ) Al\u00e9m disso, a infec\u00e7\u00e3o viral pode interromper as col\u00f4nias de biofilme no microbioma das vias a\u00e9reas superiores (por exemplo, Streptococcus pneumoniae) para ser liberada nas vias a\u00e9reas inferiores e piorar a inflama\u00e7\u00e3o",
        "id":"3993",
        "question":"What follows  in the event of a viral infection such as RV infection?",
        "question_pt":"O que se segue no caso de uma infec\u00e7\u00e3o viral, como infec\u00e7\u00e3o por RV?"
    },
    {
        "answer":"the nutrient profile in the airway through release of previously inaccessible nutrients that will alter bacterial growth",
        "answer_pt":"o perfil de nutrientes nas vias a\u00e9reas atrav\u00e9s da libera\u00e7\u00e3o de nutrientes anteriormente inacess\u00edveis que alteram o crescimento bacteriano",
        "id":"3994",
        "question":"What does the viral infection alter?",
        "question_pt":"O que a infec\u00e7\u00e3o viral altera?"
    },
    {
        "answer":" impaired bacterial immune response, either from direct viral influences, or use of corticosteroids to suppress the exacerbation symptoms",
        "answer_pt":"resposta imune bacteriana prejudicada, seja por influ\u00eancias virais diretas ou uso de corticoster\u00f3ides para suprimir os sintomas de exacerba\u00e7\u00e3o",
        "id":"3995",
        "question":"What is  the destabilization is further compounded by?",
        "question_pt":"Qual \u00e9 a desestabiliza\u00e7\u00e3o mais agravada?"
    },
    {
        "answer":"more far reaching effect when normal flora is replaced with opportunistic pathogens, altering the inflammatory profiles ",
        "answer_pt":"efeito de maior alcance quando a flora normal \u00e9 substitu\u00edda por pat\u00f3genos oportunistas, alterando o perfil inflamat\u00f3rio",
        "id":"3996",
        "question":"What does all this gradually lead to?",
        "question_pt":"A que tudo isso leva gradualmente?"
    },
    {
        "answer":"due to the interplay between virus and pathogenic bacteria in exacerbating chronic airway inflammatory diseases ",
        "answer_pt":"devido \u00e0 intera\u00e7\u00e3o entre v\u00edrus e bact\u00e9rias patog\u00eanicas na exacerba\u00e7\u00e3o de doen\u00e7as inflamat\u00f3rias cr\u00f4nicas das vias a\u00e9reas",
        "id":"3997",
        "question":"Why do these changes may  result in more severe and frequent acute exacerbations ?",
        "question_pt":"Por que essas altera\u00e7\u00f5es podem resultar em exacerba\u00e7\u00f5es agudas mais graves e frequentes?"
    },
    {
        "answer":" have shown efficacy in the treatments of irritable bowel syndrome by restoring the intestinal microbiome (",
        "answer_pt":"demonstraram efic\u00e1cia nos tratamentos da s\u00edndrome do intestino irrit\u00e1vel, restaurando o microbioma intestinal (",
        "id":"3998",
        "question":"How effective are microbiome based  trial therapies?",
        "question_pt":"Qual a efic\u00e1cia das terapias experimentais baseadas em microbiomas?"
    },
    {
        "answer":"the disruption of mucociliary function, an important component of the epithelial barrier. ",
        "answer_pt":"a interrup\u00e7\u00e3o da fun\u00e7\u00e3o mucociliar, um componente importante da barreira epitelial.",
        "id":"3999",
        "question":"What can viral infections cause?",
        "question_pt":"O que podem causar infec\u00e7\u00f5es virais?"
    },
    {
        "answer":"The upper airway epithelium",
        "answer_pt":"O epit\u00e9lio das vias a\u00e9reas superiores",
        "id":"4000",
        "question":"Which is the primary contact/infection site of most respiratory viruses?",
        "question_pt":"Qual \u00e9 o principal local de contato / infec\u00e7\u00e3o da maioria dos v\u00edrus respirat\u00f3rios?"
    },
    {
        "answer":"serves to increase contact between environmental triggers with the lower airway and resident immune cells.",
        "answer_pt":"serve para aumentar o contato entre os gatilhos ambientais com as vias a\u00e9reas inferiores e as c\u00e9lulas imunol\u00f3gicas residentes.",
        "id":"4001",
        "question":"What does the destruction of epithelial barrier, mucociliary function and cell death of the epithelial cells do?",
        "question_pt":"O que a destrui\u00e7\u00e3o da barreira epitelial, a fun\u00e7\u00e3o mucociliar e a morte celular das c\u00e9lulas epiteliais fazem?"
    },
    {
        "answer":"oxidative stress which will further increase the local inflammation in the airway. ",
        "answer_pt":"estresse oxidativo que aumentar\u00e1 ainda mais a inflama\u00e7\u00e3o local nas vias a\u00e9reas.",
        "id":"4002",
        "question":"What are viral infections are usually accompanied with?",
        "question_pt":"O que s\u00e3o infec\u00e7\u00f5es virais geralmente s\u00e3o acompanhadas?"
    },
    {
        "answer":"modulation of miRNAs and epigenetic modification such as DNA methylation and histone modifications that promote dysregulation in inflammation",
        "answer_pt":"modula\u00e7\u00e3o de miRNAs e modifica\u00e7\u00e3o epigen\u00e9tica, como metila\u00e7\u00e3o do DNA e modifica\u00e7\u00f5es de histonas que promovem desregula\u00e7\u00e3o da inflama\u00e7\u00e3o",
        "id":"4003",
        "question":"What is the dysregulation of inflammation can be further compounded by?",
        "question_pt":"Qual \u00e9 a desregula\u00e7\u00e3o da inflama\u00e7\u00e3o que pode ser agravada ainda mais?"
    },
    {
        "answer":"growth of pathogenic bacteria that may replace the airway microbiome. ",
        "answer_pt":"crescimento de bact\u00e9rias patog\u00eanicas que podem substituir o microbioma das vias a\u00e9reas.",
        "id":"4004",
        "question":"What does  the change in the local airway environment and inflammation promote?",
        "question_pt":"O que a mudan\u00e7a no ambiente local das vias a\u00e9reas e a inflama\u00e7\u00e3o promove?"
    },
    {
        "answer":"inflammation and alteration of the lower airway environment, resulting in prolong exacerbation episodes following viral infection. ",
        "answer_pt":"inflama\u00e7\u00e3o e altera\u00e7\u00e3o do ambiente das vias a\u00e9reas inferiores, resultando em prolongados epis\u00f3dios de exacerba\u00e7\u00e3o ap\u00f3s infec\u00e7\u00e3o viral.",
        "id":"4005",
        "question":"What does the the inflammatory environment dispersal of upper airway commensals into the lower airway cause?",
        "question_pt":"O que causa a dispers\u00e3o do ambiente inflamat\u00f3rio dos comensais das vias a\u00e9reas superiores nas vias a\u00e9reas inferiores?"
    },
    {
        "answer":"RV, RSV, and IFV",
        "answer_pt":"RV, RSV e IFV",
        "id":"4006",
        "question":"Which are the most commonly  studied viruses in chronic airway inflammatory diseases?",
        "question_pt":"Quais s\u00e3o os v\u00edrus mais comumente estudados nas doen\u00e7as inflamat\u00f3rias cr\u00f4nicas das vias a\u00e9reas?"
    },
    {
        "answer":" to directly destroy the cilia of the ciliated cells and almost all respiratory viruses infect the ciliated cells",
        "answer_pt":"destruir diretamente os c\u00edlios das c\u00e9lulas ciliadas e quase todos os v\u00edrus respirat\u00f3rios infectam as c\u00e9lulas ciliadas",
        "id":"4007",
        "question":"What do the infections such as RSV are shown to do?",
        "question_pt":"O que as infec\u00e7\u00f5es como o RSV s\u00e3o mostradas para fazer?"
    },
    {
        "answer":" disrupt the equilibrium of the mucociliary function following viral infection, resulting in symptoms of acute exacerbation",
        "answer_pt":"perturbar o equil\u00edbrio da fun\u00e7\u00e3o mucociliar ap\u00f3s infec\u00e7\u00e3o viral, resultando em sintomas de exacerba\u00e7\u00e3o aguda",
        "id":"4008",
        "question":"What does mucus overproduction do?",
        "question_pt":"O que faz a superprodu\u00e7\u00e3o de muco?"
    },
    {
        "answer":"MicroRNAs (miRNAs)",
        "answer_pt":"MicroRNAs (miRNAs)",
        "id":"4009",
        "question":"What does the disruption of the ciliary movement during viral infection may cause?",
        "question_pt":"O que a interrup\u00e7\u00e3o do movimento ciliar durante a infec\u00e7\u00e3o viral pode causar?"
    },
    {
        "answer":"short non-coding RNAs involved in post-transcriptional modulation of biological processes, and implicated in a number of diseases ",
        "answer_pt":"RNAs n\u00e3o codificadores curtos envolvidos na modula\u00e7\u00e3o p\u00f3s-transcricional de processos biol\u00f3gicos e implicados em v\u00e1rias doen\u00e7as",
        "id":"4010",
        "question":"What are MicroRNAs(miRNA)?",
        "question_pt":"O que s\u00e3o MicroRNAs (miRNA)?"
    },
    {
        "answer":" viral infections and may play a role in the modulation of antiviral responses and inflammation ",
        "answer_pt":"infec\u00e7\u00f5es virais e podem desempenhar um papel na modula\u00e7\u00e3o de respostas antivirais e inflama\u00e7\u00e3o",
        "id":"4011",
        "question":"What are  miRNAs found to be induced by?",
        "question_pt":"Por que os miRNAs s\u00e3o induzidos por?"
    },
    {
        "answer":"circulating miRNA changes",
        "answer_pt":"altera\u00e7\u00f5es miRNA circulantes",
        "id":"4012",
        "question":"What  were linked to the exacerbation of the airway inflammation disease?",
        "question_pt":"O que estava relacionado \u00e0 exacerba\u00e7\u00e3o da doen\u00e7a inflamat\u00f3ria das vias a\u00e9reas?"
    },
    {
        "answer":"from the infected epithelium and responding immune cells, which may serve to further dysregulate airway inflammation leading to exacerbations.",
        "answer_pt":"do epit\u00e9lio infectado e c\u00e9lulas imunol\u00f3gicas respons\u00e1veis, que podem servir para desregular ainda mais a inflama\u00e7\u00e3o das vias a\u00e9reas, levando a exacerba\u00e7\u00f5es.",
        "id":"4013",
        "question":"Where might such miRNA changes have originated from?",
        "question_pt":"De onde essas mudan\u00e7as no miRNA podem ter se originado?"
    },
    {
        "answer":" to increase miR-21 and augmented inflammation in experimental murine asthma models, which is reversed with a combination treatment of anti-miR-21 and corticosteroids",
        "answer_pt":"aumentar o miR-21 e a inflama\u00e7\u00e3o aumentada em modelos experimentais de asma murina, que s\u00e3o revertidos com um tratamento combinado de anti-miR-21 e corticoster\u00f3ides",
        "id":"4014",
        "question":"What are both IFV and RSV infections shown to do?",
        "question_pt":"O que s\u00e3o mostradas as infec\u00e7\u00f5es por IFV e RSV?"
    },
    {
        "answer":" increase miR-125a and b, and miR-132 in COPD epithelium which inhibits A20 and MAVS; and p300 and IRF3, respectively, resulting in increased susceptibility to viral infections ",
        "answer_pt":"aumentar miR-125a eb, e miR-132 no epit\u00e9lio da DPOC que inibe A20 e MAVS; e p300 e IRF3, respectivamente, resultando em maior suscetibilidade a infec\u00e7\u00f5es virais",
        "id":"4015",
        "question":"What are IFV infection shown to do?",
        "question_pt":"O que \u00e9 mostrado para a infec\u00e7\u00e3o por IFV?"
    },
    {
        "answer":"miR-22 was shown to be suppressed in asthmatic epithelium in IFV infection which lead to aberrant epithelial response, contributing to exacerbations ",
        "answer_pt":"O miR-22 mostrou-se suprimido no epit\u00e9lio asm\u00e1tico na infec\u00e7\u00e3o por IFV, o que leva a uma resposta epitelial aberrante, contribuindo para exacerba\u00e7\u00f5es",
        "id":"4016",
        "question":"What happens in in asthmatic epithelium in IFV infection?",
        "question_pt":"O que acontece no epit\u00e9lio asm\u00e1tico na infec\u00e7\u00e3o por IFV?"
    },
    {
        "answer":"as targets to modulate viral induced airway changes as a means of managing exacerbation of chronic airway inflammatory diseases.",
        "answer_pt":"como alvos para modular as altera\u00e7\u00f5es das vias a\u00e9reas induzidas por v\u00edrus como um meio de gerenciar a exacerba\u00e7\u00e3o de doen\u00e7as inflamat\u00f3rias cr\u00f4nicas das vias a\u00e9reas.",
        "id":"4017",
        "question":"What do non-coding RNAs present as?",
        "question_pt":"Como os RNAs n\u00e3o codificadores se apresentam?"
    },
    {
        "answer":"epigenetic modification such as DNA methylation ",
        "answer_pt":"modifica\u00e7\u00e3o epigen\u00e9tica como a metila\u00e7\u00e3o do DNA",
        "id":"4018",
        "question":"What mechanisms, other than miRNA modulation play a role?",
        "question_pt":"Que mecanismos, al\u00e9m da modula\u00e7\u00e3o do miRNA, desempenham um papel?"
    },
    {
        "answer":"the association of epigenetic modification and chronic airway inflammatory diseases, and that the nasal methylome was shown to be a sensitive marker for airway inflammatory changes (Cardenas et al., 2019; Gomez, 2019) .",
        "answer_pt":"a associa\u00e7\u00e3o de modifica\u00e7\u00e3o epigen\u00e9tica e doen\u00e7as inflamat\u00f3rias cr\u00f4nicas das vias a\u00e9reas e que o metiloma nasal mostrou-se um marcador sens\u00edvel para altera\u00e7\u00f5es inflamat\u00f3rias das vias a\u00e9reas (Cardenas et al., 2019; Gomez, 2019).",
        "id":"4019",
        "question":"What have  recent epigenetic studies indicated?",
        "question_pt":"O que indicaram estudos epigen\u00e9ticos recentes?"
    },
    {
        "answer":" viral infections such as RV and RSV alters DNA methylation and histone modifications in the airway epithelium which may alter inflammatory responses, driving chronic airway inflammatory diseases and exacerbations",
        "answer_pt":"infec\u00e7\u00f5es virais como RV e RSV alteram a metila\u00e7\u00e3o do DNA e modifica\u00e7\u00f5es de histonas no epit\u00e9lio das vias a\u00e9reas, o que pode alterar as respostas inflamat\u00f3rias, causando doen\u00e7as inflamat\u00f3rias cr\u00f4nicas das vias a\u00e9reas e exacerba\u00e7\u00f5es",
        "id":"4020",
        "question":" What have these studies also shown?",
        "question_pt":"O que esses estudos tamb\u00e9m mostraram?"
    },
    {
        "answer":"that antiviral factors such as IFN\u03b3 epigenetically modifies the viral resistance of epithelial cells.",
        "answer_pt":"que fatores antivirais como o IFN\u03b3 modificam epigeneticamente a resist\u00eancia viral das c\u00e9lulas epiteliais.",
        "id":"4021",
        "question":"What has Spalluto et.al. have shown?",
        "question_pt":"O que tem Spalluto et.al. tem mostrado?"
    },
    {
        "answer":" an altered inflammatory state contributing to further viral persistence and exacerbation of chronic airway inflammatory diseases ",
        "answer_pt":"estado inflamat\u00f3rio alterado, contribuindo para maior persist\u00eancia viral e exacerba\u00e7\u00e3o de doen\u00e7as inflamat\u00f3rias cr\u00f4nicas das vias a\u00e9reas",
        "id":"4022",
        "question":" What infections such as RV and RSV that weakly induce antiviral responses may result in?",
        "question_pt":"Em que infec\u00e7\u00f5es, como RV e RSV, que induzem fracamente respostas antivirais, podem resultar?"
    },
    {
        "answer":" enhanced production of reactive oxygen species (ROS), oxidative stress and mitochondrial dysfunction in the airway epithelium ",
        "answer_pt":"aumento da produ\u00e7\u00e3o de esp\u00e9cies reativas de oxig\u00eanio (ERO), estresse oxidativo e disfun\u00e7\u00e3o mitocondrial no epit\u00e9lio das vias a\u00e9reas",
        "id":"4023",
        "question":"What can viral infection result in?",
        "question_pt":"Em que pode resultar a infec\u00e7\u00e3o viral?"
    },
    {
        "answer":"state of constant oxidative stress ",
        "answer_pt":"estado de estresse oxidativo constante",
        "id":"4024",
        "question":"What sustains the inflammation  in the airway?",
        "question_pt":"O que sustenta a inflama\u00e7\u00e3o nas vias a\u00e9reas?"
    },
    {
        "answer":"may trigger the further production of ROS as an antiviral mechanism",
        "answer_pt":"pode desencadear a produ\u00e7\u00e3o adicional de ERO como mecanismo antiviral",
        "id":"4025",
        "question":"What may viral infections of the respiratory epithelium by viruses such as IFV, RV, RSV and HSV do?",
        "question_pt":"O que podem fazer infec\u00e7\u00f5es virais do epit\u00e9lio respirat\u00f3rio por v\u00edrus como IFV, RV, RSV e HSV?"
    },
    {
        "answer":" infiltrating cells in response to the infection such as neutrophils will also trigger respiratory burst as a means of increasing the ROS in the infected region. The increased ROS and oxidative stress in the local environment may serve as a trigger to promote inflammation thereby aggravating the inflammation in the airway ",
        "answer_pt":"a infiltra\u00e7\u00e3o de c\u00e9lulas em resposta \u00e0 infec\u00e7\u00e3o, como os neutr\u00f3filos, tamb\u00e9m desencadear\u00e1 uma explos\u00e3o respirat\u00f3ria como forma de aumentar a ERO na regi\u00e3o infectada. O aumento da ROS e do estresse oxidativo no ambiente local pode servir como um gatilho para promover a inflama\u00e7\u00e3o, agravando a inflama\u00e7\u00e3o nas vias a\u00e9reas",
        "id":"4026",
        "question":"What can happen  in response to the infection such as neutrophils?",
        "question_pt":"O que pode acontecer em resposta \u00e0 infec\u00e7\u00e3o, como os neutr\u00f3filos?"
    },
    {
        "answer":" also may alter the management of the disease or confer resistance toward treatments that worked before. ",
        "answer_pt":"tamb\u00e9m pode alterar o manejo da doen\u00e7a ou conferir resist\u00eancia a tratamentos que funcionavam anteriormente.",
        "id":"4027",
        "question":"In addition to worsening disease symptoms, what do viral-induced exacerbations do?",
        "question_pt":"Al\u00e9m de agravar os sintomas da doen\u00e7a, o que as exacerba\u00e7\u00f5es induzidas por v\u00edrus fazem?"
    },
    {
        "answer":"important information regarding viral pathogenesis and changes induced within the airway of chronic airway inflammatory disease patients to identify novel targets and pathway for improved management of the disease.",
        "answer_pt":"informa\u00e7\u00f5es importantes sobre patog\u00eanese viral e altera\u00e7\u00f5es induzidas nas vias a\u00e9reas de pacientes com doen\u00e7as inflamat\u00f3rias das vias a\u00e9reas cr\u00f4nicas para identificar novos alvos e vias para melhor gerenciamento da doen\u00e7a.",
        "id":"4028",
        "question":"What may studies in natural exacerbations and in viral-challenge models using RNA-sequencing (RNA-seq) or single cell RNA-seq on a range of time-points  provide?",
        "question_pt":"O que podem fornecer estudos sobre exacerba\u00e7\u00f5es naturais e modelos de desafio viral usando o seq\u00fcenciamento de RNA (RNA-seq) ou o RNA-seq de c\u00e9lula \u00fanica em v\u00e1rios intervalos de tempo?"
    },
    {
        "answer":" epithelial cell models such as the air-liquid interface, in vitro airway epithelial model that has been adapted to studying viral infection and the changes it induced in the airway ",
        "answer_pt":"modelos de c\u00e9lulas epiteliais, como a interface ar-l\u00edquido, modelo epitelial das vias a\u00e9reas in vitro que foi adaptado para estudar a infec\u00e7\u00e3o viral e as altera\u00e7\u00f5es que ela induziu nas vias a\u00e9reas",
        "id":"4029",
        "question":"What analysis functions may be useful?",
        "question_pt":"Quais fun\u00e7\u00f5es de an\u00e1lise podem ser \u00fateis?"
    },
    {
        "answer":"to identify systemic mechanisms of acute exacerbation",
        "answer_pt":"identificar mecanismos sist\u00eamicos de exacerba\u00e7\u00e3o aguda",
        "id":"4030",
        "question":"For what  purpose animal based models aare developed for?",
        "question_pt":"Para que finalidade os modelos animais s\u00e3o desenvolvidos?"
    },
    {
        "answer":" the humanized mouse model that possess human immune cells ",
        "answer_pt":"o modelo de mouse humanizado que possui c\u00e9lulas imunol\u00f3gicas humanas",
        "id":"4031",
        "question":"What can be used unravel the immune profile of a viral infection in healthy and diseased condition?",
        "question_pt":"O que pode ser usado desvendar o perfil imunol\u00f3gico de uma infec\u00e7\u00e3o viral em condi\u00e7\u00f5es saud\u00e1veis \u200b\u200be doentes?"
    },
    {
        "answer":"the best mode of verification of the associations of the virus with the proposed mechanism of viral induced acute exacerbations ",
        "answer_pt":"o melhor modo de verifica\u00e7\u00e3o das associa\u00e7\u00f5es do v\u00edrus com o mecanismo proposto de exacerba\u00e7\u00f5es agudas induzidas por v\u00edrus",
        "id":"4032",
        "question":"For what purpose controlled in vivo human infections can be performed for mild viruses?",
        "question_pt":"Com que finalidade infec\u00e7\u00f5es humanas in vivo controladas podem ser realizadas para v\u00edrus leves?"
    },
    {
        "answer":" due to the complex interactions between the host and the exacerbation agents",
        "answer_pt":"devido \u00e0s complexas intera\u00e7\u00f5es entre o hospedeiro e os agentes de exacerba\u00e7\u00e3o",
        "id":"3868",
        "question":"Why may the  mechanisms of exacerbation vary considerably?",
        "question_pt":"Por que os mecanismos de exacerba\u00e7\u00e3o podem variar consideravelmente?"
    },
    {
        "answer":"hemorrhagic fever with renal syndrome",
        "answer_pt":"febre hemorr\u00e1gica com s\u00edndrome renal",
        "id":"546",
        "question":"What clinical condition is caused by Hantaan virus?",
        "question_pt":"Que condi\u00e7\u00e3o cl\u00ednica \u00e9 causada pelo v\u00edrus Hantaan?"
    },
    {
        "answer":"enveloped, negative-sense RNA virus",
        "answer_pt":"v\u00edrus RNA RNA com sentido negativo",
        "id":"547",
        "question":"What is the structure of Hantaan virus?",
        "question_pt":"Qual \u00e9 a estrutura do v\u00edrus Hantaan?"
    },
    {
        "answer":"rodents",
        "answer_pt":"roedores",
        "id":"548",
        "question":"What the animal vector reservoir for Hantaan virus?",
        "question_pt":"Qual \u00e9 o reservat\u00f3rio do vetor animal para o v\u00edrus Hantaan?"
    },
    {
        "answer":"plasma viral load",
        "answer_pt":"carga viral plasm\u00e1tica",
        "id":"549",
        "question":"What diagnostic test is correlated with the severity of HFRS?",
        "question_pt":"Qual teste de diagn\u00f3stico est\u00e1 correlacionado com a gravidade do HFRS?"
    },
    {
        "answer":"an antiviral medicine",
        "answer_pt":"um medicamento antiviral",
        "id":"551",
        "question":"How is Interferon used in practice?",
        "question_pt":"Como o Interferon \u00e9 usado na pr\u00e1tica?"
    },
    {
        "answer":"rs12252 C allele and CC genotype",
        "answer_pt":"Alelo C rs12252 e gen\u00f3tipo CC",
        "id":"552",
        "question":"What genotypes are associated with the severity of HFRS?",
        "question_pt":"Quais gen\u00f3tipos est\u00e3o associados \u00e0 gravidade do HFRS?"
    },
    {
        "answer":"IFITM1, 2, and 3",
        "answer_pt":"IFITM1, 2 e 3",
        "id":"554",
        "question":"Which IFITM proteins have been shown to possess antiviral activity?",
        "question_pt":"Quais prote\u00ednas IFITM demonstraram possuir atividade antiviral?"
    },
    {
        "answer":"restrict viral infection at the stage of cellular entry",
        "answer_pt":"restringir a infec\u00e7\u00e3o viral na fase de entrada celular",
        "id":"555",
        "question":"What is the hypothesized mechanism by which IFITMs work?",
        "question_pt":"Qual \u00e9 o mecanismo hipot\u00e9tico pelo qual os IFITMs funcionam?"
    },
    {
        "answer":"rs12252 C allele",
        "answer_pt":"alelo C rs12252",
        "id":"556",
        "question":"What genotype causes truncation of the IFITM3 protein?",
        "question_pt":"Qual gen\u00f3tipo causa truncamento da prote\u00edna IFITM3?"
    },
    {
        "answer":"significant impact\nof interventions implemented several weeks earlier.",
        "answer_pt":"impacto significante\ninterven\u00e7\u00f5es implementadas v\u00e1rias semanas antes.",
        "id":"806",
        "question":"What can cause a slowing growth in daily reported deaths?",
        "question_pt":"O que pode causar um crescimento lento nas mortes relatadas diariamente?"
    },
    {
        "answer":"11th March",
        "answer_pt":"11 de mar\u00e7o",
        "id":"807",
        "question":"When did Italy go into Iockdown?",
        "question_pt":"Quando a It\u00e1lia entrou em Lockdown?"
    },
    {
        "answer":"59,000 deaths",
        "answer_pt":"59.000 mortes",
        "id":"808",
        "question":"Approximately how many deaths have been averted in Western Europe with current non-pharmaceutical interventions remaining in place until the end of March?",
        "question_pt":"Aproximadamente quantas mortes foram evitadas na Europa Ocidental, com as atuais interven\u00e7\u00f5es n\u00e3o farmac\u00eauticas em vigor at\u00e9 o final de mar\u00e7o?"
    },
    {
        "answer":"case isolation, the closure of schools and\nuniversities, banning of mass gatherings and/or public events, and most recently, widescale social\ndistancing including local and national Iockdowns",
        "answer_pt":"isolamento de casos, fechamento de escolas e\nuniversidades, proibi\u00e7\u00e3o de reuni\u00f5es de massa e / ou eventos p\u00fablicos e, mais recentemente, social\ndistanciamento incluindo Iockdowns locais e nacionais",
        "id":"796",
        "question":"What are some non-pharmaceutical interventions?",
        "question_pt":"Quais s\u00e3o algumas interven\u00e7\u00f5es n\u00e3o farmac\u00eauticas?"
    },
    {
        "answer":"semi-mechanistic Bayesian hierarchical model",
        "answer_pt":"modelo hier\u00e1rquico bayesiano semi-mecanicista",
        "id":"797",
        "question":"Type of model used to infer the impact non-pharmaceutical interventions?",
        "question_pt":"Tipo de modelo usado para inferir o impacto de interven\u00e7\u00f5es n\u00e3o farmac\u00eauticas?"
    },
    {
        "answer":"calculating backwards from the deaths observed over time to estimate transmission that\noccurred several weeks prior, allowing for the time lag between infection and death.",
        "answer_pt":"calcular para tr\u00e1s as mortes observadas ao longo do tempo para estimar a transmiss\u00e3o que\nocorreu v\u00e1rias semanas antes, permitindo o intervalo de tempo entre infec\u00e7\u00e3o e morte.",
        "id":"801",
        "question":"How can a semi-mechanistic Bayesian hierarchical model estimate changes to the reproductive number?",
        "question_pt":"Como pode um modelo hier\u00e1rquico bayesiano semi-mecanicista estimar mudan\u00e7as no n\u00famero reprodutivo?"
    },
    {
        "answer":"each intervention has the same effect on the\nreproduction number across countries and over time",
        "answer_pt":"cada interven\u00e7\u00e3o tem o mesmo efeito no\nn\u00famero de reprodu\u00e7\u00e3o entre pa\u00edses e ao longo do tempo",
        "id":"803",
        "question":"What is a key assumption of a semi-mechanistic Bayesian hierarchical model used for coronavirus?",
        "question_pt":"Qual \u00e9 uma suposi\u00e7\u00e3o chave de um modelo hier\u00e1rquico bayesiano semi-mecanicista usado para coronav\u00edrus?"
    },
    {
        "answer":"2-3 weeks",
        "answer_pt":"2-3 semanas",
        "id":"810",
        "question":"What is the time lag between when transmission changes occur and when their impact can be\nobserved in trends in mortality?",
        "question_pt":"Qual \u00e9 o intervalo de tempo entre quando ocorrem mudan\u00e7as na transmiss\u00e3o e quando seu impacto pode ser\nobservado nas tend\u00eancias de mortalidade?"
    },
    {
        "answer":"reduce the effective reproduction number",
        "answer_pt":"reduzir o n\u00famero de reprodu\u00e7\u00e3o efetivo",
        "id":"814",
        "question":"What is the key aim of non-pharmaceutical interventions?",
        "question_pt":"Qual \u00e9 o objetivo principal das interven\u00e7\u00f5es n\u00e3o farmac\u00eauticas?"
    },
    {
        "answer":"infections will increase (dependent on how much greater than 1 the reproduction number is)",
        "answer_pt":"as infec\u00e7\u00f5es aumentar\u00e3o (dependendo de quanto maior que 1 o n\u00famero de reprodu\u00e7\u00e3o for)",
        "id":"815",
        "question":"What happens if the reproduction number is greater then 1?",
        "question_pt":"O que acontece se o n\u00famero de reprodu\u00e7\u00e3o for maior que 1?"
    },
    {
        "answer":"23rd January",
        "answer_pt":"23 de janeiro",
        "id":"820",
        "question":"When did China introduce strict movement restrictions and other measures including case isolation and quarantine?",
        "question_pt":"Quando a China introduziu restri\u00e7\u00f5es estritas de movimento e outras medidas, incluindo isolamento de casos e quarentena?"
    },
    {
        "answer":"downward trend in the number of\nconfirmed new cases during February",
        "answer_pt":"tend\u00eancia descendente no n\u00famero de\nnovos casos confirmados em fevereiro",
        "id":"823",
        "question":"What was the result of China's interventions introduced in January?",
        "question_pt":"Qual foi o resultado das interven\u00e7\u00f5es da China introduzidas em janeiro?"
    },
    {
        "answer":"banning large gatherings and advising individuals not to socialize outside\ntheir households",
        "answer_pt":"proibir grandes reuni\u00f5es e aconselhar indiv\u00edduos a n\u00e3o socializar fora\nsuas fam\u00edlias",
        "id":"811",
        "question":"What are examples of social distancing?",
        "question_pt":"Quais s\u00e3o os exemplos de distanciamento social?"
    },
    {
        "answer":"from\naround 2-4 during the uncontrolled epidemic down to below 1",
        "answer_pt":"de\ncerca de 2-4 durante a epidemia n\u00e3o controlada abaixo de 1",
        "id":"827",
        "question":"What was the estimated effect on China's reproduction number in March based on the intervention introduced in January?",
        "question_pt":"Qual foi o efeito estimado no n\u00famero de reprodu\u00e7\u00e3o da China em mar\u00e7o com base na interven\u00e7\u00e3o introduzida em janeiro?"
    },
    {
        "answer":"high proportion of\ninfections not detected by health systems\u201d7 and regular changes in testing policies,",
        "answer_pt":"alta propor\u00e7\u00e3o de\ninfec\u00e7\u00f5es n\u00e3o detectadas pelos sistemas de sa\u00fade \u201d7 e mudan\u00e7as regulares nas pol\u00edticas de testes,",
        "id":"829",
        "question":"Why is it challenging to estimate the reproduction number?",
        "question_pt":"Por que \u00e9 desafiador estimar o n\u00famero de reprodu\u00e7\u00e3o?"
    },
    {
        "answer":"back-calculate infections from\nobserved deaths",
        "answer_pt":"calcular novamente infec\u00e7\u00f5es de\nmortes observadas",
        "id":"837",
        "question":"What is an alternative way to estimate the course of an epidemic?",
        "question_pt":"Qual \u00e9 uma maneira alternativa de estimar o curso de uma epidemia?"
    },
    {
        "answer":"9.8% [3.2%-25%] of the population",
        "answer_pt":"9,8% [3,2% -25%] da popula\u00e7\u00e3o",
        "id":"840",
        "question":"What is the estimated attack rate in Italy?",
        "question_pt":"Qual \u00e9 a taxa de ataque estimada na It\u00e1lia?"
    },
    {
        "answer":"15.0% (7.0 [18-19] million people)",
        "answer_pt":"15,0% (7,0 [18-19] milh\u00f5es de pessoas)",
        "id":"843",
        "question":"As of the end of March what is the proportion of Spain's population to be infected?",
        "question_pt":"No final de mar\u00e7o, qual a propor\u00e7\u00e3o da popula\u00e7\u00e3o da Espanha a ser infectada?"
    },
    {
        "answer":"Germany",
        "answer_pt":"Alemanha",
        "id":"844",
        "question":"Which Western European country is estimated to have the lowest attack rate?",
        "question_pt":"Qual pa\u00eds da Europa Ocidental tem a menor taxa de ataque?"
    },
    {
        "answer":"1.1% [0.36%-3.1%]",
        "answer_pt":"1,1% [0,36% -3,1%]",
        "id":"847",
        "question":"What is Austria's estimated mean percentage [95% credible interval] of total population infected as of 28th March?",
        "question_pt":"Qual \u00e9 a porcentagem m\u00e9dia estimada da \u00c1ustria [intervalo cred\u00edvel de 95%] da popula\u00e7\u00e3o total infectada em 28 de mar\u00e7o?"
    },
    {
        "answer":"3.7% [1.3%-9.7%]",
        "answer_pt":"3,7% [1,3% -9,7%]",
        "id":"848",
        "question":"What is Belgium's estimated mean percentage [95% credible interval] of total population infected as of 28th March?",
        "question_pt":"Qual \u00e9 a porcentagem m\u00e9dia estimada da B\u00e9lgica [intervalo cred\u00edvel de 95%] da popula\u00e7\u00e3o total infectada em 28 de mar\u00e7o?"
    },
    {
        "answer":"1.1% [0.40%-3.1%]",
        "answer_pt":"1,1% [0,40% -3,1%]",
        "id":"849",
        "question":"What is Denmark's estimated mean percentage [95% credible interval] of total population infected as of 28th March?",
        "question_pt":"Qual \u00e9 a porcentagem m\u00e9dia estimada da Dinamarca [intervalo cred\u00edvel de 95%] da popula\u00e7\u00e3o total infectada em 28 de mar\u00e7o?"
    },
    {
        "answer":"3.0% [1.1%-7.4%]",
        "answer_pt":"3,0% [1,1% -7,4%]",
        "id":"850",
        "question":"What is France's estimated mean percentage [95% credible interval] of total population infected as of 28th March?",
        "question_pt":"Qual \u00e9 a porcentagem m\u00e9dia estimada da Fran\u00e7a [intervalo cred\u00edvel de 95%] da popula\u00e7\u00e3o total infectada em 28 de mar\u00e7o?"
    },
    {
        "answer":"0.72% [0.28%-1.8%]",
        "answer_pt":"0,72% [0,28% -1,8%]",
        "id":"851",
        "question":"What is Germany's estimated mean percentage [95% credible interval] of total population infected as of 28th March?",
        "question_pt":"Qual \u00e9 a porcentagem m\u00e9dia estimada da Alemanha [intervalo cred\u00edvel de 95%] da popula\u00e7\u00e3o total infectada em 28 de mar\u00e7o?"
    },
    {
        "answer":"9.8% [3.2%-26%]",
        "answer_pt":"9,8% [3,2% -26%]",
        "id":"852",
        "question":"What is Italy's estimated mean percentage [95% credible interval] of total population infected as of 28th March?",
        "question_pt":"Qual \u00e9 a porcentagem m\u00e9dia estimada da It\u00e1lia [intervalo cred\u00edvel de 95%] da popula\u00e7\u00e3o total infectada em 28 de mar\u00e7o?"
    },
    {
        "answer":"0.41% [0.09%-1.2%]",
        "answer_pt":"0,41% [0,09% -1,2%]",
        "id":"853",
        "question":"What is Norway's estimated mean percentage [95% credible interval] of total population infected as of 28th March?",
        "question_pt":"Qual \u00e9 a porcentagem m\u00e9dia estimada da Noruega [intervalo cred\u00edvel de 95%] da popula\u00e7\u00e3o total infectada em 28 de mar\u00e7o?"
    },
    {
        "answer":"15% [3.7%-41%]",
        "answer_pt":"15% [3,7% -41%]",
        "id":"854",
        "question":"What is Spain's estimated mean percentage [95% credible interval] of total population infected as of 28th March?",
        "question_pt":"Qual \u00e9 a porcentagem m\u00e9dia estimada da Espanha [intervalo cred\u00edvel de 95%] da popula\u00e7\u00e3o total infectada em 28 de mar\u00e7o?"
    },
    {
        "answer":"3.1% [0.85%-8.4%]",
        "answer_pt":"3,1% [0,85% -8,4%]",
        "id":"855",
        "question":"What is Spain's estimated mean percentage [95% credible interval] of total population infected as of 28th March?",
        "question_pt":"Qual \u00e9 a porcentagem m\u00e9dia estimada da Espanha [intervalo cred\u00edvel de 95%] da popula\u00e7\u00e3o total infectada em 28 de mar\u00e7o?"
    },
    {
        "answer":"3.2% [1.3%-7.6%]",
        "answer_pt":"3,2% [1,3% -7,6%]",
        "id":"856",
        "question":"What is Switzerland's estimated mean percentage [95% credible interval] of total population infected as of 28th March?",
        "question_pt":"Qual \u00e9 a porcentagem m\u00e9dia estimada da Su\u00ed\u00e7a [intervalo cred\u00edvel de 95%] da popula\u00e7\u00e3o total infectada em 28 de mar\u00e7o?"
    },
    {
        "answer":"2.7% [1.2%-5.4%]",
        "answer_pt":"2,7% [1,2% -5,4%]",
        "id":"857",
        "question":"What is United Kingdom's estimated mean percentage [95% credible interval] of total population infected as of 28th March?",
        "question_pt":"Qual \u00e9 a porcentagem m\u00e9dia estimada do Reino Unido [intervalo de 95% de credibilidade] da popula\u00e7\u00e3o total infectada em 28 de mar\u00e7o?"
    },
    {
        "answer":"3.87 [3.01-4.66]",
        "answer_pt":"3,87 [3,01-4,66]",
        "id":"859",
        "question":"What is the estimated averaged initial reproduction number [95% credible interval] for Western Europe as of 28th March?",
        "question_pt":"Qual \u00e9 o n\u00famero m\u00e9dio estimado estimado de reprodu\u00e7\u00e3o [intervalo de 95% de credibilidade] para a Europa Ocidental em 28 de mar\u00e7o?"
    },
    {
        "answer":"too early to detect substantial\nintervention impact in many countries at earlier stages of their epidemic",
        "answer_pt":"muito cedo para detectar substancial\nimpacto da interven\u00e7\u00e3o em muitos pa\u00edses nos est\u00e1gios iniciais de sua epidemia",
        "id":"862",
        "question":"Why is there high uncertainty in estimating the impact of interventions against the coronavirus?",
        "question_pt":"Por que h\u00e1 alta incerteza na estimativa do impacto de interven\u00e7\u00f5es contra o coronav\u00edrus?"
    },
    {
        "answer":"close spacing of interventions in time",
        "answer_pt":"espa\u00e7amento estreito das interven\u00e7\u00f5es no tempo",
        "id":"869",
        "question":"Why is it statistically impossible to determine which individual intervention had the greatest effect on reducing the coronavirus reproduction number?",
        "question_pt":"Por que \u00e9 estatisticamente imposs\u00edvel determinar qual interven\u00e7\u00e3o individual teve o maior efeito na redu\u00e7\u00e3o do n\u00famero de reprodu\u00e7\u00e3o de coronav\u00edrus?"
    },
    {
        "answer":" number of daily infections",
        "answer_pt":"n\u00famero de infec\u00e7\u00f5es di\u00e1rias",
        "id":"871",
        "question":"What is estimated to drop immediately after an introduction of a non-pharmaceutical intervention?",
        "question_pt":"O que se estima que caia imediatamente ap\u00f3s a introdu\u00e7\u00e3o de uma interven\u00e7\u00e3o n\u00e3o farmac\u00eautica?"
    },
    {
        "answer":"fit a counterfactual model without the interventions\nand compare this to the actual model",
        "answer_pt":"encaixar um modelo contrafactual sem as interven\u00e7\u00f5es\ne compare isso com o modelo real",
        "id":"873",
        "question":"One way to understand the impact of interventions?",
        "question_pt":"Uma maneira de entender o impacto das interven\u00e7\u00f5es?"
    },
    {
        "answer":"banned gatherings of more than 2 people",
        "answer_pt":"reuni\u00f5es proibidas de mais de 2 pessoas",
        "id":"1071",
        "question":"What is a lockdown?",
        "question_pt":"O que \u00e9 um bloqueio?"
    },
    {
        "answer":"underreporting as well as systematic and country-specific changes in testing",
        "answer_pt":"subnotifica\u00e7\u00e3o, bem como altera\u00e7\u00f5es sistem\u00e1ticas e espec\u00edficas de cada pa\u00eds nos testes",
        "id":"1074",
        "question":"Why is it hard to know the true incidence of infections number?",
        "question_pt":"Por que \u00e9 dif\u00edcil saber o n\u00famero real de incid\u00eancia de infec\u00e7\u00f5es?"
    },
    {
        "answer":"strong recommendations or laws to the general\npublic and primary care about self\u2014isolation when showing COVID-19-like symptoms",
        "answer_pt":"recomenda\u00e7\u00f5es ou leis fortes para o general\ncuidados p\u00fablicos e prim\u00e1rios sobre o auto-isolamento ao mostrar sintomas semelhantes ao COVID-19",
        "id":"1076",
        "question":"What is an example of a case-based measure against coronavirus?",
        "question_pt":"Qual \u00e9 um exemplo de uma medida baseada em casos contra o coronav\u00edrus?"
    },
    {
        "answer":"isolation if travelling back from an epidemic country",
        "answer_pt":"isolamento se voltar de um pa\u00eds epid\u00eamico",
        "id":"1078",
        "question":"What is an example of containment phase intervention?",
        "question_pt":"Qual \u00e9 um exemplo de interven\u00e7\u00e3o na fase de conten\u00e7\u00e3o?"
    },
    {
        "answer":"banning all public events of more than 100 participants",
        "answer_pt":"banir todos os eventos p\u00fablicos de mais de 100 participantes",
        "id":"1079",
        "question":"What does a public events ban intervention mean?",
        "question_pt":"O que significa uma interven\u00e7\u00e3o p\u00fablica proibi\u00e7\u00e3o de eventos?"
    },
    {
        "answer":"work from home wherever possible",
        "answer_pt":"trabalhe em casa sempre que poss\u00edvel",
        "id":"1080",
        "question":"An example of social distancing",
        "question_pt":"Um exemplo de distanciamento social"
    },
    {
        "answer":"reducing use ofpublictransport",
        "answer_pt":"reduzindo o uso de transporte p\u00fablico",
        "id":"1081",
        "question":"Example of social distancing",
        "question_pt":"Exemplo de distanciamento social"
    },
    {
        "answer":"regulations/legislations regarding strict face-to-face social interaction",
        "answer_pt":"regulamentos / legisla\u00e7\u00f5es relativas \u00e0 intera\u00e7\u00e3o social estrita face a face",
        "id":"1083",
        "question":"What is a lockdown?",
        "question_pt":"O que \u00e9 um bloqueio?"
    },
    {
        "answer":"time from infection to the onset\nof symptoms",
        "answer_pt":"tempo desde a infec\u00e7\u00e3o at\u00e9 o in\u00edcio\nde sintomas",
        "id":"1084",
        "question":"What is an infection-to-onset-distribution?",
        "question_pt":"O que \u00e9 uma distribui\u00e7\u00e3o de infec\u00e7\u00e3o para in\u00edcio?"
    },
    {
        "answer":"time from the onset of symptoms to death",
        "answer_pt":"tempo desde o in\u00edcio dos sintomas at\u00e9 a morte",
        "id":"1085",
        "question":"What is an onset-to-death distribution?",
        "question_pt":"O que \u00e9 uma distribui\u00e7\u00e3o de in\u00edcio a morte?"
    },
    {
        "answer":"adjusted for the age structure and contact patterns of\neach country",
        "answer_pt":"ajustado para a estrutura et\u00e1ria e padr\u00f5es de contato de\ncada pa\u00eds",
        "id":"1086",
        "question":"What is the population-averaged infection fatality ratio?",
        "question_pt":"Qual \u00e9 a taxa m\u00e9dia de mortalidade de infec\u00e7\u00f5es por popula\u00e7\u00e3o?"
    },
    {
        "answer":" initial reproduction number before interventions and the effect sizes from\ninterventions",
        "answer_pt":"n\u00famero inicial de reprodu\u00e7\u00e3o antes das interven\u00e7\u00f5es e os tamanhos dos efeitos\ninterven\u00e7\u00f5es",
        "id":"1095",
        "question":"What is the time-varying reproduction number a function of?",
        "question_pt":"Qual \u00e9 o n\u00famero de reprodu\u00e7\u00e3o vari\u00e1vel no tempo em que uma fun\u00e7\u00e3o?"
    },
    {
        "answer":"infection to onset of symptoms",
        "answer_pt":"infec\u00e7\u00e3o ao aparecimento dos sintomas",
        "id":"1097",
        "question":"What is an incubation period?",
        "question_pt":"O que \u00e9 um per\u00edodo de incuba\u00e7\u00e3o?"
    },
    {
        "answer":"infection-\nto-onset",
        "answer_pt":"infec\u00e7\u00e3o-\niniciar",
        "id":"1098",
        "question":"What is an incubation period?",
        "question_pt":"O que \u00e9 um per\u00edodo de incuba\u00e7\u00e3o?"
    },
    {
        "answer":"Gamma distributed with a mean of 18.8 days and a\ncoefficient of va riation 0.45",
        "answer_pt":"Gama distribu\u00edda com m\u00e9dia de 18,8 dias e uma\ncoeficiente de varia\u00e7\u00e3o 0,45",
        "id":"1102",
        "question":"What are the descriptive statistics for the onset-to-death for coronavirus?",
        "question_pt":"Quais s\u00e3o as estat\u00edsticas descritivas para o in\u00edcio da morte do coronav\u00edrus?"
    },
    {
        "answer":"distribution is Gamma distributed with mean 5.1 days and coefficient of variation\n0.86",
        "answer_pt":"distribui\u00e7\u00e3o \u00e9 gama distribu\u00edda com m\u00e9dia de 5,1 dias e coeficiente de varia\u00e7\u00e3o\n0,86",
        "id":"1100",
        "question":"What are the descriptive statistics for the incubation period for coronavirus?",
        "question_pt":"Quais s\u00e3o as estat\u00edsticas descritivas para o per\u00edodo de incuba\u00e7\u00e3o do coronav\u00edrus?"
    },
    {
        "answer":"23.9 days",
        "answer_pt":"23,9 dias",
        "id":"1103",
        "question":"What is the estimated infection-to-death distribution's mean for coronavirus?",
        "question_pt":"Qual \u00e9 a m\u00e9dia estimada da distribui\u00e7\u00e3o infec\u00e7\u00e3o-morte para o coronav\u00edrus?"
    },
    {
        "answer":"discrete renewal process",
        "answer_pt":"processo de renova\u00e7\u00e3o discreta",
        "id":"1104",
        "question":"What is a well known approach to model the true number of infected individuals?",
        "question_pt":"Qual \u00e9 uma abordagem bem conhecida para modelar o verdadeiro n\u00famero de indiv\u00edduos infectados?"
    },
    {
        "answer":"reproductive number",
        "answer_pt":"n\u00famero reprodutivo",
        "id":"799",
        "question":"What is a way to measure virus transmission?",
        "question_pt":"O que \u00e9 uma maneira de medir a transmiss\u00e3o de v\u00edrus?"
    },
    {
        "answer":"herd immunity",
        "answer_pt":"imunidade de rebanho",
        "id":"819",
        "question":"What term describes when a majority of the population has built an immunity to a virus?",
        "question_pt":"Qual termo descreve quando a maioria da popula\u00e7\u00e3o cria imunidade a v\u00edrus?"
    },
    {
        "answer":"cumulatively, 5.9 [1.9-15.2] million people have been\ninfected as of March 28th",
        "answer_pt":"cumulativamente, 5,9 [1,9-15,2] milh\u00f5es de pessoas foram\ninfectado a partir de 28 de mar\u00e7o",
        "id":"839",
        "question":"What is the estimated number of people in Italy infected with coronavirus by March 28th?",
        "question_pt":"Qual \u00e9 o n\u00famero estimado de pessoas na It\u00e1lia infectadas com coronav\u00edrus at\u00e9 28 de mar\u00e7o?"
    },
    {
        "answer":"10.8%",
        "answer_pt":"10,8%",
        "id":"523",
        "question":"In 2009 what was the reported H1N1 vaccination rate in China?",
        "question_pt":"Em 2009, qual foi a taxa de vacina\u00e7\u00e3o H1N1 relatada na China?"
    },
    {
        "answer":"phase 6",
        "answer_pt":"fase 6",
        "id":"525",
        "question":"What is the highest alert level given by the World Health Organization to a pandemic?",
        "question_pt":"Qual \u00e9 o n\u00edvel de alerta mais alto dado pela Organiza\u00e7\u00e3o Mundial da Sa\u00fade a uma pandemia?"
    },
    {
        "answer":"spread in more than two continents",
        "answer_pt":"espalhados em mais de dois continentes",
        "id":"527",
        "question":"What does it mean for a pandemic to have a WHO alert level of 6?",
        "question_pt":"O que significa para uma pandemia ter um n\u00edvel de alerta 6 da OMS?"
    },
    {
        "answer":"estimated at $30-$100 billion",
        "answer_pt":"estimado em US $ 30 a US $ 100 bilh\u00f5es",
        "id":"528",
        "question":"What was the estimated economic impact in the U.S. from the 2009 SARS pandemic?",
        "question_pt":"Qual foi o impacto econ\u00f4mico estimado nos EUA da pandemia de SARS de 2009?"
    },
    {
        "answer":"2019-nCoV was transmitted through respiratory tract and then induced pneumonia,",
        "answer_pt":"2019-nCoV foi transmitido atrav\u00e9s do trato respirat\u00f3rio e depois pneumonia induzida,",
        "id":"881",
        "question":"How is 2019-nCOV transmitted?",
        "question_pt":"Como \u00e9 transmitido 2019-nCOV?"
    },
    {
        "answer":"We found the presence of 2019-nCoV in anal swabs and blood as well, and more anal swab positives than oral swab positives in a later stage of infection, suggesting shedding and thereby transmitted through oral\u2013fecal route.",
        "answer_pt":"Tamb\u00e9m encontramos a presen\u00e7a de 2019-nCoV em zaragatoas anais e sangue e mais positivos de zaragatoas anal do que zaragatoas bucais em um est\u00e1gio posterior da infec\u00e7\u00e3o, sugerindo queda e, portanto, transmitida por via oral-fecal.",
        "id":"882",
        "question":"What are ways in  which 2019-nCOV is transmitted?",
        "question_pt":"Quais s\u00e3o as maneiras pelas quais 2019-nCOV \u00e9 transmitido?"
    },
    {
        "answer":"the current strategy for the detection of viral RNA in oral swabs used for 2019-nCoV diagnosis is not perfect. The virus may be present in anal swabs or blood of patients when oral swabs detection negative.",
        "answer_pt":"a estrat\u00e9gia atual para a detec\u00e7\u00e3o de RNA viral em zaragatoas orais usadas para o diagn\u00f3stico 2019-nCoV n\u00e3o \u00e9 perfeita. O v\u00edrus pode estar presente em zaragatoas anais ou no sangue de pacientes quando a detec\u00e7\u00e3o de zaragatoas \u00e9 negativa.",
        "id":"883",
        "question":"Is oral swab for detecting 2019-nCOV infection, sufficient?",
        "question_pt":"O swab oral para a detec\u00e7\u00e3o de infec\u00e7\u00e3o por 2019-nCOV \u00e9 suficiente?"
    },
    {
        "answer":" patients infected with 2019-nCoV may harbour the virus in the intestine at the early or late stage of disease. It is also worth to note none of the patients with viremia blood had positive swabs. These patients would likely be considered as 2019-nCoV negative through routine surveillance, and thus pose a threat to other people.",
        "answer_pt":"os pacientes infectados com 2019-nCoV podem abrigar o v\u00edrus no intestino no est\u00e1gio inicial ou tardio da doen\u00e7a. Tamb\u00e9m vale ressaltar que nenhum dos pacientes com viremia apresentou cotonetes positivos. Esses pacientes provavelmente seriam considerados negativos para 2019-nCoV por meio de vigil\u00e2ncia de rotina e, portanto, representam uma amea\u00e7a para outras pessoas.",
        "id":"884",
        "question":"Is oral swab for detecting 2019-nCOV infection, sufficient?",
        "question_pt":"O swab oral para a detec\u00e7\u00e3o de infec\u00e7\u00e3o por 2019-nCOV \u00e9 suficiente?"
    },
    {
        "answer":"serology should be considered for 2019-nCoV epidemiology.",
        "answer_pt":"a sorologia deve ser considerada para a epidemiologia de 2019-nCoV.",
        "id":"885",
        "question":"What other tests should be considered for 2019-nCOV epidemiology?",
        "question_pt":"Que outros testes devem ser considerados para a epidemiologia de 2019-nCOV?"
    },
    {
        "answer":"we cannot discharge a patient purely based on oral swabs negative, who may still shed the virus by oral-fecal route. Above all, we strongly suggest using viral IgM and IgG serological test to confirm an infection, considering the unreliable results from oral swabs detection",
        "answer_pt":"n\u00e3o podemos dar alta a um paciente puramente baseado em zaragatoas orais negativas, que ainda podem lan\u00e7ar o v\u00edrus por via oral-fecal. Acima de tudo, sugerimos fortemente o uso de testes sorol\u00f3gicos IgM e IgG virais para confirmar uma infec\u00e7\u00e3o, considerando os resultados n\u00e3o confi\u00e1veis \u200b\u200bda detec\u00e7\u00e3o de zaragatoas orais",
        "id":"886",
        "question":"What tests should  be done before a 2019-nCOV infected patient is discharged?",
        "question_pt":"Quais testes devem ser feitos antes da alta de um paciente infectado com 2019-nCOV?"
    },
    {
        "answer":"zoonotic diseases",
        "answer_pt":"doen\u00e7as zoon\u00f3ticas",
        "id":"4220",
        "question":"What is a Hantavirus?",
        "question_pt":"O que \u00e9 um Hantavirus?"
    },
    {
        "answer":"long noncoding RNAs (lncRNAs)",
        "answer_pt":"RNAs n\u00e3o codificadores longos (lncRNAs)",
        "id":"5311",
        "question":"What plays a role in innate immunity to Hantavirus infection?",
        "question_pt":"O que desempenha um papel na imunidade inata \u00e0 infec\u00e7\u00e3o por Hantavirus?"
    },
    {
        "answer":"colocalized after HTNV infection",
        "answer_pt":"colocalizado ap\u00f3s infec\u00e7\u00e3o por HTNV",
        "id":"5312",
        "question":"What evidence suggests that RIG-I and DDX60 collaborate to exert antiviral effects?",
        "question_pt":"Que evid\u00eancia sugere que o RIG-I e o DDX60 colaboram para exercer efeitos antivirais?"
    },
    {
        "answer":"the first study to describe the role of NEAT1 in HTNV infection",
        "answer_pt":"o primeiro estudo a descrever o papel do NEAT1 na infec\u00e7\u00e3o por HTNV",
        "id":"5313",
        "question":"What was the major contribution of this study?",
        "question_pt":"Qual foi a principal contribui\u00e7\u00e3o deste estudo?"
    },
    {
        "answer":"Of the remaining 29, 20 reported fever, 14 reported cough and eight reported weakness. Additional symptoms reported included headaches (6 cases), sore throat (2), rhinorrhoea (2), shortness of breath (2), myalgia (1), diarrhoea (1) and nausea (1)",
        "answer_pt":"Dos 29 restantes, 20 relataram febre, 14 relataram tosse e oito relataram fraqueza. Os sintomas adicionais relatados incluem dores de cabe\u00e7a (6 casos), dor de garganta (2), rinorreia (2), falta de ar (2), mialgia (1), diarr\u00e9ia (1) e n\u00e1usea (1)",
        "id":"3820",
        "question":"What symptoms were reported?",
        "question_pt":"Quais sintomas foram relatados?"
    },
    {
        "answer":"demographics, history of recent travel to affected areas, close contact with a probable or confirmed COVID-19 case, underlying conditions, signs and symptoms of disease at onset, type of specimens from which the virus was detected, and clinical outcome. ",
        "answer_pt":"dados demogr\u00e1ficos, hist\u00f3rico de viagens recentes para as \u00e1reas afetadas, contato pr\u00f3ximo com um caso prov\u00e1vel ou confirmado de COVID-19, condi\u00e7\u00f5es subjacentes, sinais e sintomas da doen\u00e7a no in\u00edcio, tipo de amostras das quais o v\u00edrus foi detectado e resultado cl\u00ednico.",
        "id":"3806",
        "question":"What did the collected data include?",
        "question_pt":"O que os dados coletados incluem?"
    },
    {
        "answer":"27 January 2020",
        "answer_pt":"27 de janeiro de 2020",
        "id":"3793",
        "question":"When was COVID  surveillance implemented in European region?",
        "question_pt":"Quando a vigil\u00e2ncia COVID foi implementada na regi\u00e3o europeia?"
    },
    {
        "answer":"47",
        "answer_pt":"47",
        "id":"3794",
        "question":"As of 21 February, how many cases were reported?",
        "question_pt":"Em 21 de fevereiro, quantos casos foram notificados?"
    },
    {
        "answer":"21 were linked to two clusters in Germany and France, 14 were infected in China",
        "answer_pt":"21 estavam vinculados a dois grupos na Alemanha e na Fran\u00e7a, 14 estavam infectados na China",
        "id":"3795",
        "question":"Where were the cases that were studied?",
        "question_pt":"Onde foram estudados os casos?"
    },
    {
        "answer":"42 years",
        "answer_pt":"42 anos",
        "id":"3796",
        "question":"What was the median case age?",
        "question_pt":"Qual foi a idade m\u00e9dia dos casos?"
    },
    {
        "answer":" 25 ",
        "answer_pt":"25",
        "id":"3797",
        "question":"How many were male?",
        "question_pt":"Quantos eram do sexo masculino?"
    },
    {
        "answer":"4,250 ",
        "answer_pt":"4.250",
        "id":"3798",
        "question":"How many cases were there on 5 March?",
        "question_pt":"Quantos casos ocorreram em 5 de mar\u00e7o?"
    },
    {
        "answer":"12 January 2020",
        "answer_pt":"12 de janeiro de 2020",
        "id":"3799",
        "question":"When did the Chinese authorities share the sequence of a novel coronavirus ?",
        "question_pt":"Quando as autoridades chinesas compartilharam a sequ\u00eancia de um novo coronav\u00edrus?"
    },
    {
        "answer":"coronavirus disease 2019 (COVID -19)",
        "answer_pt":"doen\u00e7a de coronav\u00edrus 2019 (COVID -19)",
        "id":"3800",
        "question":"What is the name of the disease caused buy SARS-COV-2?",
        "question_pt":"Qual \u00e9 o nome da doen\u00e7a causada pelo SARS-COV-2?"
    },
    {
        "answer":"United Kingdom (UK)",
        "answer_pt":"Reino Unido (UK)",
        "id":"3801",
        "question":"What country does this study exclude?",
        "question_pt":"Que pa\u00eds este estudo exclui?"
    },
    {
        "answer":"a comparison between cases detected among travellers from China and cases whose infection was acquired due to subsequent local transmission.",
        "answer_pt":"uma compara\u00e7\u00e3o entre os casos detectados entre os viajantes da China e os casos cuja infec\u00e7\u00e3o foi adquirida devido \u00e0 subsequente transmiss\u00e3o local.",
        "id":"3802",
        "question":"What does the study include?",
        "question_pt":"O que o estudo inclui?"
    },
    {
        "answer":" to complete a WHO standard COVID-19 case report form for all confirmed and probable cases according to WHO criteria",
        "answer_pt":"preencher um formul\u00e1rio de relat\u00f3rio de caso COVID-19 padr\u00e3o da OMS para todos os casos prov\u00e1veis \u200b\u200be confirmados de acordo com os crit\u00e9rios da OMS",
        "id":"3803",
        "question":"What did the ECDC and WHO regional office ask the countries?",
        "question_pt":"O que o escrit\u00f3rio regional do ECDC e da OMS perguntou aos pa\u00edses?"
    },
    {
        "answer":" to support the global strategy of containment of COVID-19 with rapid identification and follow-up of cases linked to affected countries in order to minimise onward transmission.",
        "answer_pt":"apoiar a estrat\u00e9gia global de conten\u00e7\u00e3o do COVID-19 com r\u00e1pida identifica\u00e7\u00e3o e acompanhamento de casos vinculados aos pa\u00edses afetados, a fim de minimizar a transmiss\u00e3o subsequente.",
        "id":"3804",
        "question":"What was the overall aim of the surveillance?",
        "question_pt":"Qual era o objetivo geral da vigil\u00e2ncia?"
    },
    {
        "answer":"to: describe the key epidemiological and clinical characteristics of COVID-19 cases detected in Europe; inform country preparedness; and improve further case detection and management. ",
        "answer_pt":"descrever: as principais caracter\u00edsticas epidemiol\u00f3gicas e cl\u00ednicas dos casos de COVID-19 detectados na Europa; informar a prepara\u00e7\u00e3o do pa\u00eds; e melhorar ainda mais a detec\u00e7\u00e3o e o gerenciamento de casos.",
        "id":"3805",
        "question":"What were the surveillance objectives?",
        "question_pt":"Quais eram os objetivos da vigil\u00e2ncia?"
    },
    {
        "answer":"a confirmed case was a person with laboratory confirmation of SARS-CoV-2 infection (ECDC recommended two separate SARS-CoV-2 RT-PCR tests), irrespective of clinical signs and symptoms, whereas a probable case was a suspect case for whom testing for SARS-CoV-2 was inconclusive or positive using a pan-coronavirus assay",
        "answer_pt":"um caso confirmado era uma pessoa com confirma\u00e7\u00e3o laboratorial da infec\u00e7\u00e3o por SARS-CoV-2 (o ECDC recomendou dois testes separados de SARS-CoV-2 RT-PCR), independentemente de sinais e sintomas cl\u00ednicos, enquanto um caso prov\u00e1vel era um caso suspeito para quem o teste para SARS-CoV-2 foi inconclusivo ou positivo usando um ensaio de pan-coronav\u00edrus",
        "id":"3807",
        "question":"What is the adopted WHO case definition?",
        "question_pt":"Qual \u00e9 a defini\u00e7\u00e3o de caso adotada pela OMS?"
    },
    {
        "answer":"15 February",
        "answer_pt":"15 de fevereiro",
        "id":"3808",
        "question":"When was the first reported death in France?",
        "question_pt":"Quando foi a primeira morte relatada na Fran\u00e7a?"
    },
    {
        "answer":" up to 14 days [",
        "answer_pt":"at\u00e9 14 dias [",
        "id":"3809",
        "question":"What is the presumed incubation period?",
        "question_pt":"Qual \u00e9 o per\u00edodo de incuba\u00e7\u00e3o presumido?"
    },
    {
        "answer":" 35 cases (missing for three cases), of whom 14 were infected in China (Hubei province: 10 cases; Shandong province: one case; province not reported for three cases). The remaining 21 cases were infected in Europe. ",
        "answer_pt":"35 casos (desaparecidos em tr\u00eas casos), dos quais 14 foram infectados na China (prov\u00edncia de Hubei: 10 casos; prov\u00edncia de Shandong: um caso; prov\u00edncia n\u00e3o registrada em tr\u00eas casos). Os 21 casos restantes foram infectados na Europa.",
        "id":"3810",
        "question":"What were the places of infection?",
        "question_pt":"Quais foram os locais de infec\u00e7\u00e3o?"
    },
    {
        "answer":"14 were linked to a cluster in Bavaria, Germany, and seven to a cluster in Haute-Savoie, France ",
        "answer_pt":"14 estavam ligados a um cluster na Baviera, na Alemanha, e sete a um cluster na Alta Saboia, Fran\u00e7a",
        "id":"3811",
        "question":"What places were linked to these?",
        "question_pt":"Quais lugares estavam ligados a esses?"
    },
    {
        "answer":"All but two cases were hospitalised (35 of 37 where information on hospitalisation was reported)",
        "answer_pt":"Todos, exceto dois casos, foram hospitalizados (35 de 37 onde foram relatadas informa\u00e7\u00f5es sobre hospitaliza\u00e7\u00e3o)",
        "id":"3812",
        "question":"How many cases were hospitalised?",
        "question_pt":"Quantos casos foram hospitalizados?"
    },
    {
        "answer":" it is likely that most were hospitalised to isolate the person rather than because of severe disease. ",
        "answer_pt":"\u00e9 prov\u00e1vel que a maioria tenha sido hospitalizada para isolar a pessoa e n\u00e3o por causa de doen\u00e7a grave.",
        "id":"3813",
        "question":"Why were they hospitalised?",
        "question_pt":"Por que eles foram hospitalizados?"
    },
    {
        "answer":"ranged between 0 and 10 days with a mean of 3.7 days ",
        "answer_pt":"variou entre 0 e 10 dias, com m\u00e9dia de 3,7 dias",
        "id":"3814",
        "question":"What was time from onset to hospitalisation?",
        "question_pt":"Qual foi o tempo desde o in\u00edcio at\u00e9 a hospitaliza\u00e7\u00e3o?"
    },
    {
        "answer":"The mean number of days to hospitalisation was 2.5 days for cases imported from China, but 4.6 days for those infected in Europe.",
        "answer_pt":"O n\u00famero m\u00e9dio de dias de interna\u00e7\u00e3o foi de 2,5 dias para os casos importados da China, mas de 4,6 dias para os infectados na Europa.",
        "id":"3815",
        "question":"What was the duration of hospitalisation?",
        "question_pt":"Qual foi a dura\u00e7\u00e3o da interna\u00e7\u00e3o?"
    },
    {
        "answer":"This was mostly a result of delays in identifying the index cases of the two clusters in France and Germany. In the German cluster, for example, the first three cases detected locally were hospitalised in a mean of 5.7 days, whereas the following six took only a mean of 2 days to be hospitalised.",
        "answer_pt":"Isso ocorreu principalmente devido a atrasos na identifica\u00e7\u00e3o dos casos-\u00edndice dos dois grupos na Fran\u00e7a e na Alemanha. No cluster alem\u00e3o, por exemplo, os tr\u00eas primeiros casos detectados localmente foram hospitalizados em uma m\u00e9dia de 5,7 dias, enquanto os seis seguintes levaram apenas uma m\u00e9dia de 2 dias para serem hospitalizados.",
        "id":"3816",
        "question":"Why was this?",
        "question_pt":"Por que isso?"
    },
    {
        "answer":" 31 cases",
        "answer_pt":"31 casos",
        "id":"3817",
        "question":"How many cases reported symptoms at this point?\n",
        "question_pt":"Quantos casos relataram sintomas neste momento?"
    },
    {
        "answer":"Two cases ",
        "answer_pt":"Dois casos",
        "id":"3818",
        "question":"How many cases were asymptomatic?",
        "question_pt":"Quantos casos foram assintom\u00e1ticos?"
    },
    {
        "answer":"as part of screening following repatriation and during contact tracing respectively. ",
        "answer_pt":"como parte da triagem ap\u00f3s repatria\u00e7\u00e3o e durante o rastreamento de contato, respectivamente.",
        "id":"3819",
        "question":"What were the asymptomatic cases tested as?",
        "question_pt":"Como foram testados os casos assintom\u00e1ticos?"
    },
    {
        "answer":" nine cases",
        "answer_pt":"nove casos",
        "id":"3821",
        "question":" For how many cases Fever reported as the sole symptom?",
        "question_pt":"Em quantos casos a Febre relatou como \u00fanico sintoma?"
    },
    {
        "answer":"In 16 of 29 symptomatic cases",
        "answer_pt":"Em 16 de 29 casos sintom\u00e1ticos",
        "id":"3822",
        "question":"In how many cases the symptoms at diagnosis were consistent with the case definition for acute respiratory infection?",
        "question_pt":"Em quantos casos os sintomas no diagn\u00f3stico foram consistentes com a defini\u00e7\u00e3o de caso para infec\u00e7\u00e3o respirat\u00f3ria aguda?"
    },
    {
        "answer":"seven cases",
        "answer_pt":"sete casos",
        "id":"3823",
        "question":"How many cases had data on preexisting conditions?",
        "question_pt":"Quantos casos possui dados sobre condi\u00e7\u00f5es pr\u00e9-existentes?"
    },
    {
        "answer":"five",
        "answer_pt":"cinco",
        "id":"3824",
        "question":"How many cases had no pre-existing conditions?",
        "question_pt":"Quantos casos n\u00e3o tinham condi\u00e7\u00f5es pr\u00e9-existentes?"
    },
    {
        "answer":"one was reported to be obese and one had pre-existing cardiac disease. No data on clinical signs e.g. dyspnea etc. were reported for any of the 38 cases.",
        "answer_pt":"um foi relatado como obeso e um com doen\u00e7a card\u00edaca pr\u00e9-existente. N\u00e3o existem dados sobre sinais cl\u00ednicos, p. dispn\u00e9ia etc. foram relatados para qualquer um dos 38 casos.",
        "id":"3825",
        "question":"What other data on pre-existing conditions were reported?",
        "question_pt":"Que outros dados sobre condi\u00e7\u00f5es pr\u00e9-existentes foram relatados?"
    },
    {
        "answer":"two reported in Italy and two reported in France",
        "answer_pt":"dois relataram na It\u00e1lia e dois na Fran\u00e7a",
        "id":"3826",
        "question":"How many reported viral pneumonia?",
        "question_pt":"Quantos pneumonia viral relatada?"
    },
    {
        "answer":"All hospitalised cases had a benign clinical evolution except four,",
        "answer_pt":"Todos os casos hospitalizados tiveram evolu\u00e7\u00e3o cl\u00ednica benigna, exceto quatro,",
        "id":"3828",
        "question":"What was the clinical evolution of the hospitalised cases?",
        "question_pt":"Qual foi a evolu\u00e7\u00e3o cl\u00ednica dos casos hospitalizados?"
    },
    {
        "answer":"were admitted to intensive care and required respiratory support and one French case died.",
        "answer_pt":"foram admitidos em terapia intensiva e necessitaram de suporte respirat\u00f3rio e um caso franc\u00eas morreu.",
        "id":"3829",
        "question":"What happened to three cases who were aged 65 years or over?",
        "question_pt":"O que aconteceu com tr\u00eas casos com 65 anos ou mais?"
    },
    {
        "answer":"was hospitalised for 21 days and required intensive care and mechanical ventilation for 19 days",
        "answer_pt":"ficou internado por 21 dias e necessitou de cuidados intensivos e ventila\u00e7\u00e3o mec\u00e2nica por 19 dias",
        "id":"3830",
        "question":"What happened to the case who died?",
        "question_pt":"O que aconteceu com o caso que morreu?"
    },
    {
        "answer":"a median of 13 days (range: 8-23 days)",
        "answer_pt":"uma mediana de 13 dias (intervalo: 8-23 dias)",
        "id":"3831",
        "question":"What was the duration of hospitalisation reported for 16 cases ?",
        "question_pt":"Qual foi a dura\u00e7\u00e3o da interna\u00e7\u00e3o relatada em 16 casos?"
    },
    {
        "answer":"according to specific assays targeting at least two separate genes (envelope (E) gene as a screening test and RNA-dependent RNA polymerase (RdRp) gene or nucleoprotein (N) gene for confirmation) ",
        "answer_pt":"de acordo com ensaios espec\u00edficos visando pelo menos dois genes separados (gene do envelope (E) como teste de triagem e gene da RNA polimerase dependente de RNA (RdRp) ou gene da nucleoprote\u00edna (N) para confirma\u00e7\u00e3o)",
        "id":"3832",
        "question":"How were the assays confirmed?",
        "question_pt":"Como foram confirmados os ensaios?"
    },
    {
        "answer":"15 had positive nasopharyngeal swabs, nine had positive throat swabs, three cases had positive sputum, two had a positive nasal swab, one case had a positive nasopharyngeal aspirate and one a positive endotracheal aspirate.",
        "answer_pt":"15 apresentaram cotonetes nasofar\u00edngeos positivos, nove cotonetes na garganta positivos, tr\u00eas casos com escarro positivo, dois com cotonete nasal positivo, um caso com aspirado nasofar\u00edngeo positivo e um aspirado endotraqueal positivo.",
        "id":"3833",
        "question":"What were the specimen types for 21 cases?",
        "question_pt":"Quais foram os tipos de amostra para 21 casos?"
    },
    {
        "answer":"there are 4,250 cases including 113 deaths reported among 38 countries",
        "answer_pt":"4.250 casos, incluindo 113 mortes relatados em 38 pa\u00edses",
        "id":"3834",
        "question":"As of 5 March 2020, what  are the cases in the WHO European region?",
        "question_pt":"Em 5 de mar\u00e7o de 2020, quais s\u00e3o os casos na regi\u00e3o europeia da OMS?"
    },
    {
        "answer":"sporadic cases among travellers from China (14 cases) and cases who acquired infection due to subsequent local transmission in Europe (21 cases).",
        "answer_pt":"casos espor\u00e1dicos entre viajantes da China (14 casos) e casos que adquiriram infec\u00e7\u00e3o devido a transmiss\u00e3o local subsequente na Europa (21 casos).",
        "id":"3835",
        "question":"What were the two contexts for transmission?",
        "question_pt":"Quais foram os dois contextos para transmiss\u00e3o?"
    },
    {
        "answer":"that the time from symptom onset to hospitalisation/case isolation was about 3 days longer for locally acquired cases than for imported cases.",
        "answer_pt":"que o tempo desde o in\u00edcio dos sintomas at\u00e9 a hospitaliza\u00e7\u00e3o / isolamento de casos foi cerca de tr\u00eas dias mais longo para casos adquiridos localmente do que para casos importados.",
        "id":"3836",
        "question":"What  does the analysis show on the difference between locally acquired cases vs imported cases?",
        "question_pt":"O que a an\u00e1lise mostra sobre a diferen\u00e7a entre casos adquiridos localmente e casos importados?"
    },
    {
        "answer":"significant resources for contact tracing and quarantine, and countries should be prepared to allocate considerable public health resources during the containment phase, should local clusters emerge in their population. In addition, prompt sharing of information on cases and contacts through international notification systems such as the International Health Regulations (IHR) mechanism and the European Commission's European Early Warning and Response System is essential to contain international spread of infection.\n",
        "answer_pt":"recursos significativos para localiza\u00e7\u00e3o e quarentena de contatos e os pa\u00edses devem estar preparados para alocar consider\u00e1veis \u200b\u200brecursos de sa\u00fade p\u00fablica durante a fase de conten\u00e7\u00e3o, caso surjam grupos locais em sua popula\u00e7\u00e3o. Al\u00e9m disso, o compartilhamento imediato de informa\u00e7\u00f5es sobre casos e contatos por meio de sistemas internacionais de notifica\u00e7\u00e3o, como o mecanismo do Regulamento Sanit\u00e1rio Internacional (RSI) e o Sistema Europeu de Alerta R\u00e1pido e Resposta da Comiss\u00e3o Europ\u00e9ia, \u00e9 essencial para conter a dissemina\u00e7\u00e3o internacional da infec\u00e7\u00e3o.",
        "id":"3837",
        "question":"What is required for locally acquired cases?",
        "question_pt":"O que \u00e9 necess\u00e1rio para casos adquiridos localmente?"
    },
    {
        "answer":"had a history of travel to China",
        "answer_pt":"tinha uma hist\u00f3ria de viagens para a China",
        "id":"3838",
        "question":"What was common to all imported cases?",
        "question_pt":"O que era comum a todos os casos importados?"
    },
    {
        "answer":"Testing of suspected cases based on geographical risk of importation needs to be complemented with additional approaches to ensure early detection of local circulation of COVID-19, including through testing of severe acute respiratory infections in hospitals irrespectively of travel history as recommended in the WHO case definition updated on 27 February 2020 ",
        "answer_pt":"O teste de casos suspeitos com base no risco geogr\u00e1fico de importa\u00e7\u00e3o precisa ser complementado com abordagens adicionais para garantir a detec\u00e7\u00e3o precoce da circula\u00e7\u00e3o local do COVID-19, inclusive atrav\u00e9s do teste de infec\u00e7\u00f5es respirat\u00f3rias agudas graves em hospitais, independentemente do hist\u00f3rico de viagens, conforme recomendado na defini\u00e7\u00e3o de caso da OMS atualizado em 27 de fevereiro de 2020",
        "id":"3839",
        "question":"What testing and detection are needed?",
        "question_pt":"Quais testes e detec\u00e7\u00e3o s\u00e3o necess\u00e1rios?"
    },
    {
        "answer":"include fever among several clinical signs or symptoms indicative for the suspected case definition.",
        "answer_pt":"incluem febre entre v\u00e1rios sinais ou sintomas cl\u00ednicos indicativos para a defini\u00e7\u00e3o de caso suspeito.",
        "id":"3840",
        "question":"What did the finding prompt ECDC to do?",
        "question_pt":"O que a descoberta levou o ECDC a fazer?"
    },
    {
        "answer":"to help plan for the impact on the healthcare system and the wider population.",
        "answer_pt":"para ajudar a planejar o impacto no sistema de sa\u00fade e na popula\u00e7\u00e3o em geral.",
        "id":"3841",
        "question":"Why is understanding the infection-severity  critical ?",
        "question_pt":"Por que a compreens\u00e3o da gravidade da infec\u00e7\u00e3o \u00e9 cr\u00edtica?"
    },
    {
        "answer":"to understand the proportion of cases who are asymptomatic.",
        "answer_pt":"entender a propor\u00e7\u00e3o de casos assintom\u00e1ticos.",
        "id":"3842",
        "question":"Why are serological tests vital?",
        "question_pt":"Por que os testes sorol\u00f3gicos s\u00e3o vitais?"
    },
    {
        "answer":"help estimate the incidence of severe cases and identify risk factors for severity and death",
        "answer_pt":"ajudar a estimar a incid\u00eancia de casos graves e identificar fatores de risco para gravidade e morte",
        "id":"3843",
        "question":"How can hospital based surveillance help?",
        "question_pt":"Como a vigil\u00e2ncia hospitalar pode ajudar?"
    },
    {
        "answer":"Established hospital surveillance systems that are in place for influenza and other diseases in Europe may be expanded for this purpose. In addition, a number of countries in Europe are adapting and, in some cases, already using existing sentinel primary care based surveillance systems for influenza to detect community transmission of SARS-CoV-2",
        "answer_pt":"Os sistemas de vigil\u00e2ncia hospitalar estabelecidos para a gripe e outras doen\u00e7as na Europa podem ser expandidos para esse fim. Al\u00e9m disso, v\u00e1rios pa\u00edses da Europa est\u00e3o se adaptando e, em alguns casos, j\u00e1 usando os sistemas de vigil\u00e2ncia sentinela existentes para vigil\u00e2ncia da influenza para detectar a transmiss\u00e3o comunit\u00e1ria de SARS-CoV-2",
        "id":"3844",
        "question":"How can present systems of surveillance be used?",
        "question_pt":"Como os atuais sistemas de vigil\u00e2ncia podem ser usados?"
    },
    {
        "answer":"will be used globally to help identify evidence of widespread community transmission and, should the virus spread and containment no longer be deemed feasible, to monitor intensity of disease transmission, trends and its geographical spread.",
        "answer_pt":"ser\u00e1 usado globalmente para ajudar a identificar evid\u00eancias de transmiss\u00e3o generalizada da comunidade e, caso o v\u00edrus se espalhe e contenha n\u00e3o seja mais poss\u00edvel, para monitorar a intensidade da transmiss\u00e3o de doen\u00e7as, tend\u00eancias e sua distribui\u00e7\u00e3o geogr\u00e1fica.",
        "id":"3845",
        "question":"How will  this approach used?",
        "question_pt":"Como essa abordagem ser\u00e1 usada?"
    },
    {
        "answer":" to complement surveillance data to build knowledge on the infectious period, modes of transmission, basic and effective reproduction numbers, and effectiveness of prevention and case management options also in settings outside of China.",
        "answer_pt":"complementar os dados de vigil\u00e2ncia para construir conhecimento sobre o per\u00edodo infeccioso, modos de transmiss\u00e3o, n\u00fameros b\u00e1sicos e eficazes de reprodu\u00e7\u00e3o e efic\u00e1cia das op\u00e7\u00f5es de preven\u00e7\u00e3o e gerenciamento de casos tamb\u00e9m em ambientes fora da China.",
        "id":"3846",
        "question":"Why is additional research needed?",
        "question_pt":"Por que \u00e9 necess\u00e1ria pesquisa adicional?"
    },
    {
        "answer":"a 'Valley of Death' 1,2 no less, between broadening strides in fundamental biomedical research and their incommensurate reach into the clinic. ",
        "answer_pt":"um \"Vale da Morte\" 1,2, n\u00e3o menos importante, entre amplos avan\u00e7os na pesquisa biom\u00e9dica fundamental e seu alcance incomensur\u00e1vel na cl\u00ednica.",
        "id":"4123",
        "question":"What growing dysjunction has been witnessed?",
        "question_pt":"Que disjun\u00e7\u00e3o crescente foi testemunhada?"
    },
    {
        "answer":" recent changes in the structure of government funding, 2 new public and private joint ventures and specialist undergraduate and postgraduate courses",
        "answer_pt":"mudan\u00e7as recentes na estrutura de financiamento do governo, 2 novas joint ventures p\u00fablicas e privadas e cursos especializados de gradua\u00e7\u00e3o e p\u00f3s-gradua\u00e7\u00e3o",
        "id":"4124",
        "question":"What is aiming to incorporate pathways to translation at the earliest stages?",
        "question_pt":"O que \u00e9 o objetivo de incorporar caminhos para a tradu\u00e7\u00e3o nos est\u00e1gios iniciais?"
    },
    {
        "answer":"exponentially, up 1800%",
        "answer_pt":"exponencialmente, at\u00e9 1800%",
        "id":"4125",
        "question":"How much  have  the number of biomedical research publications targeting 'translational' concepts has increased ?",
        "question_pt":"Quanto aumentou o n\u00famero de publica\u00e7\u00f5es de pesquisa biom\u00e9dica voltadas para conceitos de \"tradu\u00e7\u00e3o\"?"
    },
    {
        "answer":"by creatively leveraging the so-called 'strengths' of viruses. Viral RNA polymerisation and reverse transcription enable resistance to treatment by conferring extraordinary genetic diversity. ",
        "answer_pt":"aproveitando criativamente os chamados \"pontos fortes\" dos v\u00edrus. A polimeriza\u00e7\u00e3o do RNA viral e a transcri\u00e7\u00e3o reversa permitem resist\u00eancia ao tratamento, conferindo uma diversidade gen\u00e9tica extraordin\u00e1ria.",
        "id":"4126",
        "question":"What ways to  solve the issues are outlined?",
        "question_pt":"Que maneiras de resolver os problemas s\u00e3o descritas?"
    },
    {
        "answer":" by strongly limiting virus genome sizes and their incorporation of new information. ",
        "answer_pt":"limitando fortemente o tamanho do genoma do v\u00edrus e a incorpora\u00e7\u00e3o de novas informa\u00e7\u00f5es.",
        "id":"4127",
        "question":"How do these exact processes ultimately restrict viral infectivity?",
        "question_pt":"Como esses processos exatos acabam restringindo a infectividade viral?"
    },
    {
        "answer":"'information economy paradox'.",
        "answer_pt":"'paradoxo da economia da informa\u00e7\u00e3o'.",
        "id":"4128",
        "question":"What does the author coin this evolutionary dilemma as?",
        "question_pt":"Como o autor cunha esse dilema evolutivo?"
    },
    {
        "answer":"by manipulating multifunctional or multitasking host cell proteins (MMHPs), thereby maximising host subversion and viral infectivity at minimal informational cost.",
        "answer_pt":"manipulando prote\u00ednas de c\u00e9lulas hospedeiras multifuncionais ou multitarefas (MMHPs), maximizando assim a subvers\u00e3o do hospedeiro e a infectividade viral a um custo informacional m\u00ednimo.",
        "id":"4129",
        "question":"How do many viruses resolve this ?",
        "question_pt":"Como muitos v\u00edrus resolvem isso?"
    },
    {
        "answer":" via host-oriented therapies to impose devastating informational and fitness barriers on escape mutant selection.",
        "answer_pt":"por meio de terapias orientadas ao host para impor barreiras informacionais e de condicionamento \u00e0 sele\u00e7\u00e3o de mutantes de escape.",
        "id":"4130",
        "question":"How may this \"Achilles Heel\" be safely targeted?",
        "question_pt":"Como esse \"calcanhar de Aquiles\" pode ser direcionado com seguran\u00e7a?"
    },
    {
        "answer":"since MMHPs are often conserved targets within and between virus families,",
        "answer_pt":"como os MMHPs geralmente s\u00e3o alvos conservados dentro e entre fam\u00edlias de v\u00edrus,",
        "id":"4131",
        "question":"Why  may MMHP-targeting therapies exhibit both robust and broadspectrum antiviral efficacy?",
        "question_pt":"Por que as terapias direcionadas ao MMHP podem exibir efic\u00e1cia antiviral robusta e de amplo espectro?"
    },
    {
        "answer":" break the vicious cycle of escalating therapeutic development costs and trivial escape mutant selection, both quickly and in multiple places. ",
        "answer_pt":"quebrar o ciclo vicioso de escalada dos custos de desenvolvimento terap\u00eautico e sele\u00e7\u00e3o trivial de mutantes de fuga, rapidamente e em v\u00e1rios lugares.",
        "id":"4132",
        "question":"What will  achieving this through drug repurposing do?",
        "question_pt":"O que conseguir\u00e1 isso atrav\u00e9s do redirecionamento de medicamentos?"
    },
    {
        "answer":" alternative posttranslational and RNA-based antiviral approaches, designer vaccines, immunotherapy and the emerging field of neo-virology.",
        "answer_pt":"abordagens antivirais alternativas p\u00f3s-traducionais e baseadas em RNA, vacinas de grife, imunoterapia e o campo emergente da neovirologia.",
        "id":"4133",
        "question":"What are also discussed by the author?",
        "question_pt":"O que tamb\u00e9m \u00e9 discutido pelo autor?"
    },
    {
        "answer":" will enable the tapping of useful new biological functions and processes, methods for controlling infection, and the deployment of symbiotic or subclinical viruses in new therapies and biotechnologies that are so crucially needed.",
        "answer_pt":"permitir\u00e1 o aproveitamento de novas fun\u00e7\u00f5es e processos biol\u00f3gicos \u00fateis, m\u00e9todos para controlar a infec\u00e7\u00e3o e a implanta\u00e7\u00e3o de v\u00edrus simbi\u00f3ticos ou subcl\u00ednicos em novas terapias e biotecnologias t\u00e3o necess\u00e1rias.",
        "id":"4134",
        "question":"What does  the author anticipate international efforts will do?",
        "question_pt":"O que o autor prev\u00ea que os esfor\u00e7os internacionais far\u00e3o?"
    },
    {
        "answer":"stimulate expression of numerous host inflammatory factors that support recruitment and activation of immune cells. ",
        "answer_pt":"estimular a express\u00e3o de numerosos fatores inflamat\u00f3rios do hospedeiro que apoiam o recrutamento e a ativa\u00e7\u00e3o de c\u00e9lulas imunes.",
        "id":"4138",
        "question":"What do pathogens do upon infection?",
        "question_pt":"O que os pat\u00f3genos fazem ap\u00f3s a infec\u00e7\u00e3o?"
    },
    {
        "answer":"this same process also causes immunopathology when prolonged or deregulated.",
        "answer_pt":"esse mesmo processo tamb\u00e9m causa imunopatologia quando prolongado ou desregulado.",
        "id":"4139",
        "question":"What is the flip side ?",
        "question_pt":"Qual \u00e9 o outro lado?"
    },
    {
        "answer":"post-transcriptionally control expression of crucial inflammatory factors in various tissues and their potential therapeutic applications",
        "answer_pt":"controle p\u00f3s-transcricional da express\u00e3o de fatores inflamat\u00f3rios cruciais em v\u00e1rios tecidos e suas poss\u00edveis aplica\u00e7\u00f5es terap\u00eauticas",
        "id":"4140",
        "question":"What do RBPs do?",
        "question_pt":"O que os RBPs fazem?"
    },
    {
        "answer":"tristetraprolin and AUF1",
        "answer_pt":"tristetraprolina e AUF1",
        "id":"4141",
        "question":"What is included in RBPs?",
        "question_pt":"O que est\u00e1 inclu\u00eddo nos RBPs?"
    },
    {
        "answer":"promote degradation of AU-rich element (ARE)-containing mRNA",
        "answer_pt":"promover a degrada\u00e7\u00e3o do mRNA contendo elemento rico em AU (ARE)",
        "id":"4142",
        "question":"What  do  tristetraprolin and AUF1, do?",
        "question_pt":"O que o tristetraprolin e o AUF1 fazem?"
    },
    {
        "answer":"members of the Roquin and Regnase families",
        "answer_pt":"membros das fam\u00edlias Roquin e Regnase",
        "id":"4143",
        "question":"What do RBPs include?",
        "question_pt":"O que os RBPs incluem?"
    },
    {
        "answer":"promote or effect degradation of mRNAs harbouring stem-loop structures",
        "answer_pt":"promover ou afetar a degrada\u00e7\u00e3o de mRNAs que abrigam estruturas de loop-tronco",
        "id":"4144",
        "question":"What domembers of the Roquin and Regnase families do?",
        "question_pt":"O que os membros das fam\u00edlias Roquin e Regnase fazem?"
    },
    {
        "answer":"RNA methylation machinery",
        "answer_pt":"M\u00e1quinas de metila\u00e7\u00e3o de RNA",
        "id":"4145",
        "question":"What do the RBPs include?",
        "question_pt":"O que os RBPs incluem?"
    },
    {
        "answer":"in controlling inflammatory mRNA stability.",
        "answer_pt":"no controle da estabilidade inflamat\u00f3ria do mRNA.",
        "id":"4146",
        "question":"What is the increasingly apparent role of RNA methylation machinery ?",
        "question_pt":"Qual \u00e9 o papel cada vez mais aparente das m\u00e1quinas de metila\u00e7\u00e3o de RNA?"
    },
    {
        "answer":" in various subcellular compartments ",
        "answer_pt":"em v\u00e1rios compartimentos subcelulares",
        "id":"4147",
        "question":"Where do these activities take place?",
        "question_pt":"Onde essas atividades ocorrem?"
    },
    {
        "answer":"are differentially regulated",
        "answer_pt":"s\u00e3o regulados diferencialmente",
        "id":"4148",
        "question":"What happens to these activities during infection?",
        "question_pt":"O que acontece com essas atividades durante a infec\u00e7\u00e3o?"
    },
    {
        "answer":"a 'brake' on the immune system",
        "answer_pt":"um 'freio' no sistema imunol\u00f3gico",
        "id":"4149",
        "question":" In this way, what do the mRNA-destabilising RBPs constitute ?",
        "question_pt":"Dessa maneira, o que constituem os RBPs desestabilizadores de mRNA?"
    },
    {
        "answer":"may ultimately be toggled therapeutically",
        "answer_pt":"pode finalmente ser alternado terapeuticamente",
        "id":"4150",
        "question":"What can be  done with the  'brake' on the immune system?",
        "question_pt":"O que pode ser feito com o 'freio' no sistema imunol\u00f3gico?"
    },
    {
        "answer":"Another mRNA under post-transcriptional regulation by Regnase-1 and Roquin",
        "answer_pt":"Outro mRNA sob regula\u00e7\u00e3o p\u00f3s-transcricional por Regnase-1 e Roquin",
        "id":"4151",
        "question":"What does the author anticipate that continued efforts will lead to?",
        "question_pt":"O que o autor prev\u00ea que esfor\u00e7os cont\u00ednuos levar\u00e3o a?"
    },
    {
        "answer":" Furin",
        "answer_pt":"Furin",
        "id":"4152",
        "question":"What is another mRNA under post-transcriptional regulation by Regnase-1 and Roquin?",
        "question_pt":"O que \u00e9 outro mRNA sob regula\u00e7\u00e3o p\u00f3s-transcricional pela Regnase-1 e Roquin?"
    },
    {
        "answer":"a conserved proprotein convertase crucial in human health and disease.",
        "answer_pt":"uma proprote\u00edna convertida conservada crucial na sa\u00fade e na doen\u00e7a humana.",
        "id":"4153",
        "question":"What does Furin encode?",
        "question_pt":"O que Furin codifica?"
    },
    {
        "answer":" in immune regulation, cancer and the entry, maturation or release of a broad array of evolutionarily diverse viruses including human papillomavirus (HPV), influenza (IAV), Ebola (EboV), dengue (DenV) and human immunodeficiency virus (HIV)",
        "answer_pt":"na regula\u00e7\u00e3o imune, c\u00e2ncer e entrada, matura\u00e7\u00e3o ou libera\u00e7\u00e3o de uma ampla variedade de v\u00edrus evolutivamente diversos, incluindo papilomav\u00edrus humano (HPV), gripe (IAV), ebola (EboV), dengue (DenV) e v\u00edrus da imunodefici\u00eancia humana (HIV)",
        "id":"4154",
        "question":"What are Furin, along with other PCSK family members implicated in?",
        "question_pt":"No que Furin est\u00e1 envolvido, juntamente com outros membros da fam\u00edlia PCSK?"
    },
    {
        "answer":" the roles of furin in these processes, as well as the history and future of furin-targeting therapeutics.",
        "answer_pt":"os pap\u00e9is da furina nesses processos, bem como a hist\u00f3ria e o futuro da terap\u00eautica direcionada \u00e0 furina.",
        "id":"4155",
        "question":"What do Braun and Sauter review?",
        "question_pt":"O que Braun e Sauter avaliam?"
    },
    {
        "answer":"how two IFN-cinducible factors exhibit broad-spectrum inhibition of IAV, measles (MV), zika (ZikV) and HIV by suppressing furin activity.",
        "answer_pt":"como dois fatores cindut\u00edveis ao IFN exibem inibi\u00e7\u00e3o de amplo espectro do IAV, sarampo (VM), zika (ZikV) e HIV, suprimindo a atividade da furina.",
        "id":"4156",
        "question":"What dis their recent work reveal?",
        "question_pt":"O que o trabalho recente deles revelou?"
    },
    {
        "answer":" a recent boom in metagenomics and the cataloguing of the microbiome of our world.",
        "answer_pt":"um recente boom na metagen\u00f4mica e na cataloga\u00e7\u00e3o do microbioma do nosso mundo.",
        "id":"4157",
        "question":"What has the increasing abundance of affordable, sensitive, high-throughput genome sequencing technologies  led to?",
        "question_pt":"O que levou a crescente abund\u00e2ncia de tecnologias de sequenciamento de genoma acess\u00edveis, sens\u00edveis e de alto rendimento?"
    },
    {
        "answer":" to directly sequence an RNA virus genome (IAV)",
        "answer_pt":"sequenciar diretamente um genoma do v\u00edrus RNA (IAV)",
        "id":"4160",
        "question":"What was this system used for the first time for?",
        "question_pt":"Para que esse sistema foi usado pela primeira vez?"
    },
    {
        "answer":"a near-complete picture of the main armaments in the human antiviral arsenal. ",
        "answer_pt":"uma imagem quase completa dos principais armamentos no arsenal antiviral humano.",
        "id":"4161",
        "question":"What have decades of basic immunology research  provided ?",
        "question_pt":"O que forneceram d\u00e9cadas de pesquisa b\u00e1sica em imunologia?"
    },
    {
        "answer":"examination of the types and roles of viruses and antiviral defences that exist throughout our biosphere.",
        "answer_pt":"exame dos tipos e pap\u00e9is de v\u00edrus e defesas antivirais existentes em toda a nossa biosfera.",
        "id":"4162",
        "question":"What has this focus on mammalian defences and pathologies sidelined?",
        "question_pt":"O que esse foco nas defesas e patologias dos mam\u00edferos deixou de lado?"
    },
    {
        "answer":"as a revolutionary gene-editing biotechnology in plants and animals.",
        "answer_pt":"como uma biotecnologia revolucion\u00e1ria de edi\u00e7\u00e3o de genes em plantas e animais.",
        "id":"4163",
        "question":"What has CRISPR/Cas antiviral immune system of prokaryotes been repurposed as?",
        "question_pt":"Como foi reaproveitado o sistema imunol\u00f3gico antiviral de CRISPR / Cas?"
    },
    {
        "answer":"the ancient lineage of nucleocytosolic large DNA viruses (NCLDVs)",
        "answer_pt":"a linhagem antiga de v\u00edrus nucleocitos\u00f3licos de DNA grande (NCLDVs)",
        "id":"4164",
        "question":"What is another  case in point?",
        "question_pt":"Qual \u00e9 outro caso em quest\u00e3o?"
    },
    {
        "answer":"emerging human pathogens that possess enormous genomes of up to several megabases in size encoding hundreds of proteins with unique and unknown functions.",
        "answer_pt":"pat\u00f3genos humanos emergentes que possuem genomas enormes de at\u00e9 v\u00e1rias megabases em tamanho, codificando centenas de prote\u00ednas com fun\u00e7\u00f5es \u00fanicas e desconhecidas.",
        "id":"4165",
        "question":"What are the ancient lineage of NCLDVs?\n",
        "question_pt":"Quais s\u00e3o as linhagens antigas dos NCLDVs?"
    },
    {
        "answer":" the true number may be in the millions and many harbour zoonotic potential. ",
        "answer_pt":"o n\u00famero verdadeiro pode estar na casa dos milh\u00f5es e muitos abrigam o potencial zoon\u00f3tico.",
        "id":"4166",
        "question":"What do the recent efforts indicate regarding hundreds of human and avian infectious viruses?",
        "question_pt":"O que os recentes esfor\u00e7os indicam em rela\u00e7\u00e3o a centenas de v\u00edrus infecciosos humanos e avi\u00e1rios?"
    },
    {
        "answer":" an emerging field engaged in cataloguing and characterising this biodiversity through a global consortium.",
        "answer_pt":"um campo emergente envolvido na cataloga\u00e7\u00e3o e caracteriza\u00e7\u00e3o dessa biodiversidade por meio de um cons\u00f3rcio global.",
        "id":"4167",
        "question":"What is neo-virology?",
        "question_pt":"O que \u00e9 neo-virologia?"
    },
    {
        "answer":"a vast wealth of currently unexplored biodiversity, leading to biotechnologies and treatments that leverage the host-virus interactions developed throughout evolution.",
        "answer_pt":"uma vasta riqueza de biodiversidade atualmente inexplorada, levando a biotecnologias e tratamentos que alavancam as intera\u00e7\u00f5es v\u00edrus-hospedeiro desenvolvidas ao longo da evolu\u00e7\u00e3o.",
        "id":"4168",
        "question":"What is predicted these efforts on neo-virology will unlock?",
        "question_pt":"O que \u00e9 previsto que esses esfor\u00e7os em neo-virologia ir\u00e3o desbloquear?"
    },
    {
        "answer":"Supporting industry-academia collaboration and nurturing talent and skills in the Indo-Pacific region",
        "answer_pt":"Apoiando a colabora\u00e7\u00e3o ind\u00fastria-academia e fomentando talentos e habilidades na regi\u00e3o Indo-Pac\u00edfico",
        "id":"4169",
        "question":"What are the two of the four pillars of the National Innovation and Science Agenda?",
        "question_pt":"Quais s\u00e3o os dois dos quatro pilares da Agenda Nacional de Inova\u00e7\u00e3o e Ci\u00eancia?"
    },
    {
        "answer":"antimicrobial resistance, global health and health security, drug repurposing and translational research infrastructure,",
        "answer_pt":"resist\u00eancia antimicrobiana, sa\u00fade global e seguran\u00e7a da sa\u00fade, redirecionamento de medicamentos e infraestrutura de pesquisa translacional,",
        "id":"4170",
        "question":"What do Australia's Medical Research and Innovation Priorities include?",
        "question_pt":"O que incluem as prioridades de pesquisa e inova\u00e7\u00e3o m\u00e9dica da Austr\u00e1lia?"
    },
    {
        "answer":"Establishing durable international relationships that integrate diverse expertise",
        "answer_pt":"Estabelecendo rela\u00e7\u00f5es internacionais dur\u00e1veis \u200b\u200bque integram diversos conhecimentos",
        "id":"4171",
        "question":"What is essential for these priority outcomes?",
        "question_pt":"O que \u00e9 essencial para esses resultados priorit\u00e1rios?"
    },
    {
        "answer":"translating the biomedical research output of that country.",
        "answer_pt":"traduzindo a produ\u00e7\u00e3o de pesquisa biom\u00e9dica desse pa\u00eds.",
        "id":"4172",
        "question":"What is the Japan AMED tasked with?",
        "question_pt":"Com o que a AMED do Jap\u00e3o \u00e9 encarregada?"
    },
    {
        "answer":"as to whether or not our seasonal or pandemic flu might have another reservoir host.",
        "answer_pt":"se nossa gripe sazonal ou pand\u00eamica pode ou n\u00e3o ter outro hospedeiro no reservat\u00f3rio.",
        "id":"3847",
        "question":"What serious question was raised?",
        "question_pt":"Que pergunta s\u00e9ria foi levantada?"
    },
    {
        "answer":"Bat is believed to harbor many more viruses than we ever thought as a reservoir host or even a susceptible host ",
        "answer_pt":"Acredita-se que o morcego abrigue muito mais v\u00edrus do que se pensava como hospedeiro de reservat\u00f3rio ou at\u00e9 como hospedeiro suscet\u00edvel",
        "id":"3848",
        "question":"What is a recent discovery?",
        "question_pt":"O que \u00e9 uma descoberta recente?"
    },
    {
        "answer":"potential human infecting HKU-1, 4, 5 and 9 [17, 18] . Recent MERS-CoV infection is another example for severe disease caused by used-to-be-less pathogenic coronaviruses. Shi and colleagues [19] by using NGS have discovered many unknown animal viruses from bat, especially some important paramyxoviruses and reoviruses. Filovirus has also been identified in bat with potential severe outcomes. Lyssaviruses (with many genotypes, including rabies virus) in the Rhabdoviridae family have been linked with severe fatal human cases, even in the developed countries, including Australia, with the bites of bats in the city [20, 21] .",
        "answer_pt":"potencial humano infectando HKU-1, 4, 5 e 9 [17, 18]. A infec\u00e7\u00e3o recente por MERS-CoV \u00e9 outro exemplo de doen\u00e7a grave causada por coronav\u00edrus patog\u00eanicos menos usados. Shi e colegas [19] usando o NGS descobriram muitos v\u00edrus animais desconhecidos do morcego, especialmente alguns paramixov\u00edrus e reov\u00edrus importantes. O filov\u00edrus tamb\u00e9m foi identificado em morcegos com poss\u00edveis resultados graves. Os lisav\u00edrus (com muitos gen\u00f3tipos, incluindo o v\u00edrus da raiva) na fam\u00edlia Rhabdoviridae t\u00eam sido associados a casos humanos fatais graves, mesmo nos pa\u00edses desenvolvidos, incluindo a Austr\u00e1lia, com picadas de morcegos na cidade [20, 21].",
        "id":"3849",
        "question":"Which bat virus have been found to be linked with diseases?",
        "question_pt":"Qual v\u00edrus morcego foi encontrado para ser associado a doen\u00e7as?"
    },
    {
        "answer":"reverse transcription polymerase chain reaction (RT-PCR)",
        "answer_pt":"rea\u00e7\u00e3o em cadeia da polimerase com transcri\u00e7\u00e3o reversa (RT-PCR)",
        "id":"3850",
        "question":"What assay played an important role?",
        "question_pt":"Qual ensaio teve um papel importante?"
    },
    {
        "answer":"50 million deaths worldwide",
        "answer_pt":"50 milh\u00f5es de mortes em todo o mundo",
        "id":"1057",
        "question":"What was the death toll in the 1918-1919 Spanish Influenza epidemic?",
        "question_pt":"Qual foi o n\u00famero de mortos na epidemia de gripe espanhola de 1918-1919?"
    },
    {
        "answer":"An estimated one third of the world\u2019s population (or\nz500 million persons) were infected and had clinical-\nly apparent illnesses",
        "answer_pt":"Estima-se que um ter\u00e7o da popula\u00e7\u00e3o mundial (ou\nz500 milh\u00f5es de pessoas) foram infectadas e tiveram\ndoen\u00e7as aparentemente aparentes",
        "id":"1058",
        "question":"How many people were infected during the 1918 Spanish Influenza epidemic?",
        "question_pt":"Quantas pessoas foram infectadas durante a epidemia de gripe espanhola de 1918?"
    },
    {
        "answer":"Case-\nfatality rates were >2.5%, compared to <0.1% in other\nin\ufb02uenza pandemics",
        "answer_pt":"Caso-\ntaxas de mortalidade foram> 2,5%, em compara\u00e7\u00e3o com <0,1% em outros\npandemias de gripe",
        "id":"1059",
        "question":"What was the case fatality rate in the 1918 Spanish Influenza epidemic?",
        "question_pt":"Qual foi a taxa de mortalidade na epidemia de influenza espanhola de 1918?"
    },
    {
        "answer":"Total deaths were estimated at\nz50 million (577) and were arguably as high as 100 mil-\nlion ",
        "answer_pt":"O total de mortes foi estimado em\nz50 milh\u00f5es (577) e eram indiscutivelmente t\u00e3o altos quanto\nle\u00e3o",
        "id":"1060",
        "question":"What was the death toll in the 1918-1919 Spanish Influenza epidemic?",
        "question_pt":"Qual foi o n\u00famero de mortos na epidemia de gripe espanhola de 1918-1919?"
    },
    {
        "answer":" All in\ufb02uenza A pandemics since that time, and\nindeed almost all cases of in\ufb02uenza A worldwide (except-\ning human infections from avian Viruses such as H5N1 and\nH7N7), have been caused by descendants of the 1918\nVirus, including \u201cdrifted\u201d H1N1 Viruses and reassorted\nH2N2 and H3N2 Viruses.",
        "answer_pt":"Todas as pandemias de gripe A desde aquela \u00e9poca e\nna verdade, quase todos os casos de gripe A em todo o mundo (exceto\ninfec\u00e7\u00f5es humanas por v\u00edrus avi\u00e1rios como o H5N1 e\nH7N7), foram causados \u200b\u200bpor descendentes de 1918\nV\u00edrus, incluindo v\u00edrus H1N1 \"desviados\" e reagrupados\nV\u00edrus H2N2 e H3N2.",
        "id":"1062",
        "question":"Are the modern day Influenza viruses related to the 1918 Spanish Influenza virus?",
        "question_pt":"Os v\u00edrus da gripe modernos est\u00e3o relacionados ao v\u00edrus da gripe espanhola de 1918?"
    },
    {
        "answer":"The latter are composed of key\ngenes from the 1918 Virus, updated by subsequently-incor\u2014\nporated avian in\ufb02uenza genes that code for novel surface\n\n \n\n*Armed Forces Institute of Pathology, Rockville, Maryland, USA;\nand TNational Institutes of Health, Bethesda, Maryland, USA\n\nproteins, making the 1918 Virus indeed the \u201cmother\u201d of all\npandemics.",
        "answer_pt":"Estes \u00faltimos s\u00e3o compostos por\ngenes do v\u00edrus de 1918, atualizados por subsequentemente\ngenes da gripe avi\u00e1ria porados que codificam novas superf\u00edcies\n\n \n\n* Instituto de Patologia das For\u00e7as Armadas, Rockville, Maryland, EUA;\ne TNational Institutes of Health, Bethesda, Maryland, EUA\n\nprote\u00ednas, tornando o v\u00edrus de 1918 de fato a \u201cm\u00e3e\u201d de todos\npandemias.",
        "id":"1063",
        "question":"Why is the Spanish Influenza virus the Mother of the modern influenza viruses?",
        "question_pt":"Por que o v\u00edrus da gripe espanhola \u00e9 a m\u00e3e dos modernos v\u00edrus da gripe?"
    },
    {
        "answer":"That question did not begin to be resolved until the 1930s,\nwhen closely related in\ufb02uenza Viruses (now known to be\nH1N1 Viruses) were isolated, \ufb01rst from pigs and shortly\nthereafter from humans. Seroepidemiologic studies soon\nlinked both of these viruses to the 1918 pandemic",
        "answer_pt":"Essa quest\u00e3o n\u00e3o come\u00e7ou a ser resolvida at\u00e9 a d\u00e9cada de 1930,\nv\u00edrus da gripe intimamente relacionados (agora conhecidos por\nV\u00edrus H1N1) foram isolados, primeiro de porcos e logo\nposteriormente a partir de seres humanos. Estudos soroepidemiol\u00f3gicos em breve\nvinculou esses dois v\u00edrus \u00e0 pandemia de 1918",
        "id":"1064",
        "question":"When was it  determined that the 1918  pandemic was caused by the H1N1 Influenza virus?",
        "question_pt":"Quando foi determinado que a pandemia de 1918 foi causada pelo v\u00edrus da influenza H1N1?"
    },
    {
        "answer":" descendants of the 1918\nVirus still persists enzootically in pigs. They probably also\ncirculated continuously in humans, undergoing gradual\nantigenic drift and causing annual epidemics, until the\n1950s. With the appearance of a new H2N2 pandemic\nstrain in 1957 (\u201cAsian \ufb02u\u201d), the direct H1N1 Viral descen-\ndants 0f the 1918 pandemic strain disappeared from human\ncirculation entirely, although the related lineage persisted\nenzootically in pigs.",
        "answer_pt":"descendentes de 1918\nO v\u00edrus ainda persiste enzooticamente em porcos. Eles provavelmente tamb\u00e9m\ncirculavam continuamente em seres humanos, passando por\nderiva antig\u00eanica e causando epidemias anuais, at\u00e9 a\n1950s. Com o surgimento de uma nova pandemia de H2N2\nem 1957 (\u201cgripe asi\u00e1tica\u201d), o v\u00edrus H1N1 viral direto\n0f da pandemia de 1918 desapareceu do ser humano\ncircula\u00e7\u00e3o, embora a linhagem relacionada persistisse\nenzooticamente em porcos.",
        "id":"1065",
        "question":"Did the Spanish Influenza or Swine flu or the H1N1 virus disappear in humans for some time?",
        "question_pt":"A gripe espanhola ou a gripe su\u00edna ou o v\u00edrus H1N1 desapareceram em humanos por algum tempo?"
    },
    {
        "answer":" But in 1977, human H1N1 Viruses\nsuddenly \u201creemerged\u201d from a laboratory freezer (9). They\ncontinue to circulate endemically and epidemically.",
        "answer_pt":"Mas em 1977, os v\u00edrus H1N1 humanos\nde repente \"ressurgiu\" de um freezer de laborat\u00f3rio (9). Eles\ncontinuar a circular endemicamente e epidemicamente.",
        "id":"1066",
        "question":"When did the Swine Flu (Spanish Influenza) virus reappear in humans?",
        "question_pt":"Quando o v\u00edrus da gripe su\u00edna (gripe espanhola) reapareceu em humanos?"
    },
    {
        "answer":" 2 major descendant lineages of the 1918\nH1N1 Virus, as well as 2 additional reassortant lineages,\npersist naturally: a human epidemic/endemic H1N1 line-\nage, a porcine enzootic H1N1 lineage (so-called classic\nswine \ufb02u), and the reassorted human H3N2 Virus lineage,\nwhich like the human H1N1 Virus, has led to a porcine\nH3N2 lineage.",
        "answer_pt":"2 principais linhagens descendentes de 1918\nV\u00edrus H1N1, bem como 2 linhagens recombinantes adicionais,\npersistir naturalmente: uma epidemia humana / linhagem H1N1 end\u00eamica\nidade, uma linhagem H1N1 enzo\u00f3tica porcina (denominada\ngripe su\u00edna) e a linhagem humana do v\u00edrus H3N2\nque, como o v\u00edrus H1N1 humano, levou a um su\u00edno\nLinhagem H3N2.",
        "id":"1068",
        "question":"What descendant  lineages of the swine flu (Spanish Influenza) virus were identified in 2006?",
        "question_pt":"Quais linhagens descendentes do v\u00edrus da gripe su\u00edna (gripe espanhola) foram identificadas em 2006?"
    },
    {
        "answer":"None of these Viral descendants, however,\napproaches the pathogenicity of the 1918 parent Virus.",
        "answer_pt":"Nenhum desses descendentes virais, no entanto,\naborda a patogenicidade do v\u00edrus pai de 1918.",
        "id":"1070",
        "question":"Are the modern descendant influenza viruses as dangerous as the 1918 parent swine flu (Spanish Influenza) H1N1 virus?",
        "question_pt":"Os v\u00edrus influenza descendente moderno s\u00e3o t\u00e3o perigosos quanto o v\u00edrus H1N1 da gripe su\u00edna parental de 1918?"
    },
    {
        "answer":"the human H1N1 and H3N2 lin-\neages have both been associated with substantially lower\nrates ofillness and death than the virus of 1918. In fact, cur-\nrent H1N1 death rates are even lower than those for H3N2\nlineage strains (prevalent from 1968 until the present).",
        "answer_pt":"as linhagens humanas H1N1 e H3N2\nas \u00e1guias t\u00eam sido associadas a n\u00edveis substancialmente mais baixos\ntaxas de doen\u00e7a e morte do que o v\u00edrus de 1918. De fato,\nAs taxas de mortalidade por aluguel H1N1 s\u00e3o ainda mais baixas que as do H3N2\nlinhagens de linhagem (predominantes de 1968 at\u00e9 o presente).",
        "id":"1072",
        "question":"How dangerous are the modern H1N1 (swine flu) and the H3N2 (Influenza A) viruses compared  to the 1918 H1N1 (swine flu Spanish Influenza)  viruses?",
        "question_pt":"Qu\u00e3o perigosos s\u00e3o os v\u00edrus modernos H1N1 (gripe su\u00edna) e H3N2 (Influenza A) em compara\u00e7\u00e3o com os v\u00edrus H1N1 de 1918 (gripe su\u00edna)?"
    },
    {
        "answer":"H1N1 Viruses descended from the 1918 strain, as well as \nH3N2 Viruses, have now been cocirculating worldwide for\n29 years and show little evidence of imminent extinction.",
        "answer_pt":"Os v\u00edrus H1N1 descenderam da cepa de 1918, bem como\nV\u00edrus H3N2, agora t\u00eam co-circulado mundialmente por\n29 anos e mostram poucas evid\u00eancias de extin\u00e7\u00e3o iminente.",
        "id":"1073",
        "question":"Are the descendant H1N1 strains of the 1918 H1N1 swine flu (Spanish Influenza) virus, still prevalent?",
        "question_pt":"As cepas H1N1 descendentes do v\u00edrus da gripe su\u00edna H1N1 de 1918 (influenza espanhola) ainda prevalecem?"
    },
    {
        "answer":"ongoing studies to map Virulence\nfactors are yielding interesting results. The 1918 sequence\ndata, however, leave unanswered questions about the ori-\ngin of the Virus (19) and about the epidemiology of the\npandemic.",
        "answer_pt":"estudos em andamento para mapear Virul\u00eancia\nfatores est\u00e3o produzindo resultados interessantes. A sequ\u00eancia de 1918\ndados, no entanto, deixam perguntas sem resposta sobre a orienta\u00e7\u00e3o\ndo v\u00edrus (19) e sobre a epidemiologia do v\u00edrus\npandemia.",
        "id":"1075",
        "question":"Is the origin and epidemiology of the 1918 swine flu (Spanish Influenza) known?",
        "question_pt":"A origem e a epidemiologia da gripe su\u00edna de 1918 (gripe espanhola) s\u00e3o conhecidas?"
    },
    {
        "answer":"Historical and epidemiologic data are inade-\nquate to identify the geographic origin of the Virus (21),\nand recent phylogenetic analysis of the 1918 Viral genome\ndoes not place the Virus in any geographic context",
        "answer_pt":"Dados hist\u00f3ricos e epidemiol\u00f3gicos s\u00e3o inating\u00edveis.\npara identificar a origem geogr\u00e1fica do v\u00edrus (21),\ne an\u00e1lise filogen\u00e9tica recente do genoma viral de 1918\nn\u00e3o coloca o v\u00edrus em nenhum contexto geogr\u00e1fico",
        "id":"1082",
        "question":"What is the geographical origin of the H1N1 swine flu ?",
        "question_pt":"Qual \u00e9 a origem geogr\u00e1fica da gripe su\u00edna H1N1?"
    },
    {
        "answer":"Confounding de\ufb01nite assignment of a geographic\npoint of origin, the 1918 pandemic spread more or less\nsimultaneously in 3 distinct waves during an z12-month\nperiod in 191871919, in Europe, Asia, and North America\n(the \ufb01rst wave was best described in the United States in\nMarch 1918)",
        "answer_pt":"Atribui\u00e7\u00e3o definitiva e confusa de uma regi\u00e3o geogr\u00e1fica\norigem, a pandemia de 1918 se espalhou mais ou menos\nsimultaneamente em 3 ondas distintas durante um per\u00edodo de 12 meses\nper\u00edodo de 191871919, na Europa, \u00c1sia e Am\u00e9rica do Norte\n(a primeira onda foi melhor descrita nos Estados Unidos em\nMar\u00e7o de 1918)",
        "id":"1087",
        "question":"Is the geographical origin of the 1918 H1N1 swine flu known?",
        "question_pt":"A origem geogr\u00e1fica da gripe su\u00edna H1N1 de 1918 \u00e9 conhecida?"
    },
    {
        "answer":"the simultaneous (or nearly simultaneous) infection\nof humans and swin",
        "answer_pt":"a infec\u00e7\u00e3o simult\u00e2nea (ou quase simult\u00e2nea)\nde seres humanos e swin",
        "id":"1088",
        "question":"What is an unique feature of the 1918 swine flu?",
        "question_pt":"Qual \u00e9 uma caracter\u00edstica \u00fanica da gripe su\u00edna de 1918?"
    },
    {
        "answer":"Historical records since the 16th century suggest that\nnew in\ufb02uenza pandemics may appear at any time of year,\nnot necessarily in the familiar annual winter patterns of\ninterpandemic years,",
        "answer_pt":"Registros hist\u00f3ricos desde o s\u00e9culo XVI sugerem que\nnovas pandemias de gripe podem aparecer em qualquer \u00e9poca do ano,\nn\u00e3o necessariamente nos padr\u00f5es familiares de inverno anuais de\nanos interpand\u00eamicos,",
        "id":"1089",
        "question":"What season or  time of the year do the new strains of influenza emerge?",
        "question_pt":"Em que esta\u00e7\u00e3o ou \u00e9poca do ano surgem as novas cepas de influenza?"
    },
    {
        "answer":"confronted by the selection pressures of population immu-\nnity, these pandemic Viruses begin to drift genetically and\neventually settle into a pattern of annual epidemic recur-\nrences caused by the drifted Virus variants.",
        "answer_pt":"confrontados com as press\u00f5es de sele\u00e7\u00e3o dos imigrantes\nesses v\u00edrus pand\u00eamicos come\u00e7am a derivar geneticamente e\nacabar\u00e1 por se estabelecer em um padr\u00e3o de recorr\u00eancia anual de epidemias.\nconseq\u00fc\u00eancias causadas pelas variantes de v\u00edrus derivadas.",
        "id":"1090",
        "question":"Once appeared, when do the influenza like diseases occur in subsequent years?",
        "question_pt":"Quando apareceu, quando ocorrem doen\u00e7as semelhantes \u00e0 gripe nos anos subsequentes?"
    },
    {
        "answer":" a \ufb01rst or spring wave\nbegan in March 1918 and spread unevenly through the\nUnited States, Europe, and possibly Asia over the next 6\nmonths",
        "answer_pt":"primeira onda ou mola\ncome\u00e7ou em mar\u00e7o de 1918 e se espalhou desigualmente pelo\nEstados Unidos, Europa e possivelmente \u00c1sia nos pr\u00f3ximos 6\nmeses",
        "id":"1091",
        "question":"When did the first wave of the H1N1 swine flu (Spanish Influenza) occur?",
        "question_pt":"Quando ocorreu a primeira onda da gripe su\u00edna H1N1 (influenza espanhola)?"
    },
    {
        "answer":" Illness rates were high, but death rates\nin most locales were not appreciably above normal.",
        "answer_pt":"As taxas de doen\u00e7as eram altas, mas as taxas de mortalidade\nna maioria das localidades n\u00e3o estavam sensivelmente acima do normal.",
        "id":"1092",
        "question":"What was the death rate in the first wave of the 1918 swine flu pandemic?",
        "question_pt":"Qual foi a taxa de mortalidade na primeira onda da pandemia de gripe su\u00edna de 1918?"
    },
    {
        "answer":" A sec-\nond or fall wave spread globally from September to\nNovember 1918 and was highly fatal. In many nations, a\nthird wave occurred in early 1919 ",
        "answer_pt":"Um segundo-\nonda do mundo se espalhou globalmente de setembro a\nNovembro de 1918 e foi altamente fatal. Em muitas na\u00e7\u00f5es, um\nterceira onda ocorreu no in\u00edcio de 1919",
        "id":"1093",
        "question":"When were the second and the third wave of the 1918-1919 swine flu pandemic?",
        "question_pt":"Quando foram a segunda e a terceira onda da pandemia de gripe su\u00edna de 1918-1919?"
    },
    {
        "answer":"the much higher fre-\nquency of complicated, severe, and fatal cases in the last 2\nwaves.",
        "answer_pt":"a frequ\u00eancia muito maior de casos complicados, graves e fatais nos \u00faltimos 2\nondas.",
        "id":"1094",
        "question":"What was the primary difference between the first wave and the 2nd and 3rd wave of the 1918-1919 swine flu pandemic?",
        "question_pt":"Qual foi a principal diferen\u00e7a entre a primeira onda e a 2\u00aa e a 3\u00aa onda da pandemia de gripe su\u00edna de 1918-1919?"
    },
    {
        "answer":"The occurrence, and to some extent the severity, of recur-\nrent annual outbreaks, are driven by Viral antigenic drift,\nwith an antigenic variant Virus emerging to become domi-\nnant",
        "answer_pt":"A ocorr\u00eancia, e at\u00e9 certo ponto a gravidade, de recorr\u00eancias\nsurtos anuais de aluguel, s\u00e3o impulsionados pela deriva antig\u00eanica viral,\ncom um v\u00edrus variante antig\u00eanico emergindo para se tornar dominante\nnant",
        "id":"1096",
        "question":"Why the human influenza viruses do not disappear after herd immunity is developed?",
        "question_pt":"Por que os v\u00edrus da gripe humana n\u00e3o desaparecem ap\u00f3s o desenvolvimento da imunidade do rebanho?"
    },
    {
        "answer":" lower environ-\nmental temperatures and human nasal temperatures (bene-\n\ufb01cial to thermolabile Viruses such as in\ufb02uenza), optimal\nhumidity, increased crowding indoors, and imperfect ven-\ntilation due to closed windows and suboptimal air\ufb02ow",
        "answer_pt":"ambiente mais baixo\ntemperaturas mentais e nasais humanas (ben\u00e9ficas\nvirais termol\u00e1beis, como a gripe), ideal\numidade, aumento de aglomera\u00e7\u00e3o em ambientes fechados e ventila\u00e7\u00e3o imperfeita.\nventila\u00e7\u00e3o devido a janelas fechadas e fluxo de ar abaixo do ideal",
        "id":"1099",
        "question":"What are the circumstances that promote the spread of influenza virus?",
        "question_pt":"Quais s\u00e3o as circunst\u00e2ncias que promovem a dissemina\u00e7\u00e3o do v\u00edrus influenza?"
    },
    {
        "answer":"such factors cannot explain the 3 pandemic\nwaves of 1918-1919, which occurred in the spring-sum-\nmer, summer\u2014fall, and winter (of the Northern\nHemisphere), respectively. The \ufb01rst 2 waves occurred at a\ntime of year normally unfavorable to in\ufb02uenza Virus\nspread. The second wave caused simultaneous outbreaks\nin the Northern and Southern Hemispheres from\nSeptember to November. ",
        "answer_pt":"tais fatores n\u00e3o podem explicar as tr\u00eas pandemias\nondas de 1918-1919, ocorridas na primavera-ver\u00e3o\nver\u00e3o, outono e inverno (das regi\u00f5es norte\nHemisf\u00e9rio), respectivamente. As duas primeiras ondas ocorreram em um\n\u00e9poca do ano normalmente desfavor\u00e1vel ao v\u00edrus da gripe\npropaga\u00e7\u00e3o. A segunda onda causou surtos simult\u00e2neos\nnos hemisf\u00e9rios norte e sul de\nSetembro a novembro.",
        "id":"1101",
        "question":"Do seasonal temperatures and humidity explain  the appearance of the three waves of the 1918 swine flu?",
        "question_pt":"As temperaturas e a umidade sazonais explicam a apar\u00eancia das tr\u00eas ondas da gripe su\u00edna de 1918?"
    },
    {
        "answer":"pandemic Virus samples we have\nyet identi\ufb01ed are from second-wave patients",
        "answer_pt":"amostras de v\u00edrus pand\u00eamicos que temos\nainda identificados s\u00e3o de pacientes da segunda onda",
        "id":"1105",
        "question":"Which virus samples  from the 1918 swine flu pandemic have been identified?",
        "question_pt":"Quais amostras de v\u00edrus da pandemia de gripe su\u00edna de 1918 foram identificadas?"
    },
    {
        "answer":"nothing\ncan yet be said about whether the \ufb01rst (spring) wave, or for\nthat matter, the third wave, represented circulation of the\nsame Virus or variants of it",
        "answer_pt":"nada\nainda se pode dizer se a primeira onda (primavera) ou\nNa verdade, a terceira onda representava a circula\u00e7\u00e3o do\nmesmo v\u00edrus ou variantes dele",
        "id":"1106",
        "question":"Are viruses in the first and third waves of the 1918 swine flu pandemic same or derived from the virus from the second wave of the swine flu?",
        "question_pt":"Os v\u00edrus da primeira e terceira ondas da pandemia de gripe su\u00edna de 1918 s\u00e3o iguais ou derivados do v\u00edrus da segunda onda da gripe su\u00edna?"
    },
    {
        "answer":"Viral sequence data now suggest that the entire 1918\nVirus was novel to humans in, or shortly before, 1918, and\nthat it thus was not a reassortant Virus produced from old\nexisting strains that acquired 1 or more new genes",
        "answer_pt":"Os dados da sequ\u00eancia viral agora sugerem que todo o ano de 1918\nO v\u00edrus era novo para os seres humanos em, ou pouco antes de 1918, e\nportanto, n\u00e3o era um v\u00edrus recombinante produzido a partir de\ncepas existentes que adquiriram 1 ou mais novos genes",
        "id":"1107",
        "question":"Was the 1918 swine flu virus novel to humans are was it derived from older viruses?",
        "question_pt":"O v\u00edrus da gripe su\u00edna de 1918 foi um romance para os seres humanos, derivado de v\u00edrus mais antigos?"
    },
    {
        "answer":"In\ufb02uenza Virus gene\nsequences from a number of\ufb01xed specimens ofwild birds\ncollected circa 1918 show little difference from avian\nViruses isolated today, indicating that avian Viruses likely\nundergo little antigenic change in their natural hosts even\nover long periods",
        "answer_pt":"Gene do v\u00edrus da gripe\nseq\u00fc\u00eancias de v\u00e1rios esp\u00e9cimes \ufb01 xos de aves silvestres\ncoletadas por volta de 1918 mostram pouca diferen\u00e7a em rela\u00e7\u00e3o \u00e0s aves\nV\u00edrus isolados hoje, indicando que os v\u00edrus avi\u00e1rios provavelmente\nsofrem pouca altera\u00e7\u00e3o antig\u00eanica em seus hospedeiros naturais\npor longos per\u00edodos",
        "id":"1108",
        "question":"Do avian flu viruses change over long periods?",
        "question_pt":"Os v\u00edrus da gripe avi\u00e1ria mudam por longos per\u00edodos?"
    },
    {
        "answer":"The curve of in\ufb02uenza deaths by age at death has histor-\nically, for at least 150 years, been U-shaped (Figure 2),\nexhibiting mortality peaks in the very young and the very\nold, with a comparatively low frequency of deaths at all\nages in between",
        "answer_pt":"A curva de mortes por influenza por idade \u00e0 morte tem historicamente\npor pelo menos 150 anos, em forma de U (Figura 2),\nexibindo picos de mortalidade em pessoas muito jovens e muito\nidade, com uma frequ\u00eancia comparativamente baixa de mortes\nidades entre",
        "id":"1109",
        "question":"What  is the typical age profile of mortality in Influenza diseases?",
        "question_pt":"Qual \u00e9 o perfil et\u00e1rio t\u00edpico da mortalidade nas doen\u00e7as influenza?"
    },
    {
        "answer":"age-speci\ufb01c death rates in the\n1918 pandemic exhibited a distinct pattern that has not been\ndocumented before or since: a \u201cW\u2014shaped\u201d curve, similar to\nthe familiar U-shaped curve but with the addition of a third\n(middle) distinct peak of deaths in young adults z20410\nyears of age",
        "answer_pt":"taxas de mortalidade espec\u00edficas por idade\nPandemia de 1918 exibiu um padr\u00e3o distinto que n\u00e3o foi\ndocumentado antes ou depois: uma curva em \u201cW\u201d, semelhante \u00e0\ncurva familiar em forma de U, mas com a adi\u00e7\u00e3o de um terceiro\npico m\u00e9dio (m\u00e9dio) de mortes em adultos jovens z20410\nanos de idade",
        "id":"1110",
        "question":"What was the age profile of mortality in the 1918 swine flu?",
        "question_pt":"Qual era o perfil et\u00e1rio da mortalidade na gripe su\u00edna de 1918?"
    },
    {
        "answer":"Persons 65 years of age in 1918 had a dispro-\nportionately high in\ufb02uenza incidence",
        "answer_pt":"As pessoas de 65 anos de idade em 1918 tiveram uma\nincid\u00eancia parcialmente alta de gripe",
        "id":"1111",
        "question":"Which age group was most susceptible to die during the 1918 swine flu pandemic?",
        "question_pt":"Qual faixa et\u00e1ria foi mais suscet\u00edvel a morrer durante a pandemia de gripe su\u00edna de 1918?"
    },
    {
        "answer":"those 5 to 14\nyears of age accounted for a disproportionate number of\nin\ufb02uenza cases, but had a much lower death rate from\nin\ufb02uenza and pneumonia than other age groups. ",
        "answer_pt":"aqueles 5 a 14\nanos representaram um n\u00famero desproporcional de\ncasos de gripe, mas teve uma taxa de mortalidade muito mais baixa\ninfluenza e pneumonia que outras faixas et\u00e1rias.",
        "id":"1112",
        "question":"What was the death rate among children during the 1918 swine flu pandemic?",
        "question_pt":"Qual foi a taxa de mortalidade entre crian\u00e7as durante a pandemia de gripe su\u00edna de 1918?"
    },
    {
        "answer":" the 1918 Virus had an intrinsically high Virulence, tem-\npered only in those patients who had been born before\n1889, e.g., because of exposure to a then-circulating Virus\ncapable of providing partial immunoprotection against the\n1918 Virus strain only in persons old enough (>35 years) to\nhave been infected during that prior era ",
        "answer_pt":"o v\u00edrus de 1918 teve uma virul\u00eancia intrinsecamente alta,\nocorreu apenas nos pacientes que nasceram antes\n1889, por exemplo, devido \u00e0 exposi\u00e7\u00e3o a um v\u00edrus que circulava na \u00e9poca\ncapaz de fornecer imunoprote\u00e7\u00e3o parcial contra a\n1918 V\u00edrus estirpe apenas em pessoas com idade suficiente (> 35 anos) para\nforam infectados durante a era anterior",
        "id":"1113",
        "question":"What theory provides partial explanation for the age-specific profile of the death rate in the 1918 swine flu pandemic?",
        "question_pt":"Que teoria fornece uma explica\u00e7\u00e3o parcial para o perfil espec\u00edfico de idade da taxa de mortalidade na pandemia de gripe su\u00edna de 1918?"
    },
    {
        "answer":" the 1918\npandemic was different in degree, but not in kind, from\nprevious and subsequent pandemics. Despite the extraordi-\nnary number of global deaths, most in\ufb02uenza cases in\n1918 (>95% in most locales in industrialized nations) were\nmild and essentially indistinguishable from in\ufb02uenza cases\ntoday. ",
        "answer_pt":"o 1918\npandemia era diferente em grau, mas n\u00e3o em esp\u00e9cie, de\npandemias anteriores e subsequentes. Apesar do extraordin\u00e1rio\nn\u00famero prim\u00e1rio de mortes globais, a maioria dos casos de gripe em\n1918 (> 95% na maioria dos locais nos pa\u00edses industrializados) foram\nleve e essencialmente indistingu\u00edvel dos casos de gripe\nhoje.",
        "id":"1114",
        "question":"Is there a difference in the pathologic feature and course of disease between modern influenza pandemics and the 1918 swine flu pandemic?",
        "question_pt":"Existe uma diferen\u00e7a na caracter\u00edstica patol\u00f3gica e no curso da doen\u00e7a entre as modernas pandemias de influenza e a pandemia de gripe su\u00edna de 1918?"
    },
    {
        "answer":"the 1918 and 1918-like Viruses would be\nas sensitive as other typical Virus strains to the Food and\nDrug Administrationiapproved antiin\ufb02uenza drugs riman-\ntadine and oseltamivir.",
        "answer_pt":"os v\u00edrus de 1918 e 1918 seriam\nt\u00e3o sens\u00edveis quanto outras cepas t\u00edpicas de v\u00edrus aos alimentos e\nDrug Administration aprovou medicamentos anti-gripe riman-\ntadine e oseltamivir.",
        "id":"1117",
        "question":"Could the 1918 swine flu virus been controlled  by modern day drugs or vaccines?",
        "question_pt":"O v\u00edrus da gripe su\u00edna de 1918 poderia ser controlado por medicamentos ou vacinas modernas?"
    },
    {
        "answer":"Clinically and pathologically, these\nhigh death rates appear to be the result of several factors,\nincluding a higher proportion of severe and complicated\ninfections of the respiratory tract, rather than involvement\nof organ systems outside the normal range of the in\ufb02uenza\nVirus. Also, the deaths were concentrated in an unusually\nyoung age group",
        "answer_pt":"Clinicamente e patologicamente, esses\naltas taxas de mortalidade parecem ser o resultado de v\u00e1rios fatores,\nincluindo uma propor\u00e7\u00e3o maior de doen\u00e7as graves e complicadas\ninfec\u00e7\u00f5es do trato respirat\u00f3rio, em vez de envolvimento\nde \u00f3rg\u00e3os fora da faixa normal da gripe\nV\u00edrus. Al\u00e9m disso, as mortes foram concentradas de forma incomum\nfaixa et\u00e1ria jovem",
        "id":"1120",
        "question":"Why was there such a high death rate in the 19118 swine flu pandemic?",
        "question_pt":"Por que houve uma taxa de mortalidade t\u00e3o alta na pandemia de gripe su\u00edna de 19118?"
    },
    {
        "answer":"While data bearing\non in\ufb02uenza Virus human cell adaptation (e.g., receptor\nbinding) are beginning to be understood at the molecular\nlevel, the basis for Viral adaptation to ef\ufb01cient human-to-\nhuman spread, the chief prerequisite for pandemic emer-\ngence, is unknown for any in\ufb02uenza Virus.",
        "answer_pt":"Enquanto os dados\nna adapta\u00e7\u00e3o das c\u00e9lulas humanas do v\u00edrus da gripe (por exemplo, receptor\nliga\u00e7\u00e3o) est\u00e3o come\u00e7ando a ser entendidos no n\u00edvel molecular\nn\u00edvel b\u00e1sico, a base para a adapta\u00e7\u00e3o viral a seres humanos\ndissemina\u00e7\u00e3o humana, o principal pr\u00e9-requisito para emerg\u00eancias pand\u00eamicas\n\u00e9 desconhecido para qualquer v\u00edrus da gripe.",
        "id":"1123",
        "question":"Is the molecular basis of human adaptation of a virus understood?",
        "question_pt":"A base molecular da adapta\u00e7\u00e3o humana de um v\u00edrus \u00e9 conhecida?"
    },
    {
        "answer":"exponential growth pattern",
        "answer_pt":"padr\u00e3o de crescimento exponencial",
        "id":"1872",
        "question":"What  was the initial growth phase pattern?",
        "question_pt":"Qual foi o padr\u00e3o inicial da fase de crescimento?"
    },
    {
        "answer":"469 (95% CI: 403&minus;540) unreported cases from 1 to 15 Januar",
        "answer_pt":"469 (95% CI: 403&minus;540) unreported cases from 1 to 15 Januar",
        "id":"1875",
        "question":"What was the result of under-reporting?",
        "question_pt":"Qual foi o resultado da subnotifica\u00e7\u00e3o?"
    },
    {
        "answer":"basic reproduction number,",
        "answer_pt":"n\u00famero b\u00e1sico de reprodu\u00e7\u00e3o,",
        "id":"1877",
        "question":"What is R0?",
        "question_pt":"O que \u00e9 R0?"
    },
    {
        "answer":"reased 21-fold (95% CI: 18",
        "answer_pt":"arrendado 21 vezes (IC 95%: 18",
        "id":"1879",
        "question":"What  is likely increase of the reporting rate after the 17th January 2020?",
        "question_pt":"Qual \u00e9 o prov\u00e1vel aumento da taxa de relat\u00f3rio ap\u00f3s 17 de janeiro de 2020?"
    },
    {
        "answer":"019-nCoV at 2.56 (95% CI",
        "answer_pt":"019-nCoV a 2,56 (IC 95%",
        "id":"1880",
        "question":"What is the estimated value of R0?",
        "question_pt":"Qual \u00e9 o valor estimado de R0?"
    },
    {
        "answer":" to have occurred during the first ha",
        "answer_pt":"ter ocorrido durante o primeiro ha",
        "id":"1881",
        "question":"What is the likely period of under-reporting?",
        "question_pt":"Qual \u00e9 o per\u00edodo prov\u00e1vel de subnotifica\u00e7\u00e3o?"
    },
    {
        "answer":"s first identified in Wuhan, China",
        "answer_pt":"s identificados pela primeira vez em Wuhan, China",
        "id":"1882",
        "question":"Where and when was 2019-nCOV first identified?",
        "question_pt":"Onde e quando o 2019-nCOV foi identificado pela primeira vez?"
    },
    {
        "answer":"ymptoms including fever, cough, and sh",
        "answer_pt":"sintomas incluindo febre, tosse e sh",
        "id":"1884",
        "question":"What  are some of the symptoms caused by the virus?",
        "question_pt":"Quais s\u00e3o alguns dos sintomas causados \u200b\u200bpelo v\u00edrus?"
    },
    {
        "answer":"sed",
        "answer_pt":"sed",
        "id":"1886",
        "question":"What was the cumulative number of reported cases by 1 January 2020?",
        "question_pt":"Qual foi o n\u00famero acumulado de casos relatados at\u00e9 1 de janeiro de 2020?"
    },
    {
        "answer":"k had resulted in 2066 (618 of them are in Wuhan) confirmed cases and 56 (45 of them were in Wuhan) deaths in ",
        "answer_pt":"k resultou em 2066 (618 deles est\u00e3o em Wuhan) casos confirmados e 56 (45 deles estavam em Wuhan) mortes em",
        "id":"1889",
        "question":"As of 26 January 2020, what had the outbreak resulted in?",
        "question_pt":"Em 26 de janeiro de 2020, em que o surto resultou?"
    },
    {
        "answer":" were reported in Thailand, Japan, Republic of Korea, Hong Kong, Taiwan, Australia, and",
        "answer_pt":"foram relatados na Tail\u00e2ndia, Jap\u00e3o, Rep\u00fablica da Cor\u00e9ia, Hong Kong, Taiwan, Austr\u00e1lia e",
        "id":"1891",
        "question":"As of 26 January 2020, what countries had sporadic cases?",
        "question_pt":"Em 26 de janeiro de 2020, quais pa\u00edses tinham casos espor\u00e1dicos?"
    },
    {
        "answer":"at there had been 4000 (95%CI: 1000-9700) cases in Wuhan with symptoms onset by 18 January 2020, and the basic reproduction number (R 0 ) was estimated at 2.6 (95",
        "answer_pt":"havia 4000 (IC 95%: 1000-9700) casos em Wuhan com in\u00edcio dos sintomas at\u00e9 18 de janeiro de 2020, e o n\u00famero b\u00e1sico de reprodu\u00e7\u00e3o (R \u200b\u200b0) foi estimado em 2,6 (95",
        "id":"1892",
        "question":"What was the result  of the Imperial College estimation?",
        "question_pt":"Qual foi o resultado da estimativa do Imperial College?"
    },
    {
        "answer":"y released by the Wuhan Municipal ",
        "answer_pt":"y divulgado pelo munic\u00edpio de Wuhan",
        "id":"1893",
        "question":"Who release the time series data from 10th  to 20th January 2020?",
        "question_pt":"Quem divulgou os dados da s\u00e9rie cronol\u00f3gica de 10 a 20 de janeiro de 2020?"
    },
    {
        "answer":", and later by the National Health C",
        "answer_pt":", e mais tarde pelo National Health C",
        "id":"1894",
        "question":"Who released the time series data from after 21st January 2020?",
        "question_pt":"Quem divulgou os dados da s\u00e9rie cronol\u00f3gica ap\u00f3s 21 de janeiro de 2020?"
    },
    {
        "answer":", the C i series, as an exponential growi",
        "answer_pt":", a s\u00e9rie C i, como um crescimento exponencial",
        "id":"1895",
        "question":"How was the epidemic curve modelled?",
        "question_pt":"Como foi modelada a curva epid\u00eamica?"
    },
    {
        "answer":", the C i series, as an exponential growin",
        "answer_pt":", a s\u00e9rie C i, como um crescimento exponencial",
        "id":"1907",
        "question":"How was the epidemic curve modeled?",
        "question_pt":"Como foi modelada a curva epid\u00eamica?"
    },
    {
        "answer":"bioinformatics analysis on a virus genome from a patient with 2019-nCoV infection and compared it with other related coronavirus genomes.",
        "answer_pt":"an\u00e1lise bioinform\u00e1tica em um genoma de v\u00edrus de um paciente com infec\u00e7\u00e3o 2019-nCoV e comparou-a com outros genomas de coronav\u00edrus relacionados.",
        "id":"3692",
        "question":"What study  is reported in this report?",
        "question_pt":"Que estudo \u00e9 relatado neste relat\u00f3rio?"
    },
    {
        "answer":"Overall, the genome of 2019-nCoV has 89% nucleotide identity with bat SARS-like-CoVZXC21 and 82% with that of human SARS-CoV. The phylogenetic trees of their orf1a/b, Spike, Envelope, Membrane and Nucleoprotein also clustered closely with those of the bat, civet and human SARS coronaviruses.",
        "answer_pt":"No geral, o genoma do 2019-nCoV possui 89% de identidade de nucleot\u00eddeos com o SARS do tipo morcego-CoVZXC21 e 82% com o do SARS-CoV humano. As \u00e1rvores filogen\u00e9ticas dos seus orf1a / b, Spike, Envelope, Membrane e Nucleoprotein tamb\u00e9m se agruparam estreitamente com as dos morav\u00edrus mortais, civet e humano SARS.",
        "id":"3693",
        "question":"How does the genome of 2019-vCOV compare with   SARS like viruses and SARS-COV?",
        "question_pt":"Como o genoma do 2019-vCOV se compara ao SARS, como v\u00edrus e SARS-COV?"
    },
    {
        "answer":"the external subdomain of Spike\u2019s receptor binding domain of 2019-nCoV shares only 40% amino acid identity with other SARS-related coronaviruses. ",
        "answer_pt":"o subdom\u00ednio externo do dom\u00ednio de liga\u00e7\u00e3o ao receptor de Spike de 2019-nCoV compartilha apenas 40% de identidade de amino\u00e1cidos com outros coronav\u00edrus relacionados \u00e0 SARS.",
        "id":"3694",
        "question":"How different is it from SARS-related viruses?",
        "question_pt":"Qual a diferen\u00e7a entre v\u00edrus relacionados \u00e0 SARS?"
    },
    {
        "answer":" its orf3b encodes a completely novel short protein. Furthermore, its new orf8 likely encodes a secreted protein with an alpha-helix, following with a beta-sheet(s) containing six strands.",
        "answer_pt":"seu orf3b codifica uma prote\u00edna curta completamente nova. Al\u00e9m disso, seu novo orf8 provavelmente codifica uma prote\u00edna secretada com uma alfa-h\u00e9lice, seguida de uma (s) folha (s) beta (s) contendo seis filamentos.",
        "id":"3695",
        "question":"What novel features does the genome have?",
        "question_pt":"Quais s\u00e3o as novas caracter\u00edsticas do genoma?"
    },
    {
        "answer":"Learning from the roles of civet in SARS and camel in MERS, hunting for the animal source of 2019-nCoV and its more ancestral virus",
        "answer_pt":"Aprendendo com os pap\u00e9is da civeta na SARS e do camelo na MERS, procurando a fonte animal de 2019-nCoV e seu v\u00edrus mais ancestral",
        "id":"3696",
        "question":" What is important for understanding the origin and evolution of this novel lineage B betacoronavirus.",
        "question_pt":"O que \u00e9 importante para entender a origem e evolu\u00e7\u00e3o desse novo betacoronav\u00edrus da linhagem B."
    },
    {
        "answer":"Coronaviruses (CoVs) are enveloped, positive-sense, single-stranded RNA viruses that belong to the subfamily Coronavirinae, family Coronavirdiae, order Nidovirales.",
        "answer_pt":"Os coronav\u00edrus (CoVs) s\u00e3o v\u00edrus de RNA de fita simples de envelope positivo, de sentido positivo, que pertencem \u00e0 subfam\u00edlia Coronavirinae, fam\u00edlia Coronavirdiae, ordem Nidovirales.",
        "id":"3697",
        "question":"What are Coronaviruses?",
        "question_pt":"O que s\u00e3o coronav\u00edrus?"
    },
    {
        "answer":"Alphacoronavirus (\u03b1CoV), Betacoronavirus (\u03b2CoV), Deltacoronavirus (\u03b4CoV), and Gammacoronavirus (\u03b3CoV) ",
        "answer_pt":"Alphacoronav\u00edrus (\u03b1CoV), Betacoronav\u00edrus (\u03b2CoV), Deltacoronav\u00edrus (\u03b4CoV) e Gammacoronav\u00edrus (\u03b3CoV)",
        "id":"3698",
        "question":"What are four generas?",
        "question_pt":"Quais s\u00e3o os quatro g\u00eaneros?"
    },
    {
        "answer":" that bats and rodents are the gene sources of most \u03b1CoVs and \u03b2CoVs, while avian species are the gene sources of most \u03b4CoVs and \u03b3CoVs.",
        "answer_pt":"que morcegos e roedores s\u00e3o as fontes g\u00eanicas da maioria dos \u03b1CoVs e \u03b2CoVs, enquanto as esp\u00e9cies avi\u00e1rias s\u00e3o as fontes g\u00eanicas da maioria dos \u03b4CoVs e \u03b3CoVs.",
        "id":"3699",
        "question":"What do  evolutionary analyses show?",
        "question_pt":"O que mostram as an\u00e1lises evolutivas?"
    },
    {
        "answer":"severe acute respiratory syndrome CoV (SARS-CoV) which emerged in China in 2002-2003 to cause a large-scale epidemic with about 8000 infections and 800 deaths, and Middle East respiratory syndrome CoV (MERS-CoV) which has caused a persistent epidemic in the Arabian Peninsula since 2012",
        "answer_pt":"s\u00edndrome respirat\u00f3ria aguda grave CoV (SARS-CoV) que surgiu na China em 2002-2003 para causar uma epidemia em larga escala com cerca de 8000 infec\u00e7\u00f5es e 800 mortes e s\u00edndrome respirat\u00f3ria do Oriente M\u00e9dio CoV (MERS-CoV) que causou uma epidemia persistente na Pen\u00ednsula Ar\u00e1bica desde 2012",
        "id":"3700",
        "question":"What are the examples that have emerged as human pathogens?",
        "question_pt":"Quais s\u00e3o os exemplos que surgiram como pat\u00f3genos humanos?"
    },
    {
        "answer":"these viruses have likely originated from bats and then jumped into another amplification mammalian host [the Himalayan palm civet (Paguma larvata) for SARS-CoV and the dromedary camel (Camelus dromedarius) for MERS-CoV] ",
        "answer_pt":"esses v\u00edrus provavelmente se originaram de morcegos e depois saltaram para outro hospedeiro mam\u00edfero de amplifica\u00e7\u00e3o [a civeta das palmeiras do Himalaia (Paguma larvata) para SARS-CoV e o camelo dromed\u00e1rio (Camelus dromedarius) para MERS-CoV]",
        "id":"3701",
        "question":"Where did these viruses originate before crossing the barrier to infect humans?",
        "question_pt":"Onde esses v\u00edrus se originaram antes de atravessar a barreira para infectar humanos?"
    },
    {
        "answer":"6 CoVs were known to infect human, including 2 \u03b1CoV (HCoV-229E and HKU-NL63) and 4 \u03b2CoV (HCoV-OC43 [ ",
        "answer_pt":"Sabe-se que 6 CoVs infectam humanos, incluindo 2 \u03b1CoV (HCoV-229E e HKU-NL63) e 4 \u03b2CoV (HCoV-OC43 [",
        "id":"3702",
        "question":"What COVs were known to infect humans before December 2019?",
        "question_pt":"Quais COVs sabiam infectar seres humanos antes de dezembro de 2019?"
    },
    {
        "answer":"self-limiting upper respiratory infections in immunocompetent hosts and occasionally lower respiratory tract infections in immunocompromised hosts and elderly ",
        "answer_pt":"infec\u00e7\u00f5es respirat\u00f3rias superiores autolimitadas em hospedeiros imunocompetentes e ocasionalmente infec\u00e7\u00f5es do trato respirat\u00f3rio inferior em hospedeiros imunocomprometidos e idosos",
        "id":"3703",
        "question":"What do HCoV-OC43 and HCoV-HKU1 cause?",
        "question_pt":"O que causam o HCoV-OC43 e o HCoV-HKU1?"
    },
    {
        "answer":" SARS-CoV (lineage B \u03b2CoV) and MERS-CoV (lineage C \u03b2CoV) may cause severe lower respiratory tract infection with acute respiratory distress syndrome and extrapulmonary manifestations, such as diarrhea, lymphopenia, deranged liver and renal function tests, and multiorgan dysfunction syndrome, among both immunocompetent and immunocompromised hosts with mortality rates of \u223c10% and \u223c35%, respectively ",
        "answer_pt":"SARS-CoV (linhagem B \u03b2CoV) e MERS-CoV (linhagem C \u03b2CoV) podem causar infec\u00e7\u00e3o grave do trato respirat\u00f3rio inferior com s\u00edndrome do desconforto respirat\u00f3rio agudo e manifesta\u00e7\u00f5es extrapulmonares, como diarr\u00e9ia, linfopenia, testes de fun\u00e7\u00e3o renal e hep\u00e1tica e s\u00edndrome da disfun\u00e7\u00e3o de m\u00faltiplos \u00f3rg\u00e3os , entre hospedeiros imunocompetentes e imunocomprometidos com taxas de mortalidade de \u223c10% e \u223c35%, respectivamente",
        "id":"3704",
        "question":"What is the contrast with SARS-COV and MERS=COV?",
        "question_pt":"Qual \u00e9 o contraste com SARS-COV e MERS = COV?"
    },
    {
        "answer":"a familial cluster of 2019-nCoV infection in a Shenzhen family with travel history to Wuhan ",
        "answer_pt":"um cluster familiar de infec\u00e7\u00e3o por 2019-nCoV em uma fam\u00edlia de Shenzhen com hist\u00f3rico de viagens para Wuhan",
        "id":"3705",
        "question":"What was the authors' recent report on?",
        "question_pt":"Sobre o que foi o relat\u00f3rio recente dos autores?"
    },
    {
        "answer":"a 2019-nCoV complete genome from a patient in this familial cluster and compared it with the genomes of related \u03b2CoVs to provide insights into the potential source and control strategies.",
        "answer_pt":"um genoma completo de 2019-nCoV de um paciente nesse cluster familiar e comparado com os genomas de \u03b2CoVs relacionados para fornecer insights sobre as poss\u00edveis estrat\u00e9gias de fonte e controle.",
        "id":"3706",
        "question":"What is analyzed in this study?",
        "question_pt":"O que \u00e9 analisado neste estudo?"
    },
    {
        "answer":"2019-nCoV HKU-SZ-005b was available at GenBank (accession no. MN975262)",
        "answer_pt":"2019-nCoV HKU-SZ-005b estava dispon\u00edvel no GenBank (n\u00famero de acesso MN975262)",
        "id":"3707",
        "question":"What genome sequence was available for this study?",
        "question_pt":"Que sequ\u00eancia do genoma estava dispon\u00edvel para este estudo?"
    },
    {
        "answer":"strains collected from human, bats, and Himalayan palm civet between 2003 and 2018, with one 229E coronavirus strain as the outgroup.",
        "answer_pt":"cepas coletadas de humanos, morcegos e civeta do Himalaia entre 2003 e 2018, com uma cepa 229E de coronav\u00edrus como grupo externo.",
        "id":"3708",
        "question":"What strains were included in  this study?",
        "question_pt":"Quais cepas foram inclu\u00eddas neste estudo?"
    },
    {
        "answer":" by the neighbour joining method was performed using MEGA X software, with bootstrap values being calculated from 1000 trees",
        "answer_pt":"pelo m\u00e9todo de jun\u00e7\u00e3o vizinho foi realizado usando o software MEGA X, com os valores de inicializa\u00e7\u00e3o sendo calculados a partir de 1000 \u00e1rvores",
        "id":"3709",
        "question":"How was the Phylogenetic construction done?",
        "question_pt":"Como foi feita a constru\u00e7\u00e3o filogen\u00e9tica?"
    },
    {
        "answer":"using the Poisson correction method and were in the units of the number of amino acid substitutions per site [",
        "answer_pt":"usando o m\u00e9todo de corre\u00e7\u00e3o de Poisson e estavam nas unidades do n\u00famero de substitui\u00e7\u00f5es de amino\u00e1cidos por local [",
        "id":"3710",
        "question":"How were the evolutionary distances computed?",
        "question_pt":"Como foram calculadas as dist\u00e2ncias evolutivas?"
    },
    {
        "answer":"using PSI-blast-based secondary structure PREDiction (PSIPRED) ",
        "answer_pt":"usando a estrutura secund\u00e1ria baseada em explos\u00e3o PSI PREDiction (PSIPRED)",
        "id":"3711",
        "question":"How was the structural analysis of orf8 done?",
        "question_pt":"Como foi feita a an\u00e1lise estrutural do orf8?"
    },
    {
        "answer":" initial amino acid sequences were input and analysed using neural networking and its own algorithm. ",
        "answer_pt":"seq\u00fc\u00eancias iniciais de amino\u00e1cidos foram inseridas e analisadas usando redes neurais e seu pr\u00f3prio algoritmo.",
        "id":"3712",
        "question":"What was done for the prediction of protein secondary structures?",
        "question_pt":"O que foi feito para a previs\u00e3o de estruturas secund\u00e1rias de prote\u00ednas?"
    },
    {
        "answer":"29891 nucleotides in size, encoding 9860 amino acids",
        "answer_pt":"29891 nucleot\u00eddeos de tamanho, codificando 9860 amino\u00e1cidos",
        "id":"3713",
        "question":"What is  the RNA of the 2019-nCOV?",
        "question_pt":"Qual \u00e9 o RNA do 2019-nCOV?"
    },
    {
        "answer":"38%",
        "answer_pt":"38%",
        "id":"3714",
        "question":"What was the G+C content?",
        "question_pt":"Qual era o conte\u00fado do G + C?"
    },
    {
        "answer":"There are no remarkable differences between the orfs and nsps",
        "answer_pt":"N\u00e3o h\u00e1 diferen\u00e7as not\u00e1veis \u200b\u200bentre os orfs e nsps",
        "id":"3715",
        "question":"How are 2019-nCOV and SARS-COV similar?",
        "question_pt":"Como s\u00e3o semelhantes 2019-nCOV e SARS-COV?"
    },
    {
        "answer":" in orf3b, Spike and orf8 but especially variable in Spike S1 and orf8 which were previously shown to be recombination hot spots.",
        "answer_pt":"em orf3b, Spike e orf8, mas especialmente vari\u00e1vel no Spike S1 e orf8, que anteriormente eram mostrados como pontos quentes de recombina\u00e7\u00e3o.",
        "id":"3716",
        "question":"Where is the major distinction?",
        "question_pt":"Onde est\u00e1 a principal distin\u00e7\u00e3o?"
    },
    {
        "answer":"The S1 subunit contains a signal peptide, followed by an N-terminal domain (NTD) and receptor-binding domain (RBD), while the S2 subunit contains conserved fusion peptide (FP), heptad repeat (HR) 1 and 2, transmembrane domain (TM), and cytoplasmic domain (CP).",
        "answer_pt":"A subunidade S1 cont\u00e9m um pept\u00eddeo de sinal, seguido por um dom\u00ednio N-terminal (NTD) e dom\u00ednio de liga\u00e7\u00e3o ao receptor (RBD), enquanto a subunidade S2 cont\u00e9m pept\u00eddeo de fus\u00e3o conservado (FP), repeti\u00e7\u00e3o de heptado (HR) 1 e 2, dom\u00ednio transmembranar (TM) e dom\u00ednio citoplasm\u00e1tico (PC).",
        "id":"3717",
        "question":"What do the S1 and S2 subunits of spike glycoprotein contain?",
        "question_pt":"O que cont\u00eam as subunidades S1 e S2 da glicoprote\u00edna espiga?"
    },
    {
        "answer":"S2 subunit of 2019-nCoV is highly conserved and shares 99% identity with those of the two bat SARS-like CoVs (SL-CoV ZXC21 and ZC45) and human SARS-CoV ",
        "answer_pt":"A subunidade S2 de 2019-nCoV \u00e9 altamente conservada e compartilha 99% de identidade com as dos dois CoVs semelhantes a SARS de morcego (SL-CoV ZXC21 e ZC45) e SARS-CoV humano",
        "id":"3718",
        "question":"What are the chacateristics of the S2 subunit?",
        "question_pt":"Quais s\u00e3o as caracter\u00edsticas da subunidade S2?"
    },
    {
        "answer":" the broad spectrum antiviral peptides against S2 would be an important preventive and treatment modality for testing in animal models before clinical trials ",
        "answer_pt":"os pept\u00eddeos antivirais de amplo espectro contra S2 seriam uma importante modalidade preventiva e de tratamento para testes em modelos animais antes dos ensaios cl\u00ednicos",
        "id":"3719",
        "question":"What would be the benefit of the identity of the S2 unit?",
        "question_pt":"Qual seria o benef\u00edcio da identidade da unidade S2?"
    },
    {
        "answer":"Though the S1 subunit of 2019-nCoV shares around 70% identity to that of the two bat SARS-like CoVs and human SARS-CoV (Figure 3(A) ), the core domain of RBD (excluding the external subdomain) are highly conserved (",
        "answer_pt":"Embora a subunidade S1 de 2019-nCoV compartilhe cerca de 70% de identidade com a dos dois CoVs semelhantes a SARS de morcego e SARS-CoV humano (Figura 3 (A)), o dom\u00ednio principal do RBD (excluindo o subdom\u00ednio externo) \u00e9 altamente conservado (",
        "id":"3720",
        "question":"How do the S1 subunits compare with that of SARS-likeCOV and human SARS-COV?",
        "question_pt":"Como as subunidades S1 se comparam com as de SARV-likeCOV e SARS-COV humano?"
    },
    {
        "answer":"Most of the amino acid differences of RBD are located in the external subdomain,",
        "answer_pt":"A maioria das diferen\u00e7as de amino\u00e1cidos da RBD est\u00e1 localizada no subdom\u00ednio externo,",
        "id":"3721",
        "question":"Where are the amino acid differences?",
        "question_pt":"Onde est\u00e3o as diferen\u00e7as de amino\u00e1cidos?"
    },
    {
        "answer":" the external subdomain,",
        "answer_pt":"o subdom\u00ednio externo,",
        "id":"3722",
        "question":"What is responsible for the interaction with  host receptor?",
        "question_pt":"O que \u00e9 respons\u00e1vel pela intera\u00e7\u00e3o com o receptor hospedeiro?"
    },
    {
        "answer":"its receptor usage, interspecies transmission and pathogenesis.",
        "answer_pt":"uso de receptores, transmiss\u00e3o interesp\u00e9cies e patog\u00eanese.",
        "id":"3723",
        "question":"what will the investigation of external subdomain reveal?",
        "question_pt":"o que a investiga\u00e7\u00e3o do subdom\u00ednio externo revelar\u00e1?"
    },
    {
        "answer":"bat SARSr-CoVs have two stretches of deletions in the spike receptor binding domain (RBD) when compared with that of human SARS-CoV",
        "answer_pt":"Os SARSr-CoVs de morcego t\u00eam duas extens\u00f5es de dele\u00e7\u00f5es no dom\u00ednio de liga\u00e7\u00e3o ao receptor de pico (RBD) quando comparadas com as do SARS-CoV humano",
        "id":"3724",
        "question":"How do most bat SARSr-COV differ from 2019-nCOV and  human SARS-COV?",
        "question_pt":"Como a maioria dos SARSr-COV de morcego difere de 2019-nCOV e SARS-COV humano?"
    },
    {
        "answer":"Yunnan strains such as the WIV1",
        "answer_pt":"Cepas de Yunnan, como a WIV1",
        "id":"3726",
        "question":"Which strains  do  not have such deletions?",
        "question_pt":"Quais linhagens n\u00e3o possuem essas exclus\u00f5es?"
    },
    {
        "answer":"can use human ACE2 as a cellular entry receptor. ",
        "answer_pt":"pode usar a ACE2 humana como um receptor de entrada celular.",
        "id":"3727",
        "question":"What is the consequence of  lack of deletions in Yunnan strains?",
        "question_pt":"Qual \u00e9 a conseq\u00fc\u00eancia da falta de dele\u00e7\u00f5es nas cepas de Yunnan?"
    },
    {
        "answer":"can infect suckling rats and cause inflammation in the brain tissue, and pathological changes in lung & intestine. ",
        "answer_pt":"pode infectar ratos lactantes e causar inflama\u00e7\u00e3o no tecido cerebral e altera\u00e7\u00f5es patol\u00f3gicas no pulm\u00e3o e no intestino.",
        "id":"3728",
        "question":"Being closest to 2019-nCoV, which species do the two bat SARS-related coronavirus ZXC21 and ZC45 infect?",
        "question_pt":"Estando mais pr\u00f3ximo de 2019-nCoV, quais esp\u00e9cies os dois coronav\u00edrus relacionados ao SARS ZXC21 e ZC45 infectam?"
    },
    {
        "answer":"The two retained deletion sites in the Spike genes of ZXC21 and ZC45",
        "answer_pt":"Os dois locais de exclus\u00e3o retidos nos genes Spike de ZXC21 e ZC45",
        "id":"3729",
        "question":"What would lessen the likelihood of jumping the barrier?",
        "question_pt":"O que diminuiria a probabilidade de pular a barreira?"
    },
    {
        "answer":" that different orf3b proteins display different IFN antagonist activities and this function is independent of the protein's nuclear localization, suggesting a potential link between bat SARS-related-CoV orf3b function and pathogenesis.",
        "answer_pt":"que diferentes prote\u00ednas orf3b exibem atividades antagonistas diferentes do IFN e essa fun\u00e7\u00e3o \u00e9 independente da localiza\u00e7\u00e3o nuclear da prote\u00edna, sugerindo um potencial v\u00ednculo entre a fun\u00e7\u00e3o CoV relacionada ao SARV ou a patog\u00eanese do CoV relacionado ao SARS.",
        "id":"3730",
        "question":"What do the results indicate?",
        "question_pt":"O que os resultados indicam?"
    },
    {
        "answer":"an accessory protein found in the Betacoronavirus lineage B coronaviruses",
        "answer_pt":"uma prote\u00edna acess\u00f3ria encontrada nos coronav\u00edrus da linhagem B do Betacoronav\u00edrus",
        "id":"3731",
        "question":"What  is orf8?",
        "question_pt":"O que \u00e9 orf8?"
    },
    {
        "answer":"fulllength orf8",
        "answer_pt":"comprimento total orf8",
        "id":"3732",
        "question":"What orf8 length do Human SARS-CoVs isolated from early-phase patients, all civet SARS-CoVs, and other bat SARS-related CoVs contain?",
        "question_pt":"Qual a extens\u00e3o orf8 de SARS-CoVs humanos isolados de pacientes em fase inicial, todos os SARS-CoVs de civeta e outros CoVs relacionados a SARS de morcego cont\u00eam?"
    },
    {
        "answer":"two bat SARS-related-CoV (Bat-CoV YNLF_31C and YNLF_34C) ",
        "answer_pt":"CoV relacionado a SARS de dois morcegos (Bat-CoV YNLF_31C e YNLF_34C)",
        "id":"3733",
        "question":"From where have the original SARS-CON orf8 been acquired?",
        "question_pt":"De onde foram adquiridos o SARS-CON orf8 original?"
    },
    {
        "answer":"the group that includes the closest genome sequences of bat SARS-related-CoV ZXC21 and ZC45. ",
        "answer_pt":"o grupo que inclui as seq\u00fc\u00eancias gen\u00f4micas mais pr\u00f3ximas de CoV ZXC21 e ZC45 relacionadas a SARS de morcego.",
        "id":"3734",
        "question":"What does the orf8 derived from 2019-nCOV belong to?",
        "question_pt":"A que pertence o orf8 derivado de 2019-nCOV?"
    },
    {
        "answer":"the new 2019-nCoV orf8 is distant from the conserved orf8 ",
        "answer_pt":"o novo 2019-nCoV orf8 est\u00e1 distante do orf8 conservado",
        "id":"3735",
        "question":"What is the  relation between the new2019-nCOV and the conserved orf8?",
        "question_pt":"Qual \u00e9 a rela\u00e7\u00e3o entre o novo2019-nCOV e o orf8 conservado?"
    },
    {
        "answer":"to trigger intracellular stress pathways and activates NLRP3 inflammasomes",
        "answer_pt":"desencadear vias de estresse intracelular e ativar inflamassomas NLRP3",
        "id":"3736",
        "question":"orf8 was shown to do  what?",
        "question_pt":"O orf8 foi mostrado para fazer o que?"
    },
    {
        "answer":"to form a protein with an alpha-helix, following with a betasheet(s) containing six strands ",
        "answer_pt":"formar uma prote\u00edna com uma alfa-h\u00e9lice, seguida de uma folha de betas contendo seis filamentos",
        "id":"3737",
        "question":"What high possibility does the novel  orf8 have?",
        "question_pt":"Que possibilidade alta o romance orf8 tem?"
    },
    {
        "answer":"2019-nCoV is a novel lineage B Betacoronavirus closely related to bat SARS-related coronaviruses. It also has unique genomic features which deserves further investigation to ascertain their roles in viral replication cycle and pathogenesis. More animal sampling to determine its natural animal reservoir and intermediate animal host in the market is important. This will shed light on the evolutionary history of this emerging coronavirus which has jumped into human after the other two zoonotic Betacoroanviruses, SARS-CoV and MERS-CoV.",
        "answer_pt":"2019-nCoV \u00e9 um novo Betacoronav\u00edrus da linhagem B intimamente relacionado a coronav\u00edrus relacionados ao SARS de morcego. Ele tamb\u00e9m possui caracter\u00edsticas gen\u00f4micas \u00fanicas que merecem uma investiga\u00e7\u00e3o mais aprofundada para determinar seus pap\u00e9is no ciclo de replica\u00e7\u00e3o viral e na patog\u00eanese. Mais amostras de animais para determinar seu reservat\u00f3rio natural de animais e hospedeiro intermedi\u00e1rio no mercado s\u00e3o importantes. Isso esclarecer\u00e1 a hist\u00f3ria evolutiva desse coronav\u00edrus emergente que pulou para o ser humano ap\u00f3s os outros dois betacoroanv\u00edrus zoon\u00f3ticos, SARS-CoV e MERS-CoV.",
        "id":"3738",
        "question":"What is the summary of this report?",
        "question_pt":"Qual \u00e9 o resumo deste relat\u00f3rio?"
    },
    {
        "answer":"Wuhan, Hubei Province, China",
        "answer_pt":"Wuhan, Prov\u00edncia de Hubei, China",
        "id":"4221",
        "question":"Where was COVID19 first discovered?",
        "question_pt":"Onde o COVID19 foi descoberto pela primeira vez?"
    },
    {
        "answer":"Global Initiative on Sharing All Influenza Data (GISAID) (https://www.gisaid.org/)",
        "answer_pt":"Iniciativa Global sobre Compartilhamento de Todos os Dados sobre Gripe (GISAID) (https://www.gisaid.org/)",
        "id":"529",
        "question":"Where can published genomic sequences be found for the 2019-nCoV virus?",
        "question_pt":"Onde as sequ\u00eancias gen\u00f4micas publicadas podem ser encontradas para o v\u00edrus 2019-nCoV?"
    },
    {
        "answer":"E and RdRp genes",
        "answer_pt":"Genes E e RdRp",
        "id":"531",
        "question":"What genes have been targeted for the diagnostic RT-PCR tests in 2019-nCoV?",
        "question_pt":"Quais genes foram direcionados para os testes de diagn\u00f3stico de RT-PCR em 2019-nCoV?"
    },
    {
        "answer":"smokers were 1.4 times more likely (RR=1.4, 95% CI: 0.98\u20132.00) to have severe symptoms of COVID-19 and approximately 2.4 times more likely to be admitted to an ICU, need mechanical ventilation or die compared to non-smokers (RR=2.4, 95% CI: 1.43\u20134.04)",
        "answer_pt":"os fumantes tiveram 1,4 vezes mais chances (RR = 1,4, IC 95%: 0,98\u20132,00) de apresentar sintomas graves de COVID-19 e aproximadamente 2,4 vezes mais chances de serem admitidos em uma UTI, precisam de ventila\u00e7\u00e3o mec\u00e2nica ou morrem em compara\u00e7\u00e3o com n\u00e3o-fumantes (RR = 2,4, IC 95%: 1,43-4,04)",
        "id":"266",
        "question":"How does being a smoker impact COVID-19 patient outcomes?",
        "question_pt":"Como o fato de ser fumante afeta os resultados dos pacientes com COVID-19?"
    },
    {
        "answer":"Previous studies have shown that smokers are twice more likely than non-smokers to contract influenza and have more severe symptoms, while smokers were also noted to have higher mortality in the previous MERS-CoV outbreak",
        "answer_pt":"Estudos anteriores demonstraram que os fumantes t\u00eam duas vezes mais chances de contrair a gripe do que os n\u00e3o fumantes e apresentam sintomas mais graves, enquanto os fumantes tamb\u00e9m tiveram maior mortalidade no surto anterior de MERS-CoV",
        "id":"267",
        "question":"Are smokers more likely to contract influenza?",
        "question_pt":"Os fumantes t\u00eam maior probabilidade de contrair gripe?"
    },
    {
        "answer":"limited information available regarding incubation time, transmissibility, and virus origin",
        "answer_pt":"informa\u00e7\u00f5es limitadas dispon\u00edveis sobre tempo de incuba\u00e7\u00e3o, transmissibilidade e origem do v\u00edrus",
        "id":"2185",
        "question":"Why might we underestimate the spread of COVID19?",
        "question_pt":"Por que podemos subestimar a dissemina\u00e7\u00e3o do COVID19?"
    },
    {
        "answer":"Washington",
        "answer_pt":"Washington",
        "id":"2186",
        "question":"Where was the first imported case of COVID19 in the United States?\n",
        "question_pt":"Onde foi o primeiro caso importado de COVID19 nos Estados Unidos?"
    },
    {
        "answer":"January 15, 2020",
        "answer_pt":"15 de janeiro de 2020",
        "id":"2187",
        "question":"When was the first case of COVID19 confirmed in the USA?",
        "question_pt":"Quando foi confirmado o primeiro caso de COVID19 nos EUA?"
    },
    {
        "answer":"January 24, 2020",
        "answer_pt":"24 de janeiro de 2020",
        "id":"2188",
        "question":"When was the second COVID19 case reported in the US?",
        "question_pt":"Quando foi relatado o segundo caso COVID19 nos EUA?"
    },
    {
        "answer":"Chicago",
        "answer_pt":"Chicago",
        "id":"2189",
        "question":"Where was the second reported case of COVID in the United States?",
        "question_pt":"Onde estava o segundo caso relatado de COVID nos Estados Unidos?"
    },
    {
        "answer":"January 30, 2020",
        "answer_pt":"30 de janeiro de 2020",
        "id":"2190",
        "question":"When was the first local transmission of COVID reported in the United States?",
        "question_pt":"Quando foi relatada a primeira transmiss\u00e3o local do COVID nos Estados Unidos?"
    },
    {
        "answer":"January 30, 2020",
        "answer_pt":"30 de janeiro de 2020",
        "id":"2191",
        "question":"When did the WHO declare COVID to be a Public Health Emergency of International Concern?",
        "question_pt":"Quando a OMS declarou a COVID uma Emerg\u00eancia de Sa\u00fade P\u00fablica de Interesse Internacional?"
    },
    {
        "answer":"January 31, 2020,",
        "answer_pt":"31 de janeiro de 2020,",
        "id":"2192",
        "question":"When did the United States declare COVID19 a public health emergency?",
        "question_pt":"Quando os Estados Unidos declararam o COVID19 uma emerg\u00eancia de sa\u00fade p\u00fablica?"
    },
    {
        "answer":"Fever and cough ",
        "answer_pt":"Febre e tosse",
        "id":"2193",
        "question":"What are the most common symptoms of COVID19?",
        "question_pt":"Quais s\u00e3o os sintomas mais comuns do COVID19?"
    },
    {
        "answer":"patients with underlying medical conditions and the elderly",
        "answer_pt":"pacientes com condi\u00e7\u00f5es m\u00e9dicas subjacentes e idosos",
        "id":"2194",
        "question":"What symptoms might people experience with COVID19?",
        "question_pt":"Quais sintomas as pessoas podem experimentar com COVID19?"
    },
    {
        "answer":"patients with underlying medical conditions and the elderly",
        "answer_pt":"pacientes com condi\u00e7\u00f5es m\u00e9dicas subjacentes e idosos",
        "id":"2195",
        "question":"Who is at greater risk of dying from COVID19?",
        "question_pt":"Quem corre maior risco de morrer com o COVID19?"
    },
    {
        "answer":"between 2 and 14 days",
        "answer_pt":"entre 2 e 14 dias",
        "id":"2196",
        "question":"How long is the incubation time for COVID19?",
        "question_pt":"Quanto tempo dura o per\u00edodo de incuba\u00e7\u00e3o do COVID19?"
    },
    {
        "answer":"close contact with an infected person",
        "answer_pt":"contato pr\u00f3ximo com uma pessoa infectada",
        "id":"2197",
        "question":"How does COVID19 get spread?",
        "question_pt":"Como o COVID19 se espalha?"
    },
    {
        "answer":"Although the likelihood of coinfection of 2019-nCoV and another respiratory virus is thought to be low, a positive finding of another respiratory pathogen does not exclude the diagnosis of 2019-nCoV",
        "answer_pt":"Embora a probabilidade de coinfec\u00e7\u00e3o de 2019-nCoV e outro v\u00edrus respirat\u00f3rio seja baixa, um achado positivo de outro pat\u00f3geno respirat\u00f3rio n\u00e3o exclui o diagn\u00f3stico de 2019-nCoV",
        "id":"2198",
        "question":"Is it possible to get infected with COVID and another virus?",
        "question_pt":"\u00c9 poss\u00edvel infectar-se com o COVID e outro v\u00edrus?"
    },
    {
        "answer":"168 million people across 50 countries",
        "answer_pt":"168 milh\u00f5es de pessoas em 50 pa\u00edses",
        "id":"1909",
        "question":"How many people  are estimated to need humanitarian assistance in 2020?",
        "question_pt":"Estima-se que quantas pessoas precisam de assist\u00eancia humanit\u00e1ria em 2020?"
    },
    {
        "answer":"those in complex humanitarian crises, which lack the infrastructure, support, and health systems to mount a comprehensive response. ",
        "answer_pt":"aqueles em crises humanit\u00e1rias complexas, que carecem de infraestrutura, apoio e sistemas de sa\u00fade para montar uma resposta abrangente.",
        "id":"1910",
        "question":"For whom does the  SARS-COV-2 pose a great threat?",
        "question_pt":"Para quem o SARS-COV-2 representa uma grande amea\u00e7a?"
    },
    {
        "answer":"Poor governance, public distrust, and political violence ",
        "answer_pt":"M\u00e1 governan\u00e7a, desconfian\u00e7a p\u00fablica e viol\u00eancia pol\u00edtica",
        "id":"1911",
        "question":"What can undermine interventions?",
        "question_pt":"O que pode prejudicar as interven\u00e7\u00f5es?"
    },
    {
        "answer":"Populations affected by humanitarian crises ",
        "answer_pt":"Popula\u00e7\u00f5es afetadas por crises humanit\u00e1rias",
        "id":"1912",
        "question":"Who are expected to be particularly susceptible?",
        "question_pt":"Quem se espera ser particularmente suscet\u00edvel?"
    },
    {
        "answer":"due to displacement, crowded housing, malnutrition, inadequate water, sanitation, and hygiene (WASH) tools, and stigmatization",
        "answer_pt":"devido ao deslocamento, habita\u00e7\u00e3o lotada, desnutri\u00e7\u00e3o, ferramentas inadequadas de \u00e1gua, saneamento e higiene (WASH) e estigmatiza\u00e7\u00e3o",
        "id":"1913",
        "question":"Why populations may be particularly susceptible?",
        "question_pt":"Por que as popula\u00e7\u00f5es podem ser particularmente suscet\u00edveis?"
    },
    {
        "answer":"Disease outbreaks further reduce access to limited healthcare, which is increasingly disrupted by attacks on health facilities and the persistent overburdening of health systems. ",
        "answer_pt":"Os surtos de doen\u00e7as reduzem ainda mais o acesso a cuidados de sa\u00fade limitados, cada vez mais interrompidos por ataques a instala\u00e7\u00f5es de sa\u00fade e pela sobrecarga persistente dos sistemas de sa\u00fade.",
        "id":"1914",
        "question":"What is the impact of disease outbreaks?",
        "question_pt":"Qual \u00e9 o impacto dos surtos de doen\u00e7as?"
    },
    {
        "answer":" limited public health, laboratory, and primary care services ",
        "answer_pt":"servi\u00e7os p\u00fablicos limitados de sa\u00fade, laborat\u00f3rio e aten\u00e7\u00e3o prim\u00e1ria",
        "id":"1915",
        "question":"What represents a barrier to testing?",
        "question_pt":"O que representa uma barreira para os testes?"
    },
    {
        "answer":"Providing the limited healthcare worker cadre with appropriate training and personal protective equipment, and ensuring a continuous supply chain ",
        "answer_pt":"Fornecer ao quadro limitado de trabalhadores da \u00e1rea de sa\u00fade treinamento e equipamento de prote\u00e7\u00e3o individual adequados e garantir uma cadeia de suprimentos cont\u00ednua",
        "id":"1916",
        "question":"Where are difficulties are exacerbated during humanitarian crises?",
        "question_pt":"Onde as dificuldades s\u00e3o exacerbadas durante as crises humanit\u00e1rias?"
    },
    {
        "answer":" Frequent displacement and limited contact information ",
        "answer_pt":"Deslocamento frequente e informa\u00e7\u00f5es limitadas de contato",
        "id":"1917",
        "question":"What can prevent contact tracing?",
        "question_pt":"O que pode impedir o rastreamento de contatos?"
    },
    {
        "answer":"overcrowding limit the implementation of both quarantine of those exposed and isolation of those who are ill. ",
        "answer_pt":"a superlota\u00e7\u00e3o limita a implementa\u00e7\u00e3o da quarentena dos expostos e o isolamento dos doentes.",
        "id":"1918",
        "question":"What is an example of intractable structural challenge?",
        "question_pt":"Qual \u00e9 um exemplo de desafio estrutural intrat\u00e1vel?"
    },
    {
        "answer":"increased vulnerabilities, humanitarian crises",
        "answer_pt":"aumento de vulnerabilidades, crises humanit\u00e1rias",
        "id":"1919",
        "question":"What should be the priority of the national and international bodies trying to prevent the pandemic?",
        "question_pt":"Qual deve ser a prioridade dos \u00f3rg\u00e3os nacionais e internacionais que tentam impedir a pandemia?"
    },
    {
        "answer":"to protect healthcare workers, develop and deploy rapid testing, improve surveillance, and enact quarantine and isolation of contacts and cases.",
        "answer_pt":"proteger os profissionais de sa\u00fade, desenvolver e implantar testes r\u00e1pidos, melhorar a vigil\u00e2ncia e aprovar a quarentena e o isolamento de contatos e casos.",
        "id":"1920",
        "question":"What  resources need to be identified?",
        "question_pt":"Quais recursos precisam ser identificados?"
    },
    {
        "answer":" Respiratory hygiene i",
        "answer_pt":"Higiene respirat\u00f3ria i",
        "id":"1921",
        "question":"What is an effective public health hygiene?",
        "question_pt":"O que \u00e9 uma higiene eficaz em sa\u00fade p\u00fablica?"
    },
    {
        "answer":"hand hygiene, safe cough practice, and social distancing [",
        "answer_pt":"higiene das m\u00e3os, pr\u00e1tica segura da tosse e distanciamento social [",
        "id":"1922",
        "question":"What has been demonstrated to  be  effective for prevention?",
        "question_pt":"O que foi demonstrado ser eficaz para a preven\u00e7\u00e3o?"
    },
    {
        "answer":" the distribution of soap to households in humanitarian settings has been shown to increase handwashing by over 30%",
        "answer_pt":"a distribui\u00e7\u00e3o de sab\u00e3o para as fam\u00edlias em ambientes humanit\u00e1rios demonstrou aumentar a lavagem das m\u00e3os em mais de 30%",
        "id":"1923",
        "question":"What has increased hand washing?",
        "question_pt":"O que aumentou a lavagem das m\u00e3os?"
    },
    {
        "answer":"the rights to dignity and to fully participate in decisions related to assistance in humanitarian crises. ",
        "answer_pt":"os direitos \u00e0 dignidade e a participa\u00e7\u00e3o plena nas decis\u00f5es relacionadas \u00e0 assist\u00eancia em crises humanit\u00e1rias.",
        "id":"1924",
        "question":"What is hand washing to protect one's own health  consistent with?",
        "question_pt":"Com o que lavar as m\u00e3os para proteger a pr\u00f3pria sa\u00fade \u00e9 consistente?"
    },
    {
        "answer":"Widespread introduction of alcohol-based hand rubs ",
        "answer_pt":"Introdu\u00e7\u00e3o generalizada de fric\u00e7\u00f5es \u00e0 m\u00e3o \u00e0 base de \u00e1lcool",
        "id":"1925",
        "question":"What is possible in many resource -limited  settings?",
        "question_pt":"O que \u00e9 poss\u00edvel em muitas configura\u00e7\u00f5es ilimitadas de recursos?"
    },
    {
        "answer":"The Sphere Handbook, a collection of rights-based guidelines for humanitarian response",
        "answer_pt":"The Sphere Handbook, uma cole\u00e7\u00e3o de diretrizes baseadas em direitos para resposta humanit\u00e1ria",
        "id":"1926",
        "question":"What is the foremost authority on minimum standards for humanitarian assistance?",
        "question_pt":"Qual \u00e9 a principal autoridade em padr\u00f5es m\u00ednimos para assist\u00eancia humanit\u00e1ria?"
    },
    {
        "answer":" reducing both bacterial and viral pathogen transmission,",
        "answer_pt":"reduzindo a transmiss\u00e3o de pat\u00f3genos bacterianos e virais,",
        "id":"1927",
        "question":"For what  there is evidence for  the efficacy of hand washing?",
        "question_pt":"Pois o que h\u00e1 evid\u00eancia para a efic\u00e1cia da lavagem das m\u00e3os?"
    },
    {
        "answer":"evidence pertaining to the prevention of illnesses transmitted by the faecal-oral route, with the focus on hand hygiene proximate to latrines",
        "answer_pt":"evid\u00eancias relativas \u00e0 preven\u00e7\u00e3o de doen\u00e7as transmitidas pela via fecal-oral, com foco na higiene das m\u00e3os pr\u00f3xima \u00e0s latrinas",
        "id":"1928",
        "question":"What are humanitarian WASH standards  based on?",
        "question_pt":"Em que se baseiam os padr\u00f5es humanit\u00e1rios de WASH?"
    },
    {
        "answer":"latrines in crisis settings are often shared and distant from residential shelters,",
        "answer_pt":"latrinas em situa\u00e7\u00f5es de crise s\u00e3o frequentemente compartilhadas e distantes de abrigos residenciais,",
        "id":"1929",
        "question":"What confers a high risk of  gender  based violence?",
        "question_pt":"O que confere um alto risco de viol\u00eancia baseada em g\u00eanero?"
    },
    {
        "answer":" for accessing latrine-adjacent handwashing stations, particularly for hand hygiene to prevent respiratory pathogen transmission.",
        "answer_pt":"para acessar as esta\u00e7\u00f5es de lavagem de m\u00e3os adjacentes \u00e0 latrina, particularmente para a higiene das m\u00e3os, para impedir a transmiss\u00e3o de pat\u00f3genos respirat\u00f3rios.",
        "id":"1930",
        "question":"What is the deterrent effect of gender based violence around latrines?",
        "question_pt":"Qual \u00e9 o efeito dissuasor da viol\u00eancia baseada em g\u00eanero nas latrinas?"
    },
    {
        "answer":"Crisis-affected community engagement is integral in pandemic planning,",
        "answer_pt":"O envolvimento da comunidade afetada pela crise faz parte do planejamento da pandemia,",
        "id":"1931",
        "question":"What  will maximize the effectiveness of interventions?",
        "question_pt":"O que maximizar\u00e1 a efic\u00e1cia das interven\u00e7\u00f5es?"
    },
    {
        "answer":" mitigation plans will fall short of health and human rights obligations in outbreak response",
        "answer_pt":"planos de mitiga\u00e7\u00e3o ficar\u00e3o aqu\u00e9m das obriga\u00e7\u00f5es de sa\u00fade e direitos humanos na resposta a surtos",
        "id":"1932",
        "question":"What will happen without the adaptation of existing standards?",
        "question_pt":"O que acontecer\u00e1 sem a adapta\u00e7\u00e3o dos padr\u00f5es existentes?"
    },
    {
        "answer":"Transparent and credible information-sharing mechanisms ",
        "answer_pt":"Mecanismos transparentes e cred\u00edveis de compartilhamento de informa\u00e7\u00f5es",
        "id":"1933",
        "question":"What is essential when pandemics threaten vulnerable populations?",
        "question_pt":"O que \u00e9 essencial quando as pandemias amea\u00e7am popula\u00e7\u00f5es vulner\u00e1veis?"
    },
    {
        "answer":"Diplomacy bridging long-standing mistrust of public health and biomedical interventions and facilitating engagement with contentious actors ",
        "answer_pt":"Diplomacia superando a desconfian\u00e7a de longa data da sa\u00fade p\u00fablica e interven\u00e7\u00f5es biom\u00e9dicas e facilitando o engajamento com atores controversos",
        "id":"1934",
        "question":"What is a necessary component of effective health  governance?",
        "question_pt":"Qual \u00e9 um componente necess\u00e1rio para uma governan\u00e7a eficaz da sa\u00fade?"
    },
    {
        "answer":"During the 1918-1919 influenza pandemic, between 21 and 25 million people died of influenza worldwide.",
        "answer_pt":"Durante a pandemia de influenza de 1918-1919, entre 21 e 25 milh\u00f5es de pessoas morreram de influenza em todo o mundo.",
        "id":"259",
        "question":"Approximately how many people died during the 1918-1919 influenza pandemic?",
        "question_pt":"Aproximadamente quantas pessoas morreram durante a pandemia de influenza de 1918-1919?"
    },
    {
        "answer":"Malnutrition weakened the human immune system and made a person more vulnerable to infectious diseases like tuberculosis and influenza, therefore, hunger and malnutrition were indirectly responsible for millions of deaths in the world in that period of time.",
        "answer_pt":"A desnutri\u00e7\u00e3o enfraqueceu o sistema imunol\u00f3gico humano e tornou a pessoa mais vulner\u00e1vel a doen\u00e7as infecciosas como tuberculose e gripe; portanto, fome e desnutri\u00e7\u00e3o foram indiretamente respons\u00e1veis \u200b\u200bpor milh\u00f5es de mortes no mundo naquele per\u00edodo de tempo.",
        "id":"286",
        "question":"What social and economic factors  contributed to the large fatality rate in the 1918 influenza pandemic?",
        "question_pt":"Quais fatores sociais e econ\u00f4micos contribu\u00edram para a grande taxa de mortalidade na pandemia de influenza de 1918?"
    },
    {
        "answer":" in 1918 and 1919, physicians and nurses almost had nothing in their hands to help individuals who were infected by influenza viruses. T",
        "answer_pt":"em 1918 e 1919, m\u00e9dicos e enfermeiros quase n\u00e3o tinham nada em m\u00e3os para ajudar indiv\u00edduos infectados pelo v\u00edrus influenza. T",
        "id":"291",
        "question":"What problems were faced by medical staff during the 1918 epidemic?",
        "question_pt":"Que problemas foram enfrentados pela equipe m\u00e9dica durante a epidemia de 1918?"
    },
    {
        "answer":" Today, although we still do not have very effective, powerful, and practical anti-influenza drugs available, we at least have some improved, useful, and helpful anti-viral drugs like zanamivir, and effective, convenient anti-cold medicines like Tylenol or Advil.",
        "answer_pt":"Hoje, embora ainda n\u00e3o tenhamos medicamentos anti-influenza muito eficazes, poderosos e pr\u00e1ticos, temos pelo menos alguns medicamentos antivirais aprimorados, \u00fateis e \u00fateis, como o zanamivir, e medicamentos anti-resfriados eficazes e convenientes, como Tylenol ou Advil.",
        "id":"295",
        "question":"What helpful drugs are available now to control the disease or to provide palliative care for influenza patients?",
        "question_pt":"Que medicamentos \u00fateis est\u00e3o dispon\u00edveis agora para controlar a doen\u00e7a ou fornecer cuidados paliativos para pacientes com influenza?"
    },
    {
        "answer":" in the United States of America, the influenza classed mortality rate declined from 10.2/100,000 in the 1940s to 0.56/100,000 in the 1990s; and the classed mortality rates of 1957-1958 and 1968-1969 influenza pandemics were not remarkably different from the non-pandemic seasons",
        "answer_pt":"nos Estados Unidos da Am\u00e9rica, a taxa de mortalidade classificada por influenza caiu de 10,2 / 100.000 na d\u00e9cada de 1940 para 0,56 / 100.000 na d\u00e9cada de 1990; e as taxas de mortalidade classificadas das pandemias de influenza de 1957-1958 e 1968-1969 n\u00e3o foram notavelmente diferentes das esta\u00e7\u00f5es n\u00e3o-pand\u00eamicas",
        "id":"297",
        "question":"How has the mortality rate due to influenza declined in USA over past decades?",
        "question_pt":"Como a taxa de mortalidade por influenza diminuiu nos EUA nas \u00faltimas d\u00e9cadas?"
    },
    {
        "answer":"We do not have a universal vaccine to prevent all influenza virus infections, but we can make effective vaccines to a specific influenza virus strain in a short time.",
        "answer_pt":"N\u00e3o temos uma vacina universal para prevenir todas as infec\u00e7\u00f5es pelo v\u00edrus influenza, mas podemos fazer vacinas eficazes para uma cepa espec\u00edfica do v\u00edrus influenza em um curto espa\u00e7o de tempo.",
        "id":"299",
        "question":"Is there an Influenza vaccine?",
        "question_pt":"Existe uma vacina contra a gripe?"
    },
    {
        "answer":"that most cases of H1N1 influenza A virus infections were mild, the symptomatic case fatality rate was only 0.005% in New Zealand (16) ; and in New York City, the case fatality rate was 0.0094-0.0147% for persons \u226565 years old, and for those of 0-17 years old, the case fatality rate was 0.0008-0.0012% (17) .",
        "answer_pt":"que a maioria dos casos de infec\u00e7\u00f5es pelo v\u00edrus influenza A H1N1 foi leve, a taxa de mortalidade sintom\u00e1tica de casos foi de apenas 0,005% na Nova Zel\u00e2ndia (16); e na cidade de Nova York, a taxa de mortalidade de casos foi de 0,0094-0,0147% para pessoas com idade igual ou superior a 65 anos e, para pessoas de 0 a 17 anos, a taxa de mortalidade de casos foi de 0,0008-0,0012% (17).",
        "id":"300",
        "question":"for the 2009 influenza pandemic, what were the case fatality rates?",
        "question_pt":"para a pandemia de influenza de 2009, quais foram as taxas de mortalidade?"
    },
    {
        "answer":"Nowadays, we travel faster, and we travel more frequently and globally, and we have more complicated social activities and lifestyles, thereby increasing the chances of viral mutation; and we realize that influenza viruses are even easier to reassort, recombine, and mutate in nature than many other RNA viruses.",
        "answer_pt":"Atualmente, viajamos mais r\u00e1pido e com mais frequ\u00eancia e globalidade, e temos atividades sociais e estilos de vida mais complicados, aumentando assim as chances de muta\u00e7\u00e3o viral; e percebemos que os v\u00edrus influenza s\u00e3o ainda mais f\u00e1ceis de reagrupar, recombinar e sofrer muta\u00e7\u00f5es na natureza do que muitos outros v\u00edrus RNA.",
        "id":"301",
        "question":"What  factors would contribute now to the faster rates of influenza infections?",
        "question_pt":"Quais fatores contribuiriam agora para as taxas mais r\u00e1pidas de infec\u00e7\u00f5es por influenza?"
    },
    {
        "answer":" influenza virus infections are controllable and preventable, with the increased population health and immunity, with the WHO Global Influenza Surveillance and Response System, and with standard/routine epidemiological practices, and with new effective anti-viral agents and vaccines in production in the future. ",
        "answer_pt":"as infec\u00e7\u00f5es pelo v\u00edrus influenza s\u00e3o control\u00e1veis \u200b\u200be evit\u00e1veis, com o aumento da sa\u00fade e imunidade da popula\u00e7\u00e3o, com o Sistema Global de Vigil\u00e2ncia e Resposta \u00e0 Influenza da OMS, e com pr\u00e1ticas epidemiol\u00f3gicas padr\u00e3o / rotineiras e com novos agentes antivirais e vacinas eficazes em produ\u00e7\u00e3o no futuro.",
        "id":"302",
        "question":"What factors would be responsible in future for the prevention of an Influenza pandemic?",
        "question_pt":"Que fatores seriam respons\u00e1veis \u200b\u200bno futuro pela preven\u00e7\u00e3o de uma pandemia de influenza?"
    },
    {
        "answer":" the detected 32.14% (45/140, one case from Taiwan, and one case from Hong Kong) (22, 23).\n",
        "answer_pt":"os 32,14% detectados (45/140, um caso de Taiwan e um caso de Hong Kong) (22, 23).",
        "id":"303",
        "question":"What was the detected fatality rate of H7N9 Avian flu?",
        "question_pt":"Qual foi a taxa de mortalidade detectada pela gripe avi\u00e1ria H7N9?"
    },
    {
        "answer":"most people usually think a common cold is a very common and normal occurrence, and they don't take flu-like illnesses seriously. In most situations, they would just stay home and take some medicines. Only those who have very severe flu-like symptoms would see doctors, and thereby be detected and diagnosed, accordingly the real case fatality rate should be much lower",
        "answer_pt":"a maioria das pessoas geralmente pensa que um resfriado comum \u00e9 uma ocorr\u00eancia muito comum e normal e n\u00e3o leva a s\u00e9rio doen\u00e7as semelhantes \u00e0 gripe. Na maioria das situa\u00e7\u00f5es, eles ficavam em casa e tomavam alguns rem\u00e9dios. Somente aqueles que apresentam sintomas semelhantes aos da gripe muito graves procurariam os m\u00e9dicos e, assim, seriam detectados e diagnosticados, de acordo com a taxa real de mortalidade dos casos.",
        "id":"304",
        "question":"Why would real  case fatality rate for the H7N9 be lower than detected rate?",
        "question_pt":"Por que a taxa de mortalidade real do H7N9 seria menor que a taxa detectada?"
    },
    {
        "answer":"single-strand RNA filoviruses",
        "answer_pt":"filov\u00edrus de RNA de fita simples",
        "id":"5315",
        "question":"What is the structure of the Ebolavirus?",
        "question_pt":"Qual \u00e9 a estrutura do Ebolav\u00edrus?"
    },
    {
        "answer":"2013-2016",
        "answer_pt":"2013-2016",
        "id":"5316",
        "question":"When was the West African Ebolavirus outbreak?",
        "question_pt":"Quando foi o surto de Ebolav\u00edrus da \u00c1frica Ocidental?"
    },
    {
        "answer":"African bats",
        "answer_pt":"Morcegos africanos",
        "id":"5317",
        "question":"What animals are considered to be maintenance hosts to the Ebolavirus?",
        "question_pt":"Quais animais s\u00e3o considerados hospedeiros de manuten\u00e7\u00e3o do Ebolav\u00edrus?"
    },
    {
        "answer":"a maintenance function play by the host(s)",
        "answer_pt":"uma fun\u00e7\u00e3o de manuten\u00e7\u00e3o executada pelo (s) host (s)",
        "id":"5318",
        "question":"What do circles indicate in Figure 1?",
        "question_pt":"O que os c\u00edrculos indicam na Figura 1?"
    },
    {
        "answer":"infectious transmission pathways between hosts",
        "answer_pt":"vias de transmiss\u00e3o infecciosas entre hospedeiros",
        "id":"5319",
        "question":"What do arrows indicate in Figure 1?",
        "question_pt":"O que as setas indicam na Figura 1?"
    }
]